-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 UKNOuiPqaotm9/mMOb1vsQqXnoz9COee934TP45/7sUR2aYnp9CG8IJRVYo0TJqP
 HcsR/YFfYU/9ZDSH2Jj2wA==

<SEC-DOCUMENT>0001193125-09-094563.txt : 20090430
<SEC-HEADER>0001193125-09-094563.hdr.sgml : 20090430
<ACCEPTANCE-DATETIME>20090430164902
ACCESSION NUMBER:		0001193125-09-094563
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20090625
FILED AS OF DATE:		20090430
DATE AS OF CHANGE:		20090430
EFFECTIVENESS DATE:		20090430

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		09784549

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>ddef14a.htm
<DESCRIPTION>DEFINITIVE PROXY STATEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Definitive Proxy Statement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="4"><B>UNITED STATES </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="4"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Washington, DC 20549 </B></FONT></P> <P
STYLE="font-size:16px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SCHEDULE 14A </B></FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Proxy Statement Pursuant to Section 14(a) of </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>The Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Filed by the Registrant <FONT
FACE="WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Filed by a Party other than the Registrant <FONT
FACE="WINGDINGS">&#168;</FONT></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Check the appropriate box: </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Preliminary Proxy Statement </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#120;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Definitive Proxy Statement </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Definitive Additional Materials </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Soliciting Material Pursuant to Rule 14a-1 1(c) or Rule 14a-12 </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>ARCA BIOPHARMA, INC. </B></FONT></P> <P
STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1">(Name of Registrant as Specified in Its Charter)
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="3"><B>&nbsp;&nbsp;</B></FONT></P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1">(Name
of Person(s) Filing Proxy Statement, if other than the Registrant) </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT
FACE="Times New Roman" SIZE="2">Payment of Filing Fee (Check the appropriate box): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#120;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">No fee required. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Title of each class of securities to which transaction applies: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="margin-top:2px;margin-bottom:0px; margin-left:5%" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3">&nbsp;&nbsp;</FONT></P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="96%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Aggregate number of securities to which transaction applies: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="margin-top:2px;margin-bottom:0px; margin-left:5%" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3">&nbsp;&nbsp;</FONT></P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="96%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was
determined): </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:2px;margin-bottom:0px; margin-left:5%" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3">&nbsp;&nbsp;</FONT></P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="96%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Proposed maximum aggregate value of transaction: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="margin-top:2px;margin-bottom:0px; margin-left:5%" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3">&nbsp;&nbsp;</FONT></P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="96%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Total fee paid: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:2px;margin-bottom:0px; margin-left:5%"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="3">&nbsp;&nbsp;</FONT></P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="96%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Fee paid previously with preliminary materials: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-1 1(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the
previous filing by registration statement number, or the Form or Schedule and the date of its filing. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Amount previously paid: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:2px;margin-bottom:0px; margin-left:5%"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="3">&nbsp;&nbsp;</FONT></P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="96%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Form, Schedule or Registration Statement No.: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="margin-top:2px;margin-bottom:0px; margin-left:5%" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3">&nbsp;&nbsp;</FONT></P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="96%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Filing Party: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:2px;margin-bottom:0px; margin-left:5%"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="3">&nbsp;&nbsp;</FONT></P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="96%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date Filed: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:2px;margin-bottom:0px; margin-left:5%"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="3">&nbsp;&nbsp;</FONT></P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="96%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g62758g64f28.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">April&nbsp;30, 2009 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Dear
Stockholder: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Please join us for the 2009 Annual Meeting of Stockholders of ARCA biopharma, Inc. The meeting will be held on Thursday,
June&nbsp;25, 2009, at <U>9:00</U> a.m. Mountain Time at <U>the Renaissance Hotel, 500 Flatiron Blvd</U>., Broomfield, CO 80021. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">At this
year&#146;s meeting, you will have the opportunity to elect four directors, approve an amendment and restatement of the Nuvelo, Inc. 2004 Equity Incentive Plan as the Amended and Restated ARCA biopharma, Inc. 2004 Equity Incentive Plan, ratify the
selection of our independent registered public accounting firm, and transact any other business properly presented at the meeting, as more fully described in the accompanying Proxy Statement. If you own shares of common stock at the close of
business on April&nbsp;29, 2009, you will be entitled to vote at the annual meeting. In addition, immediately following the meeting, you will have the opportunity to hear what we have accomplished in our business in the past year and to ask
questions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">This year, we are again taking advantage of the Securities and Exchange Commission rule allowing companies to furnish proxy
materials to their stockholders over the Internet. By furnishing proxy materials to stockholders over the Internet, we are able to reduce the costs and expenses, and reduce the environmental impact, associated with generating paper copies of our
proxy materials. On or about May&nbsp;6, 2009, we will mail our stockholders of record a Notice containing instructions on how to access our Proxy Statement and 2008 Annual Report and vote via the Internet. The Notice to be mailed to our
stockholders of record also includes instructions on how to order a paper copy of the proxy materials. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Proxy Statement includes
information about the items of business to be discussed at our annual meeting. You will find other detailed information about ARCA and its historical operations in the 2008 Annual Report, which includes my letter to the stockholders, and the Annual
Report on Form 10-K for 2008, which contains the audited consolidated financial statements of Nuvelo, Inc. prior to the completion on January&nbsp;27, 2009 of the merger involving ARCA biopharma, Inc. Whether or not you can attend, please read the
Proxy Statement. When you have done so, please vote via the Internet or, if you receive a paper copy of the proxy card by mail, sign, date, and mail your completed proxy card to us. Your vote is important, so please vote via the Internet or return
your proxy card promptly. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We hope you can join us on June&nbsp;25, 2009. If you are planning to attend, please send an e-mail to
<U>ir@arcabiopharma.com</U> so that we may include you on the attendance list. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="100%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Sincerely,</FONT></P></TD></TR>
<TR>
<TD HEIGHT="27"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px">

<IMG SRC="g62758g32i93.jpg" ALT="LOGO"></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Richard B. Brewer
</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Chief Executive Officer, President<BR>and Director</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">8001 Arista Place, Suite 200, Broomfield, CO 80021&nbsp;&nbsp;&nbsp;&nbsp;tel: 720/940-2100 fax: 720/208-9261
<U>www.arcabiopharma.com</U> </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>ARCA BIOPHARMA, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Broomfield, Colorado 80021 </B></FONT></P> <P
STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>NOTICE OF ANNUAL MEETING OF STOCKHOLDERS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>To Be Held on June&nbsp;25, 2009 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">To the Stockholders of ARCA biopharma, Inc.: </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">NOTICE IS HEREBY GIVEN, that the annual meeting of stockholders of ARCA biopharma, Inc., a Delaware corporation (&#147;ARCA,&#148; the
&#147;Company,&#148; or &#147;we&#148;), will be held on June&nbsp;25, 2009, at 9:00 a.m. Mountain Time, at the Renaissance Hotel, 500 Flatiron Blvd., Broomfield, CO 80021, for the following purposes: </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">to elect four directors to hold office until the 2012 annual meeting of stockholders or until the election and qualification of their respective successors;
</FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">to approve an amendment and restatement of the Nuvelo, Inc. 2004 Equity Incentive Plan as the Amended and Restated ARCA biopharma, Inc. 2004 Equity Incentive Plan (the &#147;Option
Plan&#148;); </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">to ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year 2009; and </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">to transact any other business which is properly brought before the meeting or any adjournment or postponement thereof. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Please refer to the accompanying proxy materials, which form a part of this Notice, for further information about the business to be transacted at the
annual meeting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Only stockholders of record at the close of business on April&nbsp;29, 2009 are entitled to receive this notice and to
vote at the annual meeting or any adjournment or postponement thereof. A complete list of stockholders entitled to vote at the annual meeting shall be open to inspection of any stockholder present at the annual meeting and, for any purpose germane
to the annual meeting, during ordinary business hours at our corporate offices at 8001 Arista Place, Suite 200, Broomfield, CO 80021, during the ten days prior to the annual meeting. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">All stockholders are cordially invited to attend the annual meeting. Whether or not you plan to attend the annual meeting in person, we urge you to
ensure your representation by voting by proxy as promptly as possible. You may vote via the Internet or, if you request a paper copy of the proxy card by mail, by completing, signing, dating, and mailing the proxy card to us in the return envelope
that will be provided for your use, which will require no postage if mailed in the United States. If you attend the annual meeting and vote your shares in person at the meeting, your proxy will not be used. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">By order of the Board of Directors: </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:54%; text-indent:-2%">

<IMG SRC="g62758g94c52.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Michael R. Bristow, M.D., Ph.D. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2"><I>Chairman of the Board of Directors </I></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2"><I>and Chief Science and Medical Officer </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">April&nbsp;30, 2009 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Broomfield, Colorado </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>ARCA BIOPHARMA, INC. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>PROXY STATEMENT FOR ANNUAL MEETING OF STOCKHOLDERS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>June 25, 2009 </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>INTRODUCTION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>General </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">This Proxy Statement is made available to our stockholders on behalf of our Board of Directors in connection with the solicitation of proxies for use at
our annual meeting of stockholders to be held at&nbsp;the Renaissance Hotel, 500 Flatiron Blvd., Broomfield, CO 80021 on June&nbsp;25, 2009 at 9:00 a.m. Mountain Time and at any adjournments or postponements of the annual meeting. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">This solicitation is made on behalf of our Board of Directors and we will pay the costs of solicitation. Our directors, officers, and employees may also
solicit proxies by telephone, telegraph, fax, or personal interview. We will not pay any additional compensation to directors, officers, or other employees for such services, but may reimburse them for reasonable out-of-pocket expenses in connection
with such solicitation. We will reimburse banks, brokerage firms, and other custodians, nominees, and fiduciaries for reasonable expenses incurred by them for sending proxy materials to our stockholders. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On or about May&nbsp;6, 2009, we will mail our record and beneficial stockholders a Notice containing instructions on how to access our Proxy Statement
and 2008 Annual Report via the Internet. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Merger Transaction </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">On January&nbsp;27 2009, ARCA biopharma, Inc. (&#147;ARCA&#148; or the &#147;Company&#148;) completed the merger contemplated by that Agreement and Plan of Merger and Reorganization, dated September&nbsp;24, 2008, as
amended October&nbsp;28, 2008 (the &#147;Merger Agreement&#148;), in which a wholly-owned subsidiary of the Company merged with and into the company now known as ARCA biopharma Colorado, Inc. (&#147;ARCA Colorado&#148;), with ARCA Colorado surviving
as a wholly-owned subsidiary of the Company. After the merger, the Company changed its name from Nuvelo, Inc. (&#147;Nuvelo&#148;) to ARCA biopharma, Inc. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">In accordance with the Merger Agreement, immediately prior to the consummation of the merger, Nuvelo effected a reverse stock split of its common stock. Pursuant to this reverse stock split, each 20 shares of
Nuvelo&#146;s common stock that were issued and outstanding immediately prior to the merger were converted into one share of Nuvelo&#146;s common stock. As a result, and in accordance with the Merger Agreement, each outstanding common share and
warrant or option to purchase shares of ARCA Colorado&#146;s common stock prior to the merger was converted into the right to receive or purchase 0.16698070 (the &#147;Exchange Ratio&#148;) shares of the Company&#146;s common stock, which Exchange
Ratio incorporates the effect of the reverse stock split. As of immediately following the effective time of the merger, former ARCA Colorado stockholders owned approximately 67% of the outstanding common stock of the Company, and Nuvelo stockholders
owned approximately 33% of the outstanding common stock of the Company, after giving effect to the issuance of shares pursuant to ARCA Colorado&#146;s outstanding options and warrants prior to the merger, primarily on a treasury method basis,
without giving effect to the issuance of stock pursuant to Nuvelo&#146;s outstanding options and warrants. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On January&nbsp;28, 2009,
ARCA&#146;s common stock began trading on the Nasdaq Global Market under the new symbol &#147;ABIO.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">All information contained in
this Proxy Statement relating to common shares, options and warrants to purchase common shares have been adjusted retroactively to reflect the effect of the reverse stock split and the Exchange Ratio. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>What is the purpose of the annual meeting? </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">At the annual meeting, stockholders will consider and vote upon the following matters: </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">to elect four directors to hold office until the 2012 annual meeting of stockholders or until the election and qualification of their respective successors;
</FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">to approve an amendment and restatement of the Nuvelo, Inc. 2004 Equity Incentive Plan as the Amended and Restated ARCA biopharma, Inc. 2004 Equity Incentive Plan (the &#147;Option
Plan&#148;); </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">to ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year 2009; and </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">to transact any other business which is properly brought before the meeting or any adjournment or postponement thereof. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Who can vote at the annual meeting? </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Our issued and
outstanding common stock constitutes the only class of securities entitled to vote at the annual meeting. Only holders of record of our common stock at the close of business on April&nbsp;29, 2009 are entitled to receive this notice and to vote at
the annual meeting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Is my vote important? </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">Yes, your vote is important regardless of how many shares you own. Please take the time to vote and read the instructions below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>What is the
quorum requirement for the annual meeting? </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The presence at the meeting, in person or by proxy, of a majority of the issued and
outstanding shares will constitute a quorum. At the close of business on that April&nbsp;29, 2009, 7,570,103 shares of our common stock were issued and outstanding. As of March&nbsp;31, 2009, 3,977,377 shares of our common stock were beneficially
owned by our executive officers and directors. Abstentions and &#147;broker non-votes&#148; (<I>i.e.</I>, shares held by a broker or nominee which are represented at the meeting, but with respect to which the broker or nominee is not empowered to
vote on a particular proposal) will be counted towards the quorum requirement. Broker non-votes will not be counted towards the vote total for any proposal. Each share of common stock is entitled to one vote. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>How will my shares be voted if I grant a proxy? </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">Unless there are different instructions on the proxy, all shares represented by valid proxies (and not revoked before they are voted) will be voted at the meeting for the election of the four nominees for director and for Proposals 2 and 3.
With respect to any other business that may properly come before the meeting and be submitted to a vote of stockholders, proxies will be voted in accordance with the best judgment of the designated proxy holders. All votes cast at the meeting will
be tabulated by the persons appointed by us to act as inspectors of election for the meeting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Why did I receive a Notice in the mail regarding Internet
availability of proxy materials? </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">This year, we are once again taking advantage of the Securities and Exchange Commission
(&#147;SEC&#148;) rules allowing companies to furnish proxy materials to their stockholders over the Internet. By furnishing proxy materials to stockholders over the Internet, we are able to reduce the costs and expenses, and reduce the
environmental impact, associated with generating paper copies of our proxy materials. We will mail our record </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">and beneficial stockholders on or about May&nbsp;6, 2009 a Notice containing instructions on how to access our Proxy Statement and 2008 Annual Report and
vote via the Internet. The Notice also includes instructions on how to obtain paper copies of the proxy materials, free of charge. The Internet will be available for accessing the proxy materials and for voting 24 hours a day, and will close at 1:00
a.m. Eastern Time on June&nbsp;25, 2009. You will need the control number assigned to you and provided on your Notice to vote using the Internet. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>How
do I vote? </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">If on April&nbsp;29, 2009, your shares were registered directly in your name with the Company&#146;s transfer agent,
Computershare Trust Company N.A., then you are a stockholder of record. If you hold your shares of record, you may vote via the Internet or, if you requested a paper copy of the proxy card by mail, by completing, signing, dating, and mailing the
proxy card to us in the return envelope that will be provided for your use, which requires no postage if mailed in the United States. If you attend the annual meeting and vote your shares in person at the meeting, your proxy will not be used.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">If you hold your shares beneficially, then your shares are held in &#147;street name&#148; by a bank or brokerage firm. Your bank or
brokerage firm, as the record holder of your shares, is required to vote your shares according to your instructions. To vote your shares, you will need to follow the directions your bank or brokerage firm provides you. Many banks and brokerage firms
also offer the option of voting over the Internet or by telephone, instructions for which would be provided by your bank or brokerage firm on your vote instruction form. If you do not give your bank or broker instructions as to how to vote on the
proposals described in this Proxy Statement, your bank or broker may be entitled to use its discretion in voting your shares in accordance with industry practice, except as otherwise described in this Proxy Statement. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>If my shares are held in street name, can I attend the annual meeting? </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">If your shares are held in &#147;street name,&#148; you also are invited to attend the annual meeting. However, you must bring an account statement or letter from your brokerage firm or bank showing that you are the
beneficial owner of the shares as of the record date in order to be admitted to the annual meeting on June&nbsp;25, 2009. In addition, since you are not the stockholder of record, you may not vote your shares in person at the meeting unless you
request and obtain a valid paper copy of the proxy card from the stockholder of record. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>How do I vote if I received two or more Notices?
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">If you receive two or more Notices, this means that you hold our shares in multiple accounts at the transfer agent or with the brokers
or other custodians of your shares; in this case, please vote with respect to each Notice in accordance with the procedures described therein to complete your representation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B>If I am stockholder of record, how do I revoke my proxy? </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">If you are a stockholder of record, you
may revoke your proxy at any time before it is actually voted at the meeting by: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">delivering written notice of revocation to our Secretary at 8001 Arista Place, Suite 200, Broomfield, CO 80021; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">submitting a later dated proxy card; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">attending the meeting and voting in person. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Can I vote my shares by filling out and returning the Notice regarding the availability of proxy materials on the
Internet? </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">No. The Notice contains instructions on how to vote via the Internet, by requesting a paper proxy card, or by submitting a
ballot in person at the annual meeting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>What vote is required for each Proposal? </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><I>Proposal&nbsp;1:&nbsp;&nbsp;&nbsp;&nbsp;Election of Board of Directors </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Directors will be elected by
a plurality of the votes cast for the election of directors, which means that abstentions and broker non-votes will not affect the election of the candidates receiving the plurality of votes. Accordingly, the directorships to be filled at the annual
meeting will be filled by the nominees receiving the highest number of votes. In the election of directors, by checking the appropriate box on your proxy card, you may cast your votes in favor of, or withhold your votes with respect to, some or all
nominees. Votes that are withheld will be excluded entirely from the vote on Proposal&nbsp;1 and will have no effect on the outcome of the vote. If you hold your shares through a broker and you do not instruct the broker on how to vote on
Proposal&nbsp;1, your broker will have authority to vote your shares on Proposal 1. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>Proposal&nbsp;2:&nbsp;&nbsp;&nbsp;&nbsp;Amendment and Restatement
of the Nuvelo, Inc. 2004 Equity Incentive Plan as the Amended and Restated ARCA biopharma, Inc. 2004 Equity Incentive Plan </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The
affirmative vote of a majority of the shares present in person or represented by proxy and entitled to vote on Proposal&nbsp;2 is required for approval of Proposal 2. Abstentions will be counted towards the vote total for Proposal&nbsp;2, and will
have the same effect as an &#147;Against&#148; vote. If you hold your shares through a broker and you do not instruct the broker on how to vote on Proposal&nbsp;2, your broker will <I>not</I> have authority to vote your shares on Proposal&nbsp;2.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>Proposal 3:&nbsp;&nbsp;&nbsp;&nbsp;Ratification of Selection of Independent Registered Public Accounting Firm </I></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The affirmative vote of a majority of the shares present in person or represented by proxy and entitled to vote on Proposal 3 is required for approval of
Proposal 3. Abstentions will be counted towards the vote total for Proposal 3, and will have the same effect as an &#147;Against&#148; vote. If you hold your shares through a broker and you do not instruct the broker on how to vote on Proposal 3,
your broker <I>will</I> have authority to vote your shares on Proposal 3. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Where can I find the voting results? </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We will report the voting results in our quarterly report on Form 10-Q for the second quarter of 2009. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Voting Intentions of our Executive Officers and Directors; Recommendations of Our Directors </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Our current executive officers and directors have informed us that they intend to vote, or cause to be voted, all shares of common stock held by them at
the close of business on April&nbsp;29, 2009 for each of the nominees for director and for Proposals 2 and 3. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Our Directors
recommend that stockholders vote &#147;FOR&#148; each of the nominees for director and for Proposals 2 and 3. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>PROPOSAL 1: </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>ELECTION OF BOARD OF DIRECTORS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>General Information </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Our Amended and Restated Certificate of Incorporation, as amended, provides that the Board of Directors is divided into three classes to provide for
staggered terms and that each director will serve for a term of three years or less, depending on the class to which the Board of Directors has assigned a director not previously elected by the stockholders. There are currently three Class I
directors, whose terms expire at the annual stockholders&#146; meeting in 2010, and three Class II directors, whose terms expire at the annual stockholders&#146; meeting in 2011. The Board of Directors has nominated four Class III directors,
Dr.&nbsp;Ted&nbsp;W. Love, Dr.&nbsp;Burton&nbsp;E. Sobel, Dr.&nbsp;J.&nbsp;William Freytag, and Dr.&nbsp;Jean-Fran&ccedil;ois Formela, for election to the Board of Directors, each for a three-year term ending on the date of the annual meeting in
2012 or until a successor is duly elected and qualified or appointed. There are no vacancies in the current Board of Directors. We encourage our Board members to attend each annual meeting of stockholders. All of the members of the Board of
Directors then serving as of the date of our last annual meeting attended our 2008 annual meeting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Each nominee for director has consented
to being named in this Proxy Statement and has indicated his willingness to serve if elected. Unless your vote is withheld, proxies received by us will be voted for the nominees. Proxies cannot be voted for more than four persons. Although we do not
anticipate that any nominee will be unavailable for election, if a nominee is unavailable for election, we will vote the proxies for any substitute nominee we may designate. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Each nominee for election to the Board of Directors currently serves as one of our directors and has continually served as a director since the date such
person initially became a director, which is set forth below. Dr.&nbsp;Love and Dr.&nbsp;Sobel have previously been elected by our stockholders, Dr.&nbsp;Freytag and Dr.&nbsp;Formela formerly served as directors of ARCA Colorado prior to the
Company&#146;s merger involving ARCA Colorado in January 2009. In 2008, our Board of Directors met nine times and acted by written consent three times. Each director attended 75% or more of the total meetings of the Board of Directors held during
2008. Each director who was a member of the Compensation Committee attended 75% or more of the three meetings of that Committee of the Board of Directors that occurred during 2008, with the exception of Dr.&nbsp;Gavin who was absent from one
meeting. Each director who was a member of the Nominating and Corporate Governance Committee of the Board of Directors attended 75% or more of the meetings of that Committee of the Board of Directors that occurred during 2008, with the exception of
Ms.&nbsp;Popovits who was absent from one meeting. Each director who was a member of the Audit Committee attended 75% or more of the meetings of that Committee of the Board of Directors that occurred during 2008. The following table sets forth
information as of April&nbsp;29, 2009 with respect to our directors, including the four persons nominated for election at the meeting. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:101pt"><FONT FACE="Times New Roman" SIZE="1"><B>Name of Nominee or Director</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Age</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:27pt"><FONT FACE="Times New Roman" SIZE="1"><B>Position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Director<BR>Since</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Michael R. Bristow, M.D., Ph.D.</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>&#134;</SUP></FONT><FONT FACE="Times New Roman" SIZE="2">
</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">64</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Chairman of the Board</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2009</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Richard B. Brewer</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>&#134;</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">58</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2009</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Jean-Fran&ccedil;ois Formela, M.D.(3)</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>&#134;</SUP></FONT><FONT FACE="Times New Roman"
SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">52</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2009</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">J. William Freytag, Ph.D.(3)</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>&#134;</SUP></FONT><FONT FACE="Times New Roman"
SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">57</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2009</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Linda Grais, M.D.(1)(3)</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>&#134;</SUP></FONT><FONT FACE="Times New Roman"
SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">52</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2009</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Ted W. Love, M.D.*</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">50</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2001</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">David G. Lowe, Ph.D.(1)</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>&#134;</SUP></FONT><FONT FACE="Times New Roman"
SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">52</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2009</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Mary K. Pendergast(1)(2)*</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">58</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2002</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Burton E. Sobel, M.D.(2)*</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">71</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2004</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">John L. Zabriskie, Ph.D.(2)</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>&#134;</SUP></FONT><FONT FACE="Times New Roman"
SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">69</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2009</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Each of the directors so indicated served as a director of Nuvelo. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; padding-bottom:8px; margin-top:-2px" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"> <P STYLE="line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>&#134;</SUP></FONT><FONT FACE="Times New Roman"
SIZE="2"></FONT></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="line-height:95%; vertical-align:top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Each of the directors indicated served as a director of ARCA Colorado prior to the January&nbsp;27, 2009 merger.
</FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Member of Nominating and Corporate Governance Committee. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Member of Audit Committee. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Member of Compensation Committee. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The following
information, which has been provided by our directors and director nominees, sets forth such person&#146;s principal occupation, employment, and business experience during at least the past five years, and the period during which such person has
served as a director of the Company: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Nominees for Election to the Board of Directors for a Three-Year Term Ending in 2012 </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Jean-Fran&ccedil;ois Formela, M.D.</I> Dr.&nbsp;Formela has served as a member of Company&#146;s Board of Directors since our merger with ARCA
Colorado. Before the merger, Dr.&nbsp;Formela had served as a director of ARCA Colorado since February 2006. Dr.&nbsp;Formela is a Partner of and joined Atlas Venture in 1993 to help build the US Life Sciences franchise. Previously, he was Senior
Director, Medical Marketing and Scientific Affairs at Schering-Plough in the U.S. During his tenure there, he was responsible for the marketing of Intron A, Schering-Plough&#146;s alpha-interferon. In his last position at Schering-Plough,
Dr.&nbsp;Formela directed the US Phase IV studies in all therapeutic areas, as well as the health economics, medical information, and biotechnology pre-marketing groups. As a medical doctor, Dr.&nbsp;Formela practiced emergency medicine at Necker
University Hospital in Paris. Since joining Atlas Venture, Dr.&nbsp;Formela has been involved in the formation of companies such as Archemix, ArQule, Aureon Laboratories, Cellzome, deCODE, Exelixis, MorphoSys, NxStage, Resolvyx Pharmaceuticals, and
SGX Pharmaceuticals. He was also an investor in Ciphergen Biosystems and ARCA. Dr.&nbsp;Formela received his M.D. from Paris University School of Medicine, and his M.B.A. from Columbia University. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>J. William Freytag, Ph.D.</I> Dr.&nbsp;Freytag has served as a member of the Company&#146;s Board of Directors since our merger with ARCA Colorado.
Before the merger, Dr. Freytag had served as a director of ARCA Colorado since March 2007. Dr.&nbsp;Freytag is President and Chief Executive Officer of Barofold, Inc., a private, venture-financed biotherapeutics company located in Boulder, Colorado.
Prior to Barofold, Dr.&nbsp;Freytag was Chairman and Chief Executive Officer of Aspreva Pharmaceuticals from July 2007 until its merger with Galenica AG in January 2008. Prior to Aspreva, Dr.&nbsp;Freytag was President, Chief Executive Officer and
Chairman of the Board of Directors of Myogen, Inc. from July 1998 until Myogen was acquired by Gilead Sciences in November 2006. From November 2006 through June 2007 Dr.&nbsp;Freytag served as Senior Advisor to Gilead. From October 1994 to May 1998,
Dr.&nbsp;Freytag was a Senior Vice President at Somatogen, Inc. Prior to Somatogen, he was President of Research and Development at Boehringer Mannheim Corporation, an international healthcare company, from May 1990 to September 1994. Previously,
Dr.&nbsp;Freytag spent ten years with DuPont in various research and business positions in the Medical Products Department. Dr.&nbsp;Freytag currently serves as a Director for four heathcare companies: BaroFold, Inc., GlobeImmune, Inc., Sierra
Neuropharmaceutials, Inc., and BiOptix LLC. Dr.&nbsp;Freytag is also a member of the Advisory Council for the Bard Center for Entrepreneurship, University of Colorado Denver Business School. Dr.&nbsp;Freytag received a B.S. from Purdue University
and a Ph.D. in biochemistry from the University of Kansas Medical Center. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Ted W. Love, M.D.</I> Dr.&nbsp;Love has served as a member of
the Company&#146;s Board of Directors since February 2001. Before the Company&#146;s merger with ARCA Colorado, Dr.&nbsp;Love had served as Nuvelo&#146;s President since January 2001, as its Chief Executive Officer since March 2001, and as Chairman
of its Board of Directors since September 2005. Dr.&nbsp;Love served as Nuvelo&#146;s President and Chief Operating Officer from January 2001 until March 2001. Prior to joining Nuvelo, Dr.&nbsp;Love served as Senior Vice President of Development at
Theravance Inc. from 1998 to 2001 and as a research physician and Vice President of Product Development at Genentech from 1992 to 1998. Dr.&nbsp;Love also serves as a member of the Board of Directors of Santarus, Inc. and Affymax, Inc. Dr.&nbsp;Love
holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Burton E. Sobel, M.D.</I> Dr.&nbsp;Sobel
has served as a member of the Company&#146;s Board of Directors since September 2004. Since June 2005, Dr.&nbsp;Sobel has served as Professor of Medicine and Biochemistry at the University of Vermont and Fletcher Allen Health Care, where he formerly
served as Chair of the Department of Medicine from 1994 to June 2005. Dr.&nbsp;Sobel served as Senior Counsel to the Executive Dean of the University of </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">Vermont College of Medicine and to the Executive Vice President of Fletcher Allen Health Care from 1996 to 1998. From 1994 to 1996, Dr.&nbsp;Sobel served as
Professor of Medicine at Washington University in St. Louis, Missouri. Dr.&nbsp;Sobel serves as a member of the Board of Directors of Ariad Pharmaceuticals, Inc. and Clinical Data, Inc. Dr.&nbsp;Sobel received his M.D. from the Harvard Medical
School, magna cum laude, and his A.B. from Cornell University. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Directors Continuing in Office until the Annual Meeting of Stockholders in 2011 </B>
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Richard B. Brewer</I>. Mr.&nbsp;Brewer has served as the Company&#146;s President and Chief Executive Officer and a director since our
merger with ARCA Colorado. Mr.&nbsp;Brewer has also served as the President and Chief Executive Officer and a director of ARCA Colorado since November 2006. Prior to joining ARCA Colorado, from January 2003, Mr.&nbsp;Brewer was Managing Partner of
Crest Asset Management, where he provided guidance to and invested in biotechnology opportunities. Before that, Mr.&nbsp;Brewer was President and Chief Executive Officer of Scios, Inc. Before Scios, Mr.&nbsp;Brewer served as Chief Operating Officer
of Heartport, a cardiovascular device company developing minimally invasive approaches to major heart surgery. Prior to that, he spent over a decade at Genentech in various management positions, including Senior Vice President of Sales and Marketing
and Senior Vice President of Genentech Europe and Canada. Mr.&nbsp;Brewer holds a B.S. from Virginia Polytechnic Institute and an M.B.A. from Northwestern University. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2"><I>Michael R. Bristow, M.D., Ph.D.</I> Dr.&nbsp;Bristow has served as the Company&#146;s Chief Science and Medical Officer and a director since our merger with ARCA Colorado. Mr.&nbsp;Brewer has also served as a
director of ARCA Colorado since November 2006. Dr.&nbsp;Bristow was one of the founders of ARCA Colorado in September 2004, and served as its Chairman and Chief Executive Officer from that date until he was appointed to the position of Chief Science
and Medical Officer in November 2006. Dr.&nbsp;Bristow is a Professor of Medicine and the former Head of Cardiology at the University of Colorado Health Sciences Center, where he has been since October 1991. Dr.&nbsp;Bristow was one of the founders
of Myogen, Inc. and served as Myogen&#146;s Chief Science and Medical Officer from October 1996 to February 2006 and as a Scientific Advisor to Myogen from February 2006 until the acquisition of Myogen by Gilead Sciences, Inc. in November 2006.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Mary K. Pendergast</I>. Ms.&nbsp;Pendergast has served as a member of the Company&#146;s Board of Directors since May 2002. Since
September 2003, Ms.&nbsp;Pendergast has been president of Pendergast Consulting. Ms.&nbsp;Pendergast served as Executive Vice President, Government Affairs for Elan Corporation from 1998 to December 2003. Ms.&nbsp;Pendergast was Deputy Commissioner
and Senior Advisor to the Commissioner, Food and Drug Administration, Department of Health and Human Services from 1990 to 1998. Ms.&nbsp;Pendergast received her LL.M. from Yale Law School in 1977, her J.D. from the University of Iowa College of Law
in 1976, and her B.A. from Northwestern University in 1972. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Directors Continuing in Office until the Annual Meeting of Stockholders in 2010
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Linda Grais, M.D.</I> Dr.&nbsp;Grais has served as a member of the Company&#146;s Board of Directors since our merger with ARCA
Colorado. Before the merger, Dr.&nbsp;Grais had served as a director of ARCA Colorado since May 2007. Dr.&nbsp;Grais is currently a partner at InterWest, where she has been since May 2005. From July 1998 to July 2003, Dr.&nbsp;Grais was a founder
and executive vice president of SGX Pharmaceuticals Inc., a drug discovery company focusing on new treatments for cancer. Prior to that, she was a corporate attorney at Wilson Sonsini Goodrich&nbsp;&amp; Rosati, where she practiced in such areas as
venture financings, public offerings and strategic partnerships. Before practicing law, Dr.&nbsp;Grais worked as an assistant clinical professor of Internal Medicine and Critical Care at the University of California, San Francisco. Dr.&nbsp;Grais
received a B.A. from Yale University, magna cum laude, and Phi Beta Kappa, an M.D. from Yale Medical School and a J.D. from Stanford Law School. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2"><I>David G. Lowe, Ph.D.</I> Dr.&nbsp;Lowe has served as a member of the Company&#146;s Board of Directors since our merger with ARCA Colorado. Before the merger, Dr.&nbsp;Lowe had served as a director of ARCA Colorado since May 2007.
Dr.&nbsp;Lowe is a Managing Director of and joined Skyline Ventures in June 2002. Dr.&nbsp;Lowe is a </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">molecular biologist and was Director of Cardiovascular Research at Genentech, Inc., where he worked for 16 years until November 2001. Dr.&nbsp;Lowe also
serves as a director of Applied Genetic Technologies Corp. Dr.&nbsp;Lowe holds a Ph.D. in biochemistry from the University of Toronto, Canada. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2"><I>John L. Zabriskie, Ph.D.</I> Dr.&nbsp;Zabriskie has served as a member of the Company&#146;s Board of Directors since our merger with ARCA Colorado. Before the merger, Dr.&nbsp;Zabriskie had served as a director of ARCA Colorado since
March 2005. Dr.&nbsp;Zabriskie is Co-Founder and Director of Puretech Ventures, LLC, and the past Chairman of the Board, Chief Executive Officer, and President of NEN Life Science Products, Inc., a supplier of kits for labeling and detection of DNA.
Prior to joining NEN Life Science Products in July 1997, Dr.&nbsp;Zabriskie was President and Chief Executive Officer of Pharmacia and Upjohn Inc. Prior to joining Upjohn in 1994, Dr.&nbsp;Zabriskie was Executive Vice President for Merck&nbsp;&amp;
Co., Inc. He currently serves on the Board of Directors of Array BioPharma Inc., Harlan, Inc., Kellogg Co., Protein Forest Inc. and Puretech Ventures. Dr.&nbsp;Zabriskie received his undergraduate degree in chemistry from Dartmouth College and his
Ph.D. in organic chemistry from the University of Rochester. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Director Compensation </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The following table sets forth the compensation earned by or awarded to the Company&#146;s non-employee directors during the fiscal year ended
December&nbsp;31, 2008. The compensation earned by Dr.&nbsp;Love is excluded from the table because he was also an executive officer of the Company in 2008, and his compensation is set forth below, under the heading titled, &#147;Executive
Compensation,&#148; under the subsection titled, &#147;Summary Compensation Table&#148;: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT FACE="Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Fees<BR>Earned<BR>or Paid<BR>in&nbsp;Cash<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Stock<BR>Awards<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Option<BR>Awards<BR>($)(1)(2)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Non-Equity<BR>Incentive Plan<BR>Compensation<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Change in<BR>Pension Value<BR>and<BR>Nonqualified<BR>Deferred<BR>Compensation<BR>Earnings</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>All Other<BR>Compensation<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Total<BR>($)</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">James R. Gavin III, M.D., Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">25,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8,214</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">33,214</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Mary K. Pendergast</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">40,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8,214</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">48,214</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Mark L. Perry</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">45,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8,214</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">53,214</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Kimberly Popovits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">35,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10,952</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">45,952</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Burton E. Sobel, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">35,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8,214</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">43,214</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Amounts reflect both grant date fair value and stock-based compensation expense recognized for financial statement reporting purposes for the year ended December&nbsp;31, 2008, in
accordance with Statement of Financial Accounting Standards No.&nbsp;123 (revised 2004), <I>Share-Based Payment </I>(SFAS 123R), and include amounts attributable to awards granted in 2008. These options were fully vested on the date of grant, and
therefore, the grant date fair value was fully recognized as stock-based compensation in 2008. Amounts shown above exclude the impact of estimated forfeitures related to service-based vesting conditions. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">As of December&nbsp;31, 2008, the aforementioned directors held options to purchase the following number of shares of the Company&#146;s common stock: Dr.&nbsp;Gavin, 2,750;
Ms.&nbsp;Pendergast, 4,957; Mr.&nbsp;Perry, 1,500; Ms.&nbsp;Popovits, 3,750 and Dr.&nbsp;Sobel, 2,875. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Annual Cash
Retainer Fees </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Prior to the closing on January&nbsp;27, 2009 of the merger with ARCA Colorado, each non-employee director of the
Company was entitled to an annual retainer fee of $20,000. The Audit Committee chair was entitled to receive an additional $20,000 for service as the Audit Committee chair. If a non-employee director served as the chair of any other Committee, that
director was entitled to receive an additional $10,000 per chair. Each of the members of the Audit Committee, other than the chair, was entitled to receive an additional $10,000 for his or her service on the Audit Committee. For membership on any
other Committee, except for the chair of such Committee, a non-employee director was entitled to receive an additional $5,000. Board members were not </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">entitled to receive any other cash compensation for their Board service. If a Board member were to resign or assume additional Board responsibilities within
a year, the Board member&#146;s cash compensation would be adjusted the next quarter to reflect the change. Finally, each director had option to convert the previously mentioned retainer fees into deferred stock units, in accordance with the terms
of a deferred stock unit plan pursuant to the Option Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Annual Stock Option Grants </I></B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On the date of the 2008 annual meeting of the stockholders, Ms.&nbsp;Pendergast and Dr.&nbsp;Sobel each received a fully vested option to purchase 750
shares of the Company&#146;s common stock under the Option Plan. The purchase price for these options was $14.60, which was equal to the average of the high and the low price for the Company&#146;s common stock on the date of the Company&#146;s 2008
annual meeting of stockholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Changes to Directors Compensation Following the Merger </I></B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Nominating and Corporate Governance Committee of the Board of Directors, in accordance with its Charter, is responsible for periodically making
recommendations to the Board with respect to the compensation of Board members. The Committee performed an evaluation of Board member compensation following the January&nbsp;27, 2009 merger, and recommended to the Board that the following changes be
made to Board member compensation, which recommendation was accepted by the Board: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Each non-employee director is entitled to an annual retainer fee of $30,000; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">As additional compensation for their services, each non-employee director is entitled to an initial grant of options to purchase 7,500 shares of the Company&#146;s
common stock under the Option Plan and an annual grant of an additional 3,500 shares of the Company&#146;s common stock under the Option Plan; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The Audit Committee chair is entitled to receive an additional $15,000 for service as the Audit Committee chair; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">If a non-employee director serves as the chair of any other Committee, that director is entitled to receive an additional $10,000 per chair;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Each of the members of the Audit Committee, other than the chair, is entitled to receive an additional $5,000 for his or her service on the Audit Committee;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">For membership on any other Committee, except for the chair of such Committee, a non-employee director is entitled to receive an additional $5,000; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The director designated as the Lead Independent Director is entitled to an annual fee of $10,000. </FONT></P></TD></TR></TABLE> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On February&nbsp;27, 2009, Dr.&nbsp;Formela, Dr.&nbsp;Freytag, Dr.&nbsp;Love, Ms.&nbsp;Pendergast, Dr.&nbsp;Sobel, Dr.&nbsp;Zabriskie, Dr.&nbsp;Lowe and
Dr.&nbsp;Grais each received options to purchase 7,500 shares of the Company&#146;s common stock under the Option Plan. The purchase price for these options was $5.29, which was equal to the closing price of the Company&#146;s common stock on the
date of the grant on the Nasdaq Global Market (&#147;Nasdaq&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Board Independence and Corporate Governance </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Board of Directors has reviewed the relationships between each member of the Board of Directors, their immediate family members and affiliates, and
the Company. Accordingly, the Board has determined that each of Dr.&nbsp;Formela, Dr.&nbsp;Freytag, Dr.&nbsp;Grais, Dr.&nbsp;Lowe, Ms.&nbsp;Pendergast, Dr.&nbsp;Sobel and Dr.&nbsp;Zabriskie, which individuals constitute greater than a majority of
the Board of Directors, qualify as &#147;independent&#148; directors in accordance with the listing standards of Nasdaq. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">As part of its service, the Board of Directors strives to regularly evaluate the Company&#146;s corporate
governance policies and to compare those policies to standards established by current rules and regulations of various governmental authorities, other public companies, and recommendations of other corporate governance groups and authorities. In
2007, the Board adopted an amended and restated Code of Business Conduct and Ethics that applies to all of the Company&#146;s directors, officers, and employees, and establishes the Company&#146;s expectations for its consultants, contractors,
representatives, and agents in connection with its process of self-evaluation. As part of its ongoing evaluation process, the Board of Directors will continue to monitor best corporate governance practices. Based upon this process, the Board may
from time to time adopt additional policies or procedures to comply with new laws and legislation and any changes to rules made by the SEC and Nasdaq. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">The Company&#146;s Corporate Governance Guidelines, Committee charters, and Code of Business Conduct and Ethics are located on the Company&#146;s website at <U>www.arcabiopharma.com</U> in the section titled,
&#147;Investors,&#148; under the subsection titled, &#147;Corporate Governance.&#148; If the Company makes any substantive amendments to the Code of Business Conduct and Ethics or grants any waiver from a provision of the Code of Business Conduct
and Ethics to any executive officer or director, the Company will promptly disclose the nature of the amendment or waiver on its website and file any current report on Form 8-K required by applicable law or Nasdaq listing standards. Information
found on our website is not incorporated by reference into this Proxy Statement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Committees of the Board of Directors </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Our Board of Directors has three standing Committees: the Compensation Committee, the Audit Committee, and the Nominating and Corporate Governance
Committee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Compensation Committee </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">In January 2009, the Board of Directors adopted a revised committee charter for the Company&#146;s Compensation Committee. That revised charter states that Compensation Committee: </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">oversees succession planning for senior management of the Company, including a review of the performance and advancement potential of current and future senior
management and succession plans for each and recommends, as appropriate, the retention of potential succession candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">assesses the overall compensation structure of the Company and evaluates and recommends changes to the Company&#146;s compensation philosophies and strategies;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">reviews and approves performance-based compensation plans or programs, including establishing goals and targets, applicable to the Chief Executive Officer and other
members of the management team; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">evaluates the performance of the Chief Executive Officer in light of Company and individual goals and objectives, and makes appropriate recommendations for
improving performance; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">reviews the results of performance reviews of other executive officers conducted by the Chief Executive Officer and makes appropriate recommendations for improving
performance; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">reviews and approves the compensation of the Chief Executive Officer and the other executive officers of the Company, including annual base salaries, annual and
long-term incentive or bonus awards, employment agreements, and severance and change in control agreements/provisions, in each case as, when and if appropriate, and any special or supplemental benefit; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">if the compensation for the Chief Executive Officer or any other executive officer is governed by an employment agreement, approves such employment agreement and
any amendments thereto; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">10 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">administers, reviews, and approves all executive compensation programs or plans, and all of the Company&#146;s incentive compensation and stock plans and awards
thereunder of the Company, including amendments to the programs, plans or awards made thereunder; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">administers the Option Plan and the Company&#146;s Employee Stock Purchase Plan, as well as other equity and incentive compensation plans;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">approves, amends, and terminates ERISA-governed employee benefit plans; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">prepares and discusses with the Company&#146;s management the Compensation Discussion and Analysis, or the CD&amp;A, if required to be included in the
Company&#146;s annual meeting proxy statement and recommends to the Board that the CD&amp;A be included in the annual meeting proxy statement, to the extent required; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">prepares and approves the Report of the Compensation Committee to be included as part of the Company&#146;s annual meeting proxy statement, to the extent required;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">periodically reviews and reassesses the Compensation Committee&#146;s Charter and recommends any changes to the Board for its consideration and approval;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">periodically evaluates the effectiveness of the Committee; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">performs such other functions as may from time to time be delegated by the Board. </FONT></P></TD></TR></TABLE> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Under its charter, the Compensation Committee may form, and delegate authority to, subcommittees, as appropriate, to enhance the flexibility of option
administration within the Company and to facilitate the timely grant of options to non-management employees. The Company&#146;s Compensation Committee Charter is located on the Company&#146;s website at <U>www.arcabiopharma.com</U> in the section
titled, &#147;Investors,&#148; under the subsection titled, &#147;Corporate Governance.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Dr.&nbsp;Freytag, as the chairperson,
Dr.&nbsp;Grais, and Dr.&nbsp;Formela presently serve on the Compensation Committee. Prior to the Company&#146;s merger with ARCA Colorado, Ms.&nbsp;Popovits, as the chairperson, Dr.&nbsp;Gavin, and Mr.&nbsp;Perry served as members of the
Compensation Committee throughout the 2008 calendar year. Dr.&nbsp;Freytag, Dr.&nbsp;Grais, and Dr.&nbsp;Formela all have extensive experience in executive management in the biotechnology industry, including experience with compensation practices
and policies. The current members of the Compensation Committee are all &#147;independent&#148; (as independence is defined by the Nasdaq listing standards). The Compensation Committee met three times during 2008, and met often in executive session.
Mr.&nbsp;Perry attended three, Ms.&nbsp;Popovits attended three, and Dr.&nbsp;Gavin attended two of the Compensation Committee meetings held during 2008. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT
FACE="Times New Roman" SIZE="2"><B><I>Audit Committee </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Our Audit Committee reviews our annual audit and meets with our independent
registered public accounting firm and management to review our corporate accounting, our financial reporting process, and our systems of internal accounting and financial controls. The functions of the Audit Committee include selecting, evaluating,
and where necessary, replacing the independent registered public accounting firm retained by the Company; consulting with our independent registered public accounting firm regarding their audit, their opinion, and the Company&#146;s Forms 10-Q and
10-K; approving the audit and non-audit services of our independent registered public accounting firm and the terms of their engagement; meeting with our management; reviewing both the independent registered public accounting firm and management
reports; recommending changes in financial policies and procedures that may be suggested by our independent registered public accounting firm; and preparing the Audit Committee report included in our Proxy Statement. Our Board has adopted a written
charter for the Audit Committee, which is located on the Company&#146;s website at <U>www.arcabiopharma.com</U> in the section titled, &#147;Investors&#148; under the subsection titled, &#147;Corporate Governance.&#148; </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">11 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Dr.&nbsp;Zabriskie, as the chairperson, Ms.&nbsp;Pendergast and Dr.&nbsp;Sobel presently serve on the
Audit Committee. Prior to the Company&#146;s merger with ARCA Colorado, Mr.&nbsp;Perry, as the chairperson, Ms.&nbsp;Pendergast, and Dr.&nbsp;Sobel served on the Audit Committee for 2008. The Audit Committee met six times during 2008, and each
member attended 75% or more of the six meetings. The Board has determined that all three current Audit Committee members are &#147;independent&#148; directors, as determined in accordance with Rule 10A-3(b)(1) of the Exchange Act and the Nasdaq
listing standards. The Board has determined that Dr.&nbsp;Zabriskie is an &#147;audit committee financial expert&#148; as defined in Item&nbsp;401(h) of Regulation S-K. The report of our Audit Committee is included on page 50 of this Proxy
Statement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Nominating and Corporate Governance Committee </I></B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Our Nominating and Corporate Governance Committee, in accordance with its Charter, considers the qualifications of, proposes, and recommends individuals
for Board membership and senior management positions. Other duties and responsibilities of the Nominating and Corporate Governance Committee include making recommendations to the Board regarding the Company&#146;s corporate governance policies,
business conduct, and ethics; evaluating the size and composition of the Board and its Committees; and reviewing the annual performance of the Board. The Company&#146;s Nominating and Corporate Governance Committee Charter is accessible on the
Company&#146;s website at <U>www.arcabiopharma.com</U>, in the section titled, &#147;Investors,&#148; under the subsection titled, &#147;Corporate Governance.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Ms.&nbsp;Pendergast, as the chairperson, Dr.&nbsp;Grais, and Dr.&nbsp;Lowe presently serve on the Nominating and Corporate Governance Committee. Prior to our merger with ARCA Colorado, Ms.&nbsp;Pendergast, as the
chairperson, Ms.&nbsp;Popovits, and Dr.&nbsp;Sobel served on the Committee throughout the 2008 calendar year. Each Nominating and Corporate Governance Committee member attended each of the three meetings of the Nominating and Corporate Governance
Committee held during 2008 with the exception of Ms. Popovits, who was absent from one meeting. The Board has determined that Ms.&nbsp;Pendergast, Dr.&nbsp;Grais, and Dr.&nbsp;Lowe are &#147;independent&#148; members of the Nominating and Corporate
Governance Committee (as independence is defined in the Nasdaq listing standards). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Board has adopted a process for identifying and
evaluating director nominees, including stockholder nominees. Before recommending an individual to the Board for Board membership, the Nominating and Corporate Governance Committee canvasses its members and the Company&#146;s management team for
potential members of the Board of Directors. The Nominating and Corporate Governance Committee will consider stockholders&#146; recommendations for nominees to serve as director if notice is timely received by the Secretary of the Company.
Candidates nominated by stockholders will be evaluated in the same manner as other candidates. The Nominating and Corporate Governance Committee keeps the Board regularly apprised of its discussions with potential nominees, and the names of
potential nominees received from its current directors, management, and stockholders, if the stockholder notice of nomination is timely made. Although the Board has not adopted a fixed set of minimum qualifications for candidates for Board
membership, the Nominating and Corporate Governance Committee generally considers several factors in its evaluation of each potential member, such as the potential member&#146;s area of expertise, education, and professional background, experience
in corporate governance, the reasonable availability of the potential member to devote time to the affairs of the Company, as well as any other criteria deemed relevant by the Board or the Nominating and Corporate Governance Committee. After
determining that a potential candidate may be qualified, the Nominating and Corporate Governance Committee will make a further investigation and interview the candidate. The Nominating and Corporate Governance Committee will select, by majority
vote, the most qualified candidate or candidates, for recommendation to the Board for approval as a director nominee. Neither the Company nor the Nominating and Corporate Governance Committee paid any fees to any third party to identify Board
candidates during 2008 up through April&nbsp;30, 2009. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Stockholders who wish to recommend individuals for consideration by the Nominating
and Corporate Governance Committee to become nominees for election to the Board of Directors may do so by delivering a written recommendation to the Nominating and Corporate Governance Committee addressed to the Corporate </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">12 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">Secretary, at least 120 days before the anniversary date of our last Annual Meeting of Stockholders. Recommendations must include the full name of the
proposed nominee, a description of the proposed nominee&#146;s business experience for at least the previous five years, complete biographical information, a description of the proposed nominee&#146;s qualifications as a director, and a
representation that the recommending stockholder is a beneficial or record owner of our stock. Any such submission must be accompanied by the written consent of the proposed nominee to be named as a nominee and to serve as a director if elected. No
such recommendation of a nominee to the Nominating and Corporate Governance Committee shall be deemed to satisfy the nomination requirements set forth in our Bylaws. To date, the Nominating and Corporate Governance Committee has not rejected a
timely director nominee from a stockholder or stockholders holding more than 5% of our voting stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Stockholder Communications with the Board of
Directors </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We have adopted a formal process by which stockholders may communicate with our Board of Directors. This information is
available on our website at <U>www.arcabiopharma.com</U>, under the section titled, &#147;Investors,&#148; under the subsection titled, &#147;Corporate Governance.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B>Required Vote and Board of Directors Recommendation </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Directors will be elected by a plurality of the
votes cast for the election of directors. The four nominees receiving the most &#147;For&#148; votes (among votes properly cast either in person or by proxy) will be elected. If you hold your shares in your own name and abstain from voting on this
matter, your abstention will have no effect on the vote. If you hold your shares through a broker and you do not vote on this proposal, your broker will have authority to vote your shares on this proposal. Abstentions will be counted as present for
purposes of determining the presence of a quorum but will have no effect on the outcome of this proposal. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>THE BOARD OF DIRECTORS
RECOMMENDS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>A VOTE </B><B><I>FOR </I></B><B>THE DIRECTORS NOMINATED IN THIS PROPOSAL 1. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">13 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>PROPOSAL 2: </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>AMENDMENT AND RESTATEMENT OF THE NUVELO, INC. 2004 EQUITY INCENTIVE PLAN </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>AS THE AMENDED AND
RESTATED ARCA BIOPHARMA, INC. 2004 EQUITY INCENTIVE PLAN </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">At the annual meeting of stockholders, the Company&#146;s stockholders will
be asked to approve the amendment and restatement of the Nuvelo, Inc. 2004 Equity Incentive Plan (the &#147;Option Plan&#148;), which, if stockholders approve the amendment and restatement, will be called the Amended and Restated ARCA biopharma,
Inc. 2004 Equity Incentive Plan. The Option Plan was originally adopted effective as of May&nbsp;6, 2004, and replaced the Nuvelo, Inc. 2002 Equity Incentive Plan, Nuvelo, Inc. Director Stock Option Plan, Nuvelo, Inc. Scientific Advisory
Board/Consultants Stock Option Plan, Nuvelo, Inc. 1995 Stock Option Plan and the Variagenics 1997 Employee, Director&nbsp;&amp; Consultant Stock Option Plan (collectively the &#147;Prior Plans&#146;), was subsequently amended and restated as of
May&nbsp;24, 2006, and then was further amended as of May&nbsp;31, 2007. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Approval of this proposal would: </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(i) change the name of the Company as it appears in the Option Plan from &#147;Nuvelo, Inc.&#148; to &#147;ARCA biopharma, Inc.&#148; and change the name
of the Option Plan from the &#147;Amended and Restated Nuvelo, Inc. 2004 Equity Incentive Plan&#148; to the &#147;Amended and Restated ARCA biopharma, Inc. 2004 Equity Incentive Plan&#148;; </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(ii) increase the maximum number of shares issuable under the plan, revise the formula for determining the maximum number of shares issuable under the
plan and implement new share usage rules; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(iii) adjust the award limitations for stock options and stock appreciation rights;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Board of Directors believes that we must offer a competitive equity incentive program if we are to continue to successfully attract
and retain the best possible candidates for positions of responsibility. The Board of Directors expects that the Option Plan will continue to be an important factor in attracting, retaining, and rewarding the high caliber employees essential to our
success and in motivating these individuals to strive to enhance our growth and profitability. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On April 29, 2009, the Board of Directors
approved the amendment and restatement of the Option Plan, subject to stockholder approval. If stockholders do not approve the Option Plan at the Annual Meeting, the Option Plan as currently in effect will remain in full force and effect in
accordance with its existing terms, and the amendment and restatement of the plan will not take effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Summary of Provisions of Amendment and
Restatement </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The purpose of the amendment and restatement of the Option Plan is to make the following changes to the plan: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Name change.</I> If the stockholders approve the amendment and restatement of the Option Plan, the name of the Company as it appears in the Option
Plan will be changed from Nuvelo, Inc. to ARCA biopharma, Inc. and the name of the plan will be changed from the Amended and Restated Nuvelo, Inc. 2004 Equity Incentive Plan to the Amended and Restated ARCA biopharma, Inc. 2004 Equity Incentive
Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Revise Maximum Number of Shares Formula and Implement New Share Usage Rules</I>. If stockholders approve the amendment and
restatement, the provision in the Option Plan that reduces the maximum number of shares that may be issued under the plan by the number of shares subject to the Prior Plans at any time will be eliminated. Instead, the maximum number of shares that
may be issued will be equal to Nine Hundred Fifty Five Thousand Two Hundred Four (955,204) shares reduced by the number of shares subject to Prior Plans as of the date of the amendment and restatement. In addition, the amendment and restatement will
require that shares of stock covered by an award be counted as used as of the grant date. Any shares of stock that are subject to awards </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">14 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">of stock options will be counted against the maximum number of shares issuable under the Option Plan as one share for every one share subject to an award of
stock options. With respect to stock appreciation rights, the number of shares subject to an award will be counted against the aggregate number of shares available for issuance under the Option Plan regardless of the number of shares actually issued
to settle the stock appreciation right upon exercise. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Options and Stock Appreciation Rights Limitations</I>. Under the existing Option
Plan, subject to adjustments for changes in capital structure, no employee may be granted within any fiscal year of the Company one or more options or stock appreciation rights for more than thirty-seven thousand five hundred (37,500)&nbsp;shares of
stock, provided, however, that the Company can make an additional one-time grant to any newly-hired employee of an option or stock appreciation right for up to an additional twenty-five thousand (25,000)&nbsp;shares of stock. The amendment and
restatement of the Option Plan would increase the limit regarding the aggregate number of options and stock appreciation rights that may be granted in a fiscal year to one-hundred thousand (100,000)&nbsp;shares and increase the limitation for
additional one-time grants to any newly-hired employee to fifty thousand (50,000) shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Summary of the Option Plan </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Below is a summary of the principal provisions of the Option Plan, as amended and restated, which summary is qualified in its entirety by reference to
the full text of the Option Plan, as amended and restated, which has been filed with the SEC as Appendix A to this Proxy Statement and may be accessed from the SEC&#146;s homepage (www.sec.gov). Any stockholder that wishes to obtain a copy of the
actual plan document may do so by written request to: Secretary, ARCA biopharma, Inc., 8001 Arista Place, Suite 200, Broomfield, Colorado&nbsp;80021. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT
FACE="Times New Roman" SIZE="2"><B><I>General </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The purpose of the Option Plan is to advance the interests of the Company by
providing an incentive program that will enable the Company to attract and retain employees, consultants, and directors upon whose judgment, interest, and efforts the Company&#146;s success is dependent and to provide them with an equity interest in
the success of the Company in order to motivate superior performance. These incentives are provided through the grant of stock options (including indexed options), stock appreciation rights, restricted stock purchase rights, restricted stock
bonuses, restricted stock units, performance shares, performance units, and deferred stock units. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Authorized Shares
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">As of March&nbsp;31, 2009, a maximum of 584,526, reduced at any time by the number of shares subject to outstanding stock options
granted under the Prior Plans, of the authorized but unissued or reacquired shares of our common stock may be issued under the Option Plan. The Board of Directors has amended the Option Plan, subject to stockholder approval, to increase the maximum
number of shares that may be issued under the Option Plan to <B></B>955,204<B> </B>reduced by the number of shares subject to Prior Plans as of the date of the amendment and restatement. The actual number of awards which may be granted under the
Option Plan shall be reduced, at all times, by the number of stock options outstanding under the Prior Plans. As of March&nbsp;31, 2009, stock options to purchase 19,087 shares of our common stock were outstanding under our Prior Plans, and stock
options to purchase 375,897 shares and restricted stock units to receive 349 shares of our common stock were outstanding under the Option Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">Shares of stock covered by an award are counted as used as of the grant date. Any shares of stock that are subject to awards of stock options will be counted against the maximum number of shares issuable under the Option Plan as one share
for every one share subject to an award of stock options. With respect to stock appreciation rights, the number of shares subject to an award will be counted against the aggregate number of shares available for issuance under the Option Plan
regardless of the number of shares actually issued to settle the stock appreciation right upon exercise. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">15 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">No more than fifty thousand (50,000)&nbsp;shares of this Option Plan reserve may be issued upon the
exercise or settlement of any restricted stock purchase rights, restricted stock bonuses, restricted stock units, performance shares, and performance units. If any award granted under the Option Plan, or under the Prior Plans, expires, lapses, or
otherwise terminates for any reason without having been exercised or settled in full, or if shares subject to forfeiture or repurchase are forfeited or repurchased by the Company, any such shares that are reacquired or subject to such a terminated
award will again become available for issuance under the Option Plan. Upon any stock dividend, stock split, reverse stock split, recapitalization, or similar change in our capital structure, appropriate adjustments will be made to the shares subject
to the Option Plan, to the award grant limitations and to all outstanding awards. However, shares shall not become re-available for issuance under the Option Plan if they were (i)&nbsp;withheld or surrendered to satisfy tax withholding obligations,
(ii)&nbsp;surrendered in payment of stock option exercise prices (either by means of a cashless exercise, attestation or actual surrender of shares), or (iii)&nbsp;subject to the grant of a stock appreciation right which was not issued upon
settlement of the stock appreciation right. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Administration </I></B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Option Plan is administered by the Compensation Committee of the Board of Directors duly appointed to administer the Option Plan, or, in the absence
of such Committee, by the Board of Directors. In the case of awards intended to qualify for the performance-based compensation exemption under Section&nbsp;162(m) of the Code, administration must be by a compensation committee comprised solely of
two or more &#147;outside directors&#148; within the meaning of Section&nbsp;162(m). (For purposes of this summary, the term &#147;Committee&#148; will refer to either such duly appointed committee or the Board of Directors.) Subject to the
provisions of the Option Plan, the Committee determines in its discretion the persons to whom and the times at which awards are granted, the types and sizes of such awards, and all of their terms and conditions. The Committee may, subject to certain
limitations on the exercise of its discretion required by Section&nbsp;162(m), amend, cancel, renew, or grant a new award in substitution for, any award, waive any restrictions or conditions applicable to any award, and accelerate, continue, extend,
or defer the vesting of any award. However, the Option Plan forbids, without stockholder approval, the repricing of any outstanding stock option and/or stock appreciation right. In addition, the Option Plan forbids any restricted stock award from
being granted, or subsequently amended to provide, for (1)&nbsp;any acceleration of vesting for any reason other than upon a Change in Control or after a participant&#146;s death or disability, and (2)&nbsp;vesting of one hundred percent
(100%)&nbsp;of any such award prior to the passage of three years of service (unless the award will vest after satisfying specified performance measurements). The Option Plan provides, subject to certain limitations, for indemnification by the
Company of any director, officer, or employee against all reasonable expenses, including attorneys&#146; fees, incurred in connection with any legal action arising from such person&#146;s action or failure to act in administering the Option Plan.
The Committee will interpret the Option Plan and awards granted thereunder, and all determinations of the Committee will be final and binding on all persons having an interest in the Option Plan or any award. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Eligibility </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Awards may be
granted to employees, directors, and consultants of the Company or any present or future parent or subsidiary corporations of the Company. Incentive stock options may be granted only to employees who, as of the time of grant, are employees of the
Company or any parent or subsidiary corporation of the Company. As of March&nbsp;31, 2009, the Company had approximately 79 employees, including five executive officers, 17 consultants and eight non-employee directors, all of who would be eligible
under the Option Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Stock Options </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Each option granted under the Option Plan must be evidenced by a written agreement between the Company and the optionee specifying the number of shares subject to the option and the other terms and conditions of the
option, consistent with the requirements of the Option Plan. The exercise price of each option may not be less than the fair market value of a share of Common Stock on the date of grant. For the purpose of the Option Plan, </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">16 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">and this proposal, the term &#147;fair market value&#148; is defined by the Option Plan to mean, unless otherwise expressly determined by the Committee, the
average of the high and low price of a share of our common stock as reported on Nasdaq for any applicable date. Any incentive stock option granted to a person who at the time of grant owns stock possessing more than 10% of the total combined voting
power of all classes of stock of the Company or any parent or subsidiary corporation of the Company (a &#147;Ten Percent Stockholder&#148;) must have an exercise price equal to at least 110% of the fair market value of a share of Common Stock on the
date of grant. The exercise price of each indexed stock option, and the terms and adjustments which may be made to such an option, will be determined by the Committee in its sole discretion at the time of grant. On March&nbsp;31, 2009, the closing
price of the Company&#146;s common stock on Nasdaq was $5.02 per share. Subject to appropriate adjustment in the event of any change in the capital structure of the Company, no employee may be granted in any fiscal year of the Company options which
in the aggregate are for more than one hundred thousand (100,000)&nbsp;shares, provided however, that the Company may make an additional one-time grant to any newly-hired employee of a stock option for the purchase of up to an additional fifty
thousand (50,000)&nbsp;shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Option Plan provides that the option exercise price may be paid in cash, by check, or in cash
equivalent, by the assignment of the proceeds of a sale with respect to some or all of the shares being acquired upon the exercise of the option, to the extent legally permitted, by tender of shares of Common Stock owned by the optionee having a
fair market value not less than the exercise price, by such other lawful consideration as approved by the Committee, or by any combination of these. Nevertheless, the Committee may restrict the forms of payment permitted in connection with any
option grant. No option may be exercised unless the optionee has made adequate provision for federal, state, local, and foreign taxes, if any, relating to the exercise of the option, including, if permitted or required by the Company, through the
optionee&#146;s surrender of a portion of the option shares to the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Options will become vested and exercisable at such times or
upon such events and subject to such terms, conditions, performance criteria or restrictions as specified by the Committee. The maximum term of any option granted under the Option Plan is ten years, provided that an incentive stock option granted to
a Ten Percent Stockholder must have a term not exceeding five years. The Committee will specify in each written option agreement, and solely in its discretion, the period of post-termination exercise applicable to each option. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Generally, stock options are nontransferable by the optionee other than by will or by the laws of descent and distribution, and are exercisable during
the optionee&#146;s lifetime only by the optionee. However, a nonstatutory stock option may be assigned or transferred to the extent permitted by the Committee in its sole discretion. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Stock Appreciation Rights </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">Each stock appreciation right granted under the Option Plan must be evidenced by a written agreement between the Company and the participant specifying the number of shares subject to the award and the other terms and conditions of the
award, consistent with the requirements of the Option Plan. A stock appreciation right gives a participant the right to receive the appreciation in the fair market value of the Company&#146;s common stock between the date of grant of the award and
the date of its exercise. The Company may pay the appreciation either in cash or in shares of the Company&#146;s common stock. The Committee may grant stock appreciation rights under the Option Plan in tandem with a related stock option or as a
freestanding award. A tandem stock appreciation right is exercisable only at the time and to the same extent that the related option is exercisable, and its exercise causes the related option to be canceled. Freestanding stock appreciation rights
vest and become exercisable at the times and on the terms established by the Committee. The maximum term of any stock appreciation right granted under the Option Plan is ten years. Subject to appropriate adjustment in the event of any change in the
capital structure of the Company, no employee may be granted in any fiscal year of the Company stock options or stock appreciation rights which in the aggregate are for more than one hundred thousand (100,000)&nbsp;shares, provided however, that the
Company may make an additional one-time grant to any newly-hired employee of a stock appreciation right for the purchase of up to an additional fifty thousand (50,000)&nbsp;shares. Stock appreciation rights are generally nontransferable by the
participant other than by will or by the laws of descent and distribution, and are generally exercisable during the participant&#146;s lifetime only by the participant. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;
</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">17 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Restricted Stock Awards.</I>&nbsp;The Committee may grant restricted stock awards under the Option
Plan either in the form of a restricted stock purchase right, giving a participant an immediate right to purchase shares of the Company&#146;s common stock, or in the form of a restricted stock bonus, for which the participant furnishes
consideration in the form of services to the Company. The Committee determines the purchase price payable under restricted stock purchase awards, which may be less than the then current fair market value of the Company&#146;s common Stock.
Restricted stock awards may be subject to vesting conditions based on such service or performance criteria as the Committee specifies, and the shares acquired may not be transferred by the participant until vested. Unless otherwise provided by the
Committee, a participant will forfeit any shares of restricted stock as to which the restrictions have not lapsed prior to the participant&#146;s termination of service. Participants holding restricted stock will have the right to vote the shares
and to receive any dividends paid, except that dividends or other distributions paid will be subject to the same restrictions as the original award. Subject to appropriate adjustment in the event of any change in the capital structure of the
Company, no employee may be granted in any fiscal year of the Company more than twenty thousand (20,000)&nbsp;shares of restricted stock on which the restrictions are based on performance criteria, provided however, that the Company may make an
additional one-time grant to any newly-hired employee of a restricted stock award of up to an additional seven thousand five hundred&nbsp;(7,500) shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT
FACE="Times New Roman" SIZE="2"><B><I>Restricted Stock Units</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Committee may grant restricted stock units under the Option Plan
which represent a right to receive shares of the Company&#146;s common stock at a future date determined in accordance with the participant&#146;s award agreement. No monetary payment is required for receipt of restricted stock units or the shares
issued in settlement of the award, the consideration for which is furnished in the form of the participant&#146;s services to the Company. The Committee may grant restricted stock unit awards subject to the attainment of performance goals similar to
those described below in connection with performance shares and performance units, or may make the awards subject to vesting conditions similar to those applicable to restricted stock awards. Participants have no voting rights or rights to receive
cash dividends with respect to restricted stock unit awards until shares of the Company&#146;s common stock are issued in settlement of such awards. However, the Committee may grant restricted stock units that entitle their holders to receive
dividend equivalents, which are rights to receive additional restricted stock units for a number of shares whose value is equal to any cash dividends we pay. Subject to appropriate adjustment in the event of any change in the capital structure of
the Company, no employee may be granted in any fiscal year of the Company more than twenty thousand (20,000)&nbsp;shares of restricted stock based on restricted stock awards and restricted stock units on which the restrictions are based on
performance criteria, provided however, that the Company may make an additional one-time grant to any newly-hired employee of a restricted stock award of up to an additional seven thousand five hundred&nbsp;(7,500) shares. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Performance Awards</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The
Committee may grant performance awards subject to such conditions and the attainment of such performance goals over such periods as the Committee determines in writing and sets forth in a written agreement between the Company and the participant.
These awards may be designated as performance shares or performance units. Performance shares and performance units are unfunded bookkeeping entries. Performance shares generally have an initial value equal to the fair market value determined on the
grant date of a share of the Company&#146;s common stock. Performance awards will specify a predetermined amount of performance shares or performance units that may be earned by the participant to the extent that one or more predetermined
performance goals are attained within a predetermined performance period. To the extent earned, performance awards may be settled in cash, shares of the Company&#146;s common stock (including shares of restricted stock) or any combination thereof.
Subject to appropriate adjustment in the event of any change in the capital structure of the Company, for each fiscal year of the Company contained in the applicable performance period, no employee may be granted performance shares that could result
in the employee receiving more than twenty thousand (20,000)&nbsp;shares of the Company&#146;s common stock or performance units that could result in the employee receiving more than two million dollars ($2,000,000). A participant may receive only
one performance award with respect to any performance period. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">18 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Prior to the beginning of the applicable performance period or such later date as permitted under
Section&nbsp;162(m) of the Code, the Committee will establish one or more performance goals applicable to the award. Performance goals will be based on the attainment of specified target levels with respect to one or more measures of business or
financial performance of the Company and each parent and subsidiary corporation consolidated therewith for financial reporting purposes, or such division or business unit of the Company as may be selected by the Committee. The Committee, in its
discretion, may base performance goals on one or more of the following such measures: revenue, gross margin, operating margin, operating income, pre-tax profit, earnings before interest, taxes, depreciation and/or amortization, net income, cash
flow, expenses, stock price, earnings per share, return on stockholder equity, return on capital, return on net assets, economic value added, number of customers, market share, return on investment, profit after tax, product approval and customer
satisfaction. The target levels with respect to these performance measures may be expressed on an absolute basis or relative to a standard specified by the Committee. The degree of attainment of performance measures will, according to criteria
established by the Committee, be computed before the effect of changes in accounting standards, restructuring charges, and similar extraordinary items occurring after the establishment of the performance goals applicable to a performance award.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Following the completion of the applicable performance period, the Committee will certify in writing the extent to which the applicable
performance goals have been attained and the resulting value to be paid to the participant. The Committee retains the discretion to eliminate or reduce, but not increase, the amount that would otherwise be payable to the participant on the basis of
the performance goals attained. However, no such reduction may increase the amount paid to any other participant. In its discretion, the Committee may provide for the payment to a participant awarded performance shares of dividend equivalents with
respect to cash dividends paid on the Company&#146;s common stock. Performance award payments may be made in lump sum or in installments. If any payment is to be made on a deferred basis, the Committee may provide for the payment of dividend
equivalents or interest during the deferral period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Unless otherwise provided by the Committee, if a participant&#146;s service terminates
due to the participant&#146;s death, disability, or retirement prior to completion of the applicable performance period, the final award value will be determined at the end of the performance period on the basis of the performance goals attained
during the entire performance period but will be prorated for the number of months of the participant&#146;s service during the performance period. If a participant&#146;s service terminates prior to completion of the applicable performance period
for any other reason, the Option Plan provides that, unless otherwise determined by the Committee, the performance award will be forfeited. No performance award may be sold or transferred other than by will or the laws of descent and distribution
prior to the end of the applicable performance period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Deferred Stock Awards </I></B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Option Plan provides that certain participant&#146;s who are executives or members of a select group of highly compensated employees may elect to
receive, in lieu of payment in cash or stock of all or any portion of such participant&#146;s cash and/or stock compensation, an award of deferred stock units. A participant electing to receive deferred stock units will be granted automatically, on
the effective date of such deferral election, an award (a &#147;Deferred Stock Unit Award&#148;) for a number of stock units equal to the amount of the deferred compensation divided by an amount equal to the fair market value of a share of our
common stock as quoted by securities exchange or market system on which the common stock is listed on the date of grant. A stock unit is an unfunded bookkeeping entry representing a right to receive one share of our common stock in accordance with
the terms and conditions of the Deferred Stock Unit Award. Participants are not required to pay any additional cash consideration in connection with the settlement of a Deferred Stock Unit Award. A participant&#146;s compensation not paid in the
form of a Deferred Stock Unit Award will be paid in cash in accordance with the Company&#146;s normal payment procedures. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Each Deferred
Stock Unit Award will be evidenced by a written agreement between the Company and the participant specifying the number of stock units subject to the award and the other terms and conditions of the Deferred Stock Unit Award, consistent with the
requirements of the Option Plan. Deferred Stock Unit Awards </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">19 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">are fully vested upon grant and will be settled by distribution to the participant of a number of whole shares of the Company&#146;s common stock equal to
the number of stock units subject to the award within 30 days following the earlier of (i)&nbsp;the date on which the participant&#146;s service terminates or (ii)&nbsp;an early settlement date elected by the participant in accordance with the terms
of the Option Plan at the time of his or her election to receive the Deferred Stock Unit Award. A holder of a stock unit has no voting rights or other rights as a stockholder until shares of common stock are issued to the participant in settlement
of the stock unit. However, participants holding stock units will be entitled to receive dividend equivalents with respect to any payment of cash dividends on an equivalent number of shares of common stock. Such dividend equivalents will be credited
in the form of additional whole and fractional stock units determined by the fair market value of a share of the Company&#146;s common stock on the dividend payment date. Prior to settlement, no Deferred Stock Unit Award may be assigned or
transferred other than by will or the laws of descent and distribution. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Change in Control </I></B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Option Plan defines a &#147;Change in Control&#148; of the Company as any of the following events upon which the stockholders of the Company
immediately before the event do not retain immediately after the event, in substantially the same proportions as their ownership of shares of the Company&#146;s voting stock immediately before the event, direct or indirect beneficial ownership of a
majority of the total combined voting power of the voting securities of the Company, its successor or the corporation to which the assets of the Company were transferred: (i)&nbsp;a sale or exchange by the stockholders in a single or series of
related transactions of more than 50% of the Company&#146;s voting stock; (ii)&nbsp;a merger or consolidation in which the Company is a party; (iii)&nbsp;the sale, exchange or transfer of all or substantially all of the assets of the Company; or
(iv)&nbsp;a liquidation or dissolution of the Company. If a Change in Control occurs, the surviving, continuing, successor, purchasing, or parent corporation thereof may either assume all outstanding awards or substitute new awards having an
equivalent value. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In the event of a Change in Control and the outstanding stock options and stock appreciation rights are not assumed or
replaced, then all unexercisable, unvested, or unpaid portions of such outstanding awards will become immediately exercisable, vested, and payable in full immediately prior to the date of the Change in Control. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In the event of a Change in Control, the lapsing of all vesting conditions and restrictions on any shares subject to any restricted stock award,
restricted stock unit, or performance award held by a participant whose service with the Company has not terminated prior to the Change in Control shall be accelerated effective as of the date of the Change in Control. For this purpose, the value of
outstanding performance awards will be determined and paid on the basis of the greater of (i)&nbsp;the degree of attainment of the applicable performance goals prior to the date of the Change in Control or (ii)&nbsp;100% of the pre-established
performance goal target. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Any award not assumed, replaced, or exercised prior to the Change in Control will terminate. The Option Plan
authorizes the Committee, in its discretion, to provide for different treatment of any award, as may be specified in such award&#146;s written agreement, which may provide for acceleration of the vesting or settlement of any award, or provide for
longer periods of exercisability, upon a Change in Control. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Termination or Amendment </I></B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Option Plan will continue in effect until the first to occur of (i)&nbsp;its termination by the Committee, (ii)&nbsp;the date on which all shares
available for issuance under the Option Plan have been issued and all restrictions on such shares under the terms of the Option Plan and the agreements evidencing awards granted under the Option Plan have lapsed, or (iii)&nbsp;the tenth anniversary
of the Option Plan&#146;s effective date. The Committee may terminate or amend the Option Plan at any time, provided that no amendment may be made without stockholder approval if the Committee deems such approval necessary for compliance with any
applicable tax or securities law or other regulatory requirements, including the requirements of any stock exchange or market system on </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">20 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">which the Common Stock of the Company is then listed. No termination or amendment may affect any outstanding award unless expressly provided by the
Committee, and, in any event, may not adversely affect an outstanding award without the consent of the participant unless necessary to comply with any applicable law, regulation, or rule. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Summary of U.S. Federal Income Tax Consequences </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The
following summary is intended only as a general guide to the U.S. federal income tax consequences of participation in the Option Plan and does not attempt to describe all possible federal or other tax consequences of such participation or tax
consequences based on particular circumstances. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Incentive Stock Options </I></B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">An optionee recognizes no taxable income for regular income tax purposes as a result of the grant or exercise of an incentive stock option qualifying
under Section&nbsp;422 of the Code. Optionees who neither dispose of their shares within two years following the date the option was granted nor within one year following the exercise of the option will normally recognize a capital gain or loss
equal to the difference, if any, between the sale price and the purchase price of the shares. If an optionee satisfies such holding periods upon a sale of the shares, the Company will not be entitled to any deduction for federal income tax purposes.
If an optionee disposes of shares within two years after the date of grant or within one year after the date of exercise (a &#147;disqualifying disposition&#148;), the difference between the fair market value of the shares on the determination date
(see discussion under &#147;Nonstatutory Stock Options&#148; below) and the option exercise price (not to exceed the gain realized on the sale if the disposition is a transaction with respect to which a loss, if sustained, would be recognized) will
be taxed as ordinary income at the time of disposition. Any gain in excess of that amount will be a capital gain. If a loss is recognized, there will be no ordinary income, and such loss will be a capital loss. Any ordinary income recognized by the
optionee upon the disqualifying disposition of the shares generally should be deductible by the Company for federal income tax purposes, except to the extent such deduction is limited by applicable provisions of the Code. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The difference between the option exercise price and the fair market value of the shares on the determination date of an incentive stock option (see
discussion under &#147;Nonstatutory Stock Options&#148; below) is treated as an adjustment in computing the optionee&#146;s alternative minimum taxable income and may be subject to an alternative minimum tax which is paid if such tax exceeds the
regular tax for the year. Special rules may apply with respect to certain subsequent sales of the shares in a disqualifying disposition, certain basis adjustments for purposes of computing the alternative minimum taxable income on a subsequent sale
of the shares and certain tax credits which may arise with respect to optionees subject to the alternative minimum tax. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Nonstatutory
Stock Options and Indexed Stock Options </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Options not designated or qualifying as incentive stock options, or as an indexed stock
option, will be nonstatutory stock options having no special tax status. An optionee generally recognizes no taxable income as the result of the grant of such an option. Upon exercise of a nonstatutory stock option, the optionee normally recognizes
ordinary income in the amount of the difference between the option exercise price and the fair market value of the shares on the determination date (as defined below). If the optionee is an employee, such ordinary income generally is subject to
withholding of income and employment taxes. The &#147;determination date&#148; is the date on which the option is exercised unless the shares are subject to a substantial risk of forfeiture (as in the case where an optionee is permitted to exercise
an unvested option and receive unvested shares which, until they vest, are subject to the Company&#146;s right to repurchase them at the original exercise price upon the optionee&#146;s termination of service) and are not transferable, in which case
the determination date is the earlier of (i)&nbsp;the date on which the shares become transferable or (ii)&nbsp;the date on which the shares are no longer subject to a substantial risk of forfeiture. If the determination date is after the exercise
date, the optionee may elect, pursuant to Section&nbsp;83(b) of the Code, to have the exercise date be the determination date by filing an election with the </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">21 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">Internal Revenue Service no later than 30 days after the date the option is exercised. Upon the sale of stock acquired by the exercise of a nonstatutory
stock option, any gain or loss, based on the difference between the sale price and the fair market value on the determination date, will be taxed as capital gain or loss. No tax deduction is available to the Company with respect to the grant of a
nonstatutory stock option or the sale of the stock acquired pursuant to such grant. The Company generally should be entitled to a deduction equal to the amount of ordinary income recognized by the optionee as a result of the exercise of a
nonstatutory stock option, except to the extent such deduction is limited by applicable provisions of the Code. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Stock Appreciation
Rights </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">No taxable income is reportable when a stock appreciation right is granted to a participant. Upon exercise, the participant
will recognize ordinary income in an amount equal to the amount of cash received and the fair market value of any shares of our common stock received. Any additional gain or loss recognized upon any later disposition of the shares would be capital
gain or loss. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Restricted Stock Awards </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">A participant acquiring restricted stock generally will recognize ordinary income equal to the fair market value of the shares on the &#147;determination date&#148; (as defined above under &#147;Nonstatutory Stock
Options&#148;). If the participant is an employee, such ordinary income generally is subject to withholding of income and employment taxes. If the determination date is after the date on which the participant acquires the shares, the participant may
elect, pursuant to Section&nbsp;83(b) of the Code, to have the date of acquisition be the determination date by filing an election with the Internal Revenue Service no later than 30 days after the date the shares are acquired. Upon the sale of
shares acquired pursuant to a restricted stock award, any gain or loss, based on the difference between the sale price and the fair market value on the determination date, will be taxed as capital gain or loss. The Company generally should be
entitled to a deduction equal to the amount of ordinary income recognized by the participant on the determination date, except to the extent such deduction is limited by applicable provisions of the Code. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Performance and Restricted Stock Units Awards </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">A participant generally will recognize no income upon the grant of a performance share, performance units, or restricted stock units award. Upon the settlement of such awards, participants normally will recognize
ordinary income in the year of receipt in an amount equal to the cash received and the fair market value of any nonrestricted shares received. If the participant is an employee, such ordinary income generally is subject to withholding of income and
employment taxes. If the participant receives shares of restricted stock, the participant generally will be taxed in the same manner as described above (see discussion under &#147;Restricted Stock&#148;). Upon the sale of any shares received, any
gain or loss, based on the difference between the sale price and the fair market value on the &#147;determination date&#148; (as defined above under &#147;Nonstatutory Stock Options&#148;), will be taxed as capital gain or loss. The Company
generally should be entitled to a deduction equal to the amount of ordinary income recognized by the participant on the determination date, except to the extent such deduction is limited by applicable provisions of the Code. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Deferred Stock Unit Awards </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">A
participant generally will recognize no income upon the grant of a Deferred Stock Unit Award. Upon the settlement of such an award, the participant normally will recognize ordinary income in the year of settlement in an amount equal to the fair
market value of any unrestricted shares of our Common Stock received. Upon the sale of any shares received, any gain or loss, based on the difference between the sale price and the fair market value on the determination date, will be taxed as
capital gain or loss. The Company generally should be entitled to a deduction equal to the amount of ordinary income recognized by the participant on the determination date, except to the extent such deduction is limited by applicable provisions of
the Code. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">22 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Option Plan Benefits </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">All awards under the Option Plan are granted at the discretion of the Committee, and, accordingly, are not yet determinable. No awards have been made under the Option Plan, as amended and restated by this Proposal.
Benefits under the Option Plan depend on a number of factors, including the fair market value of the Company&#146;s common stock on future dates, actual Company performance against performance goals established with respect to performance awards and
decisions made by the participants. Consequently, it is not possible to determine the benefits that might be received by participants under the Option Plan. The table below sets forth the stock options granted under the Option Plan during the fiscal
year ending December&nbsp;31, 2008 to each of Nuvelo&#146;s Named Executive Officers during its fiscal year ended December&nbsp;31, 2008, and certain specified individuals and groups. This table is furnished pursuant to the rules of the SEC:
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:64pt"><FONT FACE="Times New Roman" SIZE="1"><B>Name and Position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Number&nbsp;of<BR>Securities<BR>Underlying<BR>Options<BR>Granted</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Weighted&nbsp;Average<BR>Exercise Price</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>per Share</B></FONT><br><FONT
FACE="Times New Roman" SIZE="1"><B>($)</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Ted W. Love, M.D.,</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9,999</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">31.30</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Chairman of the Board and Chief Executive Officer as of December&nbsp;31, 2008 and nominee for director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Lee Bendekgey,</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4,999</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">31.30</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Senior Vice President, Finance and General Counsel as of December&nbsp;31, 2008</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Michael D. Levy, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4,999</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">31.30</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Executive Vice President Research and Development through March&nbsp;20, 2008</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Burton E. Sobel, M.D., nominee for director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">750</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">14.58</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">All current directors who are not executive officers as a group (7 persons, excluding Dr.&nbsp;Love)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,500</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">14.58</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">All employees, excluding our current and former executive officers, as a group</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">40,276</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">31.46</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Equity Compensation Plan Information </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The following table sets forth information as of December&nbsp;31, 2008 for all of Nuvelo&#146;s equity compensation plans in existence prior to the
merger: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:49pt"><FONT FACE="Times New Roman" SIZE="1"><B>Plan Category</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>No.&nbsp;of&nbsp;Securities&nbsp;to&nbsp;be<BR>Issued&nbsp;Upon&nbsp;Exercise&nbsp;of<BR>Outstanding Options,<BR>Warrants and
Rights<BR>(a)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Weighted Average<BR>Exercise Price of<BR>Outstanding&nbsp;Options,<BR>Warrants and Rights<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>No.&nbsp;of&nbsp;Securities&nbsp;Remaining<BR>Available for Future<BR>Issuance Under Equity<BR>Compensation Plans<BR>Excluding
Securities<BR>Reflected in Column</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>(a)</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Equity compensation plans approved by security holders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">274,087</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">274.17</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">339,568</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Equity compensation plans not approved by security holders(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5,303</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">750.00</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">279,390</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">283.20</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">339,568</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Consists of option granted to an executive officer of Nuvelo described below which is not required to be and has not been approved by its stockholders. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Non-Stockholder Approved Equity Arrangements </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In
2001, Nuvelo granted Dr.&nbsp;Love options to purchase shares of common stock in connection with and as an inducement to his commencement of employment with Nuvelo. Specifically, on January&nbsp;11, 2001, Nuvelo granted Dr.&nbsp;Love an option to
purchase 7,802 shares of common stock at an exercise price of $750.00 per share, the closing price on the date of grant, of which 5,303 remained outstanding as of December&nbsp;31, 2008. Dr.&nbsp;Love&#146;s </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">23 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">employment as the president and chief executive officer of Nuvelo was terminated on January&nbsp;27, 2009. Dr.&nbsp;Love continues to serve as a member of
the board of directors of ARCA after the merger, and his stock options remain exercisable until his service as a board member terminates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Required Vote
and Board of Directors Recommendation </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The affirmative vote of a majority of the shares present and entitled to vote at the meeting, at
which a quorum is present, either in person or by proxy, is required to approve the adoption of the amendment and restatement to the Option Plan. If you hold your shares in your own name and abstain from voting on this matter, your abstention will
have the same effect as an &#147;Against&#148; vote. If you hold your shares through a broker and you do not instruct the broker on how to vote on this proposal, your broker will not have authority to vote your shares on this proposal. Broker
non-votes have no effect and will not be counted towards the vote total for this proposal. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Board believes that the proposed amendment
and restatement of the Nuvelo, Inc. 2004 Equity Incentive Plan as the Amended and Restated ARCA biopharma, Inc. 2004 Equity Incentive Plan is in the best interests of the Company and its stockholders for the reasons stated above. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>THE BOARD OF DIRECTORS RECOMMENDS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>A
VOTE</B><B><I> FOR</I></B><B> THE APPROVAL OF THE AMENDMENT AND RESTATEMENT OF </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>THE NUVELO, INC. 2004 EQUITY INCENTIVE PLAN
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>AS THE AMENDED AND RESTATED ARCA BIOPHARMA, INC. 2004 EQUITY INCENTIVE PLAN </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>AS SET FORTH IN THIS PROPOSAL 2. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">24 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>PROPOSAL 3: </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>RATIFICATION OF </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SELECTION OF INDEPENDENT REGISTERED AUDITORS </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Our Audit Committee has selected KPMG LLP, or KPMG, as our independent registered public accounting firm for the fiscal year ending December&nbsp;31,
2009, and has further directed that management submit the selection of our independent registered public accounting firm for ratification by the stockholders at the Annual Meeting. Ernst&nbsp;&amp; Young LLP, or EY, audited the consolidated
financial statements of Nuvelo, Inc. for the fiscal year ended December&nbsp;31, 2008. Representatives of KPMG are expected to be present at the annual meeting, will have an opportunity to make a statement if they so desire, and will be available to
respond to appropriate questions. Representatives from EY are expected to be available telephonically at the annual meeting to respond to appropriate questions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Stockholder ratification of the selection of KPMG as the Company&#146;s independent registered public accounting firm is not required by our Bylaws or otherwise. However, the Board of Directors is submitting the
selection of KPMG to our stockholders for ratification as a matter of good corporate practice. If the stockholders fail to ratify the selection, the Audit Committee and the Board of Directors will reconsider whether or not to retain that firm. Even
if the selection is ratified, the Audit Committee and the Board of Directors in their discretion may direct the appointment of a different independent registered public accounting firm at any time during the year if they determine that such a change
would be in the best interests of our Company and our stockholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On March&nbsp;25, 2009, we dismissed our prior independent registered
public accounting firm, EY. On March&nbsp;25, 2009, we engaged KPMG as our independent registered public accounting firm to audit our consolidated financial statements for the fiscal year ending December&nbsp;31, 2009 and management&#146;s
assessment of the effectiveness of internal control over financial reporting and the effectiveness of internal control over financial reporting as of December&nbsp;31, 2009. The dismissal of EY and the engagement of KPMG were approved by our Audit
Committee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">KPMG was the independent registered public accounting firm that audited the financial statements of ARCA for its fiscal years
through December&nbsp;31, 2008 prior to the merger with Nuvelo described above. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">For accounting purposes, ARCA is deemed to have acquired
the Company pursuant to the transactions contemplated by the merger, and the historical financial statements of ARCA are considered to be the historical financial statements of the Company after the merger, pursuant to the rules and regulations of
the SEC. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">During Nuvelo&#146;s fiscal years ended December&nbsp;31, 2008 and 2007, and in the Company&#146;s subsequent interim period from
January&nbsp;1, 2009 through March&nbsp;25, 2009, the date of the dismissal of EY, with regard to Nuvelo&#146;s financial statements for the fiscal years ended December&nbsp;31, 2008 and 2007, (i)&nbsp;there were no disagreements with EY on any
matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to EY&#146;s satisfaction, would have caused EY to make reference to the subject matter of the
disagreement in connection with its report, and (ii)&nbsp;there were no reportable events of the type described in Item&nbsp;304(a)(1)(v) of Regulation S-K. In connection with a related Current Report on Form 8-K, we provided EY with a copy of the
foregoing disclosures and requested that EY furnish the Company with a letter addressed to the SEC stating whether or not it agreed with the disclosures substantially equivalent to the disclosures set forth above. A letter from EY to the SEC, dated
March&nbsp;30, 2009, was attached as Exhibit 16.1 to the Current Report on Form 8-K that was filed with the SEC on March&nbsp;30, 2009 stating that it read Item&nbsp;4.01(a) of Form 8-K dated March&nbsp;25, 2009, of ARCA biopharma, Inc. (formerly
known as Nuvelo, Inc.) and was in agreement with the statements contained in the third, fourth, fifth paragraphs and the first sentence of the sixth paragraph on page 2 therein, and that it had no basis to agree or disagree with other statements of
the registrant contained therein. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Prior to our decision to engage KPMG, we did not consult with KPMG regarding the application of
accounting principles to a specified transaction, either completed or proposed, the type of audit opinion that might be rendered on our consolidated financial statements, or any other matters or reportable events described in Item&nbsp;304(a)(2)(ii)
of Regulation S-K. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">25 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The following table presents fees billed for professional audit services rendered for the audits of
Nuvelo&#146;s consolidated financial statements and related internal controls by EY for the fiscal years ended December&nbsp;31, 2008 and 2007, and fees billed for other services rendered during these two years. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2008&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2007&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Audit fees(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">724,384</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">700,111</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Audit-related fees(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">89,151</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">25,000</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Tax fees(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">52,788</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">All other fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">866,323</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">725,111</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Includes fees for the (i)&nbsp;audit of the consolidated financial statements included in our Form 10-K for our fiscal years ended December&nbsp;31, 2008 and December&nbsp;31, 2007,
(ii)&nbsp;for our fiscal year ended December&nbsp;31, 2007 only, an audit of the effectiveness of internal controls over financial reporting under the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, (iii)&nbsp;review of interim
consolidated financial statements included on Forms 10-Q and (iv)&nbsp;services normally provided in connection with statutory and regulatory filings. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Includes fees for agreed upon and due diligence procedures performed in connection with the merger with ARCA Colorado, and assurance and related services that are reasonably related
to the performance of the audit or review of our consolidated financial statements. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Includes fees for services rendered to review the impact of ownership changes on the Company&#146;s net operating loss and tax credit carry-forwards, as well as merger-related tax
consultations. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Pre-Approval Process and Policy </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">The above services performed by our independent registered public accounting firms were pre-approved in accordance with the pre-approval policy and procedures adopted by the Audit Committee at its October&nbsp;29,
2003 meeting. This policy describes the permitted audit, audit-related, tax, and other services that our independent registered public accounting firm may perform. The policy also requires that an annual description of the services expected to be
performed by the independent registered public accounting firm during the subsequent fiscal year in each of these categories be presented to the Audit Committee for pre-approval. Any pre-approval details the particular service or category of
services. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Any requests for audit, audit-related, tax, and other services not contemplated by those pre-approved services must be submitted
to the Audit Committee for specific pre-approval. Generally, pre-approval is considered at the Audit Committee&#146;s regularly scheduled meetings. However, the authority to grant specific pre-approval between meetings, as necessary, has been
delegated to the chairman of the Audit Committee. In the event that the chairman is not available, the other two Audit Committee members together have the authority to grant specific pre-approval between meetings. The chairman or the other two
members must update the Audit Committee at the next regularly scheduled meeting of any services that were granted specific pre-approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Required Vote
and Board of Directors Recommendation </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The affirmative vote of a majority of the shares present and entitled to vote at the meeting, at
which a quorum is present, either in person or by proxy, is required for the ratification of the selection of the Company&#146;s independent registered public accounting firm. If you hold your shares in your own name and abstain from voting on this
matter, your abstention will have the same effect as an &#147;Against&#148; vote. If you hold your shares through a broker and you do not vote on this proposal, your broker will have authority to vote your shares on this proposal. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE </B><B><I>FOR</I></B><B> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B></B><B><I></I></B><B>THE RATIFICATION OF THE SELECTION OF KPMG LLP AS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>THE COMPANY&#146;S
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>AS SET FORTH IN THIS PROPOSAL 3. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">26 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SECURITY OWNERSHIP OF CERTAIN </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>BENEFICIAL OWNERS AND MANAGEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The following table sets forth certain
information regarding the beneficial ownership of our common stock as of March&nbsp;31, 2009, by: (1)&nbsp;each of our directors; (2)&nbsp;each of Nuvelo&#146;s Named Executive Officers as of December&nbsp;31, 2008 set forth in the table titled
&#147;Summary Compensation Table&#148; at page 33 of this Proxy Statement; (3)&nbsp;each person known by us to be the beneficial owner of more than 5% of our outstanding common stock; and (4)&nbsp;all of our directors and current executive officers
as a group. As of March&nbsp;31, 2009, we had 7,567,399 shares of common stock outstanding. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Shares&nbsp;Beneficially&nbsp;Owned(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:99pt"><FONT FACE="Times New Roman" SIZE="1"><B>Name of Beneficial Owner(1)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Number of<BR>&nbsp;&nbsp;&nbsp;&nbsp;Shares&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;Percentage&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><B>Directors and Named Executive Officers</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Ted W. Love, M.D.(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">128,156</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">1.67</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Lee Bendekgey(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">30,247</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">*</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Michael D. Levy, M.D.(4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">27,198</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">*</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Richard B. Brewer(5)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">251,221</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">3.25</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Michael R. Bristow, M.D., Ph.D.(6)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">282,158</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">3.72</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Jean-Francois Formela, M.D.(7)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,479,028</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">19.35</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">J. William Freytag, Ph.D.(8)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">14,911</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">*</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Linda Grais, M.D.(9)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">733,963</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">9.66</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">David G. Lowe, Ph.D.(10)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">916,319</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">12.05</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Mary K. Pendergast(11)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,240</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">*</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Burton Sobel, M.D.(12)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4,125</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">*</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">John L. Zabriskie, Ph.D.(13)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">46,540</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">*</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">All current directors and executive officers as a group (13 persons)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,977,377</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">49.62</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><B>5% Stockholders</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Boulder Ventures IV (Annex), L.P.(14)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">803,069</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">10.58</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Skyline Venture Partners Qualified Purchaser Fund IV, L.P.(15)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">915,069</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">12.03</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">InterWest Partners IX, LP(16)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">732,713</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">9.64</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Atlas Venture Fund VII, L.P.(17)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,477,612</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">19.33</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Represents beneficial ownership of less than 1% of our common stock. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Beneficial ownership is determined in accordance with Rule 13d-3 under the Exchange Act and generally includes voting or investment power with respect to securities. Shares of
common stock subject to options and warrants which are currently exercisable, or will become exercisable within 60 days of March&nbsp;31, 2009, are deemed outstanding for computing the percentage of the person or entity holding such securities but
are not outstanding for computing the percentage of any other person or entity. Except as indicated by footnote, and subject to the community property laws where applicable, to our knowledge the persons named in the table above have sole voting and
investment power with respect to all shares of common stock shown as beneficially owned by them. Unless otherwise indicated, the address for each person is our address at 8001 Arista Place, Suite 200, Broomfield, CO 80021. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Includes options to purchase 124,576 shares that are exercisable within 60 days of March&nbsp;31, 2009. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Includes options to purchase 28,745 shares that are exercisable within 60 days of March&nbsp;31, 2009. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Includes options to purchase 26,160 shares that are exercisable within 60 days of March&nbsp;31, 2009. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Includes options to purchase 167,731 shares that are exercisable within 60 days of March&nbsp;31, 2009, 165,644 of which are subject to ARCA&#146;s right of repurchase, which lapses
at the rate of 25% upon grant and 6.25% at the end of each three-month period following the first anniversary of the November&nbsp;2, 2006 grant date. Of these options, as of March&nbsp;31, 2009, 72,470 were subject to a right of repurchase in favor
of ARCA. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Includes options to purchase 9,481 shares that are exercisable within 60 days of March&nbsp;31, 2009. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Includes the following owned directly by Atlas Venture Fund VII, L.P. (&#147;AV VII&#148;): (a)&nbsp;1,402,163 shares and (b)&nbsp;75,449 shares issuable upon
exercise of a warrant, which warrant is immediately exercisable. As general partner of AV VII, Atlas Venture Associates VII, L.P. (&#147;AVA VII LP&#148;), may also be deemed to beneficially own these shares. Mr.&nbsp;Formela, a partner with Atlas
Venture and one of the Company&#146;s directors may be deemed to beneficially own these shares. </FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">27 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:0%">
<FONT FACE="Times New Roman" SIZE="2">Mr.&nbsp;Formela disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Each of AV VII and AVA VII LP
disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein. Also includes options to purchase 1,416 shares that are exercisable within 60 days of March&nbsp;31, 2009. These options were granted to
Jean-Francois Formela and the proceeds of any sale of the Company&#146;s common stock issued to Dr.&nbsp;Formela upon the exercise of this option will be transferred to Atlas Venture Advisors, Inc. (&#147;Atlas Advisors&#148;) and therefore
Dr.&nbsp;Formela disclaims beneficial ownership of such shares which belong to Atlas Advisors. The address for Dr.&nbsp;Formela is 890 Winter Street, Suite 320, Waltham, MA 02451. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(8)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Consists of options to purchase 14,911 shares that are exercisable within 60 days of March&nbsp;31, 2009. The address for Dr.&nbsp;Freytag is 7169 Waterford Court, Niwot, CO 80503.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(9)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Includes the following owned directly by InterWest Partners IX, LP: (a)&nbsp;702,698 shares and (b)&nbsp;30,015 shares issuable upon exercise of a warrant, which warrant is
immediately exercisable. Ms.&nbsp;Grais, one of the Company&#146;s directors, is a venture member of InterWest Management Partners IX, LLC, the general partner of InterWest Partners IX, LP. Ms Grais has shared voting and dispositive powers over the
shares held by InterWest Partners IX, LP. She disclaims beneficial ownership of these shares, except to the extent of her pro rata partnership interest therein. Also includes options to purchase 1,250 shares that are exercisable within 60 days of
March&nbsp;31, 2009. The address for Dr.&nbsp;Grais is 2710 Sand Hill Road, Second Floor, Menlo Park, CA 94025. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(10)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Includes the following owned directly by Skyline Venture Partners Qualified Purchaser Fund IV, L.P, (a)&nbsp;877,583 shares and (b)&nbsp;37,486 shares issuable upon exercise of a
warrant, which warrant is immediately exercisable. John G. Freund and Yasunori Kaneko are the Managing Members of Skyline Venture Management IV, LLC, which is the general partner of Skyline Venture Partners Qualified Purchaser Fund IV, L.P., and as
such Drs. Freund and Kaneko may be deemed to share voting and dispositive power with respect to all shares of common stock held by Skyline Venture Partners Qualified Purchaser Fund IV, L.P. In addition, Dr.&nbsp;Lowe, one of the Company&#146;s
directors, is a Managing Director of Skyline Ventures and as such may be deemed to share voting and dispositive power with respect to all shares of common stock held by Skyline Venture Partners Qualified Purchasers Fund IV, L.P. Each of Drs. Freund,
Kaneko and Lowe disclaims beneficial ownership of such shares except to the extent of his pecuniary interest, if any. Also includes options to purchase 1,250 shares that are exercisable within 60 days of March&nbsp;31, 2009. The address for
Dr.&nbsp;Lowe is Skyline Ventures, 525 University Avenue, Ste 520, Palo Alto, CA 94301. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(11)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Includes options to purchase 6,207 shares that are exercisable within 60 days of March&nbsp;31, 2009. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(12)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Consists of options to purchase 4,125 shares that are exercisable within 60 days of March&nbsp;31, 2009. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(13)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Consists of (a)&nbsp;options to purchase 17,360 shares that are exercisable within 60 days of March&nbsp;31, 2009, and (b)&nbsp;29,180 shares owned directly by Lansing Brown
Investments, LLC. Dr.&nbsp;Zabriskie, one of the Company&#146;s directors, is the President of Lansing Brown Investments, LLC. Dr.&nbsp;Zabriskie has shared voting and dispositive powers over the shares held by Lansing Brown Investments, LLC. He
disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in them. The address for Dr.&nbsp;Zabriskie is 207 Juniper Court, Basalt, CO 81621. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(14)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Includes the following owned by Boulder Ventures IV (Annex), L.P. (&#147;BV IV Annex&#148;) which is under common control with Boulder Ventures IV, L.P. (&#147;BV IV LP&#148;),
(a)&nbsp;725,111 shares and (b)&nbsp;28,651 shares issuable upon exercise of a warrant, which warrant is immediately exercisable. BV Partners IV, L.L.C. (&#147;BV IV LLC&#148;) serves as the sole General Partner of BV IV Annex, and has sole voting
and investment control over the respective shares owned by BV IV Annex, and may be deemed to own beneficially the shares held by BV IV Annex. BV IV LLC however owns no securities of the Issuer directly. Josh E. Fidler (&#147;Fidler&#148;), Andrew E.
Jones (&#147;Jones&#148;), Kyle Lefkoff (&#147;Lefkoff&#148;), Lawrence M. Macks (&#147;Macks&#148;) and Peter Roshko (&#147;Roshko&#148;) are Managing Members of BV IV LLC and share voting and dispositive power over the shares held by BV IV Annex
and BV IV LP. Each of these individuals disclaims beneficial ownership of the shares reported herein, except to the extent of his respective pecuniary interest therein. Also includes the following owned by BV IV LP which is under common control with
Boulder IV Annex, (a)&nbsp;48,007 shares and (b)&nbsp;1,897 shares issuable upon exercise of a warrant, which warrant is immediately exercisable. BV IV LLC serves as the sole General Partner, and has sole voting and investment control over the
respective shares owned by BV IV LP, and may be deemed to own beneficially the shares held by BV IV LP. BV IV LLC however owns no securities of the Issuer directly. Fidler, Jones, Lefkoff, Macks and Roshko are Managing Members of BV IV LLC and share
voting and dispositive power over the shares held by BV IV LP. Each of these individuals disclaims beneficial ownership of the shares reported herein, except to the extent of his respective pecuniary interest therein. The address for each of BV IV
Annex and BV IV LP. is 1900 Ninth Street, Suite 200, Boulder, CO 80302. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(15)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Consists of the following owned directly by Skyline Venture Partners Qualified Purchaser Fund IV, L.P, (a)&nbsp;877,583 shares and (b)&nbsp;37,486 shares issuable upon exercise of a
warrant, which warrant is immediately exercisable. The address for Skyline Venture Partners Qualified Purchaser Fund IV, L.P. is 525 University Avenue, Ste 520, Palo Alto, CA&nbsp;94301. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">28 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(16)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Consists of the following owned directly by InterWest Partners IX, LP, (a)&nbsp;702,698 shares and (b)&nbsp;30,015 shares issuable upon exercise of a warrant, which warrant is
immediately exercisable. The address for InterWest Partners IX, LP is 2710&nbsp;Sand Hill Road, Second Floor, Menlo Park, CA 94025. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(17)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Consists of the following owned directly by Atlas Venture Fund VII, L.P., or AV VII, (a)&nbsp;1,402,163 shares and (b)&nbsp;75,449 shares issuable upon exercise of a warrant, which
warrant is immediately exercisable. Atlas Venture Associates VII, L.P. is the general partner of Atlas Venture Fund VII, L.P. Each of AV VII and Atlas Venture Associates VII, L.P. disclaims beneficial ownership of the shares except to the extent of
his or its pecuniary interest therein. The address for Atlas Venture Fund VII, L.P. is 890 Winter Street, Suite 320, Waltham, MA 02451. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">29 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Section&nbsp;16(a) of the Securities Exchange Act of 1934, or the Exchange Act, requires our directors and executive officers and persons who
beneficially own more than 10% of our common stock to file with the SEC initial reports of beneficial ownership and reports of changes in beneficial ownership of our common stock and other equity securities of ours. Executive officers, directors,
and greater than 10% beneficial owners are required by SEC regulations to furnish us with copies of all Section&nbsp;16(a) forms they file. Based solely on review of the copies of such reports furnished to us and written representations from certain
reporting persons, we believe that during the fiscal year ended December&nbsp;31, 2008, all Section&nbsp;16(a) filing requirements applicable to our executive officers, directors, and greater than 10% beneficial owners were met. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">30 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>EXECUTIVE OFFICERS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Set forth below is information regarding each of our executive officers as of April&nbsp;30, 2009. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="54%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT FACE="Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Age</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:27pt" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Position</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Richard B. Brewer*</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>&#134;</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">58</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Chief Executive Officer</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Michael R. Bristow, M.D., Ph.D.*</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>&#134;</SUP></FONT><FONT FACE="Times New Roman" SIZE="2">
</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">64</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Chief Science and Medical Officer</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Kathryn Falberg</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">48</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Chief Financial Officer and Chief Operating Officer</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Christopher D. Ozeroff</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>&#134;</SUP></FONT><FONT FACE="Times New Roman"
SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">50</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Executive Vice President of Business Development and General Counsel</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Randall St. Laurent</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>&#134;</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></P></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">48</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Executive Vice President of Commercial Operations</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; padding-bottom:8px; margin-top:-2px" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"> <P STYLE="line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>*</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="line-height:95%; vertical-align:top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Also serves as a director. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; padding-bottom:8px; margin-top:-2px" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"> <P STYLE="line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>&#134;</SUP></FONT><FONT FACE="Times New Roman"
SIZE="2"></FONT></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="line-height:95%; vertical-align:top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Each of the officers indicated served as an executive officer of ARCA Colorado prior to the merger with Nuvelo.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Richard B. Brewer</I>. Mr.&nbsp;Brewer has served as the Company&#146;s President and Chief Executive Officer and a
director since our merger with ARCA Colorado. Mr.&nbsp;Brewer has also served as the President and Chief Executive Officer and a director of ARCA Colorado since November 2006. Prior to joining ARCA Colorado, from January 2003, Mr.&nbsp;Brewer was
Managing Partner of Crest Asset Management, where he provided guidance to and invested in biotechnology opportunities. Before that, Mr.&nbsp;Brewer was President and Chief Executive Officer of Scios, Inc. Before Scios, Mr.&nbsp;Brewer served as
Chief Operating Officer of Heartport, a cardiovascular device company developing minimally invasive approaches to major heart surgery. Prior to that, he spent over a decade at Genentech in various management positions, including Senior Vice
President of Sales and Marketing and Senior Vice President of Genentech Europe and Canada. Mr.&nbsp;Brewer holds a B.S. from Virginia Polytechnic Institute and an M.B.A. from Northwestern University. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Michael R. Bristow, M.D., Ph.D.</I> Dr.&nbsp;Bristow has served as the Company&#146;s Chief Science and Medical Officer and a director since our
merger with ARCA Colorado. Mr.&nbsp;Brewer has also served as a director of ARCA Colorado since November 2006. Dr.&nbsp;Bristow was one of the founders of ARCA Colorado in September 2004, and served as its Chairman and Chief Executive Officer from
that date until he was appointed to the position of Chief Science and Medical Officer in November 2006. Dr.&nbsp;Bristow is a Professor of Medicine and the former Head of Cardiology at the University of Colorado Health Sciences Center, where he has
been since October 1991. Dr.&nbsp;Bristow was one of the founders of Myogen, Inc. and served as Myogen&#146;s Chief Science and Medical Officer from October 1996 to February 2006 and as a Scientific Advisor to Myogen from February 2006 until the
acquisition of Myogen by Gilead Sciences, Inc. in November 2006. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Kathryn E. Falberg</I>. Ms.&nbsp;Falberg joined the Company in
February 2009 as the Company&#146;s Chief Financial Officer and Chief Operating Officer. Prior to joining the Company, Ms.&nbsp;Falberg had served as President of Canyon Capital&nbsp;&amp; Consulting from 2003. From October 2001 to June 2002,
Ms.&nbsp;Falberg was a consultant to Inamed Corp., a medical device company, and briefly served as that company&#146;s interim Chief Financial Officer. In 1995, Ms.&nbsp;Falberg joined Amgen, Inc., a global biotechnology company, as Treasurer, and
later served as its Senior Vice President, Finance, and Chief Financial Officer from 1998 until July 2001. Ms.&nbsp;Falberg has served on the boards of directors for companies in multiple industries and currently serves on the boards of directors
for Halozyme Therapeutics, Inc. QLT, Inc. and ESS Technology, Inc. Ms.&nbsp;Falberg received her M.B.A. and B.A. in Economics from the University of California, Los Angeles. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Christopher D. Ozeroff</I>. Mr.&nbsp;Ozeroff has served as the Company&#146;s Executive Vice President of Business Development, General Counsel and
Secretary since our merger with ARCA Colorado. Before the merger, Mr.&nbsp;Ozeroff was one of the founders of ARCA Colorado in September 2004, and has served as its Executive Vice President of Business Development, General Counsel and Secretary
since that date. From August 1999, Mr.&nbsp;Ozeroff was previously a partner with the law firm of Hogan&nbsp;&amp; Hartson L.L.P., where he practiced in such areas as finance, acquisitions, public offerings, and licensing. Mr.&nbsp;Ozeroff completed
his undergraduate degree at Stanford University, and his law degree at the University of Chicago Law School. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">31 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Randall St. Laurent</I>. Mr.&nbsp;St. Laurent has served as the Company&#146;s Executive Vice
President of Commercial Operations since our merger with ARCA Colorado. Mr.&nbsp;St. Laurent has also served as the Executive Vice President of Commercial Operations of ARCA Colorado since January 2008. From March 2001 until he joined ARCA Colorado,
Mr.&nbsp;St. Laurent was employed by Scios, Inc., first as the Vice President of Sales and Marketing and later as the Vice President of Commercial Development. From September 1999 until March 2001, Mr.&nbsp;St. Laurent was an Executive Sales
Director at Transkaryotic Therapies in Cambridge, Massachusetts. Mr.&nbsp;St. Laurent received a B.A. with a major in marketing from the Ohio State University. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">32 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>EXECUTIVE COMPENSATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B>Compensation Tables </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company has elected to use the smaller reporting company rules recently
issued by the SEC regarding the disclosure of executive compensation. Under these rules, the Company provides executive compensation disclosure for our named executive officers, the Summary Compensation Table for two years, the Outstanding Equity
Awards at Year End Table, the Director Compensation Table, and certain narrative disclosures. The Director Compensation Table is provided above under the section titled, &#147;Proposal 1,&#148; under the subsection titled, &#147;Director
Compensation.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company completed our merger with ARCA Colorado in January 2009. Following the business combination, the executive
officers of the Company were replaced with those executive officers set forth above under the section titled, &#147;Executive Officers.&#148; To provide meaningful disclosure, the Company has elected to provide disclosure regarding the compensation
of the current named executive officers, in addition to those named executive officers as of December&nbsp;31, 2008. Accordingly, the following disclosure is broken down into two subsections: first, disclosure related to those named executive
officers with the Company as of December&nbsp;31, 2008; and second, disclosure related to the current named executive officers other than Kathryn Falberg, who was not employed by ARCA as of December&nbsp;31, 2008. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>ARCA Pre-Business Combination Named Executive Officers </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>Summary Compensation Table </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The following table shows for the fiscal years ended December&nbsp;31, 2008 and 2007,
compensation awarded to, paid to, or earned by the Company&#146;s principal executive officer and its other named executive officer as of December&nbsp;31, 2008, and one former executive officer who departed from the Company during 2008,
collectively, the Named Executive Officers: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Name and Principal</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:68pt"><FONT
FACE="Times New Roman" SIZE="1"><B>Position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Year</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Salary</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Bonus<BR>(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Stock<BR>Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Option<BR>Awards</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>(2)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Non-Equity<BR>Incentive</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Plan<BR>Compensation</B></FONT><br><FONT
FACE="Times New Roman" SIZE="1"><B>(3)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Nonqualified<BR>Deferred</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Compensation<BR>Earnings</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>All Other<BR>Compensation</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>(4)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Total</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Ted W. Love, M.D.(5)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2008</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">655,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,932,481</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5,462</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,592,943</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" ROWSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Former Chairman of the Board&nbsp;of Directors and Former&nbsp;Chief Executive Officer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2007</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">655,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,564,453</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">220,080</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">977</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,440,510</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Lee Bendekgey</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2008</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">375,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">397,581</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,128</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">775,709</FONT></TD></TR>
<TR>
<TD VALIGN="top" ROWSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Former Senior Vice President, Chief Financial Officer and Former General Counsel</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2007</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">364,500</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">553,650</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">121,275</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">925</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,040,350</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="3"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Michael D. Levy, M.D.(6)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2008</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">93,887</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">727,063</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">412,258</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,233,208</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" ROWSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Former Executive Vice President of Research and&nbsp;Development</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2007</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">410,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">750,935</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">120,540</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,263</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,282,738</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The cash bonuses earned in 2007 were paid under an incentive plan and, therefore, are reported in the column &#147;Non-Equity Incentive Plan Compensation.&#148; No cash bonuses were
earned in 2008. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Amounts reflect stock-based compensation expense recognized for financial statement reporting purposes for the years ended December&nbsp;31, 2008 and 2007, in accordance with SFAS
123R, and include amounts attributable to awards granted in and before 2008. Assumptions used in the valuation of stock options are disclosed in Note 1 to the Company&#146;s Consolidated Financial Statements included in the Company&#146;s Annual
Report on Form 10-K for the year ended December&nbsp;31, 2008, filed with the SEC on March&nbsp;27, 2009. Amounts shown above exclude the impact of estimated forfeitures related to service-based vesting conditions. The amount reflected for
Dr.&nbsp;Levy includes expenses associated with the acceleration of vesting of his options in connection with his termination of employment. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">33 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Amounts reflect cash bonus earned in 2007 under the cash bonus program, as described in more detail below under the subsection titled, &#147;Narrative Disclosure to Summary
Compensation Table.&#148; Cash bonuses that were earned in 2007 were paid in February 2008. No cash bonuses were earned in 2008. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Amounts consist of contributions made by the Company to the 401(k) Plan for each of the Named Executive Officers and amount received by Dr.&nbsp;Levy under the Nuvelo, Inc.
Executive Change in Control and Severance Benefit Plan. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Dr.&nbsp;Love&#146;s position as the Company&#146;s Chief Executive Officer was terminated on January&nbsp;27, 2009 in connection with the Company&#146;s merger with ARCA Colorado.
Dr.&nbsp;Love remains a director of the Company, but no longer serves as Chairman of the Board. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Dr.&nbsp;Levy&#146;s employment with the Company was terminated on March&nbsp;20, 2008. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT
FACE="Times New Roman" SIZE="2"><B><I>Narrative Disclosure to Summary Compensation Table </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Employment Agreements or Arrangements
</I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Ted W. Love, M.D. </I>The Company entered into an employment agreement and related addendum (collectively, the &#147;Love
Employment Agreement&#148;) with Dr.&nbsp;Love, its former Chairman and Chief Executive Officer, in January 2001, and subsequently amended and restated the addendum to his employment agreement in April 2007 and January 2008. Upon the closing of the
Company&#146;s merger with ARCA Colorado, Dr.&nbsp;Love&#146;s employment with the Company was terminated, but he continues to serve as a director of the Company. In connection with his employment termination, he became entitled to the severance and
other benefits set forth in the Love Employment Agreement and described below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Pursuant to the terms of the Love Employment Agreement, as
amended, at the time of the merger, all stock options and stock awards of the Company held by Dr.&nbsp;Love became fully vested. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In
addition, if Dr.&nbsp;Love&#146;s employment were terminated without cause, or for good reason, both as defined in the Love Employment Agreement or upon the death of Dr.&nbsp;Love while an employee with the Company then: </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">the vesting of any options granted to Dr.&nbsp;Love within the first four years of his employment with the Company would be fully accelerated;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">the time period during which Dr.&nbsp;Love or his heirs would be able to exercise these accelerated options would be extended by up to an additional 18 months;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">the vesting of any equity awards made to Dr.&nbsp;Love after April&nbsp;30, 2007 would be accelerated by an additional 24 months, such that any awards that would
have vested in the 24 months following Dr.&nbsp;Love&#146;s termination would be deemed immediately vested; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Dr.&nbsp;Love or his heirs would be paid 24 months of his then current base salary, in one lump sum; and </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">the Company would pay premiums necessary to continue health insurance benefits for Dr.&nbsp;Love and his family for 18 months at the same level of benefits and the
same cost to Dr.&nbsp;Love or his heirs as immediately prior to his termination. The Company would also pay, in one lump sum, the cost of such coverage for an additional six months, provided that Dr.&nbsp;Love has elected continuation of coverage
under federal COBRA and analogous state law such that continuation of coverage shall be considered to have been provided pursuant to such laws. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">If Dr.&nbsp;Love&#146;s employment were terminated without cause or for good reason within 12 months of a change in control of the Company, then, in addition to the benefits described above, Dr.&nbsp;Love would be
entitled to a lump sum payment equal to two times his target bonus for the year in which his termination occurred. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">As a condition to
receipt of any of the termination benefits described above, Dr.&nbsp;Love was required to provide a general release in favor of the Company. The Company and Dr.&nbsp;Love have agreed in certain </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">34 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">circumstances to reduce the amount of his benefits under the Love Employment Agreement to achieve the best after-tax result for Dr.&nbsp;Love. The Company
and Dr.&nbsp;Love also agreed that the payment of benefits under the Love Employment Agreement may be adjusted in certain circumstances so that such benefits are not subject to Section&nbsp;409A(a)(1) of the Internal Revenue Code. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In connection with Dr.&nbsp;Love&#146;s termination of his employment with the Company effective January&nbsp;27, 2009, the Company paid Dr.&nbsp;Love
$1,834,000 in cash payments and Dr.&nbsp;Love received other benefits with a value of $60,353, in addition to the accelerated vesting of his options. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2"><I>Lee Bendekgey</I>. Mr.&nbsp;Bendekgey was employed &#147;at will&#148; by the Company until March&nbsp;31, 2009. On September&nbsp;14, 2007, retroactive to August&nbsp;1, 2007, the Compensation Committee of the
Board of Directors approved a base salary for Mr.&nbsp;Bendekgey of $375,000. As an executive officer of the Company, Mr.&nbsp;Bendekgey was also entitled to &#147;Change in Control Severance&#148; under the Nuvelo, Inc. Executive Change in Control
and Severance Benefit Plan, as amended August&nbsp;1, 2007 (the &#147;Severance Plan&#148;), and described below under the subsection entitled, &#147;Executive Change in Control and Severance Benefit Plan,&#148; and was entitled to participate in
the Company&#146;s management bonus pool, employee benefit plans maintained by the Company, and in other benefits provided to the Company&#146;s executive officers, including 401(k) plans, medical, vision and dental, annual vacation, paid holidays,
sick leave, and similar benefits. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On January&nbsp;27, 2009, in connection with the business combination, Mr.&nbsp;Bendekgey resigned from
his position as General Counsel and Secretary of the Company, but agreed to remain as the Company&#146;s Chief Financial Officer and Treasurer for a transitional period ending March&nbsp;31, 2009 (the &#147;Transition Period&#148;), during which
time, he agreed to assist with the preparation and filing of the Company&#146;s annual report on Form 10-K for the fiscal year ended December&nbsp;31, 2008 and to assist management with planning, finance, financial reporting, and other corporate
governance matters. Mr.&nbsp;Bendekgey&#146;s resignation from his positions constituted a &#147;Constructive Termination&#148; pursuant to the terms of the Severance Plan. As a result, Mr.&nbsp;Bendekgey was entitled to a total of $501,449 in
&#147;Change in Control Severance&#148; benefits under the Severance Plan, but agreed to defer the effective date of the &#147;Constructive Termination&#148; and his rights to receive severance benefits under the Severance Plan until the expiration
of the Transition Period and to continue to perform his duties summarized above during the Transition Period, in consideration of the Company&#146;s agreement to provide the following: </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">upon satisfactory completion of the duties, at the end of the Transition Period, the Company paid Mr.&nbsp;Bendekgey in lump sum a retention bonus of $50,000;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">concurrently with the payment of the retention bonus, the Company paid Mr.&nbsp;Bendekgey in lump sum of $250,724.50, equal to 50% of the aggregate &#147;Base
Severance Benefit&#148; and &#147;Bonus Severance Benefit&#148; that Mr.&nbsp;Bendekgey was entitled to under the Severance Plan and the Company will pay Mr.&nbsp;Bendekgey a total of $250,724.50, which amount is equal to the balance of the
&#147;Base Severance Benefit&#148; and &#147;Bonus Severance Benefit&#148; that he is owed under the Severance Plan no later than September&nbsp;30, 2009; and </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">the Company paid all other benefits to which Mr.&nbsp;Bendekgey is owed under the Severance Plan as if the effective date of the constructive termination was
March&nbsp;31, 2009. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Michael D. Levy, M.D. </I>On September&nbsp;9, 2004, the Company entered into an employment
agreement with Dr.&nbsp;Levy. Pursuant to the agreement, the Company was obligated to pay Dr.&nbsp;Levy an initial annual salary of $375,000, and a $15,000 hiring bonus, repayable to the Company if Dr.&nbsp;Levy voluntarily left the Company before
the first anniversary of his employment. In addition, Dr.&nbsp;Levy was entitled to participate in the Company&#146;s management bonus pool, employee benefit plans maintained by the Company, and in other benefits provided to the Company&#146;s
executive officers, including 401(k) plans, medical, vision and dental, annual vacation, paid holidays, sick leave, and similar benefits. Dr.&nbsp;Levy&#146;s employment with the Company was terminated in connection with a restructuring effective
March&nbsp;20, 2008. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">35 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Pursuant to Dr.&nbsp;Levy&#146;s employment agreement, the Company also granted Dr.&nbsp;Levy an option
under the Option Plan to purchase 8,750 shares of the Company&#146;s common stock (as adjusted for the Company&#146;s recent 20-for-one reverse stock split) at an exercise price equal to $196.60 per share (as adjusted for the Company&#146;s recent
20-for-one reverse stock split), the approximate fair market value of Nuvelo&#146;s common stock on the date of his first day of employment. One fourth of these shares became exercisable one year after the first day of his employment, while the
remainder were to vest monthly in equal installments during a period of three years commencing on the first anniversary of the first day of his employment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">In the event of termination of Dr.&nbsp;Levy&#146;s employment by the Company other than for cause, his Agreement provided that: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Dr.&nbsp;Levy would receive twelve months of his then-current base salary and any accrued bonus to which he was entitled; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">any options granted to Dr.&nbsp;Levy would continue to vest during the 12-month period of his salary extension; and </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Dr.&nbsp;Levy&#146;s health benefits would continue for an additional twelve months. </FONT></P></TD></TR></TABLE> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In connection with the termination of his employment effective March&nbsp;20, 2008, the Company agreed to pay Dr.&nbsp;Levy his base salary for 12
months, reimburse his COBRA expense for up to one year, and provide an additional 12 months of vesting of his stock options outstanding on his termination date, along with the right to exercise those options during the 15 months following his
termination. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Cash Bonus. </I>Nuvelo utilized cash bonuses to reward accomplishment of annual Company goals critical to the achievement
of its long term vision and the individual&#146;s achievement of functional goals for the functional organization that he or she manages. Nuvelo&#146;s Compensation Committee determined cash bonuses by reference to target bonus amounts, based on
market data, established for each executive position. <I> </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Nuvelo&#146;s Compensation Committee determined each individual executive
bonus by reference to the achievement of corporate goals and the individual executive&#146;s achievement of functional goals for the functional organization that he or she manages. Nuvelo&#146;s Board of Directors set annual corporate goals that
fall into the following categories: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Advancement of compounds in the Company&#146;s research and clinical development pipeline; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Strengthening the Company&#146;s financial position; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Development of a best in class organization capable of executing the Company&#146;s vision. </FONT></P></TD></TR></TABLE> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">For the Nuvelo&#146;s fiscal year ended December&nbsp;31, 2007, these goals included making &#147;go/no go&#148; decisions on all four indications of
Nuvelo&#146;s product candidate, alfimaprase. Given the decision not to pursue some indications, the corporate goals were revised accordingly in August 2007. Enrollment goals for SONOMA-3, Nuvelo&#146;s clinical trial of alfimeprase for catheter
occlusion, and CARNEROS-1, Nuvelo&#146;s clinical trial of alfimeprase for the treatment of acute ischemic stroke, were included among the revised goals as were investigational new drug submissions for with the FDA NU172 and NU206, and other goals
that Nuvelo&#146;s Board of Directors determined were important to Nuvelo&#146;s progress and were reasonably difficult to achieve. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">For
the Nuvelo&#146;s fiscal year ended December&nbsp;31, 2008, these goals also included enrollment goals for SONOMA-3, Nuvelo&#146;s clinical trial of alfimeprase for catheter occlusion, investigational new drug submissions for with the FDA NU172 and
NU206, the identification of at least one additional product candidate for preclinical development, partner with at least one research program, and other goals that Nuvelo&#146;s Board of Directors determined were important to Nuvelo&#146;s progress
and were reasonably difficult to achieve. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">36 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Nuvelo&#146;s Compensation Committee determined the relative weight of each goal based on its importance
to Nuvelo&#146;s success. Given the importance of Nuvelo&#146;s research and development programs to its success, Nuvelo&#146;s Compensation Committee determined that achievement of goals associated with the advancement of Nuvelo&#146;s research and
development pipeline would be worth 70% of the total for bonus achievement in 2007 and 2008, with financial goals afforded 10% of the total and organizational goals the remaining 20% in both years. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">After the end of each year, Nuvelo&#146;s Compensation Committee established the overall bonus pool based on its assessment of whether Nuvelo met
corporate goals at the target level, exceeded expectations, or failed to meet expectations. Nuvelo&#146;s Compensation Committee assessed Nuvelo&#146;s performance in 2007 as having achieved 84% of the target goal performance. The Committee&#146;s
determination was based on Nuvelo&#146;s failure to meet goals based on enrollment in the Company&#146;s clinical trial of alfimeprase in acute ischemic stroke, as well as delays in the initiation of a Phase 1 trial of NU206. The Committee found
that Nuvelo had met other research and development goals, as well as organizational and financial goals. The Committee&#146;s assessment of the percentage deductions for failure to achieve a particular goal involved significant discretion, within
the range of the percentages that the Committee has previously attributed as the value of the achievement of that goal. The Compensation Committee also retained the discretion to grant bonuses to individual executives that were above or below the
established target based on the above criteria and its subjective assessment of each executive&#146;s performance and the achievement of the corporate goals for which that executive was primarily responsible. For that reason, following the
determination that the overall bonus pool would be reduced to 84%, Mr.&nbsp;Bendekgey&#146;s bonus was calculated as 110% of 84%, because the Company had met or outperformed all of the finance, compliance and legal goals for which he was
responsible. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Nuvelo&#146;s Compensation Committee did not award any bonus payments to its Named Executive Officers based on Nuvelo&#146;s
performance for 2008. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Stock Options.</I> Nuvelo granted stock options to its executives, and to all of its employees, to provide long
term incentives that aligned the interests of its work force with the achievement of Nuvelo&#146;s long term vision to develop and commercialize pharmaceutical products. Given the time periods involved in pharmaceutical development, Nuvelo believed
that these long term incentives were critical to the Company&#146;s success. The exercise price for options granted by the Company was established as the market price of the Company&#146;s stock on the date of the grant. The market price of the
Company&#146;s stock on the date of grant was determined by the average of the high and the low sale price on the date of grant. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:3px;line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2">Nuvelo&#146;s Compensation Committee determined stock option grants for the Chief Executive
Officer and each Section&nbsp;16 reporting officer. Target ranges for stock option grants were based on position, salary level, and competitive practices of peer companies, as reported to the Company by its compensation consultants. As with cash
compensation, the Company targeted the 65</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>th</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"> percentile for option grants at peer companies. Actual awards also reflect individual performance and
potential, as well as retention objectives. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Options were granted to all employees, including executives, when they were hired, and once
each year in connection with annual performance reviews. New hire stock option grants were effective on the first day of the employee&#146;s employment with Nuvelo, and the exercise price for those option grants was the market price on that date.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Based on the revised annual performance and compensation calendar, in January 2007, the Compensation Committee approved annual performance
stock options grants, which were effective on February&nbsp;1, 2007. Using the criteria noted above, consistent with their market based option ranges and performance, Dr.&nbsp;Love received 15,000 stock options; Dr.&nbsp;Levy received 4,513 stock
options; and Mr.&nbsp;Bendekgey received 4,999 stock options. Based on the Company&#146;s annual performance during its fiscal year ended December&nbsp;31, 2007, and based on the criteria described above, consistent with their market based ranges
and performance, the Compensation Committee, in January 2008, approved grants to Dr.&nbsp;Love of 999 stock options, Mr.&nbsp;Bendekgey of 4,999 stock options and Dr.&nbsp;Levy of 4,999 stock options, effective February&nbsp;1, 2008. The merger with
ARCA Colorado </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">37 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">described elsewhere in this Proxy Statement constituted a &#147;Change in Control&#148; as defined in the Option Plan, as a result of which, all of the
unvested options held by Nuvelo&#146;s Named Executive Officers fully vested as of the closing of the merger on January&nbsp;27, 2009. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2"><I>Executive Change in Control and Severance Benefit Plan</I>.<I> </I>In 2004 the Company&#146;s Board of Directors adopted an Executive Change in Control and Severance Benefit Plan, or the Severance Plan, which is applicable to employees
at the level of Vice President and above. The Board of Directors determined that companies considered peers at that time commonly offered benefits comparable to those offered under this plan, whose benefits are described in the table that follows.
Given the risks associated with the biopharmaceutical industry and the increasing frequency of acquisitions in the industry, the Compensation Committee continues to believe that this plan is necessary to attract and retain qualified executives. The
Company also negotiated separate severance benefits with Dr.&nbsp;Levy which, to the extent they exceed the benefits provided for in the Severance Plan, supersede the benefits under the Severance Plan. Effective March&nbsp;20, 2008,
Dr.&nbsp;Levy&#146;s employment with the Company was terminated in connection with a restructuring. In connection with that separation, the Company agreed to pay Dr.&nbsp;Levy his base salary for 12 months, reimburse his COBRA expense for up to one
year, and provide an additional 12 months of vesting of his stock options outstanding on his termination date, along with the right to exercise those options during the 15 months following separation. The benefits provided Dr.&nbsp;Levy in
connection with his separation are consistent with those offered executives under the Company&#146;s Severance Plan, except that Dr.&nbsp;Levy was granted an additional 12-month period in which to exercise his options, as required by his employment
agreement with the Company, which was negotiated prior to the Company&#146;s adoption of the Severance Plan.<I> </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In the annual review
of executive compensation, the Compensation Committee determined that Dr.&nbsp;Love&#146;s change in control and severance benefit was lower than chief executive officers&#146; at comparable companies (based on market capitalization, number of
employees, and a location in a similar geography). Consequently, in 2007, Dr.&nbsp;Love&#146;s benefits were modified to be more consistent with market data and to be in compliance with Section&nbsp;409A. Specifically, Dr.&nbsp;Love&#146;s severance
benefits in cases of change in control or other terminations without good cause were increased to provide him with two years of salary and benefits, rather than one year, as his agreement had previously provided. To the extent Dr.&nbsp;Love&#146;s
benefits exceed the benefits provided for in the Severance Plan, his benefits supersede the benefits under the Severance Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Other
Elements of Executive Compensation Program </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The remaining elements of the Company&#146;s executive compensation program, like its
broader employee compensation programs, are intended to make the Company&#146;s overall compensation program competitive with those of its peer companies, keeping in mind the constraints imposed by the Company&#146;s reliance on capital markets as a
primary source of cash. With the exception of the Severance Plan, all of the remaining elements of the Company&#146;s executive compensation program, (401(k)&nbsp;Plan, Medical, Dental, and Vision Plans, Life and Disability Insurance, and Employee
Stock Purchase Plan) are available to all Company employees. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Payments Made in Connection with Change in Control </I></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Following the merger with ARCA Colorado on January&nbsp;27, 2009, each of Nuvelo&#146;s then serving Named Executive Officer was entitled to receive the
following benefits under the Severance Plan, adopted by the Board of Directors, or, as applicable, such Named Executive Officer&#146;s employment agreement to the extent such agreement provided for greater benefits. The amounts shown in the table
below assume that termination was effective as of January&nbsp;27, 2009. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">As described above, upon the closing of the Company&#146;s merger
with ARCA Colorado, Dr.&nbsp;Love&#146;s employment with the Company was terminated in connection with a change in control and he became entitled to receive the benefits described below. In addition, upon the closing of the merger,
Mr.&nbsp;Bendekgey resigned from his position as General Counsel and Secretary of the Company, but agreed to remain as the Company&#146;s Chief </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">38 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">Financial Officer and Treasurer for a transitional period ending March&nbsp;31, 2009. Mr.&nbsp;Bendekgey&#146;s resignation from his positions constituted a
&#147;Constructive Termination&#148; pursuant to the terms of the Severance Plan. As a result, Mr.&nbsp;Bendekgey was entitled to receive benefits under the Severance Plan payable in connection with a change of control, but agreed to defer the
effective date of the &#147;Constructive Termination&#148; and his rights to receive severance benefits under the Severance Plan until March&nbsp;31, 2009. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT FACE="Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:27pt"><FONT FACE="Times New Roman" SIZE="1"><B>Benefits</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Value&nbsp;Received</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Ted W. Love, M.D.(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Cash severance</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,834,000</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Cash bonus</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Medical benefits</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">60,353</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Stock option vesting acceleration(2)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,872,356</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em"><FONT FACE="Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4,766,709</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Lee Bendekgey</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Cash severance</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">501,449</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Cash bonus</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">50,000</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Medical benefits</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">16,521</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Stock option vesting acceleration(2)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">571,130</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em"><FONT FACE="Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,139,100</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The Company entered into an employment agreement with Dr.&nbsp;Love in January 2001, which was subsequently amended in April 2007. Pursuant to the amended employment agreement,
Dr.&nbsp;Love is entitled to cash severance benefits and medical benefits substantially equivalent to those shown above and additional vesting and option exercise benefits related to his stock options, which are described in more details in
&#147;Employment and Severance Agreements&#148; below. In addition, Dr.&nbsp;Love, or his estate, as applicable, are entitled to the benefits under his employment agreement in the event his employment is terminated due to his death or disability.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Amounts represent the fair value of unvested stock options that were accelerated upon the closing of the merger on January 27, 2009. The fair value was determined on the grant date
of the respective options in accordance with SFAS 123R and, therefore, is not indicative of the value that would be ultimately realized by the Named Executive Officers upon exercise of their options. As of January 27, 2009, the closing price of the
Company&#146;s common stock was $4.40 (as adjusted for the 20 for 1 reverse stock split), and the exercise prices of all stock options held by the Named Executive Officers as of that date were above $4.40. Accordingly, the Named Executive Officers
would not receive any benefits from the acceleration of stock option vesting as provided in the Severance Plan . </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">39 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Equity Awards </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">The following table shows certain information regarding equity awards for the Named Executive Officers outstanding as of December&nbsp;31, 2008: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT FACE="Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Option Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Stock Awards</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Number</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>of<BR>Securities</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>Underlying</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Unexercised</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Options</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>(#)</B></FONT><br><FONT
FACE="Times New Roman" SIZE="1"><B>Exercisable</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Number</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>of</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>Securities</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Underlying</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Unexercised</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Options</B></FONT><br><FONT
FACE="Times New Roman" SIZE="1"><B>(#)</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Unexercisable</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Equity</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Incentive</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>Plan<BR>Awards:<BR>Number of</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Securities</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Underlying</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>Unexercised</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Unearned</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Options</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>(#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Option</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Exercise</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>Price</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Option</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Expiration</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Number</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>of</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>Shares<BR>or</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Units of</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Stock<BR>That</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Have<BR>Not</B></FONT><br><FONT
FACE="Times New Roman" SIZE="1"><B>Vested</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>(#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Market<BR>Value<BR>of</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Shares<BR>or</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>Units<BR>of</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Stock<BR>That</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Have<BR>Not</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Vested</B></FONT><br><FONT
FACE="Times New Roman" SIZE="1"><B>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Equity<BR>Incentive<BR>Plan</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Awards:</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>Number<BR>of</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Unearned</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Shares,<BR>Units or</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Other</B></FONT><br><FONT
FACE="Times New Roman" SIZE="1"><B>Rights</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>That</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Have Not</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Vested</B></FONT><br><FONT
FACE="Times New Roman" SIZE="1"><B>(#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Equity</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Incentive<BR>Plan<BR>Awards:</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>Market<BR>or</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Payout<BR>Value of<BR>Unearned</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Shares,<BR>Units</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>or
Other</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Rights<BR>That</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Have Not</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Vested</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>($)</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Ted W. Love, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5,303</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">750.00</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1/10/11</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">530</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">753.75</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1/10/11</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,250</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">626.40</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7/31/11</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,332</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">132.60</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8/05/12</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,332</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">81.90</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5/19/13</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,332</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">129.00</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6/10/13</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7,499</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">203.50</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5/07/14</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">16,042</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,458</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">203.50</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5/07/14</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11,751</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,248</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">196.50</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1/07/15</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">18,750</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,750</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">183.30</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8/01/15</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10,938</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7,812</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">334.70</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8/01/16</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9,166</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5,834</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">70.71</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2/01/17</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,084</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7,915</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">31.30</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2/01/18</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Lee Bendekgey(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,250</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">168.20</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6/30/09</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,958</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">541</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">196.50</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6/30/09</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6,250</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,249</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">183.30</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6/30/09</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,459</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,040</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">334.70</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6/30/09</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,054</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,945</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">70.71</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6/30/09</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,042</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,957</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">31.30</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6/30/09</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Michael D. Levy, M.D(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8,749</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">196.60</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6/20/09</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8,959</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">183.30</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6/20/09</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,584</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">334.70</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6/20/09</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4,513</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">70.71</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6/20/09</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,355</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">31.30</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6/20/09</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Mr.&nbsp;Bendekgey&#146;s employment with the Company was terminated on March&nbsp;31, 2009. His stock options, if unexercised, will expire on June&nbsp;30, 2009.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Dr.&nbsp;Levy&#146;s employment with the Company was terminated on March&nbsp;20, 2008. His stock options, if unexercised, will expire on June&nbsp;20, 2009, 15 months from his
termination date. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">40 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>ARCA Post-Business Combination Named Executive Officers </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Summary Compensation Table </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The following table shows for the fiscal year ended
December&nbsp;31, 2008, compensation awarded to, paid to, or earned by the Company&#146;s current principal executive officer and its other current named executives officer, collectively, the ARCA Named Executive Officers, while those ARCA Named
Executive Officers were employed by ARCA Colorado. The compensation for Kathryn Falberg is not included in the below table because she was not employed by ARCA until after December&nbsp;31, 2008: </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Name and Principal</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:68pt"><FONT
FACE="Times New Roman" SIZE="1"><B>Position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Year</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Salary</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Bonus</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Option<BR>Awards</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>(2)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Non-Equity<BR>Incentive</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>Plan<BR>Compensation<BR>(3)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>All Other<BR>Compensation<BR>(4)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Total</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Richard B. Brewer</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">Chief Executive Officer and Director
</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2008</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">311,400</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">415,172</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">108,990</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">835,562</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Michael R. Bristow, M.D., Ph.D.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">Chief Science and
Medical Officer and Chairman of the Board of Directors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2008</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">259,500</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">90,825</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9,199</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">359,524</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The cash bonuses earned in 2008 were paid under incentive plans and, therefore, are reported in the column &#147;Non-Equity Incentive Plan Compensation.&#148;
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Amounts reflect stock-based compensation expense recognized for financial statement reporting purposes for the year ended December&nbsp;31, 2008, in accordance with SFAS 123R, and
include amounts attributable to awards granted in and before 2008. Assumptions used in the valuation of stock options are disclosed in Note 9 to the Company&#146;s Consolidated Financial Statements filed as an exhibit to the Company&#146;s Current
Report on Form 8-K/A (Amendment No.&nbsp;2), filed with the SEC on March&nbsp;31, 2009. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Amounts reflect cash bonus earned in 2008 under the cash bonus program, as described in more detail below under the subsection titled, &#147;Narrative Disclosure to Summary
Compensation Table.&#148; Cash bonuses that were earned in 2008 were paid on February&nbsp;20, 2009. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Unless otherwise indicated, amounts consist of contributions made by the Company to the 401(k) Plan for each of the Named Executive Officers. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Narrative Disclosure to Summary Compensation Table </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman"
SIZE="2"><I>Employment Agreements or Arrangements </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Richard B. Brewer. </I>Mr.&nbsp;Brewer is employed as the Company&#146;s
President and Chief Executive Officer under an Employment and Retention Agreement dated November&nbsp;2, 2006 that was amended and restated as of July&nbsp;7, 2008 and assumed by the Company from ARCA Colorado on January&nbsp;27, 2009. Under his
employment agreement, Mr.&nbsp;Brewer is entitled to receive an annual base salary of $311,400, subject to annual increases if approved by the Board of Directors, or the Company&#146;s Compensation Committee, and is eligible to receive an annual
bonus as determined by the Board of Directors or Compensation Committee in its sole discretion. Mr.&nbsp;Brewer is permitted to serve on a maximum of four outside corporate boards of directors, so long as it does not interfere with his duties as
President and Chief Executive Officer of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">If the Company terminates Mr.&nbsp;Brewer&#146;s employment without
&#147;cause,&#148; or if Mr.&nbsp;Brewer terminates his employment with &#147;good reason&#148; (as these terms are defined in his employment agreement), the Company has agreed to pay Mr.&nbsp;Brewer a severance payment equivalent to (i)&nbsp;12
months of his base salary and (ii)&nbsp;a pro rata portion of any bonus compensation under any employee bonus plan that has been approved by the Board of Directors payable to him for the fiscal year in which his employment terminated to be paid at
the same time that the incentive bonus would have been paid had the termination not occurred. The Company may elect to pay Mr.&nbsp;Brewer additional severance equal to up to 12 months of his base salary, which additional payments would </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">41 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">extend Mr.&nbsp;Brewer&#146;s obligations under his Employee Intellectual Property, Confidentiality and Non-Compete Agreement for such additional period.
Severance payments may be made by the Company on a monthly basis or, at the Company&#146;s election, in a lump sum. The severance payment is conditioned on the execution by Mr.&nbsp;Brewer of a legal release in a form acceptable to the Company. A
termination for &#147;cause&#148; includes willful misconduct, gross negligence, theft, fraud, or other illegal or dishonest conduct, any of which are considered to be materially harmful to the Company; refusal, unwillingness, failure, or inability
to perform material job duties or habitual absenteeism; or violation of fiduciary duty, violation of any duty of loyalty, or material breach of any material term of the employment agreement or the Employee Intellectual Property, Confidentiality and
Non-Compete Agreement, or any other agreement, with the Company. &#147;Good reason&#148; includes a decrease in current base salary, with certain exceptions; change in title or reporting relationship; failure of Company stockholders to elect
Mr.&nbsp;Brewer to the Board of Directors; a move of the Company&#146;s headquarters to a location greater than 60 miles from Denver, Colorado; resignation within 90 days of a corporate transaction; or the Company&#146;s unilateral decision to
significantly and detrimentally reduce Mr.&nbsp;Brewer&#146;s job responsibilities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In connection with the execution of his employment
agreement, in November 2006, Mr.&nbsp;Brewer was granted the option to purchase 165,644 shares of Company common stock pursuant to a Stock Option Agreement between ARCA Colorado and Mr.&nbsp;Brewer and the other terms and conditions of the ARCA
Colorado 2004 Stock Incentive Plan. The options were exercisable immediately, subject to ARCA&#146;s right to repurchase any shares that have been exercised at the exercise price upon a voluntarily resignation by Mr.&nbsp;Brewer, his termination for
cause or upon his death or disability. ARCA&#146;s right of repurchase lapses at the rate of 6.25% at the end of each quarter following the first anniversary of the grant date. In addition, ARCA&#146;s right of repurchase lapses in full upon the
earlier of a corporate transaction (as defined in his employment agreement) or upon a termination other than for cause or by Mr.&nbsp;Brewer for good reason. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">In addition to the options, Mr.&nbsp;Brewer was issued 83,490 shares of restricted stock of the Company pursuant to a Restricted Stock Agreement dated November&nbsp;2, 2006 that was amended on February&nbsp;19, 2007.
Mr.&nbsp;Brewer paid $37,750 for 41,745 of the shares and received the remaining shares in consideration for prior services. The amount Mr.&nbsp;Brewer paid for the shares was equal to the fair market value of the stock on the date of issuance. In
October 2008, Mr.&nbsp;Brewer&#146;s Restricted Stock Agreement was amended to provide that the shares of restricted stock vested in full upon the closing of the business combination with Nuvelo. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Michael R. Bristow, M.D., Ph.D.</I> Dr.&nbsp;Bristow serves as the Company&#146;s Chief Science and Medical officer under an Employment and Retention
Agreement that was amended and restated as of June&nbsp;4, 2008. Dr.&nbsp;Bristow is permitted to continue his academic work for the University of Colorado Health Sciences Center and for the Cardiovascular Institute, so long as it does not interfere
with his duties as Chairman and Chief Science and Medical Officer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Under his employment agreement, Dr.&nbsp;Bristow is entitled to receive
an annual base salary of $259,500, subject to annual increases if approved by the Company&#146;s Board of Directors or Compensation Committee and is eligible to receive an annual bonus as determined by the Board of Directors or Compensation
Committee in its sole discretion. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">If the Company terminates Dr.&nbsp;Bristow&#146;s employment without &#147;cause,&#148; or if
Dr.&nbsp;Bristow terminates his employment with &#147;good reason&#148; (as these terms are defined in his employment agreement), the Company has agreed to pay Dr.&nbsp;Bristow a severance payment equivalent to (i)&nbsp;12 months of his base salary,
(ii)&nbsp;a pro rata portion of any bonus compensation under any employee bonus plan that has been approved by the Board of Directors payable to him for the fiscal year in which his employment terminated to be paid at the same time that such
incentive bonus would have been paid had the termination not occurred, and (iii)&nbsp;reimbursement to cover out-of-pocket costs to continue group health insurance benefits under COBRA for 12 months, whether he elects or is eligible to receive COBRA
(provided, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out-of-pocket expenses paid by him not to exceed the costs that the benefits would equal under COBRA if he were so eligible). In
addition, ARCA may elect in its sole discretion, to pay </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">42 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">additional severance equal to up to 12 months of base salary, which additional payment would extend the covenants and obligations under
Dr.&nbsp;Bristow&#146;s Employee Intellectual Property, Confidentiality and Non-Compete Agreement for such additional period. The severance payment is conditioned on the execution by Dr.&nbsp;Bristow of a legal release in a form acceptable to the
Company. A termination for &#147;cause&#148; includes willful misconduct, gross negligence, theft, fraud, or other illegal or dishonest conduct, any of which are considered to be materially harmful to the Company; refusal, unwillingness, failure, or
inability to perform material job duties or habitual absenteeism; or violation of fiduciary duty, violation of any duty of loyalty, or material breach of any material term of the employment agreement or the Employee Intellectual Property,
Confidentiality and Non-Compete Agreement, or any other agreement, with the Company. &#147;Good reason&#148; includes a relocation of normal work location greater than 30 miles; a decrease in current base salary by more than 15%, with certain
exceptions; and the Company&#146;s unilateral decision to significantly and detrimentally reduce Dr.&nbsp;Bristow&#146;s job responsibilities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">In January 2005, Dr.&nbsp;Bristow was granted an option to purchase 118,319 shares of ARCA common stock pursuant to a Stock Option Agreement between ARCA Colorado and Dr.&nbsp;Bristow and the other terms and conditions of the ARCA Colorado
2004 Stock Incentive Plan. The option fully vested as of October&nbsp;18, 2008. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Base Salary. </I>ARCA provides its current Named
Executive Officers and other employees with base salary to compensate them for services rendered during the year. Base salary ranges for ARCA&#146;s current Named Executive Officers are determined for each named executive officer based on his or her
position and responsibility. During its review of base salaries for ARCA&#146;s executives, ARCA&#146;s Compensation Committee primarily considers:<I> </I></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">the negotiated terms of each executive&#146;s employment agreement, to the extent that one exists; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">internal review of the executive&#146;s compensation, both individually and relative to other named executive officers; and </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">individual performance of the executive. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">In February 2009, the Company&#146;s Board of Directors and Compensation Committee completed a review of the Company&#146;s executive compensation in light of general market conditions in the life science industry and the completion of the
business combination transaction with Nuvelo, pursuant to which the management of ARCA became the management of the Company. The Compensation Committee engaged Compensia to review and assess the Company&#146;s executive compensation program.
Compensia identified a peer group of pre-revenue generating biotechnology companies that had become public companies prior to the middle of 2006. This peer group included, Acadia Pharmaceuticals, Alexza Pharmaceuticals, Allos Therapeutics, Array
Biopharma, Cytokinetics, Cytori Therapeutics, Dendreon, Geron, Incyte, Intermune, Neurocrin Biosciences and Pain Therapeutics. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:3px;line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2">In setting 2009 base salary and cash bonus award amounts for the ARCA Named Executive Officers,
the Compensation Committee analyzed the peer group data and targeted cash compensation in the 50</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>th</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"> percentile of cash compensation paid to similarly
situated executive officers within the peer group. In light of its considerations, the Compensation Committee recommended and the Board of Directors approved increases to base salary of Mr.&nbsp;Brewer to $456,000 and of Dr.&nbsp;Bristow to
$365,000. The increased base salaries became effective retroactively as of January&nbsp;1, 2009. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Annual and Special Bonuses. </I>In
February 2007, the Compensation Committee and the Board of Directors of ARCA Colorado established a bonus structure for its entire executive team. The philosophy employed was to create incentives for the executive officers to achieve key corporate
goals. The Compensation Committee set a potential bonus target of 50% of base salary for Mr.&nbsp;Brewer and Dr.&nbsp;Bristow. The Compensation Committee retained discretion to change the bonus structure and the bonus payment amounts as it
considered appropriate. <I> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">43 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">For incentive bonuses tied to 2008 performance, the Compensation Committee and Board of Directors of ARCA
Colorado approved a similar bonus structure as they approved for 2007. All company executives remained at their respective bonus target levels. For 2008, the Board of Directors of ARCA Colorado, with the participation of the Compensation Committee
and members of management, formulated 12 equally weighted corporate performance goals that were consistent with the maturation of the Gencaro development program, financing activities, and pre-commercialization activities. These goals were related
to the submission and acceptance of the Gencaro NDA with the FDA, obtaining financing, and pre-commercialization activities. The Board of Directors of ARCA Colorado believed that these goals were attainable with a very high level of executive
performance and that such goals would be challenging to achieve. The 12 goals included: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">submission of the new drug application (&#147;NDA&#148;) for Gencaro adequate for filing and approval by the FDA; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">submission by LabCorp of a genetic test application associated with the FDA&#146;s review of the NDA for Gencaro to the FDA, sufficient for approval;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">securing financing sufficient to fund ARCA through Gencaro&#146;s anticipated launch in 2009; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">development of the Gencaro commercial plan; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">securing the manufacturing, tableting, and packaging arrangements adequate for the anticipated commercial launch of Gencaro; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">key opinion leader identification and recruitment; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">investor relations and public relations development and execution; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">relocation of ARCA Colorado to new Colorado offices; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">design and implementation of the bucindolol genetic registry; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">implementation of the Gencaro reimbursement plan; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">preparation for a possible cardio-renal advisory committee meeting for Gencaro Test; and </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">sales force and field force hiring and deployment. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Following the completion of the business combination transaction in January 2009, the Compensation Committee and Board of Directors of ARCA concluded that the 2008 corporate goals for ARCA Colorado described above had
been met at the 70% level, and each executive officer therefore received a bonus based on corporate goal achievement equal to his respective bonus percentage level multiplied by his base salary and adjusted pursuant to the compensation
committee&#146;s discretion to account for its assessment of each named executive officer&#146;s individual performance. Cash bonuses paid to ARCA&#146;s Named Executive Officers were $108,890 for Mr.&nbsp;Brewer and $90,825 for Dr.&nbsp;Bristow.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">For incentive bonuses tied to ARCA&#146;s 2009 performance, the Compensation Committee approved a revised set of equally weighted goals,
which the Board of Directors of ARCA believes are attainable with a very high level of executive performance and will be challenging to achieve. These goals include: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">compliance with securities laws and stock exchange listing requirements applicable to public companies; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">FDA approval of the new drug application (&#147;NDA&#148;) for Gencaro; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">44 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">FDA approval of LabCorp&#146;s premarket approval submission; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">development and execution of the Gencaro commercialization plan; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">securing the manufacturing, tableting, and packaging arrangements adequate for the anticipated commercial launch of Gencaro; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">securing financing to support commercialization of Gencaro; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">development of additional product candidates; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">development of collaborative relationships to support development and commercialization of Gencaro and other product candidates in additional markets.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">For 2009 performance, the Compensation Committee of the Board of Directors of ARCA set a potential bonus target of 50%
of base salary for Mr. Brewer and Dr. Bristow and 40% of base salary for Ms. Falberg. The Compensation Committee retains discretion to change the bonus structure and the bonus payment amounts as it considers appropriate. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Equity Incentive Compensation. </I>Prior to the merger with Nuvelo, the Compensation Committee of ARCA Colorado considered the equity ownership of the
executive officers and, based upon the committee members&#146; experience investing in and serving on the boards of similar life sciences companies, and upon the executive officers&#146; ownership percentages in ARCA Colorado, the Compensation
Committee of ARCA Colorado did not approve any additional option awards in 2008. However, based upon the committee members&#146; assessment of equity ownership of executive officers based on the peer group data described above, and in recognition of
their efforts to bring about the successful completion of the business combination with Nuvelo, in January 2009, the Board of Directors of ARCA Colorado awarded each of Mr.&nbsp;Brewer and Dr.&nbsp;Bristow options to purchase 25,047 shares of ARCA
common stock at an exercise price of $5.57 per share pursuant to a Stock Option Agreement between ARCA and Dr.&nbsp;Bristow and the other terms and conditions of the ARCA Colorado 2004 Stock Incentive Plan (the &#147;ARCA Plan&#148;). </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Prior to the merger with Nuvelo, ARCA Colorado had adopted the ARCA Plan to enhance the ability of ARCA and its affiliates&#146; ability to attract and
retain highly qualified officer, directors, key employees, and other persons, and to motivate them to serve ARCA Colorado and to expend maximum effort to improve the business results and earnings of ARCA Colorado, by providing to such officers,
directors, key employees, and other persons an opportunity to acquire or increase a direct proprietary interest in the operations and future success of ARCA Colorado. The ARCA Plan was originally adopted by the ARCA Colorado Board of Directors and
stockholders on September&nbsp;30, 2004, with certain amendments to the ARCA Plan having been subsequently approved by the Board of Directors and stockholders. In connection with the merger with Nuvelo, ARCA assumed the ARCA Plan and the options
previously issued under the plan, although no further awards will be made under the ARCA Plan. As of January&nbsp;27, 2009, there were 722,686 options subject to outstanding ARCA Plan awards. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The ARCA Plan authorizes the granting of awards to ARCA&#146;s employees, officers, consultants, and directors and to the employees, officers,
consultants, and directors of its subsidiaries. The following awards are available under the ARCA Plan: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">options to purchase shares of common stock, which may be incentive stock options or non qualified stock options; and </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">restricted stock. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">45 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In connection with the merger, a &#147;change of control&#148; as defined in the ARCA Plan occurred, all
outstanding options and restricted stock were substituted for new common stock options and new restricted stock of the Company. Appropriate adjustments as to the number of shares and option prices were made, and outstanding options and restricted
stock continue in the manner and under the terms so provided. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Retirement Plans, Perquisites and Other Personal Benefits. </I>ARCA
Colorado adopted a tax-qualified employee savings and retirement plan, the 401(k) Plan, for eligible employees, including its Named Executive Officers.<I> </I>Eligible employees may elect to defer a percentage of their eligible compensation in the
401(k) Plan, subject to the statutorily prescribed annual limit. ARCA Colorado elected to make &#147;safe harbor&#148; matching contributions on behalf of all participants in the 401(k) Plan in accordance with statutory requirements. Participants
are fully vested in all matching contributions. During fiscal 2008, ARCA<I> </I>Colorado&#146;s matching contributions were equal to 100% of each employee&#146;s first 3% of pretax deferrals and 50% of each employee&#146;s next 2% of pretax
deferrals.<I> </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I></I>ARCA intends the 401(k) Plan, and the accompanying trust, to qualify under Sections 401(k) and 501 of the
Internal Revenue Code so that contributions by employees to the 401(k) Plan, and income earned (if any) on plan contributions, are not taxable to employees until withdrawn from the 401(k) Plan, and so that ARCA will be able to deduct its
contributions, if any, when made. The trustee under the 401(k) Plan, at the direction of each participant, may invest the assets of the 401(k) Plan in any of a number of investment options.<I> </I></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The executive officers of ARCA are eligible to participate in all employee benefit plans of ARCA, such as medical, dental, vision, group life,
disability, and accidental death and dismemberment insurance, in each case on the same basis as other employees, subject to applicable law. ARCA also provides vacation and other paid holidays to all employees, including executive officers, which it
believes are comparable to those provided at peer companies. During the fiscal year ended December&nbsp;31, 2008, ARCA Colorado did not provide any of Messrs. Brewer, Bristow, Ozeroff, and St. Laurent with any other perquisites or personal benefits.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Equity Compensation; Ownership Guidelines</I>. ARCA&#146;s long-term incentive compensation consists solely of periodic grants of stock
options to its Named Executive Officers. The stock option program is intended to: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">link the creation of stockholder value with executive compensation; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">provide increased equity ownership by executives; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">function as a retention tool, because participants must remain employed by ARCA as a condition to the vesting of options granted by the compensation and award
committees; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">maintain competitive levels of total compensation. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Options generally vest over four years. Prior to the exercise of an option, the holder has no rights as a stockholder with respect to the shares subject to such option, including voting rights and the right to receive
dividends or dividend equivalents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In addition to the stock option grant, certain executives have been issued restricted stock upon
payment by the executive of a price equal to the fair market value of the stock on the date of issuance. The restricted stock is subject to repurchase by ARCA for any unvested portion. To date, only Mr.&nbsp;Brewer has been granted an award of
restricted stock and his grant vested in full upon the closing of the business combination. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">46 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Equity Awards </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">The following table shows certain information regarding equity awards for the ARCA Named Executive Officers outstanding as of December&nbsp;31, 2008: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END(1) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT FACE="Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="12" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Option Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Stock Awards</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Number</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>of<BR>Securities</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>Underlying</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Unexercised</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Options</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>(#)</B></FONT><br><FONT
FACE="Times New Roman" SIZE="1"><B>Exercisable</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Number</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>of</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>Securities</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Underlying</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Unexercised</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Options</B></FONT><br><FONT
FACE="Times New Roman" SIZE="1"><B>(#)</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Unexercisable</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Equity</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Incentive</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>Plan<BR>Awards:<BR>Number</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>of</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Securities</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Underlying</B></FONT><br><FONT
FACE="Times New Roman" SIZE="1"><B>Unexercised</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Unearned</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Options</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>(#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Option</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Exercise</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>Price</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Option</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Expiration</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Number<BR>of</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Shares<BR>or</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>Units of</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Stock<BR>That</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Have&nbsp;Not</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Vested</B></FONT><br><FONT
FACE="Times New Roman" SIZE="1"><B>(#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Market<BR>Value of</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Shares or</B></FONT><br><FONT
FACE="Times New Roman" SIZE="1"><B>Units of</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Stock</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>That</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Have Not</B></FONT><br><FONT
FACE="Times New Roman" SIZE="1"><B>Vested</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Equity<BR>Incentive<BR>Plan</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Awards:</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>Number<BR>of</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Unearned</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Shares,<BR>Units or</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Other</B></FONT><br><FONT
FACE="Times New Roman" SIZE="1"><B>Rights</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>That</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Have Not</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Vested</B></FONT><br><FONT
FACE="Times New Roman" SIZE="1"><B>(#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Equity</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Incentive<BR>Plan<BR>Awards:</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>Market<BR>or</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Payout<BR>Value of<BR>Unearned</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Shares,<BR>Units</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>or
Other</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Rights<BR>That</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Have Not</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Vested</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>($)</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="1">Richard B. Brewer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1">165,644</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1">(2)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="1">0.90</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="1">11/02/2016</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1">83,490</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1">(5)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="1">519,307.80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1">(5)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="1">&#151;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="1">Michael R. Bristow, M.D., Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1">118,319</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1">(3)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1">7,394</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1">(4)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="1">0.06</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="1">01/03/2015</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1">&#151;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="1">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="1">&#151;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="1">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="1">References to options or shares held by all other executive officers in the table refer to options or shares of ARCA. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="1">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="1">These options vested immediately, subject to the right of repurchase, which lapsed at the rate of 6.25% of the shares subject to the option at the end of each three-month period
following the first anniversary of the November&nbsp;2, 2006 grant date. Of these options, as of December&nbsp;31, 2008, 72,470 were subject to a right of repurchase in favor of ARCA. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="1">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="1">These stock options were granted on January&nbsp;3, 2005, and vest (i)&nbsp;with respect to 25% of the shares subject to the options, on October&nbsp;18, 2005, and (ii)&nbsp;with
respect to the remaining shares subject to the options, at the rate of 6.25% of such shares at the end of each three-month period thereafter. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="1">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="1">These stock options were granted on January&nbsp;3, 2005, and vest (i)&nbsp;with respect to 25% of the shares subject to the options, on October&nbsp;18, 2005, and (ii)&nbsp;with
respect to the remaining shares subject to the options, at the rate of 6.25% of such shares at the end of each three-month period thereafter. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="1">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="1">All shares vested on January&nbsp;27, 2009 upon the closing of the merger. The market value of the shares is based on the $6.22 per share fair value of the common stock of ARCA as
of December&nbsp;31, 2008 as determined by the Board of Directors of ARCA Colorado. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">47 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Under the Company&#146;s policies applicable to transactions involving related persons, transactions involving related persons are assessed by the
independent directors of the Company&#146;s Board of Directors. Related persons include Company directors and executive officers, as well as immediate family members of directors and officers. If the determination is made that a related person has a
material interest in any ARCA transaction, then the Company&#146;s independent directors would review, approve or ratify it, and the transaction would be required to be disclosed in accordance with the applicable law and Nasdaq listing requirements.
If the related person at issue is a director of ARCA, or a family member of a director, then that director would not participate in those discussions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2"><B>Transactions with ARCA&#146;s Chief Science and Medical Officer and Chairman </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>University of Colorado
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Before its business combination with ARCA, ARCA Colorado entered into an unrestricted research grant with a research laboratory of
the University of Colorado led by Dr.&nbsp;Michael&nbsp;R. Bristow, ARCA&#146;s Chief Science and Medical Officer and Chairman of the Board of Directors, for the advancement of research in chronic heart failure. Under this agreement, ARCA Colorado
paid the research laboratory $22,500 per quarter and $7,500 per month to offset salary expenses at the laboratory. This arrangement was in place through June 2007. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Effective July&nbsp;1, 2007, ARCA Colorado terminated its prior grant funding arrangement and entered into another unrestricted research grant with Dr.&nbsp;Bristow&#146;s research laboratory for $23,917 per month.
Total expenses under these arrangements for the year ended December&nbsp;31, 2008 were $294,000. Total expenses during fiscal years 2007, 2006, and 2005 were $222,502, $154,992, and $123,311, respectively, and $501,099 from the agreement&#146;s
inception through December&nbsp;31, 2008. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">ARCA Colorado also entered into a materials transfer agreement with the University of Colorado,
under which ARCA Colorado has agreed to pay $35,000 per year to maintain the Heart Tissue Bank associated with Dr.&nbsp;Bristow&#146;s research laboratory at the University of Colorado. Total expenses for the year ended December&nbsp;31, 2008 were
$35,000. Total expenses during fiscal years 2007, 2006, and 2005 were $35,000, $35,000, and $35,000, respectively, and $140,000 from the agreement&#146;s inception through December&nbsp;31, 2008. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Convertible Promissory Notes and Warrants </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">ARCA Colorado entered into a Note and Warrant Purchase Agreement dated September&nbsp;24, 2008, as amended on October&nbsp;10, 2008, with certain holders of ARCA Colorado preferred stock. Atlas Venture Fund VII, L.P., of which
Dr.&nbsp;Jean-Fran&ccedil;ois Formela is a partner in the life sciences group, purchased $3,674,630 in principal amount of notes and corresponding warrants, Skyline Venture Partners Qualified Purchaser Fund IV, L.P., of which David G. Lowe is a
partner, purchased $1,825,696 in principal amount of notes and corresponding warrants, and InterWest Partners IX, L.P., of which Dr.&nbsp;Linda Grais is a partner, purchased $1,461,872 in principal amount of notes and corresponding warrants. Each of
these investors acquired convertible notes and warrants on the same terms and conditions as the other investors under the Note and Warrant Purchase Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2"><B><I>University of Colorado&#146;s University License Equity Holdings, Inc. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">ARCA Colorado entered into an exclusive
license agreement with University of Colorado&#146;s License Equity Holdings, Inc. (&#147;ULEHI&#148;) whereby ULEHI licensed to ARCA Colorado patent applications covering use of Gencaro therapy and various options to license future inventions and
targets, and ARCA Colorado agreed to pay a per year minimum royalty beginning in 2006. A portion of the license revenue received by ULEHI is allocated to the research laboratory of Dr.&nbsp;Bristow, ARCA&#146;s Chief Science and Medical Officer and
Chairman. ARCA </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">48 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">Colorado expensed $25,000 for the year ended December&nbsp;31, 2008. During 2007, 2006, and 2005, ARCA Colorado paid $25,000, $25,000, and $0, respectively
and has paid $75,000 from the agreement&#146;s inception through December&nbsp;31, 2008. In addition, ARCA Colorado will owe royalties based upon its commercial sales (other than Gencaro) and other milestones, if any. In August 2007, ARCA Colorado
executed an amendment to the license agreement to acquire additional patent rights and paid $15,000 for those rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">As part of its
licensing arrangement, ARCA Colorado issued to ULEHI at total of 302,785&nbsp;shares of its common stock, which as a result of the merger, represent the right to acquire 50,555 shares of Company common stock. Pursuant to an anti-dilution provision
in the license agreement, ARCA Colorado issued 69,882&nbsp;shares of its common stock, 142,903&nbsp;shares of its common stock, and 0&nbsp;shares of its common stock in 2007, 2006, 2005, respectively, and 212,785&nbsp;shares of its common stock from
inception through December&nbsp;31, 2007. The anti-dilution provision was fully satisfied in May&nbsp;2007. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">49 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>AUDIT COMMITTEE REPORT </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Our Audit Committee was established on March&nbsp;4, 1997, adopted its original Audit Committee charter on August&nbsp;2, 2000, and adopted its current
Audit Committee charter on December&nbsp;5, 2007. Dr.&nbsp;Zabriskie, as the chairperson, Ms.&nbsp;Pendergast, and Dr.&nbsp;Sobel presently serve on the Audit Committee. From January&nbsp;1, 2008 through December&nbsp;31, 2008, the Audit Committee
consisted of Mr.&nbsp;Perry, as the chairperson, Ms.&nbsp;Pendergast, and Dr.&nbsp;Sobel. All three current Committee members are &#147;independent&#148; directors, as determined in accordance with Rule 10A-3(b)(1) of the Exchange Act and the
current rules of the Nasdaq listing standards. Dr.&nbsp;Zabriskie is an &#147;audit committee financial expert&#148; as defined in Item&nbsp;401(h) of Regulation S-K. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Management is responsible for the preparation, presentation, and integrity of the Company&#146;s financial statements, accounting and financial reporting principles, and the establishment and effectiveness of internal
controls and procedures designed to assure compliance with accounting standards and applicable laws and regulations. The independent registered public accounting firm is responsible for performing an independent audit of the financial statements in
accordance with the standards of the Public Company Accounting Oversight Board (United States), expressing an opinion as to the conformity of such financial statements with generally accepted accounting principles and auditing management&#146;s
assessment of the effectiveness of internal control over financial reporting. The independent registered public accounting firm has free access to the Audit Committee to discuss any matters it deems appropriate. The Audit Committee&#146;s
responsibility is to monitor and oversee these processes. The following is the Audit Committee&#146;s report submitted to the Board of Directors for the fiscal year ended December&nbsp;31, 2008. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Audit Committee met six times during 2008 and has: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">reviewed and discussed our Company&#146;s audited financial statements with management and the independent registered public accounting firm;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">discussed with EY the matters required to be discussed by Statement on Auditing Standards No.&nbsp;61, as may be modified or supplemented; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">received from EY the written disclosures and the letter regarding their independence as required by applicable requirements of the PCAOB regarding the independent
accountants, and discussed the registered public accounting firm&#146;s independence with them. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In addition, based on
the review and discussions referred to above, the Audit Committee recommended to the Board of Directors that the audited financial statements be included in our Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2008 for filing
with the SEC. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">AUDIT COMMITTEE </FONT></P> <P
STYLE="margin-top:24px;margin-bottom:0px; margin-left:54%; text-indent:-2%;padding-bottom:3px;line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2">John L. Zabriskie, Ph.D., Chairperson</FONT><FONT FACE="Times New Roman"
SIZE="1"><SUP>1</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:54%; text-indent:-2%;padding-bottom:3px;line-height:95%; vertical-align:top"><FONT FACE="Times New Roman"
SIZE="2">Mary Pendergast</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>2</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"> </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:54%; text-indent:-2%;padding-bottom:3px;line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2">Dr.&nbsp;Burton&nbsp;E. Sobel</FONT><FONT FACE="Times New Roman"
SIZE="1"><SUP>3</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"> </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">A member since January&nbsp;27, 2009 </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">A member since December&nbsp;20, 2007 </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">A member since March&nbsp;23, 2005 </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>The Audit
Committee report shall not be deemed incorporated by reference by any general statement incorporating by reference this Proxy Statement into any filing under the Securities Act or the Exchange Act, and shall not otherwise be deemed filed under these
acts. </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">50 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>OTHER INFORMATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B>Other Matters at the Meeting </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We do not know of any matters to be presented at the annual meeting
other than those mentioned in this Proxy Statement. If any other matters are properly brought before the annual meeting, it is intended that the proxies will be voted in accordance with the best judgment of the person or persons voting the proxies.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Householding of Proxy Materials </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The
SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for proxy statements and annual reports with respect to two or more stockholders sharing the same address by delivering a single
Notice or single paper copy proxy statement and annual report addressed to those stockholders. This process, which is commonly referred to as &#147;householding,&#148; potentially means extra convenience for stockholders and cost savings for
companies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">This year, a number of brokers with account holders who are ARCA stockholders will be &#147;householding&#148; our Notices and
proxy materials. A single Notice or Proxy Statement or 2008 Annual Report will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice
from your broker that they will be &#147;householding&#148; communications to your address, &#147;householding&#148; will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate
in &#147;householding&#148; and would prefer to receive a separate Notice or Proxy Statement and Annual Report, please notify your broker, or direct your written request to our Secretary, care of ARCA biopharma, Inc., 8001 Arista Place, Suite 200,
Broomfield, CO 80021. Stockholders who currently receive multiple Notices or paper copies of the proxy materials at their addresses and would like to request &#147;householding&#148; of their communications should contact their brokers. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Annual Report on Form 10-K; Available Information </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">We have filed with the SEC an Annual Report on Form 10-K. Each stockholder receiving a Notice or paper copy of this Proxy Statement will also receive a paper copy of our Annual Report on Form 10-K. Copies of exhibits to our Annual Report on
Form 10-K are available from us upon reimbursement of our reasonable costs in providing these documents and written request to our Secretary. Please address requests for these documents to: Secretary, ARCA biopharma, Inc., 8001 Arista Place, Suite
200, Broomfield, CO 80021. Our filings with the SEC may be inspected at the offices of the SEC located in Washington, D.C. Documents filed electronically with the SEC may also be accessed through the website maintained by it at <U>www.sec.gov</U> or
through our website at <U>www.arcabiopharma.com</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Stockholder Proposals for 2010 Annual Meeting </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Pursuant to Rule 14a-8 under the Exchange Act, stockholders may present proper proposals for inclusion in our Proxy Statement and for consideration at
our next annual meeting of stockholders by submitting their proposals to us in a timely manner. In order to be so included for the 2010 annual meeting of stockholders, stockholder proposals must comply with the requirements of Rule 14a-8 and must be
received by us no later than January&nbsp;6, 2010, unless the meeting date is before May&nbsp;26, 2010 or after July&nbsp;25, 2010 in which case a reasonable time before we begin to print and mail, or make accessible via the Internet, our proxy
materials. In addition, our Bylaws establish an advance notice procedure with regard to certain matters, including stockholder proposals not included in our Proxy Statement, to be brought before an annual meeting of stockholders. In general, notice
must be received by our Secretary not less than 60 days nor more than 90 days prior to the anniversary date of the immediately preceding annual meeting and must contain specified information concerning the matters to be brought before such meeting
and concerning the stockholder proposing such matters. Therefore, to be presented at our 2010 annual meeting of stockholders, such a proposal must be received by us after March&nbsp;27, 2010, but no </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">51 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">later than April&nbsp;27, 2010. If the date of the annual meeting is more than 30 days earlier or more than 60 days later than such anniversary date, notice
must be received not earlier than the 90th day prior to such annual meeting and not later than the close of business on the later of the 60th day prior to such annual meeting or the 10th day following the day on which public announcement of the date
of such meeting is first made. If a stockholder who has notified us of his or her intention to present a proposal at an annual meeting does not appear or send a qualified representative to present his proposal at such meeting, we need not present
the proposal for a vote at such meeting. Stockholders should also review a copy of the Company&#146;s Bylaws for additional notice and informational requirements required to be included in a stockholder proposal or nomination to receive
consideration by the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">By order of the Board of Directors: </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px; margin-left:54%; text-indent:-2%">

<IMG SRC="g62758g94c52.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Michael R. Bristow, M.D., Ph.D. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2"><I>Chairman of the Board of Directors </I></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2"><I>and Chief Science and Medical Officer </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">April&nbsp;30, 2009 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Broomfield, Colorado </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">52 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><U>Appendix A</U> </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>AMENDED AND RESTATED </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>ARCA biopharma, Inc. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>2004 EQUITY INCENTIVE PLAN </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2"><B></B>1.<B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I>E<SMALL>STABLISHMENT</SMALL>, P<SMALL>URPOSE</SMALL> <SMALL>AND</SMALL> T<SMALL>ERM</SMALL> <SMALL>OF</SMALL> P<SMALL>LAN</SMALL>.</I></B><B> </B></FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">1.1<B> Establishment</B><B><I>.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Nuvelo, Inc. 2004 Equity Incentive Plan was originally established effective as
of May&nbsp;6, 2004, the date of its approval by the stockholders of the Company, and was subsequently amended and restated on May&nbsp;7, 2006. It was again, subject to stockholder approval, amended and restated by the Board on March&nbsp;14, 2007.
The plan was, subject to stockholder approval, amended and restated by the Board on April&nbsp;29, 2009 in the form of this Amended and Restated ARCA biopharma, Inc. 2004 Equity Incentive Plan (the <I>&#147;</I><B><I>Plan</I></B><I>&#148;</I>). The
Plan was approved on June&nbsp;25, 2009 by the stockholders of the Company (the <I>&#147;</I><B><I>Effective Date</I></B><I>&#148;</I>). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">1.2<B> Purpose</B><B><I>.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;The purpose of the Plan is to advance the interests of the Participating Company Group and its stockholders by providing an incentive to attract, retain and reward persons performing
services for the Participating Company Group and by motivating such persons to contribute to the growth and profitability of the Participating Company Group. The Plan seeks to achieve this purpose by providing for Awards in the form of Options,
Indexed Options, Stock Appreciation Rights, Restricted Stock Purchase Rights, Restricted Stock Bonuses, Performance Shares, Performance Units, Restricted Stock Units and Deferred Stock Units. After May&nbsp;6, 2004, the Company shall terminate, and
no longer issue any awards from under, the Company&#146;s 2002 Equity Incentive Plan, Director Stock Option Plan, Scientific Advisory Board/Consultants Stock Option Plan, 1995 Stock Option Plan and the Variagenics 1997 Employee, Director&nbsp;&amp;
Consultant Stock Option Plan. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">1.3<B> Term of Plan.</B>&nbsp;&nbsp;&nbsp;&nbsp;The Plan shall continue in effect until the earlier of its
termination by the Board or the date on which all of the shares of Stock available for issuance under the Plan have been issued and all restrictions on such shares under the terms of the Plan and the agreements evidencing Awards granted under the
Plan have lapsed. However, all Incentive Stock Options shall be granted, if at all, within ten (10)&nbsp;years from the Effective Date. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2"><B></B>2.<B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I>D<SMALL>EFINITIONS</SMALL> <SMALL>AND</SMALL> C<SMALL>ONSTRUCTION</SMALL>. </I></B><B> </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">2.1<B> Definitions.</B>&nbsp;&nbsp;&nbsp;&nbsp;Whenever used herein, the following terms shall have their respective meanings set forth below: </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(a) <I>&#147;</I><B><I>Affiliate</I></B><I>&#148;</I> means (i)&nbsp;an entity, other than a Parent Corporation, that directly, or indirectly through one or more intermediary entities, controls the Company or
(ii)&nbsp;an entity, other than a Subsidiary Corporation, that is controlled by the Company directly, or indirectly through one or more intermediary entities. For this purpose, the term &#147;control&#148; (including the term &#147;controlled
by&#148;) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of the relevant entity, whether through the ownership of voting securities, by contract or otherwise; or shall have such
other meaning assigned such term for the purposes of registration on Form&nbsp;S-8 under the Securities Act. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(b)
<I>&#147;</I><B><I>Award</I></B><I>&#148;</I> means any Option, Indexed Option, SAR, Restricted Stock Purchase Right, Restricted Stock Bonus, Performance Share, Performance Unit, Restricted Stock Unit or Deferred Stock Unit granted under the Plan.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(c) <I>&#147;</I><B><I>Award Agreement</I></B><I>&#148;</I> means a written agreement between the Company and a Participant
setting forth the terms, conditions and restrictions of the Award granted to the Participant. An Award Agreement may be an &#147;Option Agreement,&#148; an &#147;Indexed Option Agreement,&#148; a &#147;SAR Agreement,&#148; a &#147;Restricted Stock
Purchase Agreement,&#148; a &#147;Restricted Stock Bonus Agreement,&#148; a &#147;Performance Share Agreement,&#148; a &#147;Performance Unit Agreement,&#148; a &#147;Restricted Stock Unit Agreement,&#148; or a &#147;Deferred Stock Unit
Agreement.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">A-1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(d) <I>&#147;</I><B><I>Board</I></B><I>&#148;</I> means the Board of Directors of the
Company. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(e) <I>&#147;</I><B><I>Code</I></B><I>&#148;</I> means the Internal Revenue Code of 1986, as amended, and any
applicable regulations promulgated thereunder. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(f) <I>&#147;</I><B><I>Committee</I></B><I>&#148;</I> means the Compensation
Committee or other committee of the Board duly appointed to administer the Plan and having such powers as shall be specified by the Board. If no committee of the Board has been appointed to administer the Plan, the Board shall exercise all of the
powers of the Committee granted herein, and, in any event, the Board may in its discretion exercise any or all of such powers. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">(g) <I>&#147;</I><B><I>Company</I></B><I>&#148;</I> means ARCA biopharma, Inc., a Delaware corporation, or any successor corporation thereto. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(h) <I>&#147;</I><B><I>Consultant</I></B><I>&#148;</I> means a person engaged to provide consulting or advisory services (other than as an Employee or a member of the Board) to a Participating Company, provided that
the identity of such person, the nature of such services or the entity to which such services are provided would not preclude the Company from offering or selling securities to such person pursuant to the Plan in reliance on a Form&nbsp;S-8
Registration Statement under the Securities Act. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(i) <I>&#147;</I><B><I>Deferred Stock Unit</I></B><I>&#148;</I> means a
bookkeeping entry representing a right granted to a Participant pursuant to Section&nbsp;11 of the Plan to receive a share of Stock on a date determined in accordance with the provisions of Section&nbsp;11 and the Participant&#146;s Award Agreement.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(j) <I>&#147;</I><B><I>Director</I></B><I>&#148;</I> means a member of the Board. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(k) <I>&#147;</I><B><I>Disability</I></B><I>&#148;</I> means the permanent and total disability of the Participant, within the meaning of
Section&nbsp;22(e)(3) of the Code. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(l) <I>&#147;</I><B><I>Dividend Equivalent</I></B><I>&#148;</I> means a credit, made at
the discretion of the Committee or as otherwise provided by the Plan, to the account of a Participant in an amount equal to the cash dividends paid on one share of Stock for each share of Stock represented by an Award held by such Participant.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(m) <I>&#147;</I><B><I>Employee</I></B><I>&#148;</I> means any person treated as an employee (including an Officer or a
Director who is also treated as an employee) in the records of a Participating Company and, with respect to any Incentive Stock Option granted to such person, who is an employee for purposes of Section&nbsp;422 of the Code; provided, however, that
neither service as a Director nor payment of a Director&#146;s fee shall be sufficient to constitute employment for purposes of the Plan. The Company shall determine in good faith and in the exercise of its discretion whether an individual has
become or has ceased to be an Employee and the effective date of such individual&#146;s employment or termination of employment, as the case may be. For purposes of an individual&#146;s rights, if any, under the Plan as of the time of the
Company&#146;s determination, all such determinations by the Company shall be final, binding and conclusive, notwithstanding that the Company or any court of law or governmental agency subsequently makes a contrary determination. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(n) <I>&#147;</I><B><I>Exchange Act</I></B><I>&#148;</I> means the Securities Exchange Act of 1934, as amended. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(o) <I>&#147;</I><B><I>Fair Market Value</I></B><I>&#148;</I> means, as of any date, the value of a share of Stock or other property as
determined by the Committee, in its discretion, or by the Company, in its discretion, if such determination is expressly allocated to the Company herein, subject to the following: </FONT></P> <P
STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(i)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">If, on such date, the Stock is listed on a national or regional securities exchange or market system, the Fair Market Value of a share of Stock shall, unless
expressly determined otherwise by the Committee, in its discretion, be the average of the high and low price of a share of Stock on such date, as quoted on the Nasdaq National Market, The Nasdaq SmallCap Market or such other national or regional
securities exchange or market system constituting the primary market for the Stock, as reported in<I> The Wall Street Journal</I> or such </FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">A-2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="17%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:0%">
<FONT FACE="Times New Roman" SIZE="2">other source as the Company deems reliable. If the relevant date does not fall on a day on which the Stock has traded on such securities exchange or market
system, the date on which the Fair Market Value shall be established shall be the last day on which the Stock was so traded prior to the relevant date, or such other appropriate day as shall be determined by the Committee, in its discretion.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(ii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">If, on such date, the Stock is not listed on a national or regional securities exchange or market system, the Fair Market Value of a share of Stock shall be as determined by the
Committee in good faith without regard to any restriction other than a restriction which, by its terms, will never lapse. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(p) <I>&#147;</I><B><I>Incentive Stock Option</I></B><I>&#148;</I> means an Option intended to be (as set forth in the Award Agreement) and which qualifies as an incentive stock option within the meaning of
Section&nbsp;422(b) of the Code. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(q) <I>&#147;</I><B><I>Indexed Option</I></B><I>&#148;</I> means an Option with an
exercise price which either increases by a fixed percentage over time or changes by reference to a published index, as determined by the Committee and set forth in the Option Agreement. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(r) <I>&#147;</I><B><I>Insider</I></B><I>&#148;</I> means an Officer, a Director or any other person whose transactions in Stock are
subject to Section&nbsp;16 of the Exchange Act. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(s) <I>&#147;</I><B><I>Nonstatutory Stock Option</I></B><I>&#148;</I> means
an Option not intended to be (as set forth in the Award Agreement) an incentive stock option within the meaning of Section&nbsp;422(b) of the Code. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(t) <I>&#147;</I><B><I>Officer</I></B><I>&#148;</I> means any person designated by the Board as an officer of the Company. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(u) <I>&#147;</I><B><I>Option</I></B><I>&#148;</I> means the right to purchase Stock at a stated price for a specified period of time granted to a Participant pursuant to Section&nbsp;6 of the Plan. An Option may be
either an Incentive Stock Option, a Nonstatutory Stock Option or an Indexed Option. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(v) <I>&#147;</I><B><I>Parent
Corporation</I></B><I>&#148;</I> means any present or future &#147;parent corporation&#148; of the Company, as defined in Section&nbsp;424(e) of the Code. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(w) <I>&#147;</I><B><I>Participant</I></B><I>&#148;</I> means any eligible person who has been granted one or more Awards. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(x) <I>&#147;</I><B><I>Participating Company</I></B><I>&#148;</I> means the Company or any Parent Corporation, Subsidiary Corporation or Affiliate. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(y) <I>&#147;</I><B><I>Participating Company Group</I></B><I>&#148;</I> means, at any point in time, all entities collectively which are
then Participating Companies. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(z) <I>&#147;</I><B><I>Performance Award</I></B><I>&#148;</I> means an Award of Performance
Shares or Performance Units. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(aa) <I>&#147;</I><B><I>Performance Award Formula</I></B><I>&#148;</I> means, for any
Performance Award, a formula or table established by the Committee pursuant to Section&nbsp;9.3 of the Plan which provides the basis for computing the value of a Performance Award at one or more threshold levels of attainment of the applicable
Performance Goal(s) measured as of the end of the applicable Performance Period. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(bb) <I>&#147;</I><B><I>Performance
Goal</I></B><I>&#148;</I> means a performance goal established by the Committee pursuant to Section&nbsp;9.3 of the Plan. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">(cc) <I>&#147;</I><B><I>Performance Period</I></B><I>&#148;</I> means a period established by the Committee pursuant to Section&nbsp;9.3 of the Plan at the end of which one or more Performance Goals are to be measured. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(dd) <I>&#147;</I><B><I>Performance Share</I></B><I>&#148;</I> means a bookkeeping entry representing a right granted to a Participant
pursuant to Section&nbsp;9 of the Plan to receive a payment equal to the value of a Performance Share, as determined by the Committee, based on performance. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">A-3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(ee) <I>&#147;</I><B><I>Performance Unit</I></B><I>&#148;</I> means a bookkeeping entry
representing a right granted to a Participant pursuant to Section&nbsp;9 of the Plan to receive a payment equal to the value of a Performance Unit, as determined by the Committee, based upon performance. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(ff) <I>&#147;</I><B><I>Prior Plan Options</I></B><I>&#148;</I> means any option or other award granted by the Company which is subject to
vesting or repurchase by the Company, including specifically, all such options and awards granted pursuant to a prior version of this Plan, the Nuvelo, Inc. 2002 Equity Incentive Plan, the Nuvelo, Inc. Director Stock Option Plan, the Nuvelo, Inc.
Scientific Advisory Board/Consultants Stock Option Plan, the Nuvelo, Inc. 1995 Stock Option Plan and the Variagenics 1997 Employee, Director&nbsp;&amp; Consultant Stock Option Plan which is outstanding on or after the Effective Date. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(gg) <I>&#147;</I><B><I>Restricted Stock Award</I></B><I>&#148;</I> means an Award of a Restricted Stock Bonus or a Restricted Stock
Purchase Right. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(hh) <I>&#147;</I><B><I>Restricted Stock Bonus</I></B><I>&#148;</I> means Stock granted to a Participant
pursuant to Section&nbsp;8 of the Plan. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(ii) <I>&#147;</I><B><I>Restricted Stock Purchase Right</I></B><I>&#148;</I> means
a right to purchase Stock granted to a Participant pursuant to Section&nbsp;8 of the Plan. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(jj)
<I>&#147;</I><B><I>Restricted Stock Unit</I></B><I>&#148;</I> or <I>&#147;</I><B><I>Stock Unit</I></B><I>&#148;</I> means a bookkeeping entry representing a right granted to a Participant pursuant to Section&nbsp;10 of the Plan to receive a share of
Stock on a date determined in accordance with the provisions of Section&nbsp;10 and the Participant&#146;s Award Agreement. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">(kk) <I>&#147;</I><B><I>Restriction Period</I></B><I>&#148;</I> means the period established in accordance with Section&nbsp;8.5 of the Plan during which shares subject to a Restricted Stock Award are subject to Vesting Conditions.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(ll) <I>&#147;</I><B><I>Retirement</I></B><I>&#148;</I> means a Participant&#146;s termination of Service, if as of the
date of such termination, the Participant has reached the age of fifty-eight (58)&nbsp;and has completed eight (8)&nbsp;years of continuous Service to the Participating Company Group. A Participant who terminates Service with the Participating
Company Group and resumes Service more than six (6)&nbsp;months after his or her original termination date, will not have his or her Service with the Participant Company Group prior to his or her original termination date count for purposes of
determining Retirement. Notwithstanding the foregoing, the Board shall have the discretion to determine on a case by case basis whether such prior Service with the Participant Company Group may be counted for purposes of Retirement. The Board will
notify any rehired Participant if the Board has determined such prior Service will count towards Retirement, and in the absence of such notification from the Board, such Service shall not be counted for purposes of Retirement. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(mm) <I>&#147;</I><B><I>Rule 16b-3</I></B><I>&#148;</I> means Rule&nbsp;16b-3 under the Exchange Act, as amended from time to time, or any
successor rule or regulation. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(nn) <I>&#147;</I><B><I>SAR</I></B><I>&#148;</I> or <I>&#147;</I><B><I>Stock Appreciation
Right</I></B><I>&#148;</I> means a bookkeeping entry representing, for each share of Stock subject to such SAR, a right granted to a Participant pursuant to Section&nbsp;7 of the Plan to receive payment of an amount equal to the excess, if any, of
the Fair Market Value of a share of Stock on the date of exercise of the SAR over the exercise price. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(oo)
<I>&#147;</I><B><I>Section&nbsp;162(m)</I></B><I>&#148;</I> means Section&nbsp;162(m) of the Code. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(pp)
<I>&#147;</I><B><I>Securities Act</I></B><I>&#148;</I> means the Securities Act of 1933, as amended. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(qq)
<I>&#147;</I><B><I>Service</I></B><I>&#148;</I> means a Participant&#146;s employment or service with the Participating Company Group, whether in the capacity of an Employee, a Director or a Consultant. A Participant&#146;s Service shall not be
deemed to have terminated merely because of a change in the capacity in which the Participant renders such Service or a change in the Participating Company for which the Participant renders such Service, provided that there is no interruption or
termination of the Participant&#146;s Service. Furthermore, a Participant&#146;s Service shall not be deemed to have terminated if the Participant takes any military leave, sick leave, or other bona fide leave of absence approved by the Company.
However, if any such leave taken by a Participant exceeds </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">A-4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%">
<FONT FACE="Times New Roman" SIZE="2">ninety (90)&nbsp;days, then on the one hundred eighty-first (181st)&nbsp;day following the commencement of such leave any Incentive Stock Option held by the
Participant shall cease to be treated as an Incentive Stock Option and instead shall be treated thereafter as a Nonstatutory Stock Option, unless the Participant&#146;s right to return to Service with the Participating Company Group is guaranteed by
statute or contract. Notwithstanding the foregoing, unless otherwise designated by the Company or required by law, a leave of absence shall not be treated as Service for purposes of determining vesting under the Participant&#146;s Award Agreement. A
Participant&#146;s Service shall be deemed to have terminated either upon an actual termination of Service or upon the entity for which the Participant performs Service ceasing to be a Participating Company. In addition, a Participant&#146;s Service
shall be deemed to have terminated if, in the Committee&#146;s sole discretion, the Participant&#146;s employment relationship is transferred to an Affiliate or Subsidiary Corporation and the Participant is offered a replacement equity award from
the Affiliate or Subsidiary Corporation. Subject to the foregoing, the Company, in its discretion, shall determine whether the Participant&#146;s Service has terminated and the effective date of such termination. </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(rr) <I>&#147;</I><B><I>Stock</I></B><I>&#148;</I> means the common stock of the Company, as adjusted from time to time in accordance with
Section&nbsp;4.2 of the Plan. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(ss) <I>&#147;</I><B><I>Subsidiary Corporation</I></B><I>&#148;</I> means any present or
future &#147;subsidiary corporation&#148; of the Company, as defined in Section&nbsp;424(f) of the Code. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(tt)
<I>&#147;</I><B><I>Ten Percent Owner</I></B><I>&#148;</I> means a Participant who, at the time an Incentive Stock Option is granted to the Participant, owns stock possessing more than ten percent (10%)&nbsp;of the total combined voting power of all
classes of stock of a Participating Company (other than an Affiliate) within the meaning of Section&nbsp;422(b)(6) of the Code. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">(uu) <I>&#147;</I><B><I>Vesting Conditions</I></B><I>&#148;</I> mean those conditions established in accordance with Section&nbsp;8.5 or Section&nbsp;10.3 of the Plan prior to the satisfaction of which shares subject to a Restricted Stock
Award or Restricted Stock Unit Award, respectively, remain subject to forfeiture or a repurchase option in favor of the Company upon the Participant&#146;s termination of Service. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2.2<B> Construction.</B>&nbsp;&nbsp;&nbsp;&nbsp;Captions and titles contained herein are for convenience only and shall not affect the meaning or
interpretation of any provision of the Plan. Except when otherwise indicated by the context, the singular shall include the plural and the plural shall include the singular. Use of the term &#147;or&#148; is not intended to be exclusive, unless the
context clearly requires otherwise. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B></B>3.<B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I>A<SMALL>DMINISTRATION</SMALL>.</I></B><B> </B></FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">3.1<B> Administration by the Committee.</B>&nbsp;&nbsp;&nbsp;&nbsp;The Plan shall be administered by the Committee. All questions of interpretation of the
Plan or of any Award shall be determined by the Committee, and such determinations shall be final and binding upon all persons having an interest in the Plan or such Award. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">3.2<B> Authority of Officers.</B>&nbsp;&nbsp;&nbsp;&nbsp;Any Officer shall have the authority to act on behalf of the Company with respect to any matter,
right, obligation, determination or election which is the responsibility of or which is allocated to the Company herein, provided the Officer has apparent authority with respect to such matter, right, obligation, determination or election. The Board
may, in its discretion, delegate to a committee comprised of one or more Officers the authority to grant one or more Awards, without further approval of the Board or the Committee, to any Employee, other than a person who, at the time of such grant,
is an Insider; provided, however, that (a)&nbsp;such Awards shall not be granted for shares in excess of the maximum aggregate number of shares of Stock authorized for issuance pursuant to Section&nbsp;4.1, (b)&nbsp;the exercise price per share of
each Option shall be not less than the Fair Market Value per share of the Stock on the effective date of grant (or, if the Stock has not traded on such date, on the last day preceding the effective date of grant on which the Stock was traded),and
(c)&nbsp;each such Award shall be subject to the terms and conditions of the appropriate standard form of Award Agreement approved by the Board or the Committee and shall conform to the provisions of the Plan and such other guidelines as shall be
established from time to time by the Board or the Committee. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">A-5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">3.3<B> Administration with Respect to Insiders.</B>&nbsp;&nbsp;&nbsp;&nbsp;With respect to participation
by Insiders in the Plan, at any time that any class of equity security of the Company is registered pursuant to Section&nbsp;12 of the Exchange Act, the Plan shall be administered in compliance with the requirements, if any, of Rule&nbsp;16b-3.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">3.4<B> Committee Complying with Section&nbsp;162(m).</B>&nbsp;&nbsp;&nbsp;&nbsp;If the Company is a &#147;publicly held corporation&#148;
within the meaning of Section&nbsp;162(m), the Board may establish a Committee of &#147;outside directors&#148; within the meaning of Section&nbsp;162(m) to approve the grant of any Award which might reasonably be anticipated to result in the
payment of employee remuneration that would otherwise exceed the limit on employee remuneration deductible for income tax purposes pursuant to Section&nbsp;162(m). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">3.5<B> Powers of the Committee</B><B><I>.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;In addition to any other powers set forth in the Plan and subject to the provisions of the Plan, the Committee shall have the full and final
power and authority, in its discretion: </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(a) to determine the persons to whom, and the time or times at which, Awards shall
be granted and the number of shares of Stock or units to be subject to each Award; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(b) to determine the type of Award
granted and to designate Options as Incentive Stock Options, Nonstatutory Stock Options or Indexed Options; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(c) to
determine the Fair Market Value of shares of Stock or other property; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(d) to determine the terms, conditions and
restrictions applicable to each Award (which need not be identical) and any shares acquired pursuant thereto, including, without limitation, (i)&nbsp;the exercise or purchase price of shares purchased pursuant to any Award, (ii)&nbsp;the method of
payment for shares purchased pursuant to any Award, (iii)&nbsp;the method for satisfaction of any tax withholding obligation arising in connection with Award, including by the withholding or delivery of shares of Stock, (iv)&nbsp;the timing, terms
and conditions of the exercisability or vesting of any Award or any shares acquired pursuant thereto, (v)&nbsp;the Performance Award Formula and Performance Goals applicable to any Award and the extent to which such Performance Goals have been
attained, (vi)&nbsp;the time of the expiration of any Award, (vii)&nbsp;the effect of the Participant&#146;s termination of Service on any of the foregoing, and (viii)&nbsp;all other terms, conditions and restrictions applicable to any Award or
shares acquired pursuant thereto not inconsistent with the terms of the Plan; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(e) to determine whether an Award of
Restricted Stock Units, SARs, Performance Shares or Performance Units will be settled in shares of Stock, cash, or in any combination thereof; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(f) to approve one or more forms of Award Agreement; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(g) to amend, modify, extend, cancel
or renew any Award or to waive any restrictions or conditions applicable to any Award or any shares acquired pursuant thereto; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">(h) to accelerate, continue, extend or defer the exercisability or vesting of any Award or any shares acquired pursuant thereto, including with respect to the period following a Participant&#146;s termination of Service; </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(i) to prescribe, amend or rescind rules, guidelines and policies relating to the Plan, or to adopt sub-plans or supplements to, or
alternative versions of, the Plan, including, without limitation, as the Committee deems necessary or desirable to comply with the laws or regulations of or to accommodate the tax policy, accounting principles or custom of, foreign jurisdictions
whose citizens may be granted Awards; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(j) to authorize, in conjunction with any applicable Company deferred compensation
plan, that the receipt of cash or Stock subject to any Award under this Plan, may be deferred under the terms and conditions of such Company deferred compensation plan; and </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(k) to correct any defect, supply any omission or reconcile any inconsistency in the Plan or any Award Agreement and to make all other
determinations and take such other actions with respect to the Plan or any Award as the Committee may deem advisable to the extent not inconsistent with the provisions of the Plan or applicable law. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">A-6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">3.6<B> No Repricing.</B>&nbsp;&nbsp;&nbsp;&nbsp;Without the affirmative vote of holders of a majority of
the shares of Stock cast in person or by proxy at a meeting of the stockholders of the Company at which a quorum representing a majority of all outstanding shares of Stock is present or represented by proxy, the Board shall not approve a program
providing for either (a)&nbsp;the cancellation of outstanding Options and/or SARs and the grant in substitution therefore of any new Awards, including specifically any new Options and/or SARs having a lower exercise price or (b)&nbsp;the amendment
of outstanding Options and/or SARs to reduce the exercise price thereof. This paragraph shall not be construed to apply to &#147;issuing or assuming a stock option in a transaction to which Section&nbsp;424(a) applies,&#148; within the meaning of
Section&nbsp;424 of the Code. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">3.7<B> No Restricted Stock Award Acceleration.</B>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any provision of
the Plan to the contrary, no Restricted Stock Award may be granted which provides, or subsequently amended to provide, for (i)&nbsp;any acceleration of vesting for any reason other than upon a Change in Control or after the Participant&#146;s death
or Disability and (ii)&nbsp;vesting of one hundred percent (100%)&nbsp;of any such Restricted Stock Award prior to the passage of three (3)&nbsp;years of Service (unless such Restricted Stock Award will vest in accordance with the satisfaction of
any Performance Measure set forth in Section&nbsp;9.4). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">3.8<B> Indemnification.</B>&nbsp;&nbsp;&nbsp;&nbsp;In addition to such other rights
of indemnification as they may have as members of the Board or the Committee or as officers or employees of the Participating Company Group, members of the Board or the Committee and any officers or employees of the Participating Company Group to
whom authority to act for the Board, the Committee or the Company is delegated shall be indemnified by the Company against all reasonable expenses, including attorneys&#146; fees, actually and necessarily incurred in connection with the defense of
any action, suit or proceeding, or in connection with any appeal therein, to which they or any of them may be a party by reason of any action taken or failure to act under or in connection with the Plan, or any right granted hereunder, and against
all amounts paid by them in settlement thereof (provided such settlement is approved by independent legal counsel selected by the Company) or paid by them in satisfaction of a judgment in any such action, suit or proceeding, except in relation to
matters as to which it shall be adjudged in such action, suit or proceeding that such person is liable for gross negligence, bad faith or intentional misconduct in duties; provided, however, that within sixty (60)&nbsp;days after the institution of
such action, suit or proceeding, such person shall offer to the Company, in writing, the opportunity at its own expense to handle and defend the same. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">4.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>S<SMALL>HARES</SMALL> S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL> P<SMALL>LAN</SMALL>.</I></B> </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">4.1<B>
Maximum Number of Shares Issuable and Share Usage.</B>&nbsp;&nbsp;&nbsp;&nbsp;Subject to adjustment as provided in Section&nbsp;4.2, the maximum aggregate number of shares of Stock that may be granted under the Plan shall be Nine Hundred Fifty Five
Thousand Two Hundred Four (955,204), reduced by the number of shares subject to Prior Plan Options outstanding as of the Effective Date. Such shares shall consist of authorized but unissued or reacquired shares of Stock or any combination thereof.
If any outstanding Award, including any Prior Plan Options, for any reason expires or is terminated or canceled without having been exercised or settled in full, or if shares of Stock acquired pursuant to an Award subject to forfeiture or
repurchase, including any Prior Plan Options, are forfeited or repurchased by the Company, the shares of Stock allocable to the terminated portion of such Award, including any Prior Plan Options, or such forfeited or repurchased shares of Stock
shall again be available for grant under the Plan applying the share usage rules of this Section&nbsp;4.1. Shares of Stock shall not be deemed to have been granted pursuant to the Plan with respect to any portion of an Award that is settled in cash.
Notwithstanding anything to the contrary in this Section&nbsp;4.1, the following shares of Stock shall not be available for reissuance under the Plan: (i)&nbsp;shares of Stock with respect to which the Participant has received the benefits of
ownership (other than voting rights), either in the form of dividends, shares sold pursuant to a Cashless Exercise described in Section&nbsp;6.3(a) or otherwise; (ii)&nbsp;shares of Stock which are withheld from any Award or payment under the Plan
to satisfy tax withholding obligations pursuant to Section&nbsp;15.2; (iii)&nbsp;shares of Stock which are surrendered by any Participant (through a Cashless Exercise, actual delivery of the shares or attestation of ownership) to fulfill tax
withholding obligations or to pay the applicable exercise price for any Award; and (iv)&nbsp;shares of Stock subject to the grant of a SAR which are not issued upon settlement of the SAR. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Shares of Stock covered by an Award shall be counted as used as of the grant date. Any shares of Stock that are subject to Awards of Options shall be
counted against the limit set forth in this Section&nbsp;4.1 as one (1)&nbsp;share </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">A-7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">for every one (1)&nbsp;share subject to an Award of Options. With respect to SARs, the number of shares subject to an award of SARs will be counted against
the aggregate number of shares available for issuance under the Plan regardless of the number of shares actually issued to settle the SAR upon exercise. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">4.2<B> Adjustments for Changes in Capital Structure</B><B><I>.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Subject to any required action by the stockholders of the Company, in the event of any change in the Stock effected without
receipt of consideration by the Company, whether through merger, consolidation, reorganization, reincorporation, recapitalization, reclassification, stock dividend, stock split, reverse stock split, split-up, split-off, spin-off, combination of
shares, exchange of shares, or similar change in the capital structure of the Company, or in the event of payment of a dividend or distribution to the stockholders of the Company in a form other than Stock (excepting normal cash dividends) that has
a material effect on the Fair Market Value of shares of Stock, appropriate adjustments shall be made in the number and class of shares subject to the Plan and to any outstanding Awards, and in the exercise or purchase price per share under any
outstanding Award in order to prevent dilution or enlargement of Participants&#146; rights under the Plan. For purposes of the foregoing, conversion of any convertible securities of the Company shall not be treated as &#147;effected without receipt
of consideration by the Company.&#148; Any fractional share resulting from an adjustment pursuant to this Section&nbsp;4.2 shall be rounded down to the nearest whole number, and in no event may the exercise or purchase price under any Award be
decreased to an amount less than the par value, if any, of the stock subject to such Award. The adjustments determined by the Committee pursuant to this Section&nbsp;4.2 shall be final, binding and conclusive. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">5.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>E<SMALL>LIGIBILITY</SMALL> <SMALL>AND</SMALL> A<SMALL>WARD</SMALL> L<SMALL>IMITATIONS</SMALL>.</I></B> </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">5.1<B> Persons Eligible for Awards.</B>&nbsp;&nbsp;&nbsp;&nbsp;Awards may be granted only to Employees, Consultants and Directors. For purposes of the
foregoing sentence, &#147;Employees,&#148; &#147;Consultants&#148; and &#147;Directors&#148; shall include prospective Employees, prospective Consultants and prospective Directors to whom Awards are granted in connection with written offers of an
employment or other service relationship with the Participating Company Group; provided, however, that no Stock subject to any such Award shall vest, become exercisable or be issued prior to the date on which such person commences Service.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">5.2<B> Participation.</B>&nbsp;&nbsp;&nbsp;&nbsp;Awards are granted solely at the discretion of the Committee. Eligible persons may be
granted more than one (1)&nbsp;Award. However, eligibility in accordance with this Section shall not entitle any person to be granted an Award, or, having been granted an Award, to be granted an additional Award. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">5.3 <B>Incentive Stock Option Limitations. </B> </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(a)<B><I> Persons Eligible.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;An Incentive Stock Option may be granted only to a person who, on the effective date of grant, is an Employee of the Company, a Parent Corporation or a
Subsidiary Corporation (each being an <I>&#147;</I><B><I>ISO-Qualifying Corporation</I></B><I>&#148;</I>). Any person who is not an Employee of an ISO-Qualifying Corporation on the effective date of the grant of an Option to such person may be
granted only a Nonstatutory Stock Option. An Incentive Stock Option granted to a prospective Employee upon the condition that such person become an Employee of an ISO-Qualifying Corporation shall be deemed granted effective on the date such person
commences Service with an ISO-Qualifying Corporation, with an exercise price determined as of such date in accordance with Section&nbsp;6.1. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(b)<B><I> Fair Market Value Limitation.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;To the extent that options designated as Incentive Stock Options (granted under all stock option plans of the Participating Company Group,
including the Plan) become exercisable by a Participant for the first time during any calendar year for stock having a Fair Market Value greater than One Hundred Thousand dollars ($100,000), the portion of such options which exceeds such amount
shall be treated as Nonstatutory Stock Options. For purposes of this Section, options designated as Incentive Stock Options shall be taken into account in the order in which they were granted, and the Fair Market Value of stock shall be determined
as of the time the option with respect to such stock is granted. If the Code is amended to provide for a different limitation from that set forth in this Section, such different limitation shall be deemed incorporated herein effective as of the date
and with respect to such Options as required or permitted by such amendment to the Code. If an Option is treated as an Incentive Stock Option </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">A-8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%">
<FONT FACE="Times New Roman" SIZE="2">in part and as a Nonstatutory Stock Option in part by reason of the limitation set forth in this Section, the Participant may designate which portion of such
Option the Participant is exercising. In the absence of such designation, the Participant shall be deemed to have exercised the Incentive Stock Option portion of the Option first. Upon exercise, shares issued pursuant to each such portion shall be
separately identified. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">5.4 <B>Award Limits. </B> </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(a) <B><I>Aggregate Limit on Restricted Stock Awards and Performance Awards.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Subject to adjustment as
provided in Section&nbsp;4.2, in no event shall more than Fifty Thousand (50,000)&nbsp;shares of Stock in the aggregate be issued under the Plan pursuant to the exercise or settlement of Restricted Stock Awards and Performance Awards. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(b) <B><I>Section&nbsp;162(m) Award Limits.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;The following limits shall apply to the grant of any Award if,
at the time of grant, the Company is a &#147;publicly held corporation&#148; within the meaning of Section&nbsp;162(m). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">(i)<B> Options and SARs.</B>&nbsp;&nbsp;&nbsp;&nbsp;Subject to adjustment as provided in Section&nbsp;4.2, no Employee shall be granted within any fiscal year of the Company one or more Options or Freestanding SARs which in the aggregate
are for more than One Hundred Thousand (100,000)&nbsp;shares of Stock, provided, however, that the Company may make an additional one-time grant to any newly-hired Employee of an Option and/or SAR for the purchase of up to an additional Fifty
Thousand (50,000)&nbsp;shares of Stock. An Option which is canceled (or a Freestanding SAR as to which the exercise price is reduced to reflect a reduction in the Fair Market Value of the Stock) in the same fiscal year of the Company in which it was
granted shall continue to be counted against such limit for such fiscal year. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(ii)<B> Restricted Stock Awards and
Restricted Stock Units.</B>&nbsp;&nbsp;&nbsp;&nbsp;Subject to adjustment as provided in Section&nbsp;4.2, no Employee shall be granted within any fiscal year of the Company one or more Restricted Stock Awards or Restricted Stock Units, subject to
Vesting Conditions based on the attainment of Performance Goals, for more than Twenty Thousand (20,000)&nbsp;shares of Stock, provided, however, that the Company may make an additional one-time grant to any newly-hired Employee of a Restricted Stock
Award or Restricted Stock Units of up to an additional Seven Thousand Five Hundred (7,500)&nbsp;shares of Stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(iii)<B>
Performance Awards.</B>&nbsp;&nbsp;&nbsp;&nbsp;Subject to adjustment as provided in Section&nbsp;4.2, no Employee shall be granted (A)&nbsp;Performance Shares which could result in such Employee receiving more than Twenty Thousand
(20,000)&nbsp;shares of Stock for each full fiscal year of the Company contained in the Performance Period for such Award, or (B)&nbsp;Performance Units which could result in such Employee receiving more than Two Million dollars ($2,000,000) for
each full fiscal year of the Company contained in the Performance Period for such Award. No Participant may be granted more than one Performance Award for the same Performance Period. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">6.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>T<SMALL>ERMS</SMALL> <SMALL>AND</SMALL> C<SMALL>ONDITIONS</SMALL> <SMALL>OF</SMALL> O<SMALL>PTIONS</SMALL>.</I></B> </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Options shall be evidenced by Award Agreements specifying the number of shares of Stock covered thereby, in such form as the Committee shall from time to
time establish. No Option or purported Option shall be a valid and binding obligation of the Company unless evidenced by a fully executed Award Agreement. Award Agreements evidencing Options may incorporate all or any of the terms of the Plan by
reference and shall comply with and be subject to the following terms and conditions: </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">6.1<B> Exercise Price.</B>&nbsp;&nbsp;&nbsp;&nbsp;The
exercise price for each Option shall be established in the discretion of the Committee; provided, however, that (a)&nbsp;the exercise price per share shall be not less than the Fair Market Value of a share of Stock on the effective date of grant of
the Option, (b)&nbsp;no Incentive Stock Option granted to a Ten Percent Owner shall have an exercise price per share less than one hundred ten percent (110%)&nbsp;of the Fair Market Value of a share of Stock on the effective date of grant of the
Option, and (c)&nbsp;notwithstanding anything to the contrary in this Section&nbsp;6.1, in the case of an Indexed Option, the Committee shall determine the exercise price of such Indexed Option and the terms and conditions that affect, if any, any
adjustments to the exercise price of </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">A-9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">such Indexed Option. Notwithstanding the foregoing, an Option may be granted with an exercise price lower than the minimum exercise price set forth above if
such Option is granted pursuant to an assumption or substitution for another option in a manner qualifying under the provisions of Section&nbsp;424(a) of the Code. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">6.2 <B>Exercisability and Term of Options</B><B><I>.</I></B><B></B>&nbsp;&nbsp;&nbsp;&nbsp;Options shall be exercisable at such time or times, or upon such event or events, and subject to such terms, conditions,
performance criteria and restrictions as shall be determined by the Committee and set forth in the Award Agreement evidencing such Option; provided, however, that (a)&nbsp;no Option shall be exercisable after the expiration of ten (10)&nbsp;years
after the effective date of grant of such Option, (b)&nbsp;no Incentive Stock Option granted to a Ten Percent Owner shall be exercisable after the expiration of five (5)&nbsp;years after the effective date of grant of such Option, and (c)&nbsp;no
Option granted to a prospective Employee, prospective Consultant or prospective Director may become exercisable prior to the date on which such person commences Service. Subject to the foregoing, unless otherwise specified by the Committee in the
grant of an Option, any Option granted hereunder shall terminate ten (10)&nbsp;years after the effective date of grant of the Option, unless earlier terminated in accordance with its provisions. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">6.3 <B>Payment of Exercise Price. </B> </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(a)<B><I> Forms of Consideration Authorized.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise provided below, payment of the exercise price for the number of shares of Stock being purchased pursuant to any Option
shall be made (i)&nbsp;in cash, by check or in cash equivalent, (ii)&nbsp;by tender to the Company, or attestation to the ownership, of shares of Stock owned by the Participant having a Fair Market Value not less than the exercise price,
(iii)&nbsp;by delivery of a properly executed notice of exercise together with irrevocable instructions to a broker providing for the assignment to the Company of the proceeds of a sale or loan with respect to some or all of the shares being
acquired upon the exercise of the Option (including, without limitation, through an exercise complying with the provisions of Regulation&nbsp;T as promulgated from time to time by the Board of Governors of the Federal Reserve System) (a
<I>&#147;</I><B><I>Cashless Exercise</I></B><I>&#148;</I>), (iv)&nbsp;by such other consideration as may be approved by the Committee from time to time to the extent permitted by applicable law, or (v)&nbsp;by any combination thereof. The Committee
may at any time or from time to time grant Options which do not permit all of the foregoing forms of consideration to be used in payment of the exercise price or which otherwise restrict one or more forms of consideration. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(b) <B><I>Limitations on Forms of Consideration. </I></B> </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(i)<B> Tender of Stock.</B>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing, an Option may not be exercised by tender to the Company,
or attestation to the ownership, of shares of Stock to the extent such tender or attestation would constitute a violation of the provisions of any law, regulation or agreement restricting the redemption of the Company&#146;s stock. Unless otherwise
provided by the Committee, an Option may not be exercised by tender to the Company, or attestation to the ownership, of shares of Stock unless such shares either have been owned by the Participant for more than six (6)&nbsp;months (and not used for
another Option exercise by attestation during such period) or were not acquired, directly or indirectly, from the Company. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">(ii)<B> Cashless Exercise.</B>&nbsp;&nbsp;&nbsp;&nbsp;The Company reserves, at any and all times, the right, in the Company&#146;s sole and absolute discretion, to establish, decline to approve or terminate any program or procedures for the
exercise of Options by means of a Cashless Exercise, including with respect to one or more Participants specified by the Company notwithstanding that such program or procedures may be available to other Participants. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">6.4 <B>Effect of Termination of Service.</B>&nbsp;&nbsp;&nbsp;&nbsp;An Option shall be exercisable after a Participant&#146;s termination of Service to
such extent and during such period as determined by the Committee, in its discretion, and set forth in the Award Agreement evidencing such Option. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">6.5<B> Transferability of Options.</B>&nbsp;&nbsp;&nbsp;&nbsp;During the lifetime of the Participant, an Option shall be exercisable only by the Participant or the Participant&#146;s guardian or legal representative. Prior to the issuance
of shares of Stock upon the exercise of an Option, the Option shall not be subject in any manner to anticipation, alienation, sale, </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">A-10 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">exchange, transfer, assignment, pledge, encumbrance, or garnishment by creditors of the Participant or the Participant&#146;s beneficiary, except transfer by
will or by the laws of descent and distribution. Notwithstanding the foregoing, to the extent permitted by the Committee, in its discretion, and set forth in the Award Agreement evidencing such Option, a Nonstatutory Stock Option shall be assignable
or transferable subject to the applicable limitations, if any, described in the General Instructions to Form&nbsp;S-8 Registration Statement under the Securities Act. Notwithstanding any of the foregoing, the Board may permit further transferability
of any Option, on a general or specific basis, and may impose conditions and limitations on any permitted transferability. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">7.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>T<SMALL>ERMS</SMALL> <SMALL>AND</SMALL> C<SMALL>ONDITIONS</SMALL> <SMALL>OF</SMALL> S<SMALL>TOCK</SMALL> A<SMALL>PPRECIATION</SMALL> R<SMALL>IGHTS</SMALL>.</I></B> </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Stock Appreciation Rights shall be evidenced by Award Agreements specifying the number of shares of Stock subject to the Award, in such form as the
Committee shall from time to time establish. No SAR or purported SAR shall be a valid and binding obligation of the Company unless evidenced by a fully executed Award Agreement. Award Agreements evidencing SARs may incorporate all or any of the
terms of the Plan by reference and shall comply with and be subject to the following terms and conditions: </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">7.1<B> Types of SARs
Authorized.</B>&nbsp;&nbsp;&nbsp;&nbsp;SARs may be granted in tandem with all or any portion of a related Option (a <I>&#147;</I><B><I>Tandem SAR</I></B><I>&#148;</I>) or may be granted independently of any Option (a <I>&#147;</I><B><I>Freestanding
SAR</I></B><I>&#148;</I>). A Tandem SAR may be granted either concurrently with the grant of the related Option or at any time thereafter prior to the complete exercise, termination, expiration or cancellation of such related Option. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">7.2<B> Exercise Price.</B>&nbsp;&nbsp;&nbsp;&nbsp;The exercise price for each SAR shall be established in the discretion of the Committee; provided,
however, that (a)&nbsp;the exercise price per share subject to a Tandem SAR shall be the exercise price per share under the related Option and (b)&nbsp;the exercise price per share subject to a Freestanding SAR shall be not less than the Fair Market
Value of a share of Stock on the effective date of grant of the SAR. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">7.3 <B>Exercisability and Term of SARs. </B> </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(a)<B><I> Tandem SARs.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Tandem SARs shall be exercisable only at the time and to the extent, and only to the
extent, that the related Option is exercisable, subject to such provisions as the Committee may specify where the Tandem SAR is granted with respect to less than the full number of shares of Stock subject to the related Option. The Committee may, in
its discretion, provide in any Award Agreement evidencing a Tandem SAR that such SAR may not be exercised without the advance approval of the Company and, if such approval is not given, then the Option shall nevertheless remain exercisable in
accordance with its terms. A Tandem SAR shall terminate and cease to be exercisable no later than the date on which the related Option expires or is terminated or canceled. Upon the exercise of a Tandem SAR with respect to some or all of the shares
subject to such SAR, the related Option shall be canceled automatically as to the number of shares with respect to which the Tandem SAR was exercised. Upon the exercise of an Option related to a Tandem SAR as to some or all of the shares subject to
such Option, the related Tandem SAR shall be canceled automatically as to the number of shares with respect to which the related Option was exercised. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(b)<B><I> Freestanding SARs.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Freestanding SARs shall be exercisable at such time or times, or upon such event or events, and subject to such terms, conditions, performance criteria and
restrictions as shall be determined by the Committee and set forth in the Award Agreement evidencing such SAR; provided, however, that no Freestanding SAR shall be exercisable after the expiration of ten (10)&nbsp;years after the effective date of
grant of such SAR. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">7.4<B> Exercise of SARs.</B>&nbsp;&nbsp;&nbsp;&nbsp;Upon the exercise (or deemed exercise pursuant to Section&nbsp;7.5)
of a SAR, the Participant (or the Participant&#146;s legal representative or other person who acquired the right to exercise the SAR by reason of the Participant&#146;s death) shall be entitled to receive payment of an amount for each share with
respect to which the SAR is exercised equal to the excess, if any, of the Fair Market Value of a share of Stock on the date of exercise of the SAR over the exercise price. Payment of such amount shall be made in cash, shares of Stock, or any
combination thereof as determined by the Committee. Unless otherwise provided in the Award Agreement evidencing such SAR, payment shall be made in a lump sum as soon as practicable following the date of exercise of the SAR. The Award Agreement
evidencing any SAR may provide for deferred payment in a lump sum or in </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">A-11 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">installments. When payment is to be made in shares of Stock, the number of shares to be issued shall be determined on the basis of the Fair Market Value of a
share of Stock on the date of exercise of the SAR. For purposes of Section&nbsp;7, a SAR shall be deemed exercised on the date on which the Company receives notice of exercise from the Participant. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">7.5<B> Deemed Exercise of SARs.</B>&nbsp;&nbsp;&nbsp;&nbsp;If, on the date on which a SAR would otherwise terminate or expire, the SAR by its terms
remains exercisable immediately prior to such termination or expiration and, if so exercised, would result in a payment to the holder of such SAR, then any portion of such SAR which has not previously been exercised shall automatically be deemed to
be exercised as of such date with respect to such portion. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">7.6<B> Effect of Termination of Service.</B>&nbsp;&nbsp;&nbsp;&nbsp;Subject to
earlier termination of the SAR as otherwise provided herein a SAR shall be exercisable after a Participant&#146;s termination of Service to such extent and during such period as determined by the Committee, in its discretion, and set forth in the
Award Agreement evidencing such SAR and thereafter shall terminate. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">7.7<B> Nontransferability of SARs.</B>&nbsp;&nbsp;&nbsp;&nbsp;During
the lifetime of the Participant, a SAR shall be exercisable only by the Participant or the Participant&#146;s guardian or legal representative. Prior to the exercise of a SAR, the SAR shall not be subject in any manner to anticipation, alienation,
sale, exchange, transfer, assignment, pledge, encumbrance, or garnishment by creditors of the Participant or the Participant&#146;s beneficiary, except transfer by will or by the laws of descent and distribution. Notwithstanding any of the
foregoing, the Board may permit further transferability of any SAR, on a general or specific basis, and may impose conditions and limitations on any permitted transferability. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">8.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>T<SMALL>ERMS</SMALL> <SMALL>AND</SMALL> C<SMALL>ONDITIONS</SMALL> <SMALL>OF</SMALL> R<SMALL>ESTRICTED</SMALL> S<SMALL>TOCK</SMALL> A<SMALL>WARDS</SMALL>. </I></B> </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Restricted Stock Awards shall be evidenced by Award Agreements specifying whether the Award is a Restricted Stock Bonus or a Restricted Stock Purchase
Right and the number of shares of Stock subject to the Award, in such form as the Committee shall from time to time establish. No Restricted Stock Award or purported Restricted Stock Award shall be a valid and binding obligation of the Company
unless evidenced by a fully executed Award Agreement. Award Agreements evidencing Restricted Stock Awards may incorporate all or any of the terms of the Plan by reference and shall comply with and be subject to the following terms and conditions:
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">8.1<B> Types of Restricted Stock Awards Authorized.</B>&nbsp;&nbsp;&nbsp;&nbsp;Restricted Stock Awards may be in the form of either a
Restricted Stock Bonus or a Restricted Stock Purchase Right. Restricted Stock Awards may be granted upon such conditions as the Committee shall determine, including, without limitation, upon the attainment of one or more Performance Goals described
in Section&nbsp;9.4. If either the grant of a Restricted Stock Award or the lapsing of the Restriction Period is to be contingent upon the attainment of one or more Performance Goals, the Committee shall follow procedures substantially equivalent to
those set forth in Sections&nbsp;9.3 through 9.5(a). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">8.2<B> Purchase Price.</B>&nbsp;&nbsp;&nbsp;&nbsp;The purchase price for shares of
Stock issuable under each Restricted Stock Purchase Right shall be established by the Committee in its discretion. No monetary payment (other than applicable tax withholding) shall be required as a condition of receiving shares of Stock pursuant to
a Restricted Stock Bonus, the consideration for which shall be services actually rendered to a Participating Company or for its benefit. Notwithstanding the foregoing, the Participant shall furnish consideration in the form of cash or past services
rendered to a Participating Company or for its benefit having a value not less than the par value of the shares of Stock subject to such Restricted Stock Award. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">8.3<B> Purchase Period.</B>&nbsp;&nbsp;&nbsp;&nbsp;A Restricted Stock Purchase Right shall be exercisable within a period established by the Committee, which shall in no event exceed thirty (30)&nbsp;days from the
effective date of the grant of the Restricted Stock Purchase Right; provided, however, that no Restricted Stock Purchase Right granted to a prospective Employee, prospective Consultant or prospective Director may become exercisable prior to the date
on which such person commences Service. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">8.4<B> Payment of Purchase Price.</B>&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise provided below,
payment of the purchase price for the number of shares of Stock being purchased pursuant to any Restricted Stock Purchase Right shall be made (a)&nbsp;in cash, by check, or in cash equivalent, (b)&nbsp;by such other consideration as may be approved
by the </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">A-12 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">Committee from time to time to the extent permitted by applicable law, or (c)&nbsp;by any combination thereof. The Committee may at any time or from time to
time grant Restricted Stock Purchase Rights which do not permit all of the foregoing forms of consideration to be used in payment of the purchase price or which otherwise restrict one or more forms of consideration. Restricted Stock Bonuses shall be
issued in consideration for past services actually rendered to a Participating Company or for its benefit. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">8.5<B> Vesting and Restrictions
on Transfer.</B>&nbsp;&nbsp;&nbsp;&nbsp;Shares issued pursuant to any Restricted Stock Award may or may not be made subject to Vesting Conditions based upon the satisfaction of such Service requirements, conditions, restrictions or performance
criteria, including, without limitation, Performance Goals as described in Section&nbsp;9.4, as shall be established by the Committee and set forth in the Award Agreement evidencing such Award. During any Restriction Period in which shares acquired
pursuant to a Restricted Stock Award remain subject to Vesting Conditions, such shares may not be sold, exchanged, transferred, pledged, assigned or otherwise disposed of other than pursuant to an Ownership Change Event, as defined in
Section&nbsp;13.1, or as provided in Section&nbsp;8.8. Upon request by the Company, each Participant shall execute any agreement evidencing such transfer restrictions prior to the receipt of shares of Stock hereunder and shall promptly present to
the Company any and all certificates representing shares of Stock acquired hereunder for the placement on such certificates of appropriate legends evidencing any such transfer restrictions. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">8.6<B> Voting Rights; Dividends and Distributions.</B>&nbsp;&nbsp;&nbsp;&nbsp;Except as provided in this Section, Section&nbsp;8.5 and any Award
Agreement, during the Restriction Period applicable to shares subject to a Restricted Stock Award, the Participant shall have all of the rights of a stockholder of the Company holding shares of Stock, including the right to vote such shares and to
receive all dividends and other distributions paid with respect to such shares. However, in the event of a dividend or distribution paid in shares of Stock or any other adjustment made upon a change in the capital structure of the Company as
described in Section&nbsp;4.2, then any and all new, substituted or additional securities or other property (other than normal cash dividends) to which the Participant is entitled by reason of the Participant&#146;s Restricted Stock Award shall be
immediately subject to the same Vesting Conditions as the shares subject to the Restricted Stock Award with respect to which such dividends or distributions were paid or adjustments were made. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">8.7<B> Effect of Termination of Service.</B>&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise provided by the Committee in the grant of a Restricted Stock Award
and set forth in the Award Agreement, if a Participant&#146;s Service terminates for any reason, whether voluntary or involuntary (including the Participant&#146;s death or Disability), then (a)&nbsp;the Company shall have the option to repurchase
for the purchase price paid by the Participant any shares acquired by the Participant pursuant to a Restricted Stock Purchase Right which remain subject to Vesting Conditions as of the date of the Participant&#146;s termination of Service and
(b)&nbsp;the Participant shall forfeit to the Company any shares acquired by the Participant pursuant to a Restricted Stock Bonus which remain subject to Vesting Conditions as of the date of the Participant&#146;s termination of Service. The Company
shall have the right to assign at any time any repurchase right it may have, whether or not such right is then exercisable, to one or more persons as may be selected by the Company. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">8.8<B> Nontransferability of Restricted Stock Award Rights.</B>&nbsp;&nbsp;&nbsp;&nbsp;Prior to the issuance of shares of Stock pursuant to a Restricted
Stock Award, rights to acquire such shares shall not be subject in any manner to anticipation, alienation, sale, exchange, transfer, assignment, pledge, encumbrance or garnishment by creditors of the Participant or the Participant&#146;s
beneficiary, except transfer by will or the laws of descent and distribution. All rights with respect to a Restricted Stock Award granted to a Participant hereunder shall be exercisable during his or her lifetime only by such Participant or the
Participant&#146;s guardian or legal representative. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">A-13 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">9.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>T<SMALL>ERMS</SMALL> <SMALL>AND</SMALL> C<SMALL>ONDITIONS</SMALL> <SMALL>OF</SMALL>
P<SMALL>ERFORMANCE</SMALL> A<SMALL>WARDS</SMALL>. </I></B> </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Performance Awards shall be evidenced by Award Agreements in such form as the
Committee shall from time to time establish. No Performance Award or purported Performance Award shall be a valid and binding obligation of the Company unless evidenced by a fully executed Award Agreement. Award Agreements evidencing Performance
Awards may incorporate all or any of the terms of the Plan by reference and shall comply with and be subject to the following terms and conditions: </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">9.1<B> Types of Performance Awards Authorized.</B>&nbsp;&nbsp;&nbsp;&nbsp;Performance Awards may be in the form of either Performance Shares or Performance Units. Each Award Agreement evidencing a Performance Award shall specify the number
of Performance Shares or Performance Units subject thereto, the Performance Award Formula, the Performance Goal(s) and Performance Period applicable to the Award, and the other terms, conditions and restrictions of the Award. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">9.2<B> Initial Value of Performance Shares and Performance Units.</B>&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise provided by the Committee in granting a
Performance Award, each Performance Share shall have an initial value equal to the Fair Market Value of one (1)&nbsp;share of Stock, subject to adjustment as provided in Section&nbsp;4.2, on the effective date of grant of the Performance Share and
each Performance Unit shall have an initial value of one hundred dollars ($100). The final value payable to the Participant in settlement of a Performance Award determined on the basis of the applicable Performance Award Formula will depend on the
extent to which Performance Goals established by the Committee are attained within the applicable Performance Period established by the Committee. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">9.3<B> Establishment of Performance Period, Performance Goals and Performance Award Formula.</B>&nbsp;&nbsp;&nbsp;&nbsp;In granting each Performance Award, the Committee shall establish in writing the applicable Performance Period,
Performance Award Formula and one or more Performance Goals which, when measured at the end of the Performance Period, shall determine on the basis of the Performance Award Formula the final value of the Performance Award to be paid to the
Participant. Unless otherwise permitted in compliance with the requirements under Section&nbsp;162(m) with respect to &#147;performance-based compensation,&#148; the Committee shall establish the Performance Goal(s) and Performance Award Formula
applicable to each Performance Award no later than the earlier of (a)&nbsp;the date ninety (90)&nbsp;days after the commencement of the applicable Performance Period or (b)&nbsp;the date on which 25% of the Performance Period has elapsed, and, in
any event, at a time when the outcome of the Performance Goals remains substantially uncertain. Once established, the Performance Goals and Performance Award Formula shall not be changed during the Performance Period. The Company shall notify each
Participant granted a Performance Award of the terms of such Award, including the Performance Period, Performance Goal(s) and Performance Award Formula. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">A-14 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">9.4<B> Measurement of Performance Goals.</B>&nbsp;&nbsp;&nbsp;&nbsp;Performance Goals shall be
established by the Committee on the basis of targets to be attained (<I>&#147;</I><B><I>Performance Targets</I></B><I>&#148;</I>) with respect to one or more measures of business or financial performance (each, a <I>&#147;</I><B><I>Performance
Measure</I></B><I>&#148;</I>), subject to the following: </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(a)<B><I> Performance
Measures.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Performance Measures shall have the same meanings as used in the Company&#146;s financial statements, or, if such terms are not used in the Company&#146;s financial statements, they shall have the meaning
applied pursuant to generally accepted accounting principles, or as used generally in the Company&#146;s industry. Performance Measures shall be calculated with respect to the Company and each Subsidiary Corporation consolidated therewith for
financial reporting purposes or such division or other business unit as may be selected by the Committee. For purposes of the Plan, the Performance Measures applicable to a Performance Award shall be calculated in accordance with generally accepted
accounting principles, but prior to the accrual or payment of any Performance Award for the same Performance Period and excluding the effect (whether positive or negative) of any change in accounting standards or any extraordinary, unusual or
nonrecurring item, as determined by the Committee, occurring after the establishment of the Performance Goals applicable to the Performance Award. Performance Measures may be one or more of the following, or a combination of the any of the
following, as determined by the Committee: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(i)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">revenue; </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(ii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">gross margin; </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(iii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">operating margin; </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(iv)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">operating income; </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(v)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">pre-tax profit; </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(vi)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">earnings before interest, taxes and depreciation; </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(vii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">net income; </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(viii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">cash flow; </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(ix)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">expenses; </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(x)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">the market price of the Stock; </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(xi)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">earnings per share; </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(xii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">return on stockholder equity; </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(xiii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">return on capital; </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(xiv)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">return on net assets; </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(xv)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">economic value added; </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(xvi)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">number of customers; </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(xvii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">market share; </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(xviii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">return on investment; </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(xix)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">profit after tax; </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(xx)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">product approval; and </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(xxi)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">customer satisfaction. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(b)<B><I>
Performance Targets.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Performance Targets may include a minimum, maximum, target level and intermediate levels of performance, with the final value of a Performance Award determined under the applicable Performance
Award Formula by the level attained during the applicable Performance Period. A Performance Target may be stated as an absolute value or as a value determined relative to a standard selected by the Committee. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">9.5 <B>Settlement of Performance Awards. </B> </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(a)<B><I> Determination of Final Value.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;As soon as practicable following the completion of the Performance Period applicable to a Performance Award, the Committee shall certify in
writing the extent to which the applicable Performance Goals have been attained and the resulting final value of the Award earned by the Participant and to be paid upon its settlement in accordance with the applicable Performance Award Formula.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">A-15 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(b)<B><I> Discretionary Adjustment of Award Formula.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;In
its discretion, the Committee may, either at the time it grants a Performance Award or at any time thereafter, provide for the positive or negative adjustment of the Performance Award Formula applicable to a Performance Award granted to any
Participant who is not a &#147;covered employee&#148; within the meaning of Section&nbsp;162(m) (a <I>&#147;</I><B><I>Covered Employee</I></B><I>&#148;</I>) to reflect such Participant&#146;s individual performance in his or her position with the
Company or such other factors as the Committee may determine. If permitted under a Covered Employee&#146;s Award Agreement, the Committee shall have the discretion, on the basis of such criteria as may be established by the Committee, to reduce some
or all of the value of the Performance Award that would otherwise be paid to the Covered Employee upon its settlement notwithstanding the attainment of any Performance Goal and the resulting value of the Performance Award determined in accordance
with the Performance Award Formula. No such reduction may result in an increase in the amount payable upon settlement of another Participant&#146;s Performance Award. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(c)<B><I> Effect of Leaves of Absence.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise required by law, payment of the final value, if
any, of a Performance Award held by a Participant who has taken in excess of thirty (30)&nbsp;days in leaves of absence during a Performance Period shall be prorated on the basis of the number of days of the Participant&#146;s Service during the
Performance Period during which the Participant was not on a leave of absence. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(d)<B><I> Notice to
Participants.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;As soon as practicable following the Committee&#146;s determination and certification in accordance with Sections&nbsp;9.5(a) and (b), the Company shall notify each Participant of the determination of the
Committee. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(e)<B><I> Payment in Settlement of Performance Awards.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;As soon as practicable
following the Committee&#146;s determination and certification in accordance with Sections&nbsp;9.5(a) and (b), payment shall be made to each eligible Participant (or such Participant&#146;s legal representative or other person who acquired the
right to receive such payment by reason of the Participant&#146;s death) of the final value of the Participant&#146;s Performance Award. Payment of such amount shall be made in cash, shares of Stock, or a combination thereof as determined by the
Committee. Unless otherwise provided in the Award Agreement evidencing a Performance Award, payment shall be made in a lump sum. An Award Agreement may provide for deferred payment in a lump sum or in installments. If any payment is to be made on a
deferred basis, the Committee may, but shall not be obligated to, provide for the payment during the deferral period of Dividend Equivalents or interest. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(f)<B><I> Provisions Applicable to Payment in Shares.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;If payment is to be made in shares of Stock, the number of such shares shall be determined by dividing the final value of the
Performance Award by the value of a share of Stock determined by the method specified in the Award Agreement. Such methods may include, without limitation, the closing market price on a specified date (such as the settlement date) or an average of
market prices over a series of trading days. Shares of Stock issued in payment of any Performance Award may be fully vested and freely transferable shares or may be shares of Stock subject to Vesting Conditions as provided in Section&nbsp;8.5. Any
shares subject to Vesting Conditions shall be evidenced by an appropriate Award Agreement and shall be subject to the provisions of Sections&nbsp;8.5 through 8.8 above. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">9.6<B> Voting Rights; Dividend Equivalent Rights and Distributions.</B>&nbsp;&nbsp;&nbsp;&nbsp;Participants shall have no voting rights with respect to shares of Stock represented by Performance Share Awards until the
date of the issuance of such shares, if any (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company). However, the Committee, in its discretion, may provide in the Award Agreement
evidencing any Performance Share Award that the Participant shall be entitled to receive Dividend Equivalents with respect to the payment of cash dividends on Stock having a record date prior to the date on which the Performance Shares are settled
or forfeited. Such Dividend Equivalents, if any, shall be credited to the Participant in the form of additional whole Performance Shares as of the date of payment of such cash dividends on Stock. The number of additional Performance Shares (rounded
to the nearest whole number) to be so credited shall be determined by dividing (a)&nbsp;the amount of cash dividends paid on such date with respect to the number of </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">A-16 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">shares of Stock represented by the Performance Shares previously credited to the Participant by (b)&nbsp;the Fair Market Value per share of Stock on such
date. Dividend Equivalents may be paid currently or may be accumulated and paid to the extent that Performance Shares become nonforfeitable, as determined by the Committee. Settlement of Dividend Equivalents may be made in cash, shares of Stock, or
a combination thereof as determined by the Committee, and may be paid on the same basis as settlement of the related Performance Share as provided in Section&nbsp;9.5. Dividend Equivalents shall not be paid with respect to Performance Units. In the
event of a dividend or distribution paid in shares of Stock or any other adjustment made upon a change in the capital structure of the Company as described in Section&nbsp;4.2, appropriate adjustments shall be made in the Participant&#146;s
Performance Share Award so that it represents the right to receive upon settlement any and all new, substituted or additional securities or other property (other than normal cash dividends) to which the Participant would be entitled by reason of the
shares of Stock issuable upon settlement of the Performance Share Award, and all such new, substituted or additional securities or other property shall be immediately subject to the same Performance Goals as are applicable to the Award. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">9.7<B> Effect of Termination of Service.</B>&nbsp;&nbsp;&nbsp;&nbsp;The effect of a Participant&#146;s termination of Service on the Performance Award
shall be determined by the Committee, in its discretion, and set forth in the Award Agreement evidencing such Performance Award. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">9.8<B>
Nontransferability of Performance Awards.</B>&nbsp;&nbsp;&nbsp;&nbsp;Prior to settlement in accordance with the provisions of the Plan, no Performance Award shall be subject in any manner to anticipation, alienation, sale, exchange, transfer,
assignment, pledge, encumbrance, or garnishment by creditors of the Participant or the Participant&#146;s beneficiary, except transfer by will or by the laws of descent and distribution. All rights with respect to a Performance Award granted to a
Participant hereunder shall be exercisable during his or her lifetime only by such Participant or the Participant&#146;s guardian or legal representative. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">10.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>T<SMALL>ERMS</SMALL> <SMALL>AND</SMALL> C<SMALL>ONDITIONS</SMALL> <SMALL>OF</SMALL> R<SMALL>ESTRICTED</SMALL> S<SMALL>TOCK</SMALL> U<SMALL>NIT</SMALL> A<SMALL>WARDS</SMALL>. </I></B> </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Restricted Stock Unit Awards shall be evidenced by Award Agreements specifying the number of Restricted Stock Units subject to the Award, in such form as
the Committee shall from time to time establish. No Restricted Stock Unit Award or purported Restricted Stock Unit Award shall be a valid and binding obligation of the Company unless evidenced by a fully executed Award Agreement. Award Agreements
evidencing Restricted Stock Units may incorporate all or any of the terms of the Plan by reference and shall comply with and be subject to the following terms and conditions: </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">10.1<B> Grant of Restricted Stock Unit Awards.</B>&nbsp;&nbsp;&nbsp;&nbsp;Restricted Stock Unit Awards may be granted upon such conditions as the
Committee shall determine, including, without limitation, upon the attainment of one or more Performance Goals described in Section&nbsp;9.4. If either the grant of a Restricted Stock Unit Award or the Vesting Conditions with respect to such Award
is to be contingent upon the attainment of one or more Performance Goals, the Committee shall follow procedures substantially equivalent to those set forth in Sections&nbsp;9.3 through&nbsp;9.5(a). </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">10.2<B> Purchase Price.</B>&nbsp;&nbsp;&nbsp;&nbsp;No monetary payment (other than applicable tax withholding, if any) shall be required as a condition of
receiving a Restricted Stock Unit Award, the consideration for which shall be services actually rendered to a Participating Company or for its benefit. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">10.3<B> Vesting.</B>&nbsp;&nbsp;&nbsp;&nbsp;Restricted Stock Units may or may not be made subject to Vesting Conditions based upon the satisfaction of such Service requirements, conditions, restrictions or performance
criteria, including, without limitation, Performance Goals as described in Section&nbsp;9.4, as shall be established by the Committee and set forth in the Award Agreement evidencing such Award. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">10.4<B> Voting Rights, Dividend Equivalent Rights and Distributions.</B>&nbsp;&nbsp;&nbsp;&nbsp;Participants shall have no voting rights with respect to
shares of Stock represented by Restricted Stock Units until the date of the issuance of such shares (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company). However, the Committee, in
its discretion, may provide in the Award Agreement evidencing any Restricted Stock Unit Award that the Participant shall be entitled to receive Dividend Equivalents with </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">A-17 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">respect to the payment of cash dividends on Stock having a record date prior to date on which Restricted Stock Units held by such Participant are settled.
Such Dividend Equivalents, if any, shall be paid by crediting the Participant with additional whole Restricted Stock Units as of the date of payment of such cash dividends on Stock. The number of additional Restricted Stock Units (rounded to the
nearest whole number) to be so credited shall be determined by dividing (a)&nbsp;the amount of cash dividends paid on such date with respect to the number of shares of Stock represented by the Restricted Stock Units previously credited to the
Participant by (b)&nbsp;the Fair Market Value per share of Stock on such date. Such additional Restricted Stock Units shall be subject to the same terms and conditions and shall be settled in the same manner and at the same time (or as soon
thereafter as practicable) as the Restricted Stock Units originally subject to the Restricted Stock Unit Award. In the event of a dividend or distribution paid in shares of Stock or any other adjustment made upon a change in the capital structure of
the Company as described in Section&nbsp;4.2, appropriate adjustments shall be made in the Participant&#146;s Restricted Stock Unit Award so that it represents the right to receive upon settlement any and all new, substituted or additional
securities or other property (other than normal cash dividends) to which the Participant would entitled by reason of the shares of Stock issuable upon settlement of the Award, and all such new, substituted or additional securities or other property
shall be immediately subject to the same Vesting Conditions as are applicable to the Award. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">10.5<B> Effect of Termination of
Service.</B>&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise provided by the Committee in the grant of a Restricted Stock Unit Award and set forth in the Award Agreement, if a Participant&#146;s Service terminates for any reason, whether voluntary or
involuntary (including the Participant&#146;s death or Disability), then the Participant shall forfeit to the Company any Restricted Stock Units pursuant to the Award which remain subject to Vesting Conditions as of the date of the
Participant&#146;s termination of Service. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">10.6<B> Settlement of Restricted Stock Unit Awards.</B>&nbsp;&nbsp;&nbsp;&nbsp;The Company shall
issue to a Participant on the date on which Restricted Stock Units subject to the Participant&#146;s Restricted Stock Unit Award vest or on such other date determined by the Committee, in its discretion, and set forth in the Award Agreement one
(1)&nbsp;share of Stock (and/or any other new, substituted or additional securities or other property pursuant to an adjustment described in Section&nbsp;10.4) for each Restricted Stock Unit then becoming vested or otherwise to be settled on such
date, subject to the withholding of applicable taxes. Notwithstanding the foregoing, if permitted by the Committee and set forth in the Award Agreement, the Participant may elect in accordance with terms specified in the Award Agreement to defer
receipt of all or any portion of the shares of Stock or other property otherwise issuable to the Participant pursuant to this Section. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">10.7<B> Nontransferability of Restricted Stock Unit Awards.</B>&nbsp;&nbsp;&nbsp;&nbsp;Prior to the issuance of shares of Stock in settlement of a Restricted Stock Unit Award, the Award shall not be subject in any manner to anticipation,
alienation, sale, exchange, transfer, assignment, pledge, encumbrance, or garnishment by creditors of the Participant or the Participant&#146;s beneficiary, except transfer by will or by the laws of descent and distribution. All rights with respect
to a Restricted Stock Unit Award granted to a Participant hereunder shall be exercisable during his or her lifetime only by such Participant or the Participant&#146;s guardian or legal representative. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">11.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>D<SMALL>EFERRED</SMALL> S<SMALL>TOCK</SMALL> U<SMALL>NITS</SMALL>. </I></B> </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">11.1<B> Establishment of Deferred Stock Unit Program.</B>&nbsp;&nbsp;&nbsp;&nbsp;The Committee, in its discretion and upon such terms and conditions as it
may determine, may establish one or more programs pursuant to the Plan under which: </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(a) Participants designated by the
Committee who are Insiders or otherwise among a select group of highly compensated Employees may irrevocably elect, prior to a date specified by the Committee, to reduce such Participant&#146;s compensation otherwise payable in cash (subject to any
minimum or maximum reductions imposed by the Committee) and to be granted automatically at such time or times as specified by the Committee one or more Awards of Deferred Stock Units with respect to such numbers of shares of Stock as determined in
accordance with the rules of the program established by the Committee and having such other terms and conditions as established by the Committee. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">A-18 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(b) Participants designated by the Committee who are Insiders or otherwise among a select
group of highly compensated Employees may irrevocably elect, prior to a date specified by the Committee, to be granted automatically an Award of Deferred Stock Units with respect to such number of shares of Stock and upon such other terms and
conditions as established by the Committee in lieu of: </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(i) shares of Stock otherwise issuable to such Participant upon the
exercise of an Option; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(ii) cash or shares of Stock otherwise issuable to such Participant upon the exercise of a SAR; or
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(iii) cash or shares of Stock otherwise issuable to such Participant upon the settlement of a Performance Award.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">11.2<B> Terms and Conditions of Deferred Stock Units.</B>&nbsp;&nbsp;&nbsp;&nbsp;Deferred Stock Units granted pursuant to this
Section&nbsp;11 shall be evidenced by Award Agreements in such form as the Committee shall from time to time establish. No such Deferred Stock Unit or purported Deferred Stock Unit shall be a valid and binding obligation of the Company unless
evidenced by a fully executed Award Agreement. Award Agreements evidencing Deferred Stock Units may incorporate all or any of the terms of the Plan by reference and shall comply with and be subject to the following terms and conditions: </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(a)<B><I> Vesting Conditions</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;Deferred Stock Units shall not be subject to any vesting conditions.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(b)<B><I> Terms and Conditions of Deferred Stock Units</I></B><B><I>.</I></B> </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(i)<B> Voting Rights; Dividend Equivalent Rights and Distributions.</B>&nbsp;&nbsp;&nbsp;&nbsp;Participants shall have no voting rights
with respect to shares of Stock represented by Deferred Stock Units until the date of the issuance of such shares (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company). However, a
Participant shall be entitled to receive Dividend Equivalents with respect to the payment of cash dividends on Stock having a record date prior to date on which Deferred Stock Units held by such Participant are settled. Such Dividend Equivalents
shall be paid by crediting the Participant with additional whole and/or fractional Deferred Stock Units as of the date of payment of such cash dividends on Stock. The method of determining the number of additional Deferred Stock Units to be so
credited shall be specified by the Committee and set forth in the Award Agreement. Such additional Deferred Stock Units shall be subject to the same terms and conditions and shall be settled in the same manner and at the same time (or as soon
thereafter as practicable) as the Deferred Stock Units originally subject to the Deferred Stock Unit Award. In the event of a dividend or distribution paid in shares of Stock or any other adjustment made upon a change in the capital structure of the
Company as described in Section&nbsp;4.2, appropriate adjustments shall be made in the Participant&#146;s Deferred Stock Unit Award so that it represent the right to receive upon settlement any and all new, substituted or additional securities or
other property (other than normal cash dividends) to which the Participant would entitled by reason of the shares of Stock issuable upon settlement of the Award. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(ii)<B> Settlement of Deferred Stock Unit Awards.</B>&nbsp;&nbsp;&nbsp;&nbsp;A Participant electing to receive an Award of Deferred Stock
Units pursuant to this Section&nbsp;11, shall specify at the time of such election a settlement date with respect to such Award. The Company shall issue to the Participant as soon as practicable following the earlier of the settlement date elected
by the Participant or the date of termination of the Participant&#146;s Service, a number of whole shares of Stock equal to the number of whole Deferred Stock Units subject to the Deferred Stock Unit Award. Such shares of Stock shall be fully
vested, and the Participant shall not be required to pay any additional consideration (other than applicable tax withholding) to acquire such shares. Any fractional Deferred Stock Unit subject to the Deferred Stock Unit Award shall be settled by the
Company by payment in cash of an amount equal to the Fair Market Value as of the payment date of such fractional share. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">(iii)<B> Nontransferability of Deferred Stock Unit Awards.</B>&nbsp;&nbsp;&nbsp;&nbsp;Prior to their settlement in accordance with the provision of the Plan, no Deferred Stock Unit Award shall be subject in any manner to anticipation,
alienation, sale, exchange, transfer, assignment, pledge, encumbrance, or </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">A-19 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%">
<FONT FACE="Times New Roman" SIZE="2">garnishment by creditors of the Participant or the Participant&#146;s beneficiary, except transfer by will or by the laws of descent and distribution. All
rights with respect to a Deferred Stock Unit Award granted to a Participant hereunder shall be exercisable during his or her lifetime only by such Participant or the Participant&#146;s guardian or legal representative. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">12.<B><I>&nbsp;&nbsp;&nbsp;&nbsp;S<SMALL>TANDARD</SMALL> F<SMALL>ORMS</SMALL> <SMALL>OF</SMALL> A<SMALL>WARD</SMALL> A<SMALL>GREEMENT</SMALL>. </I></B> </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">12.1<B> Award Agreements</B><B><I>.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Each Award shall comply with and be subject to the terms and conditions set forth in
the appropriate form of Award Agreement approved by the Committee and as amended from time to time. Any Award Agreement may consist of an appropriate form of Notice of Grant and a form of Agreement incorporated therein by reference, or such other
form or forms as the Committee may approve from time to time. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">12.2 <B>Authority to Vary Terms</B><B><I>.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;The
Committee shall have the authority from time to time to vary the terms of any standard form of Award Agreement either in connection with the grant or amendment of an individual Award or in connection with the authorization of a new standard form or
forms; provided, however, that the terms and conditions of any such new, revised or amended standard form or forms of Award Agreement are not inconsistent with the terms of the Plan. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">13.&nbsp;&nbsp;&nbsp;&nbsp;<B><I>C<SMALL>HANGE</SMALL> <SMALL>IN</SMALL> C<SMALL>ONTROL</SMALL>. </I></B> </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">13.1 <B>Definitions. </B> </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(a) An <I>&#147;</I><B><I>Ownership Change Event</I></B><I>&#148;</I> shall be deemed to
have occurred if any of the following occurs with respect to the Company: (i)&nbsp;the direct or indirect sale or exchange in a single or series of related transactions by the stockholders of the Company of more than fifty percent (50%)&nbsp;of the
voting stock of the Company; (ii)&nbsp;a merger or consolidation in which the Company is a party; (iii)&nbsp;the sale, exchange, or transfer of all or substantially all of the assets of the Company (other than a sale, exchange or transfer to one or
more subsidiaries of the Company); or (iv)&nbsp;a liquidation or dissolution of the Company. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(b) A
<I>&#147;</I><B><I>Change in Control</I></B><I>&#148;</I> shall mean an Ownership Change Event or series of related Ownership Change Events (collectively, a <I>&#147;</I><B><I>Transaction</I></B>&#148;) in which the stockholders of the Company
immediately before the Transaction do not retain immediately after the Transaction, in substantially the same proportions as their ownership of shares of the Company&#146;s voting stock immediately before the Transaction, direct or indirect
beneficial ownership of more than fifty percent (50%)&nbsp;of the total combined voting power of the outstanding voting securities of the Company or, in the case of an Ownership Change Event described in Section&nbsp;13.1(a)(iii), the entity to
which the assets of the Company were transferred (the <I>&#147;</I><B><I>Transferee</I></B>&#148;), as the case may be. For purposes of the preceding sentence, indirect beneficial ownership shall include, without limitation, an interest resulting
from ownership of the voting securities of one or more corporations or other business entities which own the Company or the Transferee, as the case may be, either directly or through one or more subsidiary corporations or other business entities.
The Committee shall have the right to determine whether multiple sales or exchanges of the voting securities of the Company or multiple Ownership Change Events are related, and its determination shall be final, binding and conclusive. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">13.2<B> Effect of Change in Control on Options and SARs</B>. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(a)<B><I> Accelerated Vesting</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any other provision of the Plan to the contrary, the Committee, in its sole discretion, may provide in any Award Agreement or, in the event
of a Change in Control, may take such actions as it deems appropriate to provide for the acceleration of the exercisability and vesting in connection with such Change in Control of any or all outstanding Options and SARs and shares acquired upon the
exercise of such Options and SARs upon such conditions and to such extent as the Committee shall determine. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(b)<B><I>
Assumption or Substitution</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;In the event of a Change in Control, the surviving, continuing, successor, or purchasing corporation or other business entity or parent corporation thereof, as the case may be (the
<I>&#147;</I><B><I>Acquiring Corporation</I></B>&#148;), may, without the consent of the Participant, either assume the Company&#146;s rights and obligations under outstanding Options and SARs or substitute for outstanding </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">A-20 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%">
<FONT FACE="Times New Roman" SIZE="2">Options and SARs substantially equivalent options and stock appreciation rights for the Acquiring Corporation&#146;s stock. In the event that the Acquiring
Corporation elects not to assume or substitute for outstanding Options and SARs in connection with a Change in Control, or if the Acquiring Corporation is not a &#147;publicly held corporation&#148; within the meaning of Section&nbsp;162(m), the
exercisability and vesting of each such outstanding Option, SAR and any shares acquired upon the exercise thereof held by a Participant whose Service has not terminated prior to such date shall be accelerated, effective as of the date ten
(10)&nbsp;days prior to the date of the Change in Control. The exercise or vesting of any Option, SAR and any shares acquired upon the exercise thereof that was permissible solely by reason of this Section&nbsp;13.2 and the provisions of such
applicable Award Agreement shall be conditioned upon the consummation of the Change in Control. Any Options and SARs which are neither assumed or substituted for by the Acquiring Corporation in connection with the Change in Control nor exercised as
of the date of the Change in Control shall terminate and cease to be outstanding effective as of the date of the Change in Control. Notwithstanding the foregoing, shares acquired upon exercise of an Option or SAR prior to the Change in Control and
any consideration received pursuant to the Change in Control with respect to such shares shall continue to be subject to all applicable provisions of the applicable Award Agreement evidencing such Option or SAR except as otherwise provided in such
applicable Award Agreement. Furthermore, notwithstanding the foregoing, if the corporation the stock of which is subject to the outstanding Options and SARs immediately prior to an Ownership Change Event described in Section&nbsp;13.1(a)(i)
constituting a Change in Control is the surviving or continuing corporation and immediately after such Ownership Change Event less than fifty percent (50%)&nbsp;of the total combined voting power of its voting stock is held by another corporation or
by other corporations that are members of an affiliated group within the meaning of Section&nbsp;1504(a) of the Code without regard to the provisions of Section&nbsp;1504(b) of the Code, the outstanding Options and SARs shall not terminate unless
the Committee otherwise provides in its discretion. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(c)<B><I> Cash-Out</I></B><B><I>.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;The
Committee may, in its sole discretion and without the consent of any Participant, determine that, upon the occurrence of a Change in Control, each or any Option or SAR outstanding immediately prior to the Change in Control shall be canceled in
exchange for a payment with respect to each vested share of Stock subject to such canceled Option or SAR in (i)&nbsp;cash, (ii)&nbsp;stock of the Company or of a corporation or other business entity a party to the Change in Control, or
(iii)&nbsp;other property which, in any such case, shall be in an amount having a Fair Market Value equal to the excess of the Fair Market Value of the consideration to be paid per share of Stock in the Change in Control over the exercise price per
share under such Option or SAR (the <I>&#147;</I><B><I>Spread</I></B>&#148;). In the event such determination is made by the Committee, the Spread (reduced by applicable withholding taxes, if any) shall be paid to Participants in respect of their
canceled Options and SARs as soon as practicable following the date of the Change in Control. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">13.3<B> Effect of Change in Control on
Restricted Stock Awards.</B>&nbsp;&nbsp;&nbsp;&nbsp;The Committee may, in its discretion, provide in any Award Agreement evidencing a Restricted Stock Award that, in the event of a Change in Control, the lapsing of the Restriction Period applicable
to the shares subject to the Restricted Stock Award held by a Participant whose Service has not terminated prior to the Change in Control shall be accelerated effective immediately prior to the consummation of the Change in Control to such extent as
specified in such Award Agreement. Any acceleration of the lapsing of the Restriction Period that was permissible solely by reason of this Section&nbsp;13.3 and the provisions of such Award Agreement shall be conditioned upon the consummation of the
Change in Control. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">13.4<B> Effect of Change in Control on Performance Awards.</B>&nbsp;&nbsp;&nbsp;&nbsp;The Committee may, in its
discretion, provide in any Award Agreement evidencing a Performance Award that, in the event of a Change in Control, the Performance Award held by a Participant whose Service has not terminated prior to the Change in Control shall become payable
effective as of the date of the Change in Control to such extent as specified in such Award Agreement. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">13.5<B> Effect of Change in Control
on Restricted Stock Unit Awards.</B>&nbsp;&nbsp;&nbsp;&nbsp;The Committee may, in its discretion, provide in any Award Agreement evidencing a Restricted Stock Unit Award that, in the event of a Change in Control, the Restricted Stock Unit Award held
by a Participant whose Service has not terminated prior </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">A-21 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">to such date shall be settled effective as of the date of the Change in Control to such extent as specified in such Award Agreement. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">13.6<B> Effect of Change in Control on Deferred Stock Units.</B>&nbsp;&nbsp;&nbsp;&nbsp;The Committee may, in its discretion, provide in any Award
Agreement evidencing a Deferred Stock Unit Award that, in the event of a Change in Control, the Deferred Stock Units pursuant to such Award shall be settled effective as of the date of the Change in Control to such extent as specified in such Award
Agreement. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B></B>14.<B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I>C<SMALL>OMPLIANCE</SMALL> <SMALL>WITH</SMALL> S<SMALL>ECURITIES</SMALL> L<SMALL>AW</SMALL>.
</I></B><B> </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The grant of Awards and the issuance of shares of Stock pursuant to any Award shall be subject to compliance with all
applicable requirements of federal, state and foreign law with respect to such securities and the requirements of any stock exchange or market system upon which the Stock may then be listed. In addition, no Award may be exercised or shares issued
pursuant to an Award unless (a)&nbsp;a registration statement under the Securities Act shall at the time of such exercise or issuance be in effect with respect to the shares issuable pursuant to the Award or (b)&nbsp;in the opinion of legal counsel
to the Company, the shares issuable pursuant to the Award may be issued in accordance with the terms of an applicable exemption from the registration requirements of the Securities Act. The inability of the Company to obtain from any regulatory body
having jurisdiction the authority, if any, deemed by the Company&#146;s legal counsel to be necessary to the lawful issuance and sale of any shares hereunder shall relieve the Company of any liability in respect of the failure to issue or sell such
shares as to which such requisite authority shall not have been obtained. As a condition to issuance of any Stock, the Company may require the Participant to satisfy any qualifications that may be necessary or appropriate, to evidence compliance
with any applicable law or regulation and to make any representation or warranty with respect thereto as may be requested by the Company. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2"><B></B>15.<B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I>T<SMALL>AX</SMALL> W<SMALL>ITHHOLDING</SMALL>. </I></B><B> </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">15.1<B> Tax
Withholding in General.</B>&nbsp;&nbsp;&nbsp;&nbsp;The Company shall have the right to deduct from any and all payments made under the Plan, or to require the Participant, through payroll withholding, cash payment or otherwise, including by means of
a Cashless Exercise of an Option, to make adequate provision for, the federal, state, local and foreign taxes, if any, required by law to be withheld by the Participating Company Group with respect to an Award or the shares acquired pursuant
thereto. The Company shall have no obligation to deliver shares of Stock, to release shares of Stock from an escrow established pursuant to an Award Agreement, or to make any payment in cash under the Plan until the Participating Company
Group&#146;s tax withholding obligations have been satisfied by the Participant. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">15.2<B> Withholding in
Shares.</B>&nbsp;&nbsp;&nbsp;&nbsp;The Company shall have the right, but not the obligation, to deduct from the shares of Stock issuable to a Participant upon the exercise or settlement of an Award, or to accept from the Participant the tender of, a
number of whole shares of Stock having a Fair Market Value, as determined by the Company, equal to all or any part of the tax withholding obligations of the Participating Company Group. The Fair Market Value of any shares of Stock withheld or
tendered to satisfy any such tax withholding obligations shall not exceed the amount determined by the applicable minimum statutory withholding rates. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2"><B></B>16.<B> &nbsp;&nbsp;&nbsp;&nbsp;</B><B><I>A<SMALL>MENDMENT</SMALL> <SMALL>OR</SMALL> T<SMALL>ERMINATION</SMALL> <SMALL>OF</SMALL> P<SMALL>LAN</SMALL>. </I></B><B> </B></FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Committee may amend, suspend or terminate the Plan at any time. However, without the approval of the Company&#146;s stockholders, there shall be
(a)&nbsp;no increase in the maximum aggregate number of shares of Stock that may be issued under the Plan (except by operation of the provisions of Section&nbsp;4.2), (b)&nbsp;no change in the class of persons eligible to receive Incentive Stock
Options, (c)&nbsp;no Option and/or SAR repricing as described in Section&nbsp;3.6, (d)&nbsp;no amendment to permit the granting of Options (other than Indexed Options) with exercise prices less than Fair Market Value on the date of grant, and
(e)&nbsp;no other amendment of the Plan that would require approval of the Company&#146;s stockholders under any applicable law, regulation or rule. No amendment, suspension or termination of the Plan shall affect any then outstanding Award unless
expressly provided by the Committee. In any event, no amendment, suspension or termination of the Plan may adversely affect any then outstanding Award without the consent of the Participant unless necessary to comply with any applicable law,
regulation or rule. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">A-22 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B></B>17.<B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I>M<SMALL>ISCELLANEOUS</SMALL> P<SMALL>ROVISIONS</SMALL>. </I></B><B> </B>
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">17.1<B> Repurchase Rights</B><B><I>.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares issued under the Plan may be subject to one or more
repurchase options, or other conditions and restrictions as determined by the Committee in its discretion at the time the Award is granted. The Company shall have the right to assign at any time any repurchase right it may have, whether or not such
right is then exercisable, to one or more persons as may be selected by the Company. Upon request by the Company, each Participant shall execute any agreement evidencing such transfer restrictions prior to the receipt of shares of Stock hereunder
and shall promptly present to the Company any and all certificates representing shares of Stock acquired hereunder for the placement on such certificates of appropriate legends evidencing any such transfer restrictions. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">17.2<B> Provision of Information.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Participant shall be given access to information concerning the Company equivalent
to that information generally made available to the Company&#146;s common stockholders. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">17.3<B> Rights as Employee, Consultant or
Director.</B>&nbsp;&nbsp;&nbsp;&nbsp;No person, even though eligible pursuant to Section&nbsp;5, shall have a right to be selected as a Participant, or, having been so selected, to be selected again as a Participant. Nothing in the Plan or any Award
granted under the Plan shall confer on any Participant a right to remain an Employee, Consultant or Director or interfere with or limit in any way any right of a Participating Company to terminate the Participant&#146;s Service at any time. To the
extent that an Employee of a Participating Company other than the Company receives an Award under the Plan, that Award shall in no event be understood or interpreted to mean that the Company is the Employee&#146;s employer or that the Employee has
an employment relationship with the Company. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">17.4<B> Rights as a Stockholder.</B>&nbsp;&nbsp;&nbsp;&nbsp;A Participant shall have no rights
as a stockholder with respect to any shares covered by an Award until the date of the issuance of such shares (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company). No adjustment
shall be made for dividends, distributions or other rights for which the record date is prior to the date such shares are issued, except as provided in Section&nbsp;4.2 or another provision of the Plan. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">17.5<B> Fractional Shares.</B>&nbsp;&nbsp;&nbsp;&nbsp;The Company shall not be required to issue fractional shares upon the exercise or settlement of any
Award. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">17.6<B> Severability.</B>&nbsp;&nbsp;&nbsp;&nbsp;If any one or more of the provisions (or any part thereof) of this Plan or of any
Award Agreement issued hereunder, shall be held to be invalid, illegal or unenforceable in any respect, such provision shall be modified so as to make it valid, legal and enforceable, and the validity, legality and enforceability of the remaining
provisions (or any part thereof) of the Plan or of any Award Agreement shall not in any way be affected or impaired thereby. The Company may, without the consent of any Participant, and in a manner determined necessary solely in the discretion of
the Company, amend the Plan and any outstanding Award Agreement as the Company deems necessary to ensure the Plan and all Awards remain valid, legal or enforceable in all respects. </FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">17.7<B> Beneficiary Designation.</B>&nbsp;&nbsp;&nbsp;&nbsp;Subject to local laws and procedures, each Participant may file with the Company a written
designation of a beneficiary who is to receive any benefit under the Plan to which the Participant is entitled in the event of such Participant&#146;s death before he or she receives any or all of such benefit. Each designation will revoke all prior
designations by the same Participant, shall be in a form prescribed by the Company, and will be effective only when filed by the Participant in writing with the Company during the Participant&#146;s lifetime. If a married Participant designates a
beneficiary other than the Participant&#146;s spouse, the effectiveness of such designation may be subject to the consent of the Participant&#146;s spouse. If a Participant dies without an effective designation of a beneficiary who is living at the
time of the Participant&#146;s death, the Company will pay any remaining unpaid benefits to the Participant&#146;s legal representative. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">17.8<B> Unfunded Obligation.</B>&nbsp;&nbsp;&nbsp;&nbsp;Participants shall have the status of general unsecured creditors of the Company. Any amounts payable to Participants pursuant to the Plan shall be unfunded and unsecured obligations
for all purposes, including, without limitation, Title&nbsp;I of the Employee Retirement Income Security Act of 1974. No Participating Company shall be required to segregate any monies from its general funds, or to create any </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">A-23 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">trusts, or establish any special accounts with respect to such obligations. The Company shall retain at all times beneficial ownership of any investments,
including trust investments, which the Company may make to fulfill its payment obligations hereunder. Any investments or the creation or maintenance of any trust or any Participant account shall not create or constitute a trust or fiduciary
relationship between the Committee or any Participating Company and a Participant, or otherwise create any vested or beneficial interest in any Participant or the Participant&#146;s creditors in any assets of any Participating Company. The
Participants shall have no claim against any Participating Company for any changes in the value of any assets which may be invested or reinvested by the Company with respect to the Plan. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">A-24 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g62758g96q80.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">ARCA </FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">biopharma </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"
COLOR="#FFFFFF">000004 </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 ADD 5 ADD 6 </FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">C123456789 </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"
COLOR="#FFFFFF">000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="1" COLOR="#FFFFFF">Electronic Voting Instructions </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">You Available can vote 24 hours by Internet a day, or 7 days
telephone! a week! </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">methods Instead of outlined mailing below your proxy, to vote you your may proxy. choose one of the two
voting VALIDATION DETAILS ARE LOCATED BELOW IN THE TITLE BAR. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">1:00 Proxies a.m. submitted , Central Time, by the on
Internet XXXXXX or XX, telephone 20XX. must be received by </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">Vote by Internet </FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">Log on to the Internet and go to www.envisionreports.com/NUVO </FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">Follow the steps outlined on the secured website. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">Vote by telephone </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">Call toll free 1-800-652-VOTE (8683) within the United
States, Canada &amp; Puerto Rico any time on a touch tone telephone. There is NO CHARGE to you for the call. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">Follow the
instructions provided by the recorded message. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">Using a black ink pen, mark your votes with an X as shown in this example.
Please do not write outside the designated areas. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">Annual Meeting Proxy Card 123456 C0123456789 12345 </FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">3IF YOU HAVE NOT VOTED VIA THE INTERNET OR TELEPHONE, FOLD ALONG THE PERFORATION, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED
ENVELOPE. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">A Proposals &#151; The Board of Directors recommends a vote FOR all the nominees listed and FOR Proposals 2 and
3. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">1. Election of Four Directors for a three-year term ending at the Annual Meeting of Stockholders in 2012 or until the
election and qualification of their respective successors. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">NOMINEES: For Withhold For Withhold For Withhold + </FONT></P>
<P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">01 - Jean-Francois Formela, M.D. 02 - J. William Freytag, Ph.D. 03 - Ted W. Love, M.D. </FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">04 - Burton E. Sobel, M.D. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"
COLOR="#FFFFFF">For Against Abstain For Against Abstain </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">2. Approval Inc. 2004 of Equity the amendment Incentive Plan and as
restatement the Amended of the and Nuvelo, 3. Ratification independent of registered the selection public of KPMG accounting LLP firm as the for Company&#146;s the fiscal Restated ARCA biopharma, Inc. 2004 Equity Incentive Plan. year ending December
31, 2009. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">In their discretion, the proxies are also authorized to vote upon such other matters as may properly come before
the Annual Meeting. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">B Non-Voting Items </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">Change of Address &#151; Please print your new address below. Comments &#151; Please print your comments below. Meeting Attendance Mark the box to the right if you plan to attend the Annual Meeting.
</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">C Authorized Signatures &#151; This section must be completed for your vote to be counted. &#151; Date and Sign Below
</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">minor, Please etc. date Signatures and sign exactly for corporations as the name and appears partnerships on this should
card. be Joint in the owners corporate should or firm each name sign. by Please a duly give authorized full title person. when signing as executor, administrator, trustee, attorney, guardian for a Date (mm/dd/yyyy) &#151; Please print date below.
Signature 1 &#151; Please keep signature within the box. Signature 2 &#151; Please keep signature within the box. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">C
1234567890 J N T MR A SAMPLE (THIS AREA IS SET UP TO ACCOMMODATE </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">140 CHARACTERS) MR A SAMPLE AND MR A SAMPLE AND
</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND </FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">1 U P X 0 2 2 0 5 9 1 MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND </FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">&lt;STOCK#&gt; 0128IA </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g62758g91u93.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">IF YOU HAVE NOT
VOTED VIA THE INTERNET OR TELEPHONE, FOLD ALONG THE PERFORATION, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"
COLOR="#FFFFFF">ARCA </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">biopharma </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">Proxy &#151; ARCA BIOPHARMA, INC. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">PROXY SOLICITED BY THE BOARD OF DIRECTORS
OF ARCA BIOPHARMA, INC. FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 25, 2009 </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">The undersigned hereby
acknowledges receipt of the Notice of Annual Meeting of Stockholders and Proxy Statement of ARCA biopharma, Inc. (the &#147;Company&#148;), dated April 30, 2009, in connection with the Company&#146;s Annual Meeting of Stockholders to be held at the
Renaissance Hotel, 500 Flatiron Blvd., Broomfield, CO 80021, at 9:00 a.m., mountain time, on Thursday, June 25, 2009, and does hereby appoint Richard B. Brewer, Michael R. Bristow, M.D., Ph.D., Kathryn E. Falberg and Christopher D. Ozeroff, and each
of them (with full power to act alone), proxies of the undersigned with all the powers the undersigned would possess if personally present and with full power of substitution in each of them, to appear and vote all shares of Common Stock of the
Company which the undersigned would be entitled to vote if personally present at the 2009 Annual Meeting of Stockholders, and at any adjournment or adjournments thereof. </FONT></P> <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">The shares represented hereby will be voted as directed herein. IN EACH CASE, IF NO DIRECTION IS INDICATED, SUCH SHARES WILL BE VOTED &#147;FOR&#148; PROPOSALS 1, 2 AND 3. AS TO ANY OTHER MATTER THAT
MAY PROPERLY COME BEFORE THE MEETING OR ANY ADJOURNMENTS THEREOF, SAID PROXY HOLDERS WILL VOTE IN ACCORDANCE WITH THEIR BEST JUDGMENT. THIS PROXY MAY BE REVOKED IN WRITING AT ANY TIME PRIOR TO THE VOTING THEREOF. </FONT></P> <P
STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1" COLOR="#FFFFFF">PLEASE VOTE, DATE AND SIGN ON THE REVERSE SIDE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. Please be sure to sign and date this Proxy.
</FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g62758g32i93.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g62758g32i93.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0>L4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````+````"H````&`&<`,P`R
M`&D`.0`S`````0`````````````````````````!```````````````J````
M+``````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````!1`````!````*@```"P`
M``"````6````!/0`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``L`"H#`2(``A$!`Q$!_]T`!``#_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U5))))2EE]<^L&%T6JOU@^_+R';,7"H&ZZYWA57^XW_"6N_1UH?7_
M`*PMZ7Z.'BU?;.KYIVX>$TP3^]?>[_`XM7^$M7,9.79T7-.-B@=<^O?4F19:
M!-6,PZ[=?;BX5'YE?T[_`.=R$E.=];'?6'J!KZ9GY+G=7ZCIA]!P'[:J&'_M
M5U3*'Z3(]-O_`*#^HS_1JU_XU&5_Y<7?T#[-R[^>_P#>#_@?YQ;?U9Z.WHG5
M749E=^=UGJ-#LK-ZT6322'AGV*JS_!;/8YM6SZ&S^175U:2G_]#U58_UC^L-
M71L>ME;#E=2RSZ73\)GT[;//]RBOZ5]W^#5CKG6L+H?3;>HYKHKK$,8/I6//
M\W14W\ZRQ97U7Z-FOR+/K+UUO^6,UL5T'5N)C\UXE,_1LV_TEW[_`/;WI39^
MKWU?MP&W9_4+?M'7,\3F90U#?]'C8K7?0QL?\S_2?X1<MTMG4O\`%_;DW]:Q
M69W3\V_=D]=H)=>"]VVLYM%GO]/>[_`?^"V+LOK#UW'Z%TYV9:PW6N<*L7%9
M_.77/.VJBINON<[_`*"PL7ZFY/6K6]3^N=IR[C[J.E5N+<7'!U#"UA'VB]OY
M]CO_``5)3J=&^N/0^N=2OZ=TRQ^0['K%K[VL(I(EK"QEI_/;O_=_XM;BY3ZA
M-&`SJOU=!W,Z/F.;0>_H7C[3CM>[\Y[=UBZM)3__T=7"R<KZX_75N2_%>_ZM
M]%+_`+-8^6UORF'9Z^US?TSVN_FZ_P#`_P#@=GH"9NV/;$:\>/=.DIY38WK'
M^,%XM]V/]6\9AK9V^TY@+_5/]7%K]BW.L=<Z5T3$=E]3R&8]0!VAQ]SR/S*:
M_IVO_J+B/K?]O_YT7?\`-?[=]O\`2I_;7V/9LVZ_8MWK?]J?2W_]:_ZXG^K'
M_,G]JM_:?VO_`)Q[O;^W9];=V^S[OU3Z7\Q_ADE.]]1\;,LKZCU[-H=BW=;R
M?7KQWZ.90QHJQ18/])LW.73I))*?_]DX0DE-!"$``````%4````!`0````\`
M00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````3`$$`9`!O`&(`90`@
M`%``:`!O`'0`;P!S`&@`;P!P`"``-@`N`#`````!`#A"24T$!@``````!P`(
M``$``0$`_^X`#D%D;V)E`&1``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#
M`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`+``J`P$1``(1`0,1`?_=``0`
M!O_$`'<```("`P$```````````````D*``@$!0<&`0$`````````````````
M````$```!@$"!`0"!`\!```````"`P0%!@<(`0D`$Q05$1(7&!89(20U"B)"
M(S149"4F9C='*#@Y61H1`0````````````````````#_V@`,`P$``A$#$0`_
M`'^.`G`3@*+YO[@5*8,QJ)!F2*6VE==L/1<3H'&"G6Q/+K[O27J#`E:-T(AN
MBM*84P-(C`F.SXM&G:6HC73FG:GFITYX*6;L"[<(R4-BF*60EU/;GG-E^7V_
M&O:6P<L'L5/8TPA8I+4*[\SSO=N*!++:(AK(28H"E-U0Q(QY;3%J+0UN(6!"
M'?/_`"D6G_TENO\`U_>W+[;DW\\OT3\Y_P`4/X9^UOUG@/_0?XX"<`-[/K<%
M;L3!UU2=0P861&<V1BPUAQJQB8W4IO6OAH!&E.MJ6D\@"=Z<T/`0$FJ7E]4@
M"$S1.-.F\3-#C$X`LL6VG[!>Y556U*0U;F'WDK,*)E()?-T*-4LI_$B!NQY2
MU,U"(<EI;906,M6HEVBA`S`"WNLIU3DNC]J0%8E\0OKMGXA-^!&5#Y!+NB-Y
M9/9^Y<4?),C\G-S)VA&JNBW)S:[$:(\?B[!YBK7@6P%)&>K0+4+`2W(2'!M3
M(E`@%%$HFYK`_P#P'__1?XX`=.XIN"QC!V`Q1DC$6577EQ?SNJKO$3%Z,F".
MF%T6B<F^K&+2T^NIT:JZ(#.+62>0J.4A:F_37S&Z'&D@&'B-O?`&58[-EFY$
M9(S\NVMQ7*AO3+\C;]2AT7M$/((">?$:.HEH>4FK?%J3J(*@LAO2:)"]7I4F
MT6+@"TT3)D@`3Q>:LE/NWTGNRPLZ*$A.3.,F1MXZ2.ZMURE'Z0O^0+`NG<F*
M;8FMR?JJ:GK9,9$@R%ZU,,*BXQ-[<K7&ZEC=G%26!0!\,.]XO!_/C).U<9\4
M9E,;9>*AKQ)8T@M=H@KPEHQV0G/C+'UT?C-@.&J8;A*FE?(4@AICD28E60,P
MU"<K`F5"(`I/`?_2="SBS1I7`'&RP<F;U>@H8Q#D721V-(SB=999]@.9*@,.
MJV`-AFNISW-)DXD<E,26$02"0G*U&I:1,H.*`?6V#AO<[]/99ND[A+.#WXY(
M1PAJA=5K0EKH]@UC>-2L6PK'JNR5B4M6T2]<UK0*YHO\"5*MU.-(,!H;UQRT
M+M;A&<\!V_<='FZI3'GFQYL[O;%7%$T5#A<ZQ<@+PFRT#1`:H@380F<'%>[/
M;D;S50TJ18<C;4ZA2%.>(H))@">JO9MLG.Z4M65N^3-UE[SQ</1^J[`:#RA[
MCF(.+#0XZ"6MT9<&>-.2!5<%GLI*K5,Z/2Q6<D4B").:)U3E)E`0Z)L+MA6.
MS1G[MHDK!.+'M]9H3".5*M-"48X:8\Y`M".[:B;9"YZ:B5/DI9A/;NF5JSQ"
M&(LLDO30`"PEA`_W`?_3OQ3-DVEO=[U+%:3Q1<U?=IS;>=[&(I"62U*LB%:V
M/F#"W)"P)K84MCRRA76;(FA[U/$TLX1DE1QO;TJQ8)*J5J6YQ!P#@%^^T(<U
M_O`\E32L!;K6>SMC)`'*)QDX8CDI666;R)Q?R9XX$<W5&HT8J(BI9#>0<2(U
M(X^5:48$6@--`*MF#F_BU@95#G<N5-Q1*J8BC2N!C.D>7$@<LG#FWINJ'&Z[
MAY`QR&<28\&H=`HV].>8#06AAO+*T$8$!L[']<V])V/,_<+OFL)+24_W),E!
MW+#ZBF*?HI=!,=8!%&^OZ#03!"82F4)96XQXE8M4><HG0Y,H3'!+!H9X<`=3
M@/_4?M1=#R->W=)TW4+/-T7)Y'5]8?W#QY'Y/J.OYO._&YWF\WX7CP&7P"6^
M[MZ\?,]LSY2_ON]S/I/C_P#,X]HGIA\&_"?[6]L_>O4O^N/P#W/IN1]7^'N1
MY?H[EP&TVQODH>Z=F]U/N^^:UWM+VWYVO>_7#X@\FO;O2#O?]O?0=UYGPKT_
/[R^'*Z3Z>7P#FG`3@/_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g62758g64f28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g62758g64f28.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0S24&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````.P```*,````&`&<`-@`T
M`&8`,@`X`````0`````````````````````````!``````````````"C````
M.P`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"C4````!````<````"D`
M``%0```UT```"AD`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``I`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#8LLS.KYC[+'N?N<353/M:W\RNMGT=VW_MU7&]#W5>H!%<AV_L&%KK
M'G_K>QS/ZZ?H3:G$!\FL?3W-:6@?O>HYS/2_L*UA]2AUGVDN.?N+=NNX/GVL
M;7_U#4E.,\YO2KA?CN=38WW&O6"/I;+F?G-<U=Y38+:F6@0+&AP'Q$KE?K`U
M@8\@$!TD[6MVEWY\W![WV.W?OKIL+^A8_P#Q3/\`J0DIS?K?U>[I'U?RLK$#
MGYSVFK"8P!SS<\$,=74YK_5]!N_*?7L_F:+%+ZI=9/6_JY@=3<=UMU0%Y@-_
M2L/HY'M;]%OK5OV?R%E=4ZL;/K=34S&RLS'Z'4;;6XC=_P"MY3754MN8_P!/
M^8Z>;WMVO_[6+(_Q9Y8Z=U?K7U5?790RBTYF#3</TC:7[6[+?<[:[TGX;]G_
M``EJ2GI/KD[K&+TC(ZITOJ!P[,"E]SJ357;7:&#?M?ZK'6L=M;[/3L6-]6G?
M7'KWU<HZTSKGHY>3O=5C.QJ#CCT['T^E:X5_:MMOI>ZRNW]'O6]]<_\`Q)=8
M_P#"=W_4.7"]$^M'6OJ]]0.EVLP:_L%SK*1U06&TT%]]OZ;)Z?Z-;G;?TGI;
M,KTW_P"$LK]7TDE/8?47ZUV?6?H[LK(J;1F8UIHR:V3LW`![7U[B]S6.:_\`
M.?\`351GUBZK]9>KY'3?JU8S%Z9@.#,WK1:+2ZR9^S].JL_0/^B]C\BUMU6S
M]+_W'^TDP.B8GU:^HN:SHEQR+7X=V4W-:9-USJ2ZO(KVES65^VOT&5N^A_I+
M?4NLK_XI*\5GU+QW41ZEEUSLF/\`2;_3;N_]!V8Z2F_UCHWUJ;@6OZ+U[(=F
ML!=75DU8;F6$#^:W,P\?TG/_`-)]!:W1,N[-Z-@Y>0"+[\>JRX$;2+',:ZUN
MS\S;9N5Y))3R7UV^N%GU?S>EU5!QH=>RSJE@;N;7BOWT,]3V.V.NL]6VC8[?
M^H^FNM7FW4'?\X>B]>LJP,[(LZV^<'(JJ)J]'#.WIC6FZQKF5Y%M-F39^AK_
M`*=8ND_Q==9/6/JE@W6/#\C':<6^"20ZGV,WEW^$LQ_1N?\`\:DI_]#6;9;T
MW,?CW"+:'':'<<^RUK7?2:[Z;%ICKE8`<2'.$,]33U-FTML(M_G/<]WJ-73W
M8V-D`"^IEH'&]H='^<A?LSIO_<2C_MMO_D4E/$Y.1?GW"BD>KDW>V&?GG]]W
M_HRS_KB[+,RSTKI];ACWYKF;*FU8K-[W&-L[98QC/;[K+'^FQ6:<7%QR3137
M43R6-#9_S0EE7UXV-;D6.V5TL=8]Q$P&C<3M'TDE//?4B[../ELZI@Y.'U3(
MR+,O,=:TFEQM=LH9B7[K&.91B58]'I?X/TEA?6"OJS?KWA=?Z-TG,R!@M=C=
M0E@KKM9[Z]V,ZQ]?VE_IW/\`=_,_HL9=ITG.=D].;?E65?:&#];;61MJ?'J/
MH?[[-KJ&/VV>]3QLUOV%F7E74EMA)9;22:W,>X_9O3<[W/>^KT_^N_S:2G!^
MLW5<CJ'U:NQ</I6?9D]5Q[JJZ74[#4=:/UQUCO3H_?K]WZ9G\VJ7U/Z:<GZH
MCZH==Z=E8[F56B]]M8])P?:ZZI^-DM-E?KU^K78S\]EE2Z[+ZABXF*W*L?NI
M>6-86>[<;"UE>R/I_2W?U$#J?474](LSL`UWO<&C%/TJWOL<VJELL<WVOL>U
MOTTE/(_4V[ZQ?5JJ[ZO]8Z=E9>#C7FK!SL>MMC?3L)=^D8U_J_9_=ZN_]-Z'
MJOIN]/T47IO2>K?4?J>4WI^)9U'ZKYKS=Z./^DR<6R`WV4N=ZF52[^;]GJW>
ME56_^<J_6NSQ,FC)I#Z;F9`:2QUE9!:7-]K_`*)=M]R9F=A6"UU=];FT?SS@
MX$,TW_I'3M;[/<DIR,SZU;:8Z;TOJ&=E.'Z.DXMV,S='M];)SZL>FIG\IOJK
M%ZGD_6JGZH_LD8>3F=?SZ+'Y%S&AU-/VBVQU]7VCU6L]3'HL?3BTTV/]+]#_
M`()=A3U'`O%CJ<BJP4M:^TM>T[6O;ZM;[-?8U]?O:A_M?I43]LICV&?4;_A?
MYCO_`(7\Q)2'I61CU="ILQ\3)Q\?%IV5X=M;AD-90/3;5Z)+[++-M7Z+W?IE
MQ7U5?U;ZO];ZM8.CY_[`ZE=Z^,!4#94\G_N&U_J,I>U^SZ/J[*<?^6O0[\C'
MQJS;D6LIK;R][@UHTGZ3E)KFO:'M,M<`6D=P4E/_T?54DDDE*6?US$OS,(8U
M3!:Q]M9R*]VPNJ:X/>QK_P"5M;O_`."]1:"22G(R.F98Z7DU4;/MF:]IM+3L
M8QI]*AWH.VNV_9<2O]`_9_/5^KZ:6=T[,#L)V"U@&'397162177:]M=%&3M_
M/KQZ/M->S^<_3?\`7*]=))3S]F*^G+Z;TS#K%XZ50;B;('N+3A87J/UVL?\`
MK5MFS_0?H_H>FIV]$OIZ=@X-+&Y=.&YU]['N]/UK1N?77^>UE5F5;Z_NW_S/
MIJOTC_Q8]7_J,_)6NE24Y%G3<MF**JPRUV5E&[/!<6`UOW.=6UVU^YC-N/0]
MNS]8H]3^;]5#JZ=U1W0\BBTUMZEFO<ZVP$EK2]S:_49_X5QV_JK?^`H9_P`*
MMM))3G9?32WI/[.Z<&T@M90UYY97(;9:W]Z^NKU+*?\`NPLVOZO7LR:BVJL8
MYM:U[2Z17BXQW8./7IN?Z^3^O97O]]WZ*WU*UT:22G"ZET[JF;E7-+*SBV/J
MK#G6$'[-`LRJFUM9['7Y#?3R/?\`I\;]%[-GJK=2224__]D`.$))300A````
M``!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````
M$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`#8`+@`P`````0`X
M0DE-!`8```````<`"``!``$!`/_N``Y!9&]B90!D0`````'_VP"$``$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("
M`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!`0("`0("`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`#L`HP,!
M$0`"$0$#$0'_W0`$`!7_Q`!_```!!`(#`0$`````````````!P@)"@8+`P0%
M`0(!`0`````````````````````0```'``$$`0(#!`<%"0````$"`P0%!@<(
M`!$2"1,4%2$6"C$B)!=!43(S-Q@9824VMG>!4B-$-9561U@1`0``````````
M``````````#_V@`,`P$``A$#$0`_`)9.7/+K3>2FFS]9K,_*P^30\J]A*M5H
M1Z[9-+&T9.UVZ=BL2;=8H34I->'R(HJ>2+9(Q$DB?)\BBP(I3\0=SD7(OTVZ
MBRL2FV>O2]C")8URY1CU'8]P`H%;2+MNEV#N81<`/;L41`%&F.-KLCUFW*U4
M(BM6(^RN%`3`/AC"0"<J^<%$2^(F!-)0"`/]XJ)2_B8P=`@Z*-\RN9):*1/V
M"IRD>X(="5@)1_$ND%`'R(B1TT6244*)2CW3,)BF(`@8!+WZ"REP+Y.RO)O'
MG$M;DV:6@4J7"M6Q5@@5JUF`.S2>0]D29$$R3(\LV,<BZ1/%,'394R9$TC$3
M*#W^@\Z7EXN`B92>FY!G$PL)'/9>7E9!PDT81D7&ME7DA(/G2QB(MF;-HB=1
M50X@4A"B(B`!T$!'HV]U[/VV6'G!`2,)6*L\P?<EW6-,(5K)QDE8^+=S6E(_
M+9VT-)>5E%7]\9OJF]&=<-`:LDS2#-,K9(1\E0L$=!&)[%-(]G>,56R;!P;I
MG#C4\^S?+9FYWC,-X4V""UVRS-7"?FIQOF]GILXWH9TW59;-"LV4JW:&.^36
M\GG@HD0@5]_5O[X_;O[@KKJ%+XO\;/7[F:.+UVKV'0[IN%GY".(!L6X/Y6/K
MT5"QE&=OYB1F)8\"^5(F?X6Z2+105%P,*9#@Z7EY[JO8EZC;MEKOV@<.,#TC
MC7K5@/5XSD?P6O\`?R-ZU/-VRDH[K\MG.VL1D'=M)"-UG;9@O*1360;H+G:O
MEC-G"2866\EU;/-US"@[+DUIC+OF>H5*"O%%ML.=0\=/UBQQZ$G$R*!5TT73
M<RS5P7Y$%TTG#=4#)JD(H0Q`"/\`]H/MQXF>J'+HF[\@YN6GKW>`DFV28?0T
M6DGI>F2,8#<CQ:/9NW+2/@:M%+O$2OY=^LBU0^0J:0.'1T6JH-AXT:Q[V.9=
M69[%.4KA%ZXLCO3-O.YSFNMY=M_*+E)'5]X7ZB.=:)'Q6S\=J!6G,FR434*T
M5;)2C?R$CIFV4+X"#8?9%RS_`%!WK:R6<Y"P-3]>O-W`Z(@I)Z;,4K"N1.8;
M#1Z\D4QWEOFJ`ER6M\$I2(8A0,_?Q[V078)"9PY;I-$EG*83I<%.1CGEYPQX
ML\H)",BH29WC!LPT^QP4&=TI"P-KM=2BY.UP,0=^LX?&C86R+.FJ`K***_$D
M'F8QNXB#K>@@/2]U=5<>^+_24;MZH>C)8*Y!:[A]7^93<KTHDFM&H1)+[G]A
M_*K7$DE"'2!M];^8Q%N*G<GPB$^'0'0?_]!_.(T^*G';=-_(IQ*JRH>#QZU<
MN8XHB(#W=J1Z3J0;$*4.P"DV<B)A#N!0_$`F'AHNDY76J[:KQ&LG]FG4I2K1
M<?6I2(D8?7(9[$.&3YXZ<LG+@\%(5P7*!GKXR/R"J9N<Z!GAS',"Z,*[`W6K
MIH3]:4IT=-053IIY^.=-Y9<D!7':;Q",5%TSC"-',NJ@@5P[\C(^2*8F1*0#
MCT$<?)W*FL0]?!)#"U5JR\V\-1XQX6Q3L:T`I"D4E#,E58Q*1=^)57AW3Q%R
M<YOW$?`I$R`X'U`-09L^1"!`,5()G.3$(8P&$ODTN@#W$"E*(CV#OV`.@F?Z
M"''W8;#-1'&6D\.\VDWS/<O9/L--X5T((3XEY^`H.F/4TN1>EH,S'(H2*SW"
MR3*B[T#$(P=O6BAS!W`!"JKBM4K/HM_51ADD+%H4+B?S<KK6E4)N<3M8*'IO
M(=:*?TUE&@Y.+-JQJ'**@!7TE#*!])$%.;N4IQ3$-AQT"1\@/\!]L_Z1Z1_R
M;,]!0Z_0W_\`&?LG[_M_+/%/O_[IR#Z"4[]9!HV>PGJ^H^533V,=:;JG)W.%
MLOJWR)KV1W^3(2VOK998>+)Y/5F,/&RB,:Y<$()$EIMND80,X3`P2>^BO#=1
MX5^G;BAF?)U![2KS0<]T6_WB%LWRMI'/*]=M+T'68JNV-%Q_$Q<G4:;9VR+]
MHJ!5(]RBJV$I?A\0"I=Z5DYCWJ>^+D%[!^2S-Q<LLXS1CC0\DSNS%"7K-*/(
M6AW5^,=`"&="I&M65*@&LM8SBB0A75IC1?*$.HX7,(;&?H.G(QT?,1[^)EF+
M.4BI1FZCI.,D6R+V/D8]Z@=L]8OF;DBK=VS=ME3)JI*%,10AA*8!`1#H$&XJ
M<9LXX=8'0>-N0J6$V9YDG8V=,;6B2:RTK$PM@M\_;T:^1\SCHM$\-6U+`9A&
MD%'Y$8UL@FH=50AE3AUN7W)*G\/>+N]\H;X45JOAF76[1'L>13X5YUY`Q2Z\
M)6&2OB<"2-IG1;1K81#Q^H=$[B`=Q`-<C[7>'>X^N#*_4;[<W1I)MS+ONE3V
MR<M)]ZC(L%77(^_7]WRQHE?L9"?(B@O%UR<G:A(-%#=EHZ`30*55$IP*&R?P
M':Z1R1P_(^0&:ORR5!V?.:?IE3=@HFHI]DN4$RG639W\8B5&18IO?@<I#V,B
MX3.F8`,40`%=Z#__T9/^-LP]3=-2MVE851(H0%7%ECJ^$8CV`O<'#V6133^0
M2_B"93BJ?\?$IA_#H)`.04+.V>FYWJF>LXJTQN7.9B&O32@5)]!1;=*P)Q3Y
MK,1$>NW;.9TT:$*<)1=-NDHF@JV4%+X2**E#NY+KENVI*/SRF,GSXBRB",H_
M314-'0+0X]EGLDZ_N4#$3*;XDQ'Y5U`!-,ICF`!#K<J+@RF7$R[K)<ZD$3.'
M7U3,M/CX:[M%OD4^1"683S4[B8D`-W^19DHZ$QBF,H"0_N@&3^I-T+HG(E00
M3*(3&<E$$D44"A_#781#XT$TB@("/]7?^CH)CN@JI3KWF/SQ]W&T;YQ,A^.L
MOFOJ5I[KB-01Y.3>FQU+?\C]PA33G(.\44,N@;!(&MU2JR#:I22;H[9(C4S=
M0I3G4'P")']55QC]A]BPKC[SDY%0/$:&=<;]%)G*-GXI6#;W5UCHK4UFTQ7Y
MRVJZ56X9@WKU3O-+:MX]9HY!TA)6`.Q#$5,=,+D?J]YD1?/S@/QCY6LUFYIG
M3<UC2Z"S;?$5.)U:IK.:;J<41!/L+=HUOL!(?2@8I#*,C(J>(%.7H'.<@/\`
M`?;/^D>D?\FS/0:VG])UQ,NW*ES["H[/.8G*#A[;:G3>/WV.T\<K/5(J/G)2
MQ.]M28+:76;74;&G=(FN.(<#M6S9U$KE*Z<E*Y(94ITP77UL[7)<,O???.,W
MNU1;\E^1;R>JV7\<N7^Z3T]I`Y';W"QIW(9S.2WF3>05-H&WQ-E:@S?-6*$E
M`3"S5(QFA#R9DPV#7(FARVI<?MTS&`5(WG-%QW3:)"KJ'^)-"6MU+FX".6.I
MW*"94GD@0PF[AV[=^@H2_HC;W$U#=_8G@MA24BM$M%!PZ[LH5^46LDA&XU;M
M0J%V;KLUP*X(O&3&O1*:I!`!3,?L8/V=!L/>@.@.@K=^\&ZZ9R;WS@OZC^.[
M*B6+0]QT%ER\Y`PNG2%@8Y:GQLXNS!KK!5/65:DPE;.C3-BUJMMV)#,FRBQW
M,,"'DE\X*%!-?<)PW]M_/'U^;MBNJ4[US/XR!A$]CK?\J;-R7=ZD2V9$"UQ8
M1V>M[;2"UI6SW",8/(!(KTZ2!TI90HJI=P4("??H]N8T?NGK9F^,LI(K+WWA
MMI$O7Q:NW8NEU<LUZ4GM#H,D0ZIA63;HV0]DBTT>PD00C$@*(%,4A0MG]!__
MTGD)(3.4WR?I%I37CY.IV&3@)5$Z9@42=1+U9HX*B4_B`E542$R1N_@<I@,`
M^(]Q"0[+.3CV):A)`^!BVJ<(ZC*1$-SE!K'3=A*HR4E54_$OU4D2-4>.E'BA
M3'.Y21)^ZG\9"`M=NY4KS#`M7=RJQD)/.Z@1HZ^I6!PTNT*Q1G(^514%0.S^
M9='.S75$2F-]2"AC=TB]!')M&TKW5=>2DE@5GE0*F^D"`4HS7BF1(CQZFF4H
M?=^Q/_'7_P#-_P!XIV6`ZBP2F^GVK3C/-]<O4BW62C+C<(*+B%ERF)]:-2C9
M`9!PW\OQ5:D7L!4`.'<ORHJ$[]R&``]GVK^W[BKZQ<(TZPW?5L]D^23.COW>
M.<<6]DCI+3+K=)=BY;TA>6ID:[4L,!GQI@"K2,T[2;LTF*"P(J*N1105!EOZ
M9K:.+=I]>6=5NC<A<TTKEGJUBU_DURUJ!+Q6EMK5V+0]%=FNULNN>D>(VM@P
M9LU86.3D3LBLG"";8Y%3_,43`]GW66'AT^]=_)_$N8.Y9-C4%M.(:0TH!-&N
MM=KTY/WVDQK*TTZ1H%8E'R,Y?)VGZ"A!/08Q;9VX,L*"8D`5B=PI_P#Z3;W,
M\;N*5"UC@GR\U2`Q>N6?25-APK3M#E?M&>HS5C@82N7W/+):Y!0D)0T#C5F$
MM%KO3MHUPX<R)55TG!VZ;@+F'/\`]C?!WC+Q?TFRZ[RCQ"OJW[CO:KKE=61T
MBJ2MVU^N6ZI3C6F3.5T^*E'MBOL';WQ?A82,:V<1ZH^1Q6!,ASE"C5^CSYM\
M5>)NQ<T*;R8W3-\'<[53L-6SN=U>U1-$J$X]SR9T\E@AS6ZQN8^MQ\O\5Z9J
M-T7+I$[DA5/B\Q((=!.5^J@]5,)S7XJQ7L3XWLF5CW;C91F]AG9&F.6\JGLG
M%T".K.^>Q3V+,LWFY'-$Y-6QQ+M!407AE9%,GSJ'9E(&>>C7]2+QCY1\;:3D
M_.KD+G.(<P<W8I5.R6/8+#%YU3MQB(PA4*_HL-=;$O'TQ"XRS`$T9J+6>MW:
MTJFJZ:H?3.")H@Q?V@^M7EKZK_8S#^[3U89I+;!GD_8;%>.3^`U-FZFW46:[
M*++:THA6X1)U-S&2ZHQ?+2*J\>U>K5*;(,@"96B;;Z8+-G!'W#<"/8)F=?N^
M0;S0ZY=7D<@K<<)TBV5RF[/G<V5,`E(2P4N7DVS^0;Q[PITB2D<#N*=@7R17
M-^\4H8%[$?=_P`]=6666V7O;J%I^KM6#E.D<>,INU:MNIW&Q'15^ULI&,A7L
MH:AUE5RG_%S<N1!FW2*<$@<N?B:K`QSTW^P*M5?UO73V,^R7D/G.+2O-OE%O
MV]1A=,N+2K1L96:DA5\/KF9Y'6I]\:Q3T75Z[BJ1(V*C$7T@Y34!;P66<&.H
M#%O1E[&.)O-CVG^R?F?KNXYU1=SV&R9AQHX59?I5KAZ19GG%^*E9!*OP>=Q5
MG=1ZMFM^C6&$@GLM#QQG#Y"9\Q!'Q=$$0N':5J.98S39;1-AT6B93GT$+,LY
M>M*MU?HM.AQD7K>-CRRMGM$A%PL>+^1=I-T067)\JZI"%[F,`"&L$X(>QKBS
MZB_?MRDG\RT:.N7KGV71M&S&:N6=@M:ZK7J!:[$VO%$N%6;PR2ZEK@L?NA@B
M0=L"NE'-?%\JR*[.JB14-A'_`*NWJT^#ZG_4,X<?3_DS^8'S_P"87,?B_*WW
M#[3]9Y_F/Q^X?=/X?[?_`.H_-^Y\'E^'0?_3N-\F^!>-\F9-.URRDM2K^FU2
M9*6VK@S[S#9N`E:IV2)>(':RQVB8^":Y#-W?Q@1,RQDDR$*#0VWJ"C6@`1#D
M+/@D4QC%3-0&1@+Y`4/_`)<`"/8H!W[=!Z#GU*-G0E,IR&G0,5-%(HAG[3N!
M6Z*:"781N`B`E(F'_;^SMT'9J_I_S)I-MY&\ZU<[A&)*E66AXV&C*K];XF\A
M0<R'UL\Y(U5_8H"`(JB41\5"#V,`2Q5>K5VDUZ(J=2AH^OUN!9)1\1#1;<C9
MBQ:(@/BDBD0/[1C")CG-W.H<QCF$3&$1!-]$J''N)6?ZIJ]5QN.=-&B#.2T7
M0(*E-G+=BB0Z;9F\MEB:$63;)D$Q4TSN/$`$0*'0?<OI>#+I1VN9)0\UCSW.
M"(O'WVHT>!@)6PUN6.V?IG"99Q$?*O8>4,U0<%`YA27`B:H>0>!N@]"ZU+$-
M(LD15-&K&57RWPL0^LL#6[K"U&T62)@7;UC&R<_#P\ZV?2;&(<R+=LW7=()E
M1.N1(AS"8I0`."0P#!Y=HFPE<3R238H^`),I#-Z<]:)`0`*0$VSF&41(!"@`
M!V`.P=!SS&$XA858%>?QS*YQ>JPC"M5A:8SVI2:U<KD5\GVN`@5'L0N>(A(W
MYC_3M6XIH(^0^!0[CT'7EN/V#3Z1$)W$LBFD4A$4DI;-J;(IIB;MW%,CR%6*
M01\0_8`?LZ#N+Z%C]>M%:Q`UFI,?;9J.7CJWEK-S&C+#!1,"YD5$TZFQ`ZL9
M7F<!'G\3JHHLP3*5(IO(Q"&#RE../'I:+2A%L'QE6%1."B,0IE](/&)'#\0.
MFP-!BU(?O_2!`'H%D(0J92D(4I"$*!"$(`%*0I0`"E*4``"E*`=@`/P`.@:_
MIW![A7MDBZF-EX@\7M:EWSA9X]EM+P'*;W)NW;@P'7=.7]HJ<H[7<+G#N<YC
MB8P_B(CT'K9YP]XD9$HT6RCBWQSS%6/5!9@KGN)9I2U&2Q2^`+-%*W68T[=4
M"_AY$$#=OZ>@5:X9IG.AEBB7^@4J\D@UU74(2X56"LQ(=RN1--=Q%EFF#TL>
MNL1$@&.EX&,!0`1_`.@\'^1>)!+Q%@_D[E?WZOO&LC`S?\O:E]WA)!BN1TQ?
M1$E]H^LC7C-RF51)5$Y#IJ%`Q1`0[]!F=JJ-3O4&[K-VK%>N-;?F;'?5^U0L
M;88-Z=DY1>LSNXF7;.V#DS1XW362$Z9A35(4Q>Q@`0#!VV"86R8&BF>+9,TB
MS@8IXUMG-/08&*<``Y3,TH<K<P'``[@)?QZ#'O\`*MQ@_P#SA@O]KS_P?SW^
MW_WO^'?[7^W]O0?_U+_'0'0'0'0'01D^S^_,29;G_'=,[L9WDQHD'3U21$:>
M:L+.B5V2C+!>)&MPR*2[B6L"Z96<<R:D*!W"T@!2&*;L(`XCC+NL5HM5T:$6
MR^9Q5+CY:U,MD:G.2L'-A%Q=;JL'+1RA']8<R$0F+6#?I$5:H+N@;BF``LH!
M@'H,1P34LZW[D'MENC,4DZM<\4BJSD)-7L1FA)BRPEE%Q=9"G_;&QCJ0"]>>
M(-G#IB[,:19J/02<IM%_F;@'XM/-^H03RUSD56'-AR#.]4JV+7W5$9QLT;M=
M$LDU%P3Z+I]=^WNW%OCZ2\G&8S3LSE@FD510&8/3HG)T&2<TMWL.&8^NM0&4
MB\UO09>(SS(B)5Y>7B`OUIEHZ&B/NSU=N:!9G3&0%9NW=*?(\%$_QHK)I+BF
M'+QMY$R^G6G5,5T*INZCLN`)T%C?T_O$3/PUD3NE:^\Q%JA9*'8Q;5(LL1LH
MLNS^F3^C%5,@"/<2D!CEEU\C/G5RAVNO9W)ZY(<9L/A<TB82NO8:"8QC1-B[
MTG3[79K5-'(RB'L4;_<K)`I'4A)*&73;-S(M7:R`2B4C8*G;\6J>ZO7!:?2[
M/G<'I3EQ9W+5B2NP,Q`MK`H,R\,H#-'[<U<=E5`.*8^(B41`0Z!(X;E$XLF[
M43%X7([HV;7&BV33'5PM#V&KPP]#B'"$5#6)6F$7E+8U3M%A=)M&[:70A7I/
M(QS(]TU4R!A>O\WHC+-WI6#,LJO%UG[PPM)89]$KQ<;]RLD%$I/8Z`@XN4.D
M[DV<M*.T&*TPJ9I$,5!<*'<'38OS-@5(G(.0A<`0VK2,HN6?3PQTZ[?Y2^<1
MC^R1:\(K.*J%?S`*,(%A%G@H)255?NU&K=K']SJB4Q?`0:+7/:#79UOQVDE<
M-O[:(Y"+VF)AEV4O#RDJE9:T<R1H2LU\J+24NB#ITZ8MC2!"LF"+QV9N*IEF
MSDB0.\XR<@U>1E5O%D6SZ9SM6D:I<\M7CI:8BY]*5>4M1BW?S$5,0P?;'S`7
MSI1L)D#KH`NV4!-94H`?H,"W?F7`9'$.WU3SZTZ\Y1O\#DS<]:D(&'@'NIV*
M1^V,J"PFIEZ5Y.3S1P50KX(EC))1RJ1T7)TETU$R`\E`RQD43.$TT7!DB"NB
MDJ*Z22HE`5$TUS)(&63(?N`&$A!,'X^(?LZ#EZ#_U;_'0'0'0'0'01\:?GFX
M.N8['6(#*(B_PM<Q,E-QBTSUN@8:F9C>K'/2:E^LUOB3NE;RZ>.X0K-!$8B/
M="NS`S?Y6XJ**I@OE9S&Q8EA]]C\_4"^['*QU_T%[.2J;&*/I.W6"-=R/W-^
MW<.THN'82DZBU9MFQERMH^-10;_)\:/GT"?\*L6T#&\%;UG021T-?K.ZDKC;
MU6CM.?GE]!MB)7UPL]JL:"WVR=G7\\J?XB-"`U:,&[9N"KDQ#N%`:5DG#;5Y
M#-^.G'31*XA3\FP^\RNJZY8%)Z$F)#>]$8V^?FJHPKB,/)R4DUI*QY$CZ2<S
M)6+]4GP-4VI#(F5("A<D+/9M"YM<>\PJE-G=%K?'6"E^1^E5RLR-6CWZ]GF&
MLG2<F;IN+C/UF!+*0DFY4D!05>HG.P<J*E\Q3`A@<+QUQ&SYDOMFRWMO'RVX
M[]9BW*V0\)(`K$P,36XUQ%9MF,5,O$6:3\M8A#_3KR)TD2.':RANWQ$3'H&K
M9A@/(B)R.TX%/9O&04UR8C+=?N1G(YM>:T]/#7#4[;+HWZDQU-03=3<O,Q6:
M*ILXE^BN:*(^6^01`I#_`"`XCDEG6GFB.-]&Q3,H&[YC2M!KSB\T23MT=3HD
ME7H=><&S9"1DI-M*NEZM7+DSC7[MNT9OWC@8Y%,$%"'4Z#"N(N2\D:_M?)'6
M^0R,`67O=L/7J])M5X]^:8SNH*`WSTE.91DO(?D6HMD7<@X<,7HK2+Y=T@=?
MXUFZRKL,ZS[`[1)<P-CY.:G&LRFC8.O9+QY9`_:2*D-G[.-"2M]G.FU56(QD
M;39Y-TFB50$G;=L+A,P"FL`F#).8.6:'N>>5S&::HI&5/0[]78S:K(A),8]]
M#8['&<3-J9Q!7"GUCF8LZ[!M&I%025`$W"@K`"/EW!K]MXU:S"3.W;+FV;0R
M%^RS+XSCYP6H3:=KJ+&I4U*,193^E)+/Y-*#8V:2>6!Z9H#Y5!V1E'_3K@?Y
MP$06FOY1M>0\&)/+\M8PS/:(?,I:/I$9"OVZ9F%IE&IE'#EQ99Q^E'2ER>RS
MQW).9!4[=B:5<&`A?@(4Q@;?4^/7)Z5UCB@G/YO2:'C&$YT26@JV-NCK:RI>
MJG4;P4G.VX[,S&8T/0'4$9^_:+-RDBFDF]364=N%4W)G82\=`=!__]:_QT!T
M!T!T!T!T!T!T'PW?Q-V\N_B/;Q\?+OV_#Q\_W/+^KO\`A_7T$1?"#\T?YWN=
M_P!X_G#_`/3/WK^:O\G?S']T_+4O]#^8_P`B_A]O^D^3\M?E_P#W/]H[_5_Q
7/P]!+KT!T!T!T!T!T!T!T!T!T!T'_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g62758g91u93.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g62758g91u93.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^$-EVAT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-"XR+C(M8S`V,R`U,RXS-3(V,C0L(#(P,#@O,#<O,S`M,3@Z,3(Z
M,3@@("`@("`@("(^"B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("!X;6QN<SIX;7`](FAT='`Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"\B"B`@("!X;6QN<SIP9&8](FAT='`Z+R]N
M<RYA9&]B92YC;VTO<&1F+S$N,R\B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!-33TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+VUM+R(*("`@('AM;&YS.G-T179T
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V5%
M=F5N=",B"B`@("!X;6QN<SIP:&]T;W-H;W`](FAT='`Z+R]N<RYA9&]B92YC
M;VTO<&AO=&]S:&]P+S$N,"\B"B`@('AM<#I#<F5A=&5$871E/2(R,#`Y+3`T
M+3(Y5#$R.C0W.C4R+3`U.C`P(@H@("!X;7`Z0W)E871O<E1O;VP](E!38W)I
M<'0U+F1L;"!697)S:6]N(#4N,BXR(@H@("!X;7`Z36]D:69Y1&%T93TB,C`P
M.2TP-"TR.50Q,CHT-SHU,BTP-3HP,"(*("`@>&UP.DUE=&%D871A1&%T93TB
M,C`P.2TP-"TR.50Q,CHT-SHU,BTP-3HP,"(*("`@<&1F.E!R;V1U8V5R/2)!
M8W)O8F%T($1I<W1I;&QE<B`Y+C`N,"`H5VEN9&]W<RDB"B`@(&1C.F9O<FUA
M=#TB87!P;&EC871I;VXO<&1F(@H@("!X;7!-33I$;V-U;65N=$E$/2)U=6ED
M.C%F86-F-C=A+3DW8V4M-#8V-"UB,S8Y+34V-35A-#0V.#,T-"(*("`@>&UP
M34TZ26YS=&%N8V5)1#TB=75I9#HY8F8Q.&8Y82TS,S$Y+30T83@M830Y8BTW
M,S<Y.#AB-#-F.#4B"B`@('!H;W1O<VAO<#I#;VQO<DUO9&4](C,B"B`@('!H
M;W1O<VAO<#I)0T-0<F]F:6QE/2)S4D="($E%0S8Q.38V+3(N,2(^"B`@(#QD
M8SIC<F5A=&]R/@H@("`@/')D9CI397$O/@H@("`\+V1C.F-R96%T;W(^"B`@
M(#QD8SIT:71L93X*("`@(#QR9&8Z06QT+SX*("`@/"]D8SIT:71L93X*("`@
M/'AM<$U-.DAI<W1O<GD^"B`@("`\<F1F.E-E<3X*("`@("`\<F1F.FQI"B`@
M("`@('-T179T.F%C=&EO;CTB8V]N=F5R=&5D(@H@("`@("!S=$5V=#IP87)A
M;65T97)S/2)F<F]M(&%P<&QI8V%T:6]N+W!D9B!T;R!A<'!L:6-A=&EO;B]V
M;F0N861O8F4N<&AO=&]S:&]P(B\^"B`@("`\+W)D9CI397$^"B`@(#PO>&UP
M34TZ2&ES=&]R>3X*("`\+W)D9CI$97-C<FEP=&EO;CX*(#PO<F1F.E)$1CX*
M/"]X.GAM<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`*/#]X<&%C:V5T
M(&5N9#TB=R(_/O_N``Y!9&]B90!DP`````'_VP"$``$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#
M`P,#`P,!`0$!`0$!`@$!`@("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`RH"<@,!$0`"$0$#$0'_
MQ`"W``$``@,!`0$!`0$`````````!@<%"`D$`P(*`0L!`0$!`0$!`0$`````
M```````!`@,%!`<&$```!@,``0,"`P8&`@(``0T"`P0%!@<``0@)$1(3%!46
MUE@A%Y<8F!DQ(B.561HD"C(E05(T)E%A0C4VH3-#.-@1`0`"`0($!`,&!0,#
M`P,%```!$0(A$C%!`P1181,%(A0&<8&1(Q4'\*&Q,A;!4B31X4)B@B7Q<E4S
MD],75__:``P#`0`"$0,1`#\`_OXP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&!\1;/^<H(2R=IME';.,$:,)X#M"(^G`41H
MD19I1@-F;&+9@-@V$.M!%[M["'VP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P-5^RNQ*>X1HM\Z-OL$X)JJ,/#`T2=Y@D(>YZMCFI*O"T
MM;P\M+`2H7HV`3N>0E-6;!LHD]43H>]:'ZZL1<U"Q%Z-?.%?+%R#Y%T%LO?,
MSK93O&*32-*BPI;-*NE4$C+6>\I7)P2-21TD"5.6ZO!36U&JSTR?1AB=-LL9
MGMT:5[[.,X\2<9CBO>"=S\KV>9/`P"U"I6FK.`:M";.S3#K`.CK/"]Q6.SC[
MB7)A10$>=W#42EC<OVVHE*EST0K!O:?U]=:E25+!RKR(<50M.VK)%T-!TR%V
M?44>1N*$+X]MFE:R$P>QC')8Y,3.Y(6R*,\)LN/.+J^*3"65F)>D>ERI.,\L
M(FV2I7(S='4?(5JEN9+(8'):DCUHRM00FVM%LN.4K/U%66F[^_:0)8DD+L%(
M8UJMAWO>U`?4O0P>@\5)4H8=VCRPF2-*]7=T*1HGV2T1#F=2L5+$A3C)^G$J
M%;0K(E$I1E:,7V:D<23&X/\`^0/U-V7K0O14E2ADI\A_&L.;8FZ/-W-)I,Z:
MT;S$4<>C$\F#X_-Z]TF[*F-0QN(Q5\D(CA.E:R`D9(DH3BQ,RSW@#I.9L-C&
M9*E:\AZBH")R=GA,GL^/,$PD$)BECL\7=M.*%^70>;V'&*FC,C+:E"$"T"%P
MLB9M3.+0P!,3+5Y(3PEZ'K>2I*4$Z>4'@]H8)9*%?0C$<P0B6,\,D;DUQ2Q'
MPE.[R->^L\:7-X66'N!S_$),^QAP;6R0-X53"XNB4:).L-5:T3N[<C;*_G;J
M"A(^H&C?[+9&!:6U4R^&H7PAV9UY+5T)*G6$4ZM.0N+<F5DES66,:Q"5H0-"
M2GI3=*M$:`+>I4E-?->4;@\<90S!/?S<OC[G-VNNV]8U0:T790KEDA0(W2(I
M"&MLA"MU&VSYN7E'QMRT1]LDI0MB:U"O01>V[<C;+V./DUX@:6![E3C=NDD:
M8)D97RU^,KBV]M*F7IPS8Q>T,2\$"$FE'V8FMWTQP4-@E:5N*:SS%)A0`^[;
M;D;97A*.JN=X:`HR1VU$T!*FNXM;*!26J4."1VKF;2YH@<3EK&K;$RQ,^-3_
M`#"0($";:,1XQGKDW^7VGE;'*DJ7IK[IZ@+5E;3!:[M2*RN8OE-Q;H1IC;6I
M4"=UU+35X<H_%;%*1GIB3=1YZ>6A0G*&+6C/D+_S`#H0=B5/%*4]#_(OQC.R
M)>ICEW-QA$"1V,NEICS$+#BNF8BHH_N56?HW4JB+*)0I@D?]JIS()T:<E`,&
MA@T(P`1-LK4IS"^S>:["66LDA]DA>"Z1;),[V<\:B,[01>-(88H5I)8,$O<X
MNBBKZ?'52`\M80VK%AY`RAZ$#6P[]%3!4H0]^1CBB/PMUL-PZ`B9T/85,Q2/
MKNSMTJD>V0VO=P'<Y$\-T>C[HZMB>*$6C'CUYQY!9*=([$*!BT1O9@6V3;+'
ME^2?BPQ-+%O[XSRD,$B#?.9DO4UE;Z1OC$?=FN,O35IZ7JH`2D0/[HUS)J.3
M,Y@].YX'`CV)1;,#K&V2I2N*][<?34).HW?,,6JS6V/.PV=1IY:9$A1RFVG6
MAV?[M&GAJ02!E6#N%E4QY0F5IB%*%R!HM263H9>Q*DJ4#3^3OB%6SP.0$7&Y
M"9+1DJ>(5TZ"J&[RD<UD*UM;'E`AC9QM;`"Z@<V=V)5I3RO<F5)M&&E&#`0>
M(N[9*E:<^[8Y7J^T7&F)]<\8C-D,\4<)F\1]<G>S"6AE;(F_SU00ZOZ1I41I
MMDAT%BKD])F4Y8!Y6M*$Y6G2FIRQ&:E35\BI1])W]R*MH^8]'IKA2#INO'I/
M'Y[*Q1"P2E<+=%3<S/2<N4Q(Z)%S5B2&L,B0N.E2EN*2_;%92SY/IA:-Q4W7
M,J>#%,_D7XW?ESF@;KA%\C&S1M^?E3A7EJL[3'T4O)B:B,$2!\>(,@96)Z>T
M\Z9S"&U6H)<1%N)`O@T$>MXVR5*46)W)RU5$WG]=SZT@,,JJJ'F3RR$_X-L%
MU:(1%BXT?,0KY)*F6*.,5:U*J-)Q*DZ,U:%:I!L(2B1C&`(D8S.I4O1#>WN5
M+`9R'Z)71&7-N-<X(R&[-3/S4N;7RR[2D5*0EB?6EX:$#M'7QYM6)N+)M$O(
M3*DJQ(/2@!0/:/:I*E&X7Y#N*["VB#$NAH,XB=)P57;,!3]Z9C'^4JX7,K$9
MR8X6^-+:.1,LGA5>/C@RNZ'2AH>R6M1I`I4C+V'$XS'$J4XJCL#G6\IR\5S4
MUA_C>4,+*B?W8+5$IT"/)6YP98M(D@=35=&4D*4.1K'-6M5]"4X#6A)6!$(K
M7H/VIB8BY*F$<EG=W*,&D5MQ656RG:7FBP-P+1`.(3]4W1QT>3(:0RQ9.^(8
MHJ8I).GQ18;(6AC[4I7/:PUS(`2D&(7II4E2SC#V=R]*(!,[18+EBSI`Z[JI
MNNR=2!,!V^*)UDZ*9\A32-]0F-H'-O,*<JMD212@,(TY(UK.I3J$Y1Y>R\5)
M4OPE[2Y;5<_ROJ;]\T514'`QNY,YL-Y`[L**%+&!S(9WEKES,]-C?)8T]-SD
MJ)*,0K41"O6SRM_'[3"]B5-US*G@ETIZ6HB$QRWY=*;-CC/'*$6LC;;;H>8K
M-(ASI)HQ$YC&FI0!,E//=':21Z=LQS<E0`5*%QCFG((`8>:$K:I2D`B'='),
M\&QIXM><.<5\C98J_M3.=]V:I`)MF=R&<],6U\>>&Q`^,R[=W$BBZU&L3IU;
M6\:^!:4G%Z8J5J7^P3N/E:SXI;,VKRW&V8QJD$@'.R%[!'9FX'-3(H"[B;I*
MR-9,;V[3B)OOX?7Z;'9B(<FUT$B4!2'G"),T%4P5+'07OKD&RH@">PV[&%RB
M1IE=@)>5C++F$I0"VI:_06LUB9-(8\U+E#9.)7%UZ-N5@*$F4B2C&$SX_:/:
MI-LO2Q]U\L2.CY)TBU6<>.E(JNCC:ZSE;`+-:4QZN8*HXAB88^SN\,0R*7$2
M9;+FTEO.:4:TE8:L+`4(8O76FV8FN94W2(D^2GB-24L5(KV:W%M;*T-MYZ>V
MJ(6*ZQV.U^0Q/<D.>)/)&Z'J6&,+2FF-KQ";7!0F=-'I1I]IOJ-?%N[<BI96
M.>0WCJ6O$(C\<N5,ZOM@K9&WL3.1"K(`YMRF(/2&/R?4Y1'PXI16!#$[.:8M
M2=)0M))8%!9NQ?$,(]S;)4HJ+RB\%ZA8;!#T0P'104E4172Y+%;#5K?KD\-5
M6+]VVQ)8>=(`PI77Z(Y\2R+:7\/K&@D:PA:8G`(S3;/`VRG-C=^\>521/E$W
MO:*(2ZM::K?[$^SI)%+S(A'[N0OKE5,A>R8<R/YR6/S=!&EAJ-=[=I?86'WF
M`^4GY&V2I8]1Y$>,$BN%MZV]XZWKY[*%$-843BRS%O5I)`C60]L5IY>F6QL@
MZO$*5YL!D;S%T@"V(0.;HG1[.TJ,T3C;)4KDJSI"C+N5;15/9<;G:H+2\O@R
M6(Y2=LMLCMA2VJ'Y0:(U,2`H;/8\$>&=04+>CBEK>:`0=:UK>TQ,<28F.*E7
M/R+\6M"RT6Q?>K(6ZTU)4T/G[.3&YTL>44C5V'^Z4MLCS.BBRASG@R;.]&$\
MQ@*<R4SJ,"<T8#!A#MMDJ7@4>2CBA"NF3<\785'%-=U.HO.=;E=?VI$DD2J9
M,S_?#)L_N$E@[4@;&LQ#H82@FFA4'JBC4I98U)1A(6V8*GBFLW[IY(KB9E5_
M-;SA[%*C:Z66O]$:%X5H2(,BB,CG_P!S6/[>UJX\@<7"#0]V>4#6<J+=7)K;
M5*I(F.)),&%MDJ4]DW3-"PV!W19\JM",L,`YW.6)[KE3D<J3M5=GH(;&;!5$
MOIHDOR:,+ALR:U^M$A-V(I:6$/J/>P:E%(E*.U>5(8IFJ*2WC"&Q97*1B<)L
ME$K5JE,=;Y15,RO".+UQ")&I,VA?*HKQ[>DIQ>AEGI6P_0!;-!\>6I*ECB>Y
M^4U5)'=$I;<;U=2)IHAKA4_(XW-5;TDL)S?&Z.-T%5P)/&C;!2S!<\.Z0HEM
M,:@K#`JB3`E[*-`,2INN94W7-$"_)%Q:J%O[5=`)&477S?:2E9$:^M28MK?"
M'1I7O:!S=G2+0=W;FA<>VM2D?VY4:2YA&G,+$GT:#8-7;)4I!#>_.0)]$2IY
M%KNCZR)GZA8R'9<SRUA"<GL8Z8$0-:4CD$>:W`QME^X`\#;U.BMIU1*$9H![
M+$6,<J2I8.*^2+A^9LY#ZQ=#P[Z)2V3YZ((>4,HB[R:TUA6[/<,V<@1R4,#/
M(=HVJJWY)(2C/I?:N:#?J4FSR@C$%MDVRE-K=T<K4?8*6KK4M4F'S9;!72S$
M[8MA]@+$(H"Q(%3H^RP<C:HHOC)#.Q(4FQKC3%@?H]FDA.T`2@@)BIDB)G@]
M,A[=Y>C%DM]/N=HE'V6Y2Q;""8@P1&>RMS22-M*KT]P2O(HM%GE)'T*`JUHZ
M(Y<O,3("M.I/N.U_G]JIX\BIXOK)>VN5X9:,QIF7W-&HM85?L3O))BV2%*_,
MS.PM<?KU-;3[I7,W!H3PH;FSU@J!(%*`IQ&N(9_<J&3HD`QA5-65-6K'7DZX
M<$WP5Q+N[YR[(D+Y$(BC35K;RI[6RZ-IDS@\Q-RCJ>`&O\:DZ1E6%.>F]S3(
MUAS08%P++&BW\^-LE2^"#RC<&.+*RR(KH5E3,S_,7J"-RYVB%D,187Z,*&I#
M+%#D6]0UO/9(M#71\1HGM^6A3L;,X*2TBU60I%HK+MR-LKDA/9',%D3]HJV#
M71#Y-83\^7C&VF)MAZXQV5OG-<E9H=>;=HHQ$662=7,ED*)(MV8(`!F*`[)V
M:'U%J5,%3"GB?*'P4H@BVR4_1<:/B2"3M\1/4$QR>FO)CJZ1ITFB%4AB0(F*
M7.<9.AK&O>-O29":S`:D"E8)4%.G.,!=N7`J64DGDHX@B3S.F%[OZ/EN%;M"
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M+!<2HE.4,784D:.TGD/LF;I&4,1>%3(?O852=`N5*"-A%[P:]HO14E2@\:\B
M'&DL9&R0M=X,Z1J?(I.IU'SI-&9W"E$DA=:-T)=YS*HRW3*+,+E(V"/-5C,J
MDU4A)4$F$+@C*$,(#=EMLE2DC!W'R?)[!?ZL8KLBR^?1JP6FK'*/:3OJ<T^=
MO3M)H\C9&)<J:"&N4`)DL,=FI6K;#UB%`[-YZ%2<2K+$3I4E2\4D[TY"B$XL
MZN))>D3:9C3D?=Y'834H3OPB6A)'TL>6/[8W.Y+.:RRJ7,*>7-(ES"T*5SVC
MVYI-')`"4$Z&VR5+`D>1?C14I;DJ:YR%!CA7SI:9PR(-9AR6.05DW/@/+S.E
MI<,$CKH]J4U;(DZA$_&-K@2K9U*<9&CB]EY=LE2D[;W-RH\48\=(M=NMJVG8
M]*6V#/DF(CTS$YM,U>7B/L+-$%\(W&]3U+)WASEK6%(@&UZ5*2W),<6`1)Y1
M@IMFZYE3=,8I\@/':!D?']TO.-LJ*,)HDMDZ5^:Y4POT923JOY9:D2422+/#
M`ADS`4]UY!'EV*$K2$Z"D;%&Q^T10@Z;9*ED'WNCE6.VD=2SA:Z<^S4;NM8W
M.,,D2GTF&QN#8%H$X_B)VC<5=F*.(4&WU*`Y6O5)TA1AFP",T,LP(&V9B^14
MO7/.W^4JRC]-RJ<W5%V".W^RMLGJ=X.(?%:*31%U31U6FFZHUN:5GX6@9!,O
M:M*WUXT@:$)CDF+4J"AGEA$J2I0!R\EO$#2IF2!5>[88ZP*<%UQ(6-NAUCO$
MA%,!O,XCFVR.QYHARY[FB8A_K1_1'+69.O0$*FE248<$9>PY=N1ME;?0/4U6
M<V<WRSJVP031=3T)B;7/)&OAT)D$EDR"&NAC=ZR(<,3)"I-I"THW("MP#M-H
M]`D+--.+`$DSVR(F9KF1%S34+@OS$<7^2:=S:ON5'2U94ZUS%4DOF;M):DET
M*BS$VN;H!H9D:F0R!*E0#>WM5H\21$7L:@XE&H-T'XR1BU9QG'BLXS'%U+S+
M)@,!@,"N[<JF!7I5U@TS:4>12NNK1A\@@LTCJ\L)B9UCLE;5#4YIO401;(4?
M3*=B).!Z&$'!"8#81A#O2)J;.&K3+@SQRU5X^N+4_'U2.BEU)4HYPME]E/;>
M03(9Y.)R!60NF,C2I#]DC4HV[:-`0269H!2!O(*#O_+L6]99;IN5G*YM].">
M"&7BZ/2L*V8+)]-Y<3"6MS?DZ^:-$7^P0JI*MK9(B2URXS%]A3<YJ%M>&K#7
M%*B(7'DJP$'&FZ*]PDS9,VU>6>)^4PZI(Q6-!VQ6E;@65GV+SW:1CU4;I(V5
MSI+L:W4MF2)Q@;0W3Z.F,%K5^A9T38UJG`YS:%)`-`4(_A(3%%W=KJN[6UQ4
M/X^9S4$SLH]RMZ,/U<%U5T!4%!L:"".R"81J-='7.Y7K+5]L25?,75MF[U&)
M.J(;FP;:WLY9S<2(Q2$:@SU!)RLMIHL\$11L-'6;#TO*:]@@8M`GLL$2:%+_
M`"=1?M:\X)J"B4^5O=L/-D?30UN/<GEX*9V\M"K0FJDX&]<A&G^8=WZVN].Y
M9X@ITY))H]MMT05[F\EZJ;>@&1#+8K:3!!XC!MUG=:-]IQD4T_<%;V4WLQE\
M])SB9(U*1]2_&4YE-YY1Y10AC;OZ)NA?/4?C+-Z>M2EKE<[120B;T_'.>8\F
M41R/NJHIT9ZVN@FR[@AQJMVDBMV,A-N,!1*$HE0>H5MSFVMSB,]2:ET`4C*H
MKD1-(1"O%[93?$E,5GE\0U_#!:VYFY\HI;&:N<XP-KHWF[H>.WJA4VF2IG+T
M7+K4EB:-(V<Y:W?:FI'],)44CV-6>4&[HLW-BNK.`&/J2_*:MMWG:Z,1>%U_
M;%>VG"&YL"<?:;?*HP[MU3+_`+V)86!B<*4ETH=GUM$),J":L6:]=`T'?ND9
M5%)$TI^L?'9;K6F:G6W+T@4LFT?F'"R%G70.J76$1HVH.$9?(93#FYS97&>2
M=6;9-AJ9DZF.K@4I`V(=FIR4B/XB!?*G*.2VJ2%>,3I2KBM'5O=U!-K]'>BI
M]>$+D$IKF_)F0L2V0S=,QIV:)G#G;H[4/3+F-FZ)$8CW%TL<1*E;9K:P@X!N
M@E7='-=T-DI1XVF)V!X[6IGLIQ;XWPVV1:&2I"M84RQ7?E;0=C@;Q%HI(CRU
MI)+'I%>%-0R6;V$"DD.VDY*`L(%&QAF[CYI?'S4YR/XK)US+<U0WNX=-NLSE
M=?PY'2LBB*>%LS+7L@H-DHR%5K'8TV%;TNG+;+D5@5TUR<U2I>UK.(0U9)3:
M2>>)9NSE<43E<4^U_>)5NZ#:IPSRRSB@HI)-NX+`8@(D$O8S6.1]701CB,14
M+%46G+`K?$=:K&H:E:B/,V@?"S=%&$EZ#Z[1G1&5)717CLL.I4/845<K&KMV
MC/2\>NYO9'UK9[C)F#`Z6^\R-U3F2)AD%RR"HQMD9!)CBO\`Z".L*U=\18SU
M`A;,V.3E9,PI.!^&0^OSKB<66]$Y*^\.3NI.>9RWEPE0".+9Q>I\/;X=<X$'
MXD$H+?H=!HJ2PNA&C=?>4*)N]#$^T>O?=_ES7<GEL>+Z=V9;74TD_>?`V^`=
M/HZX)=M:0WDBL:-%P:(4%%U;2W&1Z\&2K-I'@RDMJ"G4J-D25`)QUHAQ!M.#
M>T957DF[2N:M/[*@BYI`IJCO@21\J:R8BYPZ2G1AU>9K-:B;.D+GO^802\Y6
M^2M>Z6A+YLJL=A^NDJH>EJM]AJ)V4`,.//+QOY+N7MR_XZ;%I&I^=*OE=CUR
MX%\[WO7ML('6%L]S&CFC1!Z-E5/J$#PGMFY[._#CX]'R`I?[&02!B2`($42W
M!V9\FI.43-I.5ZM=^Q>*NK+>N*_FB#PQ.X<[W%-FFYW+>W"O2)^=>,7YG!SU
M$E3`_O-DM1;?46BD+0Z.K:L:/O!JIK4IDRD"1PWLFXS$?:L3%>:]^;>(;$C_
M`"=VMS+(&YYK=NZ';YHT0646'+2+EL%J!8U",%6NFYG-BYU)Y!/V2$/K,,,>
M`Y.!*U#&M(V@(]E("C=R9UB4F=;1FY_&+;D_M'J::Q"V:J8FWH=#6*UK522+
MW6[R*(R*KHC03(UH7!@9[R8JBD,6='NBBE2@[<;)D`"'`1)3B#10-Y8RB*+B
MN;"V7XQNA+EG_0T]G]R4BD=>GZ<05M/U\*B/0<=4Q-S;JZ.KX#A`6,OH<4&-
M;U)1*95\STU.3VC-^7Z5>3O1`B6Z(KR(RB$QLSPW4E,)ZFE<5>GN*-[:?0JU
MN`X2^UY=*5+S!ND+)O>\)7,95(K&7JK,F=S)+#&A)=)*!V5,RTC2LH0];"4%
M&<T;IJE,2?PR3ZVHG&F6YNC8JID-65;7M&TK+:RJITA:Z&PZAZEON(439JTA
MUG\GTKO!BLFYTTD<528:9F$2S?;TJ,DI6<9IOCE!N\%Z\N<#W[R)9DGFD.G-
M,3QJFJFJVIX^[LUW,DE21UK9:'@5A[2M0+N6TZG-#$ZR<US4>1%@.GURA*2H
M5'$`/T=)RB29B83R=^.4QX>N@;2A=C%,EYV3U)4W3]=O<D+GDBJ^.N-+H:<U
M%H/-JH3V`U1Q[;WA?6"L#B\-(69\^F=0>Q3L20O0V[\"U#)/&+T:RLG2<=9^
M@:75(NRZ5F,1Z#<'>FIJ!P;;4F<\ZBL]9)ZA3-ELIFV.P5%*>DMIBVIT`Z+!
M-S1K8EGU*@9H+NC\#=_);LO\<D^N*DYE5MP7ZD;W:^^KFOI?I%[INOT,::'I
MMC$)C$8BM85M'+*7VNW,[20X5?$E;@L?0/HG#:)=ZD%[5$_2S=4W'@1-*KA_
MC4ZCBD$FU9G=+U'(&1\<^7;,C\R?:<F2N?$7=Q[%.?(Q5#Q+ME6LEC,E@<G!
MSLVFR5`!&E<5`W!4)*M3CT4(-W1=T;HXHJX>&1TF=AQJ[I]>S67<9EMPJV;$
M=8%!7&.1E_2*NB9W==UU(P-KC+GEU:JVF3.^1U&U_4JU:]"^Q-*\GF'FFC("
MW\N1NY<FYG$W'=R\RK9>197015IQ(FIJ4HFIX<R,LUCD<C$)HEED,889HZ1V
M361.(TT61,HVY-R=^+BZ-@8U2EITMTDVI5G"#)FTF;:SNOB!;GY%1JUXM(E3
M-:)IKB*IXK(T[;+T#;K7*\^L*739V5Q)#.DT:?`V:VS0E&A+=4R\;"8D$<48
M8(W>M7<NY,:C\;,[BW#JKC6;V?%$Y0)MSV]H)[5)]_,+T8QTI,J@D[F?IRG-
MZ3J5PV929-5XR4:F+N;(@9#U19Z1*`PK>S)N^*R9UN%96!X@5!\TO!'3<SK^
M`TS<M!CI,EB?2K]D<_A6SZ_FD4=7\IX37PU0N?.<ED,O-=W!SDS*ZR`Q4<H-
M`X!4&%GEW?X\3=X\4^@/B.B$>G<S=);9LGD\-6PWI2#P8Q+)+,06D0U](2LB
M1N;E;E@K+"=#;YDD.:E2IB0+94G<Q'-2-KV<$2A'LTUN-RFY/X<;*N-M3J;S
MZ;;-S5GK-!2L=D5'PR;U"B20&OZ+M.I:M<W=N;K57+9"_KW^UW%VE[8J6&1I
M\;-Z9/H`I/>88WQ'"-%W)0H\1]A.;]==@NG2:$,WZ0KFP*UM*+-5;-C;3D:8
M%2ZH?W,(JECJ%4CFC(W5/'J=1M9:5X?7E.-*N5:1`0>\>C&Y-R26%XM;(D5C
M7U)HE?,/8HGUA(9DPWZR/M8N3\^D4O)9O&YPA:ZI>B)JV(XQ9B$:1Z;371>D
M<FXTEV3JM(@'MH`J6Z/`W)AR5XYIIQ9=CQ95:6+'95%K9;HPP6M"'M@<VU!'
M%9$KO&?V%9%=*4\@.&DD%C/<JBA2U$J+5$"6H7%?L7R+M_#)RB8)RN*5#:_B
M?N&U#96)WO6KA-\=MBT;#H9B!7%EL84+==79T,Z_L)IN&4Q*YH_+)`L`L@2!
MA:5$94Q@:$G9RL0C3AA"7=T1_'D1E$+ELWQN32Y(XTQ>4W.U0AI?*BY.I^TB
M*XB[N[*E\;YHMRS+B6(X8YW3([74Z339\E#,B-W)@R,SZ!O5A5;5B6:V5-U&
MY5\7\770L,K"Q:)9.JX:MJNWZ*4U39;A)J7&^6@_.L2YXDO+E3+$4JW-$S,R
ML!5:ABR^1!3-H'-4]L"K:!6B2NQQ*>[HN^9NCBLI3XKVM/1=L<U0ZVGJ!5'<
MG5]>7Y*0-B97,IFF@4(@=/-ZRMT,AMQRL=,Z+I'8M.(W`]8\)7-"%H5&M_T0
M@Z`/3=K?.C=SYM5W3P;21S0M+B=TV69/FJLG^C'&5**^-&5852H./)CRS422
MQ$!$F2Z=)?6K@^)Y$!P3"3@-,5NZ<LHD+A[RF_R7<W+5^/.8V#3TTAURW`VJ
MK!M[K.G>G+1D]-M,]I]I0)ZA15!%6J&U6L9[+6V/"'4R$TRW!#(0/XG$#PH.
M5AT$OXTX)NUT\$O55?,WC"LSGBX&.:F6A54LBZ2F8S3SJ:GB5P1.9J"(37LS
MKUIE1+2PW433KM)I:6^I760K'J,NJQ2[F."A,>G$I)VGLY1).43'F_3[XN+*
M6EU!%VB]H8CKZ,T!S!6%GIG&LG=?+I#.>2(#;43KJ2P9W+G*5GCD4E;I:PE+
MXW."!T5!(;`%)518E)AA;<;H4#,_!"7)JV>:W0=!J6L;=&I&LJJQ79DE<VM*
M"67)Z7H:HEBIRFTSGSV^2VM&UMJ%V;VYB4GAV@B<O6,9)P$J=/O3?JN]TXZH
MX]7]&DN*='.D43)7\?=6\M[`I8E3K[%?22*I$:.7^XAW;A_2Q,-9F?(CUO1J
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MBXX0I^R?&G9[\Q+&FO;UA4;/L**=J4C<2R6U<ZRT"JA>S.C'F^GD=<)4D[8`
M1VVX"2[&M2->X;<V==\^U!Z'6R""]6,C<P/+'B0WS/V$X=1);E*DK6:MMI0S
MP`Z)GIML)5M.LD<9%M(^F/ZK9RUXV:PC<CAI_P#RU#+HST!\FM`3E<43E<4_
M$;\3SS2=<40LYNMF.L72E715RA4YM.ZF*Q[JB-DQZ355NJW1&GBCY:J5]@S3
M!TP"G"),C2ZIX^U;"I1_1;)7J#--USKP-U\>"/5YX;"*F,EH(7=:ER12NE+X
MH8:*=M<GE#<PQNSZ$J&GX=.(='CYJ")P:T&!95'J_N;,@0[E#(YB0JO02-(<
M!OLW)!8GB\MQ=/;`LRI^@(#%I59U3'\\2<N<U*[35C24]+J"I6FY\XLC>@L"
M-&E60C>:41/3(H/--;-%*#4*U,H!O1P491S-R:<P>*UHY<Z$?[JAUIK%;'*J
MOOBOY#!%3(/:=S?;(L^&R."62H<]N8MBF<<JZ%-\6?#=$A`^%-B`\.DWTWQB
MDY7%23-Q2#<A>(H[EB]J8O5/=)#ZZP*&O<.L6/ML//9F:T-$T54U.5O)%(#I
M`XC:I-7NH;(=E*/]?ZIKD848]:^B*-%9RN*)RN*9SH'Q-H.A44]:Y79I0&V5
MV9V'9[20A02]C/9GSI>F&>K(KI4OBLXCZYW2U^X-@EZQ*:9]$]$F?3FD`UKW
M;1E1&5)CS5X]K!HISZB0.MB5Z_Q:_P!GM).U.[4SW`CF;*Z6.Y'KB?O;&_W#
M(J<$UL):\\&MLD99EZS82A'J![^7Y).5T3,2U$5>$R;2VDZOK:7W?!(U,:,A
MS_'*JGM=QFX74Y*Z2!;STC?'A^)N&[+*<PMDTK^I'V-O3*UK&YH,;I+[DQ"<
MU-[C=;]?)=T<FQJKQ]=2,C`PQ""=&4V7#:0Z$:[MYHCLNH^0N(T)>[(M2Q'Q
M#=TC9;,9W^;O`"+.VS(3F<UC1:3M^EJE,<K4CV7-T)<<T9F?BZN6P%,U:I1=
MU*N4`722_P"ZX7#W6A720D?OZZ?C0V:UFJR#'>R!DRRB4BM^D0F9N1EM<C2D
MO"3>W72IG3*3FZ(^TM7;-XA[O;3G0;ET'`Y4.9\T2SGV0NDG;^CG=[@B&1&]
M,:9T%>*%G1IZ*;1.$LO0*9G;]6(1+WCZ!A`/ZT!Y^QEMR[H;!R+QUVO-^9;P
MKJ;V]6SK=UZ75S_<<ADC+!+%B=1MP>=BJ%8(G#6^.,MN%VBF2/,0H=*6X.B6
M4HW/[@XG')QIRRB"@MT7IP2XOR5PA\/I#]<4(NFQK(CPW(#8=`[A@T-8)H;#
M[.I\WDJ4<VM\$4NMCV!.YT<MA[_)53^RNKHYNBU,6YN20P1OU?S`;M#=X,!7
M?B3MJMWSGF2;OR#V/**^JZ40>XII-HM;;%([#E\WMN46;*;,9TE;71$(V>[+
M")-IO*;Y2CDK846B(WHGVZ&`2<HE=T,T+QH]2NE3UY7+ST30Z->Q\G//C_G+
MTRT7.#TKYRJ^L]<MRB11EM>KD6[C_0"$R%K=%KSC%<=.+=0",;?D1%;,;HM-
MT/\`)MX<F,RLV=%7LT:CKF1=$R2W72<6D^7\_1MPKM?.NAYA&Z?CK7"[NA$E
MJIB8S[XVJ4[B3HR)W9Y1&+%A!NU(@!;_`,#=KY.L<-@;ZIJ]77%R`@,Q;G!A
M.AK@TQ]BD9$8<X4JCB1A6L+RCFTIFCP]?6EB5EJ#5*PS:A,:`)FA&:,,,Q]B
M<]&H'C2\9="^+ZHYY5%'[<'4NQ+7F-E2*5/Q*?4A6('-T5$U_#%"LH1ABAFK
M.#A2-"/8A>IYA:A6((#59H<N64Y:R3,SQ=',B&`P-7B[>Z('7SA)C.1Y`5-T
MTH2M"&M=W-4@UKE'3F[:I3+@2D#SN-)4Z-=_XNT1INE8Q?Z@0[!^W/5^2]M^
M9CI?.8^A.%SGZ74J)O\`MVUNX:WP?L&?T/\`M=C]3=+VG'ZW[7+Z?S[/+JY]
M_P#I?N48=/KQGMQ[:>W]+U\LLL/S/5QQ]*(^&9W)H98%N!G#A'P4$[&1!-##
M'U#8&K%@(4CE*PM)*T$%!'!..I`E5&.1@T?W`TO2'0@?+L?Q[UO./R_9^A'4
M^8CUISJ<-F=QC=;]U5PUKCRXO`Q^F?HB?I[I>YY?4O0CWS/OXZ.?9?(]Y.73
M[?U)PGO)Z^ST<L8Z<1U?1QR]:IV;=T3"(ZMKH/</BCYODY_#*7F4*VB20C]\
M53[50Z.D[*TFERE^T[_9'M.LT,6](D9@U8/9_F#KUUG;Y/VWUL^G\YCZ6.%X
MY>GU/BR_VU5Q7C.CVY^B?VQCWSO?;H^M>VGV?H=GCU>AW?Z9[CM[KKS>[ML>
MCZ7J]++&H_-ZL1TIO2=)2578MR$R&S&Q-SP\+6.)L"ARKZ3!LNO""+7>BBT0
MR(X@:CG(+G#CE)B@X.E3L`E,#Z?>Q"]!@]>4=MV4]/I9SW.,=3/*L\=F?Y<:
M_%,U67+3&YU>3T/I;Z#ZGM?M'=];ZHZ'3]Q[WN<>GWO0^0[V9]NZ4SG?7SZD
M=/T^ZC&,<9]/MIRSG?$1'PY/$19EWF$U28=S0]IS9DN5)[)(%:=:&[IU&2]$
M($[@XF%NFRYL!6TF#7Z+9]GF``7\0M?+O6LL]KV$3UHCNL9C"/@_+S_,TNHT
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M@IRVZR\]&<G)+VK:@')1[4:V$7H`7IB>V[*.EU<X[G&>IAE,88[,_P`R-/BB
M:K&_#*IT?'U?I?Z%P]I]V[WI_4_0S]R[+NLNGV7;_(][$^X]&)PC'N,.K.'I
M]M&4999>GW$X]2-DQ,7E"+;MOH34+D;_`*Y,?]RQKE29G8H'^^.IM*Y1&S2C
M!GS`B0[>/L+2G2F!"#:)48!8/W>H0^FMYV^3]M]?'I_.8^C.%SGZ?4^'+_;5
M7-^,:/9CZ)_;']?[7VV?K7MOT7K=EEU>MWGZ7[EM[?KQ,1':ST/2];J991<^
MKT\9Z454S:7:L"W=S@N/;H%VU#Q0S3Z98/[QH#M(5*]M.UNX+N-Z<?Q`-5IR
MUI']PT7]#[M_+[_C_;G'Y?L_0]3YC'UM];-F=[;K?NJN&M<>7%X<_3/T1_CT
M^YQ]2]#]<CO_`$8[+Y'O-T]OZFSYOU]GHQCZ?YOH[O6KX-N[1$@VUT)N"L<B
MWR:_AF+A+365XKW]\=3[61^,@3:-*F9TET\?AYR3'*-[*TA3F"6AWKW;#[<[
M?)^W?,9=/YS'T(PN,_3ZE3E_MVU<?;.CVY^B?VQCZB[CVN/K7MI]BZ791U>E
MWOZ7[EMZW<3E4]K'0]+U^GE&/Q>MGC'2GA$VEBNP;>(E5C,R6@'9;&XO%U;O
M!)@&QH`0FM"1$I6XY-$4+(<XA>(FH6*51Y.EKH`I(#:;8A"T$8-[XX]MV<]'
MI9SW&,=7/.L\=F?Y<:_%,U67+3&YU>+T/IGZ'ZGLWM7?];ZFZ'3]U[SO,>EW
MG:_(][.7M_0G+.,NYSZL8>EW..&..&7I=O.74GU(B(O'*L,59]YC;*O5F<QO
M9+A+W=:BL1JW:U9#,J-K3O25`D>G!8!UVDF9:]I.,7Z(:-G'%@)V4/6C1!UF
MY[3L-_5QCNL=N&,3A/IY_F35U$5>-3I>51K?!]^?TA^W6/=^\='#ZN[?+MNQ
MZ&&?9=3].[^(]RZF72RSRZ6&/I[NUG#J1CT9S[G;AE.6_&=D3+['V7=Q>K7V
M3S4]*-PQ2456V@VE6I7[Y$XW<]$8J;MF.FM0@)+86!;L#S\`Q!,^+7^IK>LD
M=KV$^C?=8QOCX_R\_P`O2]=/BUT^&_'@Y]/Z2_;[.?9?4^K.WPCO\)GO_P#X
M_OY_2\HZ49QCG73_`.7?4F>E?:[XB<=\_!,2]2:QKF->ZO0'\ZO"5HES.0NL
M1^%9M=&E5&Z&?/\`,R.#<4Y;7S,U/\8/4]H"<0+Y->F_\N\D]MV,=/JY1W.,
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METYGJ^CGE'6B,=DQNF(0[][?0G[OD4F_E,?_`,;GRXQD5UK^^.IOK4,8"WZ4
MES4<I^\?AI0F-7;^F^@+-VMT+7OV'V?MSO\`)^V_,STOG,?0V7O]/J5.5_V[
M:W<-;X/=_P`)_;#_`"?J>T?YKVW^/8]C'5Q[_P#2_<MF?<;]L]K';^EZ^.48
M?F>M./I3'PWNT3%7/[;)F4Y8DU".RR*QZ(+'N'SD-B0(A+8,H(;6]6EA*2/G
M.`7R-J5R]2>ETO<"RT18DVS!"T`8-[X1V_9ST.GU)[B(ZV6<1EALS^#&Y^*9
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M`)>?Y>G/3XM=/AM\W2^D_P!O\^E[-GU/JSM\.IW\_P#.Q_3^^G],^",KSF.G
M7=_'\'_%WZQN_M?ZELJZSG"K$RCFYY2(I@D^:QG(5H5N<"H%/U0R?HW%*2YB
M4S46DP='>]GT<#T%[?7W:WK$]KV,8]68[K&<L)^"/3S_`#/.-/A\/BI.M])_
MM_AVWO/5Z7U7V^?<=CG78]/]/[Z)]SQVQ.[#*>GM[7XOAKN=DZ7P8H5K7[J-
MSUU#RL_#?HY(D+7"XM^]ZJPGV,Q*%ZA,LDZ-WV[?:XP0WHB@*=I'$92HS1N@
M`#L8=ZS?RGMWJ]/#YO'T\L9G++T^I\$U_;,5>5SI>.C[8^C/VUGW7VWLY^LN
MVCVWN^USZG==Q^F>XUV/6QPQRQ[?+I^GZG<3GE,X1U.A&73QG'=E.V8E*4<^
MMH^;Q./JJ&=441>H>F?)-/Q6'`STD,E)K4N6*(.ICA#@)_?%21R3DH]KT18T
M(Q*-&!'\8![UQGM^SCH9]2.XB>MCG6.&S/XL;B-VZJC2YJ==*XO&Z_TU]%=/
MZ>[WW/H_4G1ZGOG;]]ET>AV?R7>1EW7;QU,,<>[QZ\X>CT<<L,LNKZ/5RCJQ
M&$X3&[+&$,_>YT+^[XR3?RER#\;@F`6,NM/WR5-]:;%]MFU>YMJ4_>/PT!*%
MPU])]!LWZWW;^3V_'^W._P`G[;\SZ7SF/H;+W^GU*W7_`&[:W<-;X/?_`,(_
M:_\`R>/:/\V[;_'I['UI[_\`2_<MD=QZFWY3Y?TO7G+9^9ZT8^E7PWNT3%5/
M[;)FTH8$]".RN)-$-4/L=GP;$@1*272LII0K2(*GCIKCI_9E2ER4'(]."LL"
M$`D^S1#^,8-[X1V_9ST,.I/<8QULLZG#9G>.-S&^ZJ=*FHUUKB\'H_37T3G]
M/]G[GU?J7HX>]]?O\>CU^S^1[R<NV[>>IGC/=Y=>,/1ZN./3QQZOH]+*>M,9
MQA$;L<H1<-K7]N-05V%RJ_`D$BD:UKF,4_>]5>U%>,*=:00DE"QXT[_:I*0O
M2&#/TD;AF*B]%^P8="%K6=OD_;O5ZF'S>/IXXQ..7I]3XYK^V(J\:X7EH]B?
MHS]M(]V]Q[*/K/MI]L[7M<.IVO<?IGN.WO>MEAE.7;X]+TO4Z$X91&$]3KQC
MT\MV[&:B68561=)+M:*)-SB\K&V(-HU5=/(;/K@@NW5X3B0`:V]"<YA60L9A
M1@Q_,[A)*UHOTWOUWK,1VO8SATLI[K&,LY^./3S_`"X\9FJR^S&WP]'Z4^@.
MIV7L_<=7ZJZ'3[OONK&/?=+]/[Z9]MPJ9GJ9YQT]O=1$Q$;>VG++6ZJ)?)-9
M=W&G546HYK>DI4RV9JR#Q6E6IVJ=T%S`D+VXEE.@AS;Y6\6U?_T_S^@0_'O_
M`%-^F)[7L(CK5W6,SA_9^7G^9IRT^'73XJ\6^K])?M]AT_><NE]6=OGGV%?(
MQ^G]_'ZG^7.4[)GIUVE9_E_\K9<SN_MU>,=I7N%DLAP!R\^&.\5?4#=`F#5L
MU>$VTV92[*D2V1('$3M]!$26YM)+6[3.HB5!H3M%`#LP(M:U\I[?ZG2Q^;QV
M9XS.<^GU/RYJXQF*O*YTO&XTO@[X_1W[<3[A[3VN7UAV\=CWO;9Y]YUOTWW"
MO;^KCT\<\>AGAZ>_N9SZDY=*.IV\988SCORG;,2D26?VV=,*_8U%".R2+26*
MHGF;3<5B0(Y+6LD/0N"A7#EK`2X">Y2I0K$Q"?:UM+-1F;4Z&$6P`'O7*>W[
M..AU.I'<1/6QSF,<-F?QXW'Q1-5C<7-9:Z/+ZWTU]$X>Q>Y^X]+ZEZ.?O':=
M[GTNT[3Y'O(R[_H1GACCW6'6G#TNWQSQRSS]+KSCU<8Z<XS&[+&X9NW.A?P$
MYR37)4@W-$DN*9&^N?WR5+]8ZQ@:`:DR:%R?[Q^'$:8E;K2;Z$TW2T0M^_0?
M9KUSO\G[;\Q'2^<Q]"<+G/T^IIE?]NVMTZ:WP>]_A'[8?Y)T?:O\V[;]`S[&
M>KGWWZ7[EMZ?<1GMCM9[?TO7RRG'X_6QQGI1$;9G=HF)M@6X"<.L>+H)V.B"
M.&F/K;8&K%@($CQ*P-)"TN#%QP;CJ0(E1KF8-%]P.+"AT(OY=B^,6MYQCM^S
M^7CJ3W$>M.=3ALSN,;K?NJITUKCRXO"P^F?HC+Z>Z/N>7U+T,??.IW\='/LO
MD>\G+I=OZDX3W<]>,/1SQCIQ'5]''*>M,9;-NZ)A%`VQT#N'Q-\%RB_!E+U*
M5+/)81^^"J=JH9'"A`TGEZE_T[_9'Q.J"+>](D1@U@/;_F#^W6=?D_;O6SZ?
MSF/I8X7CEZ?4^++_`&U5Q]LZ/9GZ*_;./?>]]NCZT[:?9^W[/'J]#N_TSW';
MW77F]W;8]'TO5Z.6.D>KU8CI3>DI"KL6Y27^S6U-SN\+66),1[C7TC#9E=D$
MVP\%A1[)CS>UG.07&''*!'FZTI=@DIP_!OUW_F#Z\X[;LIZ?2RGN<8ZF>59X
M[,_RX\9FJR^S&YU>9T/I;Z#ZGMOM'=];ZIZ'3]P[WN<<.]Z'R'>S/MW2G=?7
MSZD=/9W48UC^7VTY9SOTC27C3V9=YI=4B/YI>DPYDL4D626*TZU-W3B4IY)0
M)USB(ITV&;@5M1@UVBV;YS``+^(6OEWK66>U[")ZU=UC,81\'Y>?YFEU&GPZ
MZ?%7CP=^K])?M[AE[U'3^K>WSQ[#IXSV,_IW?Q^J93TISRPPB>G_`,3;U(CH
M[NZV1,SOCX(F7Y'9UXA;[34@YF>S%T/<T:2N6S5JUF$=OMY[TH0*G9N5"=-)
MH66B:2BU^R7C9)I@#=%!ULT(M9?E>PW=*/FL=N<?'/IY_ES5U.GQ7.EXWX\&
ML?I']O)[KV;HY?5W;QV_?='++ONI^G=_7MF<=+'/'IYX^GN[J<^I,]'=VT98
MQ..^9V3$LHFL*X#9-6S2?S\[I8_*XVD=9]+!617YR>JWXY.N-4Q9>SE..W:7
MGHSTY)6U;4`Y*/:C0@BV$`_3$]MV4=+JYQW.,]3#*8PQV9_F1I\4358WKIE4
MZ/BZOTQ]#8>T>[=[T_J;H9^Y]EW>73[/MOD>]C+W'HQEA&/<8=6</3[:,HRR
MR]/N)QZD;)B8O+%$]VWT+J$R"0:Y+D&Y<V2M.S,D!_?)4VE<EC9I`S#YB3(M
MO'V!K3)C@Z+VA4F!6#V+W!#Z:WG;Y/VWU\>G\YCZ,X7.?I]3X<O]NVKG[8T>
MU'T3^V'^0=M[9/UKVWZ)UNRRZO5[S]+]RV]#KQ,1':ST/2];J991>7J]/&>E
M%5,VF(9_;>YT&.BH-V##MP[3[NP]V+`MHPRK;5]9N#_AK3A^(=JM.7_A_<-%
M_0^[_4]WQ_MSA\OV?R_J?,8^MOK9LSO;=;]U5PUKCRXO"GZ:^B8^G9]TCZEZ
M,^^_/^C\E\CWF[Y?U-OS?K[/0V^G^;Z.[UJ^"MVB'_O;Z$_`K%(OY3'_`/&+
MC*E#,\U[^^.IOK(]&RD^C")B=)?O'X><DRD_>R](DY@E@=Z]VP^F=_D_;?F,
MNG\YCZ$87&?I]37+_;MJX^V='N_X3^V'^1=S[7_FO;?H72[+'J]+O?TOW+;U
M^O.53VL=#TO7Z>6,?%ZN>,=*>$3:6*[!M\B460T)>?G=;'8K&%;O`I<&QZ_(
M3VE(24S>:EB2!F.<0N\24+5"D\K2QT`2D+VFV(0M!&#>^./;=E/2Z6<]SC'5
MSSK/'9G^7&OQ3-5E6FF-SJ\7H?3'T-U/9_:N^ZWU-T.G[IWG>8]/O.V^1[V<
MO;^A.6<9=SGU8P]/N<<(QPR]+MYRZD^I$1%XY5B"K.O(;?5RDSF5[)6R]U6H
M[%;=VM68QU$VIWI,@2/#@J`Z;33,M>TFF+]$-&SCBP%;*'K1H@ZS<]KV&[JQ
M\UCMPB)PGT\_S)JYB-/AJ=+RJ-;X/MS^D/V[Q[GWCI8_5W;Y=OV/1PR['J?I
MW?Q'N74RZ66>72PQGI[NUG#J1'1G/N=N.4Y;XG9$R^I]F7<6"UA$\U/2@<-5
MD$UL7JTJU+W<:8QW/0G+&X1CIH,("G:RP+=@>?@&()GQ:_U`[UDCM>PGT;[K
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MMW^RL2=$``1;1K1@5C]_H$.]ZWG3Y/V[UL.G\YCZ66%Y9>GU/AG_`&U5S?C&
MCTX^BOVR_7.R]OGZT[;]([CL\NKW'=_IGN.WM>O$1M[;+H^EZO6RSN8]7I1/
M3BM9UA+2)_;9DY:H\=0;LGARV'%/KE86[$@1B1FE0VH]8;!S(T6X;D*Y42Y%
M@1[<"2Q(1",^30OCUO><9[?LX[>>K'<1/7C.HPV9ZXW6[=51IK4Z\N+Q.I]-
M?1./T[UO=,/J7HY>^]/OYZ/3[+Y'O(RZO;QU(QCNXZ\X>CAC/3F>KZ.64=:(
MQV3CNF(0W][G0OX`127^4J0?C91+S&176W[Y*E^M01<#<%47-ARC[Q^&U"4U
M=O:7Z`LW:W0M?)L/L_;G?Y/VWYB>E\YCZ&R]_I]2IRO^W;6[AK?![W^$?MA_
MDW4]I_S;MO\`'\>QCJX]]^E^Y;,^XW[9[3Y?TO7QRC#\SUIQ]*8G;>[1,ED_
MMLB8SQB2T([+HK'(DL>H9.`V)`B$MBR8AN;E26&(V`]Q"^1E2N7*CTNESB66
MB+$FV8(6@&`WOACV_9ST>GU)[C&.KEG$98[,_@QN?BF:K*HJ:C75X/0^FOHG
MJ>Q>V^X];ZEZ/3]Y[KO<>EW7:?(]Y.78]"<\\<NZRZT8>CW&.&&.'4]'H99=
M68ZD8Q&['*$?!:5[B9*W<!\O/I;O*GU>W3U@W;-7B-JQG3.J5&BD*]Q"[?02
MXEQ;3C%FDS4(Y04$G90PZ,$'6^ORGM_J=7'YO'9AC$X3Z?4_,FM8B*O&ITO*
MHYO4R^COVXCW#W7ML?K#MY['L^VPS[/K?ION%>X=7+IY99=###T]_;3AU(QZ
M4]3N(QPRG+?C.V)E[%-EW:4JM4E/S8]*T\.``5;JPVE6Q(;A&)PVF$6W$FN>
MCH3L"+_R?5XT3K8?\FO\_P"S,QVO83'1F>ZQB<_[X]//\O3GI\6NGPV^?H_2
M?[?9]'V;/J_5G;X=7OY_YV/Z?WT_ID;-UYS'3KN[S_+_`.+OU^+^U^DMDW6<
MY58E4\WO*-!,$6E%C.@K0K<XNH%>U)A6T#BD)<]JIJ,)`0F_(SZ.+]!>WU]V
MMXGM>QC'K3'=8SEA/P1Z>?YD>,37P_\`NI.M])_M_AVGO/6Z7U7V^?<]CU-O
M8]/]/[Z)]SQVQ._#*>GM[6+O';W,X3I?!B16M?VHU.G8/*K\.01V1HFN'13]
M[U5Z46$PJ%J@A7*$;QMW^U1HA`D*`?M(X#+5&:,T`(=B#O6;^3]N]7IX?-X^
MGEC,Y9>GU/@FM,9BKROA<:/MCZ,_;2?=O;NRGZS[:/;.Z[7/J=UW/Z9[CM[+
MK8X8SCV^72]+U.O.>4SA'4Z,9=/';NF:F$J33ZV39O$X^?0SJEB+U#T[Y)9^
M*PX&:DADI-:EZP^$*8X4X;?WQ4F<4Q*/:]$6-",2G1FA?&`>]<9[?LXZ&?4C
MN(GK8YUCALS^+&XC?NJHTN:G72N+QNK]-?16'T_WON?3^I.CG[WV_?9='H=G
M\EWD9=UV\=3#&.[QZ\X>CT<<L,LNKZ/5RCJQ&$X3&[+&)AG[W.A?W?;DW\I<
M@_&^IA]CU6G[Y*E^MW%OM?UGXX_%7WC\-:2_<?\`Q/H/E^N]W^I[?C_;G?Y/
MVWYGTOG,?0V7O]/J5NNMNVMW#6^')[_^$?MA_D_Z1_FW;?X]\CZWS_Z7[EL^
M8]3;\I\OZ7K[MGYOK;?2KX+W:)DJGUM$S65L":A'99$F:&J'V-3T-B0(A),9
M44TH5I$&31TYQ"_,BI2Y*#D>G!86!"`2?9HA_&,&]\([?LYZ&'4GN,8ZV6=9
M8;,_AQN8WW53I4U&NM<7@]'Z:^B>I]/]E[EU?J3HX>]]?O\`'H]?L_DN\G+M
M>WGJ9X3W>77C#T>KCCT\<>KZ/2RGK3&<81&['*$8#:M][C4#=A<L/H)!(Y(L
M:IG%-V[5@CZZ82%Q*=+*5CQIV^U28A<C,&HTD;AFJB]`]@@Z'O6LZ_*>W^KU
M,/F\?3QQB<<O3ZGQS7]L15XUPO+1Z^7T9^VT>[>Y=E'UEVT^V=KVF/4[7N/T
MWW"N^ZTX3EEV^/2]/U.WG#*(P]3KQCT\IG=$[8EE55DW42YVDD3<WO*QOAZ`
M2FN78-H5P07;RW1Y186UO1G.85<+&,D8C/E=]$EZT#V^OKO69Q[7L9QZ4SW6
M,99S\<>GG^7'C,U\7_MM\71^E/H#J=I[/U^K]5]OT^Z[[J[>^Z?Z?WTS[9A4
MSZF>4=/;W41,1CM[:<\M;X1+YIK+NTU1512CFMZ2$3'1F[(4BM*MC@T]L+B%
M*`+B44Z;-FWR(=[5?_3Z.]`Z^/?^?]F)[7L(CK3'=8S.']GY>?YFG+3X==/B
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M0EVN;2S49@E.C`BV``]ZY3V_9QT.IU([B)ZV.<QCCLS^/&XK*)JL;BYK+71Y
M?6^FOHG#V'W+W'I?4G1S]Y[3O<^EVO:?)=Y&7?=",\,<>ZPZTX>CV^.>&6?4
M]'KY8]7&.G.,QNRQ0O\`>YT-^`5\D_E*D'XU32XID15O^^2I?K7*,#;Q*3)J
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M+9MW1,(C^]GH'\'1)\_E0?\`\4O4F5M,F@_[X:H^IA<?(,`%-+%+_P#=_LCZ
MG6@%L6D:(P:LOV^@@ZWO6=OD_;O6SZ?SF/I8X1..7I]3XI_VU5Q7C.CV_P#"
MOVR_7>]]N_S3MOT?M^TQZG;]W^F>X[>ZZTQ.[ML>CZ7J]'+":CU>K$=.;TE(
M5=C7,2^V<W)N=7A8S1%E/7U[(0V979!-M.Q>DFR6%O;#G(+A#35&SC=:4.P2
M4X?AWZ[_`,P?7G';=C/3Z64]SC&>>59QLS_+CQF:K+[,;G5Y?1^E?H+J>W>T
M=UUOJGH=/O\`ONXC#O>A\AWTS[;TYW7UL^I'3V=U$5C\';3EG.[2-)>5-9EW
M&ZJG9_-3TEW,E1Y-DA%:=:G?N<3%O!*$E8X[*=-ZFX5#6,2[0&;YQA"#XM_Z
MN]:RSVO81ZU=UC.R/@_+S_,TNHT^'73XJ\>#MU?I+]O<)]Z]/ZL[?..PPB>Q
M_P#C^_C]4RGI3G..%]/_`(FWJ1'2ONMD3,[X^")E\QV=>06RT58>97L;A$'5
M$CKIJU:M9A,MUM4/*E`K>&]8)U^DA9:!J)+7[(=]DG&`-T4'6S0BUJ_*]ANZ
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MN2Y!N7MTK(9F:O\`]\E3?5R&-&)AFG3(F2;>/P^V)DQX=%;0J#`K!;%[M!]N
MMYV^3]M]?'I_.8^C.%SGZ?4^'+_;MJY^V-'LQ]$_MA_D/;>V?YKVWZ'U>RGJ
M]7O?TOW+;T.O&41':ST/2];J998WEZN&,]**J9M,=3^W-SH<=W0;MJ'!AWWT
M-A_O%@.T8Y5]J"L_`^HU]P_$(57W+>T?W#9?T/NU\GN^/?KG#Y?L_E_5^8CU
M]];-F=[;K?NK;PUKCR>%/TS]$?XY'NG^2]']=^?]'Y+Y'O-T=OZFWYOU]GH;
M?3_-]'=ZU3LV[M$.U;?0NX0PR#?)<@U+W&6*&9YK_P#?)4VU<=C12<!I$R.D
M?WC\/N:92>+96D*<P2P&P^[8?;O6=_D_;?7RZ?SF/HQA<9^GU*RR_P!NVKC[
M9T>]_A/[8?Y#W/MG^;=M^A]+LL>KTN]_2_<MO7Z\Y3$]K'0]+UNGEC%9>KGC
M'2FZB;2M785P$2:R6E-SX[K8_%(VJ=8#+`V17Q">U'\E.WFIXJ@9SG(+M$3U
M9ZD\O2QU`2E!M-L0A>@P>O&.V[*>ETLY[G&.IGG6>.S/\N-?BF:K*M-,;G5X
MO0^F/H;J>T>T][UOJ?H=/W/O>[QZ?>=M\CWLY>W=&9SC+N,^K&'I]S&,8X9>
MEV\Y=2?4B(B\<F+)LZ\1H:L4&\RO9*R8.:Q)8S?NU:S,'4#>0]IT"5V<5('7
M:>:EKF@TQ?HEGV<:6`K9(M:-$'6;GM>PW=6([K';A$;)]//\R:NHT^&IT^*H
MY\'V9_2/[=X]Q[STL/J[M\NAV/1QR['/].[^(]SSGI99Y=/#&>GN[6<.I$='
M=W.S'*<M\3LB9?M19EW%!M;9'-+TJ%#5:8FM@AM.M2OWQIC7@Y">L;MFNFM0
M@*5J+`NV!Y^`8P&?$'7RZWK)':]A/HWW6,;X^/\`+S_+TNIT^+73X;\>#/2^
MDOV]SGV6.I]6]OA'?X93W_\`\?W\_I>4=*,XQSKI_P#+W=29Z-]KOB)C?/P3
M$O6DL:YCGVL6Y3SJ\(F:6LA#A84B%9E=GDU,[F:5[.8'!L)<A.,R.3[)*UM2
MTA.3B^;7IO\`RB])/;=C'3ZN4=SC.>&581LS_,CQB:K'[,JG1PZ_TM]!]/V[
MW?NNC]4]#J=_V7<3AV70^0[V)]RZ4;:ZV'4GI[.UC*\O@[F<<XVZQK".BMKH
M/4/E3YKDY_%*6:4)6B-PC]\53Z53&.G;-^IER=_V\?9&1.CT`/JB6&`5C]_^
M4._3>=/D_;O6PZ?SF/I987EEZ?4^'+_;57/VQH]6/HK]L9]\[+VZ?K7MH]GZ
M_9Y=7K]W^F>X[>UZ\5M[;+H^EZO5RRN?S>E$]**UG6$P*GUM#G+7'C*%=2H>
MLAI;ZXV#NPX&-&T2L38>K'!3(V!PW(5JHIP+`D^X$EB0[$9\FA_'K>\XSV_9
M_+SU/F(]:,ZC#9G<XW_?NJHTUKCR>%G]-?16/T[UO=,?J3HY>^8=_/1P[+Y+
MO(RZO;^I&,=W'7G#T<,9PF>IZ.64=:(QV[=TQ"&:MSH7\`MTD_E*D&IHJEQC
M(NKC]\E2_6MD8`W@4ES4<G^\?AQ4F-6[VF^@*-VMT+7OV'V;]<[_`"?MOS$]
M+YS'T(PN,_3ZE3E?]NVMW#6ZI[_^$?MA_DO5]J_S;MOT##L8ZN'??I?N6WJ=
MQ.<XSVL=OZ7KXY1A^9ZV6,=*8G;$[DQ63^W")?/V-+0;LMB\:B:QYA4V#8L!
M(2V1)2$#>I2PU$PGN(7N+J5RU2>GTN<BRD9>TVQB%H`P;WPCM^SGH]/J3W$1
MU<LXC+'9G\&-S\4S595%36.NKPNA],_1'4]C]L]PZWU+T>G[QW?>X]+N^TGL
M>\G+L>A.>>.7=9=:,/2[C'##'#/T>A.75F.I&,1NQR4Q^_OK/]!LJ_\`CZ__
M`.PU#_X__D__`,P?_P!<^[]/]G__`"&'_P"SU?\`H_O?_P"MOV5__P!([+C_
M`/A/>/\`^%NGGAOP$P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P-1[FZH;*]>SXA$VDJ4R=",L#J8<J"4T-AN]:,,;A;3
M&"6JW0!6_48`!"`GU]!"V+6P:L0L1:ID?8=AJ]!'J%PH`->P1I9SRY)#P`%O
M]H?:IV6'9FM:W_AL6M;_`,<M0M0]KAUQ8B,7^:$0Y.$(`;&6J>UPE'J9OU`(
M)"?8C=EB"+6];]O^'[?\,5!4,A"NT!J9`E;+"C*!A9EIX4H7]J5J3"&X>Q>S
MZM<G7Z",YMT+>OD,*W[R@;]WL%K]FI1,>#?`HTH\HH\@TLX@XL!I)Q0PF%&E
M&!T,LTHP&]@,+,!O6PBUO>MZWZZR,OI@:^WOU-1/-"^EFNZYZ@A*_H2XXQ0M
M2IE:5P6&2FSY@0X*&)C#IO2JOMR4\#:,)JY5\*%.,90330"-+T*Q$SPY+$3/
M!L%D11O0_25*<HUHNN'H";%U[6S8YM3.XR@]BD\A3(G![4;2MA:E%$F1_=2B
M5"C7MV=LC1!>]Z]XPZWK+$3.D+$3.D.?IGGI\/);06]_S_T,8C-*3FED)W-_
M5/`]*3`%$E:CR9@-?_JMF&:T(GZ;Y0?M]P=:UOTNS+P7;EX)Y6GF;\7%MSAM
MK:'=JTV7.GD:0IEC4T7/=7N+T<OW[4)#.&S62($NJA:+>M%%IQF#,V,.@ZWL
M0?5..4<8)QRATW"+0M:$'>A!%K0@B#O6]"UO7KK>MZ_9O6]9EE'I;,(E`(T]
M3.=RB.PJ'QM":Z2&5RUZ;8Y&V%M(]/F<'E\>%*-K:T)/NU[C3S0%A]?V[P.5
M(?.?XX'M[>&.KK0M'H04>4G(GY[YJYCZ3O\`B#2N(.T0)(HFE653)HJ><,>_
M4&R%AP!!_;H7[=9K9DUME\ZL\\7BOMNQX]3C'TX&,V]*9FQUXRUC9M4715\S
M/FDE=RF)@CRAKG5>,06]P=',\LLL*@PK0?E!L>PZ%K>6<,HUY&S+BZ^9AE'Y
M;*H]!8K)IO+75(PQ2'1]YE4F?'`S1*!FCT>;E+N].JT[?["DC<VHS3C!;_\`
MB`&]X%=<]7_4_5%*5QT-1DI+FM2VQ&TTK@\F+;W-I$YM"@T],+:AJ>4B!W:U
MR-:E-3J$RD@H\@\H98PZ$'>LLQ,34\5F)B:GBN7(A@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,#BBD:E<AF<D/4>]P6+9&_&^ION4G'#VYKMB/V6%Q+4&>OH(0AD
M#WO6M:T(.M;WFV^3:*,0!J+8#MNZE,20I(-3IMJ5@TJUMD3?O8PLWPJC%)BL
ME<E]X"]E^_6A&!UZ:V69Z1$N=8*RNJ-V<&1:2>I.6%'K%;D:<`QL9T:(@PQ6
M-O/`%:(Q<XFA*"7K1@_]/0=;WL7[8C4&P8O]`</?P*"='^X2<U<$9:D_6PEB
M"9L1RTQ2;O?J#W!)`$.BQ:T(65J'4:C5!ZFGZX-4F#,/_";26,9@MC'_`*"<
M)`0C%L]3OW``7H._48O3T]/V?X:S/%F>*UL(_@"_]EZ77EU!:MHW-3+XH3T%
MXCY[1U2/+FV#7;$/I^_1@F\JES2K3^Q,2=3P6N$,R[>][-3K73T!O6MF9WZ=
M1%3QEUPTC7F_L]X"ZE9NUN,N<>H6<:?WVY5\>?I&C2ZT$IGG:,@3)83!H&O3
M8-,,X:W!)K6]:]0DZWZ>F]9QF*FG.8J:;@;UK>MZWKUUO]F];_;K>M_XZWK(
MC_G\\_UK7C9_[@E@Q!!"(JFBC;8]O2UMC0&)MVQ-TG4\G[F1C\WM0TXT2)U#
M+'`YQ`<4``REA@C0;"/]N=Y__2=9G\MWZ_\`9HH&H+3\3'1%BSF(1U?.Z-!`
MIS5TP4MK=^(8Z]J;(A\5<FQN=S2?K@M4G8']2B6(@F?"IT,L0@",**V'GTY^
M*&<)K)^__60NJW;K\3E7N-PO[Y*5E>V-:-40:2R4Y4L=G*LX0\)2(LF/=UQA
MJIX31C:Q0S)CQC%LM,VED>N_A]<=2(C+0SBLG#B3V?8'_LD^7IXY8%,I*P>+
M_DQR>9;+(7&'=:U(+:9:[D0(L"5R)0A,3B<9%;\V4[2,PC!;TQQ<HY0D"!?L
MTXS=>GA?_E+7]F/_`*G]R-6U56E(P&,U93\$BM:5S#6TAHB\*A3(@CT=9&\@
M/H$E$V-Q)"<`S!>HS3-ZV:<:(1A@A#$(6^/'BY3,SQ<K/+/XOH]VO&:RN^GH
ME#6;N#FNUZFM6E;*6'%119)6^!6#'I"_U;.Y:A0J5ZN(O#(B4&(?G`?MM="B
M3"-E`,4Z-WCE6D_VM8Y5I/!V2S#+A]YRY=/;%HRK/''13R4T7]Y)[!6TDSN(
MP*#2XC2<.85-A=`SQS"D.)/`R(8<TDLZC]NOD"]^T._=K-X<=T\(:Q\9X0YC
M_P#J0]3.SWS[T3P58AIK?8/*=H.4FC4?<SMA<D$$L!W<T4MCY"0>@C"3";:8
MG3ZC]G^F-Z)#_AL.M:ZL:QE'"6NI'..;^OG.3F8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`Y&0DU'N4N12T2PX@R2NHAIVQ0'[B=H#H?OU0ZVL5Z^?0@Z]!_$+T
M]-_Y]^GLUIM>MAO.FMX@JE:>KTR#;%J0L+HZ-"U4%W3.`1K"%QC6<7L]>8C,
M)+!HP/S[`$?^8(0[]8BWVN>-KJ.,H49!NPE;V!0/1B8K04IB<TP9ZT2ER^)*
M!,<`&@"5?*#1F@:WH0_;ZBFLUS[3Z5&[]7DK9I&OJ3'58D7''B$-3Z#1')CV
M\HY*/>O_`(;^3_/H7H`7I^RK#>&C-^M0U[OU]?\`]&D.O7W>[_#0]>GK\IW^
M'IZ>GN_9_AZ!_P#CK,\69XJX[2Z=B'&/*5^=1S@Q/]AI:M9',@(E)FR@OK^E
M2;2Q*+DB#L(]JY5*U:)N)T'_`#;-5!UK]N6(N:(BYI_+YS*789GB1M?CZ\/&
M7Y)[!M_M".W9;70%LL=24HMC,EOWH->XS)JGC,I?K_89":TP]6)ATA&L0IE9
M);47ZD@$'V:Z3_=<3%0W/]UW&C$?^H?T^^$U[U/X]K-VM9Y]0T\46M%8P\Z,
M3NC2SR9PW#;;B_T*D7SHOP79S&4<H)UKT`I?A>OIO>]B=6.&1U(YO[.,Y.;_
M`)Z!XK\#_P"VO=PN8RJ@/NG4LGWX5*OA1-$E7#3?R@-/X@_$"BODJV6%J/L7
MS_1?3%"#]7\?R_Z?NSZ)KTHO@[:>G%K,Z4[*Z6[\\BL)\/GF'=(SQ30^[$8=
M/T=Y>*<=M5\SK_Q7FDT<BN2Q'-V<T-460H'ZM2Q`VHQDO(DI*LDM45\J+,1$
M8[L-92(B(W8\7]GRVEX+SMQS*:0YWAB.OX36=$S>+UA#HB0<#3/I'$7H;:6W
M[$,]:N>5CJ;M0<I.&:K6+CAGG#,.,&,7*[FY<[UN7\<7_I<"8-/'?1:OZ34V
MW'^:QE!.T+3M^'@G6^%S]/=K]B0+T(GY=?X_+L/K_P#AG7J\G3J<G]X6<7(P
M&!_*3$^PY#:GF/ZNZX8N/^M^LJ;Y"@Y_`/.LBYM@U?2R*1^RTKXCF'5$D<'&
M;VG7:?3^L?-H&1.<A"OT8UI_0P1>A@T+I7PQ%Q<MU\-<W'."7FX<"_\`LG1V
M]G2D;VY5H[N^4&MLCK[H:-Q6&R4#5T*I0,<ED`D,+ELVC8HHR=)-:9U*-+7[
M.)3;,"867_@/=;NG7&8;XX5S?]$+.#B8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`XG[<UD;G4G:5P](G)'+7DHPHU6'2DD\IT6BT5H`9"?[]@V+0O4S82P%[]0A
MUK]F:;Y-F8W8C.J95S,ZI$;HTZ1&B`R+$Z=X"I<UGPD#<UPBQ%)#3D8`F;(]
MNM;(]0Z`+_Y>Y24S[I/XQ'$[DDC#*W,B8Q6`LPO18U"5T0FI?C/;W%>!>(U6
M#1NMG$F:]=DCV+V>S?IO2I*EJI.I>4<$T):H`1&:-V7O:PD19I0A?_XS!NJ8
M*@LL.P^\LWT'[?V^[W"_:5U.H\A0CIZN2UH!DG`B+089H\?N%HLU*$\LP1FU
MB_U",D81:W\P_P#+O_'7^&LSQ9GB_F;\S_7_`#SU/VGX\O$PGN6OS('-.FX9
M;O93F5+V?\--L6J\2^2P&BY&_)G`3>@D]DR-J'\C<>,!Q!@&[8PZVI*T+IA$
MQ$Y>3>,3$3D_JM3*V\U"4L1JD9K;LC1I*M,<2-#M*`/[#"CRA;3_````'_'6
M_;K6LYN;_GF]57M6'B;_`/9L.Z0B\YCSC1MRJF.6WTBACPAD0HG'+]:#8S;B
M:1-[,<>).Y,$^CY4VTB%K2D9&RMA#OWA]W>(G+IUS=HB<L*YO[[HA=],V!`D
M=J0:V:WE]9KT)+DCL"-S>-O,,/0'E[.*5@DJ!R/9]$B+#O?KL[7I[=^OIO6_
M3C4QI+C4\'\!U'],<^!_]M2=7B9<U;DTR]V3:,29[5/EK*37CH_*>7OW=(DB
M"8#5Z8%)#E-D8VU*I"?M,I4^T)9@O>#8NTQ/I5S=IB?3IVH_]F7QGI>T.5VO
MM&A$)3Y?G*[`X/IZB'F?6N=GT&!3]YE+0V+6D1PU[W7"LLR1,HRA;&$(%Y)6
M]FJ0>F.GE4U/"6,)J:G@MOP*^:JK.YN:(=4=_P!KPZ.=D5,UH(9+&J8R9J9'
M2\6!O3`3QJV8@6[JDNY(XOC66`M_3)1'GI78HXX8`)U2?>V>&V;C@9XU-QP<
M4;'J.W/_`%N/+0\=EQ^O)5-O&3TD[/L=FL@AC2H=4U;0JRI"DD[E!WXM,$:=
MCE%3S,@*^,?5#)3R%C+$B(."K$>`K=^ICM_\FKC/&O\`R?W#T-T/1W4-;L-N
M\]VG"[>KB2)"5;5*H2])7=%O1Y>C/HW$@L05[&[IM;]JA"M)3K4QFM@.*`,.
MPZXS$Q-3Q<YB8TER=\SOF:HKQMT!/&&+3^+RSL^9QEU8*.IUD<6U\?F.5/"4
MUN:["L)M*-4%QF&Q16>%7H*\(#7=04!(F+,V,T9.L,)RGR7'&9GR97N3R&-_
MC,\6K=/+KMIKEG8!?.,/B,-9'MT8$]B6KTB]0!M;5$CU%FM,C_\`K6R5J#WQ
MU,)1D(DR%,,&M@$,D`F..[+3@1%Y>2P/!A4M<TOXP>68Q!)[$K->99`T]R6M
M.(H^-S]J1VW<R@^P9VK>ER!2H&-X:WAY$U&?/[#P:;=%C"$8!!U,_P"Z3+^Y
MQ8_]P>FZZD?,'/'0)$MC+'=%,6_^"&UIV]-Z28O\#M%J$J<]-+;]2%S6&1.4
MQ=H<@"`7L*8@P\SW!T+_`#;Z4ZUR:Z?&N3MSX@O)+4WD+X[IF9HK(B3A?['"
M&**7]6^WUO+G$<LZ-MI#7)'59&3E`7?\/RY2D$ZMJT!9B10E5:"$W9I1P"\9
MX[9\F<L9B?)U@S+)@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@:S7'S/';2<-R%N=E
M$2DY@-%KEJ<I6K;7<!1?L($O;$SHU>U87Z:#]069H>P:]!A'Z!]MB5B:4NFX
MZFQ&@@'9S1L@(=Z"2GC[NFT$6]ZW[M;W(3P^G^/KKV^N][]?7_\`6M;A]C>/
MYH('H19K:2/U_:(UE=SP[!O6]"#[`OJ?>M[WZ?M]V]?_`+,66ST(XS;&QW*=
MIW+#),2F.+.)969*Y,#<H,($4(K[B8)\7F'IM^S>ADE`)T/]GJ/>MB#M9N;C
M/C"RR9B>(P_MB-WCT@:'!A>V9<0`]O<V5U1G-[DV+$PM?&<C6H3QE&`WKT$`
M6]9&7.S^V!XF6D]KKK?"G$Y#@XH#T3;&MT)51[PI0)$`SE!HB]QPUS]A2,O8
MA*31:%L7IOW['O7KK=EXRMY>,MVXM5-1U;4;;3D2A,-A-*1.'&0QM@+<V-[3
M!F.#E(#4)S"6U^TMN2L6FXT99A8M:+V6(7N_QWF4:@L7B;\7;.THF]D\?_'(
M&HDG0D?IS]5Z_0R3M[.";]:JCJE0JT9[_70Q&#WL/IZ;]-:R[LO&5N?%(4_C
M`\=B."S>KT/%/-:"MK)EL4G<]@#?4L000V63"#!6@B$@>HTC;2&=8X1X#DIT
MF$(GT+TH-UZ?Z@_5<ER\!GBI\99I0R!^/WC<1)A8BAE?RXU-HO90@^W8/9J*
MZ#H/M_9K6O\`#_\`#&[+QDW9>,MBJWKCGWEZNH=2%6Q*O*;K-`H4LL'K*+M[
M9'X^6HD[TK7K6]BCB4(`&B=GMW/.."66+0C#QB%^S>]XUG4UG5K,J\2OB_7-
MIS2K\??'RA$H`H";HWGZLQ*A?5&&&GF!</P[]P+/&8:+>C`FZ,#Z_L%K]F7=
MEXR;LO&6];A%(N[1E1"W>.L;M#U;1]@619U:D+E'EC']-I'MG6,RT@]O5M@D
M@=%;(,+$5LO_`"[UZ9E',9]\'_BI>Y$[2HCC:OX6\OQAASR.II%9-+-SF88/
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M8=_"4`&_700ZTW3&D27/"WF@OC?X!JZPX=;59\8\SUW9U?+%Z^%SR"TU!(C*
M8VL=&Q4S+SVQY8&5O6DC4M:XX@7J+>M`-%K7I[MXW93QF2YGBW4R(8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`YOK;?TWWO;%P-\$42]CA)D4II&\E*D+
M(E0:6/!"=]/1*E#4H<Y*^JG]2`HE*D`=K2(OWC-+`('NU6E-5I39GHF<ML>C
M"*).%?J+'+L-U:X>?'3%:AH;%A#^K^C^G.=2D:LPU49H`QZ(3A$8`LL1I@BB
MPZ&*0D0D<OGK;6I\"K:(QK;W*)&7IHAT41GF-C4V,3`E(*5NCT[!1N(6:/LB
M$(->[1)QQN]>PHL8M;]!7-^HK<;5(:N<;.4-3@G1L0I(0\M[8$3N/ZB*.2QL
M=36=0(I`%T:S#$0CB%(@$`$GW[QZ!Z"](5K2E*2OJ=OC_#8W8S!OVV\EF,XK
MY[3'!+-;(LW*3#VM@?68J-M0$AP&DL)A2D2@\P_Y->__`!UZ68688>W)2J=N
MFX*S1Z('S9TJ6%/\PTVE;*:DX9)(R2D#=]VDZYN.0L[6VLWO4['LWU&<<`LL
MHTS?II'`C@V,K^VF>85(TVV[D?A1H5LZUV=25IQJD#4!L5*T:[0%'TB4Y<3\
MR(6R!`(",\(@^T'N%H.1*UI%8S=KM++0;8$WP!R;FHV(*)H[OCVX%I'%K9U9
M_P!)%M*6!.E5#;W!_-`(SZ):H3+2$_H,9.MZ$$-HK1#I!TG*$]FR.K8?3C[+
M'QJ9#79KV<\EL(7(*)880N/<-JFE0F86Q02G-$WG'G;-<![(]A02U!9F*TLK
M2TNN>^3:<CL9>%L%=WE>^G-I*UL3JQ%)V<U:-,2<A"Z)6YS+>7DI0>+121(4
M88<628;O8"P^[:(LB+5.^=@.[0?9Z4NH'-4HK9>Q$J=[DZ0"8U*^K4R%,D7J
MB6E46FE0SU0`@:T?W`S1GR!,&7HDP6**;6O\V:(JP-S[(BUJ`;H>UMR%F)2F
MN+RL?W@(0H8\B1H0G"5.ARC>R]:UZ%!]HAC&$L(AZA2#5E:CS8<IL%E40\,=
M:X$J:&0]><]ENBI9)U2,:]X:-%HD/VK06(@T@LXPE8H_UQB!Z:T'UW9@F*75
MD0P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!XG$A0J;UZ9(H$C5*$2HA,K
M!OT&E4'$#+)4!WZ"]!$&"T+7[-_MU@:EU%SU)V./U['[&51C3-6KRLDJ)@B_
MO<4\SF)JA8<BFLQ<'-E:C@KVHQ5\J1*E+T$)_H88:9[`%@LRLSX)]-:OE\PN
MZO)J-W:4L&K]F7*D*(985;P&7N2HPA<K3(E+:8B+">Q@+3A4C4"$1H1FP$Z,
MV`T*]")T?"P*RFZVRA6-!5;!]V<:V5UL!3(SQE?@OZI["Z[E3*E3L;D-[4;)
M,,`8B-4)2QF%E[]_M$/T<J+TI5UN0@JO*!A_.D$.VJ>K'>$%?(5ZU.`D2O3@
MI.?9E(W;Z%N5)$Y1B4D\1WJ5O00G:`'UWK6.=D:S:V*\J9U03))8,S*9DCC'
M86VU[`(NPK3W9LB$;2ED[<U!CRL:652Y/+XH)!HS84Y1)*<D`-:&+U'B9)GE
M")AIZS$+K83HUN4(+=;EDK^3-I,H*7F/$7@1+1IDA2")$`;B$[D[-J39IIP5
MHM$_4FZWZF`#OU66DMBU`^*XM4\2K`V--;)6\JC3H8R2@M6H9E[3&49Q344H
M*0I35*T]N</A5@+T8FT:>4$6S`^FL1)$^+PT93T\KR2V%)IU,&^5N<R=C%!S
MHG2%:=7Q*EV40Q*'H[;8@`U@9&XH1*5N1^],3]2;L1INM$Z*3),Q/!+ZNJY3
M#I+:$XD"E$XRVQY<I<3%:38C0-\3;=?0Q-A`H-1HSQ[1-H-"-UL.]:,'[-"&
M$`1;3),L?/:RDDSLJ-2\Q2PFL5>1E\7P9G7_`"#$*U'30TB)_>=":56BFQD0
M%@VG$28,T)Q@Q;+WZ!]5Z$3HIA#R]*VI-4[&WOT=^A99*YV7:DA6)-+7>56>
M;HC;6]$MAC66C<B6L2A3I+\YI`"1^PPPD[>ME[6MK/MFM+-E]BPN3PR1L+(W
M1N*3%M)5.X!K5C#))"6F2$R1D:/M2A(L=`-I8TX##U("TX3!BV4;Z^P1(F*9
M'F^JI'4-?!C<G<VMP=E;BJ>5X&@O9B4MR<1?,Y*CG,Y$@6.Z]P5;V,TT9)(`
MA"```:]HAC3J3-RV`R(8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`@CW64$D<C:I<^1Q(Y25B-*/9'E0<L^M9SBO;[36HP"D&F\8M!UH>R=`V9K]
M@_=K>\"=X#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`X1RWS[T
MA$)9*HBKX0\K;LJB<F?XNJ=H]Q&_.T?=5,>=UC.>YL+J7,2P.;(X&H]G)%&@
MAT>G&`?IKW>FMQA?.&MM\X1__L,T1^@#RY_T*2'\YXV><+LGQ@_[#-$?H`\N
M?]"DA_.>-GG!LGQ@_P"PS1'Z`/+G_0I(?SGC9YP;)\8/^PS1'Z`/+G_0I(?S
MGC9YP;)\8/\`L,T1^@#RY_T*2'\YXV><&R?&#_L,T1^@#RY_T*2'\YXV><&R
M?&#_`+#-$?H`\N?]"DA_.>-GG!LGQ@_[#-$?H`\N?]"DA_.>-GG!LGQ@_P"P
MS1'Z`/+G_0I(?SGC9YP;)\8/^PS1'Z`/+G_0I(?SGC9YP;)\8/\`L,T1^@#R
MY_T*2'\YXV><&R?&#_L,T1^@#RY_T*2'\YXV><&R?&#_`+#-$?H`\N?]"DA_
M.>-GG!LGQ@_[#-$?H`\N?]"DA_.>-GG!LGQ@_P"PS1'Z`/+G_0I(?SGC9YP;
M)\8/^PS1'Z`/+G_0I(?SGC9YP;)\8/\`L,T1^@#RY_T*2'\YXV><&R?&#_L,
MT1^@#RY_T*2'\YXV><&R?&#_`+#-$?H`\N?]"DA_.>-GG!LGQ@_[#-$?H`\N
M?]"DA_.>-GG!LGQ@_P"PS1'Z`/+G_0I(?SGC9YP;)\8/^PS1'Z`/+G_0I(?S
MGC9YP;)\8/\`L,T1^@#RY_T*2'\YXV><&R?&#_L,T1^@#RY_T*2'\YXV><&R
M?&#_`+#-$?H`\N?]"DA_.>-GG!LGQ@_[#-$?H`\N?]"DA_.>-GG!LGQ@_P"P
MS1'Z`/+G_0I(?SGC9YP;)\8/^PS1'Z`/+G_0I(?SGC9YP;)\8/\`L,T1^@#R
MY_T*2'\YXV><&R?&#_L,T1^@#RY_T*2'\YXV><&R?&#_`+#-$?H`\N?]"DA_
M.>-GG!LGQ@_[#-$?H`\N?]"DA_.>-GG!LGQ@_P"PS1'Z`/+G_0I(?SGC9YP;
M)\8/^PS1'Z`/+G_0I(?SGC9YP;)\8/\`L,T1^@#RY_T*2'\YXV><&R?&#_L,
MT1^@#RY_T*2'\YXV><&R?&#_`+#-$?H`\N?]"DA_.>-GG!LGQ@_[#-$?H`\N
M?]"DA_.>-GG!LGQ@_P"PS1'Z`/+G_0I(?SGC9YP;)\8/^PS1'Z`/+G_0I(?S
MGC9YP;)\8/\`L,T1^@#RY_T*2'\YXV><&R?&#_L,T1^@#RY_T*2'\YXV><&R
M?&#_`+#-$?H`\N?]"DA_.>-GG!LGQ@_[#-$?H`\N?]"DA_.>-GG!LGQ@_P"P
MS1'Z`/+G_0I(?SGC9YP;)\8/^PS1'Z`/+G_0I(?SGC9YP;)\8/\`L,T1^@#R
MY_T*2'\YXV><&R?&#_L,T1^@#RY_T*2'\YXV><&R?&#_`+#-$?H`\N?]"DA_
M.>-GG!LGQ@_[#-$?H`\N?]"DA_.>-GG!LGQ@_P"PS1'Z`/+G_0I(?SGC9YP;
M)\8/^PS1'Z`/+G_0I(?SGC9YP;)\8/\`L,T1^@#RY_T*2'\YXV><&R?&#_L,
MT1^@#RY_T*2'\YXV><&R?&#_`+#-$?H`\N?]"DA_.>-GG!LGQ@_[#-$?H`\N
M?]"DA_.>-GG!LGQ@_P"PS1'Z`/+G_0I(?SGC9YP;)\8/^PS1'Z`/+G_0I(?S
MGC9YP;)\8/\`L,T1^@#RY_T*2'\YXV><&R?&#_L,T1^@#RY_T*2'\YXV><&R
M?&#_`+#-$?H`\N?]"DA_.>-GG!LGQ@_[#-$?H`\N?]"DA_.>-GG!LGQ@_P"P
MS1'Z`/+G_0I(?SGC9YP;)\8/^PS1'Z`/+G_0I(?SGC9YP;)\8/\`L,T1^@#R
MY_T*2'\YXV><&R?&#_L,T1^@#RY_T*2'\YXV><&R?&#_`+#-$?H`\N?]"DA_
M.>-GG!LGQ@_[#-$?H`\N?]"DA_.>-GG!LGQ@_P"PS1'Z`/+G_0I(?SGC9YP;
M)\8/^PS1'Z`/+G_0I(?SGC9YP;)\8/\`L,T1^@#RY_T*2'\YXV><&R?&'8[G
M"]&;I>D:]O2/0BT*W9K%:%#P@A%T0T^O;0CQ29U<&D2.80U2L7G,+@8:W"-`
M4(XSW)S"Q^OH/TS$Z,2N[`8#`8#`8'(GJGS*T)R5==NTM+Z![(LL[G^OX):5
MY611E')[,K*IX#8:)Z<F233=Z03%&],[80@CJXY28)NWH!:0T0/DT6+TU&$S
M%Z-1C,Q;J%#;%@]@Q>&3*'R9I>XY8<;8I="W%.J`7^(8[)6--)61S;TJCX5@
MRG!A5EJ@AV7H>B1>X0=>F_3++/D/C(J(VJ3/#4H2Z6C;=J2'!(:1IQ*,V28@
MV<6<(O2TLW6PB*]?DT+7IO7K@>DMQ;S5(T12]&8L+V/1B0M40-27LO0!#T,@
M(]FAV`)@=[]=?LT+7_Z\#[$*"%1>CDQY*@D6QA":08`TO8BQB+,#H98A!WL!
M@=AWKU_9O6]8'VP(O.)E':ZA<OL&7N!;3$X)%Y!,I.ZG>GQ-D=C#2K>WIP-]
M=AU\:-M0FF"_;K]@<#F1&_,AR7,/'(Z^3R,-=O/5"L;R5&W:'HX>R[N=!)3[
M1:*E(CRB&&2PMH`[GR!_1*0%?=?\[<J+-#O8A:+S6R=VWFNV;KF]U/>7GFRQ
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M:9D^6'C4Q4:L431Z;J_)X,9/(X.W'%D`EKS7-[_)E45;U.E`EXI-N<#<DHO5
MG^V?-O8@E!$)2+1&-L_S3;*LJ`\RG/UX3(V`R*D^M.;I6^T],K^IMKZ8I4=8
M[Z'J2!M`'^3R2FU6Y$\(GQP:F(XE:<UK36]Q+1'@/V5\7O$!.,QX+.,H/1?G
M8Y8NY1'"55*=C4LGL:A[*Z+I)YO*BBH7&+^KRIH298TUU3LI03"0,$H?$$**
M$X@3F*$I9J;7NT;^T/K9PF/`G&8;:QWR+T3)DOCY5M[-9("O).S+WR@M*H\S
ME#9$;=3*B\U`+-T"2&ZCA^X>F$4$*+;GK:_T*WO0/]7)MG7R2IU\GNIGR)<X
M7OV5TQPO`7.2*;OY498J^V,)>T)$L0=$TD(;!+R(8]E.JE6]K(4N>T*)[`:D
M2Z1K%998=F^N]ZDXS$7R)B8BVFU3>=OF*U)35;<=07:]:UI=5U[YYK;I"RJ"
M(:><9%;ATN>H$TQ,%GL<TD:1(H?IG'U+:D,-3A*VJ!L)HBM!'L&MD^2[9\K9
M]3YS.+D5/]YW0M;+G1Q_QW6VBI>\6)1#(\"6/TM=IPIKMD/K!KU-!)).S/<H
M0*B4QRI2W&"TE-V(L/L],FR=/,VSIYK<NKRU<E\_5=P[;=FK)VRQCOZ0UDQ4
ML07'FP]V8DUH1YCD:&3V4F_$!::-1:+I9,WE/*I,<X;1GK"P@`:'?NTC&9F8
MCDD8S-^3IOF4<H;Y\R7(7-D@N=DM@JT&)'0?3O/O*=DRDN+,JB,-$XZ.KW5G
M0Z5%K12HE8;7<?B_J-[7B3@5(S`"T4E4!U[\U&,SP7;*U;5\F_+M)K.R"+*<
MY>P(N(8_0[Y:3N5'"GA)+%/232XN-1Q>IDC,YKWJ<2V3+4(&XM%I(EV)P5D`
M`(98AF@;9_$J7ZXQ\C=6]E3*TZG351T+SC>M.-D4D\VHGJ*M-5A9I,#GGU^H
M98+2V)GJ1-;Q$WTYK/(^8A8(Y*K*$2H+*%L'O3C7@3%.@^90P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&!_,I<O`MP=H>4[R5Q$GI'HSE:AIYS!QC`[)-J:$PX#7T7%'M@NEI
MED&)L6?PQ_\`M)L<;##DRD<?/`J)+>1!5:WH10<W<1C'C;=UC'BHJZ/'I(1W
M%YG9#S74LY3WKSWQ3R=3?CTE9(Y6WK8Z49Q]+JSGJ"DWM6>C8'2R':"MA4=$
MY)]GKDBH9!?RD&#_`&ZC+2+X7JMZ1?"VGR2KZ(=:;[P'R/R1U-%N.9GQGRM5
M,4J0ZK+@KJ9RKRTIK*<AU[/:QCT^9`2)JG=2^]H,GLT3)]-0C4@CE*I4$(AF
M+FXOC?\`(YQ?'_1E5'[W.*.`ZG[A6599)/D&X$[5Z5AG<ADT+7J7GH2?=BL+
M_4,AM6.S-<C;VRQJ\D\QD-<.T;4MVC$"5(U?2%>AJ8>QW29V_P#C,?T.,URF
M']-?.O,5]<O>-[G[FCG675C%+ZK2JJZ:G27W7$I38D%5SI:>BDETO#Y'HE,8
M)(7)=)Y*ZO)Z<PMT)T4K4@,,T:$(@"YS,3E<\&)F)FYX(/\`@/S7_J6\;/\`
M29T7_P#]6Y?@\UO'PE2/EI3]<2'QH,_*C>1&K*ZU[2FE:<DR"45/#Y]$JC:$
MEFOYIUJ3EV2[76'):XJY#6#*XI%ZU<N6"3;6:]I@S1E%[8UNOE"XUNOE#AE?
M]*]HTQSYY;^,KAI!B8U?18^+>SZ/;>-V.V;"I)A<Q]%4G25U1>!/4GA*-X23
M=K1U\RR=4V')QB(+VH6!"8E]X@;B8F8F&KB9B5P7KP;TF&8^6WDB>._0G6G1
MM]</,;IPMUQ;SHX/":;\_P`+GK9.9KQF\JH\P,53PBR@6>S[,%\9*`R2HEY2
MH1)!9(M;D91I,<+2^$\G0]-YBW^>UY:\GH/A;I,+?SGP_8,TG\XLBC[%KV50
M#IXE*PL%7<HP.$/L#^Z6M()#*AC$[&LZC3<W)$12C9AX1>T&=OC/-FH_FTF\
M:G,'=OCC['X16]"UC4Y59='<P2KDJQ)50"JUIR^BLUF=Y)U-"K/Z>_$$,9VF
M+S=ZF<MDK%]P2GJ&[1S@-/LT(`)]CUE..435\6LIB8T8'RA,<31>4/KIPMN=
M^4*GH=8_"U`0B!OWCUK^UW]%:LG3.=Y%2"#V2X0BMIHR/"!I3O:/Z=$J5MP-
M;<#]#.!HSW!8_P!L<.)']L<.*A9ER3V??]-&5@X\YKX=>"G_`-=GGF,$5FT0
MI;#(8?.*9[C2V2U44G#\0XS&[`E]:0E(4KCOU.CDBQQ&6,L!?KZ6)B)_]RQ,
M<?-OM9G1RORD](<<R2@.<NEH#&N**F[$MCI*17%1,\J(B!R^R^69;3$5YLC@
MYBTM`YW-G>5R+9BY.RZ6)`(6X!P3#/\`X@S$;8F)Y_\`5F-/O1/B3Q@SY+X[
M*%ZGON_ND;>L2G?&?;C#SARU-89$H;%.<'VY>;G&(2N/M,4C<,:+`ELM)C@O
ML27;X>I<`%CV$01F^SV)RB<JCA,DY7-1PF5"4!R;-^3C/`'TM(I]W=;K8PU!
M;<_M:H;4=918L!YR*9/']+W_`'%Z[KA%`V]SJ94L=_2/($"XXT\X>B$`-"/]
M-;LS>Z-/XE;NX_CBP?&]+^1KFJY?'+Y"+RI2MTD.Z"OVYTM]**ZW<+_T\"/>
M3Q^(GR%5TO!ET+31Z,Q>BIQ'HR#Y$:DW3&23H"KT#LX1:9QF)B/XHF8FX_C1
M!N7.4KVIFN?&5T;>*GJRX.0TG>=O:N3C5X0R%KC',EI"Z7M0'-O5+-7D:AR.
M:R:MXQ+RRW9^0O7W!($;H4Y$#^GWHG5F8F9B.-$S=Q'&E%S_`)%Z.=[BED6;
M*CL@RHNL+P\F=AW_`+'`9@).>Z\$=`]97?SZ>K]C.).,JT%5K-:=C,-]`O02
M2M(MG^F+BO.*6X;!2CD?NKR#16MZ>IVG*U2PGEOPS\V<HKW'J\=P5>8RWMTE
M55?6G8<SH?3)"7`IWM>LD]9QIH4FK=E(FM<$:<\6C!F!+7CCK/B7$:^;^DSQ
MQ]V_S'5ASM6EH0BV8+TZX\@PVZ+6:)]7<BB;6G>6.:NU'6"B"[/R1O\`GDQ=
MDP]4L,0@*%LMK<$2GWB+4E;%SRBITX6Q,5/DX1=:\NO%]]=]CUK85-3Z64]=
M'FE\9#;*M:A$I-8I#4:KBUZAL_DZ)Y):3$)D:C:A?LA6[EC$C;5V@!-,`9K0
M<W$U$>-3_5J)J(\:EJ_"^4>[8Y$O(='[-JZQ;FL#@_JCQ'R=BVUQ-[&\=B<X
M<,OD].:Y!`QKT93;/YTY4@:V+UB-&<<88\(OIQZTL,T6*W%Q7._YK<:5SM_1
M53OEAC=NG]'WK'N2.D$'*--1FE6)HO-TI.PH]<%R6C/)J;&I)7L'H:0PUFGS
M_$ZE^_MZAS>M'?2I3#U?M*$45L\7.<:C6=6*T\W97,LF`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P.2DD\[OB%B$B?XE)N]:.9I)%GMVC<A9UJV1@5M3XQ."AK=FU2$,>$#1Z
M%P2F%#]NQ!V(._3>]>F\M+3#?W_O#5_R#T+_`+A)/R[BBC^_]X:O^0>A?]PD
MGY=Q135?I+R9_P#KZ=:O5*.MZ=WU;*V^AK#16E#X8ELJTF"OGN9M"UH=8\X6
M-!V-&@CEDIXN]L*1<VIGDA60D5E;&`&M&&A'8N."Q<<&U']_[PU?\@]"_P"X
M23\NY*2C^_\`>&K_`)!Z%_W"2?EW%%']_P"\-7_(/0O^X23\NXHH_O\`WAJ_
MY!Z%_P!PDGY=Q11_?^\-7_(/0O\`N$D_+N**/[_WAJ_Y!Z%_W"2?EW%%']_[
MPU?\@]"_[A)/R[BBC^_]X:O^0>A?]PDGY=Q11_?^\-7_`"#T+_N$D_+N**/[
M_P!X:O\`D'H7_<))^7<44?W_`+PU?\@]"_[A)/R[BBC^_P#>&K_D'H7_`'"2
M?EW%%']_[PU?\@]"_P"X23\NXHH_O_>&K_D'H7_<))^7<44?W_O#5_R#T+_N
M$D_+N**/[_WAJ_Y!Z%_W"2?EW%%(F1YQ/!VGG#C917='.NIX[1=HA*Z5"5R8
MUW,B3$Z/#VUQXI0;'QZ2-9#P_JU(BB=%Z..-T(SW[`7[6I4I9_?^\-7_`"#T
M+_N$D_+N**/[_P!X:O\`D'H7_<))^7<44?W_`+PU?\@]"_[A)/R[BBC^_P#>
M&K_D'H7_`'"2?EW%%']_[PU?\@]"_P"X23\NXHH_O_>&K_D'H7_<))^7<44?
MW_O#5_R#T+_N$D_+N**/[_WAJ_Y!Z%_W"2?EW%%']_[PU?\`(/0O^X23\NXH
MH_O_`'AJ_P"0>A?]PDGY=Q11_?\`O#5_R#T+_N$D_+N**/[_`-X:O^0>A?\`
M<))^7<44?W_O#5_R#T+_`+A)/R[BBC^_]X:O^0>A?]PDGY=Q11_?^\-7_(/0
MO^X23\NXHH_O_>&K_D'H7_<))^7<44?W_O#5_P`@]"_[A)/R[BBC^_\`>&K_
M`)!Z%_W"2?EW%%']_P"\-7_(/0O^X23\NXHH_O\`WAJ_Y!Z%_P!PDGY=Q11_
M?^\-7_(/0O\`N$D_+N**/[_WAJ_Y!Z%_W"2?EW%%']_[PU?\@]"_[A)/R[BB
MC^_]X:O^0>A?]PDGY=Q11_?^\-7_`"#T+_N$D_+N**/[_P!X:O\`D'H7_<))
M^7<44?W_`+PU?\@]"_[A)/R[BBC^_P#>&K_D'H7_`'"2?EW%%']_[PU?\@]"
M_P"X23\NXHH_O_>&K_D'H7_<))^7<44?W_O#5_R#T+_N$D_+N**/[_WAJ_Y!
MZ%_W"2?EW%%']_[PU?\`(/0O^X23\NXHH_O_`'AJ_P"0>A?]PDGY=Q11_?\`
MO#5_R#T+_N$D_+N**/[_`-X:O^0>A?\`<))^7<44?W_O#5_R#T+_`+A)/R[B
MBC^_]X:O^0>A?]PDGY=Q11_?^\-7_(/0O^X23\NXHH_O_>&K_D'H7_<))^7<
M44?W_O#5_P`@]"_[A)/R[BBC^_\`>&K_`)!Z%_W"2?EW%%']_P"\-7_(/0O^
MX23\NXHH_O\`WAJ_Y!Z%_P!PDGY=Q11_?^\-7_(/0O\`N$D_+N**/[_WAJ_Y
M!Z%_W"2?EW%%']_[PU?\@]"_[A)/R[BBC^_]X:O^0>A?]PDGY=Q11_?^\-7_
M`"#T+_N$D_+N**/[_P!X:O\`D'H7_<))^7<44?W_`+PU?\@]"_[A)/R[BBG3
M&D[MJGHZK(==E'S=FLBJ;`;U#K#9O'Q*1L\@;TKBM:5"I")6G2J?C)<FX\D7
MO+!O0R]_LR(M/`8#`8#`8%(JN9N;URI4N6\^TBL6KE*A8M6*JH@:A4K6*CAJ
M%2M4H.81FJ%*D\P0S#![V(8Q;WO>][WO+<CX?RN<S?IUHK^$=?\`Y?Q<A_*Y
MS-^G6BOX1U_^7\7(?RN<S?IUHK^$=?\`Y?Q<A_*YS-^G6BOX1U_^7\7(?RN<
MS?IUHK^$=?\`Y?Q<A_*YS-^G6BOX1U_^7\7(?RN<S?IUHK^$=?\`Y?Q<A_*Y
MS-^G6BOX1U_^7\7(?RN<S?IUHK^$=?\`Y?Q<A_*YS-^G6BOX1U_^7\7(?RN<
MS?IUHK^$=?\`Y?Q<A_*YS-^G6BOX1U_^7\7(?RN<S?IUHK^$=?\`Y?Q<A_*Y
MS-^G6BOX1U_^7\7(?RN<S?IUHK^$=?\`Y?Q<A_*YS-^G6BOX1U_^7\7(?RN<
MS?IUHK^$=?\`Y?Q<A_*YS-^G6BOX1U_^7\7(?RN<S?IUHK^$=?\`Y?Q<A_*Y
MS-^G6BOX1U_^7\7(?RN<S?IUHK^$=?\`Y?Q<A_*YS-^G6BOX1U_^7\7(?RN<
MS?IUHK^$=?\`Y?Q<A_*YS-^G6BOX1U_^7\7(?RN<S?IUHK^$=?\`Y?Q<A_*Y
MS-^G6BOX1U_^7\7(?RN<S?IUHK^$=?\`Y?Q<A_*YS-^G6BOX1U_^7\7(?RN<
MS?IUHK^$=?\`Y?Q<A_*YS-^G6BOX1U_^7\7(?RN<S?IUHK^$=?\`Y?Q<A_*Y
MS-^G6BOX1U_^7\7(?RN<S?IUHK^$=?\`Y?Q<A_*YS-^G6BOX1U_^7\7(?RN<
MS?IUHK^$=?\`Y?Q<A_*YS-^G6BOX1U_^7\7(?RN<S?IUHK^$=?\`Y?Q<A_*Y
MS-^G6BOX1U_^7\7(?RN<S?IUHK^$=?\`Y?Q<A_*YS-^G6BOX1U_^7\7(?RN<
MS?IUHK^$=?\`Y?Q<A_*YS-^G6BOX1U_^7\7(?RN<S?IUHK^$=?\`Y?Q<A_*Y
MS-^G6BOX1U_^7\7(?RN<S?IUHK^$=?\`Y?Q<A_*YS-^G6BOX1U_^7\7(?RN<
MS?IUHK^$=?\`Y?Q<A_*YS-^G6BOX1U_^7\7(?RN<S?IUHK^$=?\`Y?Q<A_*Y
MS-^G6BOX1U_^7\7(?RN<S?IUHK^$=?\`Y?Q<A_*YS-^G6BOX1U_^7\7(?RN<
MS?IUHK^$=?\`Y?Q<A_*YS-^G6BOX1U_^7\7(?RN<S?IUHK^$=?\`Y?Q<A_*Y
MS-^G6BOX1U_^7\7(?RN<S?IUHK^$=?\`Y?Q<A_*YS-^G6BOX1U_^7\7(?RN<
MS?IUHK^$=?\`Y?Q<A_*YS-^G6BOX1U_^7\7(?RN<S?IUHK^$=?\`Y?Q<A_*Y
MS-^G6BOX1U_^7\7(?RN<S?IUHK^$=?\`Y?Q<A_*YS-^G6BOX1U_^7\7(?RN<
MS?IUHK^$=?\`Y?Q<A_*YS-^G6BOX1U_^7\7(?RN<S?IUHK^$=?\`Y?Q<A_*Y
MS-^G6BOX1U_^7\7(?RN<S?IUHK^$=?\`Y?Q<A_*YS-^G6BOX1U_^7\7(?RN<
MS?IUHK^$=?\`Y?Q<BVX]'(]$65!&XHPLL8CS44(AK88\UH65E;2!FF'B)0-;
M:0F0HRA'&B'L)98=;$+>_P#'>\@S6`P&`P&`P/Y6?)3Y+>OJ!ZP[IBE;=O<?
M\S0+D#FJD+OKVG>BZR8Y#(^F)7-H[/GN15W#)$*Q(C+ON2E5#4R,L+8@=3RS
MG9/KV$ZW\F^F.,3$:<6XB)C@I;HGR\]?$7'>I:+N+DK@]OK7CODKHJN^=NAJ
M223Z;6_8=VT,?:,UJB,NID_A\R.7L,I3$M0P(T#DL+,<B`Z*"+6M#L817"]5
MC&*X6W?9^P?)5W=:=7<^\QRVJ>&IG!N#N;^M.KI59]-*;I>T-Q]+,[JX0OG^
M,09[D\=)CT>:"(TM5O+@K,-=4P32TP`A.*'LS-8QK.NJ5$:SKJJ.0^9#JBI^
M4Z"[[MR%QM?4M*W?T/QGY*J8K>/E*W)!<T`D$AKBN;EI62/"S;RCASE9\?0)
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MKJ855>]<H7I(JQD5J5S'X_)MRQ]-MF`+B8TK97!2ZDIUY2D`%!8M@]0CDQC-
MUR2HFZY+SY][=OZR/!BZ=Y29TBPNBD_(/1%QDNS?%B$<2+G-<(;..BRK\)"5
MGIQ-J<V+(]G)MG;"?[1ZWO7O_8G&-^WE94;ZY-4HMUOY1.ZI$HK?C"VZ%HM_
MYIXGX\NRZ9195/!LC70?3'4U,EW`RU2W-XI.Q-]3U80P)0B6NB72MR(4N.@E
M:^,K]EF,<=9X3*U$:SP7"MZ#\E5S]2V3R1%K.I;E"V8AX_.2>E'X*FJTW0T2
M@US32R++CMXQ)M5J)1"5DMC"]'%B$C4J&H#])\7S:`:(8MY*B(OE:5%7RMSE
M-\BODW@GBSH'O6V.U.>8YKK#H7GRMF>0+>4$*.-\S0"13:VHK:\OF1*:P5>[
M.3!;XVWN!02B&DU(6D.+"(>S??K6W'=.,1P:K'=40NT[O3K^1\TU*[<Z^3[E
MKJV>7UY*.?>.6V^(!R)N.0>G6:QH++W:4,C]7+I8ZL<R?]*BFIR+/`O1;+3B
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M=:!MTI(?$DKFVLK.H_%<90UPL-6MBPPU26F<2Q?5`#HG02O\V<8B<JE,:F:E
MHT]>0KHKA"P?&L3Y#>QZ)>*>ZL9NFI];EH`HY-3#''&9CIBHI%2D#(TFELV/
M3NC9/I0O"H<BQE_=0*BBA$$Z*UL6ML3$U&L+43$U&K2VS?-CT)(ZVA5C0'L3
MGZC*:L_RL=A\U1_J274D19->1[ERK*M13NG'D^-$OK`L?ESPO4%)A..E"8Y3
MM<6(>@A!O6[LB^')=L>')_0#XZ+JE=T<F.-K/O8E1=Q*5<LL`$?O*EZ@44O"
M!-T>)2MX8AN&*Y')SE#K&GQ"K^I6;4!THT<$&@:T7[A<YC5B8U?S_P#C>\Q7
M7U^W7P5&9'V;ROU').HY=+X[?O'<%H4^L+>YBA[##)Y)E=EK[+1SER8WD$75
M19`!0A4-R<:\#F$M.`0];,!TRQB+Y-Y8Q%KS=/(AY/7'EVQO,9&)M0:3AV`V
MG,5#-Q"X5,L/L2:<I5W<"VH9/9BKH($F^Y,MRKB&=:^HVTML$R`)*"4/0A;]
M@IMB]O-*B]O-LUUYY5+>I_R1<TU36B*-./%\<(Y_9>WY@YLVC7:(2KNF0R^#
M<M!2OPS=;CI+.\19.YN0=:WHQ&Z%:,_8(&\D8Q./FD8Z>;3GOSRD=8TQU[Y$
M*^A?D!Y!YD8N2(?34GHKG6\J.1SRP>G7J8T4AL=\AT.>6ZPHS,5*Q?+0A:R_
MM[:Y'%'.J<.M`T'6Q:C&)B-)U:C&)B--97:Z]6>6SI"_+6C'-UI43S<KI3@7
MCCJQ^H&YN?EU@F/UJWY"Y[)IC4KO-B9K%)1"$;.\P@;:)1M.M/(V9Z^P(@"W
MN5C$:^*5C$:^+>YS\I*5+X:2?*FDKH"AV7<QLUMH*J&X&_0"M%^TABJ&$&NV
MO:JW'P6<X`1C5:UH_:'6S/30_P!F9V_%M9K6FK+!T;Y0N.[LY9B/<%R4#?T+
M[HC5LQEE#6-+J*I=.8.CH534CNJ,P]`M#*9"7:]8/K7&%[7M8X@3.85B<L[>
M]%"V`=K&8F8Y+43P5_X2>].B>Y'&LY;;'DPY/NR0O-&.%CVMQ)6//S/"[CJE
MS6+FEE3*9).4%E/!X$<4>'-.4J`)F3Z4&+BP;T#7M$)E$1-1!E4:0M#I.]/*
M#/N\NS:1XSO^@ZQAW(_,_/UW-->6]01MC%VQ)K/26JL<(JOGC5-XN^0QO6#K
M@).E12=<(KZK6P@#[-BVB,:B9YD1%:\VE%V^;OJ)]I"S;\I17!Z\93_#WR[V
MS#(W((:BE>H)>=I=9J*3LDIR<EJQ.;(XJS,Z!4E2ICM%A]20J=[T,6PZU&$<
M^-M1C'">-O*U>6/LV)1OOMLB/8O*7D!8J-\<<\ZPA'3'/E*%1.'TY><:DJ5@
MCE-6`F;K!G<&EJJ7M2I0ZITH5I:\!3>,1A82MBWC;&FE:FV-.6J;41Y=;!A_
M//5O4LK\E/+WD$.H+DS5HCYCIOF=?1\FBEI2E\B;!!M2V?CGDC"MC14P=A,2
MTDE(48/:GZ@.R]E:+W)QBZB*)QBZJG0>G(-YQ"37V-VSTCRQ)VBXZ!-ED9N>
M-T(6PJ>2>B`NS`L2UX359L]$/H"K7*/+ER<MR6KVQQ)4I0G&BT'>B3LSMY,Z
M.=<"\@WD\J7ESKGJFXKYHOH)PK#IVQ?'M1E(M7.9=4(I)TN#H:#4-6]N2R?M
M5AO"]/7_`-4]JUZ^/%(_GV1[2PN'OUH>;G'&9B(\+:F,;J%^V%UOY+>!9C-J
M6ZRNFD^F'2YN$NQ.B>;KBKZCPU(IK._^4*M#84EK"3PL$G?FB<5VM:70E8UN
M!NTSB:)&,E2#T,_RYB(RUCQ9B(G507!GE.[,LF]^7X0/J_E?R,-_0O,%N6Y:
ME5\]4_JO)]R1/H+3S=8L/C5B2Z-3Z:QS09?/U@84(IT3MZG;D9[RB`[!L&:R
MQBITK5J8BO!:GA_\D75G7][15GLGK7EVY")/5TTD727)6JD>N9NFN'+:97!#
M]G@L9B\G<G&07W`$AZ@YH=WD\`!)%0"3_ET$T)9F<L8C@F41#=#JZ^>VKG[P
M2>/[ANVJOYK/K;FIMZ?OJ_['J8-W.>P3B<O<!JNJH-`%T@C3$6)W51=Q<'=R
M5*!#*2``!/H)NMZ-D1$1NGQ2(B(N7*FVO,5UX3%>1H+/.EN8N"K*(Z8[TY'[
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MCC)PIFIVBSTK/8,DC<]G,55BE3RI4Q8M,X@;UHG,K8PD%Z`(&[.$>$QJLXQR
MT;\\(6#YAK9<N4NJK>EW-,^Y9ZYA*JQK"Y_C$'-KN8\BPR;P_<XI9?#+.42%
M\=+S=3B%2%ND*5>B2>PY28:FV`!?NUG+;&D<89FN$([R7Y/KJNCRIWGS]-FZ
M.)..9TNO:L^)I6@:"B7>66_Q*X5]'.GT*Z0@-WM[2.;I,G!6WZ]-A+3,ANB]
M>@3!;3C$8WS)B*OFBGEQ\@%T<P=@\T4;%^W:"X.J2S.?[DLN66[?-($W.SN$
MV@LT@C'&8@W(?Q9$%3>J>6N1K3M""IV'T1B_R"%L/HQQN+JY7&+BZM3]9>8C
MI9-6GC@NVY4\!4P>WN;/*;>5[%06,[;4EQQ/B>+@?Z<LBN=O3@Y.];H;08$&
MW838HV><7]P`6;H`0A`&[(UCGH;8UC[$RK+K[RF4RDX!ZUZVLCGFP^<O();]
M*5/*.<:^J1;")/RD=U4@,740\16VC)2\.%I%,3@J0().6[(BM^Y0/:3?^71@
M943<1QA*CASAJES'Y;NV7NZN2%LYZYY%NYLZ7[TM#DF7\-16L6J.=+4_7C!8
MMIPUKNDY]C%@NSR:SQ=H@R1W7#=F%"D-;U@?:8;L>C0ZG&-?L:G&/Y)56/GL
M<IYSYQM"DO1E)NW>=D^1R&4-=]2(8JF`_(^?7KJ:;UZX')HI[M(F5P%5B=E&
M%R+/&8`T_1_M]QFPZ;(N9KX:)QJ9\*;M/GD_NMM\R;5S24WQ??!A<C9^-'^<
M;:`B?">])33+ITHP-`)-\NA`:A0)(FCXD7M]GW93KUW[_3,[8V7S9VQMOFYG
MWYY@.VZYMGN!TAO:_(YTFYJ[AD=#TQXVI)1);WT)T97[5+(.T-2>)2J,6&CF
MP5[^GE"Q,F6E,*DH"AK-&:;H.A:!J,8FM)X<6HQAL!:7F+ZIIWK7R]5))U,&
M/A%!T4^N?$S:*)(2G<N^(_&>>41T,DKDG5B_'`U,QZ;CYX2!>WW)RC`AW[?7
M>Y&$3$2FV*AZY=Y3>^!>(#B:T*L)@,W\DO6,VM2.MK9^"4NHBI9^=G>[9M=#
MVFAR=1](0F;:TI\+:`6A^GUSF2,/H8,.M-L;YCE!MC=Y/Z+.8KWBW4/.E'=&
M0HTHR+W=5<&LUH+)-^72(F81Y`\G-1P_\=*V96J,2'AW^T!Q(@[_`&ZWF)BI
MIF8J:<+?)UY)>P.:;-\B<*H9VA8#>?.'^.;JI1L?8.@?S?WLWAUHZTW)@/!I
MZM*8]-CO&$Q*5,E&(`$R@?S!%[LWCC$Q%\Y:QQB8BT.<_.Q)RV.4=#,L=:EU
M60[Q&R[J214>X-A:"61_M.%]/IN=))5$EDFE`W9H;(].Q#95:4983-%>U9K7
MJ,&MMG+G9M_&W1/B]I\M\3MF.#[)LKG7H"BK3IL<V>WJM*^_<O*><;ITK:%2
M.JV!JW().?;]<N;.YJ2@/"S:1Q)4(=&&["$>BS<SMY,S7)UDS*&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&!S!9?''!WKR$]0]DW9"**N"-VU6O,<2J!DFU=M$
MTFE72*E$MB$R]]2KY:PN"!CU)S90W"3F-9P3Q?0?ZWIL!6:W?#$0U>E0UZZ*
M\/;;U!<'DGGMDR2'I$?7=9<MM/.LO8VQ9JVN<;@YKC,N+8[2;)$H0@&SJTTW
M<FM:1II5`-5(DIR=1L(3/3+&51$1R(RJ(I$W?A+R>P*T*\[`Y\OWD@/7\WY3
MK_F7M5CN.(VL\T+;;[5:UY5P*_(`JB)C--F"=-9D@6[/;%2;3:H*5;)V+00:
M$->-5-T7'">"O4O@M>)=6O*7+=^7$R6URG`I7T#TQV,U%I7^,3KK#LN\%4G7
M().J0H=',,8JNN7>;+W)M2_5FK#%:=&$TO?P_)MOJ;CBN[6XXKOD'C@ZKL+Q
M2Q?Q_P!JWA64ZM.MK%I9-$+J<DLM,12NEJ$Z"@=C03\>HCFP;D79IE80T#,M
M&FTH1GN!0#]G;":;L*,HC+=R3=&ZW5_H6M)-<M&6S54*M&7TC,9_`9-%XG;\
M!5"23&MI*ZM:A.QS-@-`:G&):P.8BE'QZ,*V<``B]&`]WOUB&7".+^'3ICHV
MP+?GOD=LOEQ6YSCA2R>&"'3C^N9E$9/9Z.T'*,N;O?E[O\\4Z.?;$85T.1*V
MIL2A&V)%HS1A,"#U+,Z;HC^WQ:W5PM:U+>/'R%36Y./W_OWI#G&RJD\?HW62
M46ST3`+`C<WNVVBX&YU?";9Z#53)V5L;&YPV)/*I0!MCP3$JAU/$:,?LUH.Y
M,X\KN29CES5=SQXZO*O5?%C_`./"9W#P*[<TJ^:>C**:'Z,P[H`FYRW*UH98
MR6$O3D]NCM^#AHF>;3),-TT4U!&8U$F`(!\^PCW9RQW;M;6\;O6TA7^,;R!T
M$X%2O@KI'G>!2ZZ^,N;>6.J=73$+&?6UFG?-U9!JR']'\^+H:M;5Q4S;HJL4
M)"6I])T@-^G3'&#T/U`7-T3Q2XGBW'YQX#LZC^N7WH"57:9<30X>/KG?CY1)
MYN:[++BFU@TW+)Y(9-;$]7C),:%&YK^+0&BT4H-4!4Z,T/U#H(Q29B8KS)FX
MKS:C2'Q0=,M_BYX8XWKFT*#%?O&_0E37T7+I^SSMSI:6+:LL&?3I*R*V=H2I
M9<J;W(R4)23BQ:3[&`H[6C`>H!9K=&Z9Y2NZ-TS/!F[JXM\JW0=/UDDG=@^.
MF-7ES_VO1'5U-*:VKV_6*HEZ&J8Y/$CRQ6<T.#XYREU=75]D:':8;<>C!I$2
M<$9NC-E[R1.,>-3!$XQXU3<#@SC>\:3LOI_J3K:T:XM3JGK%UK-),3:9B#["
MZ@KRMZ6C;C&JWKV`MLK=WR5KRR/OC@O<7!P/T<K5J_30`A+T(<F8F(B.$,S,
M3I'!RPN7PY]ZVHC[8Y]06]P['^3NU>P+$Z.DLP>*GM&7]75_'K"F<3D2MJ@K
M^<[,T`:Y2U((>G`A4;*'I(J--,`=O>P;!K?&DZW$-;HTG6X=@;(Y!E4P[UXQ
MZO:Y2P%PKF.D.E:KD+`^:<U<WDCE=*>JTT<=VIP+2#;1$M0(&JVX"4&EFF"4
MAV7H7J/TS$Z3'BS>DPLGO3GN2=9<6=2<RP]]9(Q*KXHVQ:LC\ADH%YD?97:9
MQM<RHG)Y`UIU3B)N2'JM#-T048;[-;]H=[_9DB:FR)J;:]37A&5S+I'QEW$X
M2"!+XAQ%5-\P*Q8P[MSDO6S=TM:H('7;"X1(D]"<V%I&9WB9JE1]=LHSX#`?
M'K8]"UJ[M)\UNHF/%SLF/B!Z^C+[&;$Y\LSE1//H!Y1^O>\H4R7!&+)=:QW`
M>CJX%7D>@#^QQ`AJ=39%&DBL\X_Z500C"8$K91HO;L.[NCGX+NC^3LUR]%>L
M&RFY%'>O'#FE5:2U^D93(?RY%Y[$JT3PU>T-I+0!P:K!<W9\%)P.XEPU9I1F
MDXR!$Z`'0]#WO,U>C,U>CAOS-X<^\8BV^/RF+[N'B0GGG@.[HC>L8D-'53:`
M.E[!>J_5RMUCT4D-@S-W2Q]KC;\OE(R7L2)&4-8A+T5LL6_7>]SGCK,7<M3E
M&LQ=RDKUX>NW]U9/?'3&.GJ';O%59%UOU@N:9=`IP?V)%J:F5G&V_,>9(N]E
MN/[JC(FZ2A6H1DR!03]S(;5(P_`+7H3DW1_=_P"1NB[_`/)_MT_^OLU],MW>
MEE71=$N;NF>D[)E,GHEUK6UK7CE(U9#Z^C+!&>/X_856H5+-'K%<JD*BR0]:
MH5MZG19AAFD/MV``MW?55P-U57!9$Z\,TYZ!2]Z2J_[!K(F].H8AQ=)Z1N*M
MVU^!+>>^F^5:.;HDJM*/OSJUMKRW,[S;36!Q)(0&%GJ6,TU,IT$P>3?PB.&I
MNJJ8^5\#^6\%W6;>=5=$\1Q&==.<?\Y<Y]%2N7P&Y)FZ,4ZJ!FGK9*[/I9F:
M%<*9"=/:^P%:YO1O/RE$CT648'02]C,;L:K722\:J;;\N7C,J!?XN]>+8$CD
M2:KR><V^AD<]+*3_`(J3NC2VICF^S/H_ETC$^E3=&6^"2Z,T2(_6RM"T#?NU
M-WQ;F;UMIO7/CT\A]M7#S]8/D%Z+YJGT<XO@-GM//;'0$#L*..-G6]8E9.E0
ME7K?RN;.*U*W/C#"W=5LAH8"Q(=."PP_0]!#HL=O&(TXRMQ6C?KQN\<AXCXW
MYOY^DQ-?OMH4_43#7,RL.$L>D1$J6-A@SE:E,YN#8WR%4WJC_8/T5!"(0P:$
M(.MZUF9FYM)FY:.])\)>1IR[+ZFZ"XYO3DZLH7UMS_2]#S19<\$M2<V5`"*N
M2V*B-E]?-T4>8W$3GKX;%4F)2W,]0G&:27\@`:#OW:B8J(GDL3%:M<[D\#,T
M<*TG]+T=;4!:*_6^+_FO@2!*I^AD@G_<KI'I?]^4EL:9%L:%:B^US1`:?KX4
M@S#BW%0+6P:(UH66,XY^-K&41Q\5V='>(2R9!)^]&GEJP*MJ>A/(;QW(ZJN*
MG'AK?&J/QGJQ"T?A>"]"05IB;,>RMR"00\T3=+$H"R%*XTDE8'9QP?9J1EPO
MC$I&7"^3.L7`_>=[\[W#QIW+,.%T_.]D\SJZ7:9)RC7=QQVZ6.;-!,82U]-W
M!QL21+(PZM\;,9!.)Z4))(CUY1&@;**]^L;HB;B[+B[B[77QSS5Y,8_>,;L[
MN;J^I9A"*CI!32U=U'S*PV%$8?;#XX.3*<OOWH-!.W%<F4V24U1\M.A;VD/V
MYO,6*3"30Z&,LV3,<B9CDJU5XDI#-.(.S>49O;+/'I=T!VM=G8U-6K!VMQ<#
M*CELCN]HO"EG%R:'K3;]X=X=(8^E+=DY8])U1`C0$FZV()@;NUB?"#=K$JR<
M_&GWYU%([)MKO:^.8WFT8YQ+TGR1RU%.=8?94?J^.2KIB""A=@7Y::R<*ETD
M52=Z0H4:3[6U$?0(40COAV(?MT)NB-(NK@N(X<$W@'B9L>C;*Y8LOGJU8E3K
MFFXH;N*^\TL&(=HL&Y449JQ'':VOJK3FUF-(;KQJNQ`*%S<Z.R<!RMI/^F-.
M+V'_`#-U\?'0W7Q1?E_QI]T(^O>6>B^W+RY>LL7$]>6G`:ZM"F:TFL?Z1Z:-
ML6'%5RFDG5$SE2TQ`(QDBH!*Q(&L:Q.I>QB4"'KW"$).4;:B]29BJAL3UMQC
MU[KK^-]X>/NTJ#AUTN5$&<TW56W3T8G3[45EUTVRQ?.8#*4KG6BY),(]/:^D
MCNL^'X]#2KT:G9)NR]!%\J)BMN7`B8JIX*$H7PY2VJK$X5L:P+4@MTR2GK<[
MOZ,[!>Y1$U"4NZ;Q[6AK2TJG2O(J8G=&9CC<+=VE.0G(<#OETWHB1@W\PA`"
MW:3'V$Y:3#H;W[S38O2W$]S<JT#*(=4#S;\5;ZO,DCHB7I&*+UI('UJ0V>F9
MVR-H#C-.SG6XG1`WE:`4G"J5`$8()819F)J;E(FIN7)V:>`Y+5\FFZWBBW'^
M-12ZN"^H.(KHCW25K6Y<*E2TV)"$2/GMY@CH^*9*?&6.J9PE,,5-*?Z5$%L5
M&Z1E!-WL(MQGX^-M1GX^*]HEXC7FL[9H^9UM)Z[CE>3KB$/$/DCJIL1/$?8>
MB&!FK`B)PBW("%L:#D:&U8L]GKTPE[F04:MCZS:<9H#-;]TG*^/CHF[^J+\W
M<$>5>FAT/5DD[6I=9SAQ-7-A1/G=K@$7LF)V)T:NU7SK7U"-79VU;@Z1$4*J
MA$J1J5*6.DJ!.:Q`4<(.C-:%I,XSKSDF8G[5(U%_Z^YG.C!PM;%.7I*5797,
M]T06V+<E5A6O;S_0UC%RS;J1UHTP6K%"QQ9*]66VBDJ_Z18B;4IQA@"OK=[^
M0T6KONXGA2[^4\&['=/%W95G=DT#U[R'*N24;S4]`V_1C_$NL(C9<PC;HEM*
M80.4;>FANKI4UG@6MH82$H(SE8-:T<,/QCT+U#F)BJFTB8JI:I4SX.9K%T7+
MS%;MMUY-(W%F_P`I1_3C-"8V]0AC=G+R4,+.T.<6Y^C0@.B"'0&!!2J0%$KC
M@F;V;\P`>X8BPZG/C]W\EW?Z)#3WC"\@3FY\54?UUU!SY8O&7CXLJ"6E48:Q
MKR<L'0M]/U&-ZIIYU37VMDCJO@4>;ZX(-(4K`L(3Q.ZE&7\V];W\P)NCC'&4
MN.7%NUXVO')".)JK)3S2$T5*.BC;,Z!F#M?$,KMH235SCUN7)/)\P,:J=.K"
MCG"H3-$90D;%!9BC9'_C;++]2=`R997.G`RROAP:A0KQ!63%.*N..<S9I3BB
MR^<?(1$>P)C.4[,_D-DM@L;Z<L&\#X8TKOL_XA#(U49EB9N"-2$*32D@?J+X
MO9O=W1NF>4PNZ+F>5->GO_U\9*^U++K=5=!OJ?R6OO4SIV4TV6CM*X2>56JZ
MBKV_>%%3#J2`I`SJT[16*8B-;==M/W8.M;&`?Q!"7EWQ?_IHWZ_^E<T\\,5C
M2.#]0S>'V35M?]G2#R-2KR!<>WXT,ST<94[@\H($@U5MCNH6A+)WZ#RAJ8GA
ML?6Y)\B!2E<"CM%#,+V#&^-/"C=^%(Q<WA&LJ]^E&#H*867637Z^2:M^QIG&
M6;\8'EOM+-%"4#"["I@2LYI1_<%SS;-!MKBC^H`%"-M"6,[85(/CR;ZBO)(R
MJ*\F'JWP+R>2J.68GUK=JMYJ/DZAKUB<`9^;K-M^FIJIO#H3HR6V9.9VJF$;
M,BSRFB0JH7-D>V@*5^]6H"I$<'9'QA%9SXUQE9S\&V/!O,76_C\=*!XQ9)'#
MK)X]CTQ[6D*-_P#PY,U\T@E*NLFB4OYBA;[.G8Y#'$<OCS_,7UM7I"PKSW='
MHI2GV64C5;U,IC+7GHDS$Z\T0[I\55P=4W#V19$.LRMXPW=(\P<>T9%D,D3R
M@U?'I!SCU8??TF>G[;6VGD#:'Z.G?0H-)AF'A6_M-"`K7NVQRJ((RI7<Y\#D
M2G'7'D:L_=A(H[SMY">4)'5#O7S.0Z#EU6WU-9M$)G+;5BB=1K49VRNTFA*6
M1FD:.*.4/QQWO#HH6AXWZ1'.%W:1'@O*AN7O+JTR9WGW0W8?/CN]U-RU-:/Y
MLK^GXG:;'3]C6Z\(T08ST;UM')&['JGI^:%+"C#]GCX@)DQ:E8)*>7LP0#9,
MX\DT=?X,3,4T*AZ>Q%S"YV`GBT?)G3E%DBQ!&'"8E-*0$G71Q"XF'."-A5O8
M3S$91XQG%IQ`"/>Q:WO,LI3@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@</;X\A
M'=)7=%[\>\C\W<LV(BH6LJ,L&1S"_P#I.34NX.9EVII2-M;&)J:JSFJ9RVW*
M8H>`S>CB]AT,OU_:/6M:VZ6U6EHW<?D][;76AU,V\9<5UM?E0<#&(&'J6732
M\G"O)3.+-001KLBR*JYL9"82\HG]^KN+NI6CECV:C3K5YFDQ(-"]NS$1&E\R
M(C2T+EGE[ZCMRUVJ-\!<UT%<=:+.#*2[R52R_;_?:/>@0>Y7*:H4L92I6ZOY
MJQ:?6441V4I^I5IR"5`AZ&9H(=;W=M<?$VZ7YNA])=?VMU[XZJR[&Y6IV+J[
M:N:L(S.8'35QSQ;$8D0]+7U*U2=D?[$8(R_K`M36F3.)R!>G:QZ<0E)Q?$4$
M_?LS,5-),5-.4D6\RW>*;D/H#LZU^/.;(O5E-VL&A6PB+]$S612![MMAZSA'
M,\]2NC:NJMH3MD-:"GAX<D3D!0::J&A3@&04`\8RM;8W4UMBZ;2=L^7EPYBL
M+K:(UW7M>VXS<U>.U-VNA?T]AGAU(I<==BRJS:S=0L36[I6AN*:R"U_U@#35
M7R&:!LC0-Z'M&%Q]Z1C?XMA^$.E^V[\E#YKI.I..X!`00!MDT;<^=.I7:]9B
M9('=<V"0M4JBZ^NH<7'FDQD/5&;5?4&BTJ("4$`M"V,.9BDF*5QT[Y6&_G7R
M2<K<+_NT!)87<R&.IKEN8#TH3DTC+[D<IK&.:8RM:RV\Y$J46M,*]<DG_D*4
MXBBME&%Z'Z^F[&-XS*QC<6J2P/-(@KWK'R>\C/-8L::=\2\N/'2M%+EDI7IT
M'0)4+H-MN.PX8[;$S^D:>HR=(&[T`B$O-.:3#E6P!V0((KLTB?&3;I$\I86`
M^;E&]]9O/*$XJIDB<C>?'U7?8]/OJ>3NBQ!.;`?J6471,J56_,R$@;U+5&TR
MA6W*0#&<K0MJL8B0C"$.VR:OE9MTM>7&?DWF'4=@U["WFI8U$$\U\6W._D(4
M+VR5.CL<@E-VR28L;C69)"IF1`/8(^5&`&$N0A!4'B.%H1`-!UO<G&H^^DF*
M_%K#;7G%EU:>*?DKOINYV:IO=/5#B'3+SM'Y<[G$)(_%VZPYS;<B;G_4?$ZN
M#?`:MK-P<C!B1%Z^8981^@-[WN[+RG'E#6WXJ=%W7NY"JZHX*H^!1EJE=;]O
MT->=[-%F#>U"5>Q,=81:K)9$P-K&2@4HW=/,&ZR="-,&J)VFT0'8=&>_?MFW
M29\&:TF?!/\`R%]02#BWB_H'J**0MML624Y#"9(RP=X=E3$VR5P4O[,QD-JM
MW1(G!4A`8)V]VA@),W[@ZUZ>F_74B+FB(N:<H([YU7N97#XCZIC%"L:@SR&0
M1+*KJ7JIBZ@-Y[>%3I)8@&-M!!;!L,H5;G]=2AOUM6)"+86@6_;[O?H.MG&?
M!K;Q\DKX%\F_>7:CG5T\4<[<5PSGF=S2PF9U6(^N']SZ%:8U7<GF<3='1%2R
MJKT@5KP<OB`SRTHG(`!(C-';&$/^$G&II)BIIB^&/)GY&^UXW6]H,/,G"K!5
MUH,-D.L>;]]ER8ZYRE<413=MC:-TK`RHM'(@.TUC*8I<+2LT2-J4&*PA,V7H
MK:<8B:)B(FD5A_E6\E0=][NEI<7\IQN+^.Z&6.NO);%.FI[(W57.F'FY1?L#
M8X8W+*=:B7Z/R'[@THG%::<D-0A4GC+*/$3H)EVQIYFV-/-,:\\Y::0](6=S
M1-:E88G+FSQX5YVO33B3*G98V61,GCGA+?D_II88:PDZ;%D=95NU"%04(TY6
MUH%AXR@#+"#;9I?FNW^K/%>4_KJ_`\UU=PWRI4UG=$6-Q%2O<70&K>N-ZKZE
MZ/B%WLY:F!UTVR%IB+Y)YC/9J[)'$+>':1(G3($85*G?M,%HIMB.,\TVQ'%T
M[H+I:2SCDAIZ5Z,I69\I21G@\QEEPU)8`BW!]K8==FOI<L.+<$9)`'^.*4<>
M-<FI:`DH2UL4$&[*+&/8`YF-:A)C6H<GZB\O/7#H/EGHCH#BB%U+X_\`MRUH
M'4]&V6SW4=);ZKY1=*XUOH";7M6JF*-<;;(E;*K:4&_M3FH.9-N!&U.S/4(3
M-;8X1QA:CA'%9/&'D)[YZ^MQW.;.9>4XWS#&.F[[H21S-1TO*17J2U45/Y7`
M763ME0G5>!M7K%ZU@*."1]W"#1)HA>_6@ZWN3%$Q2;^0WR/7?SATA2_)'-%7
M\_S"XK4J&?WD6Z=0WF=1$!?V&"2%GBY%4U>Y)(\_JIK=4N='78DR#_0(1I"]
M'G;$6/>RT8Q,7)$7%J>Z<\DWDCJ6.\A3Z#<%5$UQGK214+2J.%7_`'U*:^M^
MM.G+E_$I*RN9I&X]6$F:"H9'%D=%H#\4K$:I(-`;M$6(6R@(QB;\H(B)9.6>
M1/R/2FU)?SMS#Q)0]JWARW457SWMO4EZ)?HO6T>LVU8^MF,:YZH*2%5TJ=)U
M-5D/1:7;=75&VMJ;:DHHX`1;T(2(BKGF5%7+SF>8*U>EH_R-%?'%S=&K6OWI
M_G^8]-R>-="6*MJ^`\^5G7,R!5<L:Y\_1F.RAX?)LLN0I9&6U,A3%DF'(#E1
MHP$:UK+MJ]W"#;5WR>R2^9YSI#?*3MV/SNY<DL5K\\=AW'T$RV3(#3IO4,BY
M1=H:P)8S"&U.V)4=D-MO.<GT9&C@B2*G).I1?$1LP_80MM\-3;?!,:^\F?0*
M=]\<B'I3G6!\^@\@\WZ'.3QY^LA>.5TE4U;5&=:%5*IZ8O8VYB'9\Y)`4!V:
M@'%)VC2HLG1IJD!I09MXUR*XUR5_+?,G-R6&Z8[5?/\`&;8OH7DLDOCEY+K]
MILO;9%;;>F&M8Q9Z^V+!FIS*J3PR'Q6+.:]:[_1E+_0I(464/8CA#*NW^EFW
M^B-R?S$=$4/7?5L.ZEY;KN$]A\IK^49`L@T$MEYE%*7!2O55X1REV&U:\FZZ
M'M\H0_A1Z<5Z9Q:U[=HXM<E*#\GQGBV2VQ/#@1C$UX-^O)+U]<G(<`Y^4T#5
M$"N&U^B>JJOYAB$7LJ<O%=Q!*[68R39R1/3K)V*-2Q>D)1JXH66+041NOC.$
M+]NPZUO,1=_8D1?X.<]D^:+HZI:2Z!:;(Y)K>"]O\V])\I4+-JA=;R4N=%/L
M>[">$J&HK=CEQH(80[$1)<G$KTM+5LX#FXY`;H[U]?:'6R^'"EV_@F%J>2_R
M`T7SHLL^R.;.*WFS95U!S;S53L4J3KB26)`WAVO:0.T8<'.QIF35+8M@VX^Y
M[;!$``B6;4)U)Q@]`^$.C)&-D1:(23S77O1-<=ZMG4?*=913HWBUOY@="6.K
M^@#9O0LK;.N)J.O*[>9C:SK`H^Y5@U0Q_+$KD@EK8:,AJ#\Y6OVZ];&-UYD8
MW7FZ,>/OJ+I[HA!:S3TY1-;5ZZP!SB!\#N;GFTQW/S#T-#YHRJG0#Y4D]6-+
M&[G.,+7(1M[XD5)]?"H,)$6,83-A!,HB.!,1'!INH[Q\I97?FN*-<;\B!3F0
MA3T$7-SNI)Z!0#F%-=153#EI[=JF1)P63HD\*S;%HT2;0O4/UGIK%1MW>945
M:IQ>:3IS\&*^Z0<8Q$?B;1W.=5AEW?OA5AZ5.K]/:>Z8/Z=3T\*):C!E3ESD
M.Q?;-N^GK;;K:G_X:WFMD?VW\1MY?^3H7Y,.U+7XWK_G9RHNMJQM6PNBNGH%
MSE&VVV;'<:OK]J/G,/GTF3R1YFC1'94<@1)C88`K8MI!@]BC8O7UUK6\Q%W]
MB1%N<LF\U_2,0YZN]Z?^6Z13=,T9VKSMQT[LC/T.MD_,,I<NCD,;=(W+&*]&
M^")EJ0$632@@M^1J&K9K29KU-WZB^,-V?T7;_1U=X?N?K.Y&:Q%_4]<\P5^J
M87AC;X5_++T(X]`-;L0H1+U#_P#BQP<(1"MQIP0&A2?3$!`>)04<,0O9[`^_
M,I+029>91SBG('7O1&ZWK8RPN;>[Y9R'&ZI564>F4SB,QOHR!4D5/U>]M.WQ
M`YJF:7'N@D9"100$Q)HO1VR]B,#K9K$<J7;K$>3!H/)KWG:'4'3=.T/SMQ2L
MK?F_J%1SBND=T==/]6V;)SD3/#I`I?62OBZN?R%_S-LN++3`*6^T]66(H/[0
M[WDJHLJG2KC7J]WZD=.OV]UA;=#@\Q]EVURRU&M[TI>!2]IK9C@SNFF+@!2W
M-^FAP=ARX8#$9>SRRM$!WHT7NWK4F*KSA)BJ^QR6I+S.]9O+?2U^WYQO540X
M;O3J=WY-:+NK:^G646-7DU/N6445")38U5/]?,11<,D%@QL*-2>WNBDU&%66
M=L(M>A0];.,<Z7;^+I3Y`^UI]RT'GVJ*`IYOOOJWK:S'6L:&K>12T<#@J?\`
M"<673BQ;%L>8$M3VL:(/7T50_4*PI4IRQ4:>245K6Q;$&1%Z\H2(MS-NCSB7
MIR[SOU6Z=%<E11CZ[XMMGF6*VS4,$M%QEE:6)5'3CW]/"+;IJ:#BZ*1K2U[8
MW.9&FMP;2STCJBT0>9KY?0%C"YTX2L8W]CICSAWZQ]-=63>F:[9V1WIY#QUS
M#UK7-LH7=2<XS-GZ.?;0;TC6J8Q)-(VU,T-T!(-T,*@P[9ZDPHP`-E?MS.,Q
MQ28J$PZSZZ>^;[IX0JMJA35*4?8/2#I1;V\.#PK;5,(;VZHY_989"U)$R)44
M\+35,+`EV0<,@&BSQ#]_J'6MHBXF?`B+:907RN3>7<<>/SI\^FHJA>>S^ZH1
MR)((B3,'<YL@;#++KMFJ3YLS.PV(M4^NZ)%7!*P"(\A,2,U4,O9N@@"(6MNL
MQX0NW68\&OD`\]A<^J3JY\1TY'4%T\K]]U=R>^UNLE[H!LD=26_T^S\\Q"\6
MIV$R`7C&,W;OI0B`G,3D.K5\`C]`/`+39.GG!M3N`^3'O2Z^D;ZK:G^=^*/W
M145V;.N4W&0VEUT_P&XI`EK^1L2%WE3%5NJN=B7)6N9'TLQ"G+</C5+@#("+
M7M]VY.-?@3#HEV_?_4]+ME7,'(_,*#HFQ[*D,H3.KU/)NLK&CZ?B,)B#C+WB
M46K8#;&Y:O9S9$-$4TL28M#O2UR4?YS2P%"]\B(YI#D[*?.W9DR:>$B^:>=J
M)<)QV/S:X]`KXGT_UM%><4,34)[&:*J:X!"I2^1AS;K1DLEF`G/[40B`2J<4
M"'2DHCVB&$&]D:W>D\FMD:WR?TAHAJC$:0Q:06F6F)B!JTQ1OSE)U0R@B4$%
MG^T'S%E&[V'0_37NUKU]-9S8<"%/F5NRGI].3.P^*E]`5`Z\\]D]*4)O=CB>
M+T=(-Q<K2@DR2[ZN715I1UFX6NT.21?&C4KBYI@A6$$*!;&9[P[V^$M;;X(]
M'O-+>B*I[78;2Y)AT6[58;.XIK6H:0C]U*7ZLI^H\A"4"_G]TD%F*X,UO$8(
MBJ=`\%RX)3.L^F.93-)!&A4%[`V>'#7^1M_!BGWS;WT[5S!&:H..X?,>K6)!
MVW(.GJBDEY&Q:!UDQ>/F;,T#NY+7]@EP-S63U_GCQ(V\<2*4-S<3\"GWKAE:
M!ZB;/&=-/YFWQ=U>>[KB725#TUT'`M*@PN[:P@UJ1<I>$`'!,R3N-MTE;T3@
M`L0BP."$AQT2?H.]AT:`6M;WKTWF9BIJ4F*FI7#D0P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P.%3_P"*"LNC/*CUAT]U[S17UL5&Y5%R,U\TRZ7N3<[+6J?UQJPS
M;,&VL#8]%/C":B4GL>_G6IP$J_8'X=CT`S-[JQB(:W?#$0INP:8\G7(EK>1*
M"<?<O0+IVI_(58S[=]96R^7I$*J#S);MH5JQ5U9Q%O0Z3)#WV;PMM<(X0]M@
MV#YE!Q6MI1AT89_I(G&:N:I8G&:ODU3DO_KK_O1=7*E[/9FMTA-2^)CF7F+F
MWI'[\CVI8.LJJEUF/LKDH(*2X_=SXBXJWQ$-:E=FX]N7,ZLQ)KW&A'L.HSKA
MXKO_`*OZ,>$R+L0<AT"P]&5#$Z*NN)5VRPJP*S@"J(*J_97F&EBC0%T$!!%:
MN,-L.D:%K)<F]O3[+^VIE84@RP#)V'.<\=&)XN)\W\</5<F\/'5O()E7-+C<
M-N=WV=;[#!5,XA.FU_J&7^0!JNLIR62$Q\U'4?W*I"SUAB$]26KUO_QA%Z4;
MT7FHRC=$M1E&Z)5?UWX57Z+3#R`,OC\Y7K*LJFZ'\5A-#0YC@CW!X"T2OIP[
MH,<K7(%[0Z/:`UK.,KY`B$)U5!);Q!)`3\WR!]N:C/ANG6UC+A?BWS\55!OE
M$3F7-Y_AMJKQS)7>KF5%(KHKR]Z/LI=:L@CCHV$(HF\1BL6E$]HP*`N"]U"M
M4FF$%C)$6+U,-#O,Y3?.V9^VW/3IOP_=_P#6"[R1=*CO=_I&V+7O:/SCG/F5
M$UTM)8I8T?XK2M9W%3W+;9.V[2:M'1_DK<M7B2MSFW@;C'00EX1"&>#6HSQB
MH6,HBH>'LKQ.=D]=PKR+W2U5V@J3JRQ)/S7<G+!()[`59STZG<.1/G;K*C7E
M_1/ZUH9XM+T[F_QX0G$XM`M4)$2P(]I]:.U(RB*CC!&41]C,6QX>>H;=B/4K
MFBCK;7=W1_D?QH*>,+%)F<4/6(.F^4:6MB%6Q!CST3DL&SQR5MLS-BJY2M"6
MUKTSMH\(S2DXMZ1G$5X7)&41/EJE\%Y;\D?$2CE&X:4Y`CW34C5>(VD^`[FJ
M0B_ZXK)]INX:B=W>3,<M,D4E-516:P`]3+E2%=IJ5G*0B2?,7O8-@^1>,W$S
M479>,_BBU=^&OMQ^*X"HF27FNYMK3A;@:50@5QULS5+:HI[TITRZN<?Z"@K+
M!K)3/P$T.C]3^C6%]6-2<Y3]<8%&(&A&[U=\:SSF3=&L\YEY*<Y(\H/(AOC2
M>6/DLCJEU\>;#WYS$6D)Z+IVJSY]15A2.MD/,MF)WJ4N[P4VF*J\CVTJEH&E
MVL1";=`."5[R]C7C-W-67$WRMUG[>KWJ7M;Q0W17H>?2JHZDMZOTJ(KG]=;,
M$F)4;?VNS&A:0UG6P@,98*Z:61QC"X?.`1)1?S:(WZF`WZXQF,<O)(J,O)R#
MICP]]:57VSNXSXDW.U8P7RJPRP:;.%-H7H</X<;XEUU93PX(FS[SIQ(^*]>F
M1I?L^R].@Q%B."1M,`)F;WQ.-<Z:W:?<R7BTX+N[DV9TD@M7PGU&FN&-V/;.
MY/Y%TO2//"^P6)@LF5V,H3S<$*;$SG.G,UH@,M)8Q(2%^U)J4.]:V`.]@"RR
MB>?W)E,3K;)^(CA>Z^/9+S8SVOX3ZCBMP0I9.66P/(DV=(<\NT_2():=.!GR
MX<+84CE.'8:J-OA#"8E)7F'[3#V+8M%AV#4SF)ULRF)UMNS(>)^D5\._]@)I
M2P9"8O[H`^ZYC)W+HJ`,^VMXGB=.IOKS1NVBX=\EA-9Z+?W?:/T`#Y]_Z.]#
MW-T?#Y)<:>3GY:7ALZMM:J^L%Z&,MM>]#1_F[QK.'&,X(FT/./,O?FSE>:4Y
M?E<+EB1Q6@9HS-FN4K8HL/7_``MB\M>4J",TA/L6KOC3PU:W1?WRGI_!7:7-
MD=K"60SDE)UO#[]\6W+_``EVAS1&^FF'GFSX#87/$44LT=F,#N+Z\AH61A8V
MREP9W0;2Z%.*8Q.6M2&&`WZ:NZ)GC6MPEQ//FZ,>.'@ZW*D\7<BXZZ?7)F2:
M6TBZ60R)I8K`?[=%6,.O]\F8V&#%6#*A`<IFY5[$I,0B&K$8(D\Y-O8#3`[^
M06<LHG*X29^*X<^X#RMY2+@JK@WQQ=#\V5Q6M#\57-SO+[9[+9+TBTI9^@*S
MX_?43Y4;#550MJ$N?Q*56,?%V<+P8]!*(;-$GC#O>S0%:MXQ>4<96\=9YRW!
M\7/BFK7GM_L;IN^^:J^C_:;EUIV5/8G<!3@V2*:`J>WK8GJB"F%O4?>W%J3$
MNU924).TAH=*DI)XBS@%F^[6LSE,Z<DF;^QC_+GSIT!>L[KY)_;[H_R9\G*Z
MME,;=:1E$T@5+W73=^JGY.H8;CA%S3(:)>AA3]%A!:G1"T*TZY.:E"J_U=>T
M&KC7C4F-<]$89.!>O8_P/X=*"EQR&T+BY'[0Y0N"^W/\=)EZ6*5A6[S8SF]I
M&Z32Y6@7S<-7QV2MC&1HC1JQQ+0Z,(+&'_!NBYGE,%Q<^%,Q:U<^1+B_MWL;
MH#C3E2'=D5KWC&J??3VE?>,/I9_H7H.HH`95B5VE89N7LB85+*HZG0+E'VL8
MG),H3&E!`'0@",7C,1$S5+<3%3R:RTWX^>YO&"KXUO[GJHHGW!8L3Y"LSE_K
M:H&>THY2SDOE-FWVZ]2(K)JN86*1N.K8_&K1EKJT*TJH"96<T;3J"BA&?(`N
M[HRTG2"XRTG2$DM/Q=],^0&T_&V_^3^OZXM9GKVFNXQ]/`KU^9X_$*ZGMS*X
MF+GN$L[4E<D;M.UM<Q\H9`G=&E,0G/+.6L.#L(B]FHRC&)KB1E432$Q?QG]:
M=!H?%W0_D(H>%WO4W"ER]:UI:<RF<Q@DI8+NYZ!3FXMRK<+I%@R$^0*I"[KT
MC8B<&XY/]S2+VSZU27HLWWZ1E5S$ZR7&M<989F\4?4G.;/,;(Y1HJM&.2\L^
M7^R.R.3>=3)W&8C";AY8GU!1&CY1`&1^1&.[75TB=&<Q>8SZ>`$!2*47^N6$
M!Q>]MT3QYP7$\?!Y^D>'_(QVE#>\.M)YS-'ZJOBXX3Q-1O-G((;PKV32-OJG
MFOJ6+]$SZ26/;28]NK1#))P]`5[0I2#S=(DB7V&>\X8-#1.,5%Z$3$3$<FSG
M69_D\ZRKWGB:F>,G]VUB\F]]\V]'L53J^S*#E)EQ02$1BW"IGM).$1#4P094
MQNCJUI@@6`5G*ON'R%%"`0;DC;'/C!%1SXPU(ZA\=G?G5M7]F=&6=RC7AEV]
M3=,^/=W0<1)+S@DC0HN9^*Y$H7/T>GER.Q;#73E)K3)D;P)64E+/3I4AA)8=
M&CV87K491%1>D61E$:?:E<W\=MBWURTGYYB/AVJ;@R%&]X\56Y9M:1"_Z0FD
M?NRH8I-'+5XOSL97OX6)9U$+@R0I/I&(P:]T+</8B#L9(M;FZ(F[O0N(F[O1
M,XCXX.ON*H7Y&^9N+>?>=IWSU:4ZK7H?G0FX$-=O39;,7>'E`DZ$X4NHZ6*G
M.7K4B2.$*RX)*7TAR1MR-7I.<I+%K>RFZ)J9XI=S$SQ;"^&SBZW>;;;[(MER
MY1:_'OS[>G[FR:LXG9KH:+J2QN;0ANEI5FW"8LBRM;"H1N?FOB!(0U-@]:V0
MVZ,-+*T$D.YE,3$1QDRF*J-6Z"SG>TU?EM*Z?-C28=$#\;[ESRIE7WUG"KW:
M2SI5%8.HWJ.:6ZD7TXX<4-3]=I/]'H7^E\OR^@<EQMKG:?\`C7.W%,7#?E!*
MXR7>$@GGBN3.85=GJXP1Y"=W7%0MB?C]?=PK>/;3J%^#5C&7L!E.&P:+UO[3
MLP6C_G^/7S;U>-[[U\&KB]W-TJ\T7)5G]/4CRA%JHYHC_7#-378E76U9W/DK
MGT*KQEL.I8C7EHQUZC[A)+`4%,7Q+5\C0E"+$6I,%H>Q?$((1;U,)J?#1,9B
M)^YQODWBE[+>^8.GH_$.`JYJ2J+,[;X<NZK_`!A,_25?RR#M$&HD9@^DWE9/
M7$QOJ^-&]!D:2$*6Q%H8``1>X9`]^GOU&6-\===6MT7_`*N\_B\JQPJ&*V[&
M-^+BN_&(Q+I-&W]OC%<W!4UK-MMNJMJ7-[Q(5Q=5-;8FCBR,)6I$EUI9H0E1
M:G7Q>FBA^N,OMMB?MMQDM3P:/T\YG[AG"GD:JWOO:Q/)1.KKH:SEK[`]3L7/
M3SU7`)TV.":=G/H&V/E'580]C^UJSBEH`FC($5HXT(=[]36-?AIK=K'A20E\
M&7;7?<_8=VS;PG5%W`?:':YM\T5TQ*>D>>(-+(%!RF:O4D?):F"8)GR5H#8U
M)HTL>22]B2F[//\`316A>@A2XG&(NM/`F8F(B^3=3EAN\BO)72W7L(1^/C5I
M41TUY$[&OQOZ)1]74I$`1.J[3W7L952%34[B6Z3)W419HBY[F)$$U,L6:WI.
M`L!GH+<G;,1KK$)-3''6FDE,<->2F<T+0?CHMCE&(4KSS6?=BWJ"T>IG7HVN
MYFY3:MXKU9,>G(U"8#3L(2.\B:)5+G%<V-XE3BN"F1$`-,,UH0M%@U,XWNB=
M::F8N_)UN\E?/_2LDL7B?LGD>%1RW[GXAM.Q7U90LFF#;795RU'>%=J*UM&-
MQJ>/9"EAC,\;41:-<TFN`0HAC),"8+UV`!F,9BIB>$L1.E3S<RYIP;WQU([7
MUUU<-"1*K+<Z$ZT\8@XUS"5:T*FZNK>4^*KN13J7OM@STE0WP>2S24@D+PY'
M-;:8?[$Q!:4KY3C-EZUNQC2.%2U<1I'FV7\8/C6NSA+R!]YOZT@A9QY,X-6$
M:X\<]R-F7*XE!]V';%L/]+:CP%QTF:&:K);:+BE;3596DYS>:3HDP7M$`N99
M1EC'BF65Q'B_$QI3R7=$>1#G5#>]05PU\R<<]G6[T[6W448GL93E3FEY#2\M
MKZH*5'3Y2E;.4]I1]XFIX7YY5_`V'DI?E(UKW%A,7C&.G&8+B(TXTU.H_B/R
M0-"7B+@*<\UP>/\`.7$'D0-Z[%VLGO&(NS/:54PNT[:MFOHHP4TD(U8K/8,A
M<+&*;U_UI9:)'I+LSWB"/0LLS&N43K,+,QQCC,*4M;PI]?OE=4%95=P]JCM^
M1?R+W(]WQ"B9S"DZ.V.))SY`5W5U?O;N]C?-L"U[K%T9&Y^;4`C0NI13DL3:
M#\VM)]V,XX3PI8RCARI;==\(W747:?3%O3KPEU'UL_S[R(V+T;378;_TESQ$
MIK`:VD4TC+G!5[5&)(E>IBE4P!0TJ7U.G^5.IV>HV6$HLW]NY<3$:\DNXX\G
M2WS10SO>X*-KZA>*ZA=K,A=L34YOZZ416[8!1$]-Y^:R$1KY5D%G4Y4[W&W2
MYQ+#&Q:[HD:T]N:2%1>@:&J`+6<=O-,:YN?O:G''6/0G/D(IN#^(GD^,_O;X
M?0<J1Y[5VI63Q:7COEK'/G(J-:4V:LT4FGM)1"&B22)G_!2'3\3(B3"CM#T:
M$S-1,1-W/'\5B8B>+NORE;,UFBJ^ZKED1-1$<M69':%C]BZER*6&W<D:*7J^
M8N-@K0I$:9+%9">]3!0B7LPU2T]"H3;^<[1@Q`!B?'Q9E_/8P\:>2SK*5>2`
M/9O&B&%63V[SY?=`55TXX=3U3+(3S'2>F):IHCGN#TA#BGN0IFB430M,Y3)^
M+7"4.CGOZDXK0""RM[O&*J>#5XQK$ODE\?OD*LQBL[L::\U1ROND81=WBNG=
M4\L'79!'Y=9D<\<3>\H+$#NS&<\Z`Q=5<2BP'LR-`6GAVE*0IM+OAV=O>KNQ
MC2]-?YK>/#EJCMK>-+L=SYEC;VNX?:;7Z`OJ_P#R*W;.XU"^PE=%SWEM?VH[
MI1P2OW^Q(G)XW$[IH@Y@;495G,11RT#@>B(TA(/!HP0FZ+XZ5!&47QT?TQ<8
M4(HY9Y'YHYN6NZ=_<:-HVL:N=GU&`9:%Y>89$&EC>71`4:62:4@7NB,XT@`@
M!$`H0=;UK>MYSF;FV)FYMLQD0P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P/P``"_=[``![AB&+V!T'W#'OU$,7IK7J,6_P#'?^.\#]X#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8',?HGICJNF;FL9E9F?GQXJ6%<QW%
MU`C^YHK+!8RU@J%&Q(5<.4GH'<4>"\/DB?`F%+"DXBR416R]D#-%H>M1$3'.
M[:B(F&84^4/G6.-T<%8;=8U<R->Y+T,OB<RC36P/U<-32EK)6OG$L0KI($0X
M68DN*.*$XFP3FYF)W$0MHM;1.(4;;)MEMI;G0%=TD(()TH>"-CKBW+4U]K:%
M+I_^B5)LC1()T;_H;U_YY#<]D;2I_P#YJA[$$/[0[R1%I5M=M>1*E#'A_CZ6
M'W2K>4<D<(A!D!=>?`9<\D8[66TO*&RIS%SRD3O7X4GB`PI>H<!MB0M%K:TL
MTQ(`PX%VR5*FZ^\M//ZZ#QAXM$#Y$)4MJU=8LL:VEF,<$L;=TM=2NY"*R^T*
MEY,Z56*MJB)*'8*,MK-2@,V!&8J+7'$IAML\EVRM`OR(5:[*),UIX]8,`<J_
MD51,]C*;2A0T+="%=B3&JVA?$94GC3^\/$3F"2/VFA4IC7(A.U*/<<<F4+24
M#AHAME*8%1Y2:#3-*ER.K[HD*M*@!)1Q_=2J`OHJ[,KE5;H;0`0-Z"BW"=5F
MC,=1;VHTY!$':#:/3K_X&-LFV4E,\EO,YLMED%9%<NE<I8WPV+Q-FC#2S.:^
MW)0@L!AJR0L%:(]R,A8I61:?25(A7&O!;,D"6(Q82<<@3J%13;)MDUV@_?R*
M-O8(JZ4B=UJIC$.N"T3UMZ"C=KL0UD-K+:!E!>?Q<6TJ]F!0""'?W/7P"WH'
MJ+%:T5K3X_W,N:4TAB<5?39M%)`_G'MLB:),R,[8XUE)=S^=56SQ.?-_XC.7
M`?9-8M;O#4A^SEO"/9B<L\\\E&J2J3FV2I5G*/++0J>$O#E&62<H)LIIR065
M#8Y8S`CBH5#\?5,ZN"K89*&HE_63!L=+1@D&,=T($[>HT0A5)BE@TC@J3HS&
MV5VRNR,>0*F'@C:&0L-H06<(R6\EUKR6P56WRU*^.DCIZ,M4?(0I5K@E6.ST
M??L06I"BE`]B;WPDPS99A2DHAME*6MT%U)7O-8H<;8;3-CVF7.B=O.D<>84R
MV.Q-.ID,9BY3E)W1Q=&DKT->9:C"4WMVG%[4D:/4$(34Z14:3(BR(MK3+?)3
M6;!)JN*)BD[1P2Q;'D5=Q^5R.'.S?JW'(#!.00(GGK28U4GL1UGE@0L;2D;S
M1(W#:<\I>-.6WJ$RPV[5VIEKR)TN:[2./(X7=B^2(),MAT'CZ:OR2W"Z9(S6
M;)ZBDR"IC%K\D;G<F*3:'N!;@K<CVI$4A(VO`<8AW]1DVRE/,V>3'E-V$P$I
M)%+M+Y.W2Y>RM*B$/B9W5&PN-51)G5G&W'%`5)'Y45<C2B1)#@EG*W(I<F+U
MLQ$?H-VR;95O!O*QS^?&XP&T%2N,S=36+7+Y8DCB4I]CR&>+*O(N`VHHZ#3E
M^,7V<*8$H+7HBP-FT*G9I:4*OZ\7TN-L\EVRR4+\ET(5JI`@L:L+6A[BTW(X
MUTY-R6%G.2JL8XLLR.4Y`I/=`B'90DC0)I8ST<B3FMIKJDVE1'+]C"WEC58V
M^!M>QO\`*SRN](DA\='/I(Y/$HCS'%XVQ,3"OD<P8Y9'II*XQ.HVWAE00+&*
M1,%=O)R%L-,)E:PU#M,2SF*S2"#6V3;+:Z]NC()SVA@2Z:MTQ<PV)+S8@RD1
M*.F/1[>)OB4EGTDDDC^52@(88E$(/#G-T<UIXPZ)3I!```P\91)DB+2(MK;#
MO)CSY8:1N_`3#;DWD:]S_P!6!0R$I9?.6N$;C$9F>K6<V.,O[L$J""C$R:S]
M%EFFOWU"P*'[;]Q+.1E7;)ME'3_*5S6X:=5\=D+@:S0]P?G>0G'1T]]7R^LF
M"!7U*#YI6S?$G9V<!D+'2AG8A,!W3H59P$X=:2:TO;CCVV3;*UZP[39+9O=@
MI-BJRS(\K40"T)3-5<Y:$4==ZXDE>O%/EMT/E#$%Q7^ATPB5PMSVB5)5"DG:
M10G`+VFB/`G3%192N>FO(E$*7C]Z-\(@TWFUA5DQS!JB:PV,F:J^8W#%8BRS
M-UK!%)2W=$K7/\4BLB)>7,C0$I)R!&N(2*S%R1202C&_L(A,NM^MY5RI6T#?
MCJV5V%*99$[<<'10TD&M,<C3U4W.=C7:J5NS3MR>'HED>'2`_0_3IU*U4F(/
M&((U!A00FR(LB+1E=Y..<X\9'6V=(K%KV2N,@<6&6Q6:QQHC[_6*=M>8$P[E
M$X0JY+__`"PXKK/81I1M`W9:8E7B/$F`6C<!)+MDVRG/3O6RWFZY.6X<Y0Y,
M[UC=3]/&>TI[MR$D5U"ULX(4QQ":*41@0HUL356%/FMM>CS#2OM:-;]>+>R$
MQ_I(BXGQ(BU`C\HT.9Z.43]\K::.D[;:==9DX-T7:3A5H*W4M.2"\V>@RYXY
M'@/23I_KMAVYE[&C,1$)SRBS%&EIQ"0V[=?)=NODM=G\@E8ISGQ/+V6>EEQ(
M^:NUGOL;KQ_<8U0</C\CF,?:EEU+2U*U6T*%:^!.Z4Q6VDN"'1C8>I,$G0[+
M/$VI2ZZ#ZOJ3HF"S"?0Y<X,K;7KH-JG3;+/LJ5VB9FXDQSU$J=]L+W(6<")Q
MA,E0N18RUA@BBC]DJ`DJB5"<J3$P3%-;F[R!IK-L[G*N*>KR:H3;;L$K4Q6V
ME"53,J8Z66U!,+9AUB,C6GE"`W:"V4D9&G9E9XS36X:)<6XMQ:LC27=V^*U7
M%/;*[,1UWV+6O-RAJCIT2DL*4*YK,#Y&2GDD:L65M-A2FGHJVQG?[7-!*HO1
MTQ$M.V()B=7]I+!H6EF_21%Q:5I:`!\I?/HH<EF(8+T%\:Q`.4$QX54G%R@-
M:`JQ%=6K:4MICT`A%`S*U4F.`=G'ENHC4IJ+Z'Z_XDIMVRNV5WO/:=0MS<)8
MTM\_F"LP%IB;6:+17:A>[;IZXXE1<R&4J=5[.Q-+<GG,U0B"X.:Q`V%MGRKE
M"DA,28/4J4J7TY>ZI9.HU-@O<-0`+KYD25>YPIV4!/3OCL@GL"12AR)D#>,1
MR1"XL+T:H0"TF-/(,^#8P&F`$$8DQ1,4Y^P3RVN+G77+TUL*O8E"C+&MWH..
M=%'A?'M8S4Y4=,06<S]EL1DT!`8ZOJV:Q_<05$)32@ZV2[+-%?*-.#0M;>*[
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M&8UV*4N"_P"`@6SI$1*1%J6B7DP8?B=4<^JF4+WAKB-5R5O44*L;+KBT_12N
MD]W79$MKF0-RIG3R"N:T8-!&)PWHM2YEJT9:-.>N5E(]W:NUF;/\F=.PMG13
M5I2/PJC26G$(2]WK)HV\-U-O;*YN^F"7G5W,$(5@I#*XQ(%29N(;3TZ4UX7F
M&%-@5VR%&RFV3;+[,OD@A#=*K@C%I5S9\*'!Y:Z,$%4D0M8Y!GZU'#:.D*2M
MT):=P4*!74K>+N0H--6BP(!'ZV4%9LXA4`EME*\&'>O)C#4"VPB6RNY^].$>
MA36;&ZX;HP>KMW]Z+4LZ7!;<,E\8)<OM+:WU>U\^;5J5B1>J+6E+`?0#6C5(
M`*&U=LO\8/*OSV-@+U(TTN4S=!!(L].4=@C&FE0I+/G)-5*>4UI7+60]!E3U
M(8M(+B9DAFUJ%`D.^4[X%!VT2_Z9MDVRVJH7J:!=$/5BLD*C\^:CZQ>U$9D:
MN5L")O;M25K>'J-R:-@5-CP\_;9)$Y''E21<W.04"[8-%+$Y)[<I2K#I,4DQ
M2J9=Y!J:A<\FM9NT1N$Z;Q5Q8FIDCK?"$JAULI8_V@PTTCW!&P;^0Y`;M6'*
M&](%<^$LJ!4D5!<4IRAL"8L!=LE(\T>0B#6#8//,,J:&SN0-=OS9CC$PF3[%
M%[+&:W5/U(VC<)$&>W`2D1B6UD22"I/JF\1)B`E.M]-J]GC(*,;:C4I6W7W=
M]@\^="EU+#P48Z_0U14UCME931TF:>[KY>;'M>PJ]55]1B&-@7H3)$W(X228
M2)2WKBQK'`L)^DZ8)B@",;BUB+BUM,7D9I&0NK:A10^["&M?)4;`IEKC70F^
M*L3>_P!FKZ6@4U?W!2\@5-T)LNVF9P8F-9\`QG&MRA8H*3-@0KAMLI4O:P>1
MGFV1LKE(4"N>DM+<U38_ZAR@CPVFKY76QU>-M@U<V(U?QK5EH0Z3V8@8US1H
MO1A;XF7HM#$>WK`DMLE2_P![GZ:L/FB/5^[PYO@C(P25WDB>97!;+%8[_4];
M%LC#MSCS7.-U@C/=X>EL!U%M&7)G,U.P,0$YIBO9QIB5*H8Q$D1:OR?)3"XV
MPSN26S5L\BC!`IS&(@Z2V(&,%@5]ML=:2IFVY!.4LZ3.K,T.\69%-NEHT0$(
M5#N_HTX5C8@5:VH*2MO@4^\9\G5)F/;1$;(8Y76LN=K'L"#&M[GIA5(&%O8^
M@+#Y[K.2O:K3XF<3$=OS"O5*=N+0(UQB-4$S2W29($M8<VSR*?%G\JW-:]K4
MR)[CEX0.(HXR;*U$QG=7JV&.`0*JA-OB((_J=.BM6)ZL*J$:IU:$>B/G]4HT
MBP*-:,A,<VR;92)C\EW/DA<HJSMC+::MP>G\B,RP+?%&E\05(\++,8*A;TUE
MO\=D[Q'4GW*>2UI3)Q-"MXT:F<BUFO\`PRU)Y#;*[96=7_7+#(.0X5UG.H3+
MH*WRV-QYVU71*'4EFNWZ7R9)#HA#F-"V#]CV]R^3NB%&UZ]Q(#QKB1&[(#L?
MQRM:A*UI$:5Z_<;[Z.=JTA\)>(]7$/I'4SFCE-8Z>W3-LMHVX9U5#E6"S262
MGM;(N@ZRL73:[6D[B2Z"/*.1*])2PFK$Q463%0UNMKR:.$*<NTFEB9*X+!S^
MDC)E3R"0/KLX(I8!EL>(T]T$[SYAC_\`]TRME06-,DJ<!206SW$G?KK98M^F
M:C'@L8V5-W=>UZ&-M<U2BH&63>46G9,;A=^(4=F!YXD5<U#!8/(+'E#5%5ZU
MMG3U*(K8L[2PI2@3.WT`7,E8HVNT-"H;]-L1QX%1'%<AO:TSBG0_-7/MIP&"
MPU_LF$)-W88AL,E^W7=K3LB<?N7C4.]B)$=+(S/EE,RTH2L\A*I2B&TA&4$:
MDP()MTM*TM85L=B-=,=',E.S*&R0Z"O=;0J6*K-8&=2[-$(?)O;1U3,Q=@J/
MJ$Y+)&7!]6-Q!*@@"M0$U0:<<66C3*%),JXLJX5>T>3>BDT*12B4(["6(28(
MVO*Z:1&M9"J@DEL/]VL8M1]J:"%*E1LJ7V"@ADH)<`-JA(`(RRSTP%)JY(J3
ME7;)ME]F;R+P]RNM'7*JL[1;8PI;80QO[X?$!'NM3VS*KNFM';AEO)V]W7-S
M(A6RQF:"&Q6V&NQ:W[L%5H7T&OJM-NA6EO85Y-:$&8I0&1"[2)"@DJID=HH.
MOTQ\C8&5'6R^W%,[DR)%(51,7C"6`M*M6H3N)J5^1GIQ(E#:4N&4F,;9-LO3
M%?)-34K/<$A%9]'-"M&R/KFD2/E0KD:E\=&>$0FT4D09B2'58(^3O]66*SR-
M.$WX425K4C^X*42A*K3D-LE-K**NR&]"5LU6A!0NA#&Y.TMCQZ!Z+;BW9ID,
M%ECW!Y6S+ALKF]L:HYIDL>5$:4(%JQ"I"#1J<\TD8#!28J:3@U+1>0J%L4[E
M$`L6(RU,XM=V3*NTKU"8^K?XO&X.Q6/`*F99_9#VL5H"F!.Z3NQ$",TE(%8>
M668)3\/TJ=4>3=O@M-F:*Z%BG03:\O<.B]DLC`B^UKX]()S"UT88[$B4@TX"
MCD[K]S.-4I7V,/I;6<84$P2=R(*^(Q2D(+4I1'28HF*4+??9KC3UF*H.PUTJ
MGR-J>J(A;V:U*@DN;7*[Y<K%,;%IX%)J=)^'X?&:YVK<`Z%\YPGA+\6PZ*-T
M*Q%P1%JBC/ECH=/3L(L&UH]85>RY\C$:DLB@CA&T;<X(8\OJ)BN&166Q[?9`
M@*=JP9HP\_*6/1WW\\P.D@&P:[>DVVV;TX+MFW41O<$3L@0NK:J)7-SFC3.#
M>M3#T:G6(EA(%*5408'U"82H(,",`M?LV'>MYEE[,!@,!@,!@:U7-2=/3Q7.
MYE8\D5L!3ISW9//DM7_B=J86EGK2U%3,NDKB>>XIC"6I[+,9R/I%IQGPDA$+
MU+'[M;U8F5N523C@6B;3FJ&V@R&9H'YR6)W)>]1MPA3BGE$351ZG6@45(<'^
M&R14PL#DGI-C5`<H^H:WXHPU9I,Y%$+#2MKG@7*S^E^489U`WLR"4S2RH*8U
MQ^QH6K<JR>V-E<GZ`VU'D\:L*%.QS_&9024U2%"@2#VI1%I'1*<E`),K)T(T
M)B)HB:0Q]X4J=U_#2UKD]E1.3P=WG,D@DP8'J.F/</DU@7A^_P`>7YM2R"*/
MD<7GDRPP]`4F<$"U`-C5GI#R#_?\FER6JEL\6//#0F4MJ236OMH=JX40"4I%
M+U"U3G,%I]:/-2?C^0S(Z`CGADMU"7G91B9,Z)HZJ6I$JU0UG+"`G;NZ2Y2F
M;\+4'<]OR:X'^:R:9R1:E:$Z*-*'Z(N4;C25IF%;S%2P_5-D=36$YP9\DE3-
M_P!0P.;ZK:4'SN&VLAN/5F':7,11<PHWG[QTKV)!/EG2DW7+GF7Q3]S<0:(O
M9RR7)(Y6YU':I$YJ;Y1(JV@"TX\YE-5'-20QL5+$'L`:N<GE::J5&6<O!9GP
M74C\;M*,SO(WF,2^S(FM<927/85M@.KA.*K9_NP&VT7*9152JK=6X2EQ=9HW
MB/,32\Z3-B9&M6($B9,@5')A3=*6NUMY@K2/<\1SFY7()FX0=D=(RK)D$AD:
M)1-WI\9[*06:B5.[_ML3)%SB\3%&#9^@)2_G+,$6`(=BUO4N;LO6U1._CZH-
MXM5=8),@FC7)G98]2&<,K:XPD[\8!D%A6=8C*-V<'2%N<WCK5'I99CV%&!C<
MF@EQ2:+1NGW$A.$O5W27+$2+QO\`/*QR/>54BL"/M;A4[-4$E;T+S#4!4E2L
MU2.]"QB4.DK60P^<H)2W0-_TF`0W.Z%D6KDB)2J;E!Z8L6-TKNE@%?%,5;+.
MYGER^>"FS+"+MDEXRBT+2G"`5H699:JHFBH*H@3>T1.'Q6!.\40,T>9W+>B_
MIS@KX8V'!2JU9ZI<6OBEZ+;Z,X\IGK28L#W+IG*V]_K9G<8>X-T(=X4<84V2
M)^A<\TA<R9+%)<XPYV-<X8W'A7,YC.YJT`C$IYYZ([9.2)F")F%;O/CWYU?C
M=Q"5639[ZCB)$BD580-RL&/$)*#8WXJ<)6YUK!H01U"X,1T->YJJ5LDC<!.#
MXC4($"<3B:D;TZ4%W2NZ4A7<:4.]`KQT8K6F['-4"J726H['CLP@BR3$R.5V
ML\WM)9=%4CQ$WN'R92>ZR5R2FD'M:]J$P+SDYB86M@-`W2EL!'_&]R8=)(3-
MV!5+75YJ]VHHM"O1STIR).E/,[W/75K52?Z=&8!;(96^ST\<P"/98G8QN0`&
M`G20(=MTKNECVKQ?\T$EN2=H?K"_#3I#BH8[LB%ZAF@K9(PU^W5"CL!1,$D*
M!8)<U88Y&T00(P/((\4[MY2\35M>7L_;=)NE6%C>."8K)K%!02RGUZCDML&)
MSOHR?6#8!3;/;"'%K^BUZC87R$1"HBX'+XL:>QJT#,WM9\'^Q?<C]&G.3>9]
MM`W%K(4^+&B3JK?Z:*G5MHX!(!L[4>PIAU/ML)KUA89'&V>MC6534ZB//R!J
M;I.<8ED;LC<9TE7)TBLE]`I2DFA;INS=+<ZP:)KVSBH`CEZ)Q<&FNS9/MJ9_
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M7TILQG`*,F29OF,C@K:!'HE<YJF@G[@K5)D)2I8:H%8F2Y7+T;SA!.D(TRL,
M[?I;&T$=43!1]PA[JT-*M8TSFL)S4\Q8G0]Z9'U+]F=X9/E^AB*+)5$*"R3B
MCR]E[T*1-$32GYUP'2-C6:3<ASW-VJ4N$B_$+ZK8EL.5)I2S'$U>,,2&K?H:
M_NL>CXE-3-B@"Q@5M+X'ZE<4%PTF6&$Z;IC0N>"X[FJ6E+$D\*<;=7(!&FQ2
MUJ>9(J]/[<ULLY9KN:&!JFT9/:E?Q+']P7-48)`G*2FA-+"(W?M%[M;"B9Y$
M6UA9O%U0#'#V.MD<QN@ZLV6!-\1,@CA,6-Q:WN3M%$N7-K5<+Z[K(B=+%MI(
MZB<_H=GA<2VE0L3)W`]O-7D`4:NZ3=*2F^.JHE.GY,ML*[53/8C:]--Z,9<Q
M8VA!T`WN[[,I0!'9IT>B3.Z$(FY_L)Z."1'U#$0L(<#$BX"I$$M,";I-TKPH
M[F.#T=7<GK5&\2.>,TR5J3I(JFJ:%HCW%$?&&F&@9PM%=P^`Q%"W`CK*26;M
M.V%*%JD9ZM6:>K4''#3-ZDRK>K>)JHI>01.P#9U9<ND-;@:T<9DMBR2-G"8X
M)$ZVDM60JOSQ,L6C2%1$X5%I@YF)SU`1NZQQ6FJW%<L.%[L3,R6R%@\*<_68
M_3^:RA@5'67/;%KRRR[83DQT%FP5UJY)!T,19*ZEZB/*7&+1).G@X0J&\.S2
MU?W5S^78M+3=8W3PY%RC:?@?G]R;`;0NTX5-JVE`T>G5(I6VGD'0,=."H\M4
MF4%,IA1KQN%#]X56M[+VN_UOC]O^GBY+E#Y)XS:<D[F\N"ZR+JTE/>7200^-
MG/-?/,/KETD5N0J\I28P1>25L]-$G22>RH,F7*DLJ+D*0`#3"2"B2@)@I[ND
MN6P'.G,%7\FQIX98([RE0V.B>.$.3A.7U`Y*-`C*`UI;![5)FMF3$C,(4;^7
M?L]!C]/30?\`#),V3-M;A>,?D(*1Z8W,R7.*#4,@4>E+4YSA)HH<9A5>6W6;
M:L=2D[<D.:AR2)68N`YK"=I1+C61M,]P=M^O==TER]K?XTJ0V*$/NI]9;I((
MXL<5"B8ED4VB73&*/;A`7DR''I(_4;7%XBQ;4UNUF%N$10QU^]1K#/N.S7%:
M8>W26E;;P!1+`ZJW!1*+&5*7@R<-34E=)0P%$-C7/6_H!.JBS$2DC*`TY"RM
MW0LD^W?.)4M``E*(XX_Z8>S&Z2Y02@.*YS4/3YEBF/Z%%2D$B5O1RJH2WSIY
MD0#UUS/M2/D@DBR(.4!8@0=\,45D>H=1`D4B2.CFZFJ$"=D3B-1&)FX\R9T\
MUFV!P33UB2J?R.2RBRRX]/%4NDRRO$#]'D,&CUB3F!M59S"TX\$45-DJ:7/$
M$:?H=EJG-6S)A*UBHA"4K5'*!2Y+E8UX0NOK@:*L?";YD-/OS;+BWBHK1JV;
MP9O='1X?6%UCZIA:TDW8YO7EA-<F870\`FY<T.A8C`%*4X2U*<D\M&A&B@O[
M9],-Z1(FA5CWC7JA#$VN&%.D4E41,=?MGX-D,"G:HQ9)('(1">+9CD@#]]4>
MGJ4N;D*YKTVK"-GCNZ5W2RJOQS\[+"00AZ=Y^ZT_^(S);$^<724M0Z=C;B:X
M)WF5;9HQIA*?'I/(';6E1VW9P<SFDQ0?]J,;@*CPFMTINED=\!4H]0],R*9K
M:\@4D/RZ8-\_4S5J73(F=[B]:Q-MG0'PJ.Z1+)3&E-0,KFF..3FE#=TYIBHM
M06<83M<ERC*WQW4D).]/2>V+B8K%7+'`R67,U2R!HYVO?949<@YVN<0G0(^#
M-3C/FSH-V2*24S.E(;TY36)I);SD"4[3=);WQGQJ4#$7Q:Y,KQ8B9H4FPYR(
MBH'&'E-:.2Q&0U7)C908])H01.'QPDCK4#:8L2NCLO:DXE;@-O2(C%@QA;I+
ME=E7<J0.J;JM.^T$CFLDG5J(=,KB?*E<9.)9(V"3O,O3QQ&O9(NPR.3H&MX?
M3BVTZ3+WY<SM@"FY`>F0EZ3[DS<4EJ89O'31,6M%VN84IL8QU,G3O99:%>[0
MI$QM3HZ79&^AW;ZYR;X0VRF4)-V#%2-@4R!T=5R1G_\`KB%)2,H@LF[IJEM(
M()P14U=SF`36(S6V439`Y.18!$!W)8^H@TIL1-!IO6J">RDD43_$*UX2P*>'
MMP2$KDC;#0HD*@U*8J3:/%-TR7;9QNKR*H[<EUM)%:TR:R6O8!6[ZBVO3FMJ
M6.0.0V-*8T:4V`(TI2.*IPLIS^8X9H@GD@)"$`?C$(;E27I35L_@JG0+(.@;
M9Q:#$AC;3&4+U$T,CC![;:+)6MNN]W5V3.TSO$G)Q/1UW:DM5+DHFDYJ^I+6
M"1.(EB,S:?:Y6U9;\>$$:W3GYHK=R6+:M@/1R3IZ=KI9.EKW)'&R(O!G)B.5
ML"='&1D/BJZK'5E2>=F+W1.C/>T1JTI&8K7&C)N[^BVVVO*@4MT*8B]H;8MR
MF)?!RY2WM,SJ%_C3>YJ(_-T*!!+(P^,TYB4\A+TV.NFE$>4:I:AKVY8C)/0J
M$QGOV.1-)$M09+XI>:9BUD-C;+;5884.*`BC3&&!\@3PP-466U14U1N&HJOE
MU?2Q\8'=_B-)QL1SXA7%/81IE`$ZPE,X+B%%W2NZ4@>^%N:8]:2"=/MJ2B/2
M*02N0/PX^\R2K$6I6G>K5F=OM</0+G>#?CANC<6LJS7M2D+9')"M6IW43>YJ
M'!"!.E*;I2YI,'WQT<[R:"&UP_?CISBY[;$VPY,?)$NCS"X5SH\\QQY0(\MF
M+_\`+20)[&LV+6O03T24IWKX@B3B;I+GB]T>X/IV*MAICK*Y^^KO;&ECW)'=
M=!X[I:.%W6R7\UJC&.$0B'P:.HT\LC25.8G:FQN0Z:RQ`T4$\PQ2*;I+E8R7
MEF`ZYO;N;"Y1.U,)9_M:N'2S3TS!G434QF<IK&K=SC[VC8$[0:IK9_;6[;0-
M6A5A-(;2`KM+=B/$<O6R];>RD.7H)13V_2M@?)G)I?+V7;;-9/,'%F4N$M=5
M-CV3:CO+'1(P,$>9TC^\RRU'/9H$*9(W)T1:5*E2IR4X`XF;)FU(J_&GS">W
MPXM&ROK%)(PYR1U?;#CZF/M5AVFHF$U:[)DY5M2@F-;539,[V`Q(7@030E[)
M6HB1$[+"'V;NZ2Y2J:\45JXRV1V5%[%M"EIT^V;JTFR7UX]0I*.'SJ20=NJR
M;F1EFG$(F,2&W6ZQ-[=]_;7%`X(U[TB3N9)1#GK:H4OD6C#/XY>7$34XHB&Q
M[>9HCD]0R%LMM]>6R4W5!'ZF!0Q\AX8U8SXT.4B8_KGR.B>7,H8Q_<5C\YC,
MU\*WX@W=)<K1N'DR`7)93):$IF5B-)36Q1..2J$L+W'T<`L..0"Q4]LQALFZ
M)SC+H]`(:9R@*4C-:W%K/4)@F(U`S$9Z@@V1-11$TU*LWQFUIJG)%&JTM><1
M9L)B:$R$HY7,&,%>PR=[@4/JAXO<EU;X?J2ZL-RJZ+_3!,.7*&`A:L4+26TI
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MKUV(>C`MTERR-947`^:1,:0N^;*)CA*IOC\'A-BS^)AB+3#F)I?VB)55&&DR
M.LXU##%MR@9Y"G9I\D6FID0'!R6D)$Y($S,EVP-B<GLMK6Q-Y8KE"]GCDK)H
M][6JH<YH4LRC]K4%)):J:U1/W5CD+"I8Y?"IKMJ="%!/SE$)`[)]AAP3R+$U
M!:"3#QO<]S4J.I")'/V)]@T3A\!0/K.YP9X?T,'C]<IZT%'QE3&#2MM;3)3&
M6Y*<>YITB=Y2N"(E6V*T)H1;%+DMT'2)2$*1*A2@V6F1IR4J8O8S#-ED)RPD
MD@V8:(9IFP%@UKW"%L6_\=[WO(CT8#`8#`8#`YB]<4=7,2GE8WC(X%,;!JMU
MOMDEG4$50M$XN)I4-L=IRU8M5$Q5TXVD2C;G&H'9LA:EBLEK:CA)E0B'0XD0
M6_9Q&HGES6/!J,OG-X11U:&SFJNNB*&@Q#8R.?,%!IZJ=]US)J^DL\NIQOR8
M6:2Y1-^,K)X;X^!N?(K%7)S85D?)/9F](UA,5JF[5B(YTU]J'SJ3]OTE5TOL
M![OCJ5P2M[:6P.KL_5]"'<R,M$FY;I&T7N;,C*BJM&2MF39T`_/C,S`,`>F)
M-&)B+3&"+`6%&V9Y)I.C,K;K['1SNHFN)JNH'>*MML,_X)D$N@DH2;M*@Y#T
M<[PQW=;`BB"@'`];(HS6I(AK5LM?(2<VL(VAU2HERY8J/TJ%J*>\BP^\:K@L
M(VLGURRR1V@#FBNQ++-B,02JX];'7E-JF"02MO+(A<>1D-//UW,;:YGLH2#B
MVM&XN)2D(BM%@+:3)HW0DD8J?D2_*06P5G*A<,5U]TW*KC&T-;F\J7!F6.5"
MIOQ4[(&9(O<UK@.Q#F<H`BB-A*VO5C"$!8SQ9-9C5-9AK_VF\7D9T]'-)$71
M+ZU5U+:TL2F:[J2LRY5`9:RLE57<ML&52"4*XHYQUNLAEL'[6A;TSJ[H2PF"
M:B@I#R'%5LVQ5$5330<S[@7-95DL[AT:ZRB'I+XA]4.SE%[,?$Y\4G\.X8F,
MQ<'9W=N9())I"XQQI366LCRXZ&$Z`^,IC:U)7$1*-$JM1P_CFNBUV9[ZDL21
M<X-5OO\`T`]-2*[^=933[9'*HG"N%6!!X_U=82N>2B]9/**<B,B0.M<5PP1(
M](ZO:6&GKD7T[B4A.$X+/5IR\#1]>AWKJRJK4ZH[C8X&YQ*)2R'=)\W1R;,A
MTDD5KQ"%U)5*Y?15C.-0/-;&1-M@[7T+6DJ<VIW4.Z\E<FL%.(U$%,?[]2*F
MH(J=$Q&X]6S1Y7'1V9=)3&C(4\IG>I]6)4[62[VZWJKXYZ9E2VV&*750VR%8
M*"@<YJ-C+,1,ZG[8@3N@P&A2IE0FGE::?>]]X5TG,\?/+L%D506`MNEMI%(U
MUBI(I.5V4IC-@MB6`.*BJ5A#0+;I2]AVZ6T::6B;J4A>HKI.M4Z6)#=!+5(_
MN\EYWR3ODT(:OO\`?)+,()+:_?32;5K7H&3JZ_EB!NL*\[G[+5N?/>PR4,=*
M1V>47"WM><D?4IJQO8V5Z2DJ%"0`]$%IUA)X*IZ^C,?LWHF_6F!4O8;'+X%"
MW5RE,L04Q<:Z3=4KI/7T!:;*@\=M;<-4P4RG(ASXV*6M/'"GP`I--1A)1H2S
MVX0W1'`B=%<-=5+W.:.(X]4%A,K39%JU^[\(N[;44J9!TQ"FGME_G=Y.K$)?
M%D:?GHB05TJ_$`$[N%BT\,!A:0`#=:^E#?XE6ROC$1.=4/4Q8I*P:A41F[=1
M5+U>A;J2LJH`3.TZ=K.V'^UIA,HU,T/U:>R'R'-;9N2/8Q#9UCNW;;T;FZFI
M=*#9DF3]PM3UXGO`UZ`YV_'8'%^D61B0UXU5U'62M95!+/ZM[`9K(E<D3IH(
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MT<>BKQ(QL=,%!O5_;(2R4#+WJMS&A5#951:49KD[HE#V%,G*;G`:M(XK1;.F
MD>":)Y;]@=_-G-?(;_6P+&<+5FM;+(Y<6@P%L5/+-,H:U1>Z?QC+H\;'@A8G
M*;Q*G91"MA"2F2B>ILC`426?]+['PW/@?#>K3ZX(9U#;:4J1SUIOICD=@L,J
M,;4$4J[Z<+9([>J[DZQVR,S`AH@*U.Z+:D*;7MH;U[X,PE*XQC:$9Q@]?3&V
M*A8J&X-^Q.ZW;FB%L<J=[XEKC6_9EPL9#\DCBYTGLLJ\#1T-`ZI,FJ**1$9D
MBB#N9*&)O4.1:`@@]*84L/.!K1BG68J_N32VKLK=?(+2D*KNLX-,KM41-C8F
M4Z-S21P22/<F#:1_/7/CA!JS7MU74-.3G^OB;`72_P!6E<C8VHQ60)L6OJ()
M"8O>HVRNDMT>JF&NTO0-AO72G.4YZ*8)]S)7$$YZ:855DKL4!%D-4UM)RM"O
MXQ)8XWK4]'3R9+GJ'KDTF<5S$3].UE*-.A6F8P9&8NM/%(X:>*F12WM"76.;
M"4,VZ6C:J4VVLCG0J9)7Q".-4?%-=4Q>.5.FH*</=9C9W5MF7,I[JI>W=(L?
M_A**)<U!R%P%K0K\*Z<5.O-G=A5ZP5!'[3N[KQ$;:D*BDP5N\=J1I?K%4W"9
MS]T4Z+JX86.,U$N/;8PAF]?1%8X(`H-Z3KU(2UR@E&Z'A%=.1IY)F@M'O2;W
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MCGL:)AE2P9B+A&X19BA)#J:0).<&9GF,)-2T&]1]GL1IA:^6JU`6IVFTB6+=
MKB1,!:AF3IR+\*_"R"YP[)*,664B67;*;4>J/1;@#N&H9/(&0ICKQ-Y(R(-*
M49%A4U'%2.U6D;Y`"]KEK6PO,@)>"3S&T)#B<3C3A_'(T^[_`.BP;XLSK6CG
M"91IQN/IP$5KR7AU3<Z30)BE;O8;Y)YQS0E4M=T.C=6AS*FJQO0V'(6]G=5)
M#0V_(8L3A6FN+6A+!(B)(B)\%O\`:CQTY(;2O*M(D[7T6CDD'>XI!8+!H&H7
M53(:%D',5AJK+GJR<)X4[(T-QL]U!*;VLD;P0YA.(:4R9"82Y'C/15)%5:`]
MJ4ZVQZ!<S-:6LY1*'>`<G2&MX-%93R^_]%4]9;TK:X``VDGEJJ,AAG/-EU25
M;&$(V2=MQC&B0`^KV/9XD8""F,Z^5D(ZU/G5U=3V8Q^*K>EF9]5]%6#*ZQ@A
M\(>Y17$VLV?]0$O$Q@%FS\ZO5:`FEV'G1\:UK:[:=4#:$I<\*TZ\QQ;0DH[I
M_'V&DL2;(NLG61\XV-'5?3LUD,'5/[CUFY3^G1,KO58)*AKC?0]?<NIQUXUD
M29>V#:M:;DYR5U;!-9)X6)<L<S0Z+:5,:+HS$$;>EJ7B4,C#[.^I8A0$O<`R
MFVGJ$5N=()S2R)QLWJTU"S5,V,E7264M[)(GA-!$SL7]M>'`AL.`LWLH"Q6I
MVTG[314+VAZV?XBZ,MR,%_15PMN<5C.'./UU4JYS06I>)37PZDE#9:9#/#I`
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MU8U#DIV:TB8KQ-+C[6OSQ:7=K.;`6*HY;?SE3*9]<$52V':%3V&WV',+"1,G
M.`3(19,.CG/:]U7P)LD[M/DB`A\30QI5ITZK>WOXFM`?EJ.=6M0VGZ,CW54-
MZ3O^YN=!V49(5#'346B\&2QQN7U78JPND>D![72(:YA.5+E,>G1D="%04Y)D
MR!0`@HW7M5G!-D552D56K5.&2?L!R-AUC2IZO%7%VAOEL)?[<9*SLM=:T)IJ
M469Q"Z6V6T;FU#UO*I&_%/S;(1$&$0L:AL:BG0IOTL"SEJB[I_'WKIR3V:2C
MI2H?';S/'ZG;.E&JQG!DO1W*=&N%OC%,!2II2S^45D@M&)1^CK0E1$EG3^N2
M*TL?^TQUH=%I9B9Q<4*?VI5,TG+4J-RT=PZ?F<_343VMZ#2O37Y0H5:TM`@C
M<I%(D,(D%XUU+Q_A5K20U6M?:G(C4A(6G_;B%Z9"#2H!IY?T:DLB:7]R:7]S
M5YQ'WIS_`$'2U>PB57R&'EU%0;R]/KM#I`NE-;6*Z<Y34ANJV.HJQH2R9&9!
MVNSXLT@4L9S(8`M<!.VKW1(2Z"T=KX9FUTG5>O=W.=_7K+W.1M5=UO,GQL\>
MHFJ9M\WY_!8Y\GD+K/?K9_#*&?7J5MS'5]W"8"UQ\>$M+?4XG(2`*HCX"QG;
MD3$1]Z1,1^*)QV<=SR*SYU"8_++OB<!62F#Q-FT&"3A;)HO0SI?G.46K"=LS
MC/*-20:-SETH9YD:Z0J-O\H=#5*IS.<$+4>RA`EM0M1Q8*>6CV^CD,3KU*GZ
M1DA\>:+*@CX=)X(I?XQ9D!VNZQB;%*GN+,U!KH;(WA2WQZ$?<GEZDK48->-'
M]$RG)7-0>L5B1$/U);5[.:2KN8")5?C8D;55<N)#RW5E8L8BT,9$KT2@+J8#
M9&.:)R_5LXO;2L*^@F<'%8[.O0(0GO+*S&J#=!5B1$/2MNSNV:V:O;8TCZRK
M<F1PI@CDF;I3#D;X[0->H<>5_I)&U(6WGYLIV-O2AI?YJ>!6E?I"H<1?<!K&
M]L`@3(D2L?(J$_?)WVO#E\XCB*4]0OUAP.-W"P<D,Q%7M,CBE[.<9M'J6.%O
M71<G40-%&2=M,(C,!4)5ISBR'K4QZ98W$."AQ4%FSX31(XZ5U!<'"<Z:WF13
M"13475O,(JDE4JKBQ'F3L<:8[PYDDTBD3\Q3ZLJ`ED[8X/+T\@<%)IS$T)DR
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M=\F8OM;%34G8N@7F,-`N;IM&*57U0@9^=H?6'3D+<@?_`$S$U1"A'^QBG@AP
M=X9LUF-^_35&(M`7KV!2ZO7R7^C:)RJ$ZPN..HHM2-4K(95]F=,\E'5!7LIH
MA^1-"%G8'3CYDM.0N=#2!NASFMAC=,XJ_'O:4\M`0Y[;G%6([XE&U9DO6+XT
MG/5AN@(1=W-;NXQ^KF*0-BJ25+2L/6V)RM3CC2M<DR))*^WIP%,*+02O.E7Z
M/?4/;C'4QZ1I1J5#H[KD):]>W(7`X6T5/%8J4"@2'K=WE*G0'/HJ'3:X9?5S
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MA-B`]5[4I>TZ\"8X4[&%&@.*+.+W[BS2P&EB]-Z]P#`Z$'?H+6A:]0[_`,-_
MMS#+Z8#`8#`8#`YE2WR)HX9U^^<U.S!4NVAAL2+UVKT5>98>@S29!022^G"T
M&_GXV`A^Y5'$&DTY(Z.94B^H(TD//`G,^/1(M;=+6M+6FR^1GDE[3-+CJ?R-
MD8GB+&3`F3RZJ;8AD70-1D2D-A,Z9]?Y3"FELCTAEE<19;(V5J7&)W)W8@E+
M$I!I*E*(Z;9*E'YSWQQBOC9++9"^5J6Y_5K4,@@4KY_N16^QL4>?ZY0?/9<$
M5UV>\P=$)_L^)_0&O*5*!:-];S$VS0G!'J[9*E$]>2JM%5P$QPA(3':4:ZT0
M3B8VQ9#5;4"=6M]5%]#'N\(;8FY5*<W_`(F@A7-C\6]M[LZM#D2J*.()3FGI
M#"C&W3S*_%[7SL_F25V;"EDDA+R\J*^1+WR$.;S5T^5W-#+F>7X=7KJZ9*./
M@YEJM4]7Q!^.7#&4A"H_#YYBGV?0C$HQ4TM2N^!W56<ZYHC_`&W*(:C9&MXY
MX(M9[']&7(7YHKM&PF68J8DZI4WM:M>!(%/M2$@1";9BD`-B``8=>V5-[4UN
ME/&=:='Q^+1U;.^7HPR2ZYG2J63G=I:+M^]1MWDMI!D#DMA5P/QU<M;W`)%5
M4-C2I^?SV=HDS6H0E&$MRE4K"`HVU'):A/$'64A:*.Z<GUC58!IM'DK\9([,
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M[OW:7WWG;E^ZH!5B-<]=1*V`^"Q&Z9(MJ%EB1QE63>YG`^9RARA4B7M"Q%&J
M]7$-FR6DW[BO.3"+$!(8-47:UF)Y%:L#*O(0@'7M8V15%8N$Y9)713MU%-B9
M,\.4".C-$Q>+5#+9.Y0Y8=$GQHLR9$MMT-H4*5$H(9E*E"O3FNB8]/LL3;XE
M+-YZZV5WA8CW$ET`31:.O,;EE@4O*$<J-D"B>5]!K3>:BD3I*F4Z-,080^C?
M$"%R1HB%3N4<TO!&S%!*HI0G`F*@F*3:+=74).$-I/Z1Y>T"2AXUN?S-=,:W
MGL/.;H"L1S#:2Q(N5*XNU+95"WI-!WLM(YM`%:=9]O."6(>MA]\J?Q*8BH.V
MN>[RFI->P%]FFY6H2/JDA!+JEM6O4YQT<;8E('1H+<IY#8ZVCD0(A/F-]+;M
M&[6FL;NE7`*VG,]^DQ,%3"Y;<M^"T?#_`,<6$N=D;(8_Q>)H"6",269OSS*9
ML_M\5B,<8XQ$&E\D+P\2&1NJ9&F)3IC-B..#[O:'U%I$7P2(MJ^W^23DEVC(
MI6U3&<.2`8V4QM;D=)W0=*)`S/<=E<J!+8Q$`P+\3R2$M3)`G\QQ>$20]N;S
M6182H-+.*^,5VRNV5@O_`&WS)'&$N2++)TX-*E:^MK8=&HK-)8>_.$>E5<0A
M:BCB*,QUU62%0IE5N1Q&BTC`?IP&ZEB3;-+":,$VR5*MF[R*44YN\M3I&:WU
MS'&8374N3/#-2=NO[H]KIR^72Q/,.(AK/!U<I;I96ZFBWK;^B5)RE#?M,H"<
M67M*;EVR5+(IO(/S@4\M[2[38HTN4/[:GACG#XO9LQ9S(>](J@^SS:>/:&OD
MS%7#.K?+M8$8CUZK;>5MS2B$K]XE!25MDJ6;M[LZ"4W<AU22QO6,Q+7`X-9;
M[/GM#+"88FC,N?;/9U;:W.K!#Y*E5S-I2U>K7%MQYB4*M,(6PG`$5O0I$7%D
M1<6P#+Y'N3GP+R,J83AJTQM3HYJPR>E+GB9BI2V$0AP+B[,3)($UFOT\>V.S
M8VY-;`B">\.;:_(5"9,:6>'>7;)4MJ*RLZ'6]#D4Y@ZY:K9%:Y\:%!+NS/$:
M?F1_B[TX1J41J2QJ1(6Q_CDCC4A:E*)<A6IR5"=20,(@_LUO>4:MJ?(SRBG9
MCGL,NG"TH2U*2R-K52MS.TAF3,OC$]FC=.H''&Z!J7J:UFY1.K9(X)I*VD*6
M0].RJM@4[V`.A:VRM2SO270MI5M!:KL:AZ^JNXHO9,RJN&!73*W)-6@"C;OG
M,(@=;OS&8P5#9Y3VPGKYF!6XC-VB.3HRM"(+4C'[`2(\2(1JI^]*QF$AE->V
M*G65M9D2L]\JE0U!9;`?(1)Y"S6S"*5]\!LA=`(W'I@`<\LJ/)U9*;U4M);R
MF&O`G#\NR[MFK*E^);W%QX1+VLIR<GZ832$G_-&S8W2%JS=U:I#+'^<5<1'H
MLX,D$<@CG,J40:2$$M*(T3FM:VA<H"2)&6(W<J2I?E_\A-)-EJL-<,Q<NDZ%
M1%YY(Y1*6FO[-4)&=3#6*M7HF)1I,G@JD%A3Q:*TVE*K86H\UZ:E:D!"E*$[
MY"RFV2DFK[HKDB6S)58425(T5HSD5<U:]KW:N9=&K)6'*9G;D5AD`D"5\C2"
M0H]QR<5_-$ZE$>$!;2I;%QBG100_(),3P*E>%U6H53L19Y8>S[>B'.S*?KTY
M/I=]!]&3:EIQ"MC7S9NDBT1^H\"4[7;3Z!K:G2?XM#+V/WA1%I&JD)EWYRQ!
MF9C?'>>O:]))(M&9PSD1:L[/F#FJALK@;[:+;*#&F,0YU<D3(FKJ+N+PN//*
M*"WHT9FU'QC]H!-LK4K,@73M+698S[5D+E*IWE+$G?U(#]QJ3H8K)2X>XLK-
M.`P6;KV=-$)X;`WJ2-Z)\`T+5@FM6M*)4:`/>PZ5,:E35M-;B\A4[I)WG[!-
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MAN9Z\077"Y!*8\@EK[72)2UMTQ<QM*Y$B7J%AK*N925`=H@&@/6-Z=2G!LTL
M@09K$TFL33#_`-PKE\L;*E7R.?LSL[/[Q'E\??*3N5GD,)/8'6MV=W=;,9E\
M%(6UI&D2JX8L(3F^!0H=D/J4[1NRMC$"[9*E)JAZ^KR[[DL2L("E=UC'7M>1
MF='V`ZLLGC3)(M2">V=!#=Q'<FCC.AET23+*Q5#(D#4K7-:S8AA+'Z%^\<F*
M@F*4VU>3CG5>_3HH\4Z)AT::JU=(K(TE6VVY/UBHIY'+,FZ^316OTU??BQSK
M6-P&N1/HI2D)5,:EM5!-">'T!HV[9-LK/<^^>7&Q=(6_<^<W(QCVD3MJIB@D
M\?6FP7A5(H5$!1FHWQJCBMFMF5()79#`W+&Z/'N*I&L=2"S@`W\GQRI*ED[>
MZ^@M3P:BK--8)O)83=L[21!)MC@E@N$Z9DBZJK*LQ.XZJMKA[G8B]U)U7NT:
MIK&W)E:+1YAI_P`>DQ@-HBRF`=?(7R4S%/RU99:XUFC\12S(R2-M?V.[QMZ1
MJF"'2K[!$'MJB:Q!,YXEC-A,B]1'FH:M[(2N)8QI0^P[13;)4HG.O(U1<9;Q
MFQ]+/)0\I)U6\/6QPVLK38GE<5+KAK^F)M^"6]9!#EUBRVHI=8B%!((^S%*W
M-M>#`MRL"90(7L;9*7C`>M:!LXZ.HX7.1.CE*9`SQ9H:#HU*VQX%(7N#2>Q4
M[4N:G1C1KFE0AC$)>=K]J@$@;ES2K0JME+4YB<*8F"I1F==O\ZUK)YE$IK)9
M8R.<)0*%JY2.J[16,K\>A?H%%W-D@;ZWP]6U6))&B06A'TBMO9#5ZL@YS`$0
M-;*4?"J9X%2QB/OGEU6],K"9.GIJ6NB-*I=E$@KJQX\RU\J722P(6A8;8D;U
M%4+!5DH632JY"T%MC\I0+A.3681\7O&3HUMDJ48_N)<Y&D-CVGDKJGC9I3@4
M[(GNO+A9+/*<UB^H$%>DQ^IU%:#E4B;+&W=+*-L5Z"GTK"N3[1@5Z^KVCNV2
MEC4IUS75^SR:PROVF:'(H=6M=V.*3OD-E<8;7`,[DUJ1%=$C$\C8VI0S3*$R
M&J5J-U;%GQ+DZO9A(B0B3'>DF)CB3$QQ:8<\^4<FY5$-V],7/R1KG$%K6=B=
M:LZ.<;=!4YE@VO5%9I:YOY,WTXQ"JZSG']Z@#65&8-4C<EK.XIU"E`G2F+M6
M<:\5G&O%<:[R;\Z)I7!4!`I\?!IA%YW)UL\.JBWT1<>:XNMIS[!+ES"HKS3A
MNH9A'K=+="9H,1,>(2)/42@6S-_$VRFV5H/'>'-["^/\9<WV>DR)CEL;A2-C
M)IBX%KK-'N62B40IE-K9`B@ZA38K"?*X2[(C'1G"L;4XD0C33P$#*-,E25+]
M5+V7`+OD]UME<-3^[1JH:UKJQ$<L=&*4Q1-/DEA*+:"WJ(@CE<:91/</5(:P
M"I;9`@,7-CL4O]2!^A.]C3C,<28I6'!O=O\`.:1(0F,51I5#)6M,6>:X4A>9
M-[1EE(N9OE*]'7$]==P.OE<-MV(`BPC'1HVF5DA3+$YH%'J(18;.-$Q3"6CY
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M<AS>DHE$64N:I$(KR27''XJ[&/38H,CZC<3+A"QR=@.)1@%^M)&CZCWA^H`6
M"QC=>;41=>:QK*\CM-5K`K"?E`S9/,8%&K.DJA@BC/8[G#=?@!]LIO;HW(+-
MW7!+!$)G*FFJW=6E:EQ8%:C:(T*,*PH20]6VRE+33=R\\*/PGZO,]1ZE<T.K
MXT3I3=N-`8-+0SMLK)(U6QMTA23]TPWB=O:%O0"D7VT"T:PHTK8B-[-U*DJ6
M&B';%-V!8];0*J2UDB,LN8N[:XNJ]ADD%V6Q@K*QIW%[/CB23QIL%8\"G8JK
M7-S8^-QAC8KVG-&2I-T1[!*GF5*D"_(JJ%U(Y<_`B-/.:=!T:FYX''&.^Q.7
M3)6E,$8YB9;RGGO5;%@+JIH,?`!<5VY#K:-N`-;OW^FDXKMTOR6M+7QV7U69
MRPS5(M**II*.U;+7U]^)[_N@=#53$@-M96#9)CG(9\5!;#,(4.!<"VWHTVF_
M_75*P>I@=!]!2(M(BU81[R842Z1.MY#(5)\#6R"N(-:]F(I*U3Q3'*SB4ZJ*
M7V^UIR+'CT!>(%*Y2NC4/4KD#7I<@5KF8HU;[2AA+2G7;*[92E3Y#J303`N-
M.4>N%L1JJY:)LVKG"EK92R!VD3W:SQ43=5K;7YT)#,EEAK9$RFGIT`$NS52#
M0E9(1I"S%`&V4I*DGD`Y$7(VQ:GN)MV6\M,Q>FL@R.S$A>M10"$0.PY<`IN/
MCQ:[3@S1:S&4P:01858U2L20LL:LA005-LE2S'6/4!7+2"AWA;##9:S6_P!(
MUU0\@7E/9;-JOF.=-4M<5UDJBS&UQV]-T4U&@C5(P[3BVF-,-T;KX?8-$61%
MJ2-[Y7KZG[+LF,U(4L4\O="'T!$6MZG/VMKME8']US8EF1[V@BKV?#H\IE%A
M*$V@@1NQNTC;]2#0_J`E`NWAYE<&P5%7-*+3>+AJRWJYCT!M"GWF.M4N8(S,
M%5E0"2Q:>1HJ1P^61>3O,,@+JN;'=/I:A5I%[,C4)%[<H!Z'$;)4'28K6#S;
M-Y$,!@,!@,!@<^;+X(3VA;,]F[U=\U05U8EAP2W7^H6J)UZ6E%9%;5M&:XB3
MPFL%5'U4\1LZ4F((%ZAO3JB0JE!0R1F_1J%"<W6ZH:C*D6E_C,KZ;IOPD^6E
M8`JE<HW"RY97*5'%R!2&R:ZHX?/T+M`F6?:1O+*N:824A5#;"=";SWEH1*-A
MT4%4F5MWXI;.I/'PT.3M*9I8=S3B=V=8`D1T^FWX?AL8)?E#--:`DT>^BC3*
MU::F-*SLW.;*UZ**V/Y@*5B@8MG&E_$W<N1;'3WQEU#93=.6263.<JV2P'&7
M.#ZWD!CA6M?BY?V$Y'DIAGLRHO9;>L[&=A$Z.+.`/[*A"<`P`U03FZ3=,,'%
M?&9&X4!@DD/M=1#+4BSN=)X[,('4%0P6(,\H4.Y^U2])4\4C37$C6];#UJEE
M4$*-GGFEJ1J-J='@)V4W?@N[\&S=2\X#@=.N_.TSERFSZ<#648J-@;I`A;4,
MD51)-726&3LV5.L>;V0E<Y3ES$K6F?`6`"7ZC8"/C+]A9<O6^:7K?-2B/@^2
M*(\6BF/5UU3.5P<-=`Y]F:YN@S892QM5KW!7&I`**-C"3#['FTB0.A[3)G5Y
M1C&\L9@T91:+Y3C#+?D7Y+%2<<,BZB[MJ2?6/,9U*^BG5TE-L6ZH11UED;G,
M%3%&HTPN3%'6]L%%&1BA,?A3,A:V@:94CVD;@A6?6&'JC3Y>MEZJC2>.9F,>
MBY!([GF#\XS>6HY=T<G!%H>TLE[*&"RVFV8<T[:4J(P-=,L;E3,`@0&LP9[B
MUJ592LTU2HVL#=Q:*/'C/<EL98(^V=0V`DW%GNJ2&C;U7=82ID75=SZS3%%0
M-63&*NS+]DF+?6<AG"N0Z7*@:/<W].B5*`;TD*+TW+N;A/\`2DL_%;U9\-L=
M0UVD^5K3U6K7MT8616R#9JYL>0320/&F72`THMVF#9,G1$,L.]$I_>4(CX1@
M^34OER15M_\`$4=Z!O"M+G?I^]M>ZW4U8X-\5W&HC)$B=UJ2VB;;:'*(.\F;
M7)PKI?,EY86N4*FG1*]Y:$J-/I0G"FW\MC*HHO0D?%Q3]RM6O+^[26&M]7`C
MC<S2R45E5L]*>8_$4SDT1AKD\#F$;=84Y+(\QJTHT2\M,G4D/36D<-;WL!I!
MTO6R];8N;\(,DHC$$@[';$UAD/@U>+Z#(:6QGB*]0Z<TR.*U3'YI4"QU<&@:
MS2R1N-2I'$,B]1.:,Y>L*+]21E`)NXM/J)Y*8J.L*4S='-Y#*$)[9(XK6$3=
M&]G0M=2P.86*\VM)8DTJVU.4OD1:V8O``DJEXAGIVIM0I=>X1)RA1)FR94)5
M?C:8ZM8;J86^ZY>Y!OF`(:ML-W-A5=(Y#)8@TM-VMJ1TE4A3L(GJ86<ZJ[H,
M7/$F<3SU[BK:$H0A3IA')AW<6NM!QZT,4V!8<8LB6LDJ2R.429L6_;8RYIV]
M=*ZDIJG5Y84+BUG)U)!4>II,<7HW0MZ4KS][]0A*""7R+66_4\]6)#HPP6;,
MCG%XBEXLUO-[PP-S<WA-002XC[%KF)*T^T):<Q.V1M&VLZY2`H"A3].8?[OE
M,V/:ZX'V-5'#QQ,20B%.,`NVP(%.H!6T>J>.S8ACAL@4$PY$CN)KDY"AD>&D
MQI4.,H;;C/&$_8?1"O9T!X`#+TJ3JKN+\>#RQ[QG0F,2UC7--N6"37,'=FIY
MK6K1-D0&W1!41/\`G6QGW2B3B9MR:1E/#WS<UE$Z4G:^B2N2T`?>,1`R&Z?O
M+8^?^,>,312X_2W'*VUC?'94\R.'O4+@$VALF7*K,Z0L,HR1QN1M![8_DL>^
MG'@ML3+BU*)(Y-+0Y#(.4)!A/;EW,U%?&A6\5CRF/$658"XE3"HE"#%:M/&`
MJ?HH@IY[4HUWM3,Q*?ZU7OG=NT=K0-%?_8*O8$/H3HMNE-TK/Z)XICG1,Z',
M7BQ)9%TRV`MT%?(ZQM\=4I'/\/J9^?%GP"]S;E+BWK6<%H/8!E`'LA5H\G8P
MZV1K8D941-*^M;QM57;C._L\DE\G&G>I$HEY)*EIB3TV))(565$5XPJ%C&],
MJYHD#2T*.?FER-;UQ1R5>8I5)E`1)C`@`W3"QE,+UYVYY<^?F,NOT$ICSK6)
M4:7&"C;+7$(KE(*QI3/9O+YM(FUA@3(QL<?C:QND:)N1-A.COA(0!&:8:I&>
MI4R9M)FU"0CQS1>,.D8=7JXI],CZ[AZ:IJQ^O:8>V;B%)L=77-5\/K]48T,Z
M<4D<&)NN]P5G/2GT5KST*((P!`6;HZ[BVSSKSU'G:GJDIPU_>RF>H7[GQ^:'
M<H#?]T=C^>)C")E'B',(THD827]9!B"5WPE@$$H\SXM@%[=ZEZV6H^:\)1V3
MD&JV6SYC$Y4BL.S[6B<C3M<9=P1R=6'?E0]$(UIS,Y-PD3VT1>9TTWIBT9VP
MZ5MRE0`TS1NRS2[N+5Z=XU(L.I9Q61ML/DD4V"HA:Z4O-C5Q55A,<B6Q28V9
M-5(I#`GF+EQI8F>7BT59P=)=(5+:J1(E"(\DPC?O;M;7=-HZO\7+4:UF1EOZ
M3N0J'HF!\(C[`]D1>2J=S"8)JR+G\GG<F7-Q4EL1KGY]8`V[LZM20E6)WYY3
M#'LA6G`B;C<PT8\>\IK:R*V45;($S`CI*G>EC8+9:U%"VQN<;MZ)LV2R^*IS
M*8BD4011MB7/J6:RS;-H)0"?I)9M(`HP19Y^-VA;<V[^;EMUSRLY`LN&>Q>"
MP]ZC#[,ZC:"F-7$+,60"<L-E0-4L/=$*EVB;FR3*/)]JE;6:4>Y-HAHC=Z!L
M`P2)I(FFLL*\9S!'$!Z227O9,W.)K533L?5+V*"LOX?KA+2\NHJ*M!)#(PIB
MU[HP1"6#4G+C]B&O="OE$`LD7TX+N-RR.=>`ZUYNN266U$75&M&_H9@2WMQU
M;UHV25"OL>0,$KG2Q_M1IC2:QYHD4R%@^1J0KE_TK4F5GD>U0$*025.5DS;"
MQ;BFU(4XW'(&#L*P4DHM6SOWLAE)E:5@)[0OY3TK&W1R6+RFHA38M<,<$4%1
M=N8UPRB&YJ1)1I1DJBOG$OR+735'/LEJ2IY-2<9M%X;H@D@K7"ZCD9#4P'SF
M!K_P:-LD<[6JCF@MD?),[SI4>_EDG)1MY!X_A+)`E]J8N3-ZDS>K6*/^-DQK
MK:%UJY]$S!R0QIDG=;R!U;Z\KB.N4^I*UG&#2.TH%)C$#49M1+)W,X*!W73#
M8AOIRQT<1FC,&J]Y=W:V6S#AXY&10V3IK1VZ["1NIR5LK5DE5:5?8,.K6N_W
MHR"X'*N%\+F;`[,EB,JV:R`)A"IS`%<A)9&?1)NC41QRQN7<OJ*\T*XU1D^Y
ML26)(V>K5U9-U152Y1D2%EL6MXN"K&V#.[X3*D#<CTLF2N2A6/1*L10M)U)^
MM`T$K0"2Y>M\TO6VN%?^,"O8.QSAJU8CP(V?M<M0.Y,5@M?5_%FHV9+.?5SH
M9%X?&64EM:DQ1_/+>(`#AJSS1N2PU2>><,)@;N+7K0O'S=2$EF3J?9DLG\:>
M*\9*?A4)D#7'&YKKVJXY*I]*F>,)')D0(WJ2+R#+"4(3'%>>,\U`B1AV'1P#
MCU$F;)FVO:#QG*68E,M9NH;/1R^.1..5/7LM-AU:JCX31T=@LQK4%>%M.X^4
MVOSHNBLM`>:^+`C5_>FQ(KT7\'U"(^[EMB6OQ)TS$SK&(@3\R,#!,&-P:&5B
M?J+HVP!HBI!(8-)98S6'(IA"G&3W#`GU5!"TP6-V6`*2(G)8`H[Y0MQ[<W3/
M$W-NHERI'8K6G-E:_C69/:7FMW$],+V]*DJYVDJHRKK*JT2-X,4$&A2,Z1KL
MU28B3)O9I&!&E3@%LDO812TMJ1'/$I3L7D"]V:YBL)3+F2(D;4:K:J=SW<HC
MC-54><'U3:QD4-GA[$]-M3IS`L8%12!*K=%PP^\@25,ENY=R0+/&'!T\_LRQ
MX79"F!2B962.W8L^L=24V.516=.E[1;HF3&R2<*(A^,;.C;K/HJ%.F;'1:$E
MO9EJA*`0S`HU"1N-TL_2/%2BKNH&"RSSG%TBU94"Y09ME;V^MBAVMJW[-M&7
M6;/K/=H@RM:!OBCG%S96^(D8PCV68EEJM,0240E+$-,Z)>BK[V\:3M*YW8UV
M5S;[T5;$OE:%RC2M^C\&-<8HV2*V:$FDI(5SEQCSK)Y4Q5XW4T$V(,"D9;2W
M@.-2#*-^8*@I&7);>I-XU5SY8$_:;"MF1R&BK!CU>/MHQXEOBS>[7E<"&U.B
M+:EC^]*$+,2MKEA;);:K:>B0LY^BE"5&2E'L.DYIJJ[M/,O3S6#'?'&QIY)'
M9U.;MG]@3]@>H(J'*%;'#6#[K'JME%&R*OXTK:65I*0%`;-4>3I:J*T`Y<J?
M'$_T)!M(0EF[\$M?E+<LM5(SJ<2^/SJ1.K?/XVI97R-.S>R;2@<QW-==PHI`
MB<TB-.XD'HSKS<VO:<0AD&I$J4S>M'A-&;)FR9M2Y'C>JA"S59'VF62QH:(3
M5E+5)/T#<G8DJ2\&&@)_!+!K)WL`@AN*++E<?711R0EN*'2=1IMDSB1Z^FTV
MR+NDN7ZCOC^3I(RIB\TOVS;"0I:+G/-\.+=VJ%MJ*%U/*TE5-S:B;FUI9$Z9
M9)6I'5"0:UR/]WW94J-,,)*+`024W>2VP-;^-2%0&Y#KH/M.62=_%-D\MWI?
M&H2D<WT+=+K0ES:784N2,^Y58;^G,M9<WB<W!5L86M$A3D$I]$FB/;M*2YG1
M<=`\@$T<DGC8KMN:6*TR6K:XHV((9"TQ-J_=Y4=2$V&B@<<;U,>:4!\@>4;=
M8J@I:Z+]F'+1)21^PO?OT.3-EHCSEQ$\4`Y,,@4]"S:PY)&*WJ>CV)Q=8-6<
M:1HZ0J8]V6-\%/:HO'4!+DYR%8[>]:]JAG+R0D``B^D"8I^>S-DS;[6EPV5:
M5U22R5UTS-B@4\>Z$DMAU"T1>!&(Y0^\YR+<J@!R:?.3$NF\71'O1"43@6W*
M"#SBD^P$GD?*:(3=I1>B$)_&14)%C4M/S7HIW,JNLJ<K%Z3R>M*ME;[-6RAT
M$D0P%6AFDABSC(JW$N!*3POI3`8D"Z%$)@@VE$6:8>W35%JO;?#I1C-#ED?3
MSB521[TU4KII>[-CD'LAE+EM-R*:O9TPDL%?6,$;F*FSD,L3-LD3JP!`I2,;
M>-,)*I3@/U=\KN;:T5RF9S?M@:JQG)GX55/T=760TN,6AC05(FB)42CJEF;8
M\UQ"-,3%$MJ)2PMK^>%O(1D`$`Y,6#1`]%ZS,VEVJNV/&S5MNSN?S][G4\;G
M.PAV\:[(&O[!IK"?:U25K4:8\9"EJ/,7'5XW5^>X,>S1[^!>^KA&?(#9006,
MI@MCG3QPM"DBQ8^QWU:$5@-PE2M9:L.9FZ'[_&4D?'>Q5[.Z'OJMF/<4#2R(
MK#^F/;"=:(<=LC:88(&P+`K6[6RW^VEXUX3:5HD6.Y6=*B$_[RD%HJ(LOC,+
MDK>VR)ILF#68E4058_M*M37K@]+8*0U/CFWAT[.C'L"0*E-\(1[1E1NTIZ><
M?&K5O-DNB$JB<DV;NO7P)T/;VJMZL@XS(J@K^R*]8V6=O<+BC0_V/)$;;9JH
MY4_.:D:M8:D3;^,H6U0E2<IDF9E:RGBZ$:F0;)9Y3(F&QD?2KCT>SS-O1L7W
M9O-D\.C]>SRK#S!MVQ.M:3J&,6DRY&>(1GU/TZLL85*%&85+Y<BT@NSG676T
MQ4<:U7C(8'9M'2H,Q:[-1P6`R0Z2/2VKYE5DC.>X:_M)T4)`^M<X6*]`2D$A
M2*]%_#K18?9M$T1-**8/&Q747@Z*$,5G6*D+0+X\\$/IZ.".3IM\8J6LNG#W
M(]M<8FJB1Y+P&T5[L>WB;-M(#P%I"DH&_7TN7=9:(QGQBM,*00E1"[RDL3E4
M`&O>HLJ88!!44#C,L#8Z^P(R.&5D%*)DAE>1M-)Y`SABS>>4W&('X\8!D*BR
M#P-R[GU3^**D2937\O.G-D*W:#'T:YJ-G'QT*:5R&I9G-IK+WU]3$,9)(#[W
M5RQ,DE)"8)"8Q`QH"$H"`%;T)NDW-DK0Y>'T%3]75]>4X7N\EA8')TD\JBK:
MTLQ<GEC]2-FTT[.Y#>8WB1M0$P+15.R/2<DGX7!$FWH.BM#*W+K@EUP5&'Q[
M,;92]A4G%[FGS$RV.1#%KV]GLL+>WL4SKZ!4;#(O.!FN3((A4[:<J3T\KR1@
M^F<7!]6Z-!\84X2KN+UM8\2YFL>OF:T)%'N@I'(KXM7;RZRRTI="Z^*1N[VW
MUN=`ZF;"(FR1DADC4+J]46G<R$:0DQ0X*_J1+3U/U9NLEW]A?X-R"@F!*+":
M/1IH2P!,,T#X]&&:#K0QZ+UL6@:&+]OIZ[],B/W@,!@,!@,#A%;O,=CVKU?V
M#:[&Q5_%VZL['JR2)+B-,L/70!C'#N4JW>GRIZR3MB5OBAE>V(J6G-+L8:XG
ME:"XN7J@/4Z)$'<3$1$-Q.E,.XS.RV[QU=(T[<\YD<Z<&SG&LAP1S=H8",RE
MPCSGS/6\WLV+`*A[,U@=F^(*SG,0#32S78"0[:=8I6*"MFB?^5PG/3Q;-\C3
MSGZMYKTS(*=="HCQRO/KXRN#TB&1(JL/M>*5Q9TWZ)<*I1+4?P$15%`8NQJ7
M(YL+`S&O*)?HO8U^U>AR8FH\2;Y\4:\CR2^)C,^?U'.AKBZ-2RC>H7ZR4<86
M2%NEL\IU.Y<UO4LKZHI&T:TWQ2YK.BI"IJC+RL%H3<-4>:FV6HT`\AC7,QKF
MTVNSK&Q9,XV-6=!V/.(/SVW5$[;B:"/PF/1U]J^#UM`N?+)B$OC$?W!WFQF5
MG=8PYO9/W.4O`$[ZD`L2M["2)J.6"U$5K/%8B.,\5M5E,NM&`<(K.'W;,D$3
MNJZI<O12D^I(0^.U6Q5?UWT.B>2(BN>H@K;%J:9P5(UF@4R$EV`B-T%0B`2C
M-`D#)I-'P=.J>XIC&Y4J99LLK]UIJ+]0125:8:>C4C_>)='&5<L:Z3N1`Y`Q
M/*5#!+ALZ1;2D)F\):LQN;#BF\],>;I26K%:A.O)IJ&NET\D+;25\ZM$-/IC
MI=0H-ZEA$_G-5@DZI_YE-;TC<VPN21<:.=?;/N&TARL\?_UX%H2R][V(09CP
ME,>#:SM-U:9[X^>E6&JE"!]/0U0HA*)$P-S]MJ`XJV*-JD+20@0_`\*F,YD?
M4@Q%I3-C$B.V`)FA^N](TF+2.+3*V)O;7#6J-J"M&^L*Q>'R4%6'+(A1-8HX
MM2]DHGV]JBK]W:TJ6<I+-L222MOK=U6*'-IC1C(H0)@?>5;PD0I0IS;$1.O)
MK2=6K%;WSTK0D3GH:9E$KF=HCA$:="^;)/7JIV`5$(]PNUOAU]`D:V/JI@I,
MC5H1IK;#4B96-M5J5!C<-":Z+"#06HGB:3.O\:MA&#J3M&1QESDB.XM'P6$1
MA^<M3R#U_$K5!,H6[="0.L7BU7:6):8@D6E3A15;/<F>RBXBQ(V5U4,28P\*
MHHEP2J),1]Z5#8Q#U78@N$UEL?O8>I"^*>F9O33#>#?!X%#C38"S]3R6JXY-
M9/\`C!AW6-;(3X,S$EN$F<&!>UIC3=K2FD_9I"3<KXJ\BM::M1?K[OAXJUIN
M!`].TA?4L58HF34Q=*(/M4IE"_E6\;(<Y^XG:B##/5,@36/7S,(A`A^S-YOR
MJ4.V\)BU*!'JL;6L5TPE[L:7\5^0Y]JZV["OAX=KAEQT1MAACH(K.9O!R*5H
M)/+U%;((DRQMK.D2:/IGE`T*8XA2A4.Y&A)`Z6>HMSG%ISA3,J456%\CCYXU
MG^:5C$8=JYIJY2ROH5N04@]6!&N3I:X((U"8O-6YWBXWI8K;V4J<&IFPI2I7
M"`GVI`^;4GI+K_Y<5_\`N2">7[U<W)EELK[':(ZM?'/I%JC2V4UTQ0U@I2`P
MOHKEZ")XZTV4IK*Q2(F;/XL\.)HY1-6M]CZ-64F5JR24"0\W4J.!4<%6D]:]
M`LJB>S-5>=GUH58D'@5GHU$YJ*(.BY%-F[CZ!+:EK-IAX6"3,#.V]*6RVR<:
ME,UJ3SG9='QH&-2A6+]&#5!4)&X]!='W^_H(`"WGS3X+J!A;K,BL1K6/%J./
MW"MNZZ6AE<MJ)[_#AY$L53"#K9&%4.1C>4"_;-M86G+3)5I*BU$?@:1J\3OV
M[WDT/KBQ[>V0MZBE,3`]D:WB)(4SO;@8I3U\O#K=R*MVFJ'1\7N[79T":4QH
MD4B8HDC$08@4H?G=VT>*Q_F5#<+L-JK=FC7`J'LV5(;.K5%:\HW;LQLB+-C;
M&I$^J.8KM,8'&51B%LJ"+M>ARH].6WD!2`*+5Z(T'8E'M&+,<Z2.=<6Q'#;V
MZ?RTQV&!528N3,K9/)!7;)9@))J9-5&22VK71<P&3,4F+_$`%!U5QQM)$2X"
MV[$DIM:6`"?Z^Z3Q2>+DG$[,K*DHI5%GUXY6E#;Z@%"60L\D+]&XXI<;1-LQ
M<UL#:A:+@*L2,2>(.UORKJ1>0EB2IY1JRDL;4N2M&,B/`,/!N;G[.36OW,\9
MVMVTS.[<R-=OU_:)[71BF2MDA96-B4LETN9E0WI-)].(1$XO3BAWEJ:G;/BS
M;&B'!(]1QB"!FV!W0_6/B/858E0R'1%O=4JH->M"NU[S273=74]DPYXA;;4,
M)8Y$XTTJXR.M874K>YQN$DF-[@Z7FL'!BR"#-LWPF_;2TGWLD:\4B(XD5Q=#
M_'?$XM3L%GM0BD&UT]7WITY.#$+E%HO$'U?!([T#-*CB3UILB$8BS*:P(V*%
M-Z%OV`CV)D!:=,FT6@*2%%S*;U9G5H+677/7=X3AU@D5MZ6Q5BDTAC;NGF1M
M3U>[S2O$A]==KR.1U^..!@*V&P%S0O\`2T/3JF%_6S&2,6U0BE[@%0XDD)]3
M$1_'V-3$1"QN;KUN*\>N^=G*UIN[HY.CA5KN#S0J&!:C\=A49?*-H)]B5E*7
MH+2!^,_>$]OSN806[.*M(,T9B)`40H9G'9DFHC1.$(6_]N=6-MB]%,LGE),+
MCS!8\@@I3<T)8.>_T@V$].12M*FE;RZR^HB875$.L^H5JMV7R2;.LR3G;4D.
M;*UFI"3T6KMA:BE523J3I&[>;I>R6#;,DAEFR7G]L1PZHX_1QJ]3:B19")4J
MDO0"IU2QF,2V+*HO8['I$::1MJCR<UMTWJ6DM4^(-IU1$Z<"HORMTB?+@OF%
M<NVVYO<^=3Y/7?30ZG<+S<X!&@/\8HU3=T3C\BN-RA[7&T4%=7.N:MDBQ4)8
M4S@9M:;=+U20P@I26/-1,_<FEJ]XCW8EL=`W%=D^E[[*UFN<8#6]4SM;!HQ&
MTDGKXOH_KEJC]IQP`8LA&U+[3B4`C<A<DB49;2O&I2J@I`)/MI1">%$\*:$T
MK:G8%4T:^W)5UC6#<L@/A%=PQ;7TUKUO>A2JP(CXW7*;/$M='9+%D\R!+(9;
ME;IF94D1B*2K#$JM,K3*G56%0#4U,U/\:KIS7/%^E>W[`;V+<<O!,5'FU\:T
MC1/8A`(3:B:SV.6=14138G*02\=-UW"W8^&12P9.,!\3:&UM,4MB,\\TX*-S
M3*),8P5$?:V]<)Q:<RYOYA;K&?UZMZEW7+55%E3!5'F^-KGQAKVVK+;88^O+
M`WH6YC2&SV25O'`+DZ9,F;5VW,PHHD"50$G)6L_8G/1I;#NN.T[<<3(98,/,
M:F9-(:7DNSUU0FZ).+B/0=/\H6$T:&L;A(@/!W1,8F4Z:#O3U3QPMO,UH:/0
M1F6HC@M1#-\#22_VJ75=(5-QV)/(K,I)0506A'YM#&92)Y=VWC*;/DQD[O)Q
MQI!)&>60NSX$A8SMISTJ(1B=46X$JEZH*@IE23_-F[;N*?<J7YV[8Z>3.@#;
M75VBQP!:]UH@?35EF5=RER9(>?:ZB3DRQ;3R^(C'B>S,Y(T'GJB59Z=>:#6C
M@+AC1%Q'\>)$6G7,LGL.NZ^\@4[*$_(7^&P&<2Z&JI.@=ER`EZCDZZU>VP]*
MA=?:0X)21ID0QDE;]IJ?X@[_`,@B\3R)XPH4KN+I/[`)P9;\<);#$D7>Y+2]
MM%4G%!BZGOI'7_/<@0\H?9FZ&IV]`W*YG.I.VE;9D[?(QZ2B2Z<-JF!V-46H
M6H>F1=N^0]`Y7-&V6%&N+E74,N`3&ZF56J`WN[_RH@DL3N)[$I):%!*]-8,N
MMVO'B/$I"1_4H6-U`C)/`(X(&W$J&UO%=T=,W3;#&3.+62/=2Q6"62^(5T68
MHG)&N[/?:3S"H<\2"UDE2UJQN1\5;T!X?EA;6TM#J<F)/T,POZ@HS.41'VI,
M1'VM<(]T;T%7UGRNOT-R2YR<$/4]@)H'7$G@3"]*[O<9SW5,HS.:D%(SHD!V
M8H]2_-2YAE#5MK4(U"!ND);FK4*65&%("U$Q_'@M0NSL;KKH6J^IF"O:4$[O
MXVYEB6MU&XQ:.:9;%4S2&7BX)7!FV3'GZT)<6DEL38D*AU0.T58&%6,I"H^Z
M+'(LHF1$5JD1%/MRC;$KL/J6KG-PZCG-WPUVYPM]`A5+ZQ9*UA<DL-N?^;I)
M*&<G;1&&=DE$AKL4H6I@'(`(E#:1LYJ6_5+FUR4&V8J.',F-.#4&;===/SNS
M)<"(@E5D`K>?OUC5E!7&'MK<[1R?00_K&$MU>/L:KQ@0.C$W."%F8C3([(I%
M(I(M#M&X",;`.B='EJ%J(6H3U)U>]_BI56-_O-DU?5L9L&Q8K<!=(0?0^ACX
MA_)^<NKY[)10QO9F]@CL@M:8LJ@V/(VQV,VE"1M5I:TK3CI4<XU*AYH+TKT[
M:#C.%EEKF8IUK?H3G57'(8W+``D566!)NS'&D72I5I;+6<+3-C5*:(=3RCFU
M\>Y&_&E&C=P*--:])[%1'`J.3?'K[I-NC=6<]3N!]!HJ<K>W+Q:X?(KM;HHQ
M3+[="3ZMN"4;$T))>PO[$V*U\JA2!-]8L;U!9`=C#LOU'ZZD1K7-F(:`J.K^
MSR85NQ+9MM[H-E?5_P!@-TGHN)JD,#G,7XVK*WXI#"4,GBC^_KG&^+EG#HE4
MIEIIJG0&@B/-(D;NH^J,U4<(A:A^9/UQV6[O<STY5\5(G.$R*$26B8&JJA<(
MJ=3DN'25TN&+DOA!(%:A5SM=)26`)5"820YQ3*]JQ#6&B"I`J%J&#AG<?5_T
M-+O+];#5+(L\7,DC0RX*SQ62V!:R-P3\ZB<XTU*EU!5M6-@G0Y]G,E2.$7BR
MR-S%`W["=I>XK(X]I#DQ!MAN?U7?=YQ+HU/6<*GKI#@.+/1B*LJT:X*R/QUX
MI;+F\^B_0,R*E3BP.CLS+^=8,UH7\C2%4D2MAA0#G<I:D<$Q(<Q$4D1%-5+K
MB\QK'QH\,1Z,3>>Q'0J5GC=+R&./MC6JF\NG_CWZ.=VMDF[4R1M(86Y2.VG)
M,'0BBT:]4_*2C1';<AEGY8URG^.:QK,O]L_IKN*EIW'*C06"FE2&/RY<V1RQ
M9[%(W#S;CDAK1RL^,-,N#-$:;F(Y0(MOMB2@(119.Q2-8E2%*/N)FVAT$H1&
M,D1$MV^I>IIY3EXH:R9G;Z'<Z8^71U>S_@M4^J90]2+J%5"^@`-R\AN5EGEQ
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MKTSJ<M1'`J+;Q]$7?U#1//O(2FCVE>ZN<ZJ%HB[PA6PI5+#F*8PN$02Z%KD^
MA&F.=40'2EZNL!C+"H&'0W]R;?\`%3HL!F8B)NTB(F9:'7-8_0MH(5,G=)7-
M*P76DPRAR86..U]]I)?'NS*CY8M*KHY-$0V7:]_E]3Q!8N((]QZ4_8V%:0:+
M>MJ@#U%1_'VK%.G<JO.X*[Y"LF22R<RA1.87T9(:806OJ(5VP/0X6'HPJ`,$
MVE9CXPH*?A:5/"%Q8'*5*&,YA;2P"<]M2K0?HS<U%I46U'XCL&X;<Z:J>R+.
MW)E3R_066IY*YC:'IG8')PCL7,BB)V.0BC\492%KPD8B5)@BFMK(/4G#-(1I
M0&`(+LU6BSPJ.".QN2=$QKHRW)E$;>LE[65S:,V87Z"/T/8GQK>XW._(@G:6
M6L5:YPBX5C+'V^E9A]S:E;<:0XD)W!&HVL$VI?I#6E4:-D>'^H>FK5JOI*6V
M\ZQY:_0:M([+6YL2D)SW&LK;<([8CE/ZD>TS=6%>M+:F@:UA:2RV-P5/TG:Q
M&F_=5YQ:I",28B]$F(:DM'=O2BVMV^1H^A5C[#C*Q-G4)N]-1T4'^^#IL-'5
M9-&[C,B/HX<!I3M+U.)*[`**0IB)69LK;&6Z?<V]4>9=L6M0DDJ[=\B+3);:
MAC+7VW1^@D8NM$QF?NQ5J&]VF_,<>FMC3E1I>B1"3NC39D9N2K&QC"C"+:Q:
MRO`4.C3Q'`+;<2L>+U,O4G:$GA4HD;=?D9;8M7]:6_+6"Q"(DR3B*V9I#8M6
M0V/N,XM"/\YH(\WDPU+)Y$';Q%8@)B2&HDJYS+5I6UX2J%05#8&PK9L6Q^'N
M7+67SZR8BXKN@Z^26!*RFJ&IW61QE-/YE7X2WP<+:W*"/4$G3AINVE>VE(A;
M7Q$J2.28A"2J`G)S6LPE:TTP7=*]P\_4G3\`;K"-5H$M3U<_([2L.)1R(FM,
ML7<MQN2P^@UQA%16`7)FR16"@<?A0@:]SEW`F$U)GC3D82:9JL9FUJ)E_2$Q
MJ7%8R,ZMW3$HG94UMZET1I]J-ITCB>D)-6IB-JR4ZO9)"D0@A^4L!GMUKW!#
MOUUKFPRF`P&`P&`P*6FW1=&5NEDZZ>6G#HFCA;F\LLL4O;L4B(C[K'JX1V\]
MH7,PS6@ICVNL5Y+X=K?_`,&\P)N_V;RU*U*DY9Y`.96!DKES8[`;YDYVM/8M
M7\,C#06X(W]4Z/US1JCW4QX0.S>C/B?X7E\A$6>2[A0GJ349J=.$U1K1>-LE
M2S3CVUQTX,0A.]VP!3'Y!+15<$IRVMVB?WET8G1Z^D3)53;K3Q%7.*-*]P"\
M%`-8SVI$J5!5"3)SS`-LE2\Q'<7-0$"5[26)&BZ_`QJ30OFC%Z1Y)>DLIB<0
M;8DBK(QH*GRQ:ZJ)>A,2?`WBT<0H3C*",I049M4E2RC/W3R#(',AI9>@JY<5
M"F"&V84J3.XA,NX.5"P61M]'(MIPL!(#*\$)]+(&I"J-9RC5@"Q)R33`-LE2
MB\]\@/-$,B<)DC?.D<K7V++V"&1")-I#DVRA8Z.UI0ZIG(+RT/;<A70\<>DL
MU2`.*>2T!IQH@IR=&'FE`$VR5*;LEB<K\W-W[HT$[AE?E1YXG`U$;>I2N6OG
MW\J%NO15@KW1?(E[G('MW%"%RR4.*M2H4'#2B-/&/?H+6E3)K.K-17K+G&;R
M9RAL5MZ(O$E:Y2@A9[40I4E&JI(YJ)*B1M[,<J2D)9``;G#'=$-0@,4IB7!K
M5I##`J4YI0525*@)OY*.<X/#YQ,%;Z4Y)F*5M<9@*-K7IEA]O)W:`TQ/$\FB
M1J<)R=NC&B[Q9F_:YR$E2_<#BB?D^14F`9=LE2V9EO1]&P2SH_34PLR-1ZS)
M.WMCJSQ1R/4$JC&U]52!`P+%RS2<36S$2)RBKDE;MK#T_P!P5HC2$_RG!V#)
M4\4J>*NFONGDEZ:69[:[QB2UL?Y6"&MAY)3W\ACN:B8G,A8J2":0K&V*J6J4
MM2LI]4EDL9J-T1'@5B)5IQF-LK4HS974/%4\KV>1^PK4C;K!TLD30>5$)SIB
MA6A?$HWE_1.4=7QM*CDIJ-E%`W)S)DK(:)&W:85BP"XK3>>:2J;-8?:+=&\7
MT;&GZMXI9,;8V.IU)9#HSHC9?+G%2\S"2*5#@<V.@TT@?K5E3O,'D\UZ4(5#
MRY:=%)PW`85`S-[5,E2]'2W:5?\`.U9L=GA3H;`9YE$0R6`D,<G;TILS-=Y-
M6,3B`6?0$KHK51QZ<K4;SECNG3J"&M%Z&C`9LTDL:(LB+6K(.E*1AMD1^FYK
M9$5C%K2%F:GM-#5RY1\I"-[!(_M!RUU&B):FTA\40]V);1+34HG(UM4`3@&8
M4,`53QY%35J[WWGR`!H87T^^86C;).[2%G8SW#;NW&K5$5C+7-7Y9M&N:TZU
M*PH(8^(7C[H<66VFM2Y,L+/&G4$F#;9*EFV_L[E]S7P!J37%&RW6S5;@WQ%K
M<$[VTN9SBVR)5#SVU_;W5J1K(4Y'R]$:T)D[V!O.6NI8D:<)JC7QXJ2I1I/W
M_P`<+(8?82*^X<NAZ=Z)8C'A`2_+@[./BFYV!W*1)&<YR41#4(`-X&_%DB9"
MVLHQ4)6$@L8PMLW14HA2?5W/NIC9E7-;8EJ@ICF5J2;:Y\=VX+/.I,;;72PK
M,?V4X"Q3OY59]%R"5*?>(`=-ROWAUK1)P0)B>)7->LEZDY]A[[6D:DMJ1EH?
M+@;&A\KEO4C6B-D;&_.K&PLSZ$9*,TEK8W*02=L;BEBT29,)P<DB7W_.I)+&
MJ2I1&-=P<G3!='&^-WE#'4R6.+RU,"HDQS*:%JMC7JFE4,Q]4MQ+*@0K'AO4
MHF]4I4$I75<D4)T1B@\@XL"I@J7[;^W.571LB[PCN>-";YC)CHDPG'I7Y&8<
M[$%1E08H<$JUH3JV*.[2S9D.`\+RTS080]MQ@5(BUZ01RI*E'#^^N73I#'(K
M&;%33A\D-T1.B-HHB@<'+;1-9D=/D#2H<C#4R8LZ-%OM8O;4H<DFU25,[(#D
MAHP'$G!+;9*E8$TZVYNKF6RN#SNWHI%)'!HRZ2^7)WPU:A;F!D9&!'+7C;C(
M#4>H\4[-<1<"'=0V_5;<2FDX"T1&DHM&[5)4JTEOD!YDC['73FR6"W3)SM6>
M1:`0R,-!3BCD"IT?KGC='NICPWNK>C41/<7E\@$6>0[!0GJ3D9R9,$U1K1>-
MLE2MZ37QSQ"I>Y))78L`CTX:T\H8G(EU7HTDB3HX+`6NYY6V"^4.EHDD>KV0
MI']26'U+`C4@.W_CBI*EJ>M\I?-3!*447F#DKC@27I,SRJ4@%M_AD<TY5S8=
MGM:],_,*9=J2)/P]7*P*_:,K>VLW1FU'M)3'F@NV5VRORS^M:_K"ZJ'IQR&B
M.W=\=F$O)FBAXTAC+!'(Z[5_$6$TA:6VN"20N\ZGEI,C8VI2STX1!/,.$;_E
M)*42(N+2M+>)N[$K]\Z!;:#CC:ND"IQ<E#+^-&M>V'1Q,]-C5<ZN0M1Q7S:7
M_6QQZI%S:U8-`_R+1AU_@`>]*TLK2V65]K<L(5-C(C[HBNUU4.AC%.$"<#NL
M7H'XF::K=2P-")&V'JI<_(["$!B/0LX%ZHAW.*1F%A4&E%C;9*EDT78'+[BW
MMSJAO2N53>[M4E>VM25(4P@.#7#8#&+1E:M&'_\`N'ACU?S-J=580ZV,A*N*
MV+6A"]NE25+$J>VN54>E_P`]U10(V^P6&K?A`!X.4.<ZDZV1ML?98VF):S%$
MK+=W&&O*<A8V!5H1G,Z\'S>Y&IT4J2I?"\.T^>Z#_>.U3&=MQ\ZK:KI9:SG7
MK9I2JD:]HBD/?9T:QH3`)A-(9:ZQF.JUR1J-4`<#F\@Q8$G:0HPX*(F2(F6;
M;NHZP0,=&"LR0,==3>^(S&7Z-0HUQ7O_`-.HD@(\G)2*'U,QH$R1N_$$I0-2
M=P<"6U,L<E9"4K_R#BR1*GD5X*@OCLKDM@3U2P63*V%^@EJ*XM+4TE1+E2EK
MBR))$Y!>]6SQPTSA$^$-CJ15JIR;UR<.@)0MIBLX92=.:8&Q$D1*63GO#FF$
M.?V'\>D29^+LN!54L;HRB7N1:"1V&_&QIJ6F.84H&QPCC.^$#2NZYO-6E-*K
M6B%/QG["5N5)4O\`*G[HY^M)OG:G4O;8JLK,@Y5,2GM<G$T@;&R!U).Y')HW
M(DVQ-4IA3"GNED2C=4PO@-.4!$'7Q&%#&G&8*E'H]Y#N:G:/R&9O<R30F',+
MTMB^ELHTH)DZV2M-C777CLB+@;<D<)0%L('1;NZE.`23$IC22I4#$4!`MV2V
MR5*U$-]\R7K)IOSFV6)#+"D"V(OR.8P=O6*5B=SBJ]H8B9*@+=DI9;2Z;`P3
MQK-6$(U9BE,B>$9XP@*5$&#5,:E3&K`5MUISL\2.'4JW3R',ECN13BSQNMVY
M]#(3"D,=53)N9D6GUL(.82'!V9*Z=%2-"<I`M.*;%H2P&"1*=EJGB5*6R'J[
MG:)R:=P^1VO&6F1UHRGO\T;E0G#6FA&E+CYJM&4L`A&@>)`B!+FC9[2A-4NA
M/W=#[TX?K$WRJDJ5:S?OWEZ(0H4L2V:R2%>OKJP;$BD32;7-;Y)$U=)9G]UC
MYX7I`A(B$E6OM?/+0F1/8F]4<ZMBQ*`L1Z1066VR5*QH=U?S_.*:?+\9[+CX
M:OB@3BYA)%PUC>3%G%,A:G$YH=DC@D2N1;F<D?$)B,D)`AN)2Y*8DT<!2G$8
MJ;KF5-TKZ&]LU99%PJZUKL7XMC3)SV=T')+$1G+DR-L:ASV25ZDB::.J64+H
MIE*-Z@[V6[I%`T2MG4(P)C2!GF&@3JFBD&I;R7\L7,-U`5-`0$:.$1VRV\JP
M"S(^:Y0)[HZ%WRO?3CCBMMC4HC43EIVEB$]3I7LMI6*R0&HB_GRSC,$Q*Q';
MOKCYA1Q=:]WM%&<,Q"X;8D;FED*%X$8UR'</6I'9A4LI3W&W`,Q$4S`3.2=(
MH.>%29"6`:I4F)-FV2I6ROORLB*$?>E69^U+:F9*SD5LZ?8P28O.=8C&8^X2
M-R&V(3=)5`W,*)M-+^D.T2<6I#LDT)9@1:"J;KF5K2MX;T!R_P!'RB'1%GEC
M!*9['&^/72PPUP`Y)G9A6&Q9I<$RX9)Y)#4NDT38[)0&N#?HU2K9#'1&<I)(
M,,2F;5,&L?8A<BZ>X72Z2%/=A00G5`6&U!CJ%*UR`&V&PGA/8U8M&H$V-+1Z
MS98M,(D[$7]E*<R-KR%B7_\`.B1``K(J5@$=K<H*7EU8D]\UZ<N9(3JQ70TM
MWV)I2P\4(9[+`Z;D&B?L)IQE=/Z-]"D`I$M$SJ`K-$[3^IFE25+[I.R>95RB
MOD9%ML6EMGN9K-$D*A!($:X3N5*@P337)D:QG(50)P/G(M,A)+\!M,4/&](B
M]#5;T5BI*E]R>P>;%=1(;W06LRN=3.[^=%V"8-#?(7=/*'Y.>L)&W1%L;&=4
M^2XP06Y2<`38E5%FI4QJ@`A$%#,"J;KF5+%_SO\`)>W=]9`WW7QBZ-04=DO0
MRG0TYM20T$1C,^^YEO128;,M4C@\T:7<"$A0:O&VN*=2$C91H1[5)4O=3_6%
M37#"";":W@##&'>ZYE1436OX]H12J8Q.7/<-)3(4R@HA6@6/SHP*`D(EA9"P
MHX.R#2P'ZV7B8F"8F%>3_P`B7(\!B\UDO[UVF7C@\`-LE<Q0HA6^NSK'"4[0
MN&"/C`02U/#T6TR!"X&MY*D2XAJ6$KC"@I#2SA-LE2OZ!WY3MG2V7P6!SYED
M<L@N]ZD[,C^L*/1!*7J6A<:D.6)4R1Z3L[XC.;G`U"8I+;G,D:-4(E4`16DQ
M,<4IK'-_(S0#$@:W*!.)UN)5;^JC[D.)&A;]LYH6Q&[M#J($B);!NT:E+>J$
M:U.J+1[:Y%D&B3'FA+'L-VRL0MN^.O*4Y_339#+)0D4SJ'51,[;!7Z49I+J\
M,D.A\RFVVP#PH(#&V=ZD#+`'@UN3+E:<]82VJSB0&%)3Q%R(F2(M"G[K'BZV
MH$V1N36?%7^&W2N=ZU"S*R).D,5+]ND=BKHW/_P-J-U@I1+Y-69,2Z+Q-I`5
M3LWB3J?>K2",5,%2\%-='\.PEMCU9U':T6`B?YW,V9`(UXF,F5O\_'+!I9B[
M2FP)7]W<GIW?I^ZF-XGMY<S=.[]LQ"2J/6E#(`F)XR3?-=$9ZBY_F%;3*WV"
MTHTIK6O0JC9G+U8UK0V,"9,S()&6O6:>4;>J$V.D==DB]N5%EC3.B)60>C&>
M4<6,2INN94\%<07M&L+5O.-T[5YA<O;72E9/=;_/?JEK*WQEM8+$'5X(NJ8W
M1E)<@RPN6-CF0ZH5HFY4S;0Z">4(9OL`K2RD6KOMU/)&$VT[%J"6TYSG((&=
M9E7WO)7MC>6.71(;]'V..DR>,L&U,A@$OLDF5M[A%&8P"]6]HS]E:^!R+$WY
M=OXE?BDCYY!>,HX!B$[]`0H@<EC*26LB9.%[<5RUH<!R@AM*^WMK0K7)GYS5
MP=[3I6DXLMU4JF9>04F$<C4@*FV2I?MX\@?&#`^[C;IT17Q+O\#(IT20K7KT
MHDS^UQ9^0*`.;>WJFLQ.1&YPSNJT83MA;6AS3+E>R$AP#MMLE2S#QW%R>P"F
MY;K=L33GUW)4,.E"0LMZ5K02=R>7R-(61@0HFI0LF2Y1*8RXM.@LP%^M.Z!0
MAWO2LDPD+;)4H=TOUG!H'5]2ND;CL>N=FZC7@A]>?765%:QK:5,\D@+Y-"QK
M[0EAFH^AW+(LVF$,J0&C%;NM4%%%!`7HX\A$:D0P$,[MY:AC$MA<K5._/6JE
M3U/!5\%LUC7,[G$E$JI>.VLWQH9+>-^`-)74&<0ER%?HXQN9MHCC5*D*7XU)
MJI*E-YMW9SC#9<"%_O"CSN[M,[_!=@C)=DS<W5RD3Q*<2I[ECV[.VDC4Y1^*
MB@QZ!W,;SU6VMQ/*3J_A.W\>U25*UY]TC1M6DUZHL.R&&(%6F,C4&$]Z7I!.
MZ8[;,`;JJ+VCV8P,*$^1MQ2QQ<=)$"$]>F*4'%&'E!&J9*EKNR^0*M%=3)KE
M?8U)6:(R3IZ6<PP`M(G5O#O(I!')E)8&CD3TV[;&TZ*MST_0]P$$H7U8DR71
M(S!_(:,HJ[>7D4S4`\B')LZJ.)6^.UV".LTFU&TBUJ=-.)KQ&GQ_@;79!S>\
M)4C<:=IG8X@Z@<%CZ``F$IO")9M9I-K9NIMFZ)B8T;M@&`P`3"Q!&`80C`,`
MM"`,`M:$$01!WO0@BUOUUO7[-ZR(_6`P&`P&`P.:EX\!26Z;#L9Y.O!%'*VG
M\A?YZ*%%5>%UDB"P)+SDP\U."LZ:G3E(B6Q))%(PE<$S<%H(5?<3E&C5AA`B
MBRM1E7VM1-/-*/'H[NLZF\DCUU)F..W!9T4G%PL+C6I3XZ.[!`+_`">@(?&(
M/(`3-J!#7(+NK<FMQ<ST;KI2B6%&D)DJE*$PQN+0RBO%JT4P*/F!LE@<3H>R
MJ84P*D58'*%+I!T5+6+3D6*G'[PI_9".22)O3V.J<%A91*.,*#`#(3,J(I2I
M^1.5DRK1?X^+4HN/0&QX+-7NV;&J"7I':NH#"(BGU#8&UKUT7;W%!!X+=O0Y
M9RF#)6)K=#3(ON=M)"1:_'GLQZ`A$D:QVXG3D7;-0;Q;KY1R=&J>N&QE3+*Y
M$V,<AL(MB8FM3MGEQG'"SF-Q:$2]O=T[>L(;79QV]C,3Z`0;LD2$KT)&%5IN
MUN"]=$K8O&7(8\6$]DN6%QUQF\CB+O>8&6G'Q8U2UNKVZXK<\020,4MN.3RN
M)ONCHX:SN3J^.\K/6(5NAE`3&(T>BFXW+-Z4\<\6Z.O%)=#C9+U$Q)VFJVTZ
M+MD?0KD:M1"[#$Z6`Y&N"AQ(."IMZE5BVOW#VEZ^F:%>SP;,,!HK<C*HI(FH
MI$"/';.&=\B\DC=]1Y&ZTL_Z.YQ+=J?4.3;%8BYV7)+#D[#;)"*S&=;:+NM(
MD);6A<$"B,A1E-Q2@Q.H//5;-;HYK:#H/%4^1N'@B\1Z+)2K7ZOV"I;$?I#4
M"-\,?:_9H9SI'U`HRUIIXT)(K,7!XY]TJTN-$XHB4K^>1]$,Y(D5`N[R-RYK
M[Y`GO15_6*1(I4@BW-,[JCFMCF[>BCZ1PGDYD-/6A>\^`SQ.7`DZ1179#8LE
M+*8O/4LSH%>F/V4C&F.`<;J1-1YD34>:JG?QG6!(@L+Z]=&,1-F,ZZ`M":QX
MG4;U!I!%8-5\0;8=#5E:.48N!!(XC9XTQ+@H>%:ER=(B^[=-IET;.1HD1)3=
M^!N1:5>)9RDI[ZOU>+"D'J=R:30R'`KB=(ZB9D<Z8K)C<[>72MHY>\<0I;&E
MK;/TPUY\7416*KE3$0:ICYHEB_YKN-R3/?BZ<#U=AE1VVH:TQ.2%1'\/P$ZJ
MI.BAZASB;K&%C/+YXSP:YH,C)L^)M<<V@89C`BZ^E2<E1LQP7N9A8=[;O$W-
MD)YQ:JL"(\^1Q_N22N[Q1M?,\(<)G(&0A[D5C+FV;4!-5DLD"@;NEV0[O"NB
MM`4;V)0,8W89HC!C)_UI$TEJ_O3CB=]%7]:A4IE:**\USNM^;6V3M[='T:^?
M3:35'+K]D^D,6F'XE)%7Z-F<)BRG+AJV1S^XD[^%(8F%]4/:)J/-8FH\T(J+
MQA)JU8'Q&MLJ(.K\]5=:]4*5J2H#%<><V2>UQ55;,#A*X]8UCV4IEI[&VUD,
MY>@5K]M"\MT,1I4S<D)``;<;GFB7C1E\?:2XXX=#:=8O,%5<!MIA4PJ7/8M1
MNE;H?;NJ2#TC))U<,RE];15@?9$J;U93VOEQIK:9[$0V\19'Q-QN\GBLWQ=/
M<V@:*`,'12V.LZBF*\I*6(%,(?#622-,!I*1TX@E2MIB5I0<]>^MPY"8[-K>
MY*G"/$*!#+6(%_\`H&IT95-FY@;9\<+SJ'.,3BLFE$P>+;M^J0.\F96^,10J
MJ8$EN3H6?W2^N1SQ*Q+7=IF-+]"2>#Z2-Q"E>-0O3&Z+`4:><DNXML'T-RQ8
M]W="QH]I?V2$T2?1B.!64;N+H'Y]?RVB[X)8B.&PL\$I8E,#<5;3%CB!.IC>
M\(RDRD>@)@JBTQQ4B8B/-(G\5:*O%\S'S&EI(*QF9P2UQ6U,5W*B7^O%SPK?
M0T),IK/()((BVF6"57L?<5C_`#@_3B6_Q^6$_$F(&BTC4Z,/,;EW*M0>(0[X
M(G^(+JC[\!C'(XN?$E-=SX=61VJ).HJ->[1>J("X7TY%PAQ6/-4;7?1KU;["
M4I[VJ+2QLA.0E)!=YN;),W`1L9?ZMDS!;6BW6L'N#N24+G!`+$+PAC=OW38S
M^B4E)I8@4)U+_'[N7M:<\)H](5:0A<,M2'9B04W):(7KXXY!>UUS.SGZ_EB>
M//X9-J.1==$'U^<(>CEU,)*C<XTU*%-FI((DBZ16E&^E?1QI$[JURT\I<O5$
MA(^-&511=0D#YP`_FV/*9G%+K1,3/9]MPFR;68G:LBI"O=FJLNB$?14&C4,>
M@S1I*B:P#X-P:W-P4)'32M"L+-(3)5*;1AC=H6]70/CFBM^=`I+W760\QH9!
MM,G*8>BCZ%>W+C(!,5:JS_F<3G%,I!J]:D^BA+K[2];2-B`!I>S1BV7I&511
M$U#"1[QRG,4@^N'<H5[!MCDQ&VLVO"BW/<FE5<7=5[@\?=OQ@:E"T%QZVTY@
M$.D?R_4M9F]J=EJ_C3MR[EL6UQLKL*,U6W,-F%QB14[4*6NXF[.,-U(&A9(F
M2TN:+9CDH?F0B3,2E2SD/G-B5,M:TZU.:I1NIVBEB<PDLP2,J2T.I/@MPJVT
MXM;TCN/<VE+1)9E,'\E'`$\5:GQ\G#IT<\NVD"<,J?#F1M3+>AS@IRA&*S`D
MM1>AF#&>,8$S<47R5(R<'7/*GL=AS"THM$)?5/0/1=E\Q,6JW+?VB,([.ZL>
M+>,7VZ>U6.A-M!NF<0:VXA*E1&QA8RD+S1&F'+R@&EMT+</"5XD(F*65_,5M
MS/ZEPB:JJGR0HBH<UIFJ62=DL>5S6_%Y:4#R(3`S]$QQY;(PL0E#.^T,S$F"
M6:J'L6]7?)N2_GKQD,M#3^(S-/8C:\DUS-FUVAA9$(=T\D6PMHC=^,B&.3:3
MR"Q)8!P>@JKSV>)2S(F%GT)I]X&H!ZT\X$G*R<K3:\^#'2Z)I9ZK=O)HY6]I
MO+C8SO%=5_MVEK;<)G,KURRTOC;-_P`8MJ/\`HX8O2.:AC,:1*U#LWZT!R)2
M*#T^T94E_BG%^<@.]R3[GV:L=H%UZHI<UM3K7AHBSB78;@R(Y-#I"ZM$4G4?
MFD6,:&F:(XF)I>V=_1RJ-KD2O1VVT*U*0HR1-11$M9VSQL6^S(V-0W]0Q'4D
MB4,B51Q5:KYZVJ9$=1PVF+5HUK0N;..WM*G&?FQZT1NISL!60WC=D(`?;=(3
MC$N7='@NYF&?QFN\3DKRY0F\DT9CB=_JQ]A\3(K]Z,9EJRMI=%WA/(+78D]G
MH89,+%U#V%2P$21B:(HY*R%XE;UMY5%%BQNCG!N8I7XQYLBC*J&P[H]J9&%V
M@RZL'@YWIC;^\C@\HJCE^OIQIM5%V:SH$<F<WKEAJ7MRLQ,>F;TCNN2FIE9H
M$RPJ[O(W)>9X\YNT3)39L(OI@:;!99).#ZY52*H%$DC#!#K"F'5$E>V.5,">
MS617+I`A2]2*2D3F0M:B0J&%*8:D-(4JTPYN\>!:U*`X3CW/K]6CA'9\Z/#1
M6!EF%L[6Z,:0"U<@L&#T]!TY#B[D.&@C5L:.HRSA'`3A"J&M$'19(2@Z$F;2
M986N>!4%?2=HDH+/5NQC5=<:N/24R(ID?SF1QMO-N!'MJ`OJ@19*G]]9@_J?
M;L0-M^M:+W\XMEIRLF;51-O&*H>;5NJSH5<Q4)6V8]RN<1M87%)BJFD5F<_-
MKLN>-JB8M5NQT*>OI,S094VG%1E!%I/I"]G%_?=_2IMZ;M*7<^$3\:,T@\-L
M"`1;HAI9XS=L2G,6N8)=-!=7)S3O\VZ`G$:20!;)['D!D0:&I3T`K0.FU^WM
MV<T36G,3N#>M.4JQMQN;3RKDW3[7MSP]LGHF=YLVRJ?MR.OYD73KT4/FE'QN
MAT$*TY,/W9*&6,)\DH5`M<$WU*`Q0D6&I`&E""!3DO5+>;GSDM33<JL2>2.P
M")E*[;8'`B>:9HF.(L&I0_6[<ELOKK%FY7)94N9V+1MN?;$*!0J6J"4[6`X]
M6I4*#AXF;)FVM2CQ=(Y%0*JCIO<QKKM:H:AJ9.PP`,>$,F,<?(>1HL`+8;,G
M@\LU.ULB%\7"TLUI8H`>E!I.4<$PJ[M;+U2NLO',D@X_NSC83".0N<DK66R4
M,2KYU:(\N>J[Z;A'0X#$0)=8T_F!GWA)`D3&:H=7IV7:_P#SO9X@EDHRVY;7
MI!.<)3':=M'G)ZF#8OK&30*616)R)O8AM\P1.MINUHNM@N3LF,=U[8J2MX9D
MW%-A8/A%O:0X1N]_('VR^?-+Y\U;T/Q'*JIL>%3"6W"S3:/U\HL691N.,E:G
MPYQW:]RQV-,=G/[K(U4]E@ET)&H:G%2R,NDI:EO^[[*4N"X*)*+5G*X)EK,[
M>.[H2%6E&[>@5[,L^L!5;\/5J9%84"?'XB.0-@D]W3C<@F;>\W<F-EBLC5EE
M,`6N+&1)`F3%DJ42-,(!X17='"5N^+%-_BNE<KBEH41.;2`UT(UR5H>ZK^DA
MC>9/I+/4W(E:T>;9\ADS5,TQ"6&%20#\:.)A;4"P9I1>@.8$7P@VW1QCB;N?
M--R?%Q(_J8"89>[*@;&*P(Q:\JBS'7L]2Q138,6O9FN3<@B#0XWRZ;TZRIJC
MZ".NCE,3)L[`1H2CV]2@,&:`;<;FS,^X[?Y#S'0W.D2MPZ,E4NDKUG='A4QR
M8#+9L>A5?.L!4LDI98%8]=R9*VKS7(EY`F2OX$PG!N3DK"UJ$2A,=F)UM+UM
M1#;XND3;4T3K4%UK3%\*=F63,DE_`#<`&Y3$><J;HR(."YC_`!$8F4MJ![I9
M`_+$>C0!6DJ3FX(R0^U5J[M;7=JNY9QK)9!RW:]&22YM)+*M"Q9W<:*Z(-`B
MHR&N+1D]FCMB*2&$PMRE4D,"17,I)2:1@5NQZA:4E]5)XAFF"VN+ODEZVIZ7
M>,\+NBDT'B-M-T,J'>I/+JVB(*X&[2*$VV_<]M'.B%Y>)7N<-Z>65NQ1AK,<
M`,`&YM7*'!88$QU^F*()+;N<\5M9?,O"*?G>U+'LH,V97P^7-]DM\=.;(<]M
MLK8@6]::RXYKMUD,IL&>-*U.DERH!38E:6EB2_1I2A.);BLU]5I.5I,VURBG
MB=>D&W!?,^D%<LD+F5`R'-_W!)$>YOA\"9I"QER"0.4TMR<.RZ12@I\^J7Z(
M4)&M,H#LI`B2)?82"[EW+[ZBX,=NCK5<)^@N`NLVQ_IZ35-)B(]"W#\8/[2^
MPVS8F%AD$B:YY'8Y-ZXVHL8+F-FD;$\JD*]M][2O;!+%(LD95%$34(K>7CI?
M[=GKG)6Z^U<:BDBL%OL-\@BN(/CDSE/C*;0A[6ZM:9CLN(,KC(OCHP"(:I_0
M/B9.B=![1)$JHG:D]&5$9,4Y^+YB73*G)-^\5J7IJ^C,'B,L2R&`N#J>^M=:
M7?++WAZ^(HDU@ML+87_\2S-8E6FR!EEJ41`2%"5.D5DZ.$W:&Y,*W\?[O#><
M[?H5XN?:PNP)+%I7!S(Q#71DKRI'B!&1%VBQT2K*26!-T[8S.<QAJ=W>F!K<
MFF-F#..3-B!J('OU;M;2];6O0')3A4E@3.UIA82&=32SF>5`L%,S0PR(1)3(
MI;83I,UBV,M"N4RIP96!O:5*1I(1*5B]09I()4>K,./'K4F>4$RIQ)PK<I$+
MAU:G=3@45[0J:#@YGC0:GVF+9UU6V7`["K!RZ!4%V*(-TJ(.V5VBCB7367#@
M&-BE8I,T)Q.(5);<7=+<>#)U[X^0Q"4)9R\VQM_E:^U(U=$R.1P5.S-#Q.4+
MMTY(Y,!B;AR9T/CL==WWI=5M`E&>M.;DK44`9ZLT\T_3<E_@B\<\9C;':_'!
M2[@5J=BK.U:Z`[C@B(L8/WG4)0U&#>MH]2081F,J:CBW#1'R:THVY"3[&`)&
MC#&Y;9F%>/)7&["K:5.UPDO$:HJ6J5U+1M'7P&IT;(2[SZ66._1R?R,V7N1<
MTD9SR^-Z1&[IT346F0M/N,1GJUAZC3=H6GDHXYE9G.M'T1#+.A*A+4,800N1
MLMT4HWW!2ETQ<J+_`(=4M]DU"*91)4<>A6DIW1K.2/Q/T2Q/L!H51!QA>UZV
MEZVH%+XQ)7%&DIHKSHI(W!!4Y%,;73.IA3%8&'2.C8'1=H'E!)L9@2%O#@T5
M1&W&,_Z>TD?/1J4JDET1*0%)VY=SW2KQ<I9W`&BA)9="A1SC`;&>[+JF"M<"
M3()Y'9&]N\[F*1XDUIG2=:XR9^@4^F8'"/')T38C+`A`!S2.AVP*26[GS-U:
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MV$%DD@]A)(=>@`!#K_\`#6M?LS++)8#`8#`8#`X\6!,ZC3=3W4Y7K<UGQ&[H
M!=W/K)RK5\&LF3L3_)JUDD.JU8B10&G$"TR/6O'[7M)SE[/,7!4S.VDK:@4:
M//1%-)*A+O6M.#4</)K_`/W#.JG^+H0PFP>?7][>ZQ1W<^R9IK5[>F:I'H?/
M?2%S2/E.0LZ*U/D46!"WNE&E&M<%BE(Y$-CP>)0VDJ?I18VPM1S21_[YZ9A,
ML_!$GL6@A2:,DOTI1L0J\>F1]Z$7*$?'<GC-)5NVJ;)7GL\B^@Z7<6<M8G`[
MKE:E$VJ_I`@^M)&K'CR*AXX/Y`>D;CLA[JZM+$JE*7*I7%%D0G[S5+6Y'1")
M/<3[,?U[3NOHQ?SZ\B4Z'SDR@3?BPZ-R$D2Y:):SD!,2%DML1%RE1Q;;\E=>
MW)?=L,U=2R.Q=F+1T?"NB9>O:&%\(1#@MZ5]5CO2;:Q."]Z4E_7'SLRQFY:8
M,)HADP\O>@%[4;%DF(A)BFB=[^0;II_)Z?Y\0,L;C+U&ZWZ9B2.R6%JF#0N;
MYAS9#[0FMQOS6L32$HUI(.KR?4\<PFE':.)<'MP'H9OM*`1J,8TG^/XXM1$<
M5NR[K'H"!6DY5[,;"JEFD3'*E]/O_1[I$Y(PUW"(NZSFL79!8$GK%QM/<)2'
MDI9B5&B#U*\'N=5:,X:H))AR$Z5"5%:)UQKT!>4IO1:&0V3!['J6Y[+M4AI3
MLL3FK4)H<X90W.TT1RJ"O,NE3BX(*^E"V0.IB1@/;B_I$ZL@W2HXSYAGLHBO
M,F%&J;]Z8BO2]RO+)>+%)FFJ9_>@)!6,FCKF[`2UZ;T1RVQQ:O0D()VB31E\
M*@DY6JFI\4(CC@$*R=EI1)S3MFJBETIMQX^NP+GZ<?;>2V6RQ%O2Q]CC,I:V
MAD6PK4DKQZD$NLZ.N%6RMFB5F6(\`-844(2;"HD2:+/YCCIP+.:22@$>V91$
M),4U?-\CM[6?'XJEIF;42D?_`-Q=>6'83V"'NE@(XU8O\L_0EVV+7)S0WV(S
M`9W0B5U6TMIR16H$M9T2I4`T`U0B1E7;$<3;"N+#\@E\DSYNLEHFE?Z<R8C<
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M3+<OZ$0][VY/E`(4Y+LKD#<M&G<'`*9"H4EHR]-L%0OOGCJ&V+T[+JE%.9S"
M(N`N`=+DN_,D4,<]RB$#C2;F8<>FTV=AR09,Q9)>7*5;DQ*E#(WEEM[FGVC-
M/T)2,:8B(28J%>S_`,E73$,M^VJG;:QB,E<:\67-&F81,;E))TCFM#HI?T')
MVOVD/2@&D<CY)D-?FH=D^\[<A>%7QZ-UHI*%MBEVP]']RR>P8B?M4AM7GJSV
MZ/1.>&5?=4>:3(Y![PL=$@Y&?F."Q!L26+($CJ]1G=\OK:N0-KDI6*0H$QN_
MISDZX&VU-J+TGT;:\BMWE:K'NZ&=I:F/HPZ/[K!Z.>E-QW+&GBF^GYJHLP^3
MGRPDYVKABD2`EC"@&T*V\"J/&"&K`J`G)+LQI,K6E^22]"]GW1S;>/8JJ!3*
M#6J8S2\13/S.YHW!=8$,:&?A*$6F*[2W(4W0EM-2L<R80%.J+3>B;3A.*DP;
MFG6FAWJ1$3$?QS(BZ7BT=HW8FX!NWH@YKADSL&LII(89%WYE6U^OC;\P)IE&
M(R"QI.G@ML2^L6L<)02)6K>TJ6:C:0:93AGN"`L9VDDJ-U<DK6E-0;M;K.>:
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MCN.?59?\:N:6UI>\35J)DG4$CIZ"1ME<'8@IL/2F*FYX`I,2",1_37;'-:6%
MQ%W#>%N7U#Z<DCM!)G""H`!L/?TJ^"I93(2HM2]/35MO)M3H+;E-AO359S[.
M%7S!51E`Q$I%3>8C=51WS@/98Q$63$++YR?)K8/>]H.C[)#@PZMX1><=BT%)
M63=0W)GM5U)+(TY3(XQWG+FT'NSHP0U&F$3MNTG1$EZ+;PHRMFEG2>!/!J(N
M\F_1H&4L+3*J5EOXQF*9J>YM$F&*,[)RV,J?]"Q<B"6,IM2\X/`%\KER"G$!
M*,;[(XZ,#B>NV4G4!-;DV:VPNU)I-Y".JVNN]W0^RBB8'%!3>"QE="6^*M<E
MDS0A0\D5UT-.GN*.LTO"MX]<A+O)Y^84%E:5R&1!C*#Y&4AZ<AB+U*C@5"7(
M.[>E)Q.&F"PN:TT@>+5LI5$S68^MWIYE'(Z1NZ"<JB;HW:3(*?M*N23>P84C
M.=VT#D4P_$Y-2T04RA!L`2E1"5"@;&\D=WS>,-D5!*XHUGSBCW1DFK9%&1##
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M(]'HDY2%S'RPU7<1=15?:OESN4^)J+'7C91-:-H51S[00:81*5"P`?>VP;8;
ME<W7+>DI[+<Z[M>VHV]-\0K*_H8&-,<4-AC;84DK6[X&0ELEM8%,P?A-[TQP
MR:(FUR()$M*#HT!_R$:4A*U)B-MPDQ%-4C>];DLR^"8*T6]%8Q7;-T=2*S3V
M1$F",K"X:=U+-J'?JR?T:6Y)'*"&:8B;6Q)M5*&^+NY[QL>R&O:-6G++NW2^
M:U$0NKIF<=$_SQ(JXK/H-I@@3S*(D$.A;_%ULF;&I`HHGR%KYK(UD703J+&S
M!D>WN`M2=0`[X4A+@G0&B&(Y(2`:*VZQ_&B157/\<'UY'[ZO>_>FF6O)9&H,
MP0][B.U*^*IUT01R=E"CI*H+-0V.RI16:ZVF\1Z7R*P524);A$6QG3MAS:-.
MZJE.E`5"8B(\R8B(M2URV9`GCHF]T]<])25/&(5.X-6G7>G?HU2D=U[5.^B^
M>FJ=L,#KIHDS8JIZKN8ZJ4N+6]31"B:3BC92I)VN/4)G)64CAJ4IQNLZPU[D
M8GBM_P`V9K&9GHF#\BKWBP)>_MLDY;>)'UPSN=P.L2TZ.Q=NL;+!HBB=%DH5
MH7EQ+(B[4J`=LTPO:FU^"MI^5>C9977(_8]I($C@]Q2L5T?3T"RJKL,Z2-D5
MC/M"U5LR(--N*WQ]3RH,WOZ2ZT42!R/)1K7@P@WZ0X)Z)))BYB.:3&JGH'TW
MUK1U:/E`@=5D>LGE^(=*6Q.SNFFM';5JV+6U?Q.IKAK%,MD$"N!VC2%)/C;)
M?X\)V*=7@]&3'_0)):@H9>DQ$Z^*U$ZK_;^[+OBE@-*ZT9/3J&IYS:DB:BE:
MF*N4/35-`(;V#,N:#=R2:NL[6MCRMDS00SJAN:DAM2HW80RBR#"E!0"VV.7%
M*CDU#LCR8W)8\%0M+3,HFA1V70K\4^(XBS(8:_Q:6+N4I#T6T3.$R)1<A]L.
M!IHT3>44I3Q$,6*0K_IP/!SL48458QA=L-U^\[IGE!=;\XVNQO\`+#H/"**O
M5/-ZU:W-TW&9LX6C/*1J:L5[S&TINT+H[L=Q2J.)TBH90CT2-R6Z+&`!QOK,
M8N*2(N*:,4?W'U=SY'H52:E/^^ESJR+V*6\:L*21YPLCH21$SWK0Y^>XN]2"
MSDEJ.QL1=:B1-R!`Q1*0(AD$+R5:U%[4OT]F(G5:B4P:.WNA+).JQ_F%BP`,
M=VJF49^RQ=TC29KN-W='_A22H$8U-*WY/&QCEM8)K0D)J!,C?UJQ4PD^]R2$
M?*N)QM@J%AK^_.IH[$8RLG-E\_05/8M9U]>A%N2"KWMMKVJ6Z7UWTM*FNG7Y
M`OM4H,A<9C(*'0HT#L8Y(%)OUR\@A*8JV@T&;8*ALWT!V3:<'H+EVPFZ75-4
M;G<%(R"WY9/+&CKD[P,4LB5,LEEM=-,3:;+(R<A=[0=G)4%&(Q<H7@;&A8!,
M0<K$685(B+E*U0B!/,X5<:>0&T9_:TMJZ7SFT[U6'SDIHG3T]T&QHFIDC#(R
MC9FV2.+PB9ZG;"-DKE3$%D.2)$ZA:'1"HL:O+/&()XPTOB?44\ID#1JK+-A;
M#$X>_P!ZQIW1(KWEG6W+LDD3O$>2%2*9U5:TO7Q&P%D)I>-39_FTAC"TY:I9
ME*)\*+6%(!Z4I[5\5JUVR/NJX97%;9B;K>M+11!#(%9S!$)@T1)Z)>NS1*)9
M>5;ES?GM6Q3Y4=$5==)J_0G*U#8%^0%/)QRD\Y&V?`,,B(2O)'Z\ZVZF>WVM
M[..=V2)O<%JB-L-V\[/S8]RA<B/6=0576J6%JW\B<ELP;+6US+-/@)B2D5I'
M73JA&E3:;]BV>J"H8>0^0"_EWX!FB>9UU-%S%$?WS.*:!-#\SQ2GY38-%]-D
M2&@+U9D$U?%4N4\\#@Z23.8%0V=T$6A4"/3(]_2'AM0M0_RN.\N@H?:;97K-
M/:ZNV.R/H>9&&V0-PAS1%;D;W_I=NII;#JM,EMU)GEE#7$2#]:%)$$4WV)[7
MI"S$Z-N-T(U,1_(J.*^:<[JO5+:7+C1T!9=,:B%X4Q#K8?PPV#-C"=&QV3`;
M5LLM!*F^1W8=/X9$86QP9,%'+TC/(HZK+1NH7L;*<)$(,G&.23$5HOOR2=C2
M_EVO(A(:ME$11/SW%K7L5O*D+!&GUFES-5,0;I)MH!(97;-4L#2VNZEZ2%FA
M;3WN4+R#?_IVM2(M0:GF,7.IC%J%>^W.E6=]`-XFU+1>#6M8%EQ>,2UTKUX)
M:.=(E5_8*/GH<QGCNNL-.WST$ICKNF+$:HVP(D+ZH3#]PDPC"=VH*A)XQTW.
MZ[\;G,=BEVFTKK!M-\8X<GL]R9VJ5M<A6OCC.7U0\M*BU+9K&&L:!U9HT:8W
MK)-*2$29)L!`!+5@TB90F/BDJY2#C+JRP;%K?J"^K/G[`M^W4]SK>;37[8R.
MS@V5:UROC:!61(U+4RMC^^2AYA\HFY;N>D3IP!/.4(UA1!R@[W;+DQK4$QR:
MM1'R*]52Z+V`M89=4"S=-L-R6L_OCA7;`[*9_%:SJODNT&V`DHZLZ"L*%0Q0
M]*[W>4!K@2^O*U(B3(]')BUY2L([MA:ATIYFZ)LZUK%Z&A\[:F1L;^:'A;6L
MT6-<=>T1CY90Y3,Y2TJF79SBZC,8SN=U,'?1$E%'&B6R8981>A&@;S,5#,Q4
M.2#OY,[SL&K;>9M7!3]?,SE`ULP8KZ?HDSLB"/H)7SG:=D1VM"F2%W],!1F5
M2IXAX#&(UV>F^7HT*564L9RW+X0E[VQ<:-5"YH+V_=$97D1EL>X"@,CDW@;.
MSUG+TLJE5G=2J[.OU[IR5AKQ[?;`TX-3O3K`S$/SF2V-R]+]0MU\R5N0;!O$
MQ"5S>@WR3WE83&UN%/R^AU/X>HQIMNP7%/%7B;(A2I@Y1?;TG%8$?;+!;28\
MXGS1&D0';.,4JV=",THPHQ5[1@FWQ-K+S/L?M6*CE<02S>BE\IJYO?9H_P`G
M64S*2FJ;MZIHX1?X]#T\>36U\L62M/\`-H\)5+B%8N4JRF9",)1)@U.Q*@J$
M=7>13JB+VVEJUV35B]FP-VE$0?7=6VQ"#E7><SW?T=53K,8FP2&YB9\VJX8Q
M4TW.!K5&F26)C5ZA84N5MR8Q*:5=L597-9U`](=)3WHWFF,VY;<&);W)-+ES
MZS0Z%+H2PV2JL;E&FKQB\,*;G>>2`\3S6SH_/IZ`\)BE0M:4HQFD`,*./W)B
M*T)B(AC;?[OZ+8+0M*$0.24VF?-65*:@CM:/L)>'R84FWL,^I&'1._;(`AGC
M,OE,/LHJT!GHT.T[,F,^Z,X$RPP1:S:A$16I$>+M0S)W1(SM*5[<B'EZ3-J%
M.[NZ5N^T)G5T)2E%N#DF:?JW#[60N5A&:!/\Y_P!%H'R#]ONWAEDL!@,!@,!
M@4H_7!SPTV*LBTFLJGVVU8-#GF9KV-\E</23J(0,AO+<9!)52->M+>V&,DM.
M@*5BD6BDX4OM-,%\?H++4_<M2I:$]D\FR%DG,Q0S&NHK6,;DDA)>K6?I15S)
M74@D`9:N@#BYMKT3+#CG<N0NZ$9)+F80%.OUZDZ.$>6<06J?O*F/M6+)'/E]
M%+4%ZRN;U2@>8/$Y'%TLO>YW&D;)'V%8AAUE/YINUKN6RHUR2/MK0Z"6CT%2
ME:32S=&`2G^HVO`UX/(T=*<=^R4KF*]><P@C+:BG,S6-=C5P`+$V2Q>E;T$I
MDBA*[!TW$R%T>TY`%2G8-J5"THOW"&>7H:I*E"85<?$T25W%>$=Z,I]81)W*
MLTMDS5=>4:?(Y&$^XX8DJF'(CU,E4,<'C:M`>O7-;6FTF(4K%[@J``9IQX\M
M9<#7@E%G=<\GU2BGRJ96_57W&OFEJ?)]&FV411WE["R2U[B<41NSY'$SB-U1
M-C@XRMG*-/4``5\2M,(8O885L4J2(F4O5W/SM((M<3V1.:PG+!4+8_G70F8W
M>,R\422L;8L>7E!,FU"H7"1'@0L9XMD*PAV8)*,/IO90M!5)JK:H^V^3[>!,
M%,2M2O6T^!LX)D])W^40QE<R8"HKZOY^=9H$.GPY<E@!$;L%L*4.J@"<@H\(
MRA[T$`1"3C,$Q,)HIZ6Y,1)TK^KO6@4I$KABNR$CH?8L!*W(H"S+BF);-2E`
MW;1CI&&UU0@0F+O4:<I41I/L>C0>S2I-7DDO3W+%8M+W(%5LU&B.7UA(NAS&
MQ@E<.,DLVKB/QU>_NEBLK4C<BELL;#F&/GC*7E_*4>4E%Z&[`4+8525*?TU(
MXI9U706T8_#DT6:K-C#58"1F4AAZU>01-&[3SH;FX0IUD<6<7!:F=-B4'HG!
M:0<(T>]'&:%O>T^")^.-1PT;D:8P,AACRB"VNY@VI",;JW`3[2`;W(8B-B7(
M@)=_'HHWW%Z+_P`OIZ?LR`HC4<6-9C&K8&14RG)$B`YG4-2$]K-0M_M^@1&-
MYI`D@TB+V:^$O8-@*]->W6O3`IZS.;*QMN70J83$N5FGPEP:G,F.M$UD['"9
M,IC\C:)C'-S>&-;DFCTKU'Y6PI%Z;:H@0_D)^(P1B<0R16YA;7*NC["Z)1H'
M-D:'%"9]%\B-<VHU:4?VU1]8W>].H),)%]`KW\I/KK_2,_S!]!?MR(^Q;0TD
MN2AX*;&XIW6$D)U;J6B3`<E2=-H>DQ"A<$K2D\E/HP6@!$+80>[?IK7K@>C2
M-'H[ZG21-I1\@SOGT05H[Y3"2DQAOR^WW_(-.0`O8O7UV``0[_9K6L#$%1**
MDI6Y"3&8^4B:%:AP:4A3,VEI6M>K^I^J6MR<";12)6I^M.^0PK01C^4?KO?N
M%ZA[-,;(%<0Z!9VL+DE3&(TKCIO2:7)DAQVU!J4A7HGZ@E,:HWLP0`BT$0_\
MV]>O[<#];9VC;@8[[:FW;J<C&W'.>T*7;@:WF#*,,0&+=E?4C1C,(`+96Q;!
MO8`[]/76L#_$3*SMS46Q-[2V(&0E,-&2SHD"5*U%(S-#T8E+;R"@)`)C-&"T
M(&@:#OUWZZ_;@$;(S-R5*A;VAL0HD)")*B1HT"5*E1IFX>S6],E3D%`)3D(#
M!;$2`&M!*%OU#K6\#XEQV/E!2@*8F8H")28M1@+;$0`I%AH?8:K2A"1K1"DT
M'[!&`]!"U^S>\#Y"BT8&0N2CCC"-*YNH7UR3":&\1#@^`-3J`/*XG:?9:MU`
M>D*'I09H1VAE`W[O4.MZ#)'MZ!2%*!2A1J`(30'H@'IB30HSRR3$Y9R4)@!:
M3F@3G#!H0/3>@#V'7[-[U@?-N:6MH;T[0TMK>UM*0K:=*V-R-.B;TQ&]BWLE
M.B3%E)B2M['O?M"'6OV[_9@?C;(S;7(7/;0V;<FQ&>WMKAM`EVN;T"KX?J4*
M%7LKYTB-1].7\A18@@'\8?76_;KT#Y(8\P-BKZYM8V=O6_;DK1]8A;$215]I
M0C,,1-?U!!!9OVY&8<,11'K\1>Q[V$.M[W@9`M(D)-&<2E3E'&>[Y#2R2RS3
M/>8(X?O,"'0A>\T>Q;]=_M%O>_\`'`K>"TQ65<P;5<1>(M1$.$H7JU30XD!>
MBW)2Y.RE[5'NYSM]8>[&_<%0A`$H$9LL(0!#Z!`'6A:=KF%C="@$.;,U.));
M@D=BR5S<C5E`=$&RMH7(!:@DP`7!%L@&R3M:^0OV!]N]>FL#_26-E3JUR].S
MM9"YS5)EKDM);TA2MP6HB`I4:M<I`2$Y6J2)@:+*,,$(99>M!#O6OV8'Q_#<
M=^K&O^P,OUQB,AO&M^U(?JQH$NU&TJ$:CX/F$C3;5F[+*WOV`^4?IK7NWZA#
MFZI8:V6D\W"2G<SIJ[PUM@)9JQY<E3*PQ=`[JW]6@B\=-4;98\;(WE26I=CT
MQ(#W,Q$D^<8])2=`M\A]XM5,!AKU/I$PQU&0]V;*=S&9N2GWKU3J][8XW'M"
MT<M$>-(@+;8FAT!(3L"8!I6S=`T8,8A2Y+2=7%XROV];71UB6;DB9.BD6U;0
MWJ-OR-(4,E*D>MG)Q_=$R8DP0"RS_D``(MZUK6M[P/M^'V':O2_;(T?7!:M,
M05GVU%]6%D":%0%GTH^'YM-6CPZ'I/Z_#[]:W[?7]N!ZM-K=I26MT@1:6$[5
M;)5Z2D?4E;7?!];LL_X_E+VL^F+^7TWKY/C#[O7VZ]`\`8S&P"7"!'F,`G-;
MIR<A!:4`1.#CHY(HTO7;TGUM6MTH0$#^4SW#]Y)8O7U`'>@]YC:W&K2W(U`B
M,<2B-IBEYB4@:TM,+8Q"3EJA%[/`1O9@M[!H7M]1;_9^W>!\2&5F2KS'5,TM
MB9T-0)FHUR(0)25YC8B&88C;C%A905`T"0PT8BB=B^,L0M[#K6][P/"*(Q0:
MEQ6"C$>$L>$RM$[JA,K;M2Z(U^O:N2.)^TVS5R9;K]AI9NQ`,U_\M;P/86Q,
M9*EM6%,S44K9D!K6T*BVY(!2U-AVDX3FYM/"3HU"@-"D*T(DK82Q:*!ZZ_RZ
M]`_2)D9FUO*:6YH;$#60;L\AM1($B5O)/VKVOV<4C(*+3EF[7BV?[M!UOYM^
M_P#^7[<#[F-S><<:H.0(S5!Z;:,\\Q*0,XY(+W>Y*::(&QF)A>[?J#>]AWZ[
M_9@>98PL;BE.0N#,U+D2DL92A&L;D:I*H*-4Z6FEG)SR1E&EF+`Z-$$6MZV;
MKW;_`,W[<#Y;C<=VJ&OVP,NUQB,AN,6;:T.U0V]+M1M*A&H^#YA(TVUANRRM
M[]@-FC]-:]V_4,B<C2*!A,/2ICS`AT`(SB"C1A!HXE1H`1#"(6@Z4)RQ^G^'
MO`$7^.M;T'D^QLGUZ-T^SM?W-N*7$-[C]O2?7H27,T!SD2C5_#]0F*<#BPC/
M"`0=&B#K8_7>M8'G31B-(TZ5(DCS&E2H%BIP0IDS2@(3HUZX9QJU<E)*3A+3
MK%9JDP1IH-:&8(P6Q;WL6_4*PN>@H%>L621&7'S!E;$BK9P5%>362UVZJ$1S
M4[,+@Q+G*).#8H7Q]S97U6G-2';&4#9NCR?B5%$'E6)HM8Z2'11%'F*)D1UF
M_#483,B./,9S>F5-K.GC92<E@"@3*BSBTXF<M(5],/7^<K98=AWK>O7(,\!.
M06$T`""0`.&88<`!8`A-,.WO9PS0Z#K1@S=[_P`V]^NQ?_C@89)%8N@;T;2A
MC;`B:V_:P2!M2,[<F;T(G`I40O$C1DIP)TVUQ"XX!VP!#\H#AZ%ZZ&+U#]%Q
M>-$@:"RHZQ%%Q](H0,)9;0W@`R(5:8*)4B:`A3Z"VI%*,&BC"R?8`96M!WK8
M=>F![M-;9HPTW3<@T:?HG1YFD:?1AVD^B=)]&C^/W&:(TF+]GKO?M^,/IZ>W
M7H'P3L+$D^K^D96E+]P7JW1?].W(R?K7->1],N<5?QDA^I7K4W^F<</W&&`_
MRBWO7[,#SD1:,)@LX4T<84X8Z(P<?"0T-Y06(9J7:$T;/HM.'38(Q$+9(MD>
MS>RM^S?^7]F!YGB%Q&0)CTKS&F1Q*4,#I%3-J&Y+L\,;>TVDCNQD*@EA5)6Q
MQ3:T`TDH8`#T'7KK]FO0/:='(\H2-2!2QM"E$QB3C94BEN1J$[28D2C0I3&T
MHXD8$1J=$:(H`B]!$$L6PZWZ;WK`^RIC9%R0]O6L[6L0*DZE(I1*F](H2*$B
MPS1RQ*>F-)&2:G5G:T(P`@["8+7J+6]X!8R,K@WZ:%[0UKFK0TYFFQ8@2*6_
M0TB@M6D'I$<4--H:542`TO?M]0&!T+7IO6MX'W(;6Y*::>F0(DQYZ=.E..(2
MD$FG)4@CQ)4QIA981F)TPE1NRP;WL(-F"]-:]V_4/$AC<=:T@$#8PLK<A+(,
M2@1(6M"D2`3';#LU,!.G(+)"0;L.MB!K7M%Z:]=8$4KBK8I5B65D1@+P<HG,
MZD=C2QVD+\ZR1Z>I3)C$P%*E4Z/"I6J"B:VEO1M;<D!L"9O:D"5(0`!)``ZL
MS9=I&&(1,"02`,7CH4`UP',:(+*VZ2#<BUQKH6X"3:3:)$N`Y'C4:-V'Y-'C
M$9K?OWO>00RN*7@%7-06V.-9RT_4PGT\$_298?)I,.5V;(7.33)UT_N^U+B0
M-T7NIA6BRAEE%(P%)P!"26`&K,VLS:>I(\P("S24+&SHB3C5AYQ21L1)BS3G
M$9IC@<:620`)AJXQ08(X6];V:(8MB]=[WZQ'K$VMPQ#$-`B$(T/M,$)*0(1@
M?1,'VCWLO>QA]J(G7IO_`/`H'_Y(?0/.:Q,9ZQ&X'LS4<O;].(4"XUN2&+$(
M7CT^[:1J1D[.3:=/3_R/8(/S_P#[_NP/MMJ:]F)S=MJ#9J0X"E(9M&GV8F4%
M)#&\H]./X_<2<6@.&0$0=Z%HD>P:W[=[U@?+;&R[7JG7;.U[=%Q"-*N<MMZ3
M:]8F;CAJ&].J6?#]0H(0*#!#)`,6PE#%L0=:WO>\#*8#`8#`8#`8'(CHKQY7
M#?=VS:<J+>B;="'%UD4CA;0N23-5]K7.]&,]:-\>?8`UO#-73NC32^/@7.K\
MI*6R-[85XV;1Z%*C(T=J,HB/-J)J%9Q?CGI1/T4^6&F)JTJR(&['7<@<G>)2
MU#SE*)O<DRZ1(D%;(56U&IB^KX-!K-TXJ'\A+KWO8R=F)BOJS0$6XKR+C[GH
M2>+*TV^/-M3%VO63G4#&WI7)(H=H7(#9J\RU;0U/T@_H'1%IW,C:&%)R:J-6
MHB"]J3Q$.@$9GM"AT<L;H^\W0V%?>`71YF<>D^Y=$-)6SH.RKI=4)T74&F.Z
M.==:<P=&I6<\?U7QFN+<R\]B:S#S`C`-2I3':#HM/L&YNT+A1LQ\7$Y5)H*[
M0^R(LED5<H2B&IE(<K2JYAD*AQEG8;C(#'F5U))F&<M)86;JO9I(49P@JE;:
MJ(4AVG<!C)NXM)E'C)DK/`M1:%V!!D+DRJ)FYQE2LC$C`W#7KZWYQA\21NHS
MI"]2'34C<>?B-*Q&+ERS3<H)!HXXU-H8VZ.9:[Z(X\L2NRNH665S:))(;>#(
M\1^)0Z#!FCG&X>?('FU'I^EC0WV"\O;G!$ST99!6AP]G<1Q=$M0J5Z$M*-T4
M)RI,PDS#75\\84_F5/?@Z267!FN<G/"F5+7F(M,P:6H]]1TSSO73.VENJ%Z:
MIBC8W!ZY_3#<#DZLA>!L5A+3F!/3EF9=VJ[GJ!XR)>*"S'_],XPVV+(G>F;`
M1_:9A>(RBIO5W4ER](NK`YW2[31PO0]EEV[-3(CGQ,N2N1;NC&[`1@UL"#3<
M6P[?XOK(;(R.O$-@5DCA<F)3SZ7.`6RQ7F9LUO-M1V=6:-AB#[,)3)WIRJUQ
M66$!P6GNKD8[""!T("#V/&]H&[GS-SK76K!)HI&$D8D:MA6IXZF9&*,J&-,X
M)C#8^SQ9@;OD?`+CSP">#GU,N,]4_L("D&0'V[,"8(6&5@8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8&E=D=UU95-JR.I9?`+^(=8K!Y/9SQ*F^G)
M.Z5Z77,+:T;E*ILGF",)C>J8&,UP(1G#!K9OUQH20@%O]N:C&9BUILNUVE6S
MTU1I[;9[#E37,7/['%EA<E91$R!^UH_Y(^T#TMV%Q?DXDIH3$9.QJ2QE#"(&
MM@%K64?J<69!:Z0+ULNDK4UG(8S*9>6RC6IAR-U886TG/<F6,,?";]V?/M+:
M1LPT*4HS8-;UZ^GNUBK&+C]TU/)HK%)HU6)#1QR;+&YJC+BIDK,D+=7YT)`>
MDC";YUH/?*=^_P!@V[7JL`:$0-EZ%K>L5*U+/:L2O]N2=FU.8=MW5/JB+)6K
M4F9=N2F3)$`'55'$Z'ZWZHY]3-9H5)B,(=J`)Q:,V#0-ZWA&1:9;%7Y&ZN+'
M)H^\M[&X.+2]KFEY;G%&SNC/_P#Q=M=5*-2<0WN#7Z_^22<(!A'_`._H.!BD
M-DUTYCV6VSZ%.!FF`,KV6AE3$K'J+"6FMH9+L)"\P7V`3B2-/I9_^;[.`('O
M]VMZP/GNT*TTA;W3=B0;38[-#C(6IQW+6#Z%R8&<@]4[OC>K^X?3K&AJ3)33
M%*DL0B2`%B$,0=!WO0>XB=P=4M:VU-,HHH<7R/"EK*WD2)H.6O$4!\?ODS6E
M+6"/<(\'Y@>JTH(TVO=K_/\`MU@>1+9=<KB(RJ13^$K$TT/VEARA+*F)01+%
M.A*0[3QDXI>,M^/T)&=KV)=FB]2A_L_RB]%"/UW>50VNQ1"1U_8<5DC9/F)P
MD\-^E=DQ+A(HZU+S&MT>FUG6#3NY[<VN)0B5!OP:"0;KVC]HOV9:F!$%'4E)
MDP6W;*32XIXA%(OQ4<GDB84YKXV$.1D8ALNW]E5MGU*>0)"6:=M^S#D@C"RS
MA&E"WH9)F@JE:6LDL&`K]1@2&;Q!8&;#7EPP222LJC4N,:BS#70$8V2M'I_&
MVE%"$HTD^79(0[V/TUK>1$>>[IJIA97-\4SZ*K4[6P3.2C1LS\U/#NO:J]2'
M+)F8S-#<K4.#P?'2R-A5E)RS!D&[T`>@BWK6"F1AMI5[/XHT3:)S"/.\;>F4
M3^C<4[NWC++;22TPUQBS05(OHC&DQ864M`9[1)#A?&;H(_V8F*TD2TUY:"%&
MTA[JVDJ@FED;3&KDI:C1YR12O))V2,W1FC34*(XX(?3U$44,>O\`*$6]!0[5
MU+4CO:373B=>_$SMZ5&)FI"JCCF2@7E?#;BM&Y)W?10VXQJ=6^DGU2D4:,]A
MZ<"<8?V*2O=:FKY+26Q*]ZHF@[&*9YHRE'U-(I+&["3.ZY*SJHNIBBL]$[N3
MJG<3B#D<>"<E-V2X&:`D/`6,0![T'>]*E%DI'QE7HFAR0O#6M;I`!.8PKTC@
MD4(GLM6C,<4IC0J).&0Y`4MY(SR]DB'H9(=CUZAUO>05O.;[IFMF&0R6:67#
MF9HBC7'WN1&B>T2Q2SLLJ>DD=C;NN;F\U4X$-3V]KRDR93LKX33!_L%Z:WO5
MB)DI*U-BU^B(DJI9.H<E30Q8D;I@>IDS*03%'%?I-M`@DAIJT(&-:MTL)^$I
M5LHPWY0>W6_<'U@CT<NFLY)5\+N0$M:6&NY^QQJ01J02]8GB2=4AEZ5,KCQ2
MC3\:A^C<'(M66$"<S>CMF"]F@^[]F6INA-T,FC;F\O,=;9`R.$@CFD`I"Q(7
M5`K>6$+H0)2V">6P@\Q:UZ<4P-F$;/`#Y@:V('KK]N059_,15)ME.E4H)$!W
ME4?1LRZ5#9P!<F*'IWP-F?2:E;\F-&VL"@@^IW8E22H&`Y*=M,$T(?J2M[M3
M5K6EIVBL>O'+ZK[=/(8O^AC:>9+?HI0QJOHX@K`<8DE2KX%QGT\;5`3&;+7#
M]$H]%BWH>_;OTE2E2AZ#H2D')WE3(DM2#C5PIIKU]DIYDB;D[2VM-K!<!5RN
M^^*#RF96GF(6PWZ$1!YFC_\`+K7[1@T*U*U+*KKBKM!:<>I<R1HE%CR1CDLC
M21M"8!:L0-$5+CQKDJ?0IAF"8M*"I0D$DTJT7M8'8]E>[18_16EE<V,B-^U!
M-&&721HGT;3M4`?9;'9P8].[>QG1!="YC(X*\'29.YJ4YS$VFO\`%%NDBE5H
MHE807HXH0BQ:%BI2DJ<[,KAE"H$\V!"&D*1L;WI6)SE;"@"E9W=6E0-3LHVJ
M7E:);'-<N()3GB]"CC3@``+8AAUN#X$6;"Q.BAE<7E)''0,L-A;6ADZA*P*I
M0^%MJ!TT7$D[BH).DA!R=?K18TH3/>84:'6O4L6*D1RY;VKJA6Z"NECN+@W(
M['M&%4[%AMS0O>!JIU8"M0BC*%26WDG#0HE*A*/1BHWVDDZUZC%K6\L1:Q%J
M6YL[XYEZV#6!E%35?+D]OT>Z="0I4.-/C4F45XQ6""K'[;F<Y(TX6>3,<\V-
MO5M2CV+2323/<#T!O>)B8XDQ,<4;IWR(43=ZVPS8G%[^:8+63=:[G([HG-`6
M?"*+4IZ4E3E#;$+CMMR!@1PN1JF9]95P`E)%1IAY:!2,O6PDCWJSC,$Q,(PL
M\I/)N^=Z'Z6BCG9]GP[ID+V92,-JFG[`L&XIR7$43TYSTY%5$>9%<P1)J[;8
MZM.?352<DIMT1\9@OF-)+,1C,S1ME+&_R.\H/$??I6RS9[=HY'E/)J98[HX3
M*M$*/YV%D;1<_'H25+6G6'$R,^6(M+O<4`;/[QZ6!)$6/09MDJ60Z=\@7.G)
M$NCL(M=98JU^>(P98,A*K:J9]:*:K:J(D*6)J+>MU5!V-Y*KRM"9(KTC^YKO
M8$PPH\18!EI5(R48S/`B)E('?NCF"/W7=7/[W921LL?GJ@$O3MMHU+8Z[:(K
M3)_UYBF4&OI*,YN7&M*%&6K6(TXS5:=(M2&B+]JDK8E25+75'Y<N7%\,896E
MA_4ISS*+/9JHCM4E\LW.9=#Z_P`FJU\NR*N[-6!47,DSO#9+5D<6O*1V2E')
M/ITQ@#1%GEF%`NV?)=LMZ$ESQ<=(G7Z\M$YAL-15XYV:\LTZA$BB%@QZ.,[(
MJD#HFD5?O:)))V60H6Y&9\C<>G`J"9KV;![M^F2M:2M::U4MY$J(Z#M<JIJG
MB]_RE3IOBB]TL5/0%G$TM&C9M3<4OB-M$IMPUA#"8\_N%=SAI/TB5*RU`52X
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MO6#GV)N\73.]NN;RT-)RXW[2`XE"WZTJ5&$I_4W3;-UH;9>$ORS\P+7^AHXQ
M0_J64+^D2%>JN,C?*MWNB-:],#J]LU@Q!\4`B(/PW,ZD61M<*6-JS12A@3IA
M'J=!(V$P3;/D;9\GP=O,!Q0THX"\?B.SW:+3.$1BS9#-8[2UE2&%TG6TXF3W
M7\)GG04F:(\K:Z>C,LE4;<"49[N83O:=&<L,"6B+&HTVR;97A`._^8+.G^JQ
MA4W7/$U!TU;O(:YF!&WHDQHO*DJ^D%I3B//!AR0!3>U?@6-*5[<YCWI"YE[+
MTG,&(>M9-LPE3"!W1Y/.6Z-?IE$9&;;,KFL"L9\K:20BK*:L&S)<F6Q"H()>
MT[E*5AB+*XKG"!P*L;*9E[LZDA&208L"F!HQ3_I98QF2(F5FWMW3SCSG"H38
M=DRMW)B%B5Q:%L1!WC\4D,B"[06H:D<KPF;N%*W(#%B<9-=-1JM*0:6`]6;[
M2"P;-%H&2(F>!4RJ*9>5+DF)HV14U.-I6BHE2BBD\,9J7IVP;5D,W_F.JJPK
MJJHZ',,/97)TD2=XK:KGEQ4#3%#^B`FT$[V"&'6[ME=LOL?Y4N-=PT,W9IM+
MI:@75U4%B1IDB59SM]FTUW>UFSRFJTKV'P9,Q_BMZMYWL^M'IF4Q@*0#LUJD
M!NUI2<LLP8&V4VRSQ?DNY)!"^;)L[S.2Q5+U5>AO-581V85_,HO-D5W(7.0,
M#[`[!A[RT)'RO7",R:-*&QP.="B$B=<8G!\HM*2!&-L_@5*JG7R^<NL+A=;6
M_0+K9B6<_.D28++`\<EW<WA;9/8<MB$-K:*-@U,4`%[D]E.,Z;%$?0IOD4.[
M>HTJ3A&3K8L;)\EVSY,E-O+1S+6:2*JK(@O6<#,DD0G]DN;5)N1[X1R&NJKK
M"2L$4FEL6I&RH8H?Z_K1H=),D%MY7IBT8TPQ'!%LL`A:;)\C;/DWDL^[ZOIV
MF9AT#/96A;*C@L&7V._R]$!0](]1!`U[=]N;60SE+E;WM<BV':0I(`XU6,P`
M"@C$,.MR(F9KFSY-<*K\AG/ML.D2C*%';L&G,L>+?CW[N[9IR>UI.XT]T?#X
M=8$Y;I;'I2SH5#*+\%6`SN3<=L1B9S3K@_3F#&`P`&V5J4%;O*OR&\R"DF-C
M=[0?4MXQ6BIBWR]CIJQGB!5DU=/*-(>>R+UF;>PJ&&GG6VW'?P-25Z.3G>NP
MF*-$$&%FCNV3;*[JM[7H*XG:E62#/S\M<.@(U>DLK0I?$WUJ`Y,O.<Y8:[M(
MYR-6I"@,I[7*)*D*3%*=@&N*&(TG0@!%O4J8*E2DD\J?),3EMZQ9]<;51H^?
M&"Y'J8S[]S%C&5>^KN>$B%9>4.KZP0,.XW-9U6`'``7)J2';4;,`:%/H_9!_
MQW;)ME8%P>0WENB(KTY-+,F+TQ1[D-EJE]NM65#Y&Y&M22ZF]*XUTGCR1`@4
M*I:Y/A:THOZ9``XTHXS18]:%DVR5*&W+Y0N4J*G:"#S9=:JY*;6]6W!(K&@U
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M/LD`8U0]N1'O1F+BMI`#$?\`Y,L8S)ME>KAVYSTUTU:=^+).\EUI3-L/M*3Y
MU#$I&8N;;!CEDME2NS8D9@-PG1U1DS9X(3A5IRC$QA0MG!'LH.Q:E3=%2L/H
M[H6N^6:AD=VVIN3BAD9<8@S*DT+BCW.96Y/,\F<?K^)L\?B<;2+GQ]='F5RA
M$E*(3E#,$([6_3TUO$1<U!$7---U/EGY?^V0DQDB/4<QF$VDUPPT%00OE:[I
M'=L2D]#%0-59[1/ZH0Q$4RAQS`AL^/J`F*TH"%*=U3F$C&$>MY=D^2[9\FV<
MFZAJ2$3*HH'-W)\ALCNZO;(LJ#IY/&GAF(TQU(P1J4S]MD:I8F+*C$I8([*"
ME@VQ;\2L1"58((=_2'^R5*4U09?+AQJ_R.M&-O>K4$TV0U4BO-L4VE;(!5-8
MN/2K8U/%!1*ZK'TP"B]4S&UFV0-AS:WNYY!Q8'5#M7]-]8F^2[97;*.;\Q'+
M97[QRUM=]@M:VJY["*HE;4Z\@WHWN^K5LEXB31`ZQ9FU3$@*WR?2HN=-2]$U
M)@F*SVM86K"#9&_?C;/D;9\F>F/EJY9K99$T5FQCIVMS9#!-VE(OQIRQ=[-N
MH*SW8SO5A-A7HG%#S5E1PQ1*V0_V.+R4F2_0^U9L>DV_ETVSY&V?)TW+,+-+
M`:4,!A1@`F%F%BT,LPL>M"`,`P[V$8!AWZZWK]F]9EE^\!@,!@,!@:0=(\T3
M2XY793VP.D81H)IQ!T'S0A(>E#D4>5-+9<HNK871:!&V+"PQA&2RFZ6&`$-2
M'8@_&29K>]ZL37XK$_U:(7)XMIW(;"3NE:&U_'JU6/*]`57\?DPZS:8*A>XM
MR>F<+'94K=4LR,.DY<@H!Q$8B9%$7<5&SD!X7L@6U18=1E"QDV,[$X[MJ\KY
MB=D5J&N6E*75JVO9')Y<\B7JBV_22T2OM(H`[5K,2-KA[L/>V22QQ^B3XR'G
MK=K=O",1"`,B8B")B(U:L7!XOKE<XNL@50(Z"CL,>6`I`%M3A01(^+RM/17.
M=;%R=&XGTM8"\F/K'FFEXG%O8!1MW<Q#:U!KL$"<]+NQE',B8NY9R1>+JQ!V
M%6DKCRV!)$1DTG;]9@&.2&PHYK=I#V,MZ716>C4)ZJD,CG4S<8UI`UK2DKM$
M%OUK.A+$Z'H-"`4W11:YJ,X@MZ"<V]E4:^%U='DEXU_*(#5S(SNXI6F8C7>L
M9%!!*Y+88:O@DX>(2>J<D?VEN?@RJ0,+:G,(->W+0B0$)RB9B29BXEJ;TKXV
MK%8%'1<S@$-B4J@CK#'E97-?1]U-1I`[>:/KRCRZ.W446I\MQ4P'2N,J7%0H
M_%"QL`@/#LI@TX%?5Z1E^*QEP6A)O&/9$O:K9E2EKIF*3R9G161P:*1)V&-J
MK@#/U4JOB7U%%9T^U*XD-$1LN-($I;HXAC`TI[ZX*AJ&=0D+T!0C*(^Q+_!7
MSUXKN@')G2QN+OU<5_J24C8L(FDN4S=98CBWK)BV7[INB#,W/E*-JMD5M#C;
MY"(J4Q!=#$/X>.=$"F-+"/H2M-T+N69!?&7/2!@E,H;:P12G[DU2%C0N<I-L
M%97[T1TS3%NO!D8E+?4%8LK4-YBM5C$;]ECS(G^ZJ`A$49L2A<<W):I4WB8O
M10Y%-)LF@<28S:Y60UMD,.G#BC!`U<9K:[JKCIC3$$=/,\A?$%A$622]NR4J
M5M#<C.=7A.>D=3`)EBF[H-S=!BXTL!WY:Z^J!\@%!50Z],3L<C::UK5T>'JJ
M(VQ&U52U<.+:\+C:_AQBQ2_GUJO4J@IV8)&R5I0!?(/Y1[S<7$^!>L2HN4>,
MJRC+]:)S%G.&H*V'98I*@C;)+CH,FJ=H:^D%O0"=UC#"CJ>1+W=TEQKCLA:@
M9WN(%%KT1(E*IQ1G&IR[NBB]$+_M06.R/-4HXHKKEHC+#SS3$$>]1^1F0MIA
MEFU37%HQN3.3%&&BHUC_`#-EM24V*)8M4!D<;^8*AP&YH7/9A90VXW/,DX8L
MF*OE"1!?$8#`G2SK4C4,L^`4DV3"2T^@Y1K:D:L0W&%ZFQD$A;+'7JX;`H>(
MA*2+DR4T]*H*2%;7'$K%):^:[FR/<G!%O]&6\V674=A0Z!@0P5A]Y3V)^)6B
MMJ,OS]!FB7CTSH%1*E"5S9>=ELV_>/1VG)6U^@?A`:,N8Y5%2D37%DJ2X-GE
M2=$1FR4SK`D]=Q6<39W:8^U*GK[LCBKP]]JJ8TUD)C6-.WZ5-S/T4P%&A^;1
M81HEF@B%H!.SDY1,>:7HH:W_`!M7?8LQMUW9"*;A2=TM6Q+99Y9%I0Z-L[O9
M#-[@HFR4546\:YU._M$89&9JIHQ)]8:5+D8E)S</3=LE*J)46,HA;ALV;QS:
MZ#A:*TK`I#%H5T37DM7VO5DI>)"\3"*0*QG"S)--`IS']#$8FM<FDJ+S%Q9#
MMH6)J1_`J,+2(4J7XDY<N+ODEZ^3624^+^>)SY5$H)&Z,/@\;-E$EKN4R=V=
MRYQ9R5QC50L</H2V$I5>NR9FKV''5>6+3J4K>_?IO9QE-99A!_I=T+N8F$>-
M"\83*G69NB"JK7,C5D_B=NA%BV*M/A-\,3K-[PE9X+":V^BDZ6(.T+.N(IR;
M3G,J>*S7IO."!4C2FE["W15%Q2[+LX=O:8<3\N<SP\ZFCGZJ*Q(KFP=.(TZ%
MD)4#H)_J8ERKB32JI[26LS`TO+UOZ@LEE0/BYC$,A.XH#!#T=(F+LB=;3WC_
M`)#MVA;\G4]D^JZ2PN1UV6RK=LCT*8R&3SU8=`E2J2M2Z0UJR3RO&<7X<<?O
M+.=*Y$R.KB>E7-R)E^,Y.:F8F*29N&GBSQ978^1:0Q%0U\Z1HDNJ6:GQ2%F=
MI.I=;H&Q57VS`5EL6BFU7C?INE$U6=,M1ZY)M0]'%_"YB&O4>Y,`>MT7;6Z$
MLF?B\LM5;USR*(GUYJ`/;VZS:N&-?)Q1^-.C8O'1HM<XRZN(W403&NK5K;4)
MK*J5'2)_;26HU&-*PEGEFA#-T:)>C#VOXU[SGKJXRMA@G.<"`^.+!*G*K:TF
M!T,CFU1T7Z7@+A"EL@?^?K$;')+&&JYVQYV\!8"=.KE]V`D;V?8D:C+NCS7=
M#9#FCAZR:1Z'B$U>&ZIG6*P6.7.CW;I#])W2\K!';J&D2VF*2DAYB_N$PUM^
MZX]O)6JY"XGKD!+8()"8PM2#>9RN/-)G15-K>,^P'I"4^0`^MV67`L>U;,EY
M+,N3Q-9;Q\D[04]$0F/R^4N=83YM-,9H:XF^Q6ZL3Z0B?$Q)):8Q*,2DJQE_
M'W&Y`G3Q36(AK1F)8RJX<I^R3"HG96D_&6D"R50>&\PO]*+*W=K4F%&V2,4>
MADWEA[NS%'18]$<D1AT2E:U!I.T;=%^1N3EH\7DV1&FGN;E5[XY,S-!&^"2)
MY4R)^D<9<(O-.3)`N=D;Z],2IY3.9[=S^M`!8%0)8<:)'LT>O<:(IN@W-S^M
M.?;3Z7@G/[8C,@T3DU8]64_>$H2*']\=&8V(UG)'M8K0,;L7%D2U;(7%H5)Q
MEEGHTJ<*@1A>S?8$)@Y$Q%_8D331#QH>*.QN"[X8+"4SR&NE:*.&ZTI^0UU'
MU#T:1%NGD[I"55Z32!Z7,+:3NM[75P-(]F!.&G5A?E"P[:4/U(QY<LMT?>LY
M7^+7&&^)3K&.5=U+2#4Q\WUX;T^MN*&2OJ"+=$=$RJQCZ;O;I\5E3E`7S_+:
MV!2L=E)--/3@UIQMZG0#'8@CYC!)U"H6[NBXG71=T:2MZ&>-GMOF27M%B4-:
M=*WK)*AO+I.;4^VW\<MJILD-<]H5]72NYV>4E4I52F,UZ_U_T)`/O[&0PLAK
M:[,CDL2':;U`PG!FZ)XI<3Q?*P_$-;5P69,>@+<FU;S/H=RF'C,E;'/V.16K
M7T2,<>4Y#!WKHYP<:H8E*B$[#.OLCC^%DR\AZ$D^<D(U"/8=F!;XB*CAJL95
MIR;B]*<Y=FI^HGCHSC&5T(TN]Q<]P7FRREEZ!EQQ]2IJYLV;3R*7'73!&V!Z
M;[-<TS;:+\C51=T5,"54J*;SON0"P*"AR)BJE(F*J6H+CXK^N#.BYGUPW=(5
MV?9]I6[U67+JLF,"8I;2[/0EY5`52D";S%(H4VV'93S$6*I*T<G*+O3F&+J%
M#<Y$)A$;-TI/NZ*HW15<FLJ3PV]8ZKF(,"B'<P)H9">FH1;\<XV;NJ>M2*"B
MC,P\W6S3\_=ZUM\R#J;8JO=EV!8"!^)AS*WD1]E1M`$P#SQJ%&Q7?%\[I=T>
M=NR\,KZ_)-SK=7+TMK&MJI;VWFJ.5%5;C%;#L"PXDHDTMJ%^CTI:#);/(\V3
M=]C4">34!!+NI2#6N!)I@C0;4EF!S.EVS>MJ/\?7C/+Y;GLYN6U%3?(+><T5
M,QN'/,(LNV@Q)OB,"Y`Y\H.3(GRN53E'ZX='==-JP>%:-P4,RQ>%M4I=_4%&
M:V02RRO3DLY7HUIN/PX3ZR^N7+IUIL*)1C\:]L!LFVF1`O>TZBR.5`<\5]`8
M['',P,</*3V_5ULQIW<X\/6Q(BVQ_6`&K#LX1.6,HJO(W:4OKC/BCK6`6GR^
M^=.O]!F0G@WEJ9<KT*KI5PG"R37*GF(JF8C[4M)HE48C[56QR&`4NTI@QQL5
MOY(G=:L4Z7A)+3D[3,5IS)F.7-J[8?BO[%MIIN>JY-)><HY4B:S_`"9WI1S\
MR2FR'BPYC8_<$&OB`5TQ6>U*Z]:(_7T,KQMO=>I>#FQ9(E3B>F3@)*+`$P0[
MNB-=;T7=$?:]B'PZ6['K5=+T9YG`7B;R*Z.BEL@B$HG%H.E9%55=W,333$5L
M.'1!:@7Q"#])U9+6HW93JWLQ0G6+O#DA4K]C-3B(;XJC='!B>?O%]UA1-)4B
MAB%;<HP>[N5;/H6VX3I#TMTQ9]?]&O<"IBT:%LMKL958]8B64'M]AMFJU[(H
MB[:\I$CI[`'HQ)R@[VG*)GG4DY1,\Z=%6?FOJ:9V/X^;EOV;U`_6-SF_]-2>
M[]0!#(&.-'?OLKR51"$12KD:YL,5/3?`$[RB;E+BZ";E+F2A&NV26<?M,#-Q
MK$<$N-:<SHSXG.W:SHF?\X5_,^9ET+Z\YAJ[G#J"7RIXL?<EIX^`*;'BK[.Z
M19D,(,;[0*E=13_Z9*TO2F-A;)$C"KVI/3G&DYK=%WKI*[HN_!<]+>(FQ:9[
MCIKJZ.SV&H(VR=$]EV5>$'3KWQ2.Q(S9C?=;+RQ+DWRQQ.0*VZVBUR.#(_F&
MFE)E+8>6`L\_Z%.$<G*)BI-VE,-V#XO.BKDEO0<HAK-S18:*V.FWBZ8.V6'8
M%TTS8E4KUG)5&41"[;KB_*:CRV?5W85>3FLG%8N8T!1[9*F):22H6I3B0ATC
M*(HC*(7QVKX]^@^E:+YPKIOM:&RBQ:EYIZ0J&P['L0U];#K#L.Y.0'Z@T,\$
MF:6:0#+)=;`=?NSJ$S?R$I#3-E:/,UHL2,HB;2)B)\FJ$=\1W47.%L/UA\SR
M.BYI$XAUY1]]\^57;<SGL):8/5,-YOZ?K"84RKD<5K2<K&YGB]C='JU45T0D
M6``PE`2F[(V06#=WQ,:^"[HGB]4<\0_3M<K8C:<3L2D)/=-;CHVZ6=L?%,WC
M]:S+H*.=1]DWY=4&7')XY('^(5*\QKK54SQEY+)<G5(L0%*U3?L.A%#;XX<C
M="4=.^,GO;N5$SR*^^G:MJR>P2A+5;JY;J0BR9[B3;=MFW:BM1@9W1PL>!.#
M\DA54L535\U$RYE"T2UW/3NBC12$L[1!TC+&.!&41P6-T7XZNC[UJ[O5`O6T
MFKG77$WX%L-LC2R96''X4%PYE;*+,MJ*R&7L$.-EL>:I4Z5LYIF=Q;$IZTM*
MI(/&%.=H0"T91$QY6D3$4J>0>._N4EJ8T=.P/CBHB9'R/U7QS-8R]="]*W"Q
MU]&^C+.A,W!:D.D<TJ@,VLB0MZ5C7#.8'52SH@*C"BR5H4_K\=W8\[XKNCSX
MNB>J5N66<67IR<W1ZLH^HB$/7\W4`ZW#'U=F5]:=8Q6JX5&X])KFA:@IL.4M
M<T=?NC4[I$OOT%(5]2F$=L1?NS<7;-ZVYJ5GXUN[Z1CE>SRJ?Y<4,QK2U.@3
MZTY3FG0?0]B4A3M)7]0E?U8[12#=`3:NI#:QYC/9D#W,"F0Q@(9B$[JI;$8T
MNM`/WK=C/&VMT3Q7ESCP-VQQA)(+$.>['Y[>*KG%>\-Q3H6>V$EF>K%B*_D^
MN8S4]EDU'!$+$X1J8--Z0&)ITK<8[/3.?$UIZA5[7#_2+#)RB>*3,3QXO\XA
M\33KR9=_.=X?6Q04JB-=]IQ>^EC=8%J25/*WJ_+MA5B54I@D:EWR12--T=C3
M"L(>=-Z1E^18:7O1:K6OD`RRO0G*XKDH:]O$WUA:UO=G2*)NO.-5Q[HNLNM(
M>ZS*`S:YXP?TDGO"#:B])1[HSGU,Q+*<C\KHQQ'I2NL5G-<I)(](B-[3)]J%
M0<L9146L914)`_\`A8G!%AS.(T_9S-2O-=A7MS?=TC5$OTCNFUR5'.M$3&+-
MD>*:>@6*RXA(&V072^MKL,AW4+425M:@_`0`[82PM^GF;OQ5B1X3NB5D:CBR
M8V?7$YL7GBCN3Z5H/3Y-[335==$6Y,Z2O&;M,.ZRK5F:&Z)S"'V10\NB[2J+
M.0O8V*2H#EJ`'Q%:TL;X_$W0LF(>+SI:,//;99%7\<+5G33SUZ^L=K6!;_0]
MI)'UFOZV%EG1VJK9Y<=(2QTT**.#8<6P/CLU+_NJ0L/UZ0)Y_N),FZ-..ANC
M3BVJY;X#M.&<,]6<IW(OBK"Q=`CM]FJVG8U;-K7W`N;:WL.J66`M]=1BV;E:
M&FQ9*RIY8B<9&$HU`F2-)KL)(A)T20#8I.6L3"3.L2YS-/@JZ*20U>0\6]5;
M]-YAXV[=I>R52I=*@-<L[\N.2R@<GOY0I!$=*3(>?`9^[LPE6R`.7Q!(UI'H
M/K[=;X_G_)=T?S;.3'A+OAUHGM+EME;>4!UO>5^VAT35=BN5LVNEF9<BD_1$
M-NZ-0^>0I-2"QE9F;Z1D5HEJ]`[N!Q0Q%#+3F:V/TEXW$ZV7&DSX-L>M>>NL
MNT.`[%I"R8GSS#;VE,]K!\1QB+V]:KI4#G%:SO"N;+^UN=H%59$;(CSI)X[$
M5:,Q0W,8C4"DXLP@W>]>\$B8C*XNDB8B;C@Y<*?#7U`2EJUU50/ER?LT1MCK
MV?)^;WSJOK6)0VM&CHJ/\\H&5#'.DV&OEUZV@[`D]2/;T[B?DR4@)L@TF3Z$
MG2$>S6^/-=T.GGD:X;MKLSF.HH'5\NAU,WI7DF8#MR@USD;NP,L#G];R>B.D
MX6PR#;,9(W0M]IFRWY.TGJDA`U3BG0FJ/I]Z$,O..53Y)$U*@K>\;W1SM*KZ
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M.(!GF(8^SMC(B&J,^92-(U(B$"8:@WT#\IXB2`[&+TU[A>N\YL,Q@,!@,!@,
M#C+Y+[%[TH&F.LKPKFQX7'*PC<2;P5"7$4C0Z7&RR&2._-,19!%,TZ@:ROUC
MCJ2'S[0/N#D<C]CJUC,#Z$F%D[QVS-2U%3,0UK?+(['=)A$^>'OKWH[DEQB7
M'?1'9;S.^@X?Q.^7I,)+"[7!!8O#)R*M(C)N?PTK5T>2`?7I/']%/:]`^HM*
MG)'L`LM1QJ)U73CHU2I#R/\`<MV]3<^+5,YM2OF.Y;:X6C&H$YPSGINXR1,=
MJ\257TCT!6$BF\B9S^E&N^)2B?'MV@*1(K&C6'?3)?D.^-22&SCC$?QXK,1$
M.R%LJ>NN6O'OVU9=B=!DV-<T`YVGE@5?-T\5B"4,,D,`YL9P+%^FY)#&!D=M
MN%MQUU?0E+$"@K0%H2_0)'M2)\14Y1$<&-)F'%^;==^2FMX'52VQIOWPT5G8
M%RV&\Q!V9*3X@_GMFM.UUQ,NMNQ#05TL95-'#@D:N%E4JV@6TR66+V(L\OX3
MS-)0F;K'R_T;K&^2=KNV.XY#0ML7>^]C1*NIKQ%X\^2NJ2H?`HG4,BJ_L6<W
M7'9O/'=ZG3H\1E>[+J^FJ*+H84VE09:QDIY0J6*4JD[_`,)/J5%U6DRE1=<I
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M3:+]62`$=B*^0H5:$^2J$!K@$_0S1"S4;O*F:BX\%I<GWGT-;'C]MUWA]@O+
MWU#5,ROBIS7/K.NXA%Y?6DXKV5KB`Q6Z&F@'ISK:RI37$85$!V\18UM9Y6:2
M0;LIOV>H^&3$1EY$U?DVMX7LV9W%Q!RA94UDZ616K8O+=)6%,'YP1-Z8;I+9
MI6S(\.$C<F%BTTI$B1U?3CS=DI0IB?V#+*]F@_Y9E%93'*TGC,0TAX<ZCM-E
MH+M'H>_[^5=)\YTFX2"15ET`YP6#5D=9+?5-<&+NBG>NH]"4#<VF40EMID=&
MR"*UWUKDL3(S]B7N2;Z1:?J8BXB.*S&L1'%RCJ;RU=MRSE>KGUAFB"YNE*Z\
M@<!)N>(-%<D0U9;7*ED<R6IULZ4]&V"00]H7H)7$6**/\):G-*D(.<7^%$C^
MI.`J.V9J<8ORIK;%^5/];O(QUY9E/V-U57O8CRS1*D.,'GK^!PTZMJ:/@W0V
MEO?_`&)6<,A-@D/D`_&Z!',*;JJ-1I""/NC*Y$N!Y:C8CE8AA.;8NICG_I!4
M<*Y_Z.R_D=O"YJ6USQ:-97N36C+&K,IY1=E-_ARL']4\518UW556\PL>R4\H
M4J[16UK!FR3J&$M%!4)#R*4R1L5G*](T1Q`\XQ$W$LQ$2ZI'.C:G;U3L<X(B
MFM"2L4K7$:DG2)*0W?+]><H4^_X2BT7TX_EV+>M%[`+W>GIO,,OY0*2\KO2_
M3=/=O,M>W?$TEL26R*.M_D<AS30BF9.R<Z7O?QE2%\X5[,;IAJ>J7V_-QF(D
M_AQ]>DKTSG2&>-Y9QA@"PZ+ZSC$3%\&ZB)CP=.:@MJY;R\7MJRQNZ-O:#7W3
M2SHB/R*QI55=%16^8;-N?)G,=J*NL^,(FNTJ#DLA9TC`G8GM]CR0IN?20C7H
M2V\X_P!A&:B,O)--WDT!2W_VBYU:2%P\A4SKI^IWQ/U_Y,E$XE=<<Z&K+HLF
MV"YJ[K(9-$1E6M;`#FZFPUZ0U'(F-.UR)09*2AJW@1A:3W6HOASI=/#FOGR?
M^3JX*"Y/XCGM9.Z2HKTON/,_2DQBRR&.4Z$96%05,UW!:U*`9B8_)7-F<;1E
M3^RP=(['$D:;3741PE!)A>AA8XW,^!C%S/@IJ?\`E!Z'*[<>ZOCL\/%S%T7U
MMXY:UY2L5AC<75#9$MF5ESM;-_U&[KE$=<`!,M2GKE,DL?<%AAZD@YH=22#`
MZ+(`%MBO.I-L5YTZ!^.JQNU;*L_I%FZ7G*!\C7'#NIY"3A8&N'I3.B[:9E"2
MUG'IF0$,[.A4PQ>ZTK-H0V$,"0PEN)>%#X:(GV;1:)SE41IS3*N7-H_SCT-U
M_=2KB9X=^VY:(WR=UST^_22"PN`402HXR>*?0ZG,:7TAMTK9\<C$M>GMO[OI
M83-PR8+@[.0%&MHE@0`UJ8B+TX+,1K7)44![H[RK6A>2[`/G=W=@2GI+QY=I
M=,3)K0,7*L/65I-($CH(B#31N^XM-.LQ]>5B:_.)@T'U#N\KCWD7J0N"6221
M=N-S&D5*U%_>G7-W47=]O6%<$[>+/Z2=ZTJ"IJK>Q/$-2<3-/.C9)7[QIU1?
MKF&SX]+(T3U*\NC[;,U.<M"BQ8VXGZQ*3ZE)BE)8),8Q'G_W2:CP_B5[^%?J
M7JCH>4V(U7E:%M31BCG,O)-@/D?Z1B?/$,M5NN"[(J_S=UF-1M_.[:W-KWRQ
M-HAM$)B<GWY'43JD5I=_$<E6$@F<1'`RB.3GMQCY:^O9E<W)4(O:YPBAU<R+
MJ"==AR)1!H.TD3NHI]1MJ=!<G)S%2&.("&/\"P>IW_Y36H2,Y>-K#]6,SU%[
MM3C%32SC%:<7MJ3R)=>]0<AVC,4G8LXK&\ZJZDY3=QF5Y4E7-*!9SOY"[6J"
M+1"MW]@N*FW=6L>>:CY'*HVF>6XLDMQ<V8H]4>O+'[=IQB)X:5_0J(G@V]ZP
ME_:7-MH]H(8[W_?,K8^?/%\_==PIBE==<M;2+;14*[KKQ$4_J6.@V=R5Q]J4
MUZC>R4Y)R<0W48PFC&BW])DBIK2.*14\N:FKRZ8[MHVIN:ULTL?R0,2NRI[?
M4HL)$SQ?QEVETFX5C5/*)5I)'"K6F!1U52^Z^12<D]>O2.>Q3$PE.<!.4,(B
M"AV(QF>7\UBIGDW8Z)MSKH/A:@75:#I[5?=)Q+GRM[HE%BT2S5#,(':CK(6)
MH),2J29E!9I%SHP\$R,MQ,-8"T`=KR0_2GZ1[^(S,1&^JT9BMU<E"6]V-VIS
MY=]V\VL\DN.[8W7-^>*2M2NG']JYG;D<&:N@+*@S7;;;9$?;4D$?'AXN!N>C
MF].='HJN2M?U)8PF(!A^7=B(F+^U8B)U^U11GD]O.^IGY3HG`NJ7JN$-?U'T
M!T?Q@NK^N(5I;%6+B!TF-86#`7EWM2K9#&K*C]ZNS:R3/:A$-:N0M#D820J2
M;!Z!NV(B-%JJT;O]F7!V'SGXI::L>I>@Y?/NEY9-><70ZS9S#:G4/LG16-)&
MB5RF`&1N-0"/0<AK<F(\]A1FIVLMP)2C+,V>-5K9XLQ$3E4\&=)R\G,]]\P/
M4LHYNZSL>$WLAASS?_8]=QG@>3/=7MLD!47.K_5KQ=:=8MB$>AKN^S(F40*M
MC@&JW!&O.2*I8G%L90`%[!J,8N/"FML:>#HUS9UQUCU!U9S[&838B%-R[T'3
M5?\`DC(E7T,1-FT/J?4*;*LG?#QB`^,`,/++Z3=$CV:_C#MV2,H5K7]7\P2S
M`YF(B//@DQ$1YJZM+I3R"*/(7U%%J7EEU.E,T!:,<:I>SJJ[H,7*L!HU9PXR
MVM+7)]L!Q:T]]G7T1:\@1+F)"@.7-AI)Y92HKZ41OQVL=L<+_P"Y45KQ::\Y
M^0KNZ554:TR/HJV(RLLEN\6M>RBRNE*WY<:[(HN==NRTXV:7U2<?J-B*@LAY
MSE%>&D-\-<YH4I.+EYVB%!.QHEZ3+.,7I'BLQ']4UN_KOR#1ZTW7D6G[_P"E
M+GE53W;V!5L/LZAZFY6D]P7,Y0;G'EFXJH8+?0V%$66GTZ&G9]=:]@F3FS)F
M$]2D`GV,HE5\PM(C'C*1$<97G$>A?(J\W%V:]6!-KW:VCF"+N3<]IZQWQ?KD
MV"V:Q>.^O;BD$>E39-6-7UK*=E7A*52M(H81*F\11R(L9OTQ:L(96-17/_J:
M:?QS4KR-W[VV^Z@I$SNNW7%L<+Y\4,"G33TE!.8V&WT[SU*1*I5<!D,;J+82
MXX9S%:,#/91Q1\<=:D&G%*XIRSB34BLL%G&/#Q68C^KJ.DL3LY1Y.3>4066W
MG\Y@;P]QDV"4AAPY@=2ZAF-IDOCO2$N."+$UE7^29*_Q'K6G7\/!TV;6;-WL
MS,Z;;Y\&=-M\T+<[WN^3=<]%2]9V(AHR`<N=64]S5$.3':&5HXQWHILG5`02
MTC6MT>GUN16B7<%W2JP3$,'6-#P0WMP&'VB;701BL.U14::S!45PY.:TR[=[
MKB/+E67#$^T!V38_>7`EW]&-T=!75,Z8./[:BD@I'<.6U:C:X<!W55U&5=L*
M80[H9B9(%"I\0$J-*2U&U"?>JQNJX2U475<%7-?E([XO118CC!+-L!G9GZ6^
M..FX%#:RB-!M-D)9^\61(J.[(!"7JZXR*ORY!,;FBSVU(C)(;MG;=-0=E[(#
ML8MMN/\`4J/ZNOG5=K=94GXTJJD#',>C6;HV5]`\[UJ\N4K#Q\^=)F-=L=-1
MZ$/,62*XJU'<AAF+C$'W:%I5[+"U)P&$#6G!/"H,UF*G+R9BIR\G.MAZ]\A=
MIRFCZ+8;+ZS<)]'7KR'QFXXQ4C;X^8OT8U**!NBAV*J$UU2*YF8WF%X?HK7-
MKE#=SZ_.TC<3G-*(D)HR%@@ZK&-=*T\6JB-=%BS#L;N"!IO*!=A%C=#*XAS)
M9EOT_4[]+HMR.HY`ANDKY2D"9I#*$+(TMW4+]/*E3V"YRMQ^H^"**R6PT!A^
MR=:+Q4:1XI4:0Q'1?4?:'/EFO?(T6ZDZ0Z03L%^<@K!6]3E:\JN_6:^'7QS_
M`-=SZ?44Q,\@@T=Y_>Y"4YT(TRID$H:4CH!A=OI-&*Q;2".D1$Q>BQ$3KHQ_
M/?4_D+Z*L3E-C)N7H";1:3<>U+?TJ>>9OY!F,)S/8?6M\PN-S'H0=XL.D8Y#
MNF(:RH96S5S[36^0(',I.G+,^+ULQC%_:DQ$0ZF=Q%]#)^NN"HS5O7%O4G7_
M`$#9TTK&PX%"8C0[VT*4-<TC;UX`?FQUL>I)M)6]_DKA"TC0NWI:-(%LUO:<
M@E5O:C>,:J=(2.$N,4Z\IG?0N>DCPF!8U=/"3G3R<3!ENQ>T\[.4?NV64IU%
M75=U2[5XP)%<B=8ZJJB+OJAK&7)&9D2+SU0#CRUH0?.'>V+_``:J+_!UE?9]
MUG3WB[[,M*533HJ+]`PR!7))*VD?3`N/);8,*6,\$0BB;P@(Y6:5%+.492/9
M9BM.F<R5+D(_Y@J@[(V0',Z3E'"F=)RCP<54GE,\@5I)K._#5J3%G'&ZZX@H
M<A@@D,I%OG"CJ)HZQHGGOL^00USM.+"@Z:03&36.Z,+86]B_#C8:E`;[2=!&
M;K6V(:J&\TDM#R'`Z#YWH!MG'?/RJ>:9E<EGQUM<_%B7=;8[?S2"K]I?+9DK
MTP:HUS@J"$&EE)$<%.,>O@,+$J")4$W89\-7IQ\TTJ]&;L:UNQZ;O#MC17;5
MP3>+4+T5XXJ^A$'E<!YR)8?PQV+=E.EV&C=%T;I=ADJLV/QB2+F9F-TO`,I"
MI$8HVI6!+4@14UIXFE1HTGC'F([@985)XY.)*V);7@?.?;]YLTJ=87'U$(G%
M/.W2=*5;S3?KVG0,C82+7-Y;Q.6R1MB0U*G5?AP)R[Y-'A/U=D?S7;#LUR??
M=BPIQ\@E1RB[[QZOFW)L>AUBQS5VT]5E=RQY:YG74U?60,1F5*":HI9]>V5(
MZ]6JF`[<<9W)K2GZ3&C7!V2:#,QPGQ9GQX0Y-V3V_P!OU/SS54V8.S9%?,O[
M1X5A?5@M1>O.?4SOSA8#ETCR/"5#7120,311X=?S&/=".\1:T4Z,>3"WYC*4
MF.(![6E@U$8WPX2U47]DND7(/;]E1+@SN'J;H>:3>=1WF>S^BD4#;[P9ZEBG
M2[.Q4K$F1(MJGH2,T0@;ZT8[2-M]$[(FLAN)T:K8ES2H&(S:D`Q9F/BB(YLS
M%S$0YL5IY9^Q@<^<HR/=@-UZ6;2W:5K0?MD+#7!,37W?S;%.;Y9TX].<.A3Q
M$6%]C\@AU6.HCF@*-*WC=W6&&D[&:6H,T;9QB_*FIQB_)L%S_P!7=_W,5X[6
MZ.W8@D4$\C$`;YFX6X>P0!OD=)I.89_(9S>"Z%L)<-*;WXGI^DG)A86X*U,K
M_#KH4J7E_'HT(`IC'6?!-/P7SW!Y,Y+S_P"3OD[G]@L5I8Z<9C*W:^G8:?$E
M;L?,7'KF8/E35">*;@CZ]!``4J]1Y+(W`)S@W?<&]\*#OY]!T`,QQO&9YD8W
MC,JWY-[0OJ'W#S;)^B>M2IW5G6$K\A,8F$!LUBIF$1_GH7-'1;E6]/2:%R^)
MQ:%R(ECD.]M\46D216[:7/#RAVG.+4"T6;9B-:CA1,:<.%*M;.ONO[T':$9U
MV6JYH#SY1G>/3K7.4$#IMS%<"ZH>Z>DJ1K^-S`$ZAKNRFTA2-?5`U)9`0S`;
M7ES,?DYI[H4/0!&*B.7A_0J(_CR65`_(CTO8L,CLM72TJ#2B9^0O@6N%%=!8
M8X)3$:GZ$X>HB]YW6J=.Z,Y[R:W+Y7*7U<0N4"-=2DP#`@4A+(]H$XQ$_=/]
M2HX>3GO4GD*\GDJYKGT@A-VV,YW.HYZ\>DXC[3U)`N9(V8\75U=U=6\)C4AH
M%#3<:+4/W)5F0):\L+@Z28H;PUN@RBB_I%Q1^@:G'&_+5:BTZE7FKZ,;W>ON
MEFB6OJ#GAOZ+[<8;6IF1P:+ER-BBL'JKD6MJ_J][6`C1$A0/M-=6WJ>E5J"C
M0&KC=FEGC.3:)`&;(X<S;'#FL;C7IGR5WS:/.5=6!;_2TQ6QJAZ\DU_N//K3
MPM"V,$X'W3U=2<VD]K(;XBZ.0*X@=#J>1(0(($#;H60WJ!A*TK.)&8F,8\/Y
M^!,1"0<N]Z=H=+7U$^/;%NZ55%*I@M\B5B1&VJXA%8'NLTYY@UP%P^A9$T;F
ME=R:'D2NGIE"9/$7=(8W#$H0_1JE.CCU(%(9,1$7HDQ$1:#/G5G?,7XPXSO8
M?8]N3DV;<L3[L_HU;`(QQDOO"M&=`@JDQLG1E#S2'UL1</&M6@.>02=IC2]%
M.AKG=,(#J,&B"2[6-S%<UJ+F*?UBQQY1R./,,A;EA3BWOS*UO*%P(2J$)"]&
MZ(2%R582B6"&K2%*B#PC"4;O9A>A>T6]BUO.3FS6`P&`P&`P.<E^=S^/<V>S
M3COH.7$/$J2M!DDFU7RRC[ED48'&H>C06"?*7!\(K1Q@BZ+QS2%,J,<P+S$*
M9<660(T*KVE9J,<N,-1&7&$`[#N3Q.6C'82J[);ZBM]HBK=3%G5\AG%*R^V'
M5"W],F2M!4+E%F!H@4ED"L-J[K1T*$W)DY@CP-GM7)PAT3[D1E'`B,N2+S/L
MKQ"$N#(@L)P@K2MN5WIOH;Y)ASQ;T?+"]PV5DU#1EMV`Y/-5H$M6+XS)*F):
M&)TD9K,-(4T$[*&%-HL8KMS*RA?,@[PX"MTZ_J#F5AM<G8()';LC/0[?-:JM
M-)3K5&:M(<V*\628V5)8"BJ):W1U.0K2N)`7@[1V@F`!HSTWK)MRC4J8U5V=
MY$/&%(X=";[76$PKD-+62U55`%#A2=P_O1KRPK9K9[%'V:.58IK35MLY=DU0
ME7B;UI+-I`[,X#=D'F%:%Z-N7`K*Z9B0T;XL2:+J7K"94+0#52W/$,W8E03V
M:TK]@-JF(+7XR;)-,$4DD403%@UN7N/UR!C&VA4E/!P-ID@58@:VO*ZYEY<$
MAB_7OCF:.?WNT6J:UQ$J*MSH9\I^<)I+`)+#M/?2ERRW;/+8':%:RV)-4L99
M]-)(^[&\)G]J2B$0JVJ5^U*/9VY65^:5-M8;8WX/.7JYL7EBQ*KY\A5<N%MH
MV^R*=CW.TME:%3;;#6,:NAO<G-GK^NY&N&YQ*J7]M=B'4O?TS,VF:+`H(T6,
MH&HWSK"_%.K8F?.GC%YTYF23F0Q2EH_S#TQ$JFIAM_`-5.$\B=S0==#WH%.0
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MJ7:0.3:TKW`"[;:`DHLDK9I)1Z8RK4K)^*?@7BCAO.T714O5E"13FKN*<QRM
M(\RQ>K%3'!+^EPBI(1$FA6P:C:8+LVKD$*<!MZM:06V*D1`32CAD'$C-3NO7
MC!\5Z\7AN#K[Q3P690CH6UI75^K"<7J:L\8L@-8364S-E_E8EUC5#.).^*8Y
M"7A\A<#I663V3LRF3NP$3`W">%80K=%*1;&B,N!$9/6JI;Q)%MTPNM12O+ZQ
MJX"3N&Y!-@50TNR*@T;8S%=6J36#9$<5E;2)6ZUPS),8SEJR_J7?:@C?U(A:
MTO/AKJ7E^*(6/V=XBKN9:PZ4M!ZKRSE5)W:T06JGV34):4EMFM[KDL4,LR.M
MK#7"BL5-N,*^016(Z?V]1MG`A5EM92T@P8TI1@&W*-"LKI+&_N_Q@0]HBG,*
M>:QV%1:UHW'!-M:N5*W!$(7J/=/261ML<23E0[5LUQBN!6[*W!R*+32-0U*%
M:M2/W`T(T/N;<N)67%E8Q(/%SV%.93RZSQ6F+9E%1U+*J;4P!^J9T3,)=(1.
M?1>)3.(UP\RB)-D0G]<0:T8&S(%XXPL<D#(_-B0`QD*BR<?%&J?%&KZ0?J/Q
M?5!4B*B8!+Z?KZG$M&=$6BFJYBA+ZQ1@NDJ.FS]7W1SZHC147)T,B/3PMS1.
MJ<XO;FYK-*3"RE._E,Q64SYE3,^;_6V)^+3M=VJRM`UG0%Y.O/,5=7.I8I)J
MH^L%6$,K.RG6B7=%'4TIC",EKCL=LNKCV4QM]=IS%+.69\(RRR3<?%'WK>4-
MJ(*]\WW6TMO5\%31.>)%=?S>O6FUDD;6*G<^N&Z7':G4-0:6-9;\)A.F,*]5
M2$!'M5JD!8M`,]A6\FL:)K&C28%F^(6L*LKV4)B^>HS5@Z^JWN&M5*"O%FVT
MB*5F*NZ=I2WXXW)(P>N0RM@-D4=B\61`)+D!IIA3<@2&"),)+OQ2M9<&93^2
M_P`9=10W=O-MF(XE'[[MJ5IY`Z,%%7B=(7V]XRCA,%D<?L^+L56K)=#K=TW%
M,#>2U2-$W/*].%+I*2<7H.\;<IT\#;EP8WFBS?%.9UC9"/E^"P1DZJLUPD#3
M:DMAG,MG1!Q>GA(U)K&EK#+[3558T0MK>3R3B7)T0*'5.I5.(@?4%F+?:'$Q
ME6O`F,JUX+"2S_QIQR?Q3G-("F&6=PJ/7SR]"*Z!"%J(;'%8W6E9W-?U-QGU
MCY;4%BU6+W&7IS;TQPB%J4)?QZ-&F.`4^*KY'Q<5=S6LO$'6E7QOR-3BK.:H
MG6XX!5+K&NCG*MP)#]5_,X?&*FJ;Z4PMBW)2V]P@K\UL:-.))HTAN,`2,!91
M8O8O.?A+RG19L[OKQR\?W?4L-EKU5M1W,_5'7M+U\I:86]&"C5%J9H7&JEAT
MKFD6CCC&:QJUQL#U;XUN1KFMK4NFS2$0Q&_,'%93'DE3,7R44&4>%YYL.VN>
M%3#S.FE570Z:?O/9GVLCH_#D\3Y_@\LA=FLZ>P'J+MM>3#=)5[:CVV21M;'5
M>ICC:\K"%Q*<LP\.K\:_%Q>MZ[8\1EF0Y]OJ2/L%DK<T/5%4:]*WNA;8'8WU
M/XI.N_FR*AK!760+1<HVKEK";)H:K)9S6L]4E-5(#Q"`8+3;GP*RAZ+&[W\1
M,K^UR6S;'JV0D].4HYUXXR215783FWR.AFRSI/7+_#K<?#8"<@KJ#,=KNCLU
MN**7&LY*!S/4`4!+$(6-N9$9<ED5S!/%SS)<<@I6JZ_Y]JBYZ<K%XZX?(7#8
M.2WR"%UM(&ESJA\MDO;6T&IR@.K"W*&=0%.:-<8B]H!$_$:7L<F<IXEY2QYO
M1'BU8^5`0@J14Q_*0?0=:W$W0!HA3PZ5XZ4=>L_>8[59D<A#3&EFWH<_LIJ5
MMS9'$"0YX&Z%Z3!0A,V6#:LKOFFLSYH%,.W?$F]HFJ:R1\B4R/Z:.:K#.VS<
M^7+/I=,';E6>-<4:7>?QF)U:_2V*R>B+&1I$)9$@2-[@R.919?QEF!UZ6(R_
M!8C+ER6Q?$C\9O/<.;H7?;-3$`@]!\U6'.62/O\`7B\UDK[F>9G,E(6>)B1M
ML;7$DQB3FS%O8G9J2Z,5*PKR`FIQ!$$63XN*7/%\+<[,\;<:;EU76A,H<[-=
M!"C\O-A2.J[#L%'`MULAIY]8I"TM40@LC*$7`VVZX>J^H1!."V$NI0S-EA)4
M;)1&7&%B,N2M:-O7Q$-3$3>=()*EAK52W/4@N%KF+?1\ZK]="^<(*RM=5N\U
MC2-]KYA>/P6BC,41M"8QO3F;6MJ0L*71R?6M[LQGPGF3NX2M&TKP\<_CV7U=
M(9P@C-)KIS'I1$ZL>(51EER;:]BG$^(L:10QI6U=7LI*:C)I9$B"ZEM!HDZA
MT<CAF)R#1A,]LB,LB(RR2I'TQP*@:+`G":4P5M;KRL:QJ_M!U.A$H;E=@652
M=%NL@L=AFZ15%R'-8\0FB*O4A4;6E!#IO:=)"Q#-"`G:LDJ>#6=IZ"\.-P5\
M!>8QUBZULX4XCYG1BG_--H12./\`1$/KJ9="--5LZ:PJJ8D\EKB*U_4KO(T)
M*0"E"A^WZ&0("D\@)UK.)\UK*%P<,2SQD6HW,C;P]&JL1`YK:%RJ.,;#4,GJ
M>0UO'^@R0.KE)&9@GD,ADE$Q7"&'Z-.>2"#TST:VB]R@TPD6@S+=']W-)W<^
M;5C]_7@AMB5VSUZL:Z*D4_B<603BR+?D'/MCM\[?(;,%2'G='*F0;]6B"36C
M'W94^I8H-8PD.Q&OK"4I@@Z-+T*UG'PM5G&C.V[=WA+E=>PM]O")5<K@<NC;
M;4["18_,5M-8T-;<X2!E/:!2V.2&J4#[!Z9IF3SY']-(WU*@C#.K=?:6M+$:
M9K:(SB=.)6=^;8'FR[_&BS]`ZY:YG:XS%KVJ6%OM6%PV*T+:D1*A=<M$GD4S
M6QI/-'*N6J$I(,Z2Q&YN3:,#IMO>50#C4`U._7>28RJYX),95<\$UN@OQTPG
MJF&VK=<1IA%US&HG!CX78S]7`W:RFF+6+:;50$!4-TM1QQ>81]RLZP2&!$,2
MCZE%MS,WK9*4P\S$;JTX)%U4<&JLULGPA<NR6Y126)<^UU)+DFMDP6]E,?Y\
ME;D=)I%3+C`YW:B6P5D-KAV3-D7A3S8S$\NR]6-,QA6+P*S#Q&A-,!:SF/)?
MBE)K8?/#`FGK1RQ:$6YL=I!="ZN5WX3U5:F40-T>+?LN66I4.IK.X]%'2M(@
M^6I:TX=WR-$O;J@5/CJ[&*$03AJ0B&C?Q@^+B_Q'</AEDW/]>\OIA<_.G.4_
MM>ZJUK^DS:U?A0)TM?FE:ZVA<[.FB*F)!(;7.NG)L4/!ZI240G,/V`U,:<,X
MGWSXKOF?%=\U41I?X%.@:\I.'H*AY^=:N0V%'*DH%LF?+E@5U##;!Z@T[2EB
M8*Y43VK8DTNBRWS8*<J-6(S#2%JA,1]0=\IR71NOS(F^:_'&K84[N'Q95D:.
MB2GR,H4G2$JG[:K@C#SQ<,FBMO2T$B?:;M!`ZZ8:I>8M)7).Z5ZN;'TI2:/X
MD"#9ZK046P'"SMRX^"5EQ>ZR_P"UAXQ8C53%,*PK+GF&KK94V15R:#T!-Y(V
ME74G9PP$B4D**N@$LVUSY2Q3G[&UF+1DK%:9;M"AT8$.R@HW9<#XLE?.E>>%
MR?$1FS'ZFN='03%<[A4<9>7VDG=N=XY=4D87;KMVAJ=K<X<A=XZ]K6^2+I>J
M`-.006O6'[,V%:,PK+><:%Y<&P2#MOQ[W1>E!0-/8\,FER+"&:P^?G%P@TTV
MA;7FUJ2<YJR(XU8SK$D\*C5GS:@)&K<BHZ>YI9(HCRPPWZ+X3-[W-N40E37D
MJZRIYXEV2UF?A6T6*ETT\+;GVLVJJ'^H)*?#6]+U2J!8[[7QDOW"S:P:%U[.
M4>`XC:3W4I4]K$P/:48=H(=JRK="_%Q5O0?3'A/1<_7U`Z0<Z*A'.::`+;EN
M^%J:DFM8PB5UQ)AMT`63T$<G$%C.K,CS^K2H632EF)<P*E9B1&'W''IRS+E&
M=W/$F,K\V3*GOA>N6`+5#O&N?UD%MV:6]$98W6'3#_!PJK$A`A]<VS%[2C\\
MA,<=(3-"]L0I\-'(D[<M<])?N*4*C0=#Q\<'Q7YHPSUQX,K,C]8L2&D>:WEM
MCL^KRH*JB3K13XV/K),^GXXEO^OV&.1!\AC?)6]OM"+K]RH*W24#9]*0J5'G
ME:1J]DKS@^)L5>?17C$JZ1]8);WD50,,FI]LYIN7K0$AA#XXKVE$5*&-%R_-
M)68BC"_<J5LLL;FX#&)#M<I;%19'N"3OV;W(C+DD1ER?":61XM*0E<IB4Q34
M-%9;0',#Q,)<R"K@UT6UWR9T18:9OEZIT3MT6<RB*KGL\2E*)`CW\B<L.M+7
M`HI,+Y]OBE?BE+*55^.;CFN.I'#GZ-T[1=9<Z/BYPZE=:PKQ4R,48D3#`&>P
M%P)&Z1Z.CW,72+U_(T1XDR`QR&UIU($N@$C_`-#2=TS%\4FYG7BT^B=O>"^!
MU[9%CPF#TE%XQ<MTP^O+0:X]RS93?.IC<")$KZ%@3#(JF0U*"SM!TFCJB7-(
MQ,Q;488E-7$#$9H8\M9\&JSMM7:MG>.>#T.KOZU8_%&VF>O['K!Y>%+E1EC+
MWB[;73I&Q76"R352WP!98CO-TR*LD0D_U[(%86!G(T;K7Q%ZU(C*ZCC"?%=<
MX5:Z=J>)A79%9W8)YALMMFX8\.906<13GZW[`G3FRQ==..<E;E(!P^K7]ZB"
MJ-+'^01!64^EMZM%I0K1'``'8P9=N=>167!9\9NSQF5=!>?95&GBE:\@%>Q[
MIE#SXY$1%9%6>L(O1A#JV=1IV$L]@0ZK=EA(8N>C?-*@("1'%%)P_(8:0`R5
ME)64L'$>DO%_T<QSQ0VNM9R5)TC:T4JJUV6>5?,(?)IY9L>J)98U?MEHQ&Q8
M;'96VDI:9K(UW87-Z2)6PQK:]&HU`O:'U5E"5,-<62Q_!BRK7!LBE84RN7]S
MUZ8_OXX?R3:$M/O6J+)L]_CH)#+'.-T^\B%7D]L]@6J4RYR.3-KHH3A<R3#"
MOA5;OQ_@U6?X+'@!'AB[#?(5R1$JTYQM%QY7U-=5=4TDHQQ96>%)*^F9<+LH
M-5"G,&8H],&)AG20I+(=,2AS1"7:*&N]PA%CW/CC7Q3XHU\4]?YIXH%W5N[/
MDC=S^;U]"&>]HL1/7.N3P6:W-O,,/CQMXM;9(CHP`UQ6UA`K*1`,VF-.5?:5
MYI:/9B<"D);XZK6CXJ\DCEX_&/!XO0,LF$7I!ABI7.;M->?7A97B@M"V\V\\
MI8!T@L'&1D1X8V>*UH"/L$K1MAVB3R%#>6H2I]G)S/8^+5-5#V-T1X6VE`@=
M9LCIB0)[K^T6\C(8N?I]8SA/U/3[&P]`)IF8QPFM)(Z.#O9S+0C7*'$PU/I7
MZ1U(H6Z*&63O=B,^2UD@EO6=X&"2X1>EGQGGB3%QEBK>=0NRVNA)Q808NP7;
M*Y]=-<2`#[":[D.HZDF4_'(7<D2D1'L?CE`#M%K3M%#L>IP@^+@VCJR^/&$]
MV+2+;7*BJF6U5+_9M:T>B<*LD\`FK9);E@;5U/:T'9")=#(Z[QIUL:&N:64N
MC>HTE,<#C-:&`2O0BM9F,HXIJH2W;9\'DEBO(]>7$T<XRB!)89`IURZT2*EG
MZ00>LJVL%X0PZNW]Q7`@JR/4A7L[?VQ.VH=RDYE:W54C"3Z&C3^A=C?%S"_%
MQ=K0``6`)980@``(0```.@@``.M!"$(0ZUH(0ZUZ:UK]FM9AE^L!@,!@,!@<
MP.I^6;AM;H.UK&AC?'549EGC`Z6Y99#'1])0JCKALZ;1%]B3>K0&)C?ACJAO
M9C]J%^][`0+6@[`+W9J)B/Q6)C^;D;-?$!U)!V:+G5HGL6V#&F)>,!Q?&V1]
MJSZ,V6"6\P+ND3+LB557<[J'23U%&V5/8[,*/?:C4Z0.SE04I9&O?Z[C*.?F
MUNC^JQKA\9'6UXJU]J#9)I$G&/<W\JP4'-UC]F2^VX[TL*G.F;VL"UJ+ZCMC
M:=-)+)89K6<P;!LS^M.]6YS5_3G!.1E*B3INB-//P-T0_`O'!U_+V;OJFW*N
M91$6GI6<=<SZM[0?NVY5+N>4Q]D7D.\ZF8I!Q8W)-Q"-JW]2W(V60O*`LU:G
M3JG`\&C]J!%B;HTGP\O]3=&B=V'P/V7V3>33T=>,#;>65CW=W'K0^P"E.E%Z
MJR(I4/-4+ZP42FUVZYH5'XB83-)//.A4[:SH6W0%J>/)!B4&@,/,3E-T1%1J
M7$14.BEL5_9]]<.=$4"AI-DE;\Q"E%(0*)]-61/7ALZ"A=<.K*VM4XEMHL9,
M>L2.2:RVEK/-1/Y9JA8T2'1+E]0L`5[S<Z1E;.EN/[SXJ?(1T[4<:HBV[+1T
MY4[3*>K+3BX+MFI?;MLPI18]7P^CJ5KB8V`8XURXV!,X2W/T\D[9-%*]U61S
M:QI1Z-<#4FC"M;L8FX:W1&L<5IL/*ODMA%[5_P!?JZ"JFU[>*L=',Y_7AG03
M-"6A>\/GC>I+EV6R`,P40U_*$W`N6#.BK:<"`:DYK&`T(=#%\>+QJK_BR\:K
M^.+9"2^-JY-\)>-WDADL9P9Y7S3=]#S2W+2K&3IH=((JRQ"+6,&<N]0.DE8'
MTL9S/():4B:"53>(PULUZC++%K80S=&Z92XN9:R7?X9[!99=*%/-RR1N%4UY
M4''K)%:7F=ZR%MA_8RVMNDK\N?I*O.IQIRP+GQ3/RK-*=FU]4&?3%R)6:$U.
M)O&J3&6,_'BL9>/%9+7QYW%&))`:C14[5KS37,?;?1WD$KF[R;C1ML[O)SL(
MWH&?UI0+G!C8GHZ"S17/;Y$R2F3*W!0SZ8FL1R4*@:KZ<F7''G,4EQQYTIFO
MO$ETE$/'?VQQ)+8U44M?KK=XEU+4-C09W(K0V.=03X3));8@*$YJ)2NT1C5)
MSZ*@)@SZG%HPZ*+B6\T)7T@BS+NC=$\EW1<3JZE=N<5++SJ_C:DJB3KH!7-%
M=0TA,'H-=SYZJ*30.EZO@4_BH"JTE<54(9$RO+.%V;4J4M`H3*/I=F:"8'6M
M^N8FIF9\$B:N7,.O_'SW5RHR2-33M55MT&Z6]277/+#^U6U?I[2[5PRV+V)T
M!=U+73(IL]Q66N%H,<C@US^Z<M8?8_GN2(@18U0Q&B+UNB?N7=$I!%>'.WZ:
MY][SX:B-*P^RZUZ2I4^"U_TLYWPPQE82]LGCHIWE]H!(ZH61=Q?0%OME5,+0
MC@N?M2H7`!PM"T2+0UXS,3,Z_P#<N)J?XXH+</`G>=T2-EZ4D%'ML0GJ&W>2
MT0J"I_LQSK*>`JKFJ@NI8"Y6`3TU$8K&38O.I9..A22R4+448,N/-PB3E0A*
M#"B[&6,:7I]A$QP2R<^-'JZR+$5=`*FF6M/VAM\<)B_DZ;=9R2QH?T2P<XS&
M?K+A@G0MBG%IE=C3N+$NK1)(K*781Y2Y_1!(7$FHSE0!3=$17VFZ(BFR_#?)
M/6]*]K6G/95#8]3G/3HV7T=(8G#;[D]HTU;=EV3<K1.(-:=#T5-TKP^\EG'1
M@MT43EJ2/6FIWD+GH29&8626J#)F)CS29BO-HO;7A<Z9FUQWI-&=T@I$>F'>
M4/.KW1L@`F4M'CQN)]L6R.R84).!(+Z9\D]E7D^J$S;ZZ^JTTI=^NM;!O+&<
M?R6,JXMHN?>8NY.3NJ%%M1OG2"V_#+"2]*PR2B2W_'("NK]AM7R.=`=)1:4%
M-[K$WG<I]E36>@/.0$"3&%+BQI?D]=>_29QF*O\`BB9B8IM[XPX+U=0M3HN9
MK\H",06)5:99"R(W'';N89Z"R#I9<DRE[<F'7R"+M;M#=`CLF+-&-0M5:T:4
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M'%@GRM*SB]-5I!Q=22*1Q]+<K`5**HYW*K.)U^T5\.0PDN?L[I.I.L<@KQ.*
M0IO-8$BGV&C$67DC*(F92XN90R@>8_)=ST[1P\NJN>+HDMV4GQS15XV+9UE*
MCF.J%G&DOG<,76:L@Y#*8\6NVW-3;TED34W-[DWK&69GG%JQ:(_\C+,XRLSC
M+S.7"G<,JY]Z`\>QD$Y\C=$K&7M9QK_JR0S%QE4^LE[Z&M:26_4#!NOFIC;G
M.N-MCK+CVRQUBQ0Z$O#>EUIN+,$HV).W1>[F7%VCMI<'=N]HVXVW[<T!8N2G
MA387$L%5Q*C.B"WBPHQ6/-[UT7-9_=C!:31#F9O12E7*+L(019L*3&JR6E&:
M-9L`U(DP$98Q%<>)$Q&BE4GCB\A$)A4EJ"/4[3<\46YQ5TQPU9EWR>^%380M
M?;DZ5L.>JNQYBQND<F<VFTLLJ(3D4E?6,!Q1Y,G&>B).+1:(&7=V/\[+B5EO
M?C![C3=`3+J-EFM;/#C*I9<]%BJ%4V)&N6&<EOW,A?,E<R!XO34C4E.:PMRK
M:+3L^(_9`%)'A>O%I>8?[@FS=%4;HJE25#X>^P.<7)`^U\DKZ9Q2DHOX\;7H
M.E'F?@9F_5C4?.;(L7J+G0,M,9'(F.Q1SG]FOTCA3T:D4H4+DYITYA8$Z<1I
M:<XGB;HGBV$NOE[R"6?=E"],R/G).GD:*I.A8E,ZKY0[QE_(SE`55@]!PRR*
MX:IE:D30IC[P</P-%O\`]*QEIT;,X2$W9Q*;8"BS#$3C57_(B<8T_P!&V/D@
MX#G/:UP<0O3>FCI=5Q:53*&]A1YV<RBU4IYYDHX!:H8BVAVF&!^&*YZ0C)0B
MO:'7TQYQGI[="],XY4D333WCSQD=;T[%H@JMLR$R*S7'DKR*5A:<C02TI0!T
MLV\)[0$<Y\*),&B"8L;#*/H9M`X*]^FD"DKXMA%Z^N:G*)X>,+.4<O%@[^\2
M?0UU5%%XP-S>XW)H)X4HSQTQH*_OV3URQ2CIUC3E!,A=D$18YO13^G#C4X=&
MZ=BU36>$0]B3;V+UQ&41/WD91'XNMO6=`61;]?<E1V%(V=0Z5!UQR1<,V`XN
MY;:0FA%/S1N?)NI;3AD&:<7),@3#VF3!T':D7H'0@^N9B:O[&8FG)Z=^)GH-
MZGEA6FS.CRIDDT[#\BME@A;O?$F54VAJGHSE/H*J*FD[54JLXZ",MC.DWG;.
M2[*DZ,MQ*1'JA''F@T(&]1E'\H:W1_)"&#QW]M23F6HZ<=Z=E$-D=3E3),N5
M7'WE)>IFB0GR#QW=.\SI3*Z3R]&<&H8D&S+"9-#8D/L1_1+1GZ#K2+V;;L;O
M_3S)F+O_`$\W0CQN<07%QS8]Q`L=Q=;58+!H[E]MAUR6!:;M8MJPQ76\-?(_
M->8U>W?XB-U-`YLY+Y%$UJ`@G1A4E6)5GRFI2#AS+*)X),VXQP;Q$^09%S]-
M:^75WIF>FCER"4P0V2?M1XL<VR)=$^P:/O5`=0;HJC9(.-86U0VOWS9R9J5"
M*5NJEJ%I+\K:4J#K=C;6Z+MMMT%Q-W=9U6U,;6O/\N@MR0]KON'PJS97Y,++
MG/1%+R*Q'B"O$6ELYNJ2HI/'^B^47H;.=J25:^,KB:`QJ1_1^X!QFBY&6,3Y
M?8D3'\0[`T?1%I0CLKIV[IH-A6Q6UN?^-J^8'MI4E)U3O,Z7-Z%,L<\^-%E:
MVP->SK';3$6OD&$P)I@-:U\._7,S%1'VLS,53FYT1R1Y!>C+AO>XG^LJ,8'Z
MJ8U4$1YO0M-K.!;+T<TTQWU"NO(TH?2U<<=E]+N#C6-<H(TOVN&Y%BDZL]62
M$#:`&MZB<8BOXX-1,0J\''WD2C4X-Z)CO-M0R*Q+T<?)`?.J=?\`HQK:F&D4
M_7FN66"K]R&<IX`\I[(`Q,U`*%C^G9T'M]R[1"8PWV^\2\:J?(N.'V/1'_'A
MY!N;@QFAN<WUA<H'*+&X7LR1]-I+5CT/<HEKFRE:/H.XZYL^I9?5,_=[5@DM
MBM,[=8>2R+VM6WNCD6%2K2A0Z-4MV,ZR;HXM<ZX\+W8,3NIOG2Y-7FX0PR>R
M+`B48#-$IXHU/>@(ATA#+Q>P>K?\9XGYK8ZG_9K]IFU;AZ[_`/',]]WP;H69
M7_BSZ6MCEKG3E.^JML:N&2K+2Y_D,TFLO[TE'3PD`:PYHO2MRI_S]'I,E"32
M)]?6Q((V]M#(V")2F;+(]-!`WZUMNB)N/Z+NB[AM-S9Q7VE4E;^-UWLIDKVP
M+IY:L'R$V?>!3-.$T?8II+>@6;H%3`CXXXFLZP")//958#>)9ZIQZ9"EA@A@
M-TGV$69RC6N$TDS$WX.@G8M/6QT51%-L$=CK(SSQGZ2XON6:1M;*"36V/LM2
M]!5?:5F-R"1Z;TY+^J8V.-K@(Q!3D?<32@:"$OY-:#(F(EF)J7,.Q?%A><EO
M"QKU:WF2#>I+Y(9C>S5!CKXDY%-&4.]<:N-/()FHJ#9XH*3;PK%5!2B5[1[=
M`-G^;ZCXM?'EW15>36Z*^Y%>=/'[W%3W1?(#XU0>(U?'Z^A7+39T):T!Z*DJ
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M212B&<U61'V9JFLYZ!M].01*U+:`"-HK\I2W_,K4*=!"C*(^XB8C[G1>#\@S
M&9]S\O\`<MMT[!8'.(EP])*[M-GC,PT\M45Z,52&%)HSN.MZ,!#;*4,2@4EL
M!G:9`:4%8E:'@:7T`%0(L$OX9QCQ2]*\W-7R1>(OJGJKJ/H.UZRU!"(#=,<W
M$9*VO4L(;EDVCL`YE:G&FFYQ3"0G?0@8^N80TF"^38]%-YYJK7[-"#NXY1$:
M\5C*(CS7%%?&OURJ[%%U[9CA44HBMKW!;]179S:<Q(]KQ\03VDF>@&9&ZW(&
M1&$S=*C15%%)..'?8TY1*]S<_:N,.V/1LW150;HJEZ0;Q^VA`/"-/^$V"/QU
M/T)-N9[FA[P6JF1KF@D]RV8CE!A[S(['<2U2YT4.K@ZD!-<U.C1E$@`#7^F2
M`.FZ-^[DE_%?)SO-\:O>QC:1-Q59-A_3]A4S=`*O4>168+.F3&&!<AW904PD
MP.Y"X\V39E;G)]G#`4S1HD]4!M:T3B66:24X&)]:W8_R\/\`1;C^(=3.DN1+
MJZ?YBX5K$0+%IJ3U=T/2]AVRX(>D7&9796T0@\&LF.N[W'.B'%N5/%A62C7O
MR`>W(\D1SCLTX1WOULS0LQ,1,RD3$3+FK!O'1W'3L]YYD@J9DECG5335BU#.
MI31GD!G?+3[:<[6==3"Z-]!6,ZMXW*161N]6)]#()''7@X],CD*]:F`$2?1(
MM7=$W_T6X7):GB2Z#L*R/(P6V2:`-M63N,2"0<+-+\L4JT#3:'0=G53TAU&S
MV,V(4:@]@ADONFB&A!LU,!0:8S/:\6BA_M*&C*(KQYF[@B5^^,+J'R*62Y6E
MT_`&[F>-VS;?/D2L>JJBO]/(YRP4'1]!]?Q:1353:+'%6)L>)+8UA]%IV@#4
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MW>:F/I/K"+LKB%*,+XI=H0ZG@2%:"`*T1`/\/77I(RB)F2,HN9:80CPQ]0)1
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MM[(*4!5A;L9UDO&=9?U.`"((`!$+WB"`(1#]/3WBUK6MB]/7?I[M_M],YL/W
M@,!@,!@,#A5U/Y,I)7/E%IGAV(VI4\)ADQAC'64]T^)FA]MALZ$Z6CMIN'.D
MJA\17NS>HD40KYRJUO*?T^M:3G&3=L`:8#U#O6XQ^'<U&.EKIX*O/H,FA^J[
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MJ3I!XL6/RN(.U`1>?O#6;2U;/]L/#BV2]RE30LV.P$C<6TC*VG"!K!ZJ2MFC
MW\>9BJF^*15>;A--_.!W7%Z[>U9+O6)LSL_A>GYGS^>972;:,CJI[FSD^V#I
MT2!7^QQCA5!M3N\DH1[V$K<>.'_\1#S>R&ML2ZE\9=;=E]"=L6-&95)K*U0<
M!LUQAI;?&.48.HI,]`EYPKBPR4,HZ6.M!/-(_,S)A.##0HB(TI)%K25-\V@G
MC&7G*(B/-F8B(\U(6GY`^]V3KCL2,5@N7R^I^>9S>,8>XJIY6>RZMJRL(1PF
MFO:-6V_];:=T\376"1>3DW-FX4:0H6N#6OT+V$A]BC5C&*B_XU6HI4//7E9[
M66QA!)YU*?WD1AKNSBV&S$^8\UH>>;4(?K@I>W;DN:GF>LQ3"1.#A%3X<S0]
MRB4W-2("G,+P<!*%<66,PFSC!.,,E:/D7\A5(<\U]:,BNBH[+D/9G&+1UE4R
M.OJ$3F*>9G\5T<I1YQ@+$S%S)P-O&(N<`Z<^WMA[L),Z*9(SAWHWXENB$\VX
MS->$E1,_9+I?X_+LZLZ^Y8Z#<'>WDS!+V>];(J6A^@)%SVT02>!9X&GC#1)'
M"W.6%\V<B(;-89:I,ECXVEQ6MJM4C;TZPY(F^8'RYF(B4FHEH_S+T_Y(>DHM
MRE6I'6]306S>C*%O[KQZM]UYDC:M!&HK3LVKBH(W1D5@^YTF9WQ([2N:F/\`
M(GU0<%Q2M98$B0!(C=*@:F,8N:T68B/LA?EV=F=6V%XDJ([YH^Q(=0=EO<3I
M>4V#&EE6-]KQ*5*K-G$,JQY11T4C?VA<P1]`]24YZ:U.A*CU*0!!)N]Z&(W)
M&,;]LI4;J5M+/(EU;371,HY1DVY+:CQ$>V_'70!W1+30C-'ZB%!KYBU)N=Q-
MLU7()6K31&P9@NF+D)E3DE*@H@JDH0#%KT]&V)B_*5VQ,6N+P_\`2_8O64&7
MV?T1+;.4M,LK)J?HJ%[Y1@E05.0^O,@>$P72J+19+-EC[:[:@;V\&A%N30TZ
M$486=O\`:/8`LHB.!E$1I#4IL\I79<NB[5"F)YJF/7!6;=4?)72DI?80)=%(
M'W!T!W4KY)CLU<F$IY;#$D:A%?53)IF5'P*R27(<E8RCE`"!>@[MC[C;":VM
MTWY$8JWV=4K/U=7)-B\T]U<M\JR>X2>98L[(;F@_:8N>E40D+U#39LG98+9%
M')K6<2UR5K-V@?`@1F#+1_(+6*QX\I@B(\.2H;?\MW77-UGR)FGCU"9I459S
M/OVM;<L8BND3&NA*6F(SRG$:`N5S:T3LH((C*6]KM*224@(ADE-C\$X0M%H/
M<)MB?Y&V)6W%?(CU/(5T3NN8WS7]2TY6]O<1\YV#6(N6K`M,%JR^_P"@J"MZ
MR)Y/;'KQ0\O'/;?(7>^"66!*S49,<"YH22W(Y1I;H!#;'#F5'!O1U5+NPV#O
M3C:K*FZ8C%?4ST2"T1R:#N5`1B</+7NAHHV3I\TVS9QE;8O%^\E(Y_;Q^Y-K
M[2$O1Q/S#%L.LQ6V9GBD53CPX>9_LZ3\^1*1QJ+RJ"3\WC%RM!VELEY_:%$?
MLFT57;?+=#-DHH-I52\I)/F!%`[4>2"T!QK>2J=%:$0S`:_;K>V+^]=L6E/5
M'D5[YYTA].Z<[;MR)O+]375]M2)RLCQZPHF:&O\`6UE4/75.1ZSJ]C-T.,7I
MNEGEZLDXA;-U$@*3EA7)C56T@->\*,<9_P#JL1$S_P!U]MO>W=[?T;U6XV`D
MGQ=8<F,9[[,JMK#FN%2^DS7R)\(07HF9UY)NK5]DIYI&'A7:$B5HFXQ)&G0)
MB43>'Y!:4C&7-N-1Y_\`5*BO.577'Y`/(3SK5C,5*;OK6XIWTCRWSYU%6<FJ
MSG5N,<:.<9]U5S33-@5I%Z_#.%R6ZHN\Q'H<&H8J<U:)U6NS4:$\XP*@&DZ,
M<9DJ)=_.07JSI)SS7TAN&03B2V`\DOJYY<K*I5!SS.0DBDKP4UH9'4+9()0C
MB:Q`UE$E!T%<=M62$"G?MV=L`<3QT9GBV5R(8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8&M$CX
M[YIEP;,_$E3,+NIN&T8#=-B.BI:^_?'ZT*L_`?[N9<2_%NP'IB6PS59,>F\I
MN/2)2-(-:T5Z&G_+;E;EE7'E:@76H[4H==7+>;4MW2&S95:L+`ZR).AF;[<L
MK=9O:*MR6)G@IV)*FDF?%BA8G3J"4VPJ!D@+`1OX\7/$N>+'.?'_`#4[6VS7
MHKJ2.%VG'SX*J:90WGO#1].KK)HLQ@@2LQD:7-%'%BN+L=QR9&F-/2&&:3.Q
MA0MB``G1:YJN1<\'SKGCKF>HV&D8M6U21^(1WF^36!,*/9FE6^@;ZYD-I(IN
MVSQ<QISG8X`RWY!8[T3M.H^=,F+7""G+*T65\:YG[RY6E**EKN:3NL+,E$82
M.\ZIA=+'*L9"<I<2E,273F,*H9*U"-.E6$(50GF,+34@]*2CP@`/8@:`/T%J
M6C5/?C&X/$UQYF'SE$C6V*,R>/1Q.<[S([;0SI*WLNHDZ)&>;)AJ`!*KJX)&
MV:'L>S-@<Q&[%\Y*<TG6Z5N4AA?CVY&KJ[1]$0:KW.,6P:Z[?%+RU6I<)$>7
M/.X6BKS;HY5WN?BK=S7;AS<G1;,4-!@O:G+,]?F+"9J3E,Q7(N9BESE<[TP2
MRWM'2X(W@9>FG:0OMZ(-+GG9=ANTK@+#5T@6.0]N6SF\;E`HP@;AA0B2@"4G
MT,&@F[$8)<_@7*M?Y%^3]36)6(733$GF,&;J4:XV\I':4I!)DW.9<H(I`Q>B
M2OQ+:_.%;I)JZIV]6X$JE04JXP@PP96]`TW27*L(?XL.`H"EL!!%.<(RUH+,
M)CJ&2H12.?.")&Q1.QFZW8_$(.E<Y8L(K&!M]F-*9ZTP1H+2RF+B`#,2C]NM
M:N[(W2VOKZE*NJJ1VM+*\B***/=WS@JRK2.;%3GI%+)\7&V2)'2Y0S'KCF9N
M?'&/QM"0M/1)TPEPDP#5'RG>IF\W*-;Y_P"-KB:SJHJNDIA1C8JKBD02%/5+
M6SR^Q8F\PINEY2A-,6-JFL2E['.!1N9I%(B'AL.<C6]U(T`M42:`LL(;NF[6
MYXK]EG/-*3>F4G/$BKF/**2;VJ%,;;6S>4I8(TV,M<NC"\P9I:TT?4M9K:VQ
MEQC"`:4@@9980I0`WK9?J':YN^:6C[[RCSW)9#*I6^5FU.$@F]NU%?,J<S'*
M0%FO%MT,CBS?4<T/+(=RDY*Z%HX4U@()*`6D.TD#L\HW8A[$N5N4'YLX.Y8Y
M#=G=YYXKIVK\][9-1M6WBM&W9?'$K)IU^]!;V.)3J>2>+1HH#E_GUMN1I1Z#
MO8-;^/>PXG*9XDS,\60=>&^2WR/](Q9WHR&.#!UY*4LWZ-;E`',9=GS!`V,;
M4VR5T-^XZ4-+TTDQM"<C4-@T1B->GTM)V!9L1XER7/%Y8+PER?6]6(*8B-0M
MR*OT-O1B_3$#C))M(WY[NF&RN/S>-V9+IS))*[3J:RYLDL4;#]*G=R6C,*0D
M)S/>F+"5INF9LN9FW^O7"'(\C5V<M?Z0C#R=<S)>$;M`+DMD2Q+,6/I`%?@N
MUN<T)[T-$`F>ZJR/[/V264),)L+$EV0(1FQMTERAC[XT.&I-/Z^LY\Y\C:Z7
M5BTU<RQ@[;_-R&!6CI$I.13ITWA::4$PRSW:L"DA6F)?)6]V7-GQ`V0<#8`^
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M;%`N>(\RM<R=*Q<G=,?)I^]B1D4O8*&UJJC,54O\M=%<&K^"6(VD.S?&F0;?
M'B51>M_1;#O8=V<LIXERW$CU>1"*RF?S1B:S4<DM%T8GF<+QNSRN+>'*-1AK
MAS*H);G!P5-;*%)'69,0(M`2E*.$7LTT(SAC,%E$UP&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M.!5R>3?I>#^2*;\I0*/53-X1";(I.'*ZT2U'=;G;IU=V30/[U9Y>[C=+')3J
M;AL5J9Z'KZEM=VQ.>XH"Q%DJ`*3"!&;C&-MSQ;C&*M*;L\CG0L;X;\9W04);
M*^8;*[<<J916`,%$W=T4S0\%@<RV!=[X.`4I3DM;K:EIA,@B!*-.22L6&)4!
MQAY_O"4,S2,8N8GA"1$7,3R?B3^4V=5?T]X^^>9L.JGMLO."0=UZ<EZZ*3:C
M9K')1T8Y2.$<N%5[1EG2I7840)?[&A;@FDC6^A7N+0E4)1&B)V/W";8F)E=L
M5,M9I_Y<.RZT;>RRYW&J4@-EU,W_`'NL*/FE#]&(9RRQXWK^OZ!8IM&WI'(E
M$%[:K"15A/$S\>[P-S87!KD*A*U";3-*@&`L8QIX$8QHW\=.O.EH1XZ[3ZU<
M28K95@U%(5,R?FE9RWT+RPG<:1@<WC@[:(*IV]9<MM1KEC75B9_7-CH<H$W*
MUA*884QA.C`CE1NKDE1=0I-L[Z[$Z5NI52W)@.:XHCETVZUE-2V[;D8G\YBC
M[0'(CQ35*."H#!#[`AZN2R6U^EIX\IB'5*N3(66*M.C_`*-<J-![FV(BY*B.
M*"5UY%^W[GE7.\TAV^88?35V\2VKV$ZP:15I9LEL:+J>?3ZPA-FUF@L1#<<<
MC#V3*+$G2E2R/@F!.!(SIBPGHU)H_EQ.,1^*U'WMM?%'UOT%V+4QUI7BYQ8W
M3U`:<E[,Q1GD/I?F=''G"P8PODCTWMTQOV6R5BO5C3>I!*9XBVBT`0E?,,8P
M+$WMF41&D)E$1P5;9W>755?]:7`UI6JAG?E2E^O>,^3)1%E$9GJ2^EYG7</I
M[2.QF">$SE1!CM0N?W&AT8S'1L(EC00?O2PH\(-CNV*\Z(B*\VL3CYA.@;'@
MODP?J.4\NM+QQRCFE^42&3M\LLDBXN4JN=;CJN9ZES5$+.BCA#K,=+AI54H1
M*AC`E31UZ;##&\\1^CL;:J^:[8TM;3#W-W*3VA$>49E*:/'IK@?+$RG4DKKA
MGKBRV:6*;]E5EZ>VP$U@]OR2%\XMS%&(:D2I729J%:0Y6:H7"_\`&(,3EJQJ
M_P#4K&K;"]1^2970'D.Y,Y&1HJY55Y9Q+$COE^?7\":PHJ_WR^2BON6D=?L0
M7A)]T(D%E0-R32#9B17M(C5HC-?#HSWCD8WC:1&EN:)?G;OYPK^VD9=9U-&K
MNJ6&>0:;K(_(&N6J&*3P>A99'&CE^TH^B2S%,O.A,Y+5/C5(@?5".V^QU662
M-%KVEYK8NV'5VBNI.I%Z?NVG[7B5065TOQ^PQF3PQ73Z>35Q6MU([3IYPL>K
M&!2T3^3S1T@$C%)F58RN@S'A<D^+Z=8`1031$EYF(TF.$I4:3RES?A/F;OF'
M5JAF-VM%62Q_B=@VDEN:N&BF+VYNNV`,$#X"O+K`R`2RF[J=WM;$I+^\BH]L
MS/*TCK(XY*8]\RP@I*H+&`.MD<OXU6<8Y,Q9GE,[4Y[KNV"YF'C_`*$Z*AX.
M))VW4#1D=NJ*3=FC'2ME1UBGE<'()H^N[!/CD,2DZ$N)3)K>R2W![4[(6L1/
MQ^P3;$\+HVQ?.FTC%Y27R8<&]0]E5PQU[894.Z,=Z3YK`F4O;'#9DVS.Q*RK
M&DY%8C@-6YN2),6_6@D4R,272<9:=,>4442<'TUG;\5)MUIKE<?E9ZPXZL-+
M3/0T/I>VY'6_2=!MMW6/2L.GD48U?(EU45?-JRRQHW7\@GLR=HW8M%**(>5S
MHF-=7A*ZQQ%HXDE.H/V$G48Q.L+MB>#8J6]T=.R+Q*R#ORG5?/J*Q(,Q7Q9[
MNWRJ'3B85I-:UIV;6PP-[7$RX]948>6I\EC-$6M22ZFKUR,.S#Q:2B`:7\4J
M-VV4J-U2I.V/*QT!S5*;1HZW6>!SRZ8M%>!G>&RVK>>[[+IQQ<^H;TD4&LP$
M_?$DGG[#5:!@A*9%J/[?I"W[7.H#AA$I"(*0I&,3K'#5=L<FP/CK[9Z/ZPM^
MUD-DK88WU]$91T3&V:*QSD/IF"!3%U/T$]U'%UY'5LYF3O0%HKEC(P[4.#8P
M)`K-*E`_;HH*%2#&41$>:3$1'FY^)O-%UD9(.MB6=HH*>%T/6?D>GZV#-]*W
M[!WJDV3DB8S^%43-Y]:,JG!U;7C%[GDT+`TKD<1`A6('`\P.S2MI5)0+LBH^
MYK;&C9*/>4"_*GA55W;TFK@C]14RD-Y0N;2$KD;IKCV1PJ7POF-=T15K<V1_
MHZ:/[I,FF<&P.1,NG9&F^W*W!0A3IQZ.`=H<VQ.D<4VQ/!&Z6\CG=4SO:1U=
M9Z"IX0KK"O*<DM@PR-<<]5SUO62F><<QGI66QUQZ58+$/I2DC(_)I$-G3DR<
MH:@TA*$S_.)23O+.,1!,12F>>?+[W7>G/MM6!"8)5%W2"(5!R-/'>14_S#TF
MR*Z+FE]REM.M:MG2A9[894^ZDD554JXZF;7N%.C:FD*3184YA@5!.Q)QQB5V
MXILR>5SJNP)GS;!H+,Z!<"K#HQ]L&;3ZN.)^W>B&YWES!U#*Z&,95=>0V0PR
MPN9SDS(PDGOZ.;IE`(X_[5(!K%):<)YC;CK?]4VQ'%N=Y)>X>C^1[3II+!6>
MMXC0SU'CWRP+MMFK;EL>M0S`$_B<=0U58,ZI=8J4\JL+Q#G1Q<DL_D3&_,`G
M!,6D-)*``\S<QQB?M3&(F/-J5-_*)V^MD%\*ZF8.8"XSS%6/=]]S=@GD6LI8
MZV77?(77UATBV0R)R^/62B;H1+)-6<'VK&[J6MZ0B>AZ$%&6E%[`6,8Y\UVP
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MXO?42X>[+N=IN*O>;4%'%1^<0OE:!6`3?E=IU$WL20QYZ->52Q,G6QSY0[*+
M4E:WK;C_`!*[8;$]"=M^0FAK%ZO(,D?),CKWG?A-)VDSMYM$W/')I(BI.9;$
M4C<'>%;E?1B=C4-,MK`2]><-N^4U`JTBT2G/`)3F8C&8CC=D1C/XL=VIY4[P
MY_MJPZ]8W2DZWAL1O3FZO%%K3NF;KO$F)PBU.0+UZ,G,F>ZZIR9LLPDRAKD%
M5)$B8QO^$AO;%!ZA9H990CRV.-D8Q+7.3^=#IJMF*-F6K2E7P]?8G#-:W?7D
MG&W3(N)+^A9[<-NM$)A[TVKY44^,42OV@*L52V)MRDPMV0*TYK>K4J#S`!#=
MD<O$VQ_-N%Y1_)#T7Q]?=<U/13=5#ZLDW.\\N1E@$QI^[[6GEZ6%%+.@,)8:
M+KI73DA1%UZ[S)OE2C9+Z\MS@V(U)18CPZ*]^3'&)BY3&(F-6N"+S/\`0C!T
M/T3&Y'%:LG,`H%T[Z>Y]3,1J.Z8A;-:TOQ]%)DY1JU7/H"22IWHFR2)=8#"U
M1-S;V1O`J;W!^)-]`Z(-*R[8KST7;%/WT7Y2/(;R/7;TBLJ&\KVC=4NI7GGI
MBIR*SC%GLT,:HC/KWB%57'3<J0.]B/3M)9+%VJ8I#XQ*$BQN3.QXC?J&HG1.
M@&(QQF=+HC&)^Q7TG\X]\R!TL%Q@3KS?6]0K.TE-*4I<,XJ*\KG0O%&%<WVQ
M9[',GJ#5%.FZ7R:33JQ*M&A0FM``)4[8M`,:<T0-F;;(Y^!M\6S#-W9Y(W*5
MU(YR>.<U55&IQX[YOWC,*?F%/V^=:\*5U6SUJT2NHE4C,NAD0IW"0S.?Z6I5
MBMB3J6AM*^B5(SE81*-S;C6GB3&-?>MR^?(+U95=&\375"J8A5G@[6I&%02-
M1YG0OZ;\$=SW?#(?*J$#)5ILF&(KFY]4K7U*^F[!IS:M-Z4>E@_J!:"C&)F8
M\$J+F/`\D7D#Z=XP&TQFK8'6-NV`+E-=;`&5Q:I(V`G%N-G5'(=!)XM'"R)<
M3IC8I6WWT[[2%*#E1Z9PTA$,\PHHXL]CC$_88XQ*[>2^S+%[UICJ*>\\/-71
MA;%+B15_S_)YQ#97(V!$TJ*/HFRW`FWX>T3B,O:^7QJ56&]LKDD0N35]*I0`
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MR[D`B6BM&R%#%,JK^VQB7Q"1.K'*VG2M;],D$D,!N[8OR:VQ?DO&9^2#MBO'
M2=3A45SS+J:YHJ+A&R[\87>B;ZI2W[%0]<SZ<Q.4+*Y8)W93@ZTR\P!JCA"M
M+'I4S.BU4HT8G//3[,`,MMQ_%*AL'V5V[T=5?<]:\M5"MAL>B4DH>,6R\O[E
MR#TWUC(5;V_W8OK(QF4%\\3&/I:LC1+4D"?][?R!MX3]B]QGM`(.I$15RD1%
M7+2<?FBZ?DD@N.G(75-3).@:XLKR)`A<5?6N7+VJW*3Y<8K5=*.FT3"VS!,K
M,5S67TZ^PV0#"884G?$/R%EIRU!)>79''EHNV.*2V]Y@;XD,PBCGS2&L2*'L
MRZDU25U/U'.'075<U=`QKC2.]-V.[)ZJY]FC%,I&2@ET[;XSHY"1\#8-L<#5
M7OT#U*1A'/C_`-R,8YM\(!WI/FBNO(+.[?CT=D*7AFL:\L`'X-ATUJ]WL`#E
MQ?!.EI>2YPVP7>1R&"+ULDD*M$C;5VM+&A+\9"WY5))Q@L[>%<TKAYM"+J\G
M_=7+D12LU\*.1B[`M6J^9+ZKFPH97%RO-;U%#;<Z3K*B;=AMCP5+9;A-+04U
MJ@M1N<V-Z97!H'(/A5%B;"!`+T/48XSPM8QB6!BWE=[BG4RHF`_9JUK]3.ZV
MLR<+9B@X2[6O,BT&:)]5/M&5_9,;J^"35CL7GVM;0@;>F?DRF;!/`F&=OU4#
M)$7O;;$:_P"J[8_B7]-N<W,P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!2T?H"M(
MS-+[G[2V.!4EZ54Q97;"@YY<5"9W.AM>MM7L6VQ$<>),Q!(B#2029I*$O1IH
M=FB]1[WO+9<M&6?Q!\R,-=0.KFNR>Q4T6J630Z54WO785\B>:9<(-!II6K&D
MJ9\%,-N4`9A0:?.+:J1MIA!"M-LH!H1:)+]MWSQT:W2FJSQ5<</S;,M3F&RF
MT)Q-OW5B77;:<\DEA7ZRJ:6"RCKA=$+GE"MQGT27L*]B*6B.0+21JUIAQRC9
MHCC/<W2FZ417>'GBUP(L]"I:[C$TV.WO+0T,?[^K4VQTDT2>XHM?\L;.=&H<
ME&CI%)*;?A+2]+-,84P]G("22A%I@:)TW2NZ6XE;\V0JO*@E5)+I7;UMPV:@
ME262*K\MJ<73+7%IF34%E>X\.83YW>'\$=&W:&`E$$[1"?Y3-EA#L8O67K:7
MS:P.OBDY!4T?SU0L8:;3JV,\MQJ10NEY;3UTV55]J1N%SA.4FL6(J[+B$A;)
M2^QZR`$%#?$RT\X*U224I_R*"BC07=)$RO5LXGYP83:ZU&H'J,-M3\VS7DRO
MV!@=W9O8(]1L_'!!R*+D-@%8BE*PW]V[5HIP.V8N+^(S?R[$<;L4W3_,N53T
MYX[X)SXDJYCJ>\.J$\/K&6P-X;8;871]OVI&BX?7,"G<&CU8L;+,9@M:(["#
M")BG-5HBTYR91]G1:V5HQ.F.(LY7QXDS?%D);XW.9YOT/(.F)&5:JR=R670V
MQG.,DW-8R*HC;1KB"H*ZKRTAU`C?R*^66%!(XUIMM#DI0'FH5J<I65H*DHHP
M#=-4NZ:I&47B>X698<E@\5IE%"&C^6:QN2)$K@[FNBC_`&#3-IM44;)<ALV0
MLQB1XL*5G&0Q&M3/KJ:J=4C@(]04>$Q2?L;=DFZ4\DW`5-2"^4W1C=->B:_L
M+[%4\9?DE6=#6I7$(G4?I1<]KZ_:+"@T5D+=&YL@;MR1P).+<"#@JDRPXHS0
M@#%K<W35%S5/Q:7CDY$N>66U85D58BDUD7"]5<_O%DK51PK!AKA3)$=#7/[I
MYA__`!VK$T?71DA=\3*<D`I7G*3S]&#4&^Y&4Q]A&4PKN5^);B*9MR5"]5T_
M;4I*;Z'H,+\@G<K;I(?5W3]CG6S:D>5/:-R*6J?DGJM0N:3Q"V<S"5'!2"*"
M:/6[NGB7-WS755?#7/-4UA<M4)6.6V$Q]%!>2KZD-SV+.;=L*WDSW#4U=J$$
MWL&=/KS*W)K101&4TH4@%129O1`]J8LK8AB%+F[)F94W6OBFY!K<YI7&,MEV
M<]-4C4/HY%=]OV!<+^]-FZ.L'G%J@4B<YV]O!SU6T:I^TWYJ;V0_W(B=N)JD
M01J1B.W=TFZ7SK;Q1\D5BN1.K:GN:6NK$[4>IA;G9]^VU9RVNHISC9+=;5-U
M97YTVE3SN*U9#YRUD*PLZ?6BU@2PEJAG`"`(6Z3=*U8QX^N38CSY='+#/5J4
MNA;\FUHV#8=>F/#WML-DEOR`4IERB-*BEY+E#B$\AV%8U`;#DOV8\HH:+9(B
MB]AES=\RYXHG6OC4Y>K8YE=MH+)LF8MUHJ[?>;%NJUYU;UASV6GTK,N=T::Q
M9;.G=W<YA$V*G)XY,K<RJA;:T9)^S`$:/$88.SE,DY3*=Q;A/G"%\9*N!(U%
M'=LYE4US,:HU#RY4_F.R:#3E2^*GUH1RLY:9(4^_=(5(4YVC_E3E[`$`M:`'
MTES=\RYN^;U3GB'GRQEMN.$ICSZJ4W>V\YM-@B32Q^0A<47*TT73ZG`(0)EA
M86D;-)7$TQ6(CV"<2]Z+4>\&M:Q<ERQ'/W"]3<SSN1S:L)QT,!!)'.QGLVKY
M5T%:,PI-F>;5G*RQIDZQBHG^0+(/''!9+7-6I)-2)"QIOK#PE["$T>MIRF>)
M,S/%`IAXO.0IM&$D4>(A*R$*5#UPRF+6BP)6TO3C%NXGN1R;HR&N[LB<2U;I
M$9;)Y()S2H#MC):7!&C/1Z),3%BU=T_QY%R^+YXP>:9Q1+WSE;CO?=\5<]6%
M6]F!;[WZ#M6V'EBD55.S0\Q--%I',)&Y/,;CVE3,`"QN2&EI%Q!QY9P!`.,U
MMNF[CB;IXPE<@\?5*/\`?5@=#%S'H:-2NUUS(Y6A#H9T):43I^PU<?KMNJMN
M,F52LL@2PB0ZU"&A*D,TI2&:-^``Q>H@ZWINFJ-TU2&2#Q6\?OS&RLA,:GL6
M,CE(T#1+#(H-:4XADM:F'E=_(DO.DV1R:/NZ%U!;M/N03PL\HV9MU`C7*DAI
MAJ0\9.VZ3=*/H_$OR^QKH.]PJ7=1UM*H5&)+%E4VK?JB[(5-[%3S6T'NYYHZ
MVY*V26IGJS)!++,D:YU7*W4U088:HV`/M)"`L+=*[I6WT_X]^;^NIA'YO;J&
MQ"GEKB"FM9,37]KS^MFBUZE6R!)*EE0W$T0U]:45C5JID*3ZH38X!&#0CCP!
M%HI2H`;(RF."1,PJ.<>(CC&P7XUZ?6:VD:1U,MDB916*WI:<+AME1R[KD=KY
MLB!V5'8G)F='-:\?[&>U!XF1;\B`*07TFB_IO4O=W2NZ5R5YP;3U57S+.@(#
M,N@HX]3F=R.RY96B"_[/*H)\FDIC*2)NSVOHT+_JN3E`FIN2[)UM#Z$*$I)P
M/090-Z;IF*E+F8J4*??%IQ3(M+ER^IB`31VMNU+I>[50N:MOMY]E]T-M@L5A
MH7JS4FRI>YPMYC=FNC6%B-5":DS?].240`*5/\;=D;I1N6^)3C*5+GQ[3QNQ
M81+)`U\MMSA.:UMN?0&;A5<;-4@8J!D:&41QZ1.K?+(FQR,Y&<Y$F`5+TQ*<
M"@0]$%^C=)NE>K?PWSHU<XL_*S=%GPBHVB:QBR!ISII+'*8/UA1BX&F^@S:6
MS]V=E\QE<ID%K,Y;L[K5ZP\]R-,-`<(19FPY+F[YES=\U+37Q6\ORV:.%@LS
MOT!4LN7V7;]M%O-&=#VK3ZMIF=^ML#17.I8CH1(FHYG:K(75NUNCH@($!&H>
M0G+OCTH4'C'=TKNE?D@XTH68K[`<9Q'GJ=*+6YE8N1;(%+Y9(GO<SI-@4S=8
M0T/AREP^I4R)P4V([&+'G1@7-28HT,1WO``6I<I<JEJ/QG\PTZHBKJU$VK.)
M9%+>3W83/;=N*P+4G;[,6RE)1SM'4DJE$S>G1QD,1BE.S!<S-K0>+:!,49\N
MB]G[$:*SE,FZ4+-\0_#2JJI%2CA7,B=*X?XY4L12L3I/Y:O%$(U1%Q3Z\J>9
MH(X*7(QQB*2O9M93J4V_2&@$2S&%MOKM$4`G3=*[I;MGTE7ZF]FKHXUO7;M1
MFJ5_I)`ZZ=5X6TNOY-,8U.W9O&QZ.^V&KCI'$D1@58B]GEE@$6$6@#%K<N:K
MDEZ5R:]KO'?RLYO#*^N,%7KW)DMSHZY"S5LE>E9+F]];-KZT=#1-_1J51J1]
MK&S$3\+2Z.*@&-FC$B,TLH!J1.,#=)<JSK_Q.<>5ZUKFLEHM:;_.OI@#6YVO
M=UG6D^1*$<]RX4XI^GH8\S>1O+A&*<ATC,&>&/I1@2+?=Z*_J/87L%W2;I2:
MC?&%Q_SFNJ%PJ6"OT=-HU7%5U=$F3>3N21L50VE9I0+,<M3+G`XMV'NN;`="
ME'U&A_4+3]*Q^IX`CTW3,5R+EL-/^9ZELVPEEGRYG<ELN74+97-:E4G?71$C
M,J>V7B,/LU:/MR906CTY+G&((1%+M!^J3A`()8]:&+6Y<Q%%RH*K?&_0%4P^
M!0)%)^@YS%*KLFI+3K-HMOH2T[13U_(J0:G!EKUOA^IC(73;!%&UM<1%'-2?
MV(E6BBOE+%\0/2SE,FZ5I7KQE0_1LQ8)Y:3"^.DDC4430MH5-<I?&(DAA27-
M3]^$$#2M:M.0<H#9-%QU3\PM;,VG3&I_7XCS0BD3,<")F."54)S%3',W[X@4
MQ%=Q%+>UVS3H:Q&\IP7*VY;:=A)&1-,'QJ1*SC2&)(]&,)*@Q&ET6F"I&:8$
M`1&"]4S,\29F52QSQ\<RQ2+UI#V:,2(ACJ7G:W^6840;-)&H/14[>2J'K+#9
MEBHY<(YR=G$^"MVT[@=L2M)HL>BAAT8/UNZ2Y1BMO&W0=/VJV6S6,OZ.A"]$
M768'*"QWHVV&RHI?NHZGB=)PLZ=56ED9<,F"A-7D':TB@:Y*<)6-&`TWW&:]
M<3E,\3=-5+.R+Q^TK(+_`)UT85,>A8O,+16QIPLV)PCH.TH?45B*8G`6^L6<
M4UJ=CD*2$R,`86U)TAH520S1VB0B'ZBUK>3=-47-4@BKQ0<1JD3VE_=H](E,
M@YUH3F-P>VB>S)DDH8!R\\HI#0<A0R)H>$3NVVI6+VU(E+;*4YQ;R6-`FT(X
M020!U=TFZ6#!XE>7$">O#XU*NGH/,:]';BK=K03J.Z(E;T_=;VD\0F-L/5KV
M4S2I-*;%=)C(8&T''C<5!H"@(""20%DE%EA;I-TI6'Q;<>&6_);?<X=,W\4H
M>K)F"FIY#:5@O'/[58]RQ1V@]MVG'*062`=>L%D6-%9"Y)71T3(@&F;<UAQ>
MBU"M0<8W35&Z:I7;9X=.0VB+I6!"]=+EOK5-JXFD:M0SJ.ZS[GAP*=AL^K^J
M87#K2.EIDMC5>P&(VB_I$#0E4%I_1T/,.^8T>QXWSY+NE+U/BJY:>9_&K'F+
MIT'8;TR-5/M<@;)]TC<<GBULF4%)7V8T\\7G&%TLVT7*]0.3R(]:C.D):_7S
M!*^0(PEAUIOG@FZ5J7CPI4=\7-'K]>)KT'7-HQZ!(ZQ!(*+Z`L^EM/<%;Y:K
MFZ6.2E%7[^S)9(WE2)<:=[%83->AFP__`!WZ9(RF(KD1,QIR?*+^/GEF'VC4
MUS,D"4EV12KITTYP22JI`\+%28'7<S>+!NUH>`*%0R9`P/,M?E2M`B5A-(:1
MG"TD"5H0]"7)<JB1>)7C^.5'2%,5NCN&FHQSK-[2L*IWJF+RLRLI]'9+<HY'
MJPCASZ+2!!*'!$]HY2K2?3'*1DE(OC(`'198`ZNZ;LW3=I:R^-6@&6SGBU/Q
M=T<\.LQ8(O'+3BLDZ-MB05M=Z**5,EI-$IO"O'21*8K:SJXU\B*3."IY3JCE
MYP-'G"$;_FQNFJ-TU2.5SXG^0*U2;3M[;;4L4I'RA5T9>;-O&T;,?X'%.9+&
M0VO1]30%ZFDD>7")5!!YPWEJP,"08$JWTT%7]1H!?L;I7=*V+WX4J._K?C=[
MO<UZ#KBSXS`M5@1)*(O^SZ3-=X+J5;FFH[)2*]?V4F1-X9$+9^@*M&:UZ^W_
M``_9DC*8BN21,Q%<FS<"@K97C,N8VEUE;RF<)3,9<:JF4K?)BZDKYM*'66.+
M<C=)`L7+4D=:USP8G:VXL84C6WEDI$P"R"2P!B)K@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@<*;J\M%BU1Y"I'R&WP*B93&6"S*9K$J+%6=*4O5#\EMRC#+:7W%&
MZM31%QCKG3]5K0;(D:\UQ2?2HBC3/DT;HLHW<8Q.-M[8VVN6A/,'SM:,9KIM
ME269(+DD/,T3O650Z`0*93R/!FB^@HET5,*.KUX:VLYRG-HQFMI>F=@M)"7Y
MS6\S0O=\Q9Y14G"8^Q)QG[D[KKRU<DVE,J=KV)&VFIF=P"F@`1\^MW4"ZM]5
M_8T@J64J+0T0H4E,+6TS^++D2E>C$XH$1)'UJL].A$!2)MF-3;/'DRL,\F5%
MWESCU->?.YKO*G#FRJ9+9YD9GC`]0/\`$[(*MY'8E6R]")<G&K.K>UFV.'&-
MCF6#Y1D$G>\DLTK9>-LQ,1*;9B=5-LOFPY"15'%K`L\-IU_+%0VA/.ZV<:GF
MJ>70AO,J"+W;)+17L+B@2NG[CV2O)6E=0R'8-Z.2&A``D2O1B<#9-TNV6Y-J
M]NT;45[TASB^GS!_L^_6\+]#&Z#Q)PE:!%%#9(RQ$F8R!<WB_P#&C&Y"_IB3
ME*4"S:(@0UBL)"$HQ2"1$S%I$3,6HIX\L_(S7$XE+$1]M2H,]C=2R2$1N&5#
M,9-,967>%E6A4E:,S)&VY&8O5R"0SNH7E)]+Z!VG`$DX[8"3@CU=LKME9]!>
M0SG#IE^N&,5&Y3)\?J:9ETF<FQ9"W9K4SF*MTDF4'52FKRU0="FS$"?5Z\L6
MC2-`$)Q1>F@;)/2G'IQF.*3$PUYYY\P7/-TL?,VI+$;:K*:=%Q.JWU6TNE<R
M]UAE/OUZ/$G8:0AEI602R(V&-O-SND26`BHCP%ENY>TYO^B6L2;.3C,+.,PM
M:\O(_2U5S_H:C6C\1.MR4!S_`#2[I6I50J6.%71(##5,@MAB;I[)(PA=7UL2
MO,;8MJ-'I4!Y!WNTC(.&YF%(QHQF8OE:1C/'DKMR\PO(D3/E+=,UUFIAP.(3
M>1269,5/6$ZUB\N5212"R:Y8]7\L"SZ#+7NN!6&VI%J$HK2SZPX1!8#32#PE
MMDKMELA$.X*BG//=A]&1V-W(KC]5R^95[.*[%4TK+NAEGT%DY42?(@=6GTHG
MG3J!S4D&Z,WO2,I">%6>>2G`<87-LW25K2AXKY=^.ID\TVSL:^U3R[H25HI;
MI".II:"(0(VW;%LRH($WVI*PI3&*$+WNUJD>V``3CS`?6D!,T+:0>E.KLE=L
MO=RYY)X#U/:MZMT6C,DB5&5-0%+7PPVC8\7E,!<9O%[2?+Q)-FC2QR1N2!65
M8HBM4I'5F>2!"^N(6G:,+*$3[<3C7VI,5'FH2,^:RFEZ?H:RI#5EXM5`5#'^
M>9+&I0GIV?:GSY&+JKVT;/76)*88Z-S<7%:O;X/7I3DVO!R@('(I:%,6`3B(
MM$*[)TCFNV?O2?7FFY?CJRT/WI,%HP!DA%^S&HXV_;@<F>D,OK^`5[5T^FG0
MANRVE"-BJN)H[3;1.9XM'GI$JY";[!B5?&5-L\C;/)(^]/)L9QS-G6NF6F))
M8#L@YN!T<7+@IWPV$";2^AJII-1$!*&!E=%)L@/;Y^J<$P2Q[&<K+0I`%#&N
M`(+'&R,;8N0>8+GF+JRI2_?B5EKK\$OQ:N*/D"F;%?""YV+J!'RTIK9RBKVA
M;H<QF$V`:8D-^O>$I@3-`/\`7Z07S8V2;9X)5W3Y!W/G'GSF6[:U3U)&T'25
MN06`$27L&03&B*^K..S2K+%LHF0V8I!''"3Q1>G'"2&[:10B"("M;H(O3TUO
M:,;FB(N:E6M+>9RE9G4D'E%H5E<T/M!VIFH+.ET$@E73ZQF%(^7S+E4"HV!0
MF6$QQF_%TLOZ1(#3X6V?2IW%Q:]_5*"DQ19HPV<)OR)Q7(G\L_(ZUQK1@;S+
M@<);;T/E4S@$*2TS.=RQZ25FXV.RW8R&-)K:4)JEE"/U6N2"9MJL9"IE5GH`
M""9]Q1;.FV4VRVCY[ZKIOJ,B4KZ9>G.2L\01U@L='TUC<&UE.W;=51&Z(FB;
M'!8664XN)=?3MH5KR"_4:`Q<`D[VF^X(9,3'$F)CBV.R(8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`UWCG,=;QBQNE+2;S'XZ4]3&P\VQ3%JQO.2MNH36#74S23$`@:BE
M;00=&FDLU0`XY7HQ:(9FO:$7QZMZ5X+<N?"/P?\`([6U2Z/L\JNIHCTUH=CH
MY[:T#]7Y2DXQ@J.#4@DM#\3[K44R.G"FOJZ;$ZE`<XF0]2?I2<8R;&K4[,UO
ME=TLNA\,',9"FF_NTZNF2L]-6U)+M:XR\K*F)8WJP)19QUO.+@`IBJ-E6UNB
M-F*DPL]-!CXJ4X,@@M"[2IM**3%S?)NE=%`>,^AN=*%N_G*&R"QG2NKRAB^M
M'8+XI@B5YB5<&PIU@#/$8FNB,!BI"@,<CKTHT2Z/9+P^+%(_F7K5AG[<3E,S
M:3E,S;7];X1N7W1H9P/-E]!R"<L\F3+RK;DTBK*36(H@B*J8G2;=4)IK]4[C
M$DT+:JYA3>F2+TS2GE25>6-Q+=PKSC5`[OGR7=+:OIC@&G>J[#H:?6/(;`1$
M<^R:*RR*PJ.+8D5$W%XA,UC<_C"XPU_AT@EL+=D3]%4I)[E$G6..KBTB.;5B
MD]$;LG68RF/O2U'UEXAN=JPE4?E2"QK_`)(9"IE4THK]DE4TB:U@@;-2-JVU
M<-=UY'4K=`6I9N%-<KNEZ`=I8H5NBI)L@LQ;O9(1[LY3*[I7EREP!2?'4GM>
M0U0X2\]%:*]><1%I"*&B8X`T.LQE\_<XY$E<<AD;E+JWK)3-UAOU,D<GYT*2
ME)$9:L"1(02&3E,\4F9E0=;^'[GJM'RFW)OM'HA]8Z@#4.S8)(9M$C8;:"KF
M^4RN4\R+[01-4`:7-X64";*]I642!6VA<$K<WZ>0NAB0!F[OF5W2G70_BZH+
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MH9W_`/OY%%S1K3.>.BK<Z<A:-84U0IH0Z;G2P;J>$SH2222`]H"G3$?3B*V<
M.[I7=*8<R^-RE.82;(0LTUN6TF2R*;@/.IT?N&7,LD:8E0]6CL8FOJKB`&&*
MQ9:CCT:9+.<&X)RL]:XJ4H"1*%)IX1G&)RF4F9EJPY^"KF-]ABF&2*Z^J).6
M>EA#`6^2:;UH_NJ&!UW2]D\^1"!H4+I4*J+@;&*JK/6HTCF8W&R)$X$$NB9Q
M)<]J%9]WSY+NE.I7X9>;)<^ER%=8MY)UJ><&3-``#I5SJG:B7ZL*FJNRHNT%
MR:J'X34SVFTTC'%[FK(V!Z;G-$(UF7-99YY)DWR;I;'].<!5%U5-V.<3F66?
M&5#56+C43FQP-[C;4P2F&JK2K"Y&U.^)GJ)2%:2NCT\J9L4(ST!Z(7PC/).^
M4LP.@(RF."1,PJN<>*7GZ:'V0X!FUP1YVL_=I;?E:!TKY];-%V_T<#IZ8-JJ
M'SJMY=!Y5'%<]!M'MI?FUV;#F46TZ@@X[0%(6Z5W2N..\#T3%ZGX\I=J',]P
MCB*8Q><5"F7OJ-R6.;U$Z]G=;MY<X/7-!Y+PV&,]B+SQ)DA2`HE4`CZ?1!!(
M2,FZ;F?%+FYGQ>*X.`:<N1\NR6.LDLR*32Z5O-C_`/C"%2%F;'NL)MR:_O4I
MI:=UA]QC3NWMDA9'Y\,.5@<R'5O7E@T0<FV0(TLRQE,%J8CWBGI.O9A2]O0Z
M<7B\VYS<EDR^J7:36@D2(GB26)++%L*_%,^^@A"M`Z;ZMF-AF"GJG;<<+Z=M
M;`M!+<%N(+VW3PY+NGAR9SQM<&N?%-*PB,O\O5)ID)==\KL:`0&3+GJDSY3=
M%CM,N9BF\^51ILFDB%1T"C#3"8PX*!-X0L*8[0T(-G%@3LLMTI,W+I?F4,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
(,!@,!@,#_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g62758g94c52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g62758g94c52.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0C,4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````'@```.@````&`&<`.0`T
M`&,`-0`R`````0`````````````````````````!``````````````#H````
M'@`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````!B\````!````<`````X`
M``%0```28```!A,`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``.`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#TAW5\(,=96;,AK26S159<"YI+7M:^ECV>U[=CO<JP^L_3'FIE/JW6
M7/LI96QA#O6J#S;B.]3T]N0STK-[?\#_`#F1Z5/Z1&ZT.K/P_1Z265Y%[A6[
M*?[A1603;E-I_P"U%S&MV8]/_<BRKU?T'JKG6XG1STW)#<\,ILPB<8FFQS*^
MGUO;^T&/8?3MORLJUO\`EU[;*LVM]N/Z_HV546V)3TO2.H6=1PAF.I%++'O]
M"'A^^H.+:<C<UK6[<A@]:O9ZC/3_`,+8K=EE=5;K+'!E;`7/>X@``:N<YQ^B
MU<QE8'3F=3H?G]2S;,EE#C5776]K'CZ=O[-^RT;67_9W>EMZ:_\`:?V/_#?T
MFRRJ:OJ"S[<<FY]C'V,=EC(%VQIT]*NS<QC?H;_Y[U+/L_VW_`_;$E/1=-ZN
MSJ/VC)IV#IU4-IR2[6P@>I==L,>GB[75^A:[^D_S_P#1?L]V1>9=58&.8]KF
MV-WUEI!#FZ>]D?2;[ER_UC_YESF?MHY`IWU_;S7]M^R^I%7H?:_L?^3_`%=O
MV7^>_P"Z_J?X)5<['^KIKZ@<7*RVYSJ1N#VYA>*6C79Z5?VW]FVM;8W?3ZO3
MZ[K-]-7J_HTE/68_4<+*NMHQK1<^ASF7&N7,8]IVV4ON:/2;>R??1O\`63=0
MZCB]/QS?D.@`':P1N<6M-CFLW%K?:QCGO>]WI55_IKK*Z6/L3=*=2[IV.['9
M1706#TF8K@^@,_,^SV,94QU6WZ.VM8O5\=]G6MV3F48X#:/V>VRJRWW>IM=Z
MGNIJ]+[8[%?^AM_IG[(^U_S6+1F)2VSJ_5+Z6]2LOZ=C93'.KJIEAF7C[.ZY
MA]6F[T&UW>KD?SWJ_H<7IN7BO6T<_IV)=3T]U[1D.;%=!<7V[6C^<L^G;L:W
M^<R+O[=BS\W"])K+NK=0S<BG>T-HQ:W,9OG]$_\`R75^T/I_OY7H*G=_S!].
MS?\`9O0]#]9V3Z/I39M^V>E^@]7UO6]'[3^L?:?YK].DIZ7UJ=C;-[=ED;'R
M(=N^AM=^=O\`S56OZM@8[Q7=8YCC8*F@L?[K'?1JJ]GZ6QW[M:Y^^CZN69N'
M99E74^G;0:J<QE[K+'^K7]D;A6=3!OJK^V?9_M?V/_@/M'I5K391@,^L(MRL
MBRW,M;9^SJ+FN#*FM#&YOV1[FAMEUS_TC]UC[?L_]&_5?524Z=.9C7N<RJP&
MQAA]9EKVF`_WUOVO;['M>A=0S3B5U;&>I=D7,HJ9,#<\^Y[H#O;32VV]W_%K
M$MJ^JEF0^MESJNI.S];6AYRQDETLV^K79;]C:WZ'Z/\`9OV/_NLM!N-73U'$
M=U+,LRLD[VX+',#*@\,_36#TF>G]N?C^M_.6?T?[5]CIKJ^UI*?_V0`X0DE-
M!"$``````%4````!`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O
M`'`````3`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``-@`N`#``
M```!`#A"24T$!@``````!P`(``$``0$`_^X`#D%D;V)E`&1``````?_;`(0`
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("
M`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`
M'@#H`P$1``(1`0,1`?_=``0`'?_$`&P``0`"`P$!```````````````&"0<(
M"@0%`0$`````````````````````$``!!`(!`P0!!`(!!0`````%`P0&!P((
M`0`4"1(3%181(2(7&",D,3(S)28*$0$`````````````````````_]H`#`,!
M``(1`Q$`/P#OXZ!T#H'0.@=`Z!T#H([&Y?$YDU(O8A*([*V0@\;BQ9W&S0TZ
MU%R>-$%A,CCA%P+<NDF1Z/E6RC9ZS5YQ<-'">2:N&.>//'`2+H'0.@=`Z!T$
M&LNS:\IJ"R:S[8FT8KJO(:,5,2F9S$RQ`1P$-1YQPY<D"A%9!JC[BJF*:6'J
M]:RV>*>&.6>6./(4RW_Y0+4=%(Y&:EA9.@0EAM"I*KB]G4A:M][HWU'`R#KD
MI*-=O'%5;<;:0B"X9\(\<S6SBL48!\\^%7H)=OFGDH$OU.J'R)SN\:^N>X[E
MV(J6AX1G*B9&JKYENNDLNC8E[)0+D:(9SVM-=ZIC=(:Z5_$WSW`BR9CCTLE+
MI5FBBY<C,N[[H+I.@=`Z!T#H'0.@=`Z#XIR21V,HL'$D/A8\W*F@\;%KG"C$
M2B2D4A?HBP`!@J_7;X/#1PFX3;,VJ?.2[E=3%-/'+/+CCD/_T.P.U?)!K97D
M_D--PM2RMFKVBBBK:54IJA6<GO:90L@F@[7Q$V<;BS;^,J9*N>&6>*"$SD$>
MS7RYX]'&7'YYX""*;(>26P<GJ52>-Z)U6T49)N0Y[=/<6OH$X]>3A?CE`A#-
M381N8XP=Y,TTL\4<BJ&/&2W.*BN&2?..88G8^3JRH9;-F:@W!K<#DF]L7#UC
M*JMHW6*W'=GQ.YX%;2L];"K'<SNR*WIM[3$%K-[7[E*=DY",S8`^'0[!BX+/
MBPL>Z#'51>0S;Z=WOM7J$*A6MUV[.T[):H!(H5.I9<2I/7C[S7"$UFQ#8VP)
M:3D1^6QB%+%AK6/.@H<"<GY;,D.9A!R(0P58!&-4*<G5V>3";71.KTM:\Q>A
M`"54W*[-(R0C!ZDGNX]RQ**N;`KJG=>8P9<US"ZAU;IIXW8Y+.$7LD+2B:K8
M%S1IV`27;A?IT#H'0<[7D5\I57V):,A\;&LFQQ*O;`QX&);G;15+'C=D/-1J
MB+2<5"I``B2D+!ROEO?LI-'FH7@@NDB)@2;I9Z0>(%4AX]T%U>L>L]-Z?TA`
M]>J$B:$/K2OAG+$4Q]Y1\6+$'2RCX[*I4;<^I_))A*C#A9^4).<LW#QXOFIG
MS^O''`9ZZ!T$#LZTJVI6!R:TK>G<2K.N(8,6,RN<SD^-C,7CXQ#\<9NRIHNX
M:L6B?.>7&&'&6?&2BF6.&'&6>7''(:FZE;T#MT3YTY3]!7N,UG:`,W\'VKM&
M-"ZP@=TF._&)(-ZAKR5&&=UGX>Z&/5W*,E(1T4(=9,U,&V:^.:2N8;W=!CBW
MK;KVAZSFEP6M)6<1KVOP;D_)S[W%9;%JS0R311;,V31)=^5,%7RZ31@Q:IK.
MW[U=)NW34653PR#GTFJ>U&_NS]:Q)8X6IB81]U&+^0@3V-U_.1/CFH=3-XM6
M,SMB!3R-SRK[,\E6S/&.60(:;:E!%0@6[QTQ;JNT57\@"QNZ81/-5=G+&WY@
M<->7175IU75M:;2P`0S4)7-7,+HTA8I:(6M0#5/'G*;@Q"5G$UI?!O5@_(-V
M^!(%DX*IJB2X6+Q.5QJ>16-3B&'1<HA\RCX:5Q.3`WB)$+(HU(AS8N".B"#;
M+-N^%EQ;Q)PW63RYP524QRQYYXYXZ#6W;C>;5+1:OGUD[271$JN!M1),RP$O
MUURTWE#0/BER0^FP$$@2F,KS:9KI8K9,62R3;E7#E?-/#GU=!,]7K_:[1T9!
M+X&U3<E,!;$9/2\?@U^14/"+02CZ9-XR"GS<2#2>68@6,L'MDR8Y%TY3?\CG
M2.;ANW4SY2Q#/_0.@K'D'E?U]`S>7P!"D_(%*S<)E,AAYAU`_')NO-P#DO&"
M3D644!R"-TD0%'A7*[;G-N\:JJMG+?+!9+/)//'+D(/"?,E0MFR:>QRL];?(
M18&-6RU.O['-QC26YW(V$3[XUJ8?0>2#W8AE*ADL"#'[=8BP4&\.&'#A'A?'
M#)5/'(-FZ3W[H.\K`95*-%7]5MHEV1XK'()L=JYL7K>9F`B,)MU3Q2$.[IK*
M%`)HU%IN.,E\1;UVNBGQRIFGBG^,^0W5Z!T%6=-D65\>4;=4O+!;PX-T?@VL
M='TUB;1;NH]![&N6NI/>]YR^&M\L.<&LTEL"L"""7Q#+CEXW&#^&R&:2#QW@
MN'__T>^`-'@$<2?H1X&'!(E#!60DT0PQD+2(GSCQ0@;./TV2"&#PP8?K9KNG
M*G&2SA;+G-3+++GGGH-0=_-X*QT!UUD=Y6(LR?EEG2<1JN!K$\!;^S;0+,2#
MR/P\>XX;OG2#7%J,<D2CE!J[79!V+MPFW<J)8-U0J,IJ8["Z::\IVK<`2+6O
MYP/+3*D#4,I7EMP,;0)\VB?"E?U8;:X.%BT3U@T8K)3(C,GV2BJ:959^CBZ>
MDRK-5V&P%E!(AX5/&A)&%<3B.D]D+@L@%&'.PERO0H#"X-X=L)PPC9K8FYCA
M)NJ#:1J+'CSN4D&[W/EH/B<=Y88JY<)899AXM8-GJ\J_7V(ZW^+BIYIN\*K&
M/%W$XVR+*E8'JV=GKM1U*[6M"7["+QZ0/]@+6GLR.+G"(RM`\Q7>$B>:"SD?
MC@HHW#5O0;<[R&WTD9V"YKZ]-H;PM>//`X.F5X00T;\;>GT.5*<EH^-EDYN.
M/G+;NB_N>&[)22/HHWL?(5P16$-U$$F:ZZ@96W%KOS/&RM6QN/6O<DDRGC<\
M>LUSX_1.J=&UQ4`P(6B[877`B0[A2&2VM)YE,&95WRK-LS.(X:Q'NG#>%NWJ
MS1JW#(,GT\\G\WU1<0&8[!-"!8*$>"HK0B%RR1626P_E4F1Q4>[A[Y`*TK6P
MI9#8D(-O'CJ-U?!JV7(,V"8?@RY14[GD)Y#_``WP2J](_P"NU2S>+1G8`E:M
M$[&3O8<M4,<?Q^U+SH"T(5;4'%SVI(T2A;977<"5@S,"#A`XL/1C\9000:NL
MG6"SIR&'ML*#_P#H;O>$84M!]J/'9441L-M(V%C7'1U:[)5#=L`#-VK+X8;7
MQJ96/L",?.Y<J[<MWKQNQ!D1:+;A5F]P66X]L-8=']$?*=XRM.;<A&J&N^I<
MAV0DT:=6985P7EL]8%QV)LSL`BT?N^`S*&,ZSHB%1.,)/"3MD#(2"?*.4454
M5B>3C+);A(,Z:J4=Y4F4R)W7/8%,#NS\@"/XH1O+?[8^!CZFK2//6_#I010F
M@V@<KL^I$0;LNV0X=Y&)ZQD3G!'%7,QEZ^4$0^KX\=9L_)%%H-Y&M_;"6VW8
MG9G-Y/I73DCC(:)ZW5)50>7%X[`;>;Z_#LB@5_<M@#P^9A-Y*2,I*QL:^:,,
M'7>-5G&0=#O0.@YZMKMHV%GW[*I$-$C+?'ZL76XUVTAUF5(\HAMDO)*%AHF:
M3VY[4014X=AZ.T8`GD>'QMXCP.CCE.0&LN%'K".J9A,=.O(1XJ-;:IRA0OR!
M4YL==TY.2:Y]B+&K%4E:<]N*Z)9FU?6#/W,)J43-I`'CC7/AN*C@G%)5$#&!
MH\6AGFDQQRZ#.K[R@SVT2S*,Z5>/;<_8AT6S3^/M*WZQ/:0:YMF.://"YDG8
M6SH2)60[8#7F>."R0>$EWJV&"W+5%QGABFH$)UVTR\DP6E(11=C;9T7JU645
M&D6:T>T@J)[);/Y92@A*3!J,QN[MC<ST/@T=C#@\W:`<AM;?(M&;3C\.\%.$
M\L`B=G>&+G^>:_O77R[(8(+QP(YQEK?<:HK#W=-RRS_L2QL%?KF:R+9.K).<
MLB`L%<AT5&2=:20V(X+*NP@<<]4564#R2SQD[?!]H:@VN$;31?<6P(##<1Z8
MK>5&=AJ_JBS^XE7RMN:ZU/K6[@]/1$K)8[)\0'LE8\2,"QK/!;`TZ<+.O?"%
M[DV;Y$*D+48PVKV_A>L&LUHR"?`[?V$T=U4,&'%*9L6D=SKV'6':%Z3:^U(.
M,M!)V6XPL-&$B!47=C<$'F/'+]N^:!F#Q%Q"(E+`WMV7I!_9Y;5G8"SZC$4A
M-K<G=I6%++])TI5^$*M/9UO(;=+G)6_BMCRE\E'0CKA?!B^$0ILX8H(CU&>/
M(1N[]M=L+AORUO&1K\H4KG8\C9KXY--B\H2LTC6L6@AV+0DL"O*(/7N)*,6!
M<]@'#1B&PQCW.:B4E#%")%LU9B^$U@MIUWU^K+5RGH;1]1BGPV&0QH[Q2<FB
MCR02F3GC!!T<E<XG$H)9JE99.YQ)B+HJ:*N\\W)`D[664Y_.?XX"D35OQO;<
M;#V;*-B_)_)Y9!)>7"R**N:UHK9>?@S$E;G),#D;8"/LZDB]<FZ<UHKQ,`@T
MC\$CQ51[+7JK@]-"!%[\>/&AFJL\]B_'GL)LDP*T%MO:WCK?!ZK?TL?A=QO=
MV);54B;N)([NJ:'()9UA%=R\@,F=RT<W0BL/'SUN-:Q?-\T;X*$W*20;#R3R
MI:_F0K0;K)&+CVXNF4!^7<#I:J*?L\,0<$W7+5J.2MF>3^&Q>OM=@+5^2:_+
M/IH0$JC6JO*O#9=3C!!0,RZ-:Z3?7VKYJ1N*2BI?L+L-;\TV/V&.QSAWC#T+
M-GK4$$:PR!XDN/ELH#5-<Q`!$@RKS+ETZ'@DG"O">:W**8?_TN_CH.>K8BN:
M*R\QVN5I^238*.)8XN.8CXB]84X;:^=/\V.F&%/K-MRUK'*P+FGE]G7LL728
MQL+F;0[1@V$+(8.22S7A$+4F7]._[XGOQ]6_OK_6`!Z_G/LOWK^K'\D&O:_C
M_P"?_P#6?I'\H>OY_P"N?Y?DOC_E_P!WQO0;'SW^._KZG\H?2_JO>,_=^^_!
M_7^_]W_0]S[#_P"-[SWO^S^?W^K_`*?UZ"4#^P[!C\5V?Q?9MOC?C_9[#L/9
MP[/L>V_U^S[?T^U[?[/1^/3^GXZ#V=`Z!T#H'0.@=!5;IU35(F,\+'T8VRV;
MBFK0RPI,JSH*/1J".M3I$0930XK+VU-&K[UKD5BMJD+R?!^DAS6DT9P_%'++
MX?)!/V5,0M2Z!T%0.C8?Q>"-MMN?ZRRI"4[=%+AOTQ;W%@MYXWET<*/;6YXV
M"BNOW\C1R.!5Z>$W@ESS*E(#WX?*4*I?,/%GO#3T!:I$?H_Q[CZ']4^*[Y?N
MOJ/Q'Q_R7[>Y[CX;_6[[\?CU^K_)_P`?GH)5T#H'0.@=`Z#P)?%_)O/9[#YG
JL1WR'M=O\G\;[Y/XCO/3_M=CW/>]MZ_\?K][T?KZ^@]_0.@=`Z!T'__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g62758g96q80.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g62758g96q80.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^$-EVAT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-"XR+C(M8S`V,R`U,RXS-3(V,C0L(#(P,#@O,#<O,S`M,3@Z,3(Z
M,3@@("`@("`@("(^"B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("!X;6QN<SIX;7`](FAT='`Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"\B"B`@("!X;6QN<SIP9&8](FAT='`Z+R]N
M<RYA9&]B92YC;VTO<&1F+S$N,R\B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!-33TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+VUM+R(*("`@('AM;&YS.G-T179T
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V5%
M=F5N=",B"B`@("!X;6QN<SIP:&]T;W-H;W`](FAT='`Z+R]N<RYA9&]B92YC
M;VTO<&AO=&]S:&]P+S$N,"\B"B`@('AM<#I#<F5A=&5$871E/2(R,#`Y+3`T
M+3(Y5#$R.C0W.C4R+3`U.C`P(@H@("!X;7`Z0W)E871O<E1O;VP](E!38W)I
M<'0U+F1L;"!697)S:6]N(#4N,BXR(@H@("!X;7`Z36]D:69Y1&%T93TB,C`P
M.2TP-"TR.50Q,CHT-SHU,BTP-3HP,"(*("`@>&UP.DUE=&%D871A1&%T93TB
M,C`P.2TP-"TR.50Q,CHT-SHU,BTP-3HP,"(*("`@<&1F.E!R;V1U8V5R/2)!
M8W)O8F%T($1I<W1I;&QE<B`Y+C`N,"`H5VEN9&]W<RDB"B`@(&1C.F9O<FUA
M=#TB87!P;&EC871I;VXO<&1F(@H@("!X;7!-33I$;V-U;65N=$E$/2)U=6ED
M.C%F86-F-C=A+3DW8V4M-#8V-"UB,S8Y+34V-35A-#0V.#,T-"(*("`@>&UP
M34TZ26YS=&%N8V5)1#TB=75I9#HY8F8Q.&8Y82TS,S$Y+30T83@M830Y8BTW
M,S<Y.#AB-#-F.#4B"B`@('!H;W1O<VAO<#I#;VQO<DUO9&4](C,B"B`@('!H
M;W1O<VAO<#I)0T-0<F]F:6QE/2)S4D="($E%0S8Q.38V+3(N,2(^"B`@(#QD
M8SIC<F5A=&]R/@H@("`@/')D9CI397$O/@H@("`\+V1C.F-R96%T;W(^"B`@
M(#QD8SIT:71L93X*("`@(#QR9&8Z06QT+SX*("`@/"]D8SIT:71L93X*("`@
M/'AM<$U-.DAI<W1O<GD^"B`@("`\<F1F.E-E<3X*("`@("`\<F1F.FQI"B`@
M("`@('-T179T.F%C=&EO;CTB8V]N=F5R=&5D(@H@("`@("!S=$5V=#IP87)A
M;65T97)S/2)F<F]M(&%P<&QI8V%T:6]N+W!D9B!T;R!A<'!L:6-A=&EO;B]V
M;F0N861O8F4N<&AO=&]S:&]P(B\^"B`@("`\+W)D9CI397$^"B`@(#PO>&UP
M34TZ2&ES=&]R>3X*("`\+W)D9CI$97-C<FEP=&EO;CX*(#PO<F1F.E)$1CX*
M/"]X.GAM<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`*/#]X<&%C:V5T
M(&5N9#TB=R(_/O_N``Y!9&]B90!DP`````'_VP"$``$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#
M`P,#`P,!`0$!`0$!`@$!`@("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`RH"<@,!$0`"$0$#$0'_
MQ`$7``$``@("`P$!````````````!@<%"`0)`@,*`0L!`0$``@,!`0$`````
M```````!`@,$!08'"`D0``$$`@(`!`(#"`@0!PH"&P4"`P0&`0<`"!$2$PD4
M%2$6&2+6%]<86)A9,2.55K=X.9E!49$R4B1UM3=7=Y<XN-@*,R4U-G:6MF%"
M0S1TU29Y.GJQ8E-SL[2Y<8&AT7*28Y-$5)0G*,'2U.151J9(&A$``0,"!`(%
M`PD/#P8,!`4%`0`"`Q$$(1(%!C$305$B%`=A<3*!D:$CTQ47"!CPL4)2DM(S
MDU24U%465E?!<K)SLR0T=+0U=;4V=CC18E,W>#GAPD-CPT2$)9:VU@F"@T6&
M\:+5=Y=DI.25M__:``P#`0`"$0,1`#\`^_CA$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$
M3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%Z59?]=I*6V<Q
MLM/9><4ZM+Z'L*8^'0TQAE3;K3B,N96K+B,HRE.,)5YLY21>[A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1::=X^PETZUZC&7RBCZZ2,3+,5#.L6
M:)/FC\18.KME75I:&AQ,4_AY16GQD*SES.,L+<3C&%92I/=Z#IT&J7AMYRX,
M#`>R0#C(QO2#T./JT7WGXO'ACH'BQO>;;>XY;J*QCM(Y0;=S&/S/U"PM2"7Q
MR"G+N9".S7.&FM`0>N/<'N=[_H._-GZO#5O5C]>I>TZG2Q<@@!LKQ5\0=Z=V
MS?LMR;(8M\:*Y/1=`;++:T,H1@=E3649=SA_'?VNV]/GLH+AYEYDK'$T<*5;
M,&"@R_2GA7CC7H7ZHV/\47PTW)X;:/N^_NM9;J>H:/<W4C630",2P[FM]':&
M--LYP8;65SB"XDST>'!@,9EAOW']YCZ)L6S1Z]K3)"I;DZ[Z_'-NA;$N*\$V
MOV:W-IRRORVTVIMU9*-5M>0W8:T+0VU-<=6M#K:DM(P.W+%LT4=9*/BD<>T.
M+8H7BG9X5D-1T@`5'%=+8?%5\.[G<>E:3+=:MW:]T+6[QY$L`<)=.T'2M3@#
M3W<@,=<7TK9007.B:QK7,<"]U653W5>Q!NF(L$RKZF3-4F_*RB.!M"(__HQ<
M^U-?'8\CEQ=<_;(.DA*G?N_NG7I64^7"VTM<V3:>FMFR-=-EJWZ)O2V`GZ#K
MD=['5C['6?B:>%UAKITR"\UHVX-GBZ:W+OWQ:[>F?B+4#!^JW(;A@UL(-2UY
M?R=D^ZAV&I^]=A:T&UC5#P"J[U[9ZT&R)@&SK*.`-%:;U[L"I2)C[5Q9C.E)
MQNU243W$,MM.QDMI;;:6E3B\;3:NG7%BRY>Z42.@MWFCFTK+(YKJ=C@`!0=!
MJ:G@->T_B<>%^N^'6F;MN[O6FZE>;<VW?R-;-;B,3:OJE[9W+6@VI<(V16\9
MA:7.<UY<7N>TAK;"L7N3;S$5*OG8]<UFN65[DZ9Z^2&W@UB4PFF;"#;#(&B#
M246E"TV*.]5(V(SV5*CH2MSSLKSE.4Z(MLV#YG1ETN464DW$>DPL`'H\.T:C
MCY5Y?2_BH^'5[K=UILMUJX@AV'JFM-(E@KWJRELF1,)[N1R'"Y?G;0/)#<LC
M:$&)Z)]T+?\`LNOZ$)GZSJN/)V?^"[%AP*!6:.S'S=-D:UJ!;(I$FWS%Q\-#
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M^0=6ZDNS%;U=DI>=F6ZGF6'`=D5":%`NEM;[#PW1[:;:AYB:N[F7&'%N..HR
M-2EO"$N^+^<?R:L!>OMLTN1K&D=H5J9WQ?2X]EHZL37A@NOL_BD>&L^\=:V]
M)=ZQW/3])MKF(B:#.9)MTW&BN#SW8@L%I$U[0`TB<EY<64C68T'[D^]=HF=$
MCK!7-9QF=F*T>D^L4%L<=R-^$BM=:C!WY7F3:IB6/AY6X2>(WJX>\B&8^%^I
ME#F76H;9L+6.=\;I:Q<VE2/H'3`5[(_T;:\.GAT<'Q*^*?X<[/L-QW6F76KO
MDT@:MR>9+`X.[C/KL4/,RV[*YFZ9;F3+EJ72Y<H<T,HO6_NY=D[<7`P"=3T^
MTT4UT=MLA4.O6MI:2(SMK<]%1V6LO75_&(BJA7F'UISC*LSU+<PK#6<,IY]Q
ML_3(HW/:Z;"4-])O`V[9?I/IB?4PXXKZ+NKXD?A1HEC<W-I>ZZY\.JPVS<TU
ML1DDVW:ZNXFEJWM=YF>P'`"$-;0O!>9WN;W3.PFOM::KMX2L:I>*WBN=Y2Q1
MLD!L[\&/*ZUZ[KULHB83,>XQ'D,$219Q)-*W%Y?9PG#.6%8RK/%MMK:=+-.Q
M[I<L1MJ4<T$\Y[FOKV#T#L]735><V)\3KPPW+NS6=$U"[UIMGIUUM*.,QS6[
M7N;KM[/;WF<NM7`ED<;3;D-`8XDO$@H!=FJ?<&W/>-D4:H%J_KM@996YBI[T
M$2?:F-YCZSWG<D?"N/V60RC&2>M(",^9"OVEU_']<I"F^)=[=LH+:29CI,S:
M4J13TXF_2]3SZM/5^?[S^+'L';VU-1URRN=4==VA:&!\D)::W^D6IS`0`GVN
M_F.!';;&>`<':MZU]V_LG;JDT>*U73[<M6A:!LU3<&NVMF/]8;-1NRUE),82
M]=I*\"DS]/BTLM>;U4-.R<*<7E;:FN?)M336S\IKIJ<TMQ<TX9XF_2#&CSCT
MX8"F/U_=?Q)_"?1=;.FV=YKI@&X[RPJ^>V+N1!=Z%`PX6C1S,FIW!<ZF4N;$
M0QH:X/G?8?W2>P>IZB(/URLZIE2IVC>QFR7VBX&SR&,'M2]I1FE*U';Q%N$)
M:1<FJ2UO3&\YRX[.\%MN--XRUG5IVU]/N[ON\CI<O.B;4.`-'P"0_0G',<#T
M#"AXKSWA?\3SPQWIKLVEZK=ZRR&/<.B6(,4UNT\G4=O/U6<G-:O',;<-#8G4
M#6PU:YKW'.+5@>XGNR4=V,,<KVN,1ZC4NPQT:I(>P8==F:H"=AR-=1,5FSY2
MY'E/ZG'8EX1A"G$NR,(RWE:,MZ';;L6QQNS25>^$'$<)#"'?0_\`.&GJ5KT^
M-N/BM^'T.G:5=MNM5YM]>Z)#)[;#0-U&71(YRW][X.:-1GY9-0TMCS!V5P?0
M&K_=F[&W1<U)2J:C9Q&JG7$XCX(!:FO&7MWKV%VM9&U>M<W_`!8B6(@MJ'C'
M@IN)C"7,N+\7,]A=[0TV"F1TV+YABYO_`"<QC;]!U#'R]7!?2]X?$J\*]`;&
M;.]UMQ?>ZY"<\UN>SINM2Z=`<+48N@8'2]#I*EH8WLJ2[;]TWL)1C6MAP:L:
MH>9N'7/KQMPFL@!L[[C-CVOVG8TI9(</+%QBI;$1JFYEZ&A>%NM3_!QQQUO'
MHYX]OM;3I(9)'NEJR[DB%'-'99"'@^B<<QQZQA0<5U&ROB=>&&X=/U6[O[O6
MA)8[JUK3(PR:W`,&G;>.JP.=6U=65UR,LI%&NA[+6L?VUW+]=MBF]M:8HNP[
M''&Q#5F@D9,^.(9D1QS3D0X4&MXBLRI4V0A.6(2,Y\SJ\^;.?Z'T8\;J5M'9
MWTEM%4L:12O'@#Y.M?@[Q2VMI^RM^ZCM?2G2OT^TD8UCI2USR'0QR',6M:TX
MO-*-&%%=7."O`)PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")P
MB<(G")PB<(G")PB<(G")PB<(G")PB<(NKWW:/]&P#_T\L/\`J_;UYZO9_P#.
M;OVL?NT2_7_Q*?\`6O<_T;#_`%SI"Z0>R_\`IA[]_C`ZY_\`H9NQ>>OT_P#F
MNT_:Y/Y2%_0CPF_U&;9_NU??^>[)6':/\$6[OXSO2K_7Q[1\UO\`X3;_`+1-
M_)[9>7TC^VVWO[H[I_\`*&WEK[KS_!>W_P#*]P_PH>X5SM9OX2?.S]C:+Z?N
M;^USO/IG]7[+7-WK_I;[G_C<>X[_`*L>F>8:;_-,?\4LOW5ZX_AQ_J2T'^Y.
MQOZ_U17/=_\`!O3/_6?]7?\`LONGG%M_X4_^BI_V42\%M[^U=_\`_M!N#^4:
M4J[ZC_\`,_I]_P#;=?\`^'+1?-^I\;O];+^XRKU'C9_/N^?-K/\`5&KK&U#_
M`$CBG\8/NM_KS];.:9/X&S^*Q?N$BY.M_P"JR#^[&UO_`"EKJEMB_P!'OKE_
MEWV1_P#0M:+S`_SM)^UL_E<JZ73?]:&Z?[N6/_\`T&\4EZ=?\Z.HO_RSJ?\`
M]A>B7,M9^P7GFG_972ZOQT_FC>_ZW<?\LW>M2-&_\Y:?_D1MW_T1[:/.WO?L
M#_XP/Y&Q?;/$/^:+[^\-M_Y'T]6[V?\`\!?7G_H5[M7\"E*YU]C_``B\\]C^
MZ/7A_"/_`%A[I_C_`(<?UK=K:OKO_ARU-_\`*B?\`W;?G7:C_`)O4_=;=?&_
M%'_5YK?ZZ/\`KC;:Z_\`1G^#=G^*%I_^"7O9SMI?X9_\[_I+=?I3Q"_M8[^^
M^I?UEM%6WW6_P:5S^*;W<_\`H@@/FG1/YS'\8@_DK5XSP`_M?<_WTVI_Y,D6
MPH?_`)W;P_R<=U/^RO=;G$D^PP?MEM^RME\QO?YDV]_2NU?Y3M5::Z`_X0K_
M`).NCO\`J75?G<ZC]#^V77\I<ON_B9Z$']*;M_\`--PI[V-_YU:+_B/]*_\`
MZ(/&YP;3^#3_`-)3_P`F"\UX6_S+N+_]Q-T_^3'+Z@^DO^BWJ/\`N0:_[5G^
M?,==_G:;]</V(7\@OC`_ZX=;_;XOY-"MJ.=2OC:<(G")PB<(G")PB<(G")PB
M<(G")PB<(G")PB<(G")PB<(G"+3KL3V0(Z\)_4>DPV7K-F(S(*&9L>4]%!HF
MHPY":B,)@RHDP@ZRK#BO6SZ3*%)\R5Y5]SD!7$JK70=V`[!3VLN*MC;*,87G
M+K51"3H^,(<PWC]MC`5*\<JSX?2C"<9^CQ\<X\;E"*0SMW=@&F8JL6B,RI^)
MF:RB/383STF.K"\(6I#H1:8_FRRK.//Z?T>.<_1CQXH$4>A]I=VULQ%DGI4*
MPBVW&OBA,P-"%O2V%Y\7,-.APN9D1[&$*2VYG+C>%?UR<_L<N4)@NR:DW`/?
M:N(M@);RAI>/EYMN2TIB5&=:<6Q*B2F%XPMJ1%DM*0K'[&<X\<9RG.,YUG!1
M2KA%I'[AO>_4WMO]6[GVGW'",'*U5BU4KHVI5IR`W:+C8K<>AAX(2O)*/Q8+
MLZ-"=DD7L..)PF%`?7^RGPS6M+C0*@5-%MW4K4!O54K-VJI&.8J]QKP6U5LO
M$7A<4J!L(V,7#D8R\9SA<></EMNHSC]E*L<BBP^S+G-UWK^X7H=1;KLZ=4P!
M$[%U]KB&&(WRX.CV%/I`U*!83E:"S3L_R^2.U)GQ6W%YQC+F/''"+H&OW^\V
M=(-1;"FZ9W%U\[[ZKWE!GP!;FF+AUQ@QM@R")OT?JQ$'"X.PIS!7-KS):P-<
MC//-2_53Z:LXSS8(W'$4HL\A\E%>6Q/?1U1HFNB[_P!F>C7N6=:M3D9$")*V
MWM7J_#S1:U)*2DPQ[-O>I&P[B=J[LQ]64MMRX+;JU>"4HRI2$J@97`$$IDKP
M(*[8=#[^TSV>U95MVZ`V-6=JZKND5V57+E5)N98V;B.^Y%FQ'VG6V)PLJ-EM
M+9E0I;3$N(^A3;S:%IRG&)!!H>*P((P*S&V]OZNT+KNT;:W1?JKK#6E*'.%;
M3=KH9A@J^'A(SA"529TUQM"Y$I]:6H[#?G?DOK0TTA;BTIS`">"<5U`ZY]["
M'VEEE9?0#H5W)[E:Y"%9X>9O,6$UQH72Q6<-3GXJ-3K?OZ]46;:Y3#F4I<:9
M@-N-95C"\)SG&,YEE/2(!666G$A4OV#_`-X8!=)S$$9WM]N/O3UI@G')3-6M
MN!>E]HT2SR8D9N2^/$7BF[5S591=EI65KA-RURD-)\^6_+GE#,W`A4,KP*^A
M2N'A]IKP&SB5.+%6,,+/#%NHPVZL>7@L$(:G$84O"'%1I"<YQXY\,_T<\UK!
M95YYJ.T[(D.ML,,-K>>>>6EIIEII.5N.NN+RE#;;:$YRI6<XQC&/'/"+0CV]
M?<6T9[DFN-I[-T4DQ'!ZJWIL'2!1@\H?B:4=ILB(\#O`YF#)D*15;_7"48D,
MR]AM_P!)U2'$)6VK',G-+<"J01Q6_?,5$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$4'O\`K2@[4"M5W8M3#7$&Q*>G-"SD1,R&W+D"2@)Z
M0EI6<8PZZ'-RXV<_T6I"\?T>;[>YGM7\RW<6/I2H\X/SP#ZB]#MK=FY-G7YU
M3:U[/8ZBY@89(797%K9(Y@VO4)8HWC_.8T]"K`WU,ZV62Q%;<=TO1"EE.%X9
M\P:EAT.3B)F!29FMX1&6[Y\>K)C40@^+1G./HB.*1_W><AFJ:A&QL;)7!C10
M#JJ<QIZN*]?I_C5XKZ5I<.B:=KVHPZ3;0.ABB;+1C(GW;;YS&BF#77;&7!_Y
MQH*YDCJWUXE#B8F1J"DNC3)RLV4K"4)1Z$\_3;4<O%6*R487CU)@.W66>0CJ
M_P"\DRW%?3YLXY/?*_S!W-=F:"!Y`0&GV&M'J!:(_&'Q/ANH;V/7-0%W!;SP
M1NYAJR&ZMX;2XC;A@V6V@AA>.ED;!T+$0^GW6`?!P-A:.U]&@8^8XQ%:"-I9
MQ@O.MY(ECR^?_P#'9]^,NK_IK)/Y_P"_YF=7U)QS&9]?/U9?K6^L%S9_'/Q>
MN;CO=QN'4WW/8[1E-?:V6T<?1]"RSM6CR01_2KS*=0>L9NP$K66TCK\A8S%A
MN-K*&905MR=.L>P08VM78S(>ROQ7.LP$/%B2U_\`A&6$X_H<,U;4HXQ$R9XC
M#6MI7H8:M'J$U"EGXX>+FGZ9%HUEN'4XM*@M;6VCB;*0QD%E*^>TB`IZ%O-+
M))&/H7/)62D]6>NTR'&'2M/4=^##NX/946*X(;4RQ?:TP3C`+6VGS?09$QS,
MI#+O[*,/K_I\Q&J:@'9A*_,6%G'Z$TJWS&@]9<2+QB\48)W74.NZBVX?I\MB
MYPE-39SF-TUN?^:D,49<WI+&]2X=?ZD]::I&KL2N:5H0>-4OE/U:9@A6VD!?
MD)06:#_`X\V<LY'%@D20U_8NQT9_H<K]5U&3-GF><U:X\:@@^P2/56_4_&SQ
M9UF6ZFU77]2GEO>9SR^4GF\Z.2*7/ACGCED8[K:]PZ5ZX_43K+$-+L4;2=!9
M-N%[.><)H#(Q*69N=I"W>TDE+\_TRCELKD&?(5X?=2(K:OH\/#D.J:@6Y.:[
M*`!Z@!:!ZQ(^>LI?&[Q;FL!I<NX-2=IX@@A$9E[(BM;>6TMXZ4]&*VGFA8.A
MDCATKD/]3^MTD2&`OZ9HC@:NEIIT(-4'1\(-+DJ+&UE.(16L+QA$F50(30E>
M?I\8;:4?T,9X]]-0SF3FOYA`%>F@<7#_`/,2?5*U1^-'BK%>SZE'KVHB_NH6
M0RR<PYGQ,NW7[&.-/1;>/=<C_G7%W2O?7>K'76I/UZ36M.T8+(J>0&:V]`#M
MLN!LU:+5H-=S!5A6<LY#Q*0);8_L$CV<?]YQ)JFH2AS9)7D/K7'CFS$^OF=Z
MY6&J>,?BEK<=U#JVNZC<17O.YX?*2)>\.N'SY^OFNN[ES^LS2=:CXOI=U2"/
M1Y`G0NN(#\09(#1G8P%IM;(J5<9VPI$!O.%_<QGKL3D$\I__`"MU2_Z/-CM9
MU1XHZ>0@FO'IRY:_4BGF79WGCYXS7\;XKW<FJR1OF$K@Z8D&1MJRR:\X>D+2
M-D%?]&T-60.=0^LEE%"`9[25`*B`$6_P@H^8%;<CC(FU!D8-L5B&CSX]%NX"
MH;3$[P_X5MO&/H\.8-U746.<YLSPY^6OER&K:_K2<%Q=.\;_`!<TF\GU#3=P
M:E#>W+[-TKVRD.D=I\CI;(NPQ-M(YSXOI7$E9X/UJT(`*#S075%-&E16%X'3
MX@IMJ3#PZ*L`-S##F%>*,+$6LE'S_P#>ICN/^^YB_4K^1I8^5Y8>(KY0?GM!
M]0+K;[Q8\2=2LY=/O]:OY;*:F=CI"6NI)#,*CII+;P/_`%T3#T*)"NEW5,)#
MP/$Z&UU`@IKHVI8BQP;:6<5H1`M0L8&\F5YQ\%#'7<NRA/\`8$'L>/W7,SJ^
MI%V8S/S5KZM0?GM'K+N[SQ[\9=0G[U>[CU22X[T^YS&4UY\C[>227AZ;GVEL
MXGKA8>A9"R]1.LMQAL#[3I.@G(,:OV>JL12`9MYAJNW2VLWRU!TMY7A/P1VY
M,()2$_\`?RD^?DCU748G\R.9X?4&O34-R@^HW#S+BZ3XW^+>A7#KK1]P:E;W
M+[FWN"YDI!,]K;&SMY:T]*&U)@8>B/LK,-]8^O[,@G+:U)2D234.RCBKR1+>
M')\&XL66+:8TE7F^[:.Q[B41(Q_X1,Y[^RYB=3OR`#*^@+2,>EM,OK96T\P7
M!?XN>)CXH87ZWJ!BMY('QCF&C'VI@=;N;U&%UK;EG486=2C@GIKU9!97D/HG
M78[+D.L#W,Q0;3>5PJ76V*?5(V?!?TM`:O&;@QL?^#CHPGFQ^L:F_P!.=YQ<
M>/TQS.]<XGRKM;WQX\8]1`%]N/5)0'W#QFF)H^ZG-U<.X<9KASIG];R2N49Z
MA=8["^+DF](T`G("5FLTP2]*"MK<'U6FVY-]JP&,KSXRV-!W).",=O\`81*^
MZ_[G,6ZMJ+06MF?E+RX^5Q&4GSD8+38^.'BYID<T-AN#4HHKB\GNI`V4@/N+
MJV[G<3.PQDEM?:'NZ8\%>-9K%?I@(?6:J(A`0`IMUH:)',X8A0VWI#LIU##6
M/'"$N2'UKS_\96><.6629YEE)=(>)*^>:OJ^IZ]J,NKZS/)<ZG,07R/-7N(:
M&@D]-&@#S`+.\UKKDX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$74?M4.J?OO8CV6T?\X(Z$N+0A.$)R+&)\SC^!N7&6O']E2\O,Y2G/CG']
M#8."JO"GTP378."UB:5'BK<1%EH4.9G1;`,+-(:;2*5`'HPLS`RZI><MJ4C&
M4H^Z1Y'.2M45@PJ@'+C'411;@M]X5&$1C,H;A^!Z;,J3*)R6GF69"6Y,J$VA
MEAKR^ICS*3YLJSC.951:P[-HKHK"E8&NQFGO/AIJ7AI1"8CP5X/SF&827TN2
M8^<>;"LMLHPM.?I\<<R!56W?4%E4?3K+&?ZUJT6/#7@EM"<MJDM.)SA+,2&U
MCS>?.<^7"\85G./-G./#&+N*%;1<Q47R$>_EKG8'N:;-WGU'U`6(KJ_MI=/;
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MQAAR2U%=KK)!QKQ3EYM"%?MB%XQLEXA9R4KY5JWWUV'<??#]]Z@>V:U9C`KI
MGU?OUB';`!`I[T!FT3=3#<E]\74B]&4I+YV:;91203R_.D6A:Y<?"'I+V59-
M[#,W251V6YNE?=E0Z'2]74NK:YUU5PE*HE)!CJU4JE6Q\<4"KP$1&;ACA0L?
M%0VQ%B18[>$I2G'T_LY\<YSG.A:E2'<GJEJ[NYUFV_UAW`'A%:=M>G%J]B7*
MAIERJK878CJJQ=P?[8P[&L-..X8(0W6W&U8=8PG*O(I6,T$@U"H-#4*=]>M<
MV#3V@]):DM=HBWBS:NU+KK71^YPA+H&+;2])J(BM3[*P%>(%G1*#DD8J3\.J
M2_EGU?+YU>'CP<2AXKKZ]YG?%PU=U`5I;3\O+?8KO'L:F]+-#M1W<)G0+)O&
M6Z"N-T;0C"I#4/7NLFS)9R2A/A%=CLJ5G'CCE8,:]`5:,:]`7S6>QI(G^U=[
MW7<;VJ;8:)N:[VNS*C:F('E-QGSQK789S9>H;`^A'EA))7+1]E)-2LM8QAV=
M!::3G/D2GFQ_:8'+-W::'+[N>:5J3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$757L)YF/O78F
M7DISA5C1GTU)\F%IR*&)7YW/AVLMMJPK&%+\^/HS_7J\/#&P<%5;-T:=E5$4
M2!A8;35:-YGG`==8/%418)6$J,@BXF2P_`D.17/!"\Q\N(_;%*RO*$9SF#CB
MHI14]B2+,+A`@4!N;*]=J=EAKRK=90PZVZY-?<:'*990U#QE7DSX+RK'AC&7
M,XSD0JH+N>8,F96Y!C!<X??E._'0%E$RYJ75I<].5#*I?RA/G5E:%(0K'CG.
M/H\,^`**\^IGESJ?S(3Y$JM-@4G'[.<8\\;&,97Z+7JY3C'E\WBOQ\/V<?UB
M8[BA5H[CVO2]$:EV7NK8Q1H+0M3T2U;#MY1Y:$8AUZH!9ITJMO#BDX=DJB05
M)9;QGS.NJ2A.,J5C&8!4T"<5\Q?M1*]U>'IK:W;NK=->K>QB/N1[>L7;L[:M
MO=J[KK*\N4.[P88K4=`)449UZV&*$5ZEZ[@,-#6TDG_4BS/.M#:E*;QL=EK2
MO!9G+PKP75U[)=BV+[7_`+Z?8+H/O2N`M6C.T4(F/%4ROVJ;;Z2#M;+!'=.B
MF:K;9H.LR+,)51CIFOQICXV$Z_*6VVMIM:,IYD_M,J%D[M-JOZ`7-"U+X!_?
M]#6"Q?[PY[>]?J=NEZ_M)RN=/A%:OD`0(L$ZE'B/9C8403:X0&P,2@)N57YS
MJ)3<2:VY$D*:PAU*D*5C.]GV,K:ST2L?[X%R]P+J3V0Z_P"I_<7[+;-[H^UY
MMNR!3=K!:^J53ZUS-E@*P7ARK[K'83FF0X!Z?;Z?A^,;@0T$$P#L-IK"6X[J
M'_AS,I%6X.1M#BW!R^XSJV(Z\!>O&GHW4T110G7&70P!C3\+6T&*.IBZ4=A-
MF!4X3'BMM^*B;<W,B0X]C,MV4XXN1G+ZG,YTFM<>*UFM<>*^&+V2)+6I/]Y8
M[KZ\V&C`:X6LSWDJ=?A2\MK7)/JW0(V8S'CONY2I:I]&!RIK*F_'+K"<YQ]S
MGQYN?C&#YEL=BP%?T&>:%J3A$X1?+GO?8':3M_[UKQKJ1IW4N_:![1>NI%/)
M"-P[C,:CHS?:CM!7'U'SP<V#UEL]\O:M>:U&H&9BJA-8A2'7U_$(6IM"M@`#
M,32JS%`W'I72G[^`GO;UX[?=,O=<V[UVTOHJXTNXTJF-S-&;TLVYHETM6IC)
M'8]88N<D]J75JJX\>IF2H5&&TSTSH3*FW,MX;2E>;,I!:"LV4(("^_+3VTJE
MO#4^M-S4*>T4I6UJ'4]AU2>RZV\F2`N(."?%K4MK*D8>3#GH2XG]E#F,ISC&
M<9QS010T6DBAHK&X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%U&]@X)2I;RN$J9'<1%L3T$U`?
M;C*4U+AOP84;*FW,C4M*=8DQ5M.JRZYEK./H_9QS8W@LE+:)LQ0ER(ZTOS-0
M5NR6TL*0Q&DDVV'4Q)<^1,]5Y]]KUL8QEO"4XPG&,8^E7B(44]*[>=='XBQ\
M1D86,@8>5`>ALRDE(<IV2W.QER+GUR27%_=NIRG#B%YQCP_9Y*(M:[M=%$52
M5J5Z[\E:\R,IC885F3Y?(M3T6,RMG+;BDJ\7&TXSA6<JSG*E?3D$781U-#$@
M^F0ZR<=<9PR4,G8R'4*;?<@SY?A%E/(7!@*QF6AGU49RA7G:6A>%9PK'A@XX
MJ%?+5_O#7NU=>=MZ@$>WWH&]V/9$#:6[*E4NY.P]4U.W64%J[2U$OP]6R*;"
M/CP+PNR7HH5%>D_!&O2\QHL"2S(PER0RA6;&D',5L8T\2OJ9ZG[KZV[VT?4;
M1U-O-5OVD:W%9US5R=.Q+;#"$T:#!"YJN(LZ'`F#YE<BM,QGHSK+;L=2?36E
M*DYQC600<>*P((./%?"5_O(_831I[W`^J7:;HWL?&R^R/7B7-J^XV-=UBV%!
MM*N^@=G#[-KJ)9[./#X&.V-!D@;%SX++SLEF'&3AW"491A6Z,'*0[@MK`:$'
M@OK=ZC>]/T.[7:<-;+8VU!U/9]::C_"]O[5^U15AI5MTO6ACPH7:39UL\'@1
MC-/#V`NS%:,CERH4K#K>4JPM66TZBP@K66D&B^,SW9^]^A=^^^!U)[<Z87L+
M9/7GKG,ZN,7'8E:U??%0CS6MMSG-DW.;28!0`+)6.`,"'4-LO-M):G2&EXC*
M=1Y%JVM!#"#Q6QH(;Y5]@G:*A],_?NZ`[AUEI#;%2V1#BDG,Z\V0-@G(,_3W
M86JB6C=3?.!CPL/9`4E#!EN*7@R8K3[H8G(:RC"EIRG6*L=BM8JTXKYL_84]
MVXM[<LG:'MM^XR(V-KNCZKV%:@^N+\_1[I;PVE[K#.36MB:EMCM8!F9S%')'
MUK+!2;#+L2*Y*D>KE$61'<;V/;F[3>*S>VO::MP?=D]N/<.V=XZ-]]3V<#`7
M;.S8+=*V39*92U,SL[9C5(<D97]GZ^ANNPXUUS8:9&S7[+7L99F%QV$+BX=D
MY>;<Q:X`9'J-(IE<NVKIQ[]W0OL;4H8O=>T:YTJ['`8:8FU.O/:@LSI>QU2R
M066D&4U\QL3%;#VVNJF^I\(\RZB=Z*<?%18SGBWC$L<.&(6)8X>95IWW_P!X
M8Z7=<M=VD'U7O`7N[VAGCIXW7NKNNZY>UZT*L3L=QN$?V3=*)'-@A%7#/YP\
M_$BR)):=Y,,LLHPXJ0R;&3QP"H83QP"IS17N,T+VMO:<T*3[AW2YW+O-M?2E
MX[/-:+,B+M8MT[-V-NN]VR]1XA(#\%+G4JKC+#:&!LUV<N%#"Q(BV6TX6TTP
MNEN9V'HIE+G8<%@_]V;[$]>;+UILE'*[303[^;\V[O?M;VCH-J`V&M7V38;)
M>D#,GQC1X9%2?I`ZLY"ICRHKS[#+TM;:O([YT82`UK]"CP:^16;_`+RSLWJ.
M8]OK<?63;^R@@OL78:J`W1UPUE$%FK'L"Q7&C6YML,3!`P0PC)CB2OPQ(+,G
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M&"HQU>,8=7`FY;<4SAY*<86C.%-K\,>9.<X3G%!(X(M?V^EVO&EIRW:[YAI&
M<^G&5-`980C.<^5KRXKR590G&?H^G&?^[RYD7(<Z;Z_<0I&+-=&O-CP]1J2#
M2XGZ<9\4*4#6G&<^'A].,_1QF*M5SP'3W50@FR2*O6*W8CYQEH?9)8UX;GRX
M7X8?8'BA[DEO"E85Y%KRWG./I3G&<XR+BHMIF&&8S+,:,RU'CQVFV&&&&T-,
ML,M(PVTRRTWA*&VFT)PE*4XQA.,>&.8HJ^M&Q:;0#%1JQ#+[)N]F<#*T'%C'
M5K(S7W\+GRLO)0R.9:A)=S(E+<=2M+?BORJS^S:$HIXE$(;&>6AN/"BM>O+?
M])MMAE'CE3\F0O#:4I\RL^9:U?LYSXYSR(HW1K34+M6X=MHTZ`4KAUV;)BDQ
MS.6&)[[$Q^!-?4E33+BGL2XBT*4M/FSE/]''AQP12)T>/D+>=?@PWG)$?X.0
MX[&9<6_$\V5?"O+6A2G8_FSG/D5XI\<_L<(N4A"&T(;;0EMMM*4(0A.$H0A.
M,)2A"4XPE*4IQX8QCZ,8X15_?+[3-3`EV&R*6.@SBC$-EL8+?E2BQTFO#42&
MTU#9RA9$D]C"&U/*1AQ?AC*O'PX`JBGC*&L(RM#"6,R,^N\CTVT+RZXE/G4_
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M>4!A$:[&`=>;4.+*3\NAVH]#AI;"L"\DH\TG/E%).6(\9+^$H\%+==\C><.0
M#%`N7==AV#6-)UJ`A@@)':E\E!JF%`0T)$5ABR2(&)EA*.1FY&76JZ#5AUYU
MIEQ3RD9QA.?IRK"E?,BYVI]DG+0_M<&:?$&IVKK8[6OK`-B_5X>;?;"Q"<QE
MT?(*F_E;@H@\[%6XI_*5MH2O*<9\WB(0K5ND[CVABP5K:BYD"=4M\[IBZ]$4
M22_))X%5H+$DBF['4RZ[,Q`9]>5`DNR$('H^(\N'%)_K?#*@X(K0[%&#UDVO
MI#4M4',&"+9>1M(U"FRTQ1+<*LI>B`)1Q3,Z/-R'BF7%OO-MM/*?RRAI"<K7
MC*8.%4'"JL/3VUC!BD;!LFT"59B1:!>;E7)-N$L.!JT1#U9QEN268C3"I>1&
M9C2LO,9\[V5+4SX>7S>/C",<$*B;NXMEV'9NLZ=7A06LP;:].N!82=BJGW$;
MJT'Y&?FYEM@PV.#2KC/>2U"8;3*?BXRG+W@KU&T6@Z4Z%Z]I;;V\)W=4-4:\
M#521BQ")\]Q9C#LZ7'&XCH95<R/PY@;D>""DG5HQ$2V[)G+AN(PIO#K.>`!2
MI04Z5(=J[(V7J/1S5J.)I,^_14,PRY".B:Q5$$9+K[0_`X/*)12Y.85?^'BM
MQT2$)3(>4ZI26&\XS!0E.E4*0[+;K'G;&)GP-?!\534,2X7C,Z)+5C7%DDCT
MOPAYQUNS_P#&IDY+<:;8&1TI2TN6TVJ0O++RU6@2BVI&;+*5O3E9OFTAZ(5I
M)"`N9=;`M(Q.)V4ZIML37`8^=/SZAPDZ^VWB-F0K"'LKQE?D1E6)TX)3'!1"
MB[)V'<=T'ZA(S5HE7HM;1*N$0.PZ5E0;9897J`*I)L*R6&5DPX1A4B:IF(AI
M3KGII\4IPO(@41;,<BB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")P
MB<(G"+KI]S6\7.@Z&`F*-;+%3BSUQM<5XG63,\)/<C1NOF\S4>.N6.?COJ98
M,"(DI"<J\$R(S3F/ND)SCTFU[>"XU!S)V->P,;@X`C[-$.!\A(\Q*_4OQ2-O
M:#N7Q(N;'<-E:WUDVQMG".XB9*P.=K6D1.(:\.`)BEDC)I4LD>T]EQ!Z<^QW
M83?0/M%NL"%W5M42#$;C$CQ08;?[1"%#A[OMQ6RZN0(8^,4;B1X*[C';+992
MC#>2;:97E]=.%X]9I]A8OTZV>^&(N<PU)8TD_OD#B16M,*\:=GA@OW3X6>&/
MAOJ'A!M[4K_0-&GU&?0I'R2R65N^1[QOBVM0]SW1ESGBV)MLQ.;D$PUY9+5/
MK#OG=Z->[*F-[@V:U+@=G.GP*#*9O%D:DPPEC[G]E:Q80\9]LBEUD4>K=?@C
MYL=.<-2H4-EAQ*FFTIQI?863980V**AMYB>PW$B"W(/#B"YQ!X@DD4.*\WIO
MAQX?.W-I,#M#T@PR[1W-,]IM("UTL&U]!GAE<#&09(9YYIHGGM1RROD80]Q)
MHW6O9'L+.U.$(S=Y;:F$'B5X0[.E;!M,B6XB+LKO!"BH7(=*+=4B-"J0MEO&
M<^"&AT9./!+#>$]G<:9IPNG-$$(:*?0-^EMO)_G.]<]97T7=GA3X86^]+BU@
MV[HC+9L5I1C;*W:T%UCM-[B&B,"KGW-PYV&+IY7'&1Y.6V/V,[`#^T^W*]!W
M=MB(!'=I^_\`7AX6/?[0T*@`:7HG49:H!88]!/$6**JY4C(DCXZ$I:B2'W'&
MDI6M6<X6FFZ>_2XY'01%_=;0UR-K5TCPXUI6KA@3Q(P."X6U/"SPSNO!S1-3
MN-O:*_4I=G;,F?*ZRMS(^:ZU?4H[F5SS'F=)<1L9',\DNE8QK7DM:`+<-[[W
M@SKNASFMP;+;FS/<7ZX4>7+1=K$F1)IAW7NQ9IJIOO)(8<=KI:9!9=DPU9S'
M><:0I:<Y3C..+'IU@;J1IABRC39G^BWT@]E'<.(!(!XA>)T_PV\/'[HU*W?H
M>DF"/PLUR[:TVD!:VZAO;%D5RT9*">-KWMCE';8US@UP!*KCJWV(WX?`]97#
MNZ]JF7#HW0JC;I6_6<@Z847W!UT%EEE')9-Y<]9,:<FQY"G<KR\S+>0OQ2XO
M&=VHZ=8-[P6PQ`CF4HQHI2*8BE!A0@$4X$#J7J?&#PN\-=-U'=K=.V_HT#;>
M76.4([.W8(N7IFN21\L-C`8(Y(HGL#:971L<*%C:8VM]B=_/;\(B7MW;9=%-
M;F[5BFQCNPK6X.0,`][=!5,&/Q"655&^#"54O+&0V_+Y(H^4[':PEIQ:,X/L
M+'NC#R8JF",UR-K7N\AK6E>(!/60":D`KDZIX7^&K/#>&]9M_11>NT#;TAD%
ME;!YDFVCK%Q*_.(\V:6XCCGE=6LDT;)7YGL:X9RS=A=],Z1T.79W5M1DJ5VA
MMN"4(LWZSM32<$=[:M(O(^$1DMDTNSHD&ZSGB[+3N5H;)N*E)QA[/GY!I]@-
M1DCY,7+R,PR-IC=R--,,.R`VHQRBG#!=?I7ACX;N\0MQV+]`T9UE#I&FOC8;
M.W+8WOWU=VCW,:8Z,<^U8VV<YM"Z!HA),?94UZK[]WE8;#U&8/[AV8:8LKO7
MK%B:*W>QSVSN#>O.H4TQ@NB41=P1^:3+,1=D>KY_6<GR%+\<O.95CJNG6$<-
MXZ.&)I:)J4:T4H^XI3#"F44IPH*<`NA\9/#7P\TO2][R:;H6D6\EHW6N08[2
M!AAY5[N5D7*RL&3EM@@:S+3*V&(-H&-IJQHSL]V0+/5W!7?>X26']&V4P]B=
ML:V2_5*L=YMJU%@DYZY5SSSF:J.CC4.Y^[3!8;8QGTD)3CMK[2M-8'98(12X
M`P8T8=VC=3A],2?/CQ7V/Q$\(?"JQ9==SVWH41;N*"(9+&V;2,[1TZY,8I&*
M,-P]\Y;P,SW2$9W$FXNQ?8C?H;3&DB0?=FUQ)$Q1/=.E%2`R_P!H@3R,G7VN
MJU-H<F9,BDVI#\BES)#CHIQ2LK@.KRIC*%9SGG76>G6!N+JL,1#'65*L:0,S
MG9L"*=JG:^FZ:KPOA=X7>&M]OS<-K?;?T::UM]1\/6QLDLK=[&-O;Z=MXUK7
M1EH;=-:&W#0*3-`$@<!1;"Z&WAN8QNFF"BVU]BDQDLF2;DCY]Q/RX4AMO3_;
MPFA#T9^>MEQ*2-9'/XQG&<8>@1U_US+>4\/4-/LH[&1[(HPX`8AK:_9+<=74
MXCU3UE?,?$?P]V'8[`O[VRT72X;MD+"U[+6%KVDZGMJ,D.#`1V)YV8'T9I6\
M'N!T:T_V:['3Z.W+G[[W'/E?DQ::-_$SMDW"8_DT0T=W/+D#&79!=Q>2Q`K6
M!LF1)SGUGGQ\9:U*4PUE/:RZ;IYN,O(AR\X\(V#_`)6`=#>%"0!P`)H,37]#
M;X\)/"RVW"8+;;>A1P_E=J<65EA:M'*9JVUHF14;$!RV1W$[&1^@QDTK6@"1
MX=9';SL;V!K5&%SJ[O#;(*8KJWVI/+DB-@VH<\LZ`[]A*<",N*B%&<K*A:BI
M0N)(SXO1AZE1VU):5E.=.D:=82WPBDAB=&;B$4+&G`VH<1B.!<<Q'`G$U*\I
MX(>%GAGJVY);;5-O:+<V_P"6&WH<LME;/`AFV;)=31#-&:1RW/[XD8.S),!*
M\%X#AL"WO;=>;-NEC.W-D>@*TUV]*#&?KI8/2'DZR"[1O5PA"1\?Y8TT"[7H
M"H;B,87'5"8RWE/I(\.(=/L1%`>3'5T]N#V6XAQ@J.'3F->NIKQ7S1WASX?C
M2=`D&B:5S)M>VS'(>ZP5?'<3;?$['')VFS">82M-0\2R!U<[JZPZ)[+=B##1
M');>FVR645;I;(1F=L*TR\H?M?5>CV*SO)]<HYY7;"?ENS9JL?3)E.*=<\RU
M9SSM;_2M-81D@A';N>#&CT9WM;T=`%!U#`+Z]XC>$WA=8OB%EMW1(@;S=33D
MLK9M1;[ANX+<81C"&%K8HA_R<;0QM&@!3/=O8G?PRP:0CC-V;7',%NG/1^U%
M&H%_M$-!&S6KNU"JUG/SDQR;>)9>QUG.1T^0YYG9<'.6'<K:SE'.';:=8<B=
MQAB+AJ%PP58TT:(`0T5&`!-0.@XBAQ7G]@>%WAK=Z7N&6ZV_HLLD.^]V6T9?
M96[BRWM]JNN+>%F:,Y8H)_;X6"C8IO;6!KP'*;9W]O1>G>U!!6Y-H?,`'3_L
M=9`4]-[LR)P6Q!:=T\DACPF6@DF0.,B9%H).1I3*D/,+GR%(4G+R\JX\]A8L
MEMRV&(5NH@>PVA!-S4$4H0<K:@X&@KP70'PT\.V;XV=;-T+1^[7.^-#@F9W.
MW+)8);G<[989&F/*^*1MO`)(W`L>(8@X$,;2'4[L1OV39=C,2-V;6?9A[I6,
MB,OW^T/-1!J970!K`^*VX34B/!\EQ+X])&$M_P#&DOZ/[8=\_(?IUAD;[3%]
MB^D;]+='JXU:W'C@.H4[W7/"_P`-8M)TJ2+;^C-D?H(D<19VX+GY=Y'.XB.K
MGUM;;M&KOWO#C[4S+P-D]B^P$#<6L1T'=NUX8\BKVCTSX$;8%I9@S,;'U]L*
M=L+XF(@HF.]F\S(K3I?*DYR1<:0J1ZF4)\,K73;!\$^:&(Y6WQ'8;49'@-QI
M7LC!OTO12I7)VGX6^&ESL;6+JXV_HK[F(>)!8]UE;E[>XWMDRRRN,>8=T:YS
M;:A]H#G"++F->=>.Q6_H?57M38HN[-JQS]=T#I<T`-LWVS-%0I<ML;KQ!)DQ
M4]!),F!/(0C<QEYYI27'6Y;R59SAQ>,Y0:9ISM6M(C!$8W7$H(R-H0&3$`BE
M"`0./4.I<?;WA;X:3^,NS=+FV_HS],NMRZK%-$;.W,<L4=CK;XXY&&/*]C'Q
M1.:UP(:Z-A`!:VF^?MG[:VE?=^[\#7C8MWMX@-L'MC"$"[+9S)L>,AUS?51#
MU^+`B$9DAB)'!B93D6(AM*4QX[BFT82G.<<\_NBSM+;3K>2"-C'NCMR2&@$E
MT3B:T'2<3UG$K\W?&UV5L_;?AKMJ_P!O:5I]C?7&F;<?+)!;Q1/D=/H]S+,Y
M[F-:7.ED:V20DDO>`YU2*KN\YX5?SX3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$6L]:ZWP110\DY;B=AIQ/8\W:$"FXAI$QFK+*G-$&%
MV`K&FO3[/`&26DJCPW/1A84E*G&7%)3Y;54FJFFU-1)VD6UY+F68F%%4>P2[
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M`R\2MSC4J9+A@U)<EYCP(`QQUC,9"DR([:H^%985YLXPJK53S9.GG;W$UO%'
M7$Q67-=62&?C$,-J-$B&8@>:(1ZTB?,0VHGC$SU4RY")64NXRKT\JSXX`T46
M/TKHB!IMZUR8UJ/V1VS&2)+_`(V??RF.Q,F*DM8F*>ES)!HPAK"&W)TAS*U8
M3GTT-86YA8FJI-5??(HG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<
M(G")PBZV/=(KU@LO7ZOP:X",V"<W=+:\N$#%SB\M#+O73?0]IU<8>Q(>2VY/
MG,,)5E/AEYY",?=+3C/IMJRQQ:@YTK@UN1N)-/\`EHC\X$K]7_$]U33-)\3+
MFYU6Y@M;<V%L`Z:1D;21K>CO(#GEHJ&,>\BM0UKG<&DCI=[+:PV60[5;S)C]
M=7R<-G;H#RH1"%3[#*@S(J/;4MU>7)BRV!SD>0PD^XF#E:%93B8K#/CZF<)Y
MZ[3KJV;IUJUTC0X--<1A^^0<?47[V\)]W;3M?!O;EI<ZIIT=U'H,K7L=<PM>
MUQWU;3!KFEX+2809:$`\L%_HXJP;#K;8JM<[/830+LI^3VEZ:DHS*:H>R]('
M">[/9XP4GL-X@96]"&B2<:5(=3C+;,:0TXO.$.(5G1)=6QFAH]II;S#CTF"V
M'SP?6*\SINZ]K#=&CR'4M/Y;-G[G8X]XAHU\FU=OQ1L)ST#Y)(Y(V-.+GL>Q
MH+FD"A=9:HVG&U$#BR-:;!8E-D[VIR,]2[(T^A+VS>]LEE2F5C$N)P['-PG$
MY\/ND3&58^AU&5=K/>VANW$2LH:=(^EM?K3ZQ7TK=V]-G2[WN)HM6TQT)BM*
M.%U`0:6&T&G$24P=%*#U&.0<6.IF=F:KVA)[8[@*1M;7^0,E=L/</*12+%-L
M;T"2,/Z#T]!!$8\QL:J.]`-38CK,1Y*LMR76U(;RI2<XQKL[VT;I4;'2,#NZ
M68I4<6R/)'J=*X&T=Y;/A\%M#LY=6TUMVS9>R8W,-U`'MDAUC4WS,+2_,'Q-
M<UTC2*QM<"X`$%7`=UKL9S6^OXZ-?W=<B/[D_6BQ/L)J9_+S-?':YV3'('76
ML#_.V&@/R&T/2LXPPTMQ*5*QE6,9XT=W:BZD)D90Z9.WB/2+V4'G*\/IV[-J
MMW7J<KM3T\1.\)]>@![S#0S/OK!S(0<]#*\-<6QCMN`)`(!5:]4]7;-&`.KJ
M"6N+Z/4-&=?DD4SJ=8HBH&8.Y^MDR;B:E\<WF+F'$'2'7?/Y?3:8<4KP2A6<
M;=1O+5PN<LC#7FTQ'^BF'SR!ZJ]7XR[QVC=ZCN\VNJZ;*)9=9R9+F!V?/I6N
MM9EH\YLSGL:VE<SGM`J7"N-K6K-G-]@B4YS7%^1"7NSMG-1,73K$F*J&3[]=
M>S8Z6F1D;AE4:>&@OS&',9\CL5E;J<Y;0I6-;KNV[HP<QM1;QCCT]WD%/77(
MU7>.T7>&<-NW5=--P-O[=86]Y@S!T>SM:B>W+GKF9*]D;A2K9'-8:.("SMHU
M?LQ>BM`P4:ZOBYL+:FX)$R&BGV%4J)'E>V+1*Y%?DQTCLO,,2;#'<@-K5C"5
MS4*83G+J<IP%W:G4I'B1F7+'C4?=<KOG$'U1UKK])W?M(>(VY+EVJ:<+>31]
M,:UQN80USF[^O)W!KL]"6PN;,X`U$1$A[!!4WZFZTV.+LG3MPGKZ[CFQ+W7+
M)5R?4S\-`S`_7'3>//R17('MIA8@R!$MM[U<I]-<5Y*O#+:\)QU6\M7PW@;(
MPEPFIB,:ON:4\]1ZX70>-.[-JWFE;Z;::GI\KIVZYRPRYA<9,]]N=S,@:\Y\
M[9(RW+7,)&$5#VUU.T+J#;4%ZMYFZMV/#PWH:T0',RJ/9X^&YSG?/;1QN&O+
MHM&$RG`DIJ8EO/W>8KB7<8\BL*SV]]?63@_++&?WR#Q'#NL8KZXHOM/B1OC9
M5Q'=]WUC2GUW);O&6[MW58-GZ;"7"DA[(E:Z(NX<QKF5S`A73V2U;LXAI/1<
M2!KB^S94&A>["S.BQ*=8I$B&]:-;UB/6FI;#(Y;L9RQ/M*1`2O"<S%IREKSY
MQG'.MM+NU$]W61G:-C3$8Y7.K3S=*\#X5;QVC;;^W'-<ZKIL<,FI>'18YUS"
MUKQ;WUPZ<M)>`X0`@S$5Y8(+\H6Q?7_7M_@;OI,V=1;E"ALE22WI<NKG(T9I
M*],]QXB5.2'H*&FTJEEXC6,YSC]LE,I_KG485P]0NK9UC(ULC"X@=(_TEN?U
M#ZQ7RSQ+W1MFY\/-0M[?4;"2=T+`&MN(7./_`'IMAV`#R3V8Y'8#T8WG@QU-
M#]-ZCVQ%HC;$G5^Q8[_Y+>EAWHOTBSM._,(NA^[4&5!]-P6E?QD::8B,N->'
MG0[*91G&%.HPKM9+VT[Q7F,ISCTC_2P'YP*_1N^M[[+FW&9(=8TMT?Y7ZH^H
MNX",CM8VH]KZB2F5S(I7!W`MC>0:,=2S.XVJMHEZ"+CBM;7\G(QU3[9#,L#Z
M;8YKV"1/W"@AX:/RU&&NN8G$`:<S6&O#U'8F/61C+?W7-.CWEI'?A[Y&!G>(
M36HIA:`'V</.O)^!6\MGV6YY9;W5M-AB_++;DF9]U`T9(]ER0O?5SP,C)O:G
MNX-D[!(=@MAV]<[#Q9]WNYH5U].;I3N3#AN?54[Y)<PL`[6MBHD9?P'E?DE%
ME(R8S:/%;^9#6$85ZB/'B&[M>5`.8RHGMB<1P!@KZU#7S+Y@_=6U_>C;S/?+
M3\\>X-KN<.\0U:V*;;ID<[MX-C$<A>3@P,?F(RNIJOH+4NU8#)+$[66PX>55
M7I`TG$JE66/YG0O4VB"S#:?5&(\7!)-A<:3C'TL2$*;7Y5XSCG;:A?6;R,LK
M#V[KI'3</(]<8CR+[)XE;VV9<OB[OJ^ER?OW=A[-U`["7<=Y)$<)#A)&0^,_
M1L(<VK2"IQO/5NSIECT2Y$UQ?I3<+I9T4#3'(U.L3[<0P%[RPS1@3*6T-6F.
M2$A\?%R6%YPZQ&_;5I2C[KG!MKRU$$XYC*G4;AW$>B8``?-7I7G/#W>.T8=)
MW&R;5=-8^3?^[I6AUS`"Z*7:;HHI&@O%8Y)?:XWCLO?V&DNP4Y_!GLC&F>V,
M7.OKQB43Z:=E1(V,JI'TR"!4A2^F#4`9!9R/P[+(3G0\M+++>%..JBO82G.6
ME^71<7=L9;>DC32ZB.!K@#<_Y1ZX7GG[MVJ=][,F&IZ>8H=^:%(]W>8:,C9=
M;I+Y'G/1K&"6(N<:-:)(R2,[:PNF:MV<U9]DN.ZXOK;;^[G)C#CE.L2$/1,S
M/;Q5B4TI0W&'(WE`SL^?'BGPA/\`T_M+GEY#[RURM]L9]BZQ]+=?Y1ZZ[[7=
MX[1?I&E,9JNFES=OAI`N8"0[)O493V\'5FAP./ML?T[:X_9NJ]GR=S:LEQM;
MWZ1%BJ]GO,J2Q3K$['C8JFNMB1[3F0\V-4VSBM2'T-D/-G'P2UI2]Y,YQCF5
MI>6C8)PZ1@JV_IB,<T@R^OT+E;0WEM"'8>LPRZKIK9GCQ,RM-U`"[O%]9.M\
MH+ZGGM!,-/LH!+,P"YU[U9L^1U+[9BF-;WYXF4Z]:0'C!K5-L:YY*?"V5UQD
M3(4"&D;F1,EQ(X^0XZVVE2VT,.*5C&$*SC."]M&ZO:/,K,C;F4DU%`"R:A/K
MCUUHVYO':$?C7LJ\DU736VD.Y]6?(\W4`8QC[#7&M>]V?*UKG/8&N<0"7M`-
M7"O8%[7M)N=:["=@Y]CJ-HK\&?L7MY(@S3=?+"8DV.5[`TZ<+?B29\2.S)9)
MP65O1U(4I+S*,K1E2<9SSSNZKFWFTVV9$]KG"*WJ`:TI$X'UC@5^9?C?[@T'
M5O##;%MI5]9W-Q%I>VFO9%-'(YACT:Z9('-8YQ:8WD,>"`6.(:ZA("[@-YR+
MG$U!L.3KW!+ZX,U@BX'4$CHEGFE)1C,Y^O1'&WDR[%'&^LL>UZ;GJS$MI\B\
MY\N?&V`A-Y&+BG)SBM<!Y,QZ&UI7R57X;\.XM!FWQI<6Y^3[QNO&"7FN+83C
MV!.X$98#)E$SJMRQ%YS-I4:N8(S&Q5(L.O;UV4SJD5<MPQSV3@:QG[,2KZ]$
M6LQ$-A7[L`+[*/"*O<QN&P+9-+BI1UY3*42F$#D)[8L&>2.YCM>]ED=*%H:#
MS6@@Y2&`N:>WEI1HK@<R^PFU@=>:AIFY].VG^6DUAICH>3+!#;LF&L6T3HI6
MVDT=A#+<6LA=>.MRT1VC`\NAD==.-05Z[[E8;U08UUG<=XM)AK8$MG75KDWA
M(L13B\38/U9%G[3L&-7JQ9++03>!SIZ6=G-SE/,P80F3\))6N5S)8+(F5ESR
M60@L[;<E2X9,Q#6$N:UXJ&!@(Q<YXJ,/<ZIM[8<CM:L=T^\6GZ-`ZR:;ZV;:
M<R2ZB=9=XDAM[)T]Q!!>1<]MG'9PF$-=<7%[%SXFMA@R+1V49KM/<FD]M_64
MEJ;6@6\Q+4,VI`*Z[KD$X&QL+:Y=_71IVC6X]9Q[DUJ1'#-LVD:K/C#D1L,*
M\F_E:9S'AHAY0F>6%IC(>2#DC&<9FAII0NK&[I!KCZ)VC^$\FJ7S;>'1/>F+
M6[^6T=;R:<^.]G?%+W+3HA?1"[MH;=XB<Q]TYVGS@4GBEY@S3*SM[I?I4NZ#
MC>ZJM-QKC15?+L%[3MPD`P<LI9@K<K3*$@49N(U@15Z\+B.O@XD4PU)-2_C\
M^IB0O&F(V0G$#FP/;S92*-C!HT4:VI[)JXN-'$MHUN7"BZ'2';`CW`S0+JWV
M_>6_OKJ\T1BM]-CFY-O&8[6W;),>ZR&6XGN)&LNY)+9S+6#NPRF)INWJT;W8
M2V1<(^PG+?)#HI0:>=>MSEC8<BW4C.:E!0\*O%:P"K-7EAZFZN-/;K\DA!(N
MM-SGE-//X1G@:JRQ;;,-OD#\YIER^B!B20XEU78C.`1BT5`7S[QBT_P_M-J6
M,NV!8LOCJ$K(1;"`AUJQA;+*^:.XFGN&RW(#X3>LAF@:YUO&'QQEPWRYT"_-
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M)QE6-]M;ONIVP1T#G=)P`H*DGR`"J[_:^W+[=NO6^WM-="R[N'.H^5Q9&QK&
M.D>][@'$-9&QSCE:YQ`HUI-`:4C=KJ-)(547]4]D,S+$7:!%FW@(?RT(G)V[
M*T9$CW1UJQNMLXE[*A.P4+&Y)(]-'KJREG.',\TZ3.&O?GCRM;48GMCE\WL]
MGH8:]K+U<5]`E\%]Q16MY>=]TIT%K`9HR)I:WD;=-;J[G6H,`)RV#VRD3\@U
M/+`,E6C'0NX%$)PG)(RC[5GS))"K1*N&8K@1!6\0KBK8'R(]6$2;0Q"^3R&-
M7FG5Y(/P)#;<7'F9PIUI*\W:-.UP#I(@*.+C5U&EN2H=V:U[;>`(QXKE7'@;
MN.TN!%=ZCHT<#(KAUQ*9Y>7:/M>Y<Z&X+;<OYK3J%JT"%DS'.D-'T8\MY#';
M_6$B3%RV(OOR*75HUG3;55V,FO,JEZAD;U9KK^?FWSE-B5K6*N;EO$-4;"\>
MAZ_K9\G,3H]T`:F/F!^7+4U^R<JO"E,^'&O31:I/`[=\43PZ?3??%EXZW[MS
MW<\Y=3;I!G'M?*Y'?W"*IE$E/;.7D[2V!J5RKMX&R"M:G_'PXA.>&F+S'DQE
MQ2PMW#!&`ZW)::5EV&_]PI2/,WG./N5*Q]/.OFAD@<&2BA(!'F/`KYEK6A:I
MMZ[;9:M'RIWPLE:,S7!T<@JQX+2<'#$`T<!Q`."E'-2ZA.$3A$X1.$3A$X1.
M$3A$X141O.V7L,C6U1UJ5`5ZW;/O<RJ0[/9P,FSB*_#"Z]O>Q9\M8*,9KZB,
MF>U2,04)5+:2UB6I[[K+6$*Y]A#;O,LUT'.ABCS%K3E)J]K!C0TIFKP/"G2O
MH_AUHNW+]VK:YNR&YNM$T?3FW+K>WF;;RS.EO;.Q8T3.BFR-8;OG$B-Q=RPS
M`/+AHO"[K;A,UP-L2##I$(!L6=!U94*K(!E)$RJ;)FT?7-B:O!DXFP-*L%4P
M<MQ%EP:B-$7F%%AK3+2XX]G/?'1+-DAMG9S)&#(YV84<P.>,H&7!U&CM5.)/
M9X+]%7'@!L6PU6?:UQ)J$FI:5&_4;FX;-&&W-BR[OH#:10\DB&XY-M`X3F24
M<V2=IA+6,I)<=J]RAY%QDEY=+*">NUHJ]0VPU#J1""0VLJ\;KNFIQ9JIN?6J
M6Q1Y`0-6HI-V+E!1$F>^_&PIMM"%<U>]-D\,#`\/N6N='5P(CRQ-D(=V1FJ7
M$`]F@`.)74_`SL.^BL8K%FH0WNZ;.XN=.+KECV:=W32K749(KD=W:;MLLL\D
M#9*VYCA9'-1[W."PF>TO8E,%RMY+:RS=6=5.=DE'_J86Q7G**C6D>[XU3\IS
M<O7;*YLKV8/S[,OS8$XP]\'\1]/-GO5IN;FY9>1S>33.*Y\^7F5R\*8Y:>EA
MFHNP^!WPN-P-6Y&K^\#M9&A<GO4?/%V;]UI[X\SNM#'R`)NY\NG>*Q\_E8+.
M9[4[F,2Z<X)F4L8,[$V>TU34R)=1(3"&J,47=U8U05+VSQM,9J\R#@(X^398
MP@6W%(LM1LJ=:6K/-?O59,#\X>76S6ND[0`DS1.D`;V>S0@-)[514X%==\#>
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M`7S;R9'`]#`_#*H<)C#ZL//N<RATNR=`'O#^9%$V5_:`#VNC?)E:,IRD96BM
M36KC3`!9Z)X1;$N]OMO+QFH.U#2M'M=6OW-N&-9>07>FWVHBT@:8'&V?%W:W
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M5:XND;G)R]H=@'+08DBN`6FW\)/#"^CL-<@M]6CT;7-3@TBVA-W&Z6UNYKO4
MK7OTDG=0)XVML89>[!D=7S3,YP;&PF\=$;]O%XND]-T>KGU,N5*O6S*+&%AI
M@PM2:_0=H3M>R0EEFNEB:+++*B78!#,AN/"]"7\6SAM;6&LIX%_I\$$`Y&;G
ML>UCZD$.+V!]6B@R@&HI4U%#QJOG?B/X:;>V[H$3M`;=>_UAJ%G87;I)6R1W
M<UYI[+ULL#!''R&QR":$,<^7/'R9"YK\]8+6_<;U=9ZM];A=*NA$9*L]%JH=
M("74K*Z0)[=@EE:<@2W`U@E0PAN]GQ/R=Z#+=;?!D947YAZ$=[$A/(EVW=13
M<E\D8=D<XYLS:",CF4JT5#0<P(](`Y:D47HM5^*OO#2-9]Y+S4+"*[99W=Q+
MSFW,`9'IKXQJCVB6%KIHK.&3O39HVN9=P1S=UYDL?*.TVC]D6/9P.[E++6F*
MR_6MP;8UX,8CS&)K90'K^[%:L,.*4Q+EY9D$&AV?6;7EO.'D*RE"4*1SJ;ZV
MCM9(V1NS!T,;SY"]H<1P'"O_``KX[XA[4TK:.HZ?9Z3=NNX[O0M-O9"YI88Y
MKVTCN)(L6MJUA?V2*C*0"XN#E='.$O`IPB<(NOK??:+8FI[I?S(J+69^NM5K
MKM5-52:+G*LEGLUSUI;[\//PK,R5:8$#`DT8)B*B8@2<R([LYS+J5H8PCT6G
MZ5;7<$;'EPN9:N#@1E:UKVL(+:8D@N-:BARX4JOTWX;>#^U]Z:!IEC>ONX]T
MZR)[B*Y;(SD6]O:W]M9OA?`8R9))627,@DYS`Q[;=H86ND+H.8[+;_JYF\4<
M@:UT6L&C*^;VC?+`Q1R@\?L2GC@&E;,Q2P8S-TE_5`NJ-M(C&R2R_/\`NAD)
MSX;PDOH3O9IFG2L9.UL@CG<(V#."6.)D;F)R]H>U@Y:#TG8X!>BL/";PTUBP
MT[<-M;ZI!IFXKF+3[.$W<;WV-T^;5;<W4TG=6]YBS:?`_D9(<)[AO-]JC<?>
M&[+[VMMFIU)%EZ$%G]@)&+#K$[)I1(FWJVJ#R6UE$PMF%8MT+%Y,RP&OH'HR
M</"D(G3I?BVIMEE'(_3+"&)\[VR.;;]EXS@<QQ$="TY3E%7FH[6`&-25JOO"
M;PYT72+[<%Y!J5Q;;9;R+^%MTR,ZA</CT[ERP2=V?W2)LU[-F9EN"888*/#W
MR.43B]VMQ$J>-VC&@T6,!M\R)J<#3W099R2"VC-U#4-@L7LA8,6'#A:GIL9^
M;#<%IBQW<CH\9Y,M+KCN.;CH=DV8VI,AD8.875&,?,<S(!EP=0`YJG$D9:47
M=3?%^V+:ZY+L^6347:E8QNU&:Y$T8;-I[=3N;(V;(>12.ZY$,4K;@R/;SWRL
M,!8UBE*NT^YPL^W,EYU*)PNN]HJM;VRN)4"$29MAB^;K+:N$$JHGZU/LT.8"
MKD!LD^RKYJW***5'QZ+'AGFKWJLGM86!X=<M<Z/M`B/)$'D.[/;!)H/1H,<2
MNG'@YL*_MK&2RCU"&XW19W$^FAURQS=.=9Z5'J$L=Q^]P;QDT[S`QP[N8[<"
M4YY*A3.I=EMIC]1;CN-U13K#9JKI'6V]JA@(&)`@L6/N"MV8@%I)N,X<+RR3
M-1/5AQMTBV]&=G0'4*RRRYC.5:)M,M'7D,,&=L3YWQ.J02>6YH+@:`#,'<*&
MA'$A=!K?A-LZYWOH.A;?-_:Z1>[AO](N>;*R:5SM,GMV2W<3A#&UAN8;AKFP
M%LC8IFN`>]A`$/)=F]X5BQVVJ%"M&,/]?3$"5M,Q'ID\?^%6M6*X4(2'AU<=
MBVRT40T,K-MENOKR\50^3BQTI;;9=<1S<W3+&6-DS&O:+AI$8S@\MP:\DN.4
M9@7-%/1HTG$D`KO;3PC\/-7TNRUJSAU&"/<\#VZ?$ZZ8_P![IX+6\DE=</[L
MTWD4EQ;1-8,MN66\DI+G2,:Y<(?V8[!G9M+IL(WK8=9]R4FN;KIM@>HY:8)H
MU,-TW<5N<U\9%_76*NS%&7]9P(F"_P`1!\[)&8[B-A<9I*LG:9IT8?.YLABA
M>8G#.*N<'1MS@Y.R.V3EH<0!7$KD7/A+X8Z=!?Z]<6^K2Z1H.H3Z5=0B[C;)
M=W45UIEL+V*3NCN1&1?S2=VR34=!`PS%LKR,?#[E;@L,.L6L0S2Q@#=1AK6F
MN0,VOD9Q'7US27U*`7<+*5;L$--M"OS+Z5?5`1''^5N%!;Q(\7GUYR=HMG&7
M1/SF2`9WD.`#VTD.5HH<I[#16IXNPP"Y,_@/L;3)[O1;UVH3:GH$!O[Z9DS&
M,O;4Q:E,+6",PN[M*&6=NP3%\U72W+C%1D;1L%*[4-ZST?%O.TTBR]JC;@MN
MATN#)0BB5VT6^JW^W4V,<<(6PZL+3!)03472<KXJ>ZB&KU&&U/+PVE?7#2>]
M7YM[6K8C"V7&KRUKF-=2C15Q!=E%!CQ-,5\RA\&W;M\0W[=V=SH-&?H=MK%)
M&R7D]O;7%G;73H0RVA$MU)')<MMX^7"TRC+(X,;G+8-;.^PMRG6B;K36]J-W
M(;I`-OH&-LB!(D'+HEBR+&AB4\G\\:0A^3;G28;X5IS+V9062]C^TUQY+^^'
M0'<YC;F5C83.8B14NS"I(I2OHY75(I1P'I5`]%HOQ;;QNNV=ONS5;*WT&7<,
MNCS/@,DDS;R#F22L9'R2:-MA!=<QP#.7=11_9VRQ1]@S*UN--..-*8<6VA;C
M"U(6ME:DXRII2VE+;6IM6?#.4YRG.<?1G..>>/'!?F1[6M>6L<'-!(!%14==
M#0BO'$5ZU[.18)PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"*$;'H0K9U+-T<S-*C(!M$+.
M28-Z'',#98PE#,#2`YTA!)C\2H)(>RZE+\9]E>4>5;:TYRG.^VN'VL[9V`%S
M:X&M""""#0@T(/00O0[5W)>;1U^WW#81PS7-N7^US!SHGMDC=%(QX8^-^5\;
MW-)8]CA6K7-(!5)1NJ54CDJV6S?=EORPYI@^?R[+I&&M@$XNYYF_(;ML:8HK
M*8;<78\]V0E`3Y.E497PZ\*;QC&.<=6E+7LY<0:YM!Z?8'+$79[?T@IVLV.*
M^@2^,^M2VEW9#3=);!/;F&&C;NME&[2VZ,X6Q-V<Q=8L:PF[[T1(.:VCB2L:
M/Z@503%;:&;+VQ"GC)M3>J)I$V@/$J0.I?X1T@P(%N5KQ\7.%ML;7--.K+1B
M4QQ#[><OX6TA6,W:Q*]U711%I#LP[='%V2I/;J#[6WT2!AP7+NO''6KV8OO-
M)T62VFCN1<Q%EZ([M]UW'FS3%MZ)&2$Z=:N:+>2")I8[VO*]P67KW4_7U=-U
M^>R=N9.OU\4''HH)N35R5.*R@NH'-%QS)MERJ(/SITG7#JXDAC!!`YYQ67<Q
MO/GQYA)J]Q(QS2U@D<XG.,P<*R<V@[5`,^(-*^5<+4_&G<^J:?<VTEM80ZG<
MS2O-Y$VXCNHVRZF-7=%$1<\EC&WP$C'\DSM:`P2Y5:VK-2T73->GU3789FOU
MV?9[%:\!XC;#,""1LY%PF18&QHS$=F(.;D.92RSA.<--XPGQSX<XEW>7%[()
MKEQ=*&AM3Q(:*"M>GK7B]X[VW%OW5(M:W1<.NM4CLX+;FN)+WLMV"-A>YQ<7
M/(%7N)[1J:*R><5>43A$X1.$3A$X1.$3A$X1.$5*;[":D+T3$C<UJ9HM5`FQ
MY>'=%WR7K.56SCK4L%%DCKG!+!)0J43@&I(]:42$_$QICK.<*2YG'.=I[[QE
MQ2R9S)7-(RY,]1QQ:0:T(!X8$`]"^@>&NH;VL=Q\K85D[4=9N;=\;K7N;;]L
M\(+9G-?:OCE;(V-\4<P)8<CXF2`@M!5,S=.=.TV.ZB)!BJP2,+5J)5DI36T9
M4$=2*'BNUJO?A'@U5NQM1Z/.S6*F'C_65AJ-)1'@QUID)RI2W.:V\UGE1O#7
M%IE[+N6"7/JXY"[+VAF<XY#45)PZO>6^^_'4Z5I]]%!>26LFLEL%V=/:]]W>
M<^>;N+[@P%UVSO%S<O[@]TC"^61IB(`:WP!:TZ@N%M.2A5V`FBIYJ>8H+3NX
MIIG.['Q]C,7IZQ'8#MF?9W$1K]R.SR[,F4W.S!GR77$>3^M2DN=8R3A\;FL;
M0/\`:P.54!M`<OM8+0&T%*@!9:ENWQQ;9:[#>:?<V]G;.9%>$:8V+WJ#X(K0
M00O$`.F,FM88;9T<;HA-#&QKLW$Q3&I>C?X/VD8V'7LTS\("J8BT_A[)Y6Z=
M5744E6DUW+-PS,>K>:6VD7]5<R<QO@<8SZ'G_;>;N]Z[WC[$[G\K-EY(X5S<
MW+EIFS=KF4K7IZ%W1WM\8C\IG..EW7O][V=Z-O[SQT$//-W[ZBU[KD$_>B;C
MWQ$>?G$CF9>PI2=UIU`;([EDE+P##$@2AYO8&&MRS@[FDII"SC+ZP>!1F[,R
MC3DZPW<3$+O/1$0?CR#"%KPY]*,ZH[G6"V`,C+FNJ&>U`\T!I90]GVP!I+16
MM`5T^G;M\<GVN@PV>G7%Q:7(?%95TMDHU9K+>2S,,SC;DZHR"TDDMFMD,W)A
M>X-R^D,F!U)U2CW:A0:Q9A<>X.ZWBD*)606VRJ)9^L,U\[6A>UAP"%9O5L=E
MBURS$F(ULPV_/].6ZYB3E:$+;PDN]6,$CI6'DB6CG&,8.J"8R<O9;5H)CP&%
M*=?#U'>WC/+M_4KG5[29VAC5G,O+B;38RV&X,T,\FG/F=;T@@=/!`^33LS(<
MT;&F$-<YKN(>U;U(^LVVE'[D)B6897&#FPX,O<1.#-UA%FRJK8'=AQQRK.TY
MK6P'2]*"%)1QI$23+FCV)*W5.+6IW*.ZUCE0\MA,1=1AY0(>1F&2N7M@!SFA
MIJ`"13JWZ;O#QL]Z-$&FV$[])FNC%9/;I<;V:@YC;B$63G]W(OX88KJ[MX[1
MQDCCBFDB:P-:T,\0VI>H#]EU>P-L5:,FB]+E$J77'=J23<?:M?91;B#E[*UM
M^Q2HVT",)5X/2TFI+,QY#A*2]ZOF2E31]WK(BE+F.;&'T<[ETY9[(R!V7L`Y
M6#*"!V0*==O]Z^.4>DZQ+=VMW!I\&H-9=3C3FQ'3IB;9@LXYQ`UVGL?W2SC-
MK&Z)I;!#'DH2'Q:%JSI%(J%0<8V0")UXO>IM:"V=[?A4E(V`>F0:Y79NJ"MH
M<N#LF\A'@])##UUR0](85&%Q499SY?%6YUUKHF>#$X2",.+>2!D%21(&Y>R:
MN<<X`-7'%=Q<;Q^,'%KE\V72;B'5(-.9/+;C1HV-LH6OGG9J,=N+4-M)1+=W
M4POF-8\27$S@_&@O'55&T&&O>UIFM3(<[<?F3PK8(./>'K=]0G3A<S;)]7CU
MJ06)1]?#SUD+D"4@>RQ%:D2W'%91G#2$M\"[GU!]O"+II;#2K#ERYZ`-#LU!
MG(:`T$DT'GQ^>;SW%XE7^W-%@W9!/;:%RA)93.M!;=\$,45LRX=.V-CKU\,$
M<,#)GOD<R-K0'#.XOP*.FNA5`LUDB!LQ^OLY<2)$678-ZL$&LQFJX3J8"%56
M"M@E)KD:D`S4QL!\)Z2PSLA3\53;^$.IV>_6H<SFM<QLG26L8"[M!Q+J#',0
M,]?2I0U&"[)WCQXD#4??>UN;2VU-U.9+!96D+YW&>.YF=<&.%O/==S11.O.9
MF%TU@CF#HRYANJA4ZHTUBT-TYZ0[%L=VL=K.-NGIQV/'MIB0UBT)AIFS)C85
M,HO&<D284?TF43WGW/32XZYX\&XFFF+.=2K6!HP`[(]&M`*X8`FIH`*T"\!N
M77=;UV2S=KK6B:UT^"WB(A9"YUM$T]WS9&M,N6)S61ROS/,+(V9BUC:3SG'7
MFTX1.$6LUZUOUPL>Y!SUZ)`'-G&ZA/=;U^2O+L%FVUX<'M%<<M)'6^3$>!8Y
M-?K]G,0F2CD-UV+&DO)PYCT499[2"YU*.R(@#NZM>.V&5RDEIRA]*@$M:2VN
M)`PQ-?K>W=U>*NE;#E9MV*Y&T;>^8#>QV@>;:=\MO.+=E]RG/@;--;VLKK=L
MK6R2,C):<[@^IQVL>E4VO:\EQ]DA3@L]=YXBL6:3OHH8E[6L,AVK0IVO35A>
MM[[^S!O_`*``HN04ER6SAL/$:]+P3E*^8ZZUQLD@,1:]L8+F\H#ECM$/`R]@
M]MQS"A[1-5[2ZW=X_6^J:I!+I-Q;WEMI[)+BW;H\<3=.@:+A[+V*`6P%A)^_
M+N07<;8W5N9WYZFK>45UITS@P-LDY6Q0M?17KH+<N]CB;R(!)^F+0DW8R@^O
M`S3%JCOZB:F'[H85D7%7":?<)R6<M*1X-(Q9<ZTYT+1$YV9ARMY0(E;0`DC+
M[9@UO:-:90:]*U6>[/'FXN=%M(=*N+IUU82"T@=I#)6:I;\J"-\\T1MW#4BV
M&UM1WB02N8V"*0/#JO=EG]-].4V&Q@7"U4C38VI<OF*&C:4N.*K.O,U$+2U[
M*BU+%E3'K$[%(KXZ!]:&6F)2(<5G.)*<YRM>`O=9Y39`U^7G8/Y8JY^8NR%V
M7M#,2>6:BI."X4>^_'8Z7::DR"]?;OUND5X=/:Z2>][S+="P=<\C-<,[W-/-
M[WN<^,RR2`Q$`-;Z06M>G[D[3,T9>@9F>>D$BVOG7=RS2SN[B(^UR[_)+G6E
MV9U&Y)]=O<IXNRN6F=\O(+5E&&\?<8LESK.6=KHW-:V@?[4!R@6Y*#L^U@MH
MW"E1U\5GJ.[/')EOK]O=Z=<6]M;-9'>@:6R,:2Q]NVS;'"1;@Z6R>S:VV<(S
M#SH0`XN/:6>U[J#JY*H]X&4>PP;90\2CE8ORX^V3-J#P1H>GD::[KJP$_K-,
M3`J=%JAAU$`,^ZB,'5E$IEMM]*7L:[F\U43QNG:67%`YGM8:22X.S@9<7/<,
M7`5=P-1@NMW/OCQAAW#IUWN&UDLMR9(KBS#M-BMY7R2W3+H7T,?=VY[F\N(F
MF:Z8TR70#H7N?&3&HN)UOTYEL:=+0]AA#RS]I+RZ"?E[NG&9N[;*W90MD(P#
MQ1ZTO.;D<$VZM#9"(<M4]$*3"9:0A"/%I>U]SK0,['1%N5@#QR@!$VA`(&7V
MNK7.%12H)/E7<7NZ_':&37;*?2[BV;;6<;;R%NDLB9I,!@E@8^&,6X&EB2VG
MG898Q"98Y9'N<YU'MQ,[5W22+4[DZ_LD&)`@KU"KYRSL;^*C)6N3T2-90<+5
MHNSMW%F30PC0R\FH**ZP]&CICEI2,,X\V,HS;=:X9F`1$R.C)#>2#G&!,A;E
M[9JUISFIJT8KFV^\/C!3:U8,CTFXGU*XTY\T-N=&CD;?0N=!,[4)+<VI;>2F
M2TM9C?/:]Y?;0N,AIVI.8U'T_:LFSHA&P5D.9&4:,1N=89VI)#1]75MR-49#
M=]$UJ/8HS&L)\MJC@9*CD5F&\I8Z,]ZN%+4IW4R[UDQ1.:USF&2C7<L'F.[7
M8+LO;`S.&4DC$BG5U%AO;QR?I6D3VMK=SV$VHN9:W!TYLKM0G#KEILY)S`XZ
M@QIN[Q@M)'2M`GECR4:`RS1VGM-7G3U3JE:(SB]$8G,7FF7BJ7XV_8U6.42(
M'G-@!]E"C#AR98390Q-D2Y^);F9V9LA#WG;><0KBNO+V"]?-*`VXIE<US!EI
M0#(6$4````%,*"F(7D;K?6_-N[ZO=:U:*.#<;HS:75I<6<0@$#8V0BREL)(A
M$V"*.*)D<)C'*Y43F97L:X8(KU0Z^,C34@J"FPVY].GT@W8YMZMC!ARD3*F&
MI[@&=:I9_P";?*8<*OQ)L?#DG/PQIO)-M29[CLA>QNKZB7-#'`D/#@T,;3-F
M+JAM*5))!PQ;V?1`"[&S\:/$Y]W;QV5S&]\5^R[B@9:6QB%VVYENA,RW;#R^
M8YTTL3\K/;+5PM'`VS&1-V9BQTQ(L:*EQ]Y,9AF.EZ4^Y)E.I9;2WAR3)>4I
MZ0^O"?%:U9RI:LYSG/CGG5DU)/6ODDTIFF?,0UI>XNHT!K14UHUHP:!T`8`8
M!>_D6M.$3A$X1.$3A$X1=#?NNU#>-AW+K27JZ@;KMPB/K)V.1F:QZETWL")C
M$E6HNYB,0LUEVM09(,AB+E"O@&X[S>6U)=]3Q7E*??[1FL([*5MW)`QYEPSW
M#H33*.#1&^H\M?(OZ0?$OUSP\TO8>K0[PU/;]C?.U<.8W4-R76BR.C[O$,S+
M>#3KQLS,U1SB]IS`LR4:">K7\&7;[_$GVV_FTM4_[2//6=ZT;_3V?W[)[BOV
M)^5W@=^<&R?_`!WJ/_Z&OJ$Z0CK.)ZI:4&W,590=HB55UHP)N%`':LLT*3\Z
M*J2V7U\).V8=5Y*F5(5B.U/DIRA25^;&5Y3CY5KCXGZM.^$M,1?@6O,C>`X/
M(&;ST"_D!\82ZTB]\9]P7>@36EQH[[P&*2UO7ZA`YO*CQBO9(8'W#:U&=T+#
M4%M*-!.U7.I7QI.$3A%K[O#>N-+G=)CY%:^="-J;0CZ_/FLF&Q:***EU\U/;
MMTAEV%);*0HQN'#BR6LNQ<,1I3DG+F<,9;7V-C8=]CG<'97Q19P*5S&H&7CA
M@21QJ12F-5]-\//#D[^T[<%U%=]WOM&T=UY#%RC(;N1LT3#;`A[3&]T3I9&.
M#9"]\;8@RLF9NFYKW'943!63#UJ!'PH6=HS`RK1;;<U)MXJFW>MU*C-"FZIK
M"UH%&MHQ[3!D0VIRFF([LMECU7E*4I/=,VT'4K*XN.0'*UO9+F.<ZN:1M0S*
M0:<0":!?=[#XJT,QABGU:YEN)/>]LO=[:V+;:2ZM)[F[,AN=0MC)%I[K>5DK
MH0Y[VQR29(P`#LYOGM57="1=1OVD3$A/[&*QWK"/L%G$UV91Z-"P&CW.TKP[
MB:S8Y]/*6@8RZ-BKPY(0^ZXVYX,YPKJK#2I-0,PB)(B;@0TG,['*W_-#@UQS
M'A0`\5\B\-_!K5/$F;6X]'G?)'I4+A`^&WDG;=W;N:ZUMQ3*8&74=O<.;/(,
MK"QC7LK)4?N^.PUCT[<*L'8I(N34RD")/+WJTFC]>K+4R6?:#?5=FR#*?9*M
M5SR(2U36G[-.!C9GW$=F0I>7W(S3].BO87O+R)@:!K0'.X5S92YKG"N!#`XC
MB1P!>''A?I6^]"O+Z34)F:U#(YD=I;Q0S3EK83+W@P274%Q<0EX$3F6$-W/%
MVI9(@WEMFJ&\=]Q5=E=AQE8I$"ZG=+SJS%JX$?>A[1C8[;FR:_J78F%#XXDC
M+J,VBWHW\&TS)0]\SSEE:%-)>\4<R#;[I1;.E>6,G#BXEAHSL&1F-0'!S14T
MIEQXT7N-O?%LO=4AVO>:OJ$NGZ=K\<[KB9]F\Q6)%C-J5EVW2,;<LN[.+FN<
MPM[O[8UP>64=Z+GWSC#+F7K53JU6EUUFU:JK-?V-;;H9#54WC8>N-M[`)D51
MZ[1K87C,5Y_6&!*,(:>Q)G2G?.IA,;/JY0:`7P"69[Q)DD<6-:"X9'QL`[3V
MC'F9NB@`XUPV:#\6Z6[T&#5M:O+QFJ.L]1N)K&VM8I;B+N5]IME&S-/=VT3C
M.W4.\FKF\N*-F42&49+'J?:XG8-0[KV84UG+K9/3>N,WN15B!B<VZ;=3KV=>
MD1$/3JR-+"AI%N&GX-^0/3+<AR&GG8C+N51D\6726QWD%JV7,V>7)F`&';#.
MAQ!(Z0'4J"*D8KRNM>"]IIF^-O[2L]79=6FO:KW-MPR)A$([ZRS+B&7$D<DC
M"X\UC)C&)6/C9,]@$IMO16SK#M2N$SI\2`$*BDF841D#^$=+;C:Q\6:ZJ2WL
MK6NLR?J(5*QA*HT:3'4G_P`+A>%(3Q-0M([241QEQJ*FN3KI]`]X]<@^1>(\
M1MHZ7LW58=.TV>YG#XB]QF[C4$/<P9387]_'0AM2'R,>#]!E(<;PYP%\]3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$
M3A$X1.$6M?8^"8;1J.Y0*0>V.)UYLR=8;13:Q`A%CI$29U3LVA0I8\1/EPFB
M:AMAN,)QUO"_,W&RX]X>#6>=GICF$S0.D;$^2(!KG$@`B1CS4BM*AI]7#I7U
MCPJN;!QUS0;G4+;2KW5-(9!;W5P]\<+)(M1L+Q[7RL:\Q\R"UE#211S\D=:O
M"ZWX?7?>(FG`M=S=:6$K8-=S86S[#8&%B9`*\55O5>EJY)U*`,O$DH,V.;-I
M<@0J"]AN/Z0)AQQS##\1;GI3J%@^9UR)6".0&-HQJUW,D/,(I@T!P=7CVB`*
M@T_5<_BAX>7FNW&Z;?5K6'3-4C?I\$)$C9K2X.HZK.W4IHA'6*!K;IER)FYG
MYKN1C6F2.9K9KG46WCA.^-Q=:W`/([!WJGW/7ECGPX$7&EA=/[+[+VN=>O"O
MF2I]/+G*U9F"T>*TAUV3/GN1%8Q(:=2G1WNSC9&3+&X6\;FO:"?;2Z%D8RX4
M<`YI:3T`5X$+H/RWV1I]IIKIM6L)XML:=<VM[`QSW>^LESH-AIT(M/:\EU'#
M/;OMGR.+6LAA;,"8GL<8M^"G;*A2[+C0UWP.D:,=ZWIU_F`$P51L1>B(NO,7
MUZ%@Q\$W0\D6<US)I+GE^`3B3Y?@,X=YM[U:9^5WB/-S^=GJ:9.;GR5I7-3M
MY>O#TL%W'Y9[*%Z-)_*33N]-W$-<[[GEY9LAK#KWN8?RLYO,A%]W4MKSCRJ]
MY!8I7C4NW`A6B+E:TN9=[KU>KC:]AGX,$?*<W4-N?9RC;7`RJ*G!+$RY$`-:
M"/&9##J6GXTZ&B(C"I*VT9U=[LY&24EC:+F-K6`D^U%L#HSFPHT%Q#0<00:\
M,5TQWMLC4+/46PZM80,W1IUK;64+WO:-*DM=`N].F;>>UY;5DT\K;5CVES)(
M973.(B:YPYVJ=5;8I-CID<MJNWQU8V0`W^T6'QQ,J'4:&$UAM((K42YC99*6
MKN,G65D3'%-Y5&<08<<:=RPU)6WC=W5I/$\LE9]C,5#6KGE\9YE*>B0"XNX]
MG$5("XV\]Y;+W!I5_+9:S8N'O5-HQC>Z1KKF\EU#3Y??,-,=3:2,@=<ON'>V
M--JUKV<Q\37+;J_:L^[J(1=4W*3$UQM^];KLDU,(5E&S*1=]XZ,V@'I=8]0H
MG-AM`^JTE]J4.=PC#$RN,1\JSZ\-3B&ZM&P93-&#+"R)HJ>PYL4K"YV&#2YP
M(/2'D]#J-$WALVVV\+6;6K!D^JZ'::5`PODK87=II.KZ?+=7%(_:;=]Q=L='
M.VN>*^DDI[7.&1";H?=!R+<*P-UO9@1'=%C:V31;#+;&Q1>I*Y#N78BS9IEL
MG,$7'*U84"-B1&&X3*74K=L4AM&<XCS?3W-O[*,LE=*QS8&Y'C&LA+86YFBG
M:%6$U/T@/2VO>V_B/L'3IK'5[O5K2YM=`M#8W<#3(Z34IW6NB6_>K9A8!/!S
M;*1[I7%I#;&)SA66WS\LCK+:1IZ^VR+HF]1`NV-6VW1]1I4P:"CE*->2NK^O
M-+'7RQC\F<Q@%003UI.AY*M+7Y(H:,]C&69,92HVYM&".$W$9?#*V5SJFCFA
M\SBQIIBZCP<O6XCB"M%KN[9U@S3=%FW'IS[_`$76+;5KFZ;),Z.[M(]0UJZ?
M9P/Y6::YY=_#+W=P%9+J5A/,BE`V.ZX:[V37=A%\EZH6KLBA:^V=0R-O.LQV
MA&R;9<=Y6+8M<LH)^/)E2C8=H/)<(R9#K:%,23KD?./B$2D(ZW4[BUDMAD>U
MPDD8\-'%C6Q!CFGH!K@!TAM>%"OE7BKNG:FJ;8@[E>P746I:I87C+:$DRV-M
M:Z1!8SP3!S6MBE,K1`QC7$/CM&R@\IT+G:IUNE=VVM<?#YE[S?NJ++1R%R1\
MQGU'$J($IUI3V3&5DO;-L[6<-%=D-3(,&J3![((#$L28I`4Q`99FJQVTL^A]
MYK^]^1E<&X!W%S>22&QQT#*$O!+WEE6O+B6K[/JVX/B^OW5S0S;K=OFTNV6I
MY;+G*Z6ZM_>*2>*VTW3A%'8EDLVHQ3.O+R2Q,UM>27,DD`78_P!9JD0I8':P
MDF$LP5^?V%W5:XR[(0)$DFA%UN<RV@C8%\F4*.M!I80S'0IE/P^&9S4E*F4N
MX<4OS6J3-GDB>QS"!;Q-[(`H6MRD&@&-0<<:@C&B_*GBWK=KK^I:->VEQ:7$
M<>V-*MW"!D<?*DM+5MM-%,(XXP96RQ/(<<Y="Z(AY9E#=DN=8OE"<(G"+J][
M+Z:VK?=@[0J]1IQB7+V0NHVNJ;'1F&Q6*^,I^F=H4<Q5"IIV8U*$ER!RP8BQ
MX_I90^Q9774YRTU-RUZK3+VTM[:*69[0(LS7,QS.+I&.#@*8@`5)Z"P#B6U_
M8'A+OS9NVML:/K&MWT#(=*%S;7-B<QN)I+G5-/NXKF.(-+9(V0P\Q[\P+'V+
M&$9WVX?7)_6NT+*=V+<1>D;V,`;OJMCUC2*M/%!()/6]IEUCK-7X]WMXQLRX
MU5ZZZ4U20?P0;4M7I`HKGE\TJ)A?)CN;6*..%\\9D@<U[G`DA[<TYRM-.T:2
M`4_SCU%>ITW=FS])TW2]"O-PZ;-J6WKR#4+NX9)*^.^MVW&O3.M+:0Q`W$XC
MU&%G)<`,UW,VM(9LO,K^M=HU:X:_N9;3UY+A=!SFZ[?Q@X4+(%=LD)UDW\_&
MNM'%N%&TV\:%>V+"-+=<RTZE1J0E*<R8TMMO&2YM)89(&31M?<"K"20(P&Q=
MEQIV2<A;_P#".@M*T:GNS9^L:%J>@66NZ=!?[EC,]E(^21D>G,9!HP=:W<@C
M/=I)18RVH:,S2+2(D\J6!SH#%ZZ;Q@Z^%ZPEZQL$^S5"1$V@5/MN!G:]9J@S
MUYUMKZ1IH2>65],A99QJM.!<P',(B_#"FGUN)CNQUJY!U&P=<&Z$K1$_L`8U
M#N<]_,(I@T!V:O&KB*5JO2S>*7AW<[GFW?#J]M'I-\UVGQPD2B:"Y.MWUZW5
M)(1'5D#(IVW7.;63F7#XVL,K)&B?+U-MHV<O,N%K.YA_R@[S3;1KLQ-'P(CF
MEX=+[-'MJ'R%\0LGB;3)]BKTY!Z,RTEUZ1.=S$6E,O"F\<?O=G'&QKI6.[M&
MYKP"?;<T`C`9A1P!&4]`&/HXKS3=Z[)T_3].AN-7L)_R8TZZM[V)CWN&J.NM
M`ATZ%EF>7DNF03,-F]SBUK(6B9I,!:Y2*JZTV@0TGN*J1]2V^JF+=U[U5H8:
M!(QPD!!2ZZ@U?>VK:4DOH,*A(I]I<F0ZV,*95E$]Q+2O*F)X/)US7-JV^AE,
MS'L9<22DBIHV1[<HX5S-Q>YO0*]."ZO6=V;/MO$#0M:EUNQO+&QW/J.L23,=
M*\QVNIZA9FVC:#%G-U;ALM]/;@5A:7BIFK&8\7UCM6SW&]6H;JB[AQ?8*Q#V
M*$V2&0()#4#X+9^I;"2N%\@))+>I[9]NGR;"UEOU779`MEI:4S'H[2]C+JTB
MACB=-&Y]NTYZ$D259(`UAIVJ9@SHP<3Z()'9V.[MFZ1H6G:-=ZUIT]YMBU>Z
M\,<CWLU,3:?J4,=M9OY8%R83=1V3LV5K67#WM)@CE>W%"M9[2!3-?6Z;HR]S
M@NI-<U32MSIL,8"DE+[<Q>NNQU/G7JNCL&4Q[%4/F>SQ[&"JUHRN,:DNJ3AN
M+)RC-]S:2-DA;/&))I'2M=4T8TOA<&$TP=1A.7K:!Q(7-O=V[.U&#4]#M]Q:
M;'?ZWJMQJMK=.DF;'9VLE]H=RRTG?RLT%SR]/F?W<`T?:PL!SS1!V,@Z$W6"
M&U*J$-<64Z4TR>QLBYV&&D;*&;6K<@WUX-9HE2(2"+2K*?=':]F1G(4C#24N
M5R.A:L)DPLNY&_L9'/E;(QK)FY&@UK&:3#.X4[(J\&H^G/4ZG+N/$G8&HW5[
MK5KJMI;V>O6W<;6!W,;)IT[8M;B[Y<L:P\B$/O8I!*PN)%]*YH)BN`S8"Z4_
M=J>LHYJF"KA5'K%V(N6Q;=4Q0\V_>Q6E[UM>_P!R9"-`J)L#7UK^;)9/"I1(
M:(L$`@TQF5'2IQ25QW>N@FL??0F8L>&V[6-<2,AD;&QM:O8]M*AP#G,(K0X<
M1\ST#7?#X^+DK]>FL;V.UVO:V-M<R/B%G)JMIIUG:F4S7EE>V_+K#<1P3W-E
M-"Y_)E(8"V5E$V?5O:JUTZ[5VZP=TW"I&.LL*NX"O6A@*7+;[#56I'#QQT,"
MN9!^&.L%3&L!(+:3LR+BY1";ZL9601/5V$5UI44[)(#`R5MU6N6H$1<X`5+1
M4AQ+CV`>66CZ'*OHVD;Q\&M%UW3]4V_)M^QUN#=SY^:+<RQ1:/+<7,,,0EFM
M6!SX;F1]W,39Q2>]<EI&TAMLZV'<</6AR!"6VU+90N)&6ADAE[,]I"F492U-
MS)<=D9EMXSX.>HM2_/C/FSG/CGGC'>D>''HX>IY%^$[IKFW,C7%CG![@2RF0
MFIQ9E`;E/T-`!2E``N7S%:$X1.$3A$X1.$3A%T*>['>Z35-SZSAV>QS0TN3K
M!V3'CQAFPYR78WUK+M>ME=/Z^[>A(5ZK>4^#LZ*[]&/VCRYPXKZ!M"">6RE,
M30YO-ZV#Z$?331_./G7])/B6;;W!K6PM7GTBTCN(&:N&N<Z2R91W=XC2EUK6
MF/.!!JV*1O\`SE:M'5C^&34G[^BW_5W>/^Q)SUG<[S_1CUXOPI?L?\@][?BV
M#[?I'_JM?49T=*##74_210/,<(#)E4=<AS762\=R0W@T5;RM3)ZI40NC[M&<
M?MXB"O.,>/IYQX*5\IUUKF:O.UXHX/X8=0ZG/'_YBOX]_&&L[O3_`!IW!9WT
M8BNX[T!S`8G!IY49I6&YO(C@?H+F8?YU:@;6\ZE?&$X1.$6MO8]_3#@RIU_;
M]+L-_P#KI+N-.J]8J]?M%D,$5G==VJ/<F6H-76W)98<H2225OK4G+/CA3*DO
M^DK'9Z:+W,^2S>V/(&N<YQ:`*/;EQ=_GTPZ>G"J^K^%4>_6W=[J>Q[^UTSWO
M9:W5Q<7$UO!%&(;VW=:DON`6DB\Y!#`#FH0\&/.%4U<,=4;<;G5VE:SLMT:V
M31806V2@M%NY*JQJ7M26^%D!+FN<EH?5_4D4AUDC%?:8E"\P5H>2PK"DYY<L
M>K0L$D\K&&*0EM7,#LT>-6TQ=Z5014.KA5>UU6P\:-$T^/5=?U>TL'Z3J+Y;
M9LMY:1W#KK3FB5LMJ&5?<4%VU\$C'/CN.<UT9D!!60$["ZMWZ*U.F5NQSQ-A
MJ%1TF`L5VJEY?$7C7=^L,JJ@F*\=.IE,%@Y\WG*)\U3B"*D>@_-5AG,9S.+[
M;5;<T:YF9KW2D,<RK7M`<:@<"!P'H\0W&H7&O=K^,6VYC;P7=I'>VM]<ZM-!
M:7%H);2]LX&W$QGAARF.6&*AAB#3`#S([<9^:P0BY[`Z>&*UG8][![,$T.F:
MZ!1X=VG!MU@JCL;4,2U`@8IJ=($OQX^V:1%/6B)(3$.-3</Q"#LU#+L.1(>7
MR(;;662=V@=$9WR&K08BYDA:2:5^QNHTBK:4(#20X`+T.@[9\=+#5?R5VY<:
M1/N._P!4F<ZT9+I4US8ZFZWFFD+&R!SM-NW0V\C#):.BR2PLMW/9/%%&V<VA
M[IS58%2R>'"XPW6FT:GK^KD8C-HE,0KQL5NF[=$NOF!KSJK`"()?%V`B1FNR
MAK/PN94MQ/H.+3QXAK,KGY"2Z6)SW`Y?19FC.!X$=I@``=C0<0O.:0SQVUFY
MO?>Z69]UJVCW-[<,<;=I?:6)NM-D`B>!R9F4N+*"")L<[N8(86'F-!P%.,=4
M*1;U``.J[M22NG;%3`;1$C1]@#P0`[<K)<*E1&(Y26Z\.(_6$GOLU\(O]N;5
M&*N.+REMAK+.R:/5IX>9)+'(R9KC0.820UK7/P&(H(FUX8MITFO9Z[8>-&X-
M#&IZEK.GZA9:[:W4QC9=V3YIH;6"VN;PNC:`]G(CT>UY@[!$ENUC:ND?GP]W
MV=T\FO[.V3=D;,'5ZR4.W.V6Q)<W8'UON.F4ZOS*=;'JT`KY6/5]AR0]:(NI
M86Q`<GRX2/C8&7V6,26\X+766B*V@Y1D;(VC?:B^-SB'-S$C,RKAC4T![+J$
MT/.V]M#QTMX](VIM\Z3+JEIJ5L((*:5+?:7=74S;JV$\TT;KBR;+.QI>'S-A
MCE/=[D1R2&)VQFO;-IJHAM@R:M=+*5K]+"`K?;#=JO\`L38HZ!72E1Q;`Q4*
M<O-@LWF$2:OG$KP'.^BO&<94G*\XYUMQ%>S/C$K&B1[BUH:QC"2'92"&!N.;
M#%?*]SZ1OS6[_3(M9L+2'4[^XFMK:*WL[*Q>^>.Y[M+'+#:0V_MK;CVOV]N8
M<`0U<:5VAUPV<C5<:+V+9;.])LD657ZSKRSF2HA=08H;UC6:8CP?(.9&*V2(
M;6I:O!3LA2$^.6G?+1I5R8S*XQMBHWM.>T`YLU*8XUR.];RA;H?!_=3M.?K%
MW-I5II#60.;-<7MO%'*+DW@@$1<_MF3N%RX`#!K`XT#V5L>V[8HE&MVNJ-9C
M.1UDVH2+B:9#^!G2&9TP(/21G8FSH\=V$'8SAYF.RY+<9;D39+$9O*GGFT*X
MT-I//#)/$VL40!<:C"IH*#B>DX<`"3@%Y71-E[CW%HFJ;BTB#FZ5HT44ET[.
MQI8V5^1F1CG!\IP<]S8PXLBCDE<!&QSA5,?N%H*95472%;Y<VOI);%%D),6M
MV)^2"?U,9AAMB/6`<@9D@&A5?$YN<^^^TAM0I7QS>5Q,X=SS#HVH"7D.8!)1
MA&(QY@)90UH2ZE`!]%V>."]G+X&>)4&LG0+BQ9'J9BL9&-=/`&S#4HG2V0A>
M9,DK[C(Z)C&.+A<#N[@V;L*QP&Z->V>SKJ@4PY,G_.K36X<[$&6V#+V"DP@L
M^U"`9IQI,`Q+"-&TH>^'6XC#\2:UA6784I#7%DL;F*+G/;1N5KJ5Q`<2&DCB
M`:85Z"T\'"OE-2V#N?2-(&M7\`CMN[V\[F9VF:*&[?*RWEEB!SQ-E,1+<X!R
M20/(#+B%S[5YQ%XU.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$
M3A$X1.$3A$X1.$3A%2.[+U=ZHQ0:[K6)5G[WLNZ2:D"E75!9^KB4":/<M@E9
MY2($E0"<WU1=*=AL-M2&?)(E(=5E2&U-KYUC;P3&22Z+Q;Q,S'+3,:N:P`5J
M!BZIP.`ITU7T+P_VYM[6I-2U3=C[QNW-)L&W,S;0QBXD,EW:V4;(W2M?&RDE
MVV5Y<QU61N8`'/#VZ91N]5[*@QU[%4BHHI]Y=B:]H(F=,,_6*!M^92M?V9B1
M:B;+N!TNAJ+W&;`4B+%8FH;%(D8=7\;Z,7NSH-NQYMWO?SH^V\@"ACS/;V1Q
MST:#B2.U2G9J?O,OQ=-N6>HR[<O-0OCKNG-=>WDC&Q<A^F-NKV`MMXR,[;SE
M6L4P,DCXBZX=%D;W?F32!/<'9(R587#U<HKH?1UCK]3W[)&-V!F<:FW+<%PU
M/7S6K8LDG*:$PH4>L,FYD0FY/<6B;F"V^E;&93VOWFMG!O+=)GG:70UI0!L;
M9"),,2<V4%M.&:F-!UA\#-IW<-JW3;O41?;AM9KG1FR&$LB9:Z9;:C/%J#FQ
MM,CWNN'6D4D#86@Q"X=&6R<EF$_+"WC@>L-FGZOS?FM=*[`*3AVT8K*]1HUP
MS>LU!'_&&2"=A9,O9"_,\N9'>1/S'X'PS\#C9[S6&;/GF[OS.3]#FYF?)FX4
MR4[67C]#F^B78_`9X>&Z%_W[6/R:.J#1N%OW@:D;XVG>3V,G<N4.]=WISZGN
MO>*CO!SJNW^R24RO?(J[1&A.\;'8:MH*829L+\L')I>XJWJ:QEMI0HY2*V7C
M3H9YPW"BC'1ZT)B_`./*6[B6WK]YK5K7<QTF>!H=*!EQS1ND`C-,*4RDNKQS
M`895UH\#MIVD%U[XW6I.O=NVL-QK+8S`&RMNM+GU*"/3W.C<8G,="VTEDG;,
M"9.\MC#6<AV8UKVUOUWM=,;(U2H#:@]=PVDKZU$D&95BC[<(52WV*>9K,QU]
MD<JAP)]:C0FX\B.N=(205(R^W\+EF1KNM(MX(7EKWF;(965I3EAS0`X<<Y#B
M:@T%*4-:C@[L\$]M;?T6_=:WM]+KC=/EU:S+A$V!VFLN;:!D5PT`O[X]D\DK
MGL>(F&$1<M_.YD7JM/;'9`BXSPHVM4A8>Z["M6FM/NSLGED(-_IFS]>:J*'-
M@JCS6HY"K$"ERG3V8L!$.2S'$(94^XN=AV)8M(MGPA[G29V1MDDI2A8YCY`&
M88.`:`2:@EU:#+0Y:/X+;4O="CO[N[U`7VGZ7;ZIJ89R0Q]G=:?>ZC'%9!S"
MYEPR.UAA?),98W/N72"-K;?)-&9'=B_A&SAZP5"G.5C413%"W1&%NFTF2=^>
ML.TZHT1U[)DRW8<"JL%-?07E1Y[,N2ZP:6G#Z%0,YF;1H=O)ECC>_FS#/%6E
M`RD;J/ZW4><00*MX=KL]O%\7[;6H/M]-TR^OQJ^N0]\TIT@BY4=F(-/N#'>M
M:T.?<&.]E:'PNBC:^U:>6X7-(/=*[:[N%+LU9(U;5\B[ZOI]@W+L1</-I8KI
M;58&GZLN#E?J"'B4B=`O+_X27X"9LMR1!PL/\3F+A,U+$6#2+%^65KI1;RO$
M;/1S"0ND;5V%"WL5H*'M4KV:G"'P3\/KT6FK6MYK#=O:Q?0Z79!W=S/'J,US
MJ%J)KFD88^T'<63&*-K)J77*YU;<R375I+L/9MBW,C`LHJMC:=9JI<=A:SGB
M\DF2T*I4;9,_792+><SY<F%(+$&LCBK3L1,9EA$QV(IMQ4;$E_@WVFQ6T`=$
M7F9KVL>#2A<Y@>,M,:#%N-:T!J*T'@/$'POTG:V@Q7.DS7<NNVE[:V5^R3EF
M-]S=V++Z-UID:U[8V'G6[FR&1SS$R8.:)>3'&0ON#:`/`';&/7;Y`[YU5P4%
M(\2(L,LI+V(+,D-48CQ:M8#KL&1M:8!DC`L.=\(126].).C0G7V,.;7[=U".
M01.R!V5Q-210,($GI`5Y=0YQ%6Y:EI<`5VVH?%C\3--U(:5<BQ9==WN)GYY)
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M!@S.%U+4MX90UKVL-1QJ:N(Q`&4"AK4?HKP_\%](WMH&GQ/N[F'=VK\Z:V($
M9M([:VO;:SE$S2.:^9_-N)HW,D8Q@MV1N8\W&>&$$^V.Z:X3M-0-5K6,RWZ>
M$F-B;9DC,6F.!.:X&!M0V-L90V91*1.$W!T;M.0UF1.<FQ,/@_-ACRST8A[V
M:192M9,QTHAF(9'7+4/)D%784+:Q\!0]KCV<?0VG@ML'5;2SURPN]7CT/79X
MK'36R=W=-#?22ZG`9+PMC#)+82:>QP9"V*3)=TYE;9QG]XSMAM^S'JW3P%?U
MM#.[KDI+Z2(EF;.^)`TZ&4V:DOG9,.&68F&CJ:_KR/*8R.='LYD%\L93G$%3
MTN.TBSBC=-(Z4QP"DH&6I<0RF0TP%7D&H)HVOT5!JO/!;8^D:;=ZYJ5SJS].
MV^SE:M'&;<2S73H[`Q=P<Z,MBAYUZ^-_/;.[);<P&MP(X(U'[V7N?68>QX-&
MJ*:99UQ==54+)G&?K)%W1,U74]BQWCA9M6!LC7RREAE"5)8AM3D)@)F>HK$G
MX=C:=!@;*;9SW\]O;<<,IB$CF8#CGH`[$D8TIA4]M)\7/;EMJ\FU;C4;XZ]:
M!U]<2M9%R':4W4;FQ<(8S[8V]Y<,=R"^5T),Q@R`Q<V22_E>[+%$+!&.U^A.
MPM'V2O5S?<P:Q8F'SN+MM\GJVLEM6PGRLS`9,0:/2<FQ2;Q%2O5S`;>PI'QB
MM7O/:O:TQNDK.TF('+AEC$C@\T%<3E!;E^FI]"NI^`_:5Y:VTNFW6I-N-PVD
M\^CMD,!$/=-,CU">/4'B-O-+GO-I%);M@`R]Y<PAW($NJ?::\HU5MN\7VJU5
M1ZEZAH>\*J+JTLK'%SZWM>NV`G3JF<DE%SI*#@4W69,$B18PF/):4B2U%9\<
ML8TS:5;][A@@>_EOF?$XNI4.C(#G"E,"'`@'$'`D\5TFM>#FW7;ST3;VV[V\
M&FW^N7FDW$EPV-TC)].GACNKF%L88TPRQ3LF@@?5\;@Z)\TE!(8A.[:;:KQV
MP5<]7M=2B6DRT5>\R0IFRL0+!5SMOI`0!,UE`E%Y$@$5;KEP>)2FR3Y)'Q`W
MX-&<8E8E1][=(LY(VRQNE#9Q[4#EJ'!KB0\TQ&9H:,H;@[-T4/>6_@ILK5-.
MM=8TVZU1EIN"!PTB.0P%\-Q#;7<LS;][8FMFC,]LV"-T#(#DGY[L83#+PH7;
M7=II^KU<75]71[KM:K`=N:S>G9M3]=$:Q-U3;%MP`NC;!"//GW>.C6+$/,V&
MY&@Y6:P_B-E,%;,JNTBQ8'2O=*8(GF-],M2\.C;5N%`WMDT-3V:5[51R+CP4
M\/K".\UB\O-8?M_1;R;3;\,[N)Y+^*YTZVYUJ2PL9:.-^^412M?+2UY9EK<-
MDAXL?N[?3<<+9`-/I[55VN130=012CQM9P5L7!+5@14Z_P`J-*;AD*F\3V#.
M7AB`Q$E-,A48]9Q4_'P>1T*W83%(]_-A&>2E*%E)#1G4ZC!B215W#L]K=+\7
MS;6GR7&E:E?7QUG18C>:FZ,1"&2QR:A+DLVN:7LN1'90C/,^2-SKIWM;1;>W
MW^UV@$TW3D;8&V8\.-8X^S[-I24)J<D=`'V;857O5DI&<UJ9>CP$.%%'&ZP\
M41\W*QVH,3S-NR7%M^=SKCI3Y[TV]F28C$V6KJDM8YK7=K("21F#>RTU.(`K
MA\T?X07NO;[?MG93Y'Z4_1X-5;)<M>]\%E<6<%W[>VSAFEEDB-PVW/=K=[II
M*.9"UKLK8-:N^FM6*78S^NJ];;_81>IAVZ!%>8&-"HQF@&F`Z1%C2;G3&Q;0
MV<=)2`Z,>IE]183/8PWY(RW>;XMOW)G;'<N9'&9C$36M'BM10"M0`'=65S3T
MT7H=&^+=NR37[73=TW5CIFES:U)I4LQD,CHKR)TO-@Y3&F0O9#&RY/9R"VN;
M:0NS2M8MYFEJ<::<6TXPMQM"U,.Y:RZRI2<*4T[EEQYG+C><^"O(M:?''T9S
MCZ>=$<#1?G9[0QY:UP<`2*BM#Y14`T/$5`/6`O9R+%.$3A$X1.$3A$X1=+?N
M7A:T4VQKYPW6>P!M]&O'$-2-1[XWUJ@*RSBR%%>B3#ZFTKLP.2*96O*OB9,N
M/)]+*4>CE"4KS[3;37&UD(?"WVS@]C''@.&::/#U#Y^(7[Y^*9?ZM:;+U-NG
MW>VK>,ZH"6ZEI&CZC*3R(\8Y=1U6PE9'0`<N.)\>:KL^8EHZX/JCK_\`>!W7
M_3+[G_[)_/1Y9/\`2VGVF'\*7ZI]^MR_C/8'_AC:_P#ZC7T7]/HT*)UIU%&'
M0K:-A-5MW$>#>K5:KM;8R,ER2LMG+5=ZS3K69E>96<X<FC(;N&\I1A'E2E6?
MG6K@C4I02UQ#N+0`#@.`#GCUG.\Z_EIXY2W$WBSK<MU)92W!NQF?:6]O:VSC
MRHQ6*WM+BZMXF];8KB5I=5Q=4D#93G6KY0G")PBHO=&O"ELFZWN0'8(?71S5
MEH+6`>7L5:;M`&5]9J=8:!(@SX"[-4U-+4U:?4CN8EX_MA"$Y0O"LIYS[&Y;
M")89(W21RL`(:[*>RX/J#E=]+CAP7T78.Z+/1;?5M!U+3)]5T[6;..%\4$YM
MYF]WNH+QKV/%O<U%;>CVF+T"XAS2*K6VK=6:/1MM`98G9FK#=WC"ZDZ3';%U
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MO:Y3M>UX?"K4>`2<K%*N^OK]6A6T'&[).!7`R(%4N-"B26!0526"#\AUM];J
M<XUOUJ@)9#E?(YSR<U1F<U['%G9JT$N)(+G8@`$47`O/'@L@GFL]"9;7FIW5
MU>SO=.Y\8N+NTO;.>33P8&36T4LEU)+)&^XN@7PQQ,?&UAKZ(?M]ZW]6V!S=
MSO9?7!LCL8A6Z!#.EZLW24;$HM(UQD0-L56+"2Q2O4^F5)\:&@S/58BP"3C"
M\.(99\M=N&Y.1[&1BY:&!SR`[-D<Y]2'`@%SG!SB,217"I6RX^,WNO)97VGV
M&FP;JMXK%D]XZ&.X-V;*[N[[FO@N(Y(XY[JZN63W4T65\DT#9&ECGOK:Z>M?
MQ8FQ1;!L`L?,VLCUU,V`_*#PF)!$OH`K4C/QSD5F3Z25WB;5?-+2E6,1?B5>
MGYO+CQXGOGE>TQQAK&"8`5X"4.%.'T(=AUT7BSXL<B]M9],TR&VL+*+6XH86
MRO(9'K,=S%D#BVM+1MQ2,D>V<L9J5*@4_IM(,UBN:^-;7(3=>ZV'%QNI0;-2
M'PR]8;(L_*![UHL"2[J;G(JM0?DB!N6X@M/H25/2\2Y*4/)Y`UEK)77$<(%S
M(09#F)!IB<K:=G,ZCCB[$4%!@O2VWCO%8:O=;FT_18H]SZM+%)J4QN7NBN"P
M\QXMX>6.ZMN+D,N9\TEP<\89`8(2YAS'Y(P@#2.SU2I]F(-0M]XE3:X#*-,)
M":UDXK*!\*M@U0V\2%4E%C]::B$I/A#CREQ&/".VRVC#WX?)/:S3-%;?`D<7
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MR2%SAC94A@JP]'RT*8:2E/BM:M5IJC[2$6[&,,1<XOJ`2\.;DI4@EM&U`+37
MM$KK]F>+^H;*T.#;EC864VDNNKN2^;-'%(^]CN[7N3H!*^)TMJUEJZ>-C[=[
M7YKB1Y)[+1'J-TZJ5&V#2=@0K,3E/UVF7ZHVBN.#!S=9O[MR*-RQ]D-#<Y>^
M'/UH.Y($I>2IS,X8XRS(\R8D;T]L^M33V[[=S0`Y['-->TS*,0#U$T=3"CJD
M<2NTW%XZZWN+;.H;9GM(61W5_9W-O.)'FXLQ:QEKX(I,,T,\H9<EI#>3.'R1
M4,TN:04SKYC7P[JW1:Y(@_4KKN,,O.$,1&!A`T83K\IKH0RT*A8S%CLE(UQ)
MD9J\+^YD1VDX\^75*3JFU#O#KJ>6O/N",*U`&</.)ZLK0/(3U+K->\3ORGNM
MX[CU5LGY0;HFB`9F,C(HN^QWTI,C^TXQNM;>"(4Q8]Y[.0`[1<ZM?'DX1.$3
MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$59;3U
M:)VJ&$C9YVTU0E73K=DK5LI)*&+L]?+_`"DO7I<@;)(C3`U2"5=L$^`^A^*^
MC+$M>4X0ZEMQ'*M+M]H\N:UCVN;1S7"K2*@XT(.!`(H1B.JH7KMG;QO=F7\]
MW;6UG>VEU;&">VNXW26\T?,BF:U[62125CGAAF862,(?&T$N87,=2B^E6F<J
M(QHZ[C`K[]>0(!U*#8&V`%,-MUFI5!&P*IXCEF(=[0"HHM")4B9*C(>8<?3'
MP_*EN/\`.]^[W`G(9`ZI<1BX9G.R.QH6U<[``&AI6@`'T!OC_OT"*646$FIM
MNC++<OA)FNHC<7-R;*Y[8B=9F:[N"8V11R%KVQF4QPP-CYT/J!K*.0!D9)J]
MEG(LULO=8I(T*6/V\=AW<]LH.;V?!B`(D<G,`WNSSB,1L=@7$1E[$9;*X;3,
M9O$ZS=%KFAL8J*-H#6,90PAAJ:`L:`:YCA6N8DGCS^.6[I;6XM8;?386OC,=
MHZ.*0/TR%UI#8RQ:>]TSG1MFL[>&"1TYN)#E,K9&SODE=@<=(-6?5Y('-IVD
MJ1A&0J[*JTCOK.]KE5-1KY6I'2&*]B.J@9I[28GT,8,>LGXWX_X_.96=GO[=
M\SF9(J<<N4Y<^;/S*5]/-CQRT[.7+@NQ^4+O+WT]\A9Z-RJ\T0=W?W<7W>C>
M^^09S\W?.]$R>GW;*>1W;NU(5G9G4#6DF>=(QCE]%/RR3AJDMC30E$33QJ9>
M@^S3)35\*77Y<48[8+X!BD)C))!2(YZ>8R&D0G'8R];=9N0UK2V,@"CJ@UD`
M:6`/-<:,)`+<IZ:Y@"NN@\<MVQ6UM:S6VFS1LB$5V9(I"[4XFVDMA%'J#VS-
M=((;.:2&)T!MY!F$SGNN&LE;[`O4/6=<+`"P$U?1>*\+C(8',6&&\.GW2#6K
M-4H&V"J9@>5,E;)B!;?/3B5AY$%U]QM]V(X]'C.-'ZS=2L<R1L9S'C0U#2YK
MC&,:9*M&%*TJ`:$UQO\`QPW;JMC<V6I6^FS=ZF<2\P.#V6KYX+E^G1Y96M;8
MNEMH3RRTS-8UT;)VQRRM?^$NHFN"IBQFY5@V!B8:<D%`R6CHQ#%!N1$[2[6;
MV#1T9`J6/MQZVZ^%$Y*Y:IL'XIAW#49IF7,:D&ZQ<L8U@;'1N!P/;:`YH8['
M%H:]S12AH14DAI"T\;]U6=C:Z?#:Z9R+<-CEK#(3>6K(;JVBLKL\ZC[:&VO;
MFWC$8BFY;V%\SY(('Q\>/TVU(W-$/S)=S+CXT+*+4`*'(;X79A[$J\D&;GL!
MID1'G$;2P4V29E8<A/P(BWI3?GCK3#A)C#K-WE<&B,.)[)`-6#LC*S&@;1C1
MB"<..+J[9?'C>SK>>.".P@N7R?O>:.%PEL(<MHPVMD3*YC+<QV-K&1*R:0,C
M?EE:9[@RX_'2O6BQC$&9;MI$9[SL^'9[),LXOZQ7NEDPE,K,[6MOFQJY&C2Z
M2_7M>!8N4168A'PA9>^,^)DS'I&?OW<Y\P9"&X96AIHQP+G![1F]*KW'$EN-
M,M``.2?'[=K;QUS!8Z-%;-:QUO`VWDY%G=1RW5PR_MFNG<YMV)KVZD!D=)![
M;DY'*B@CBLZ@=?:+KNS6NS"I!\FY9HQ<9"#GIT*8!IE>L-G,76P5BG0(HV"Y
M"!FK4=D3'D2W)KR?!F.VXW%CQV&^+<:C/<Q,B>&@,H20#5Q#0T.<:FI#0!A0
M<214DGR.YO$W<6Z=)LM(O6VT++1\<CY86/;-=3PV\5K#<73W2/#YHK>%D33&
MV)I[<CV.FEDD?44;HKIQJK,4R69V.3K@R8.FUL;*L\.&U5'ZP!G@=>2`?R4(
M)S\SUBDF[-"D9?Q11)-+,N7)EOQ8JV>8=?O>;SFMB$A!#CE/:S$%]:DX/I1S
M11N6K6AH)K[>7XQF^WZP[7H(-*AU6:-[)WMMW.-P+B9DUZV;FRR>UW_+;%=0
M1\NW-N9((8H8YIFR;)4'7@G74>TQ0Q`U-C6N[V2_2F#$J)*0-,VZ2V2/QQ'P
ML&$J,+G&U2)WHN9=RW)EO80I+7IM-]9<7#[DL+PT%C&LPKB&X"M2<0*#HP`Z
M:D_*-R[HO=TRV<U_%;QRV6GP6;3$US2^*V:8X72YGOS2,BR0YFY061,S`OS/
M=/><=>;3A$X1:\WGK+K;8EWEW2SJL4I@N-9A62ELE&&*7:)\*MVJH"+&:@8@
M*+9/A:U<Y\6.Y&G1V,X4PXZTZ]$B.L=C!JES;0""+*"#5KJ=IH):XM!K2A+0
M34$\0"`2#]0V[XN;LVMMYF@:0+5DD$I=!=&,FZMV/GM[F6")^?E\F6>UAD>'
MQ/>*2,8]D<\S)(9^1GK=Z/"P2MNT#)1<Z<JX6,G9!*SNS*Z18HD*31[Y)C5R
M+%F5+([60*,EN`R/F89@9Q\1YI4Y4G?[]7()RLB:V@R@--&$9CF9VO2J]QQ+
MACPP;3OOAZW5'+(;2QT>WLQ&SNT$<$@AL)V&\<V[LVNG<YMSGO[R0NF=-$73
M#VJD-N(??GIWKIITK-&6O900TLU%+TH^*/AFRVIV(QFXG5@-<JE5J7"A@)DS
M8!A#S)-@HXN+,3']3#,6&B//?FX-`YD3F9:.!!I)@T5?VJU`8VF4MQ%:5+JZ
MQXZ[I>R&WO++2;BP%NZ.[ADAE,>HN=%:P\Z^RSM>Z9K;*U+'0/MP)(C+E,DT
M[I?0KI3IC*9<!I=QBUEVL)`C*=&L*&J]7#2*37]=(V(!_P"+U&H^P45"K08R
M9CTQ^.AQI<E,?$I^0\[??N]P<<AESU+J8D9B_(<:9,SB:``]%:``;!X_[]JR
MY>+!^K"\YTETZ`F>>(W<U\;*;M\IUD;FXFD,38F/+7-B,IACBC9SXG4+6T>>
M")RCU]+2HA-!N[?,C(=4;<)B)?)FS@Y#:$&'78<(DJOWN>[/A,C&Q45M*L15
M-+@I3&QB=8N2US0V,`BC:`^UC(&$,)<2*L%"79CTUS8KC3^..ZY;:YM(;;38
M87P\JTR12YM,B=9ML)6:>]T[GLYUFQL,KIW7$CB.<'MN"9CR0'4O7`&I62DJ
M.W\T!M@ANJ&VC=BBR)<F@#:89HU3UZF;$$09+-8HPLX](%K2K!))'"94F7)>
MQE2I)J]S),V?+&V1AS"@-,Y<'.?0D]IY`#OH:8``+5J7C7NK4=;M-P"VTRWU
M*RG-Q$8H'-:V\DNHKNYO<CI7M-Q=R0M9<`CD&"L,4$3*`<%OI[KA4H*1(6;8
MIDQ'-/&[L7*'`SDS;SJK16[C#@[+;BUN(/FBQ)VH#5161;`G#<:,J+G*HK\E
ME[(ZS<T<UK(FL+:-`!I'V7-JSM$@D.=4N+L37B`1R7^.FZA#<6MK::5;V+K<
M16D4<,H9I@%O/:N?8%T[GLDDAN9Q(^X?<YI'B84FCADCQ_Y%FM&QST2%;MI#
M2$>1`CU6R0K.+^L5!IXL3=P$'6]/F2:[)C1:2P"V0<BX;ELS"'EG8<^+]>-"
M=C9>_=UFS.9"6D',TM-'N):2]PKZ56-.!`PI2A<#R?A]W8^Z;/<6.C2VKFO=
M<0/MY.1>74DEI,^^NFMG:YUV9K&TDK&^*&L)9R>7-.R7F2.F6H7)1=R'*N8D
M;)'I9JU?%G8K`76AWS49YRZ4!#HI\@.M3LW6P63ER9(GQ$/Q7%-QT8F3L2<1
MK=Y1H<(RX'M$C%X[79?C0MH]PP`-",>RVFB+QZWPV&!L[+">[9+6XFDA<9;^
M']]@6MZ1(&/MPR^NF98F0R%DC0Z5W(MS%+"W6FAF-8@=9R2EJ3BMW!S8PJ[J
MEA)]U1L68=,V,S=IBS%?)5,F5/E+(1S,CR1+HQQF<ZRF*AK#:$:6:G<,NG70
M#.TS(6T(;DH&AHH0X``"A#LU0#6M5TEEXM;CL-W7.[8H;(][L18R6F65EH;%
ML,4$5HT131W,<<,<$'*?'<MN`Z%CS,Y^9SH9+Z5ZAF,E\O$M@J*F]<O:G(6)
MRW.2CKM!S6A80?7\RYL*4RJ,"-B_K%"RMI2F;#)E2LY4B2\RO>-;O`101Y&R
M\P#+09\Q).!'$'(>M@`Z`5WT/C]OB!\`9%I@LK?51J+(!;!L(O.?)*^;*Q[3
MFFBD[C+1P#K*.&'!T4<C=LXS*X\:.PY(?EK88:97+D^C\3*6VVE"I$CX9F/'
M]=[*?,OTVT(\V<^5*<>&,=034DTHOBLSQ+*Z1K6L:YQ(:VN5M37*W,7.H.`J
MXFG$DXKW\BUIPB<(G")PB<(G"+H[]T?3.]-E;=UT5U7K7:=V#C]<+'DB%#"]
M32<"&2S9R\GX.8[V"@RK&W,S%=0O*82L0O(I.?#U?4Y[3;-[:6UK(RXE$;C)
M6A,@K@,>P?FQ\B_H7\3[?GAWM39&J6>\=6T?3[V750]C+R7<4;W,[O$W,T:,
M]L!;F!%91S:@_095UD_DJ=Q/\078[_JI[:'_`)GYZ3WVTS[I9]5<?Y5^M_AE
M\#?SEVM]\[Z]T7TM],*W:*AU>TY6KJ%.5VTB*R]&,A++&H,,X.DY,E'4L$(V
MKVF*"R[EAQ"L8&(2SY%8\?VSS\^<ZO+'-J4LL3LS'.%#B:X#Z;'YL,%_)OQZ
MU72-<\7]=U;0;BWNM(GNPZ*6!UXZ)[>5&*L=?DWA%003.2ZH-.SE6S_.M7R%
M.$3A%JYVETU;M_UVJZN%D`(:B$CDPWLDF='23Z),($)E+J0*-7(9FN2)[KUR
MF0RJ9'QS*8;H9O.4N97A/.TTJ]AT^1]T\.=.&T8`:8D]HYB'4[-6TICF7V'P
M=WYHGAIJEYO"[BN9]QQ6[8K&.%[82U\TC1<S.G=%.&`6K9+<LY3C*VZ<`6Y2
M5JZ$Z_[[,ER;5_U[2W[I:=@=<;L4WVU9`3LNMO:7!:W%6\F`@-C7+<DW<G=?
MS/@XK>6(C;!Q3<B1Y$/-N]J_4-/9&#;R/$+(YFB+*>US"\M#C7+1N<5.)[%0
M.%/L&H>)GAM86,+]M:I?MT"STS7+2/1S!,&SC59KZ2VCF>7BVY-J+V+FR.SR
M.?:!T469T;F6+U=T5?Z*;U.1LNM:KJY.J]$%-3V.>".`RI3;!\J5H\V(5DMU
MZ`RTBO5G%0F/Q72#^9ZI)ES"66D^LI[CZK?V\\<K8I7R\VX$C000(P`X4%3Q
M=F`-!2C1B<*>6\8/$;;6XM.UJUTG5KW6#K.XX]1@9-%+''IL,<=VQT;3.\DS
MS]YB9(V!@A#+5A,CSRVLV,TQJS.KS>]%QA\,<&V'N1_8@1$:=(GR9;976^N`
MILB5>EK=E8)SK77R"U8<<<SEO*,XSA.4I3UM[=]Z9!4DOCAR'"G![R`/(&D+
MY9OW>/Y7Z?MULLKY;_2]!%C*7,#&M,=]?2Q,C#0&\MEO-"!E`&;,""02;TYP
M%\Z3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X1.$3A$X1.$3A$X1.$3A%U;>[QVSVGTUZNU':&I+?3=?'[+V1T)J,U?+UK
M2R[A!4NE[-N3=?M5H_!M3BP6TV^>#&N9D,08#WQ4A2/3;2I:L8YDP`FA6314
MXK2W7_NC7+743KM>MQ]E-:;[T/9JO[@NR]U[;IW4[;G6L@,J7537.H;/7:]6
MM8[5LY6XJ-CRMG)X?E80ZT<5*C,1D-J:RMS+*#@!C@K2O1BME8?O0:)*TH?-
M`:&[26C>4_:QO4?Y)-7IFNK#V$C&*YI\;V`-6%Z")VI*UH[48FFC,(RF6S97
M7'79;8]MI1+SQ$8Y#Y**93ZBJ]_WKA%3VAVD&7[J]V/SK35%NZ8:]TMBJ:RC
M?A7VA>>WE'A6.LU0I0+;=ZZ=!VN>9-18\49(A1'HD5M:YJFGU98;N3ACBF57
MX*]WC0<[;2]6%-4=BZO";L=EU4[M<_1*VSJ-'96CZBD[IO?5OZUP;O.D*W'4
M:J-G1)"L1/JZ^;'2A\4H_(:\JIE*9538_P!XS7N[J;79^J:GN[1)PQ<O;WM%
M?=WKI0"3SM#0?=W>8O5U2M=+#@]N1\#A5CG0R8=TD0E,3`;V$$4C2$?#;;UR
MD<?*F5;G=6_<`UWVVV!;ZEKC4O80/2@\>Y$-?[[N>MD"M%;O$Z]V',U9<2.L
M+N..&'<*'7*`ZB-$/1`A`K`3F=!8D1$N/(A;10BBZTK%[J6Z-=ND]2[*.:TK
M.WM6^YCN33FZK/)IY/`,%T'TGJ4WW)L>ZDUB.;E38IN;U<<#C69B%R&5GY:G
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MGV4/!+AI)"HA6VF$X9<C*4\YYG?/A*`;48<4`J,.*X"?>PZ\/*TN#A:6[+3=
MF[;L>ZJP4TPW5=;1=HZP)=>=MC-)[;AV4"3VK`AW@W6[R79],11I5L,S1V')
MC$1QAM2N7(?)1,I4*K7O+_+;ANFF[*ZH=AR%@#^X'?.CW7ZM:EJ%3LIK:A"E
MZISLIPG*R9V8*CP9S0H`3)D'W/@Q\`5.&9RI:_C%LLO4>A,OSE?,_P!WSJD$
MI%<V-9H6T:U3[!4N\=T45)U8.]D.'Z`7Z+KC<S9*&+LY&6\3L%EFM(K$:&B4
MX5PM.'/AG%);S,IX?-BF4JGK)[L]TD;6ZB:X!],NT&M4[_V9O#7NRH^[]:!:
M[;=:QM;:';VU7K4"8'['?IUUKLR.?@%B,P85)-PQ`XG$4A!9G$5-R\<4R^5<
M?4_O,Z;11^ML780?<FQY]UT]U.N>_.P]#TR/J^C]&&^W:(0O2CNXALG9-C,Z
M[7LHY)0XF`,=L[8&++CND);3#B'E"TU*937!2ESWM^K@N?M%=OUGV4HU,UE3
MNW=K8V99=<`,4G8TKH]=TT7L'5-<2`]X+FBQ^N$I,9Z,Y-A#QLMB1GPEI<8D
MH9F0IE*WQZE]H`?;C5.-KU_76QM:#_K`1K[8;8R*1+D$\0(HZ<S8JK:=97;8
MVN;O4"D4FW\,3#&IT;+[;S"\MOL.MHA%#10BBV<Y%$X1.$3A$X1.$3A$X1.$
M3A$X1.$3A$X1.$70[[KB8.=RZT5+U_;+<K&LG<)FU_KS)W#'BIS:B^?A7C;&
ME]F?*WO%.5_"_%Q_N58<]+[O"U>\VG*&6<K>8&$R\#(6?0CH$C*^L?/@OZ/_
M`!,'W`V'JS8=3L[$>^X[$VM#3"[][Q=H1'5+#F#HYG+?B"W/V<HZMO*&_P`2
M>R_T'"/^R?SU7/\`^>9]\'W9?L//??G!I/\`XM9_ZB7U`](<-)ZI:42R)G@F
MTU5W"1!2H+H4^#X&BN,M2:@NMT]0)><_=8:^6Q/%.<+PC.%>97R[6W9]5F=7
M,"[C7-T#I)<3ZY7\@OC"%[O&?<#GSQW+S>#VR.Y[XQ_M4>+;GGW/-ZLW/DH1
MES84&U7.J7QI.$3A%JAVS*;=DU.LZ]T='M;5]OIY]:[+5G!@]^HUNH#GK)/)
MO'+`IJNPL%ST<6(4Q(<P[*B$9'HIRIO.4]MI#+03.N+XL[O&W@ZIS.<:`4&)
MH,SJC@0*K[1X*V>R(M:N]S^(;K-VV]-MA2"X$CQ<SW+Q`R,10@S/Y<)N+D/8
M,L<D$7,(#@#J4&VOLN[78C9&)>[ZKMLI?.N*J9I]0Z^IUY!JA&N:Y8WN'L0B
M6&<I.*^#G.VK$HN^\U):D0VG(LCU,QT.]P^TMH+<1D0/M!'-FDJS/F!?RBT@
MYJD<NC0"*$U%*T^V7VR]I;?V_%I,C-O7FR8=-USO6IY[/OK[AD]\=(E@D;*+
MOG2L&G<NV8UT;F2O;-%E$KF6+U`M%T-&M9I1:]R6QB?HTD1[`M;1CW)T16=O
M-%:2FL1*_.N0B%D6?G-S+&B:+%O*@MQ8K#CC+2L1UO<;68H8V2]B%E)P(LF6
MKHZ.S$AIQ`HRCG"M2:'C3RWCCI&@6&GZN766@V4D6XF,T8Z>ZU$MQIACN^\.
MF9:R/YD+"VQ,5Q<,$KI))&L>\<QK++ZL6Z=<KAMXC%NFQ3E1B210L4(VE&.1
MK3*.PCUS38KZT+*5P`.I-:LF%QH(@'!QZ:1XIJ<ZS&=F90KC:M"V&"%I9&V8
M@DEE,H%&T94.)<X8ESCTN+02&U7DO&31+;0=#T.UFT_2K;7'LDDDET]T+K=L
M+X;7D69DCGF?=SP4DEN;N;M&:X?;LDE9`'#=3G1KX"G")PB<(G")PB<(G")P
MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G
M"+37O'U%7W-U-4M=0=O6W1EDH.ZM3[WI.RZ4`JEG.5^[Z>LK=JJSR`=V'%JT
M1B_-64*=;E1WFU83X92K&<XS0:*@T6J-]]J>=V$JP.N=ONWFW.RLL/0>V&KE
M60I0-.:S+OT?M70-?4@B,8CZSI]?!Q)VN9E"27#R\Q'779LQ:)7K,-MM8N:G
M`45S4X!5Z!]FA=/U_0OJ#VYNFL^QVM-I7?85-[%ZPZ_=:M=X"A=CZCB:0N6O
MX^FJEKL5K62&+4J"W,3/E,R2T>RXR29DHQX1<7/Y,$S8^16(KVEP*MP-;-E=
MF=SV(2N]]#]KF:U=XE4N!VT[4Z'PX`2KWRT;))CDVTR7VA6QC+%APXOR9F9<
MF,80XM*43-A3S^RF9>PM[2=.+[XM6QW^P.UL:7.;JVAVI!]8LAJ&NC57M=MS
M5Q[5-JW)%N?R!.Q"@YD;:")>#6I,]0F+8)CDO&%(REA+-A3I3-AY5X1?:)UQ
M%B:=BHW'?U8TYI;VZ-+BUK#5?/SH9[<^\)&\*2<)(^$PEHCLHM(S`,-M>#,>
M+CS1<(<^GC-^K[*9E<'3WH"0Z@78_(`]H-VWO18T?L$-H[K/84U41K'2XC9^
MSY>V;1YGZV)''=H'AEAFNP`).PO2980$ZY!:RO#BW<BZO1BH350W9GM,]=-O
M=P-]=N+X2MQ2?V*ZAV/J+?=;,28<*J(#W(4FH6O9H>6VPHG!V,6UK&BUW$KQ
M4EF!%1Y<>;]@'$"BN8THJ0&^S9)37I!:U]T]V7WL&/OW4.QT/L%9:'J%)6D4
MGI)83Y[2NMVJ`)JPVF'H+KUQ-.GB,QI4TP0(?$KRC#+;/+F\F"9O64L<]G76
M:Z7M"E?AHV(F+M#K'W;ZQSYV`U6^)%`>[G9(QV2M5I@H^#]%TW13AA8P8TYC
M,=^&C"Y"5.YSGDS)F6F'V?':>-[DNOI]2I&TJGU.H_=D+W++'"FW]%6+0%B.
M#^K!74MFO(*G0ZZ'[+!-R;"MS\*,]6Y>9E.$I;G$H\M:Y;;;.689?+16HIY:
M+LWWA[;M'WAV%LW88KLRY`3=FF=&YDBNBQ@%\3%5T;[`W#L%4VV9$R.Y-4F]
MF;BZ.)Y4KQ8B,H7'\KN<YY@#3!8@T6K?8/V0M?=@JD9U^;[!70=1;AO?LGNV
MY5PCJK2UYRF?V4VS'VP8EZR/7.HEK)IK:%"ELK&`;D!EL$V!S[B7FGW/3<;R
M#Z*YEL!5/;%`5;LM^'Y.\[Z5!CNX5J[GU351&NU%P57-BW_K18.ME]$+N'P>
M;:<!V`67C%V\RWEOPYD!*$+RAY]2YFPHI7"BUZ>]C?6ATA=PM[[([EN.ES=;
M[Q4V@Z;4%UX"'ZIKW?*WC-D;0<`W(376[=8+)6MBCDD@D\J_*3&;;9C+86VV
MYEZY^H8_Y%<WKJX(/MD;%G3]%W;9??#?.VMQ:8W;<=GKV'<*AK%(H[1;[I#\
MG^TZ4`ZW&`XE-UQ4BM&3F2[-$-((K/2IA)2\OR,>E,W4,$S>LJJ!^R-KZN1-
M74T-V3W#`TR,UUU`H'8[3[`'7J@?:9?1Z0/EZ,/6JPR0$BUZZD.K$0X]CCUR
M7$8.#X;+"L,Y2IU=S^O_`)4S*W'/:@IR!=/AB=][4K16E.^XA*"V@`)HJ3D0
MA[AVP,;#MT^.V:`&P67=9$4_#B69$*3%GQLJ1.:>PK..3-^I["9OU%=?M]]"
M*AT$U_LZHUJWIN!3<&V"6X+I*#:\HFFJ!`LD^L5BHYA:]TWK`:(H.O`SHNI1
MY,MF`QYIQ1^3+=5YGL(0<[,H35;\\Q43A$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X1=(7N@U[1)C;VNG]JZ/JFT3+6MW6AI@_N#<FNI(X9FSE%Y&L"];V<&*GL
M9E96[\1(;7(PI64>;R8QC'N]JR7[+.46D[XF<W$".)]3E&-7M)'F&"_H3\4#
M4_$:QV/JL>S=PWNCV#M5!DBATS2[YKY.[QCF&2^MYI&'+1N1C@R@S4S$E=:7
MU'Z<_FB:X_2A[4?C"YZ?GZU]V2_:+?ZQ?K/\H/'7\^-5_P##^WOP)?2;TRAU
M6!U?TY#I-7@4NJL5=Q`6KC+%8[;`#1?FY-68L:QVZ<2LA9O+V5K]26^XYC*L
MI\?+C&,?,M;=*[59G3O+YL^+B&M)P'0T!H]0+^4'CU/K-SXOZ]/N"\DO]9=>
M`RW$D$%L^5W*C[3H+9D<$9I098V-;A6E25L[SJE\B3A$X1:S]J=Z$]$:\'F*
ML.$'+Y:++#KE.!&T%WAQ!^+`(VBQ*EM`&WC"4,5*NSL,.-HRVD@Y&2[G"%Y\
M>STJP9?W)9*2V!K27$4J,0T<</2(KY*T7UOP;\.K/Q'W1+8ZQ+/;[<L[1T]U
M-%RP]@<]EO!E,Q$53<SPE[7',86REG::J89[6W4[)/[$J/U"*:4#7CKE6(`6
M4#L3.Q+.&W\`UA/:-#+&BUY!Q3(.=L]C+8I85S,E$-QE4AIU>%HYWO3`QK;>
M;F"]=',ZH(R-,1>*%N6M"&'M9L*@T(7O7^#&@:=#;;7UOWRAW_<:=KEP^5LT
M!L;>71IM088I(#;<YT4K-/?6X%TWEF5L@B>QI:Z7Z"WMM"[%-01-BM:]FQMW
MZ0,[B`XH8>P@Y],7725#BS@5B8.6FUMG1Q&/L.-\*394/\),-UM4;.'4*1IU
M"PM8&3&VY@,$XC.8@AU0^A%&MH1D-6FN!&.&/1>)7ASL_;]GKD^UCJD<NWMP
MQ:9-WR6"9ET)V7CF30&&WMS"]CK*3F0.$W8E8X2C(X.GNGMM7&V[(V;KZZ-5
M'*ZP$I=PJI6HL%&A9NMW,A<8>,#"!(H23;1X-5:98=,--"TOSW9#&(#2([;\
MCCWMI!#;17$&?M.<UP<14%H;Q``RUJ2&U=A0YC4@><WULK0M$VII&Y]`-]EO
M+BZM;B.Y,9DBGM66KO;&,CC[L^;GN>VV<ZX+(6Q2&Y>Z1T<6R?.L7R=.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$
M3A$X1.$3A$X1.$6CGN%;KW!UEZY%NS.J(,2S">OEA"[6WKKI8J'/.;'ZXU[$
MM.Y05&FS9HYD)L(#5I2SX=Y;V&94D/\``NX\DO*T5H!-"J!4T6A%(]UC9FHA
MD"J]J-*V"PVP$S!@;HV;0YU*!4/6N^MN:1MW;G4G5\-4)1A^Y6=JO:18%`9]
MRPWD>Y8GVEN)PRZ^Y$RRUX+++U+:X+[F^KIVF.T.\#%!NX6K]6M0:?V]9X"'
MP90S:H.Y.OM6W\!KM;98FLQ4&HD*V1PZU2W6(RIV,N>HF/\`MF)E-0.M3*</
M*J^O7NA6#3MDZV4G>'5*U:PN^\MF"M<6NI2=VZ5MAW7B+3MVG:<IMU"!Z?8#
M!S8E),G[O$E22&(@B..BMO-.+5.PS#>9:UH4RUX%3WI[[B[_`&ZSL"*.ZYW[
M7)8)I"C]@=8C++;J067MO7U_L>VZ.!=B2*_.ELT\L_=],E(N(Q#[KX.1$E*R
MGU7&6A;3IZ4(HM<&?>RIEPJ(:Q:4ZT[3V\6.P8TV'6H%MU_4W6WJ?UT"]E>Q
MH*49M!2&'CVCKU5[6&!D(&7/5)6DDF$SEMMB3)9N3K*9:<54\GWUF*BYL,]:
M>O=BM=++;K)"^O/U(L`&+9;KU\JO6+1/8:X7@F$)3II"7LMD7NL4L56F&6)!
M=XQ'@-Y:>A2WU,BN5;0]RO<,OO4[L?0&HFMB&TNN'Y(>R^PVY$5^16Z];J!7
MZ?N?15/D;28=MA$;,L,&L5/8<U;E:AM?'D'%84E;:F<)7`VH\M5`*CRJ^NLW
M?6N=GMG[$U+6];6NKV73U=N$G;KQDD%F1=>7:O;WVEI$)KTJB`ZJ1(-W!G41
M2S0EI2EO`)V(XOP7(3C`MH*J$476SI+WGMED]+::1;^OIS8^S+1IC5Q*W;5`
MFZ33];.;OW1U]W!O/5]3CTR8;^L[($VG3TP>3F-Y2R*5*C.8R]AQ6&\BT>HL
MBW'R+.4OWU@8^J!6-L]>KM]=JSU"KF^-PRZ(9KQ,,'V:1ZG.=N_J&)#8G3IT
M"HV36C+6(5AF2\0HALG$$O\`F>RM_$R>7"J9<<.M6R6]Y&-KZS3!N[.I>U=7
M5:I18#.TK@F^:SN::#:;)U<V+VXI]12"KQ=1"T3RNK]93F9LF&KX(<5D18_J
MO)<<=99*\"IEZE[^MGNI7SM-V%ZR:WI_78A2:'LP+V9>VZ8LMK!&)=7*:CJ>
MAKG0Y]#.#94(7>:N9$[NA1BKL.,\N*8<<AXSCY=+<=%H`XH6T"]VX?>8I.G+
M+NR,5ZZ;5-4#6A;>-%U_L(78J$A&Z=O]:9M0@[IUN!JLHRV<J2@SMJ=2)*E\
M,0#"Q,W&%1\?"JE`RO2F4JP.VGN%;-ZFD>JMBV%H5877]]U+V?W#V<$Q[=6;
M1==1#.OFCT;075ZK-'F1]?N9ATJZN*\]%]:._P"BG#2TI<]3$#0:]:`56HY7
MWMW!I2E[%+:M+U>B+U7NH+9=0SYP*62L'8$3V"Z@ZET\_5-T?VK5Y.JBXSL2
MX]/--QE1XWEDX6VI\?EEVY%<JO"M>\D`N!V@0A_63;@BG6")UR@;+V*:.4F'
M%TU<>TNS-JZ/U@$GU"82BVR]#5[;U6]&>)"HZHBPT^*4:RMI?I<9/+BIE52=
M9O>'VS<](:2K][ZJW*^=O=GTKK@4H])JUTUA4:SO.+NO36W]O2]DC#I(XY7]
M5A!P#K[:WW!!-UV<A:8#*,*7+7B,+,>."I;CAP5@)]\C4*D0[W^`;;2>O"Z>
M!L)3=BR=+PX)/VGIA8^[8&DJUTDPJT3"V=?4LL)F26U?`13;,="77H\G+[+(
M?5_X:*9?75F]8O<$V1VYV_UV54=;$M7ZR-#.UH+>-:L;,&VN8N>MP?6:UZC,
M4;9@;X<(9JY*O;BFIE.QV?(LFW(AJSZD!:EBV@*$4"[=N8+%.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$71-[JU#VM:]QZVFT$N6'#HNM'8LUF!W;U-UA9<FYM)
M9WU'*EL"@VTG87,,*1C!%AYMC&/VGR>=O*E>\VG<V\-G*V9K7$RUQMI)SZ(^
MB8YH'F./3TK^C/Q--R;-T78FK6^Y8();I^K!S2_:FI:^0WN\8H+FRO+:.`5K
M[0]KG_\`*9LK@!U>_@;[)?OFL?\`.X]:_P`2O/5=^L/I(_O"?W1?K_\`+SPI
M^X[3_P#C;7?_`-57TZ])A1T'U6TL)LTF1+/0:LZR2DR]FU_<DEY[YR46E;VS
MJL*"5ZX+])2?[9BQ&6T_\'X9RC.<_+M;>V359GL`#2[@&.C'`<&.)<WS''I7
M\BOC`WNG:CXRZ_>Z2QD>G27@+&ML)M+:!RHQ06%Q)+/;"H/M<DCG'TJT<`-I
MN=4OCB<(G"*E-X;!U_IRNQ-MW6MSK#.K,G(6N-UT'#.73"[2]#9-QZS'DR(;
MGD2)&JGD<-O(S\N'.KSA?IX1GG6-O<7DALX'!K7BKJDAO9X9N/2:##B1UKZ!
MX>[8W-OO5'[)T"[CM;>[9S9S/*Z*UI;AQB=<.:UPKS)!#`7-(Y\[&U;F+AK<
MFP]8*KM2:8$]<X*6J5;M:5B=O4#4]:.5:NV;:8FO3J).CY:LC=UQ$?9O\"+D
MK%$+9AYG_2ZF.EUU'9\O59K0,?<GML>X1%S\SFQDAP]'+7L$Y2ZIIPK0+ZL=
M,\7M9V;'8WNZI"_4+&_N&:1-<WXN)X-/DF9>,-8#:Y@;.:3N\ER'2B'!AE+&
M.DG6:V:+>*!F=<=?I6C)>U->KV#3"4RM:]%M[`H84@':E)A3J-9K*\/4`D7"
M`^L20^"=;01PXTTKRR/2U:I#?ACC<W(N!%)D<,SSD>0>(>UM:Y2,PKPH3PKU
M/BWHOB*RSN)-U;G9N*'1M4%E=1MGO9#97DK)2W.R[@@#^<VVF8+F'FM<82Q[
MQ6+/96D3>CIETW97-/TN#6R5/M(H;?C@JLP@0>U'"$.:6RX%(1LI<.P`Q&5.
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M=]6V@]R!U!IENLETUA1)E6MDT]96`U@IUYUX2I^NSY[74L_'IQ:X2]9W6:#%
M&"8ET_'%SWX#$E#2E-<5(P2I&"IHCKOVSNCW7[<-8C:^2KKYM?7^PF]ZJ%O;
M2W_7#-*T;J=NM6,!?+&0.7V8*^K^L1[0,:/<E,.K;CLPHJ/4:;0FU<X^57M.
M/E6$NG3[VJ=`P];62R42"+D4?;FH*,,*1]I[DLEH;VCM3=]3NVI9V[)K.P2-
M@N<J/N%D:8@$[LLB@-Z67FW&(R5XXJX\$JXK9;3(_I3IG:5HH>I8-=HUPU7U
MNT",,%%%#^*L/Z^6_8&[)^CQ<&VV$M+K!2))O2K8\RII]V=E<Q&'7%-N14XA
MJ>*AJ>*U3[H:C]J'K?JBJ4+L?IYT%KNZ[BW1O&"-UE7=XDRPJT7*$6.]EMLV
M<WIB0Y;:EJ:16[;)3=WILJ/5_DLU,.6RJ)EJ/BMS="HS="E[_6KVP=W]FMTZ
M'A4.`6WM10NFM\[<`TJX[8J`FMB[O0INFM?Q</4FW`:L('WG5.M(XXY68&&H
M!\#"&++PY36(2L*N`KT)4@54^.:T]N_W$JIK_M!=`5:V*`I8*>-!6:QVFY:^
M;!U%J^##1.L7ZL1K)5X<FG&KEKN#+D"K%$?'$DP&%.LNLX3C+M-P3$8*P.J_
M6.I=<;CVLV8;V%3[KL_MUOC&X]@'@5:&Z]$PQB:4#HNK:5`!(L]GDRODM&J.
M'7B+TQ3QHI)GSDM,(=PPU":^8*$U7"I737H)7D5*G4G7^MD_*GJ3/J-<AWHR
M7D+7HFEVS6%2<ACI-NG2"S%%IM^*C'D+2\WE$Y69>%NX;4E5R5*BX;VV?;V"
M3LT`=JT5\=C1,G3DVAR]P[3)NDM-S:<5U.E9VID=C2\FR4+7AF16(-HF1WCH
M\(I(V+/:BM-,HN9R5/%<_9>N>@+6\*[JW9%.IY7:NY)9_:&0Q218"XJ9(T/H
M)S3I$Q>6E%'ZT"A"M!;2?$MQBB&8A*#-=<])YYO+R%74KT*U=1274_3;I5K=
M_3]PU@"BHG::*6RU:MN"]U[)N1."YNRN!->G/C[-8MAGIMVKELKM1%#8`\N^
M1&,H#PDP66EPX^6Y4E2I6I7='7_M<]8[K8]M=D^O^P2)GM$DG6[E:*#J[LKM
M6E?'V&S:L$F)9F+JR,?H>F[7L^S"ZM$F%&6`I6V.P&&7WYF&5HQD,QP!5&8X
M!;;]XJMTQE5.F;$[C@1)X)KTW."T^-,EV=V=)>WFU!T%9@6:I52<25>:M:AV
MR&1Y@?,C3QB8SR),AI/H(=;Q%>A05Z%&A_0?H(2K:M<1Z.(LS0")=-?N2"6Y
M]E6S8@>?9[?K_;=E8>OY78I38\*_#[;J*MF81-1%)T&H'%5!D16FO+RYG<5<
MQ5;T7VU>F<3L\SN2.X&NI"BZNZ]!]1ZM=N=G*HUHQJ`MMXX`V0?4K8)&1MDA
M9S.UG"$(A:H1%V`6A?,(LE4UY;Z&8THA)HK,*^WQT"O-6D:H5JVL2!NOZSI:
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M\VFT.LY:R1,]M^B<`?1'_,R?/'FZ_P"B_P`3:QM[K8NK.FU/1K$C5@,MY,V-
M[OWO'VF@Z%JI+>BO.C%01R_HG=7_`-:#?^(WL=_U)F?[>O/5<MG^GM_JQ^"K
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MOI\7L.:-4EU#(>]6P@$LF=Q#7C.\`\2]SJ4S$Y108U(X4\]XMZOXD/LIV[KV
MRS;MOJ^J=\NGLM[R,WE[$R0-YC[N>X#.2VYF>VVAY+&F9SW1GVLLF'7G7/7"
MC6K:\K09J#+F39-8KUYKPBX3+*'J<NDX/A1PF'`DSI^`;S4K,YM]K#F?!]I:
M/!'DRC&G4;G4IXH1J#2``XM);E+@ZA)K05Z*>0KHO%#=7BKN+1M%A\2K>1D$
M;+B>TFEM6P2W+;ODROD<]K&<X%O)<QU/0<UU79JG:CG4KXVG")PB<(G")PB<
M(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")
MPB<(G"+1'W!.M.VNV^JM=:4UIL,5JROSM]:JOFX+G+&#+&:C:]U*8=V<*$U6
MGV.O6&GVTJ;VG5*VS*A&F\#%B?C/52]GRL.5I`-500.*ZO=3^T'V2U[:NN4(
MGM[65HU_HW\)5=M.3T(L])W-7=+7;:6SO;6-W&I!P00%#G:6N&\S+5C$Q'VH
M/P`8:U`=RC[EG(N&/S>=99@M=Z=[*';R/J'8%.+SNN%1-78%O9*05/LDB+3!
MMFVST6HO6-R6*%TG0.K*Q70\_8].=**C0P?JPPLEA#T@E.9>D/W.*]*N8*>W
M;VANVUOW5O?:9:N]/[)`O^T-=7#ZFD"$BM4;<@#5O>.M=F0HS9]8K/7]N7#E
MV'58]^O%99LA?"$LXN1)S(2.DH@,,PI3%3,**)6KV2^TA/6H84T6T242.&ZB
MG3=#L6V8*U:^T%OWN`V<IIP4<N.B=I@X6NM*C^WE>;J,N54)N9'U9=]*$'>Q
M`D1V<?-ZBN8=*[)>W?4[M[=>K?4KJQI!K4-_UO21E`K7;BN;>W'L:@$=W:]U
MA30`X7JR%LRNZNV+97ZEL2W#4O6V0_!BD#`>'F`IQ*"4M2,014DK$$5JLIU`
M]O?='6?O%V,[)VCL"/VKKW?NO',30<VAUVMW>-LHQNS8&Q\QRYL(/9R<JVN:
MG9F`0&4X\F0X-RU#7'88&0_.+@13I0FHHNOP)[+>Y:'3*C\AJG5R[S`8/K_8
M-MZ6LI(Z"U3VOOFI.R7:'9QP+N@LSK&P_,1\ND[P#/#2Y,(=6@R`8C2(*H+3
M2\99PKF%5D*E[17;^BOZHJ,.V:)M%*'#>I%COMK(V^^C3U3LO7"G]FZDYK'7
M-6=H1IJP:^'PMXB88`F0+#Y480"4P["\[C>6F<)F"G6F/:(VIH;L'[?6P]6U
MWKK1JYUXT7H.@[Z+BG(IA%JLNNZ/L8/M.=5]=6/2Y"="O5[M6P'ID"\@K;4)
M[Z)4]1X<66J/C`N!!\J9J@K99_HIO\A[M03NY/;TC&U)6)ECCCRM?<B@=L&Z
M;9NM`W5S58N`R%J5)VVF`.SA"YV)Q*]21*0K\1J$(B2HC[LF5&6BE1EHM/=N
M>TSVH/;X[#;,H0#I_.5>9G=DR!V7L')8_L7;@OMA^!F36=5[@K!O4MFJK-7T
MT(U\3KP5^=*M`YAAX?*P(PTS+@R:'"E,>A7-A14;5>@O8'0NZ.K>M:_2V;43
MU_5.SO93?E3JXNYDM-689IWL7M7LO[<^N)&X(>I]>TF3<QV\=L2X4P,%!LRF
M84!V5&%186(R%VH()^;RJUKQ^;K7?WN33VR>P3_2^98(M?K-9USN>I[[W[29
M!B=)?EEZ1JVZSJ%5`2XD!Z!86:IO\J!+K5)7&;RD&A]&5.)0VK6#2JPX+1/W
M&?;KW-VJ[$4K:>OPN@[2#;H&C:2HQN$O8AEST$4TYVTJG8>P7K2C0FC6YB98
M-NU`:[727A,!.-X&P<NORHV78^,FN`%%0:!=8VZ/;D[@Z1JN\MG#Q^O(?9?=
MV[^O@;K?*ZTTXZ<#Q]I%-G=HZ3M?85PK-%TIKP'I^B'>L?98J].*6$F;D1)8
MQ?S(_.><B(5D'`X="RJ"NSCJW[:6Q.L/N#'=V4"%JFK=:,:K_!]%'Y)QKIL.
MP11>LM(ZZI+`..:U*+N&GY0EK4N5'F85Z,5<TPW!5%"#Y?Q+W,2ZK:=*Q+JB
MG2L]TOZ&[\TKWL[.=FMLQ]&-4_=%9VA566=6YAC9=NR>[$']HT>Q6FE#]24M
MN*29UY9/EI>09L-Q+RS3,I],Y$*4S$C"X$4"$X477$+]A'LTTC<P>=V&I.*U
M;=/;YHVN(C$RU.+KUCK%8+=<^CCT]M8/#,(-4.GUQ/5VTN1\//-SI_FCM3&\
M9SFYQ\WLJYU85*]F;L$(V5U8O<Y_7@:O4*Z$+78Z")V["<;ZZ$,=J1?8=1W1
MAD/U1JL`DY<P@I(PH'JXW5L%,SP9<?EB'9$13,$S#U5?70/VL]X]1!&K*K>B
M.J]HQ:QV,UMV3*WUVU'F+Y73<;K5N+1=PUZ+DKUXC-QUYK>18A2:'!E/C<0A
M)8@TZMM<)K$^.<#P0NJN_OF"P3A$X1.$3A$X1.$3A$X1.$3A$X1.$71_[H@_
M6LS;NNE7;1O7[:<Y.MW,1"^W:P&.&AT3%G*Y^7#)!+LOI-UD7ZRE.^1(^8GU
M5JS\1C.<MI]MM>*1]I(YDLT=)/H#AP''VB7'_P"(>;I7]"OB?W&ZH=CZJ-`W
M#N;1[?WU&:/39Y8HGN[O'VY`S0=6!DI1M3-$<H`Y6&<]9OR+0/YGW2;_`#>U
M7_;\YZ;D3_=%WZ__`/AK]:=_\2/SX\0/ORX_]&KZ5.F+05GJ]IQNO5>I4L*F
ML._`5>B0HPZHAVE&":E1@<*)==C1X\53N5+SA)LCC+BU9]7QSY$_-M9:6:G,
MTN<XAW%W$X#CV&?L&^9?R>\>G7S_`!?UUVIWE[?WW?!GN+MSGW,IY4='2N=:
M6+BZE`*VD'9`&3I.SW.L7R).$3A%KIV&T>1W[#IE-F695<U[!-%CUX:'1!,X
M_8'6JZ2#5@-$BV0%8:UD4P1-N$)*Y$9;S<F!%4QX+\5H[+3KYNGN?.UN:X+0
M&UJ`,07&H(=6@H*'@35?4O##Q"M?#6>_UZ"T%WN>2WCAM"]TC(809V2W$KG0
M303\PLB;#&&/#7,FF$E6T:[7BM]9-](BDZC<[+K<V!M=VZ_7"W["9*VER^/N
MZ&%ZY@I6,K+U7CAF[!=9.KX<AX@LLE`]V?(RW&>])K"NQDU/3ZB6%LK9&1RM
M:RC<OMI><79B:-SD4RXT&(J5]1U7Q<\-W30ZWH-IJMOJ5EI^M6MM9&.W%F!K
M$E\^DEP+ATIAM6ZA*QL(MB9FPQ!TL>=]+$T%HC9]))ZBE['DZ_BQM'Z3,:>K
M::(3L)F;;\V(A1)).PV.4<KE80$A0X^O(F(HMAN?C#\IYQ<K]K;2KCZA?VL[
M9A;<PNGG$CLP`#:!U`T!SJUSFKC3``47EO$KQ'VAN"TUR':K-3?+N'<$6IS]
M\CAB9;<AEXV.&!L,]P97N=>R<RX>8>Q&QC8>TXB3=?-*W/4YZX/E"`<9428^
M'"$4RMV_8-M!2#R+7=+":V"F'L)^;(HI*R1+)%CR!`Z3,B8<B9=5)=\6DM:M
M1OH+QC`P.,H)JYS6--,K0&593.!0D.<`<:4&->I\3M_Z#O33;&.SBGFUN&5S
MI;J>VLK:9L)M[6"*RS608V[C@=!(]ES/'%)ED#!$RCR_:CG4KXVG")PB<(G"
M)PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<
M(G")PB<(G"+63M'V*8ZSU:DW<E7Y5BKY:\$05GBC,(=/QP(K5>S=B27ZS#?E
M0()`_(DT-F*PQ)D1XZL2594ZCPQGE`JJ!5:Z6CW(:F%D+!Q]0;&A6V#/K\0V
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M7,96MEQHE,:*+W'W+Z`%R[7X-'N`>]9$$7FQEEQ3"D(7:ZWL(=0+11;)'I]^
M*EA9"&0DN>B2PVL7);1EZ,]*2G#;C*4`7,J'N/U$LV+&$]9;%)V$J68I@^;6
M8%1BU<WM4Y89P>IZL"O6&_12Z#)9J+E62L]B$#1A&5O2H^7$LI95<JM>P=ZM
M1U'7FM-D6L#L``+VG5#UGKPF2&#2SS#]4-5T7::O.B"[#.BJLP&`=?*NM1GY
M+#@D00?:><^'\JYE*E%&"_N&:MK-7O!RUZ_VQ7SNN)0H;<*&Z-IA"SC2Y^J[
M&NP,4Q(%7>96"$DI6-<.R4+9(KCHR0B-K<2Y\2F.RE*%2?=7=BJ:#>;:OVJ]
ML8Q$UQ6[[9W0C%`+-54E<V+\FHZ\FJ1?FOFMR/&M;$QR%CL2P[,GT%O3FX[V
M'D@*H!51>=[@VO@LR&/LFK-O`9YF\`-;UF*_%U\1S8[G8=B6'2T41"?#[`(1
MH:&=W5MVK.29BXT;XJ3&FI6H6[F<VHE"KCIW:>@WS5&R-Q5D+<I]7U=`GR+'
M#P+'I/.DP5*%76V5D6-R7RF58Z@V4R,GQU.-X08BR(K:G%-^;*F-$IC15@![
M^ZBLEI"!1%:V#*K%IV,/U-4]E-P*RNEV>^E2P!D8,$91:E6)T82JEGA6*,36
M/;'R!#O@VZJ7C$7+*4HN9;^\50KX/39NNZJVWL3&[:G$N-<@56+08<L,**VV
M@T$$W95VV_5J%%EF+GLT1#0F*[+0PTX_)?6U'CK7Q1**O8?N=Z"D3"C;X'84
M09`JE<ML8WB)4",.;%M-7*'@PAZ,'N)`B#LI$S!C@8X\@S%DOF24-M*?2>P]
MBY2KE*L?=7;N?K@[,JM-TU>]B'`EPT=3[!(@3*,,!Q+'N.Y545#HS$L]=PDM
M5OS4K"HBQ)6SBOMN8;:D3VU*4G$`JH`H6/\`<7UJ=17OJSJW<-@DWM$R/K.#
M%@T*%)V`?K``!9MFUD7\WOP]D(3U@)L3>2#Q=8^#.=COH&/SLH3Y[E*44?\`
MM1M"K?C,1ZIM.2\0L<4<+@M`P'UA(5)T4P9?V0BH*LZ;?%JF!\R.]#0_!:(&
M6)33HV/+1ZV664IE*N#:/="H:POA'7KVMMGVPLU;*SK0#-K+%(2*MFV[5$U\
M8'ZV$OV&[`9$(G'K.SA1201(-0PK<7+Z,3%26%,9@%4HH_J?W!-*;>DWCY&'
MV"*"T#61#9Y^QFJ_$P*8@5RMT^S72O9P**E)C-EJ<2]065M.M(8(OMROE[LM
MN*ZYBEI"4(438[OVLT9W(^&TP=#`M'=:KIMZU5RYD*I%NA'8HV/'L=0H,4A7
M;J?KHV`9HJF2#DSPFL^8HRTMV,]%D,.,J44,%>Y[4PH*.YM74&RJU:R-HN,(
M`"K3%6L[5GIU2M^W@)>V`7(5M=E/JK,/4,U$^`^W')39[C*!D:8T^TYQE5HK
M2VSWZU_H?:5YI&VJI9P-2KN-3QZ[L(7\H+C+"2V)*:0:C31OS2(6`LT@-(6:
MF.O,Y;R$%DY2<YS$PVZ#:\%*5&"E-)[M42\!;K8(FO\`:8D;5-;6K:HGYL)K
M6)][JM`+3*WL!-7&#[7/FL&*A:H*QST0H@<Y+>RA<3XAE7J8F4I15A;O<:I4
M6&F5KO6=\OD&?L&JZWKEJ^(IX>F6:PV"VA(KC`:?+M.3,AA[61-RVC9BX+0T
MA`2TQB2W*>PRFY5<JQX7W+:$0!192-3[>/F)E;F&J^T#%T`=&V-]3ZC)N6TY
M-,CGMFLN"8E&"#WWU-''A[\[/E9A9EN^/&4J478J`-0[(!"6(?AY,`\(&FH*
M9*,-2$PRD-F=&P^VE;B6WL,OI\R<*5C"O''CGF*BR_")PB<(G")PB<(G"+HM
M]U&AGK7N#6\P3LW2](:C:U<C.#ME]QMP];RTQS%H+NYFCZQKAAT8='82YA&9
M[_[?ZN%-?UC:>>VVP]C;63-%<2>V<8XFR`8#`D\#\W2OZ*?$XW%IVC;&U6"]
MTC7]1>[5@X/L-LZ;KD;1W>(9'SWI#X7X$\EG8RD/XN*ZP/P-73\X#JC_`#I_
M:7_^"YZ;G0_<][]ZL_RK]>_EWH/YL;T__C[0/KE]-W2D5*"=6=,BIIRMV25#
MK#S;QRG[%L.V:T24HT5<P^(V+:THL-JC>5>$^O*QA:5IRWC[E">?-=8(.I2D
M->P9A@YN5PP'$#A^KQ7\CO'Z\AO_`!BUZ\@M[NTA?>`B&ZLH=.GC]JC&66RM
MZPV[L*Y(\""'G%Q6T?.M7Q].$3A%JGVOK.V-BU:L:LU0W.&R+B=D3K9<V;46
MHT:K5ZI#GS8Y";8`#V`T/*F;LD0VVPS#<3-@M36G%(;RK.>VTF6TMIG75W0A
MC:-;E#\Q<:'LD@$!N;$G`Y3Q7V;P7U;9>UM9N]X[S,<L5A;-9;6IMX[MUQ/<
MO$3SW::6&)\<5IWESGNE:8IG6[V!SP`M1PXO<MNNQ"TGM:;BK&^#M[ZXD@-@
MCO6H?K*FUZO5S7`_>L*810<9H\BFS)(>T-X'+8?EE<3F'&X^776W6NW<^SAM
MQ$R6%U@V.8$=DO<XEYB(%"[,*LQP#:&IH#7[=?7FP]#V]%H^FZMH5WX;VVG:
MY'-"X6[[^ZGGGOGZ0]C#";L736RZ>[GA[([<Q2,?+D8YC[$Z@5*YA#>M'D4_
M;U.9&Z-)"=_R-F2[6T+MVWGBM*<K4H&.MAJ>LL<%-PK$N67'L(A.19K+2GGL
MY:0QQ]9FA?'*,\+ZS@Q9,M6QT=4$M`H#5E&DUJ":#&OEO'+6]!U#3]68Z^T.
M_DEW%')HS;!MN9+;3!'=B=LS[:)@CBD+[$16TSS*)(I'B-@#W22OIC7]R5XI
ML!C;`P\HI-%U^39;&;CVD9'G[';L]_18X0)@W:K"$M0E(18R4T=%,08SL:0Q
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M*L&MUN+,NRR(07K2\YM<DN4VY+>*,S`$\*+2(V<S?!DXK(B2$1K/\M'R9:6E
M0&5*Y>TF*Q>O;G[95LKNO+.[1*C4Y<B4T]&`W.AW*,[3G26:1*A2[NZ2#+`C
MM>P9=H!0@9PF[]4VG)D:&*EXPYAG+M!7M!2S4]MZ![B&N=9*OKV*BOM;"-&:
MU1S=`OPUNPD6Z:#MA39,IPJ'CE:Z+M(R[21[4H\[!^L3'Q3#.)<21Y71S<4Q
MXJX9.U.DQQDY3)\NDNPM?O[2+2PY"GGH8N.R2<NPW:]BK.90&/`LE?)3OK#`
MG$A*I<"1-:G14NJ?:=;3.T%,5J>'W9[<EI+%-B6S3\"H*,9F&<$+7KNQS+0;
M(DQ@C9-@.9US711XU%?^"2Y-+%W(B,_#!?5?>S$CQW$Y4<KVEF=V[(]O.!J?
M:P6O*$-DPA`FMV)JG77SJW/V"$NRPB%EJC5@I9ZIF:TU)!F!DZS+:?K<-YJ5
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M6-X=--6`2-<JVUKRZ1VFQMMFQ[8CT8DF/&(VR9N[=MMVL^*D4(?0"JB=ZQ8A
M\2=!#$(4H]#0$6AU^.Y&PH24Q4]@4OV[!>L]>EI@G7_U-GZ<&Z[J)X\+,BR,
MB@Z=+4:AI'R&_@1<X!<:78&@L"1E3$(]"D1$M9PVF$M+#M53%2<3N#H5%I(8
MK"F4<)4--5FM@P<4C1[/7GJ!48Y`'<J;$AU\M7(!D4"F/T869%*Q'PS,C18<
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M&B,,/MQX-?\`6+2W71+*6Q4A^6^Z['6X\XI2I2I4O*:$TT:OZ]IEM<58CL%Q
M`'"K3+')>)8>K!8*;`3T>=68[9881K8Y2)J48EY;@1VE.9:9;0E4\$J5Z:GU
M\TG129<O4-95(!,/5J/3RV(`QM,*;68\$:,R'6+<RX,1%FC@L)B7Y&4KG-08
MR9&7<1V<(5*5*\*CUYTC0Z\3JM2UE5`P`W7R=5-CF1^)"#-<,O3'R84N],7)
ME$Q\K,]U&6WUN82SE+2?!I"$)5/%2JP<KJIUUFA`E=E:AIKH>N8CI"Q<P'$N
M0F6"=F,+BXF(?3.?A$"%T+KG,.N+9())RD24NMON)4J5:E9J]===%[.)E3.Q
M-4TBZ$C@UD07D60'$*X(CV*Q?*4TQ*9EH<CNJ34-GV`9ES*/45`+2&,JRVOR
MX5*E2LU6M,:JI]DNEOK%#K@6R;#0RU<RL*`A#QUEGUU9COMJRJ/'C27Y3K\A
MMA#3<J2ZM]["WE*7E4I50)WJ1UH=2/;SI6A-,B*-7=:B(T0,W"B":54<C<5<
M,+APUL11V:\T&B,PY+*$2X\>,VRAW#2,(PJ5:E0;;_1O0NV=;*UBS6H6NPJO
MB(V9E'K]0200&)(]$Z#C_66N6*%"B&&<(RMUAEJ2VZRTM#F,)4A;,>*5-:K;
M,2+A`Q0P*-:RP.#CX0N`QEQQW+,(?&;B16LNNJ6ZYEMAE./,K.59\/'.<YY%
M%D.$3A$X1.$3A$X1.$70G[L>PY]/W/K.%$^/RB5K!V4I,3?.J]4)RKZUEV?%
M0:^[CUN1)JQAO'C*9BOLX\<-^KYDJ0GWVTH.;92G+7VWCRG2?0CI:QU/,OZ1
M_$MVQ;ZYL+5KB81U9JX;VM'U#4?^KQ'[+9Z7?,CX_8W2,=]%DH0X]6/X<3?]
M@:_3+ZW_`.U1SUG<Q]+_`/VTON*_8WP>V/\`S'_A?7/_`$\OJ-Z.EW3W4_21
M=_+N79U4==7EZU`KNYG.#95O&56NLV*V@C?CA'CAV,1E(QC[G*\*3E*?E>N-
MR:M.VE*.X92WH'T)`(]9?Q]^,-9,T[QHW!9,H&1WH&%O-:#[%&?X//!;31<?
M1?!&>FE""=K>=2OC"<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<
M(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"*JMLZ;I>
MZ0P\#=VBCL`8Y:G(N!1)X8]A5QUO=]5&O4=92I2\*J>P2*6O_D<A3;N/NF\8
MY0:(M<R_M\]?2UPNMX2S;A9^_NV`E8Y8LP-:D.V8]93EH:M<,G*!S#D$H"F6
M!]J%&;EX$^@EKXB'(<9:=2S%7,5R"W0+K^:P*8FLW10V+5:I0;"'3:G<C+]0
M*;%J+0:DW5EV&Z]/`YG449,?^%<ARGWV7&U/?#294=YF*5*Y%,Z*ZDIMVH.P
M<6?:=HLVNK$4M`.;;[;!,.O%)U'$ZWAXE2VP,(E$@"*4#B0<18#\*.2;CM**
M(GK::4A4I58DY[?.D3TPE->/[6'O3B)-,?`F[(@H#4@Z2N)RP:G#X2(6J/KH
MZ?OA*:^RYETDAQQIIF:U&CQV&F8I5<H7[?N@!<UP@WB]RIBA=T!MO3+A(<S'
M#W>BF=;SQS"6HK",,C*<;<B0E*PIUKTFW%K<=3E:KF*5*CWV;?7>/"-P`LC8
M-6CFR!I;V:M8A8*5'K-J>-S+E0D3X5=1/GU6X$;!(D3ESG9A9*DL-QYK#$:.
MRTS%,Q4\VOTATUN:WV>XWB7=9TFR2*^<:!X-CI53KE[JL$$*K^R`%;,`RHWZ
MW#P]=CQ,HG)FB9$=3J7X3OJN95*G@E:+!1O;\T!$RVPS]>4!Y,`7!M%<3:O3
M`7E5<KN:_4)MJ@,CV\N2J<Z])(CL0EP64$9;CCK;K:66FF8I4J0U+H]H>BZ@
MMFD:M`M`RE72Y4R^'%YLTN><>L=&1KU(B0T5)-S%MQ9+NM(#TQC*%-2GWI;B
MT^>4[G*IK7I2IXKD,=+=-YTW=M'%WKO9:C?RE8)6$D;M3^;:MNC0:>'I`N#8
M1<89(@CJI7Z$*'QO(GUWF(ZURG9$F1)?>5-:I7&JA5H]N_K[<%F_GJ[U*B%2
M9B6/%8L<-(>J"#KNQ2<^G5D6H*N''J6;7M`F:1&E)EN-STQ6\._`Q(\-#,4S
M%22T].J580G7*@J<C2]<:+O1N_$H)B(G-AMY"=5KH(C#5R:_BOUX<%GV&[.E
M",1L?B$I<.,W%CQL-MJ:52J@\WVW]$E(Z8Y>S[C*XEPVAMH=F7].'[R.$5YB
MI4>%;7(H6-\6UKBMQTQ!&8V(J\X\79JIKZLNYN8I4J>;BZ=5+>>QFK->K9;/
MJ)C5#&MB&M09#(D7894(\5.!['82"$O2Y<BM2B*)`UMGX?T9K.'75/MY]'D!
MH,$K@L=:^A>C[J3.S[!.V1)AECR[0,`1KQ,'!*=87K*C83Y>HM#XT:>/EN;;
M@CKDG+TB2EBRAX,AG#;4?$?+,4JK&Z^:!:TDQ?)BSJYYK96S]G;0M$(2F1$J
M>#&P+6LM$^7#23Y,G'>"5^)"@^/Q6(ZEH>6VPREU+;8FJ$U6QW(HG")PB<(G
M")PB<(G")PB<(G")PB<(G")PB<(G"+IT]QU2$[3H/FT_J;8N?P?N_P#&FP.N
M-?W.3@?^D1'_`(O@GB]-LCXF#G_A,Q$NMHRXK+GD\59SGVFVOX))[=-'[9P9
M,8@>R,2`YM3Y:>1?NOXJK7.V;J5-=UO2O^\Q[79:Y-I<;_:&=M\,=U`)'_0\
MTM<<H#<U!1=>GJ-_FO=:?T$*5^*SGH_^U77WV[W1?J#EO_/#=O\`XONO_P!0
M7T%]2<XSUQU/G%=`5/'U<<\*Y5J;$U[7Q/\`QJ1_M873(`X1$K\?/]=Z*(S.
M,J5E7AXJ\<_.M8_G.;M.?VO2<[.3@.+B37SU7\Q_&T$>*NM`W5S>GO8]ON+I
MU[-)[6SM273Y)73.Z,YD<:`"N%%L7SK5\L3A$X14!#VZ9D]IK%H90L8FOAM`
M4S;K!I.97SETS9=BWVFRA;J<O9A?+(\*ILNMYPWAWU75^*LI\N,=@ZS8-*;J
M%3G=<.CIT4:QCJ^?M=:^ES[(L(O!VU\2!-,=3GW-=::8NSRA%!8V=TV089^8
MY]RYKJNRY6MH*U)O_G7KYHNO_JQV[N6^K)J0+8:O60K&P^I(GL*2>#+*J=@V
M,AL>32W`<+XZ9(1D(B"SAY.7,*?]7.?%?E^CGH=5T>+3XYGQN<XQWAA%:8@,
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M(<,_,#[=K1VLN5SJ@FA'YOK;QG4TS0\8.+&$T[8[`TK4)A1+,O"A@:S@;>6E
M%!OPKS.,DX[U<:2WAWSM>5Q7BG.?#.&GV;+QMP7DCDV[I!3I+2T4/DQ5\-MC
MV&]8-R2WTTT)T7;-UJ<7+R^V2V\UM&V.3,#[6X3N+LM'5`H>*=7=O&=[Z3K6
MS[`+&!BIL[L<4^.#YE*'LLTO9EPH\%UG,UZ1)]27`KC3SOBO./6<5Y?!/AC#
M5;-FGWSK5A):UK#4\>TQKCT#I<GC#L>P\./$"[VAIDTUQ9V]M8R!\N7.3=6%
MK=O!R!K:-?.YK:#T6BM34KU:QW$:O.\NS6K)XH7#$Z/-ZI&`24-4O)$PU?\`
M68N[D7"^'GG(R7(,^<IEGT4-XRRG'F\5>.>+JR9!86MVTDOG;(2.@9'EHIAT
M@>59[NV+I^W?#O:.\K:::2]W#;ZC)-&[+DB-G?R6C!%0!U'L8'/S$]HFE!@N
M3:=MF`/9+3FE(XL8\#V1J_=E[)EWLROFT`AK`WJ$8*A0$H>3#S#(M;%DJD9<
M0M?F8:\F4X\_FD5FR33)KXDYXI8F`=!#Q(23YL@ICTE:=&V38ZEX4:[X@2S3
M-U'2=8TJSCB&7EO9J$6IR2/?49LS#8QAF4@4>_,#A3BZ[W&;N78/L?J":*%Q
M`NEX.EI8,K%5+R4++V96+"<*I+8>>7$2D?(#H1']%",Y0M7G\V?#.+<V3(=.
MMKQI)?.9*CH&1P`IATUQQ*W;IV)I^@^&.U=\V\TS[_7Y-5;-&[+RXQ87$,,?
M+H`[MB4E^8G$#+057*ZX[;,;HH]GM)L6,$RP6Y][ZTCQA6968[PO5&W[GKH0
M0>^+>?<P0)C*TT_)PG.&\/N+\B4H\$XFI6;+*=D3"2'01/QZY(VO(X#`%U`M
M/BILFQV#N&ST?3YI9X;G0-'OW.DRYA)J.F6M]*P90!DCDG<R.HS9&C,2:DW[
MSKU\U77]K_MW<K?M[7VNIM7K,49;]^]SM239\597,Z*'ZT3Y,2KE(N'9BX_S
M.P(8QF?A:5-8SG]I2CGH;C1X8;.2Y#G%S+>VDIA2LXJ1PX#H]FJ_3&YO!#0=
M$V/J>Z;>\NWW=CMK:VI-8[EY'2Z\QKKB-U&AW+A)]IH0[Z<N6PG9G;9G2&I9
M>P@(L88)1[WIVJ)@E\RDP51-C[@HFN2<E68;S#_Q,`9:WGV/NO+Z[2//A2/,
MG/7:99LOKL6[R0WER.J./8C<\=?$MH?(OF7A)LFP\0][,VQJ4TT%H[3=3N<\
M67/FL=,O+Z-O:#AE?);M8_"N1SLI#J$>&SMNF:-N;K1K2`+&3!>[K1LH">(3
M%2L3P\>DZILU_@/",,O-QU/3"(-MA[UDN)PRM7EQA7AG"ULV3V5U=.)#H&,(
M'0<TC6&OJ'R*[1V18;BV%NW=MS--'>;>L[":%C<N25UWJ-O9O$E074:R4O;E
M+3G`K45"_.TFWC6B-'VS:5?%BS1:OE*%`C#3.9:1S[=LV)4Z;,6_F$]'D^>-
M"L#CK7E7C'JH3YO%/CC-TJS9?WS+20D-<'FHX]ECG=(/4KX/;'L/$?Q"LMGZ
MG--;V5S#>/<^++G!MK&YNF@9PYM'/A:UU1Z)-*&A30^WC.V"._81<6,&-ZD[
M`VW4(=8W,K*R@:O56CGHQ0G\4\]C!-^1:7D+PUY&O(VCP3C/FSEJ%FRS;;N:
M23-;MD->@N<X4&'#L_\`"GB/L>PV7:[:GL9IIG:WMFVU.429:1RSW%W"Z./*
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M^W(^O&PD%4V4ZVH,L:]E]67$J?\`7_85Y?HYV6JZ+#I\,TC'.<8KL1"M,08\
M]>'&N'5Y%]5\9/`K0?#71M=U'3;V\N)M*WE'HT8E$8#X7Z:Z],K\C0>:)!D%
M"&9.BN*["^>=7Y@6N_5'<9O?^A*-MJQ"A80Q:7K@U+&!52U#(V*Y>K-58V8R
MISTB5G+\0&VZYYEY_;%J\/!/AC'8ZM9,T_4)+.,ES&9<3Q[36NZ*=:^H^,^Q
M-/\`#/Q)U'9.ES37%C9MMBV27+S'<^TM[AV;(&MP=,6B@]$"M34K8CG7+Y<G
M")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+5WMAM.U:,H=?W&#1.)5JBW*
M$K9-6'CV2,VTU.TA3E,#PH+:8<HDS,';)L`";ER*I"OAHSZ5^+:E>%`K@J%U
MQ5CN9OBA7R&+WU<)=6UZ8V/JZK@-IW$#KFJ:Y-1-46)C3?9UV#96).'H@JV[
M%G1RT.058%YCPW,IA*<83Y^94'1Q5IU+UFNV^SOPT[#2WV$?')K%XJ'X$M30
M!VM7P.\:F<['6RHVV,EA^H3[M;`X74@QB4DJ#)Q<"8^,$Y3KC&%Y6IAP2BSF
MM-X]DMRV2AC+;=-W:8EGNQ=?M`<7"JNH!;-JZM[TH.S[_K07*^,JFPG/_0X]
MJB2%S/\`6%F%1U*^.90^^RM,H`E`%4KW;GL7)U0]='-Y&@V_LU4-$KFBVJ91
M'XUAUB:ZUXO9_L<BKR:DJTS9=7NRR9'!)J8W7(S]>0#?B9>?>2_E05\BM/66
MP,?LKO65HSL@YM.[S=1WC3&[.J^EKK>8(.L@A58BV8CU^@[:V12B-OKQ:MO4
MN[5J^3+".GSV)[`B*3]!Q6'8+B6Y05"E!50G4'83;.P>PX;75A[(RF==O#'A
M>KK,YL?0VM[+NRMSMK=BJ=7-G!J09TD;E;C+%@U/#--R*S*!"7<PVB#<1;,[
MRN*"E:*GA51X9V;[-Z\1K[,RY;:V34!(383V[=@62GZFDPJ^?VM;=C:NZ\LD
MGJ_7Z3.#1:=9M8#Y3C4$1/\`BD6=;T]Q$?$;"5`5*!2,SW#NASK,TMSL?2Z=
MN4%N!0[8,:;;]=ZQM@^CKK)\P""S+)9M>W^CZD(6&='AO"B-H#1A9UQG`A$V
M-(),2&V7'R)3'R*T=N=N=N5@IUH-U0?L&1KN/IRE[%[)'I=!I\'(MO?<)NAZ
MIFWH5*+/EJ43K5SCSCA$>#21])N'EB1E$7P>5`!ZJ`+3(#VB[9#PFLPVV=SF
M]6RK._K`Z9=V3LW06M2\P/:NNEIO<BUC-M&.O!'70ZA6^[P<Q!P)0>2;B%0!
M)E^:U'6PRK*@Z,5:#H79/O3LL=UQ9=W4VLWFN2+LWU+I&Q]#4Z>X!)6&WW9T
MAOOZWV&H`6$1"^RY(P%414UX;`0\A:(R<-M-_$YRO$"OKK$"OKK5![L;8&[=
M8*BKNO98?7`)"M1O77;&(&U%:S.Q=L#:5K`_$T2V2%:]31-A)%/V0J19$!1L
M8X<D(4$8?^(&R6U6GDQ5IZZYA;L5V%V=:=H"F+AN33U3LFT]4E^NEJK5+U>/
MCG]8BNPE*ZN[M%1%6RN;#*S(,[%E@VV,HP/'%(3YQ.&E.PHOERH!Y4I11+/8
M_840A=!=U[?O40?$[=E-16,]G:_6Z99->ZL!;;V_5(18Q0R&C1Z].*)P*D#B
M.$[#,,LD,S//'Q'7(1G"@IPZ$]19'L%VI[&53KWU9NX_9&*C:+=2][6.>9(S
M->:V>VJ_K]D6O413-?O6M[DQ8#>RJ^ZV7:I@5D%..OS\QHDN"E"<M@!4H`*K
M.ZT[?6D7;Y]EVCV&K8:NJ[6VJA6NOV_:.F<,T#6L6U]A0X*':M>1-<5*WZ.P
ME=4KL1,BP6$P]->4A"7DN.KRZ(ZAT)3YR_;=VKVQ7#5MN]>W$7MYJI6/?%VW
M-UZ'UZF%H>JNO.@[PS9:M90*!E7^N$%W;.I`\:/#(3YTYFT9MOQ@K#>(C'PZ
MG6E`IGK[>?:I&E.U9;8%CGJV#H:GUX%")8IH&'&G[`MOSG<R"HZ`P#;B$606
MHME4P+E"4NL9EP)*UXS(4[GD(%1U)05'4I!U/WIV$V?LTOI7;]B-Q)#FFML[
M%!WVOU4&$:-5>U;P?K&JS(R6^`FAH.P-7!X1,#/@NM.LR,P(95^*M!!O'!``
MJ$-`J%%]@.XU+JC#8JW'=LM3M3U.[V:W[%72:_8J21*=IR^KY<FL@*AIF&)N
M'KT03GQ'2%0/2RA3V'\J>3ENT;5*!;']--C;"WGI7;3]HW\2)7U^#'>R0IVS
M](7FV:REK=LJ\):I@#2P%K5I!YZ!Z.1-D:L;^,1U(];U&G5.0X'@AP5-UVY=
MD;#5-<BYG8_=$&?*K'MWV4Q9(-:TXR>+S>T-YN@7;T`AB3IR2&8@#1<6-@>B
M/#CNB\L(4XXYYE^>X5X#I3U%C+UV^MQ6H]?!0OLE4Z\=7LSL%4=XDL;;T?J0
MH'DT4Y:(-&K]Q/WG66R@55-/#!7JM"\B1\TKAA3J'<(:<PL!CP2BL#L]VIV%
MIGM]4!T?9/PFI`U*TO9+#1(IF@RR]LKMI*;Y8V"?":WD4.;L3861XZG"'I1,
M-8A42M1F53'XTIKU6'H`"/*@%0M6CO;#O0_7!X`HC:%+VCJZB[DV)MM*@FI@
M&*\#,V#KS:]6[#N5>C4[:S-TUGJBJ[6/"B0>O2(9XM`K$QY2TD,>",J-]1*!
M?02%-"+".9*@RPTX->=EQFR8B6Q-'OR1TR0-(-L28STAE2HA&(ZRXG"U90XV
MI.<^*<\UK%97A$X1.$3A$X1.$3A%T,>Z_HH-M3<VM#!$UH@8\-UBZ,:;VM1^
MW-I,.-9M1>4I8V7UY-#*Q'&Y6]X>G.2J?ZN%9QGTLHQCWVTK^>TLY61"8M,M
M3D-N!7*./.[5?-AZJ_I!\2_Q%O\`9NP]6L;2#<<L<NKB0G3KO;5O$#W>)M'M
MUJ*2X,E!QA(ART%,X=7JT_([K'[[>FW^:#W./ONYZKWYN_I;OZNR7[$^'36/
MN+??_P#LM@_@R^H?H_5HU)ZHZ3JL.35I<4+5'8K$FDC-@AJJZC)HJ]A049M6
M1+V%$BX]7PRDHXJ1E>%9QX(RC&/EFN2OGU:>63-G<['-DKP'')V/J</57\@/
MC":Q-N#QGW!K-PV\9-<7H<6W<EE+<`\J,>VR:<&V3G8<;<!E*`]H.*VKYU2^
M-)PB<(M$]_\`6C;>P]A[4V%J[8X[7QJZ=?M6:BK1=DE8A!T$;I&[K%L@\3<(
M@HJI$<67K!U4!OT'%/+=4M+B,-*\V>^T_5+2WMHK:ZC,D;+B20B@((=$&`4)
MI4.%<?4-5^C/#3Q:V3M?:^C;8WAI4NIV%AN;4=2GB,<$L,T5WI,%C#&&3.`=
M)%<0B8YVAH:&EKB\4&=%Z-WQ$V7&M,O;BY%4:[;V[<KM>^LMM<PYI8UUX=UH
M%U=\$Y'P/4@7LU>#OR_.?E;><?$(5F5]SS6Z_L#:F(0^V]S;'7*W[()LY?6M
M<6=G-Z712BZZ\\1/#B;:3]&@T0,UIVR;;2Q/R+84U6+6Q?RZAG#L]9+`=SY]
M.\.^Q.')Q6L%?Z&;WJ6MA-=J.UZO5+T$Z2#>M(BX5XK;A4H5?(6TL7E5I&DH
M(J,4B`<B<JCI<;\DSUE9QZ7DSYN=K+K]A-<F2:)SX'7QF+2&D%ICRY2":5KC
M3A3I7U[4_C(>'&M[LGU37-%O+W;MQX@OUZ6VFCMI&R6;]/[IW=\;Y'1NFYE'
MEIK%E'IYL%L.:ZU[8L&T8-R,[`&%JZ![H@.P]4"E"EBG.UO68SK'/T[-I`:-
M)A.PA1.3?BLHOB-'4B`IF0XZIS$A:D9ZZ/4[2.U,#(R)'61A<0`,SS.),Q-:
MD90&U..`%*8KY?8>+&R],V?)H-AIDT&J7.P9M$N)8XX&">_DU]FIMNY7->'R
M1MLXX[;.\&8.8Q@9RFAPIA73/LHJJ8<_#>.1MEGIQN7K[#V7BRWA=AA[%O\`
MM8+>JK<F+'D>D^V+`!Q"8ZWTKQ-:>0C#3:D8\V.;[]Z;S:<@]T[[',696T+&
M1ECFY:TJ2:TX'I*]Z/'GPG&M9?R>E.RG;[TO6GV'(M!`ZQL].EL[BU,&?DF2
M:64O#"#$YI<7N#C0VU;.L>WK9LY-M*;$%DZN*[9Z4WQ5`)8M99N:W2-=Z*9U
MU:ZR)AOP7H`LJ?O#LHJVU'4F(ZF2MUYQ+ZU)SQ(=4LX;7DLC(E=:2Q.(#>TY
M\N=KB:U(#:-J<12@%%XK1?%W8^B[0.B6>ES0ZQ-LK5='N9HXX&\^[O=7-];W
M$C@\/DCAM!';N<\&1I8UC&F-H*KFN]/>Q%1U7^#^J[F&UB6SUX[A:Z'R`%AN
M8L=`VUO;;<6_ZHV/';@P(SC4G7P=4N.[.2C!"(_)7B)A:%K5SD2ZSI\UWWB6
M$N'>+=YJUI)CBCR/9B3Z9H<O`@8T7JM4\<_"_6]Y?E-K.@RWD#MT;9OGMF@M
M9'OTW2--=9ZC8N+WN!;>RB)[823!(R-IG+7-:%,L=6-T0MHW2_A-F"A+=VWC
MU/V&;S!,6B$4,TG2&NA=-V-5SCL6`E)%RZ3(*G&8[CCD60RK'Q*D*\4\T^^U
MDZT9;/B)Y<%PP5#2`Z5Y<QPQPRUX\0>%5T)\9-A7&S[#;.H:3-.[3]O;CLHL
M\5N^.*[U:^DNK&XB#GDL%JUX#GM#9&/!Y0<,5@9O4G?LZ&&).[>&KOP'4/?S
M7P>ZO'K@\<$&NSFRP5NTJ3&&EP<E8D/5]>`1H<C+:T.PE1F404N-MIRG8W6+
M!I<P0GN[IK1Y;E;0B!A;("*T[9)(ZZDNH5V5OXV>&MO//:LT.4;:N=<V;>RV
M@AMA#)%H%A-;:K')$'\MSM0FFDE8""V4/>ZX+'N(.1@=4=WC+U:KM`VD*AS[
M?<.C!@Z0B&K7%,&Z_P!;_(SM\.:ELP$N$$[&A./M1V77'&9B'E)F9;2I7,':
MM8NMV0.B):QET`"UM`9OL9&.&0TJ>(^AJN+<^-'A[=[<L]OW.CS26UC8[NBA
M8Z*W=%%-KN.F2Q-+Z,-B\,<]S6AT1:#!F("](CJ?O:MP,#JOM@;6XKQ/O^<F
MQPAVVC(THYV@OLRXZ7,O1X4%AN03UEF>\J2^O'JPY#JU0E.>;*LU^KV$KLTL
M1<:6@%6M.$#,L@Q/!]!0=(]*BSOO&GPYU6Y[UK&BRW<S8=FPL=+#;2.;#M^S
M;:ZI$'/>2V._R-#&#LRL:T7`90!95GK?V81&FMN[V==??%=$XC#^;=>?,W-Z
M^W)XWV(EYSF-E2,[I!K3%4I/BHKX>0CY&_IY@=3TRH/(%*W7T+/^6;2'I_Y,
MX_YOT-5PY/%;PE=+&]FW`V-LV[W$=VM,6:U:B+1&^EC[U2@R`'"W]*US.P4<
M'],MG"[D&M<"ZU6"^&VYWNV1$DPY)]@C$9[2MD\T'$-YH6WEDM59$QMPBK"T
MI;4CQCK=SC'-KM;MGP.A<QY#H;5AJ!3VBF;IX.IAU]("[2Y\>MHW>@SZ+<Z?
M>21SZ)M"Q<US83&X[>,??,P,AK'<-81`""2#25K!5>LUU%[!6BC/U&U[B'6?
M+VI^A]95\]L%R*07-E=:]NM[#W/?'&9T"1_;VS1T2,TQ,\N9LV1'1\;Z:$)7
MA'K&GQ3\Z*$M]MNG8-:#DFCR1MP/!AKAP`/9JL]/\;_#+1]Q-UO1M"EL\NM;
MPN/:8;6-XL-=TTV6EV8+'M[%@]TCGQ5Y43'N[OF<XM4M3U=W+,V93[V=V4+,
M,TSL%V=V>"Q.,6><2"4/<6J#]!H%3".2X*D#WJ@3,)>>CM+;AQV,*^'4M?@G
M.KWULVVK[>.,@OMX&&@:`71R![W''',!QXD\:+I#XP;#@VE?;<T[29H'W^V-
M`L)LD5NR.6\TO48;R\N90U]7BYCB+6O<'2O?3FAK<17EDZ<]C;?JU-`M6ZAM
MGDO=:.JFL";U@L=U*#B6X-+[;>ONS=ERFIH^2M]^]!&XL9N>M&24IZ.A,K"&
MT)5SD1:UIT-WWB*$M`N9WBC6@B.2/(QF!^A-3E]$5PJ5Z?2O';PLT/>)W+HV
M@2V<3=V[BU",0P6D;X],U7319V%@TL>T`6<IDD=""((VO<82YSB%:U2ZS[9J
M6RY-L&;!%C:T:[?;7W]:`8HI8H:K%0KOU\>UA7:H6B,P68)0J&OC,,NME]2H
M;:(K;K;BI#:$\XLVJ6DUJ(7QDRMLXXFD@8.;+G+@:U`+:MJ,<2"*%>-UKQ:V
M7K6TF:+=Z9-+JUOL?3M&MY9(X'<B\M-:&H3W,;B\OCCELS+;![`)29',<T1.
M<52V.EO9;%;;DYWB-7MC/2[6_7:7LK-EO*;%+V14]K3;X?NCMCP/4?6*,")J
MHZ7U+S.<>4K#C>$9RK/-]^]-YF7D'NG?7S9,K:9'1A@;EK2H(K3AY5[[X??"
M;WV,0V]*-E_E]?:VVPY%IR&V-SIS+.&U$&?DB2*5H>6`<IK0"UQ<**]"76[:
MIO:`"Z&[\+,`JOW1D=A:X*)D[#.D`=7N]72.ET44*S*A.Q!A%%\+RBWPS*D#
M_0DNN^I\0XI&>`W4[5EHZ!D9:]]ER20`*OYXES''$90&U.-0!2F*^=6GBMLW
M3]H7.@:?ILT&HWFP6Z+/)''`QLVH#<#-5-Y*6O#I&&SBCMN8X&;/&QF7E-#A
MK;6>@N\Z;KL77ZKM.J5ZZ@^D=LZTAK8"*6X/*%[`.;8C;`'6T<1@"6BD$'#'
M,Y:4ZWG$U,C/W+64_=<[.7<-C/<&2:)SH77S9BTAIJP1Y"T@FA->CA3I7U?5
MOC*^'6O;IFU/6=&O;K;]QX@VVO2VTT=M*V2RBTYUD^V?&^0QOE<\Y@UU8BSB
M\'!;3%M';WF;,(VJ%MM<6IR>UU!W!%KOUEMK>(^FZ[H"%KFR:S^":CY'H2;V
M2PX<^7IS\L=ROUW%8DYRGG4LO[!MJ(G15F%H^.N5OV1TI>'UK7!G9S>D.`%%
M\=LO$3PY@VE%HT^B!^M,V7>:8Z?D6QS:I/K+[Z"_SEV<F*Q+;3G$=X;3E,!B
M`*L7JAIPYH'0=&U+9"@DT:JSUP=F$P?QGRN3BQWJS6J+B-\?'BR_%B&<;;<\
MS:?VU"O#Q3X9SQ]6O6:AJ$EY&"&/RX'CV6-;T$]2\MXT;[T[Q+\2M1WKI4,U
MO87C;4-CER\QO(L[>W=FR.<W%T3G"A/9(K0U"V)YUJ^6IPB<(G")PB<(G")P
MB<(G")PB<(G")PB<(G")PBI+?78S376.H#+WN^X_4RLF;+#IPB6U7K5:II2S
M3Q9@W&$#P5,!V(],DY#U^=*7EN*I#4>*XXM24ISGE`)X*@$\%.ZU?:'=ZY6[
M35K76['6;D(`':L7&E8,P=8`UJ&I,5L@+=0[E,R,=%*^(BY3X^NUC*D^.,9\
M)0J)-O5,'G1-=F&H3)4L!.V,=CTGW(*0-<6`;,3I1EIA8<6RS]98.6T29#*Y
M*'<J92XEIW*"*3LS8,B3*AQY<1Z9!3'S-BLR&7),-,M"G8N93"%J=CIDMHRI
MOSXQYTXSG'CCA%@"]QIX.O%[J4.B&*]7P1@\6.HD-2X\(`#9E3#,W+D/XAUV
M+!;'.J<PWA>?,RK'AE6/#A%Z@E\I-GK`"WAK.$(5:V!8E@KYCXYAF$7"3QV"
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M`(*UL&6FC849$B9/B"BMP%L27&FUHCJG,^IE.%XSR@$\$H59Z)HN8ZB,W+@2
MGG8;9!MA#\=]UV`XO*&IJ&DK4M<-;GT)<QC*,J^C&?'D15)"[#:*(ZO1NQK9
MM.9U8W`)DTWDD0;$AV1PFQ.5`E-4X61#D,1H]F9S`RM2$X5)RE"?'*T>-H:T
MZ4H>'2K141K[2/27.#-MQY_PGIJE0D(8*(RV_F-Y,KPEJ>A3Z%^3Z',97C/A
M]..1%AK-L*ATNKFKM:[A6J]4:U7CML.60J8@1`XJL5B.J38CLN<Z_AAH4$81
ME4I[Q\C/["LXSG&.$6=P1"N8A._&#?\`CB/F4/4MZ,E1*,W'1,6]%PM6%RFF
MHV4N*RG"L)1X*SX8X11XKL77P<U4*X8N%9@G;VY8OJ2*EEH*)MF73QCQFT+"
M,J=\TU-<%,K?F+;\4QF\>*\I\<>)%P0FS-:V:T6^F!+0")6BE2ZR/MHEI>,/
MCIEQKJ+=5XJWGFFXT]TS6\XFLXCK>\6<>;/AX9\%$H5Y2]FZW&7:K4"5:P,>
M[7P5:RU5"X?2J6?&Z^EU8?:UQ9#*%Q5+K\R]"VW&5NI>\9R/(A6//Y6*>52_
MYT'^C_C89],]8O']OQ?I)MO(C+'8_;?IGHD.);RS_P`)A:L)\/'/APB]R20Y
M;,F2F?"5'AOO1I;Z93&68LF,OTI$>2[ASR,/L.?<K0K.%)5]&<8SPB]3!D1)
M;R[&*C9#2?HRXQ.BNMXSZ$>5X96VZI./[6EM.?\`RMU"OV%8SDBC4C86OA]K
MKM)D6VLQ[E=%6G%:KF"D'YU8%T=F!(N.!\%MS,B4NL-%HRIV,8\8WQ#?G\,K
M3XD7&HVU-=[+K4:XT:WAK#6I9LQ6XY:+(RPPX?`6(E4BPC#<U$:0F=%L8>3$
MPWE&,N.-9RCS)RE65$HI7,G@X:W&R$T5$<RA,AU$R3#87E&76HR'W$O+3G*,
MOR$-X5GZ/.M*?'Q5C&2+R64#H>=;<(C$OQI44:\VN7%2]'FD<,JA0'4J<PMJ
M5.P\WEIK/@MW"D^7&?''"+!UV]U&U@<6<*9CN@U23<-4V>Q+"Y0_6YY`::0_
M%-QQ\UAN#*&/YRMQM*%LH]9&5-*2M1%Q)^RJ$)O%1UG.LXN->KT'LY^I5G"W
M'"!H+34@U64C&PPTXPU&%)LD'*LNK;\_Q"?3\W@KRJ=*+UZ_VEKS:E-!["U]
M;@]GIED@N$@IZ#(RW$G067$LO2$MRT1I+*67%)PO#C:%)\R?'&/-CQ<$4^X1
M.$3A$X1.$3A%3>R.O6C]P%1YS:.K*7?#`H?D2.(V4+%)RX0U4ER9F%'>?3E3
M<?,IY;GEQ]'F5G/.;;:C?V;#':ROC834AII4\*KW>U/$_P`0]C64NG;/UG4-
M-L9I>8]D$KHVODRAN=P'%V4`5Z@J\_(?ZA_FZZH_ZIC_`/\`<YR??W6/NF;Z
MHKU'RA?'#\Z=:^^7_P"5;"5&H5BA5L33Z6"&UFK@8V888"'C(AC!L7+KC^6(
M<9K&&V6LO/*5X8_HJSSKIII;B4S3N+I7'$G$GSKYCK>N:QN759]=U^YEN]8N
M7YI9I7%TDCJ`5<XXDT`'F"D?-2ZI.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A%J!W%ZQ5?M%7=.A+O<RE,I>L-Y`ML6EP':K=03-E$0:'L:A*J0Z_T2VTF
MUTQPO*V"TIR7$G)6]'9<B*0I$E7AFP.)RL!+CZJWVUO<74PM[2-\MPX&C6-+
MG&@)-&@$F@!)PP`)X!=<&Q_:%UJFSQFJ)L;3>K'IVT[;L.*+FZVC/V>H:GA5
M[KW7:H5U211>`Q&N;9Z[B-)X@5.UNMS8(&#;"B<P\+E.9>S:V5S<S6N+00*@
M&E36@KUGH'2N5;Z;J=W;NO+6VGEM&RLB<]D;W,$DE>7&7`$!\F5V1A.9^4Y0
M:%0"3[+A^VZY/C`?8_74L5<;_M/<XKY'JV5FAG'-R[#ZX;07JXO"B;`GQS^@
MJC^`MP)7![;F5PZX1C1\*7B%XR8[-&\L>"'@T(.!!'7U%:+JVNK"ZDLKZ*2&
M\B>6/CD:6/8]I(<U[7`.:X'`@@$'`A;=]5_;3+];-E;^M7X6@]DJ>Z-(4C4Z
MP*JA8GCKINJTL-3W+Q9[K9=@6.\258A"5M(&#R\&"ZW(R]Y69B,R'<"ZH7')
MJ%J36/9MV!K;75+K,SM'KL/2Z@#)#[JIW5$T9"#TZN[-?VM3X=7L#FQ83\=(
MV?.GY,%[*HV2EL+;2N2K+67E9M+GO#6`EY-`!B2>'!<BUM[F^N8[.RBDFO)7
MM8R-C2][WN-&M8UH+G.<2`&@$DF@7KUS[(M0,5V@$;5LK16PJ^)S4"`012](
MQHFHVPH8KHQ).71*_+OMJAB\[<J.FG'+0\U)?8,%[(0?7A4=U;#I^>-Y8\%K
MP:$'`@]1!ZEE>VE[IMW+I^HPRV]_"\LDCD:YDC'M-'->QP#FN:<"UP!!XA9J
M-[*92//JQ&5N+5UOLM;@ZD2]8;KIF0=LL61JK8/72X")@,N]>%D!&"\;31QA
M>5*<RU(*QW495B/(1)F;#A@N/V@T/(.0D@'H)''U145\XZU'J%[."=+XTG/L
M'8W44R/H:YU3:=O(7;79%;@2OZ]VUHK8[-_UY),[2Q`T_?-F0]!.0+L>2R]`
M*X)R%^AAUM]Z727%N:ARDTKT5ZO96PPW`MQ=F-_=7/+`^AR%X`);FI0N`<"6
MUJ`0>!"Y_9GHJ6WCL;M;V=ZO;>U+LS:=S%?6C2XS4S5*C;4J>[&:GUPH.K2V
MP-Q$=EYKAK3.H+SU[9N:0ZAT>5\8N6F/F3(2EB1B'4H#P6D'H*VLW_[75?W!
M0NI^N@Y^BC*_UQU(?TN4S<M=XNA&RU.R9TW*,2Q$[YV(6'+F)6H,,$%/IE-3
MH9F8EQ/FSC*H'4KY5*XU6)ZK>UK)ZT]HQ._6MLC[#70&N;11:[3(55+5V161
MQFP&'Q%*`285L<"1M4``$V.Y'"/0'VHYAG,F-\/A6$II=445)J*+6JU^RH`7
M6B,$YN?53UQ,ACX(2=NVJ8\V.2#QJ=<IK%0*Q9=T8G%J7#L\V-8"$!I]"%8&
M9>\$.H;?:S;G=Z+20.KRD#V3AZJY=M9WMZ'.LX996QY<V1KG9<[VQMS90:9G
MN:QM?2<YK1B0%CA?L]T.:SL3%D[(:MMK^RR_:1ZBS)=921S&NF]*':->U6^Y
MA3=ARQ1/:>LB^S_1R1',19TJ.P.9]5IY,=3.9CN!6K']D5.!P'''#`4!]8KG
M/V_N"+F"2PO&\A@?)6&0<MA:YX<_L]EI9&]P+J#*Q[JT::8J_P#LY:ULY:Y$
M!/9/40/6A>D]E=>`*6Y5H::IK![=#/8`S7053'C-@"P,6M1V]U/3+(%>9^&,
MXKL5]#3#B&WXCDW%<O+?FX^B:TP%>'7@MC=M[D,S;<:=?&X<S.&\B7,69FLS
M`9*EN=S69J4S.#:U("VK[0=!HO8[8&J;+'WMJ"AS]9:CJ>H;!"&T[$T]KPX#
M-%5CI.@B+=^&KU##VB?-8J]J@28Q!XY6(L<6AQMU'GSB(Y@T'(ZAJ0:&A`%3
MT8T&/FQ7&&B:V(63]SNN1*QSV.Y4F5[&,YCW-.6CFLC',<X&C6=LD-Q6,[*>
MVYKG9^B>KNAZ3M33FHT];=>;"TK"FJI05U+LN]:M!U,_]5QD2SA7*P9.V-@?
M(-Q5+DN$Q1>6P]XO2FW^&QS'M!CR"*\#PQQ\V!Q\AZEE#H>N3LYL%E=R1F(2
MU;#(X<HE])*AM,AY<E'^CV'X]DTH_'LX.,+U7<V.R%:<":?/U0Z:$1`M@C5<
M8]K8-38AN13[`O9BB5+L-4/:X<&B)3\Q;`0%/F0'6LL)5'7*29@S*<YI04Q-
M>&'36N'6N*;'4!=1V)@F[[+R\D>1W,?S0TQ964S.Y@<TQT!SAS2VH(5;]>/:
M+CP-;:6(;1W)HFJ;+!4;4MP'U"@U$*V$UW;69/2\=`V95"+&PC+,W:=RF=:R
M(XQ<QKC35C*V!#L9*$LK:E9F*<$]A]`X@X'B*DCAQ`Q(Z!Q7-?M_<#<Y=8WH
M;'-+$ZL,@RRPL,DT3NSA)%&"^1A[4;`7.`:"5.:M[/%7]#`XIV*TZ8)@3\B!
M4VJYKJ,/:A7X?$UR/JVXC(]_8IJ1)[5VAK51";;+)'<C22Y%276&8^8;F786
M3-%2QX;2O`\.OAPQ'KCK6$NB:W!'SIK*[9"8C+F=%(!RADK)4M`Y8YD?;]$9
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M`[>LB*KJ8_5AMJ$D[KV-N4JY;)6*V8V2L_8:IJ[#9@UZV19`U4"%7(2,,I4O
M"X]SJY^M;5]W_:SB=O+CM38;%[JE<MMY!]>*T%<L5!>LD>%6=.$-U2[54#LZ
M'8@QF95;U*VS"*?#0GH.6#=8&RG%/+884Q&NHH'45!77V7;+;&)X?\-FO&Q*
M-ZM[5:L;^I;)C:^PQ12-M!B9G>VS(VTVCVQ+UJU&S\M:^+LY'/U]@2QYEN.N
MY>89@F996Y^R^1L\&[-L=A<MYLE++IB5\C2)$ZI2]MD.Q:]J2=A6R"NT9?-Q
M+1I:`/UJ9A>*4R@R)#^%>+V8^&=,RN'JC[7A7K1V0IF[G=GTZW"Z;JTE16<.
M:\.-[5)/G=4=>=9/UXAM$Y?[%-EZDI2]`XGU@$]&>>&+/S$*EN93ZCL+JBB%
MU11:D5_V=MC:SL.B`(FQU>T`I6^J-+W-8==TT7JJH.=;]?@[9:KR(V>"+;"L
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MKJSF@RLSBK,SWL:Y["QXC+VYLKG-=HIV;Z8;NW3M$W9ZT*KT*`6I5Y#P[+;-
MBD3]C"?!-=F!L6D#UR0STR!1-W,;J#N2X3#V(@"$(5$4U)PQ$QGOM+UJQLK5
ML4I<7!["6M8`#]A.8T.+XN6ZA.+RZM14K]&>$?CWX?;!V?;Z1JTUU)<P7]I*
MZ"VL60P2YSH,CKMX;*&OO-).E70BE>TR7DMR)@^(R34P.[^L?=]_K)UNUKUQ
MF!=5W6L[FMVR+S&J.X;/1X6O*^=V#9]@U>B"G*XV'`[!I]:&G_D4P?/B21KB
M&6LLP7&_!V-T.J7,-U?OGC+GQD,&8BA<6L:TN(J:%Q!=QKCCBOS7XQ;ITK>7
MB)>Z_H\]Q=Z>Z&SA%S.PLFNG6EC;6DEW*PN>YK[J6!]PX.>Y]9.VXOS+%[?Z
ML^X#L_?-AW16]J7;6`J5:JR6JNL0?9R\,T2OB*K%ZN)B#9M/$#Q]0+L$RU5V
M++GM.0LMD$EF697K-N82UUX+0*+YB"%NMMP#N7L/I+85,,:@"U&S5K86HS8Z
MEV.\13U(W*$I9C6&VK-4I=A9J[*80"R2(Y"K/./CY$9;\=3KB5QUK;3S]*N8
MK.^;-*7-9D>W,T5<PO8YH>!45+20[B#AABOJ/@UN[2=D;_M]<UF6XMK%UG?6
MW>K=F>XLGWMC<6<5["S/&726DD[9PULC'G(>6YK\I&JQ?K=W7F&EOT&96NO]
M():ELD$1JO3VR2@&EZZM5EM-_+EA#4:`-&#I]I+.V844<L4$='7&(09+,5UB
M)E+,ST#-3T1L=)PZXG$S27R,!<]K6L`-34AHHX9"34$$@G$?I2R\5O`"#3Q'
MN1EWN;<,.MP/DU#4[".:ZOK>"WLXHY2Y[Y'LMXQ!<6[;*:=X?#+$^9DDP,D'
ML!]0^TH7:!6P-7>TO"9:F'5&G>PVQ8T^QAM=)[9MZ@H]O?C/.'YXZ-+O5"D$
M9?JNORFHLI+ZGUI<P_)-8TM]J(S&S,*X<IE`7\CF.;A0&C90!@!44I@L=1\<
M/!V_VA#IC]/LQ>LS#E#1;%S();[\G#J=W;!P$+'N;::PR"/*UD;I(3&(VEAC
MM/J+ULWA6"MK(]G_`)3>(5GU>]KMT=9[1)V?*D@GMFWZWQZI8)5G4:D'`T`'
M;TQ<8FRY^<HQEG*W&TISGA:WJ&G7,0AT]N5HDS&C0T'VMK20``!4MK@!UT7@
MO'[Q(\+MV:-;Z'X:0&WMH]4[U(UEI'9PN<=/L[225D438XV.EDMB]S60Q--<
M^1KG$+KW3[:G="D:IU=KG1=I"Z-8K76<94[4C2^TRFI'B.\:]4.XTT*6D%:2
M`%3C8=>T-@ZYF2W)"E,S6ACF)##K4=33_G\S:U/6ORU45Q5Q4#KY[DFC=_A]
MG%=@W;=6C];`]R8K&J7-[6(T9M88EL'>TNE4>YXM48HW<+&8!W>ES(9V<Q*G
MA45E<'Y@Q%2M@A*M(ITI4$45A=P^M_N%;)W[L"QZ`VV9IM#.ZAD@J47&[RLU
M($U5;FL]E5HW0LZI&!90>1?K+M>PURTC]@Y>R2"P0CD!KR(SZ,H"VF/%04Z5
M)]H=/.PVQ>HM?ZZRSX^P6X+OK<-K$;)V5L"W7>P@-1#]C;:L.GJQ+MDF4U=;
M*3O&L"X:BGG9,QU^-7BI/#KLM;:4/]SH6H6^FWCKJXS%F3+E:!B21B:@CL?9
M&X>FUO#BOT+\6WQ-VSX2[WN-W[G=>26?<'6[;:W9&[GNGFA;S9#*'1M.G@'4
MK8%CBZ^M+1H+!FD9`KETFW_=[1V/L,6DZKHK':*O5"EA8XZSD))#JP[3SFO4
MR-JU!8Q(D<;N%D;"KL?D$H%.(/54"EYY>,O/L]Q#K5A!%;1F25YM7.<26BD^
M8/[#J@D-%<G:S#*]]!P!^Z:%\8#PTV]H^U=+FU#6=1DV?=7-U*Y]NQK-PBZA
MO<NG7(DYCXK:`RBQK<FX:;/4=2+(V]B.3U,=+]^Q;$"NWX&M"S6*]U9=ZLO:
MF?M93%3LAMS7Q\+^'69+^"3%3CXJ9]6_@WXSYO%8+S\YEJ=\C*Z=9L#&Z'G3
M@NNN?GRC,T9@>5U_Y]00S.UO9Z5LD\>_#6;2[G;_`+_;DCDNMXC<(U$6T?>8
M(A>PR^]#6YLWHM[]S62,M._VUM[0&5>WEZZZ,[YI5EZGNE!.M[/#ZHV6RYLU
MMG6`UFQ=G8U[V(_/3?[3'?>E+&6W7<.1BY,LEI!7$BWMY1&=CMY2_P`QN-<L
M)HKL-=(UUVUN5N44ARLIE%`*M>?:SE#:,X@\%HW3\8GPXW!I.]&6D^JVD^]+
M2#N]LR&+D:`ZSL@PV=N6AHDMKYS?>MSK9EODTT@RLD<#&IAN;I_NN[[Q[)[*
M!TO5DT#OC6)#1U?'&;"38E4*2J#KV,WV.?;:2N#)MYK`QUB7#@M122(U.KOE
MFY5E[#&FSU>R@LK:V>^4202"0D`=K%_M/7E%<"26U?)V>OH]A^..P-O>'FT]
MIZAJ&L1ZEMS5V:M,^*",MO&Y[UQT,$T>VVBYC7QRS.D@+]3U2MN`&<RZZ)K7
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MX-#NW7`EE=;-FN)WS->(G6OK#J+V`UQM?0VU%:ZU233U_P!2.:8E5R#<R<!_
M;9QD;LGX/L&^2E19<`+;V991F*PR1BD2+3%TL:U2LY2RF1PKG5M/N;6>UYLH
M[Q+S*EH/+%6>U4P);@3V2UOM<>'5XK=_C=X9[JV7N39HU3683N;6QJC9WVL;
MVZ;$9+'-HK8VN:^6V+8W2/=!)!`Y^E:4T0@&0Q=PK2G%--J=;PTZIM"G&DK]
M3#;F4XRMO#F$IPYA"O''F\,>/AX^'/'GCAP7X8>&AY##5@)H:4J.@TQI7J7L
MX6*<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<
M(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")
MPB<(G")PB<(G")PB<(N/+EQ8$63.G28\*%"CO2YDR6\W'BQ(L=M3TB3)D/*0
MTQ'8:1E2UJSA*4XSG.<8QPBHI/:WJXK'F3V3T$K&?V,IW%KO.,__`%<6+PY:
M'J2A7E^57U>_.1T)_GAUY]\7%"BD53WWHN^&V*S1MT:FN=DE,R)$:OU/8U/L
M1N1'AM9?EOL"@YB9/>9BLIRMQ26\I0G'CG.,<4**V>1%4NQ-W:ZU5;=-4N\E
MI0<SON_3]8:T<^4DY8HM>H%'M>Q,5\@8B17AP*41J]))NP\S'&42WH_H-J4\
MM"%*(H71>VG7[8FGR>^:_L44UJT0`V7;Y]C-MRP2VJ3J.S6>IW>])#DV(YIZ
MF0"M0G*8)(CYBS(R$/,*<;=;4JD$&G2K0\%;]3O]+O(T$5J=F#FXEFJ8*]!$
MQ)C7QLZGV:*W,`6)(QW+9%D64CNXRTZXTA*L^*?Z[&<8BBA&L>P.I=O8O.*/
M;H<Y[7.S+IJ*W0R"'@L\;>:#;)='L`],$LB)*E0OK1"<BQ)C:%19RT_M"W,9
MQRD$*T*Y&T-Z:ST]!HY&\GU0H>Q-NT71=6>&P)QW$O9FQK!BKU<!+P'8F9&I
MD&\^B_(?]-B)G&<O*1C&<\`$J47OM&]-04V;1AUBV)5X,[9.QAVHZ/%;)LSW
M;!L@M72UM'5"*D?F7Z1>360<J=A#OIIQ':\V<X\R/,H44Q^NE.S%3.Q;*SF$
MLC(#HF?/A?PJRT26D?+%ID?%>DHC&GKPPXQC/JH>SA&4X5GPY$7[FZ4Y,.21
MS;*U@?#)1@TN?DZ+Q#BF)N8J88F3*S*]!@E+5.9PTPI6'7,O(\J<^=/B18&B
M;8UULTAL050K:)M!#4]\FZPV)&%NN.+JM]'`P-CGUDCE;;:?F$,/9H3KGIY6
MVE3V6\J]1#B$*(K#X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$6O';S&%=3NSZ5
M8\<*Z\;JQG&?V,XSK:RXSC_ZN.4<51Q7\ICNQW%[1U;MEONH5+>%WJ%0IE^F
M4^HU2IO"ZW6ZW6*U`'B`@80&#C(D&)%A0(J$YSA&7'5^9QQ2W%*5GD@"BW@"
MBU=_+@[A?G);8_ZQ?_RW+E"M`OIC_P!VFWOM[=O:NF1-OWLML=5)W0[+J!*U
M,C"!RN_6KJ1VS8LD(8>Q`:,-"3.*]!6]$R\J/EZ*AS",+\<YUR"@P6#Q@OZ%
MO-"TK1#W'NMFT^T'5\Y4.OUGK5&[*42ZZ\W+UQO=P=(,5FH;@UG:AYL*2-O"
M1Y4D@22"9(BY7HQW5JC$',>7.,YQF@T/D5!H5U!&_9$V5%M,^B5"!U^=U@SK
M5`(!OBSDK',WPW68?M]%NG6>IY6M9HTL5)T+8]L3\;(GR<',L_&NO?\`%+A'
MTYV,\XX]/_"LLRN7HW[8&^-"]QZEV)V((U/6J^(U>%@MQ-8;$;?S5'<];-,Z
M,EZ`'UYOK_4#EIU;5[/K.98QLF7:F`S3LJ,[&K\8AB9+?CG`BBA((6LO8GVU
MMM:UG]T^R%HJNLA(QB1W>W9K.]:%"[)VCV3W/M;>6[=0[5ZBT:^:[JVKFC$F
M'HK9>IQD^.N.3-1V9!#'I-P([)":[0[@`J#P"[&`W1O;Y?H]T@U6_+K0_<5!
M[&Z&[;]B9%DES(+)'8DS9I/>_8EL8\,@&ES34K8%R*-CT.Y2RXA*$K?;3C&>
M2HJ>I2HKY%H[4/91V=KD%H:/4:MUM9*Z]9Z#DK6MB41@>7:.F-$=I=+=@-W@
M)JM=2ES=BQ2^Z*Q9`4Y]MB>>D55EF7('K8B/(N<>7I5S53JS[*VU==1]$Q]P
M`M'FQ^IKAL:S&*T_:F+Y53%V9ZD5?0>O-VURMQ-!ZMK8&\'MA5_Y_.^(ASC,
M3X>%/E&"IEIR3D7CH0N'0JWNWL6;RCZ@J%"U]$T/\I%TWJI&OVJ8=I33J;M#
M:%`Z;[=ZV;;VD=,GM";5#HMH^[7L8?&F'JW*.E&(C[S<L25:@RFP>*JY@NY[
MH+U(M'4LYVT'G:_KO`?;V\Z_M6I[#JY.1.OE[@/Z5UE2S[>UVI=1!R,601=:
M>3EMS%$"F2F2SLI>(SSCJ%XN-:+`FJ[%>8J)PB<(G")PB<(G")PB<(G")PB<
M(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")
MPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PBH#MA$ES^K796#`B2I\^;H#<<2%!A1W9<V;+DZZL;,:)$BL(<?DRI#RT
MH;;0E2UKSC&,9SGE'%4<5_+:[<>WSV%VCV7W/L[7;VJ;/1MC7)^[U8QC:5<`
MR7A%D'CR;$4H#LV0QP,9&*?5&F19$="F9+2TXRM.,*SR`X4Q6X$`46NOV8';
M?_\`HVK?\\^O_P#SKRY@KF"^C/\`W<SJWM#KCVQHR-FN5'!FZ;6(DQ=?IME8
MO,\?6J;U9[-BS%JLLVNQY8.N!73M\&#XF94M#TJ6_E*$?1C*M<AJ,%@\U"^_
MOFE:DX1:4[:WSM"B`=C6*\4X;HRBT'LKUXI%8V@?O5./@]F:7N=VT]!V#?R<
M5;+*-7#8KMM-`76BCF)+.!^9Z'6T.M93:!6BU=VE[DEDK%@O<6EB]*%*F,7;
MG@5U.7DRH#3@-(K(ZS![?MP@!@380RK]BL$$PM?2X3F69KZFU^>7E>647*J`
MIWOWOC>-2NU==?U[3#CIS2-6V8S4S%E-0+;9S%UK6RS/C3&(`:;\=3=5R=>Q
MU6N7EAQ^/"-QW,(96EEN8`!0"J\-K=O=U:_U[I6\RAFM1)"=N??NH-J0)KAY
MFFSYNL5;8J`.QASTUA1>OU5DS2&[.1PXT]*0$B2FD+5Y,O\`%`3@E%'=K=L>
MP)&H=5S>K9VLZR4W-9+34R:Y\8C8*G;C5?WGJS7U<-T<PY&^/=HEVJTXT=8\
MC3DQ^O2$OL.X4Q\3B@"IJE`IAUS[O;&WCLFX:^/:S!TM%<U<0L3DN'8X$PXQ
M90=?UJ0EFFZW/)(LS^O+44V!)CA9KXF*WXA5X4_)<?<:A0BBA%`M66_<2[,@
M]9:TMQ:F4XM'0)KI<O(9:+(M^R&JEK6!)O`&5!R('URJ6?9VP+.-;!Y@I<9A
M9;<8RV^N0TANY0LJ!6/`]P7L;8@;Y6M:LTQ)8%"Y6)1AZYF306RD!E?[/WF8
M:K4RAO7`"BNS:QUNS"8:06(/-%C>/4=RW$\DIE"E`I=I#O7MG=^]=<U%ZGU7
M7%$*[+V%6#XXB5%F+F[%&T?<<VJTXQ#@FYTRH7MDCJU!QUN;&@.S1,WTV8OI
MQ\RY4+0`A``4*">Y=M.T6&Y0ZKJNCV(%1+,^4*3(A>RME#.N\6S7M49`U\4W
M%FRXVRL2;JZO*3+0A6%1L(>&QO-Y^7**)E4XU[W9VD9TQMW;A:9J&2Y'W=JF
MD5Z<HN41J33-<O>I=/V8XULZRQ1\<Y\91;-;)\`SES*<L&G$QUJB-X4Q&$"M
M$(7(UGWLV=N.@[?*!:I0J[9@O6*Y;>J$$64.VHM1;<`J8.77(^S0\D4,RX"V
M=/L>#-4]),=XB`'O+RA:U94W"`$HKCZ>]K[7V$-68!81E*=0`J04[@M2"TTE
M($S%VBUTQP9?(C[.(80M=V:DFT@FF',X<KY-KZ'$-MS)<(HH11;Z\BB<(G")
MPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")P
MB<(G")PB<(G"+0#W'[^*JNC*C0[#?X.J*GV'W?K+0-ZV60LT6FL5#6]PEDCN
MSELVN9*A1ZZ4M&O*F4`P9V7FEQ)Q9EYM6'$(\<F\51Q731<NM?7F8<V`]0>V
M?M65VID-R1#>O09ZX:H.V0!JEI]6?D4NVQXHT6T,;C92F37G@94S/RA7HW4;
MY\*;SJ>HK*OD-5@CG673\AN\X%=R?:3961O@(E5?@RNM`:HE3C_\J1`SI,E?
M$44&YXX^(KY1J^E2/ESZ%L$>?'IJGJ*M?(5)C0'K_P!9ZIMCL;4NT'1HWNG3
MFR-9;>T#!Z[;*H=*S9J369'RW<VEI6M8YPY:?E>W*$7)"F1DZV7F0HF['FL2
MH[C+$9#$X4-%..&-%]1O-2P3A%3&_MZZZZX:U);6VQ)GCJ`)*UT.>,0A;A5@
M+]:3D&N#")9EK.%1P^#!..T\_P""DM>JG.<>'CG%`K@%0*KJVV#[JGMH;EIP
M"O[`<OIJJWWY,2I41='MX!V\R/P?W.U_+J[,!$A166Z/>KT^FDH;CK36;+/;
M!/I7F;Y%Y97!7*5L7JSW0^F.RI6PPM-.V&"O0NK;GLO9<6?0B(EK6-#UO2Z!
M:[BDHRVVYF&[7F+M'$NPXJ'58,BB$%.,N0'?"%I"E"H3!]X;J.:'!2$0'NTA
M")5@W9"CD/5CIB-4Y(>'O"9BK6&6*+D(#EJ.0>O=I<@,CG2$>4U$;5A_"9#>
M5,I5RE<Z1[L762!>@]<SD^3J5MNFNM<ZQM@(!(6-L=DNM[WIKK)S!4O\EJ$:
MA.%-(3L!ID8G)('$>IB'"<_:</,I4RE8\7[N'6N$*S/MXB_MEFA4EF>4H]`L
MEEJ,V[L3)4X7IH#8)X\`2+;4FT=;=A0,7"98P-=4I,C+N/34R%7*5^'/>-ZB
MUX,LV<#;L'#(?U0C%7IVL%16@MJLS-]*OT68[*-,QI%XIX+5%D)E(,-<E2(P
M5Q,54J1(@,2V0IE*YTWW>.I(AJPL,!=V2Y``D=8"!A&I";Q"]U&F$]QB]A;,
MU]`3,:R<UQKI6@K:Z6FJ^'>0T+Q\/'D+EP4260IE*B%M]Y#KC4+`>F.:PW:0
MU""K&T[+)WG#I(^'3+`8U=NC6>@9K-768,#,S:W.M^PTLJLQ%X6&B-P_VU_#
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M$^'D6R]76KE^>KFT3W_VQLG<VN:5L'055H.O-I[(VWUZKM@$[4F6?8`?L)U\
MUX6NVW!5KHS]$"#!^N,DJ99A08FP6D$'G`\=^5!C-DFDL0M`"E,/*NU+F*Q3
MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A%C2H80=AJ'G!0TS`6M#JH)6#%(PU.-YSEMQ4:6T\SE;><_
M<Y\OCC^APBB_X+]:?XNZ+_U2`?\`F_A*E/P7ZT_Q=T7_`*I`/_-_"5*\V]9Z
MX9<0ZUK^D-.M+2XTZW5`*'&W$*PI"T+3`PI"T*QC.,XSXXSPBF_")PBJS=E!
MU)M'5ERH&]P]9/ZDLPYB%=@]QEH@UJ:.;(0YD9!68Y+@IC--DXS"T+]9O.'4
MI\,^/ARBM<.*#R+7-/1KH>5%:Y/-:0U)/!4`@;L>LS$=W+X<'.MN]:_V;-$0
M,]DJJ"Z@MO2IP+)G[IQKXN-Y$8Q'6XRMF<K4J1#NA73T69NUB%:&I8XMLQP^
MYL&8/48B)O#%MN^P]D6<=:(\<JW#.@K%=MKV`A-'R&W(,IPCE+C2FVF$-,Q2
MI7)J/2?J?KM53;`:L#Q95:?`IK4H[9K?9BRI583MU\%B23MME,E+#('L;LMV
M$_&NRE+8+/(7YFVF4LJE*E1Z3[=/2N56J33%:#K,:I:\K6LZ75*T-+VX2#AT
MW3[UIDZ\J!`8+L4.)8JL"D70HXX.)(EPYZY>53&Y&4-Y0S%*E>Q/MY]+_GR;
M$G1%8R78"1P"58+6S,)J-&.-V..1^3?6'(=-I1+;2S@U\/\`.,C,?+_BO@/[
M6XS%*E9(MT(ZC&P96N3M,"$BC5U$[$(('6"Z!IR[F%Q;VH1R.8#V2`8@/.0K
M^;AR6H[[3$T>6E1)*'8SRVLLQ2I525CVJ^F0NK6VN6S6B]B3;SL2V[%LMGL=
MDMD$_(FVF\[9N?U<%2:X?#HK%+B1MTV`3)#BTPQAH<2E(*,3%3):GKF*9BK2
MM'1_I[>V8-<*:R$)^0Q-G,P!]5N]XID\7`W'L$'M;9#3"J3;@)"-#L.P1,$I
MA/FPB$^E*8OH-K4A4S$)4A>LGT%Z9NN50D8TE550M>5\A6*[`GF+/BIBJ;-J
MPNG+J$VL/V'%5*4D6`#L)'B9T60,%2?4EPV6);[S[BI2I2O>WOTYJPJ&&#Z0
M")BPVL-_$DK!=3IH@I,NXS4RCMB.V8E8+&1P[?BR/BI\F3)]"2EGU/18CH:9
MBF8K)(Z/=018ZIBG=,4[$&HD]6S:>V5F&9K@<UI_:MFW-JR8*DDS$B4DK5MI
M7<H3C.X7EYUP@ZP[ER.OT>*E*E8$+[<W2<#2KKKF!U^J;E(V%<]>7ZTULL1M
M1\?*L&H[8S>=7-#$GK`2=K=8U[:F<RPP(8J&#'*=>0Q$0W(?0XS$I4JR*]U$
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MBG2-R'+O!VMV`Z^W^G`CU7UE'@:)UW0;[I4I<:M4VS%3.!+PQA%#+'VDV6"4
MQ(GD%15-K9PC&:#0J@T*U=W%U,[/68Y8*-69LT[JZ`PTP(=.7.K5^E'ZO$HF
MO0U3!A=4U8:$JM#O8"]#K04+$AP43$G12[32%R&\MQ!=J%:A8,_H[W,(HJ?+
MUOL$@)LHXNUDC!MVVFR]8O1FME+OLINS5"%F.7;H&O;W-J%'HR@.&8*AX<J<
MD)BH5A4B?:M2H5F[WZA;IO\`LS31X58;G/S2M)!:V:V*(V\;I1]&Q*13]Q1A
MIG+`XE#F*,6BWWT<\Z0CMYRY$9E1Y2L1E89>@(HE119G5^I>[<+77:N!L[8-
MP(WV[5Z9'UR3`7$'$9:M+YC8,Q!O6"YQXS&H[**D5`#<1ELU>'F<.5EN/&<]
M0U+5%0I@M;QW7CW`JR8;MS%@ME:P4E@;A<_J[M0I;'I5D!:VTA4X\\R-LFQ3
M<Z?"B5G7%A'3A6?K>AXH:8<8S.>P@Y!M6JU"M;K+KKNS'O?7:^7"7L^-K.2"
M^+N%)VCN65:R=8@EM3"6#DZW>E9&BE@NQW;")1$;!G0K!"@#)J8[?U;>A>C)
MA+4-*>5<B=K3W!1)FX2P<^U&(Q^=::U*1,W2*Q%>L-BLEWGCMTTZ&2D/MTC7
M->I;M?&-UJ*B+-8G1W7&1Z\^M.F.RE0JFI'2SMW5QN``(W8Z$$;&WE$J16MV
M3H%K+GQ.G7:WKJ=*N$&3(LSX,CLJO")F8KLS"$P&VFY;/IH=C<M0E0OVY]9_
M<#NE6V56[Y9K=?AUQ.66-+KHG;D"D`2!@O-NKU-NPIW-F*.Q]458`0%P#55S
M'$1",AA"T`Y*X[DZ>!:E0MJ]U:>[57??!%VI6V]U[59FR:UP3-US<4NI"6M-
MQIVMV+]K\#4A4F.7`;2>,C3YC-FBMLRW`LO`]HAA:D1V8"**5%%7^S.IV]MI
MM=*V[B2M1(OK:IQJYN:VA=Q&JP;'RQ^SM`W+)YLF&)BR)^Q$@VM2+6"T3&2:
M)2\*]5O+ZG4@0*JU&*SNB=1]X@J][*W#L6TEB-DTS*`4J8.N@3`Y-\?K4"+5
M2E07-F62+5;/5,LR8Y(A\A$P9I%[$QUDO]R\RJ.A"1T*CZ_HWW(,.CGCMTNC
M0B%1(HOZOB]LO1B16LP;18'+143!LQM:YR@FZ;X#D1GQQN/++_(G5-L-VIB/
M&RP_:M2H5B1]/][;,<K%6EF[WKZB`#1@ZY8I'8)-C,D!I4=22]#JQHL"8'VN
MQ*U\=K\F&>4^AIHLU)?;;>GQY+SRYV?53!0[677#NN[9]`RMSE;S=!--V91[
MI)^<;@A)'4:76&2J=DE+37D6NW/;,AWTE-8DU9IV<1>!8:>RAL*TX@>BU;C1
M*CH6<V5HWW&B>PMN2*WMDA^"64=D3J(`$7MR);"%4%[%!G,5J"^@M1I@4O;=
M?[/MPG#^;`,7%>IH'*9L3+WQ4<"WI3L]*JV-UB[^5X#?_J\=V%'M=AGB+78R
ML7=X]B#M&RJK.EA-?2T$$VNF.4J17)%./LVZ8-)`YAE$YB4W*,X:^7*5:E0I
M(&ZQ][`.W&+4/LA@`)M&S1%NNTFK;,:F"G51;:+0(5*#3S]6@KJ-;H`LM$(0
MODY)LJX<B.J&2)C2Y0U5J5"[HA$J;.%#II(6\$(2X4:1-#R)4.:^+E/,H<?'
MO3![TB#*=B.*RA3C*UM+RGQ3G./#/,%BLCPB<(G")PB<(G")PB<(G")PB<(G
M")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB
M<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(L>6+"@`HF=.DQX4(%'S"Q@P
M6F1APH2*'1G)A`F3(3'&8D`?`B,K=>>=6AMIM&5*SA.,YX1=+>[_`/>)?:"T
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M*3HJ%IPESS8H%50*K4>B^[OTMM6JB&R#^S`=$/P]/[2["L:<.GZ_(VV3TAK>
M3<9L"]CZQ!).-NYV#1*C]9@P[+Z9[P2<Q(6VAOSK1<A5RE;):6[N]6]_':E3
M-:;FHYS8MQU+4]V#M;-'ASEUC4&X@0ED%D)PJ/(?0B8P(L<%^5&;<<?C,2V7
MEIPR\TXN%I'%0@A5;J_W,.I6P[CN#6Y?:52UOLC3&Y[EIJRT.[V<%"LDB76M
MP"M'AK5#AL3'L8`7:^6,3%@86I,AM9>$F0AK,EGSTM(2A5B[?[R=;-*T&F[-
MM&P1Y&DWGL=6^J@8_6G(Y<>WN,[L8CJT@!GRTR&8T=FFVL&2:,.86M43Y;(3
MA"W48;S`"4`)4/,>XKU>P>I0.A;'JNU<'^QCG6JZDZ1::_*&ZDMT?6.V]HS#
ME]DS)\5N+5HHG31:/F8QEYE<AM?D6I,>3EJY3TIE/2O?(]R[H%$IM,V#,[<Z
M-A4S89JP5VF6"=>!D.">,U.?61UGA1?BEM/M*KSET$O3%NH;;C0R4>4XI,5U
M#V65W4E"L+K7W+>I=[)=C`!_:=0U=9^KEKW4)VQ7+]:J^+)@J5I'8+FNCVU9
M243G&8M(*%W(BXZW%XDMH(Q$O-H<DLI6+3ZZ92IG']P[H[*;U$ZQVETRM.^E
MCV]/X^N0Y#E\<)W-[7$5L,RM27L.)V$PH"\EY+68QGPA/>G)4EO,RNZDH5<&
MI^QVB-[&=C5[3FV*1L@WJ.RKJ&R1E2.12TNGV%$DE"^`+-L*SY$KGA9T9#R/
M/'<E09+*5Y=CO(0((XJ4(XJZN1$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%TY>_L_
M9/LH.U8FO/;)AQ[4&I=1N!/4U`7LZYB]?V/856&7>2Q36;-49!()(KKS\8JM
MN:A4<7(D.^5>$93S-GI!9-])?`UU/HND^L.F]]=J8NA;1V)V@&;U-J'J4SW0
MZO1QV@;_`-A=C[5K#!BD:XT/]<[0=W'?PVH!YV<J<^2:A!,XCIS"5*F159W$
MDG+T+:22:+MEW-[M_P`?U!JU(UE[)%/$=R1(XU%VC8MH^WQ0"G6F9-T''0WV
MO:`4D;-:NHR'K27):^8MS%8S6T.XP3]'/AYL0S'TL/.H&8UK@NG[N9UET'>;
MK3M^Z:U!VBUOJ?L1J?4.V*0;ZK]=(6Z^MQ+8!?7=:1N:L:IBQ[S1+!J,S0M[
M03PM^JS999X1)C)4RXW&<CHQD">!XJ@D<5_49ZNE+><ZS]>#6P6;.Q?"VCM4
M$KJS=A+8"YHMDZA@9-AQ;@+4XFV$LWS9Q[,^'B3(Q%E>=KU%^7S9XYXK2>*K
M+OEU.1W8ZO[`Z_1MA$]06>PRJE8]?[?!"4'+!JS8-$MH6Y5.[@QCA,-B7/%D
M@J491\5'\[+SB//C"L\`T-4!H:K00W[,XN0>(U:K[S;J76V1%BVL7JB'JR#*
MNP/<PGHS,Z!@K)#VJNWL*<UO"U/)05=K2A'K/GFLY^8IA.+B9RS]/3_PU5S>
MNIEU6]JTUU_[+@>QESW76MG$1]=B%)PN-K2W5B8UN&5H#6'7.U6FIO3MT6NH
M56DFJ5J]E]`UL`\<Q*G.,OFI$*/%C-"ZHHA=445`]BO:OV/!KW:W8HFY%^PK
M]C%]W[AUQT'0:#3-;WRL[Q[O7JA659\SMJ[;1BUBP@]0':"&)C5/113\=<>5
M+5F:XU`@(!W1YO85#ENF.Z%VF/T@ZI=<16RQE4VGU]N_7#=AO8)2L.WH'<=Q
M:MV(%VYM(@:!QSM.F38FTKRLR\X^S-C/1WB.'\87Y,MKF;M$]"E<:]"TKI_L
M-58+09>L3V^GB%98/M!@1D-1#\6^KTH.TYVLU0"I-EL=JVM<Q<JV"U]J)I!$
M\0-"@&G!F<,@VED)3O,L_2KG*JT][,V_H176VLJIN2CQ`-_TGW4UIV5WQ$U&
M0,1EUG>=#ZDZ3"5011=D;^N-YSL,]J[4$]R)95&R0X5-@-LK'8'IBP.,PX^9
M,PXK:ZZ^SD)M``D'&[VE@I<>R]JKM32B]<P2ZP=KWSV9ZX=G->R#\:9:D-6\
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M1><"3:<`"5@O%DK;T*,B:CX90H="9>^Y4_E?)8VC?*5O8*-\ZU9,]Y^NI"6?
M?BZVOC39-[OPY#2YJ3K,PIE/9YP6K4&'418>&H^:8F&Y\UPSX8`>;'U<\OF7
MRY3Y%:+N6_W2?O\`7/778ZQ^WA:I,LSJW>XBV;/U>TX^XZBA;;HM=R:N#$!#
MKGE9!;"I`=Y^2C&/N"0EEQ./-)?4K"5M1FZEC(,*]*_H:\T+2G"+1O>4#LO)
MH.[V[,X$(T)S=&HY%&&:`8V)$W,]U=8*ZPSNP38GH<W!:;LV8VW:<L8JN69+
MH);+,/'S-2?&BBHHM+;E>NT,<G5]6Z$U]V9%Z/DC):(#^PZS<Y-V9!R;A?;"
M(L4.\$QA&[!XT7-<%C80NS'!AV``(LQI8>0MSXN'EAQ/%7#IHK)V19NV]$QU
MWG5HEN:$)F]5:^(V8L3JDGN*77-D#FZ^0F'25:8&%")'890^W!"/MRLN*0+(
MD9:6_-$>E19@?73!<('6^V%XT3V('7AC;5-O=TV-JF0/@"9IF0^)!%-U(F;+
M`T&4],E.L5)BGR9$-QV$\G*!'E4AWP2A?+A5#15]-W1[F@3"(,L!,)>KK[5!
M<\41IVQQYH"'=(VK#.QK:`A5K5=Z$O7#6QNU60`W7</V$LL>"9F+`R%I=E35
M&IV5NZ;9W]:*STCO4M=IAWP;8HIG<E$K#T^HT,[,.]>-EHD-['C2P,VSB*T*
MV"L>B.P^G#<"?*:7(B29#$9+4PJ>I3#%:&[&']IB.[MKF;P`WS`UL=)#,;#I
M.H2&[CB*W71=3HD>C_@VO5=17X&P!YS8[K\AMNEA`IL-"8*?67$EJ2S\-<*+
M(4IY5*M<L][15&WNV.K=W,[G)Z2M`Z^D]@6ZX``$'>.2&W'-?V30[4P*>JEG
M=AT1=;8>B5M\0&4YF/B5+019D(P-/44P]15H-C[MK&1Y\O6.V-\J0?7NR:U$
MI%.J/:BJV@YK=N;O,TQL:D%[/MVU%*OLNX'GZ]6\U:W0"-I'BI<<B'EM1F\*
MA,$X]2V(FP.V(30FIRE''W@V>#M2J)!<8.;/:M$V'V`@V:K.SKAKS:]2KEW#
MUWJQL(C6GX!DW(GF"%4#S)SZ8CC[B7&%5,%"GM3[*)V&T45,3M)-ND;'945M
MJSD;?N`/0K1J`*+.YZI_@^M44_"JDJ\+DQJ@Y'^J\E!YE^.>P8SA4J3\4JK5
M9[KCKR^4CLY4XMO:W(S71FJM11ZTQ<`W;Z]0%'Y^H2\G8#TK9WU\(:&#RF+Q
M,D8(1K5!F%%2U80RZWE4+TH>'E0\%1^ZG>X=FNA\_IXEM.78H.>R(!L2#;V/
M.K[))J\]H*H^RR6!'X6OJM)IU!#T.2P-+QG#MC>D"G:W)@2&ISTJBG2@HO.L
M!NP:;X(>M@SLNG3T/7MGJ#H^KA.SS90]K')_:4@;L]F&=V(_;:W$ERL@43J'
M,FRMNIAK:6-)I@,Y@.,/55J/56QNGKWV;INA]LRX`:X[`V?J_5O72SN4\]%*
M&+39[S!`8>V92!HTY*4:%V"]ZKKH4C%&3)"B0LG84IFK=FXDN/0@54PJM<;B
M:]R:^PJH[:(.RM<623!133KVJ*.7R)G6.OHW/0Y%AGQ&IQ9B%53EMIK%Q&.X
MS%\@L\+8F27&EL(Y>RF"V*IEO[XHVLB(6'G&Z@"V/7AUE)2=7>$?:U;QLS1F
MJ9AU4F00?@TZ.UK8U8[4[@$S#CYEC\O93\,U(:?G9HF"AUP)]]J=NKL==-:O
M[)O(ZN%B<+7^M+C2\OZYM0^Q0ILNN1*R=PT/2@?4'7&).9D!Y;RWEJB37<X1
MEI#"B8*[`6R=^PM5=;=L[6%[+.?53?&P/PF1=>ZQV2[<[%JV7KG=U.H1BRZA
M&T&I78HA5O*5YV2TW6(;;;J62.(;##>76F&/F3#H6IAF?[CT72T:LN-;.P7>
MUZ5"#7A-,=GWS7IVG:;UJ\+M3-PADI4JZ7"U6ZZ'VG,D?CH+DX*VF.SEQEUQ
M^C+57LU7)N^W/<+M5.V8!FA]C54<0+V84`)T'2EV);`'$F9%WBZ\ID-UVDU=
M,:J;!K(L01)V:"^4P`(RE-/%(69*($)1JE`N]/F"Q3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%\EVX?]T@ZL[BV[M;;
MY;MGV.#E=L;,ONS2@@8$U2X,$D;]:RUKG#!RY=4>EK@0)1933.75K<RVC&5*
MRKQSS:)2!2BV<PJNO_\`C9ZD_GB]G/W!U#]Y_'-/4G,*W,]OS_=JNO'M[]LM
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MXZAI&8!UJ46I;ON:OPCL>@5[7]2W-9E52!/$7JE7XE4];7PL$J`6R[#(#I9J
MDGF0`>*V52Z.C0B%EEX;<0U.S#<4VIVY>GH2BC]X]U%V0+V>(U?K`4_:1>OK
M!>-<V.TWEP=39P<)4=QF#$^P2I-2ACW;%73&H)<1`<1.*PB$K*XKI:"_&FIC
M,JN56ZSWZ5<]4]L;#3:I%&6O1X84QKB;DE(L%?V,>V+.L]/U*XRX6#TF!%18
M+\`3#>=1+E5]A$A#OSAQE$E;#+B%**OIW</<E[ZK=2+_`*C)+.;+W)L.QZSO
MJZ5JP?;C4>WZXUONN?>ZV)I%TO.O`;)$!LO52AA:5DKB"A$>6Y"6XPMA["@J
M05:"I65L/N4S]?`JG7+;IURQ[N<'GA]ZI],M'Q0@+<=>N7*/L&*V^+"VTH/&
MNXUX5>#N2&5QGE*8;D2F(_K3VF7UDHL0_P"Y9<H=EL[\K2-;CTC%4/6:B1Y^
MV&!EM*B=>V+L^Q?S5J<74I("O39E;ZX25A0[#L[+I"2VU*G1V5OOPF5,JY?8
M+N'NB@=BXU:I[6(VK8U>T%/EOFJ96L5EA_:_X9B1^#>+N4OX>TU&V3*_KIMB
MIQH@.?!GV-<8=*<2J>CTP`H@`65&>Y/YZW7C[^K1DT<7`V"XMNN;9K`RV/T'
M71[-+V&;GT3(5^<(O3]J;SFNUW#SL8[#PXK!.+(COQ6V5**=;:[TQ]5[](Z"
MJVI(%QM!<C5PP4HS=7JN.);&LYK287(:XSU4`H)!-00>YA,YUZ/,,&4Q&4Y<
M&-LR(+L@!454IA5>D#WVD[#U3O"UT762Q-TU#ULE[YD"KA867:]%?LFM(NQM
M0BRQ`-#S*>&7@=\>MQ]A.%1T"7T^&5+3E++BE%5H7W&SP]1%YW1<,X"%6&P1
M[_=1>P@P>4U+KY[X.P.A*HQ5B#UH0$J*(Z![[LZ*^6>::9<3$2I3S3*KE5RT
M+O>]L+3$S:(W3Q$(8F[*UGKNE5RVVIZM@CF=OP:>7I)^P6TC3VYU4'M"K@U@
MEY`Y%+<QG+4!PDT]&D/*8J4HO7IKOZ*VQ%NEAFZU>I%(K^J+IM<!8S-Y#2)!
M@5K4=2Y=\8L(]`R-`J$4<_>X2(<SX^>S,8:??<Q&0EKUQ;1"**&EO<-)LZ(I
M>]8FL(0^(WO;8^I]GU(I83#)"".USK;;5RES*;./U.G$72A4C11Z&VS0H3Z#
M$I_UD)PVEW++C16F-%RI/N1@QC!D06UK&:V$"V;^!Z76X&R1,VOR[FN/L=EH
MJ*M;]?'S9>N6SE`Q'DF5BF78;,EUUV)AV([&4RJ46=U#W%V3>SN[0AS7U'C)
MJXG:YW6IBM[&B6T*0G:BI6CYUKJ)R6'$89E0F+9M]M$0U$>RN9&:>2]`A/,H
M2^("4"J4+[FUFDTZGSG=&@3ULL]1+GXL8+M^!`#2'-:4.R6O<<DG\3421*I0
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MDQI<)VK#)UA;DDG7VUM,0F7%YPK*<)S1QP5"TTQVK]O1V:`(N5[6V*W6`%<S
M4[<[J)OUZ[D$R8(`PH>M*IWUQK8JJ4)EVR1YR8<<7"K<GXYMU$9SU%6CE:%>
MPKV,Z!ILXBH)US2C(>^2B=6L=B1H.8JN1X&O+`XT`*'TR:!A9K5K%U@$685F
M0A^K#R(N2I4UI3>5\4<I0J<S^R_1$T#_``<V&16BE2N%F*&B5:N.H;C.IS\@
M[9ZR=5L:TM66DO5T11+5:]EB)(RSDE,`B4DLPJ%+<\?%$HY*%6IK8_UZW)5K
M/N715&U]>#GEF!G9C]+BT>Q%SXBKC\A:[8B-AJT6Q"&9]9(#L17I49QO`>9'
M>:2N,MOS"","F(P*T_U_VAZL'V<M[XZW4#1J;M4XFX'IQJGU[8-/)1*\8V4,
M&SKO<JY1<5T%;8&=9%I`QLHZEZ2GRMP7'9*EL)M#T*T*M7';7V^@82WQ$/5$
M6#NL:1,V:,9T7;(L`J\4F[!B'1VSX+.ODQ5V"&W1;1,,CRZ?CX0T9.FS&FXB
M5O*4<I0JXL;CZZ:YV;5M$L#:K7+#(EU^;K<!3J?)((^,M8PB-<-18-2K,@=4
M!C(V0W$>*NO,Q<LS\-N.MMJSA4H:52A6@&XO<5Z443;_`&FU5?NN3)W8&IKQ
M"&['8>H.OB)+;R`G7IG>NOKD#66;:^NB'[#"13(:IKR5A[#B.I]R/%<;>YD&
MG`JAI*M8AVFUB3U#LZR[6Z;PQV^]1;OUEUWG]<"_X([B5+;DW.>UO;=*C:UL
MM'GHSE9MY3<0@VX7>7&P*DYG/O,_$QL^K*8X'!*8\<%BS'N/:5A[4K'7K>VB
M).MNP&T"W5>MS--7PQJVP68U*W-M#:-+'3(7RDJ8A7FJZA*ZV?-JG,J6G(\I
M%?9;8D+=9;932HX)0\1P6KUY]VCI]7=65[=8GJ@#*(LN_P#:H-F%<9FC-7%Y
MI_0.O1U_UUL\$6NTJ(/L]QVYIVR!".NX4=_YZ08-1H;.6G,K0FAA)H@:5:>Q
MO<PT=3CNZMQ3^I"98G6U-V"1$;8LMBT)3]I7^T=?3-/%7RJ*HEI.Q=N`*_0K
M@96,P=?CR8$$J"F>NB(PB))D@T\*I0K8C578GK]7M45G?-HI\.M!.V%LL55-
M/U2TA-_Z["`]1ZUOS8T7FUZZ8)U-C7D>I:IFQ80P>RMM)<FN/Z2I#[V>0@UI
MU(0:T6P<;:_4X#2:Y8LLTRI5$ZW;8XB(2UQ-JSL6;0"C-<N-<(UJ=5X!.O6:
MM&&O@I(F9&CST/1G$89SZ#GDF*F*C]/W#TMN];.T.NQ*$JL6VQ!%66@D]3$*
M^+LYK9]@K,"LGCM/.4X=',Q]BE;()E02DB,Y'*1Y;$Q#SC'@]A0ICQ40C]P^
MLE=L>XZW?*^QK&%K.SW2A32I37=DDC#E>"5:"8L9@E*$4=T,#K]M(`2`T+%D
M2W7+2\`<3"0^ZA+"+0I0K%[$[+=5=)3M9:H+:8+#Z3:`(':0V.(T`:35::)-
MA=C%8QPA1A].<.AK.)B:]FJ(0\BF20R*[E^0EMEJ1EM0E,5,Z_L3HB<%;%(5
MT/IV6'T139]2M,B%JV"F&&UR2)VT',K]0PFJ)3;*(;L@HX+3%`XG#YQ1F7$0
MER1E;:IBF*C=G[C=7M2BV8M3J4Q!Z%6G"(VD1-5'M8$45Q+-:&V&!!S;ZG5Q
MC$ZMML@XI<0EQ,V#C$1N0PC#*<-VA]1*%;95G5VI8,))*OZMU\!P>%!<3,#*
M76ASLJ#!KLJOAX,Y4$:UB4P)K)60.80K*D,PGW6$8PTM2<XXJ*4@:53:K-/$
MJO4JS6R-IFLDK//`@10>;8R,:/B)'GGI0^+'?+S8\5.&D.R%..(;QY<9QCZ.
M$4FX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1.$77+NGW%(6K.P]QZT4?J3VX[)W[7NO-=;+N\[0E5U,5K
M5:`;3(W493F)\_8&X]>3EDY\C7Y+*FV8KJ$(:QG*_I\,9!M16H"R`PJ2HC]I
M#M/]57[E_P#U$ZS?[4G+E'6$H.L)]I#M/]57[E__`%$ZS?[4G&4=82@ZPMA^
MH?<:N=O(&XOENI=RZ2M>B-IXU#LC7N\0U/"W$/:W*+3=BQE(:H]WOP.2-EU>
M]CW6W4SO-E2U)RC'AXYQ(HH11;@\BB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G"*NMK:NJNY:1/U_=$$'*^2)UDM)2*GN#9OQ=3LP>V"O)+
M:2I6&%%0C.'V\XRA]C*VE8RE>>`:(M36_;<ZSM!0`=`VV8<JSK6`!?Y]&P3%
M#&AQ"O\`R6&C`G`F/"<J1-T4I]$7!#+.<2L2<$L8G<RS%6I7,H'0/4M8'$OK
M:6MM_L!2-L`$LR3.$(<851;S<S]Q10*^*:E/MC*R`DV&1B,A3CSOJ/.JROR*
M;::F8I59B%T%Z\,1#,$D-M]DC'0XZJ3&['<S!'"*&!L>M[)5]?1LH<CY:J-6
M=U6*BPF<^:1\)F2EYYYR4\XI4I4JX-(=?J5U_K[%7H1"T9!L(E8^7F2L:7$=
M>?\`ET>/,<B0APZ&F:.$!XL%EUMM"EQV?.]ZLAQY]P35":JOC?23K]8ZJ]2C
ME<,$ZU)JXBG2ALFRE\MR@(,KL<T/C/N(D(=6XV0VJ76ISS86KSM8SG]I1X*E
M*E1*9[?/7PA66J[-8MTAYLN(.N6-1N"@ZZ4%PMCB9$EIMH,@`*R9![7.0I"8
M$"(EEF0TN)B,_%BO,LQ2I5B7[J/J'8^P:]LJP,V5L_7+'KNT1XPZP/1PTLEJ
MN5(GT=<@:\S)3#=$3I"E_%051)[C2G8JW\PY,N/(5(2I54[-]M3J'N*^'MD[
M$UW-L%OLDK<;Y<HNT'H+K\7>VI:'IG80IIP=-B/Q!DFJ:T"R8"&EH6),P\$8
M:V92E.9N8C!,Q`HLZ(Z$:,&Z4OFE)I':UG;V7?0NV+EMFV;2M1O>Y/;%2D4^
M10MEL[5>EH/C+=KO.O`*`;D7T8\!D1';2SEOU4NLQK5*E1I'ML=:TU4G5UJV
MM*=-,ZE69MQ#;5S)WTH=TO:]EWFH6^9<")&48<MCMPVX<(39>%X^(>D-IPE#
M4=EM#,4J5#H'M%]#`L8F(K6EXM1JAFB3J$3HU1*SJU2I3!/6KVI2%NS7Q"XL
M5G9$VEYC-N6%OR%5RQT.9E[XJ,V[AF<F8KQN'M/]4KX6M9>TO;F)+M@2V17!
MV=R7*.&`7+880``V1MZJ"H\MJ(!VQL2'6X[I@JTGR2I[DB;AA$R5)?=9BF8K
M8`KT^U[9M5U34UYNFY=ABZ?:#=M&6R\;,,'=AR"9T';*Z\V2N#C;,^7!'BKE
M*1";\$YB*;CK;RE;"%8E<:I5<"S]0J>>!:+I62#Y"H:GW7/WI9';7B4?M^P;
MC+1=S$F44-LS!@Y*K!>;JZ1+(=@R(;\9&8C$>.WZ2F54JL#7.@FCZN?J%F'E
M=IO%:@:K)9#L[8962W9(E`D4]_65;MK7I(P:K>M,40:@0QGTW/!MQ<MR4[(?
M<<5*5*SE]Z/Z,V,:LIBQ,W-+5VDE)]W!B[D5'`+>1E-&<`R!T>SGS.RJ1,L<
M^6&RRXRF+*E*6O#OD9PVJ4J58&Q>M6LMHWP-L6U-6%9\+4#])8:&V":.%2@]
M@!6ZMO.3A[&?(^1'B;X7;B/X4E369JE9PI2&LH5/!*J$U/I1HJE5/:M'KXL[
M#K.VVDL&!S9K+*J^AHP;LT9RI38D6-/'38EML4LJS*D.RY;<I;:,.XC1XT=E
M4\4J5`Y/MT=>RMJ(76RR]GVZSEQDT>7-6C8),H5*/%A]6'&R,XJIEHJ^Z3;I
M@]:(F7_E8Q3;F!L6$V^^ARYCP2I6Z]>"-5T3'#QYQ,@Q%=FK8D%Y>9TU#,N=
M)FM0_B<MMYS$'(D8CQDYQXMQFFT9SGR^.<5%FN$3A$X1.$3A$X1.$3A%U4[K
M+=E`]^VO6=9A=O-V2)N<YO"E79FHV2UZOB:M9Z6HH,(+&?9=>#'R;6]6E*13
MV4222YV?FC8R6C&/6R%/F\ZRP51QMH>XE"$6+8<>MGJNP#K%8M$JOWZH55@3
M>C$JL:RK!TC=;&1@55ZJ!JY#05-*^`A5/+2HV%$(D3+<N'RT:E`I+*[&=J+1
MTY,WO1\_8^T]C-[QV?3:?;D:JJ<.R$ZG4`-QF5=RWTT!2K4&8AE[F&AA'I4`
M.PAQ<A"7Y0AM;Q*&H*X\$H*XK3_W&^R?8#6O97:%+H>SCM0A[5Z55*OSZ2\1
MKXBHP3<C7?=69:+$'MY6TP+%JG;]>LY*D(`)'89?L4J5'8<7)^&;S%K0"/55
M:,/555`O=([-9V/81!C:[-<TW$WK4Q04T.IFE+YL:#5([.V@[=0B#)]BJ5?/
M:IM9JJ5M\O:U%9LD*.,MO+.1E2'?EK**>5,H]56#UR[G[!C])-ATS=6YJ`K=
M50[!Z79UD*E;8KY"67Z_3=W:P+2#;MM^MHZX6:Y#*?@_(M;4J7ED6N/AAMIP
M?Z690@5PX(1CAP53T+OAW&*;]ZHFKIO2@V>L8/!(>Z7Q<[7%<G!Z+NL)U.EV
MFG5K7P(Y(KEUM>O]HI,CF9<]A\P-K2;"]%6_-9CMKM&T*N4479=N3?'=9[:6
M^P.C,6DY5:'LJ#2CK\;5$>?`UI5?JIH"R"S>N2P^A7DSM"]FIEUL39@?\N/Y
M&CFVG<0(F66WY>(#:8K$4IBMB>N6P.T<:[8;[+)*_*=A1),"MBX6NX0<'3+L
M*MEYC1@PPB$;FF,A;)0:\T5=D')4K#3N6DMOM^MAI<-.A0TZ%1URN?N$5@I>
M;7!?O=GK;EDO$`%1`6I:$N0`KD^S]HPE;-!B3(`O8BZJG7=>:^*,Y=CEI$I5
MADJ5!)9DPAS#LJX*OJC9O<=-VK0NQKD-O'R4/?6JGLRIL4L8$?AZL?K]4:L&
MRH(5D"%>MMY/'IWES'(PH,0>-C3WH`QB>AJ,NG+P"8*X=T[K[8,[=W30=:23
M+E(U:0J,R79];:XK^S+XPSM37!0_2ZI%J;L8LEZ=5-@T),4VIZ+E]%;N\.;G
MT4,_'1Y043"BRNL-F=W;YN76M3NM8M.MJB`+S%[L*,:T#MUHH0A%>P)*'5ZC
M;SK)2.5IY(".HS+I87EYS/Q&6FY+4QV3Z"C0/*IAT+&7;8G?>!=;`-'5\_$K
M8#9E@I5$G5W6]?LS.T9;!D-:Z"3M\I3<OZC:BLU%OZ@1DYCX%8TW3)#F),;$
MI")(`*X+6BM[+]S.LT`V'5%V9+D5"AU*$-F6/4D^Q7D^\-7JYB:=2:B:G/P5
MW:V'IML'S%(BVU,:%$B35!H,7Q*S,J-5P6WF]=A][(.Q-2!M.T"1(HUXI]#D
M;")DZW7B$G7-ALT^=1[1%G2XIER*J53I=J%V:2AI4IA<(%.9:6M+B?'$4IY5
M!3I5'=91G=P7L\+9KH1W"P`;(ZY`6VA7*LCI%-S6K<Y8B!B-7R$YAPI`AZQA
M3H2VI,&6N0E]2HD]Z3AGT6Z<M$*Y]OVA[B9?9V[`]%"7VN4FND;T;HDXEJNJ
MDW)SU'!=A9%8H@J:3IXH60K&R2U3I&<R8\VPS5QC.<,E($N0[#&09:8IA19/
M<M9["S?=%T1<JQ5M^O\`4X'6ZP&WH@!:"T37YW=I(+MS.C[I"J32TR"E`U8/
MGD8E\=B/1X$LJ?JCTN/,P#>5&"F7RIA3RK#7W=GN!P=N[&BU2E;+>UL(VO7(
ME;'MZI'3"!FO0[CM`"2KU;LV-<2PT$!9:X+KQ?!":\9AJ9E81)L5:=D/LCJ`
MVB4%%8/8F7W%MG9!>M]?$=F5S5.#NI+`#OE+I(ED916Q1"OR;2^2+6*LS`M]
MR?5+(,J844GLQVF%MS`,9#,4F2@I2O2@I15D3V[[FSX>?,K%,-/7.3!$C3M8
M/:E##J?1SUH7("TTS13CLF+,O(2(*?:L-L;<G3U")C*H/FC>;X7%HWU$[*O;
M25K[LV(X;-;?$FQU<MVMM@DQNO)%*K8J+K^P9U_H"XT0(FQ",)L!:PH/[#MU
M>G>O+=C2'ZYG+*&G&7'I,-.A3!3'IN5[5/S'XV_F##-?(:^@D`H<K40]?:HI
M\'?KK4VJS`*0<N&C7SFBC!)20LK(G2?5>]1MUMMS+6!IT(:+?GF*BZMM'_RN
M_N!?Q1?;^_[7=Q.9GT!YU3Z(]53/M[W@G=%]CU>\=@0`V)T?N%-G`I>ZJN*L
MIJYZF[!#7B9.NU38H"`H@R1HN[@V&0]6GCXR'XUP8:&R\+P7@N-0"HPXH!7S
MK8SJM>=Z;.TI6=C]AM<!].WV]23-J'ZF@/SYIS7%!,DY,S7E3V+/F/NL2]K#
M:@Y$^LN(:&8$8PM^-'2IMG#KD-*X(:5P6H'M^?Z2WNY_Q]ZU_J5]4.5W`>94
M]'F7:3S%8IPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(M!.Q
M^E^Q>S=6[QHTZ[TVYC-@[\Z^$M1`HFNLQ6M;:<"[`TG+V&$V3&D7@:WMJ.W(
M`6(O,2F0*^+%2<0,)5E.,*H(!5!H5JKMG4_<+$HMIFE![%+UA6!HZ`*AT4)1
MM=:JQ6A=$HS57)ZT2P97>A5S([$F6S!D7-*2X,4<B-Y,82B$Z]E4<>E44XK\
M.GO=*""2)*@`K-9"PLPRU8*K<1VG88Q\U72%SV"9&:I(,?!R9>J[93-=@*2+
MFDY#Q)DK>'YKKOJ0G7(;LI@K$W[J#MG9-I:5(UB[;<BRJ_I8*[9+=1IFOHU6
M1MFG4[<JR9&96[&-G!TF;C:;.$A^3X%R&]`<<2C#*H^'FH"**8+*Z\_+ILVM
M.TD/<`N1,MTP;&1K>KNUVG,UUBP/6FZY<'T8FF=Y#E670$5Q3J2:'?1(9?S\
M6M]<F/&8`BBN%<%3=P$>Y.Z%'591S;ED^N5;+QS,@;%TI6)@L]?=-5ALXPFX
M!@F&*X*UC>9!=8B*H>RY,5YDI-)DLP6W[V4[/%2:,6]Q2JTX8,K([:-LM%YB
M$)M;=N@;2V1>L(=/L.QQ(\#;945H+)C2;/08U2E(7*64D3##\M2GF$8?0V[/
M2G941F!.ZD/8\ZY5]KM1/HA<14\$SEQ$Z"E[@`T",9CA#V=?5L;!^J@;:!(=
M"<D2HRX&7)0[+#[S&2"4-I843!9$X][H(RDNV.62V`1N!5N/((4VL`M(K@BY
MU:?J,<"!KA)D1-E5UJ^N%";A<K(8LT>+(C-X^&8'8==0[*=E6MO.W]N[+V$O
M&O='F]F`QX>I:<P34(`:DE4>H5R]Q;XW>SXLY;0LXN6W&-,#A"QC+N)8=H<W
M)6J,XI2_""E,4%*5*P,%7N'O2YH:.]=2`DI:XU"N!&["-.L)KN2!.[%+3L/6
M>!D"$H_K<-3:=71@E$]IZ;**6R6Z\A7PJDQ'93!4#D+[D@LI#L`8;M,'88M&
MI]&M_P`(`U&3J=?;&R-HE*&+TS7HTAC!D0Z^[4$W%\HKU6EKE,,S8L7$E4:]
ME,%<R:)VSM5![C3+S#W4O8-FK6F1`+Y1G6XR.T=I6W-KFK3'ZWQ8\]J*_6!U
M$+!GQSUDR[*G27/1E/25-NM-L,$PPZE:&C;7VHNM[V5JZ]V<DX+K&D)-J8F2
M6Z`-V")L^UYQFLZFI-]Q6("1M>V!6:1KI=J)X90RU\=;VL>'PS#+28:)@M4*
MI2?<<UEIH2FE&-RNS+7*=)W,=;H>KK??:9.%"1XP),K+2XOK$9USM?HOGF9D
MJ5'S!0^XRJ`CSKY26DIA5;8=G6^]3<SYSJ(];(0V%1],"R@>E5W7!-IZS%T;
MJF;0L@`58(I8].-"K4&H</,99/Y:P"GSLI\[BG9<>"G2@ITJMWS/N%)DLX=8
MW(JRXM)Q!5H;7-$-ZJ5?,6Z(WKH0#7(5,N+'6Z;K%,F19YCTF08C%LQ6XL[$
MCXEKE[-$P586BM^XM&+T(S\UW;9;;6Z+`(G#"Q>EFZJ)KVP`FD).T&P4*LAA
MLPONZMV)5X'B("X<\?&#PH*VT/2U-/2G9045UZ<']V)>Q;%;MJL['DW$#U?V
MB#KRY`C6H34N;H>@:`+:XS71(DH0*2-CEC-;L"K$U/D31<&6RIJ*XQ$=92]#
M3H3!5Q:Q7N=U`,RS7KWLNZ,DG5_/"Y*L:0(VBOK'B')%8Q5Q%?KM;@D&CM],
MMLFDR4J;P%AX2AR&AMZ2J]E.R5DGK/[D8VRO.)!;1M4,9NPPI(Z$)TY4A5NK
M$]+.&`4*81C6G%,JM0&-..1I<F27@V'#V/,3$D6\15.RF"HI_>GN&UZ=4M>$
M+#=(.Z[C,L"=)T<^.TD]FWAY54V"7,$MQ0I(@/9L0@!H8,9!$!<(5'CN1Y&"
MJ&(SB,JM&\>A7L^HNW;JJ6V[,U<.@;KCVUZY1)!J:R>MU?"5XJ3K!"X6N/48
M1F(#G.QE6D761<54Y68@]2VI,9QQAM]QYMO`TK@L3QP6R_(HG")PB<(G")PB
MZMMD=[=G:ZWMN2B$=6`I>LM8H)PEVP/86)-HA9E@NN:JM9"%?(RAD<FR];MX
MKB2!K#K"\0HZ9&).%(RT]D&@CRJTPJI[7^_`(GJG=U_,ZVLD29IV11QS=4RI
M3Y^]-[*.JIE&/11,$:2S"K=NM++J6)0Y9^)\(AW#;[\Z+-@1E$HJM3[E-%J-
M>L0('H8W7#%!U]2[KB@/%`U:;5%N\L[&'UNN@!(<C;I)R+*I%G?DP6*_\7$@
M0(<Z4S'BE&G6F6JM%YD?<_@PH)&U9Z\VYZ@)@D9E=LZ[Y0V9Y_TT[@@@H[@)
MV3Y0KAJQZ4+15JD2\LPX[L>2M><*<::9?73*N>%]QE3FV7-9&M/'WR*KPS32
MX^LM33F:%BOW:LZDOY<E8AXV8)LHR!LRVQ,P7EMA6G0J7G7%HFI9@OLJ9<%8
M?:7?'8&C;OU-J[057%VZ3:]?6F^30;NO"-MP>D`=CZJJ;(LO<HU]IPG5%66$
MND^0^<E1RF&G66U(CO91F.^`%*E0`4Q5'!_=.%XH9<\1TY8"Y:O5L:ZT1@I+
M@JW>;@'K8"P[*!U5+M;/SWG`<,RN0.CCOGDJ3$B2)$Q(^*RJ3EE5RJ5)]SZF
MMFFPT+2.P'2A:T8E1A,%MR78)>KVV(S4G:\N")!3X"HDQ2VTC<M3)(>:AIYI
M9>/,A3(<9E3*I_N#NU9]>]@!>I:YJYBR!'#LW6:24^U"PA"S;D+"]$FJE7H3
M3RG7JS38PK>$)X@;?C3LK6VXRQ&RZF/B8`PJI3!<NZ^X%6*=6=1WO\&%M*T?
M86JAVW[46C&*\P4U_6"]FIU)'Q$`W)*\W$R[;+O%9RB$^W%^$:>D(?7X--O,
MJ47IHG=NTVFR[KAF=/M`A6CM),;(LXL?=15EL$JU)FGRLJO!",%I@`7#O4".
M.F,RL9:6@D^_#6C/I)<6(2BI6+[GM8MPZ>6TQIPQ)CR"4R79+88(58=!;DC=
MAZKUT+5+'QB""!^7<:_M>FD8TA#OFA`3K$A>'%QDPWF56BM317N%0=FU.\'K
M?JFTUC&L-&2=LVTR';F$:R7,4VG5>P;0J]4G%1XB#-4()V=M@2XW-E9GL-K=
MD_!9PVET6T4(4=OWN.O5?7NTI$34>8>X==K37ETTO>`9&HKNI"D[JO8EGZVA
MDI>*UML'IU;DJ3&BH>2Y.]'#>%QWE)9?65IZRQIKW(YF#1>I`M1SF=B,S=H5
MH!0;#8@XO$\O4,U:?7[-8[3/6.B5ZL&Z_)*2X+L2,6&F4LMIADE+\^$LJ46=
MUS[@I;9.E=XW<#JHDBU:>T!8-I"2!Q!4#0-@VJF`#L:VAHA"3!7@6+AWZN2(
M["HLPMZHM;;ZWF7\KCH9<4IBH8)]S(Z`@CA>Q]$GIUS+6>[R!,?7,]VQ#2NK
MJAL+<%2*6M#,`:7F"C@5C53K?P4Y4>+.6\V^J9";4ZW&9>K@E.I69V)[WE=)
M[@@487K)^SU<=88M`/$VR.7;`=VC;ZK5#E`J=;K0>,6L3`!UR]BW")M$`CEM
M&)##,)UYMOU0;4*`8*!%/="!Q,Q'I6I;E5O5Q3Y@H+9%P(IZY(L]#+&9D.$W
M/<$BPHFNW)4`40*MRB;@QQ2LDH,!+L;+K*KE6?:]R-*)A0>5T<3$/C"1NA)E
M.;(JY0;/W,',SA+=!&+`P"I8N+*X&.KAD8,*5/F/+8BQAC\IY+.&5**OZE[L
M`LKEPN=TA<DU29\):HDFKYGV`W7=7KU[HXO.-VB!'#9@,V.'?]NN0LPY$D8U
M\JAX?]3,M3<-]E3*K45WQLE3T/LW<^P]7C6R]6W&7H-=US6KC&+SY@,=K`/M
M/"L'0L"PNV.PIJWS"8XT.&JPTVUXOHCQ(\N>TIC1*8T4?S[GM>:+NHFZ4ND"
MJ8@W(ZU;I!P7D:Q5@9[:%.K%B.SF8+M6JT>TW#39V,XT0+,/08V(CZ<25/NL
MQF52BLW0??`5N_8]<UQ*U?8*#,.A;]_QM8B$IB"]=]:W:V5"UTP$P5K0"=/E
M#6*@\0<9GMB3S<-]IY8E,?#TAH6T%4(HM_>8J+JVT?\`RN_N!?Q1?;^_[7=Q
M.9GT!YU3Z(]53?LGT.A]T=P)5VDLL&\]2:;17H>MNM`A@L'@%]Q6<><"V7=6
MVC;<].;*>H0&<TQ0HL9#+-=(OR2_BX21`>A0.H,.*`T&'%;%=5M>[HU-I"IZ
MRWSM"!NJ[T-PQ5A^UV1\L8?O=!#EYD/7!W8462MUES:#M);A-V.5%5\)/+MO
MRF<(0]AM$.)J%#Y%I][?G^DM[N?\?>M?ZE?5#E=P'F61Z/,NTGF*Q3A$X1.$
M3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X1.$7CA"$Y4I*4I4O.,K5A.,97G"<)QE6<8\59PG&,8\?Z&.$7EPB<
M(G")PB<(G")PB]>6FE.(=4VVIUI*TMNY0G+C:7?+ZB4+SCS(2YY$^;&,_3X8
M\?V.$7LX1.$3A$X1.$3A$X1067J_6A`K8#L_7E'G&[:T/8M1>94P,HG96!/R
MSY6R?GOP')1=H;\EA^@F0IS#/PC/E\/2;\JI1<"#IK4(P9<P@W5NO!X;8JWG
M+^)A4RNQ1MV7(CKBOJMD%@<W&L&78[JT*^*2[XI6K^RSXDJ5A9?7?0,\+&KD
M[2&HYE?A);3$"2M<U!\5&0U&!0FT,0'1"HK24PZN-9\,)QC+0^,C/W++>$VI
M2I7KN_7G2^P*&?UK8-<5%-2L@66`(P!5?$"5H&3L&\2&8+\*$TN#E7UF)9\S
M?ESC)"3G_P`.[YP)"5*R:-%Z3;15VVM/ZO:;H\Z&3IC;-!JK3=3(CV,1A\ZM
MMMBDH"2X,=.$,N1L-J:2G&$YQX8\)4HIO`JU9%/"Y(RN@AT@&"Q5@C\`0/B/
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M`$0C`;RC@]C^<3/CHS.$,R\2W\.I5ZKGFM2K4K]SUPZ]9#&*[G1>GU`+#)DS
M#P56MJ<H4:E3)@DC+D%(&0^8L]V40`07W,NI5E;T-A:O%32,I5*BD@S46J`J
M[:X'UG0!2[Z,B!;PH;3Z]"S<0T`8X&@B;/\`##V\'1D00\N*W'E>JTB.M3>$
MX1G..2I1<"9HS2A`:&#3]0ZQFB*Y)%3:^+E4.K/CPDL%-+D@LD3#=%JCCWQ)
M"P3WXRFDH4R].D+1X*><RJU*M2O?9]+:>NQJ?8[EJK7-KL)2MNTXB>L=*K9L
MS.J3[JWGZS+)DALF:^!=><RM412\L95GQRGQXJ5%%3G6;1)D+:!$;5](K#]L
MK+%2(V&H52MUZS,!X%=DU,,S`,0Q/K,X!5R6N%#;7AQAJ&K,?+:HZE-*5*M2
MN%1^K.A:)K,1J:'K.H'J@*9DI7'M=9KAR06ESI,N80)%?6$M0G)DR7/>5Y66
M&(\="\,QVF6$-M(5*5*D\70&B8,X&3@Z7U1"(UB5#G5N=$UY4HTJOS!PB(`'
MR@K[`AMP7(@@X$>&RMC*%-1H[32<X0VC"52E2OQ/7_1":6G6Z=+ZI3KQ!A5A
M314Z]J>*?@\K"L+-?5O`GY/DJXE:DJD99]52%93E6<9SCBI47+(Z.TL86)<+
M:BUD2<`CK((!KG42KRE!Q5QQ,Q;1HO+XM?P$"SX(R/F#37E1,^(=]7"_47XJ
ME*KAA^OVAZ]-A$@&EM4!2`T<D0/G"M>U,?+A"T'?K0@?%D11+3K,1-F_XQPA
M.<)^.SE__A<Y7Q4I4JWN1%UM;F]OFTW_`+)WGL[J7NIV0ZP7+9>MM9:PO034
MH/0!ZN6$-J4G>RE0G/-[=TWL<G")1G]BD4N*C2&6W$+3C*?N>9!V%"%E7"A"
MCGY`W:G];QWC_P"H'2/_`&5>*CJ'LI4=2?D#=J?UO'>/_J!TC_V5>*CJ'LI4
M=2OWIUT]:ZEQ=W3"&[MI=@;SV!VVG<>Q=B[:AZ['6&?96M?4?6D2+$':PI-!
MJT(9$K6OX"$(;@)7E>%*4K/CR$U4)JMR^11.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1.$3A$X1.$7S]?;+=N?U,_<']U"'XJ>?6/@ZV_\`G%I_K-]V
M7ZK^3SX?_I%V]]2S\*3[9;MS^IG[@_NH0_%3Q\'6W_SBT_UF^[)\GGP__2+M
M[ZEGX4GVRW;G]3/W!_=0A^*GCX.MO_G%I_K-]V3Y//A_^D7;WU+/PI/MENW/
MZF?N#^ZA#\5/'P=;?_.+3_6;[LGR>?#_`/2+M[ZEGX4GVRW;G]3/W!_=0A^*
MGCX.MO\`YQ:?ZS?=D^3SX?\`Z1=O?4L_"D^V6[<_J9^X/[J$/Q4\?!UM_P#.
M+3_6;[LGR>?#_P#2+M[ZEGX4GVRW;G]3/W!_=0A^*GCX.MO_`)Q:?ZS?=D^3
MSX?_`*1=O?4L_"D^V6[<_J9^X/[J$/Q4\?!UM_\`.+3_`%F^[)\GGP__`$B[
M>^I9^%)]LMVY_4S]P?W4(?BIX^#K;_YQ:?ZS?=D^3SX?_I%V]]2S\*3[9;MS
M^IG[@_NH0_%3Q\'6W_SBT_UF^[)\GGP__2+M[ZEGX4GVRW;G]3/W!_=0A^*G
MCX.MO_G%I_K-]V3Y//A_^D7;WU+/PI/MENW/ZF?N#^ZA#\5/'P=;?_.+3_6;
M[LGR>?#_`/2+M[ZEGX4GVRW;G]3/W!_=0A^*GCX.MO\`YQ:?ZS?=D^3SX?\`
MZ1=O?4L_"D^V6[<_J9^X/[J$/Q4\?!UM_P#.+3_6;[LGR>?#_P#2+M[ZEGX4
MGVRW;G]3/W!_=0A^*GCX.MO_`)Q:?ZS?=D^3SX?_`*1=O?4L_"D^V6[<_J9^
MX/[J$/Q4\?!UM_\`.+3_`%F^[)\GGP__`$B[>^I9^%)]LMVY_4S]P?W4(?BI
MX^#K;_YQ:?ZS?=D^3SX?_I%V]]2S\*3[9;MS^IG[@_NH0_%3Q\'6W_SBT_UF
M^[)\GGP__2+M[ZEGX4GVRW;G]3/W!_=0A^*GCX.MO_G%I_K-]V3Y//A_^D7;
MWU+/PI/MENW/ZF?N#^ZA#\5/'P=;?_.+3_6;[LGR>?#_`/2+M[ZEGX4GVRW;
MG]3/W!_=0A^*GCX.MO\`YQ:?ZS?=D^3SX?\`Z1=O?4L_"D^V6[<_J9^X/[J$
M/Q4\?!UM_P#.+3_6;[LGR>?#_P#2+M[ZEGX4GVRW;G]3/W!_=0A^*GCX.MO_
M`)Q:?ZS?=D^3SX?_`*1=O?4L_"D^V6[<_J9^X/[J$/Q4\?!UM_\`.+3_`%F^
M[)\GGP__`$B[>^I9^%)]LMVY_4S]P?W4(?BIX^#K;_YQ:?ZS?=D^3SX?_I%V
M]]2S\*3[9;MS^IG[@_NH0_%3Q\'6W_SBT_UF^[)\GGP__2+M[ZEGX4GVRW;G
M]3/W!_=0A^*GCX.MO_G%I_K-]V3Y//A_^D7;WU+/PI/MENW/ZF?N#^ZA#\5/
M'P=;?_.+3_6;[LGR>?#_`/2+M[ZEGX4GVRW;G]3/W!_=0A^*GCX.MO\`YQ:?
MZS?=D^3SX?\`Z1=O?4L_"D^V6[<_J9^X/[J$/Q4\?!UM_P#.+3_6;[LGR>?#
M_P#2+M[ZEGX4GVRW;G]3/W!_=0A^*GCX.MO_`)Q:?ZS?=D^3SX?_`*1=O?4L
M_"D^V6[<_J9^X/[J$/Q4\?!UM_\`.+3_`%F^[)\GGP__`$B[>^I9^%)]LMVY
M_4S]P?W4(?BIX^#K;_YQ:?ZS?=D^3SX?_I%V]]2S\*3[9;MS^IG[@_NH0_%3
MQ\'6W_SBT_UF^[)\GGP__2+M[ZEGX4GVRW;G]3/W!_=0A^*GCX.MO_G%I_K-
M]V3Y//A_^D7;WU+/PI/MENW/ZF?N#^ZA#\5/'P=;?_.+3_6;[LGR>?#_`/2+
MM[ZEGX4GVRW;G]3/W!_=0A^*GCX.MO\`YQ:?ZS?=D^3SX?\`Z1=O?4L_"D^V
M6[<_J9^X/[J$/Q4\?!UM_P#.+3_6;[LGR>?#_P#2+M[ZEGX4GVRW;G]3/W!_
M=0A^*GCX.MO_`)Q:?ZS?=D^3SX?_`*1=O?4L_"D^V6[<_J9^X/[J$/Q4\?!U
MM_\`.+3_`%F^[)\GGP__`$B[>^I9^%)]LMVY_4S]P?W4(?BIX^#K;_YQ:?ZS
M?=D^3SX?_I%V]]2S\*3[9;MS^IG[@_NH0_%3Q\'6W_SBT_UF^[)\GGP__2+M
M[ZEGX4GVRW;G]3/W!_=0A^*GCX.MO_G%I_K-]V3Y//A_^D7;WU+/PI/MENW/
MZF?N#^ZA#\5/'P=;?_.+3_6;[LGR>?#_`/2+M[ZEGX4GVRW;G]3/W!_=0A^*
MGCX.MO\`YQ:?ZS?=D^3SX?\`Z1=O?4L_"D^V6[<_J9^X/[J$/Q4\?!UM_P#.
M+3_6;[LGR>?#_P#2+M[ZEGX4GVRW;G]3/W!_=0A^*GCX.MO_`)Q:?ZS?=D^3
MSX?_`*1=O?4L_"D^V6[<_J9^X/[J$/Q4\?!UM_\`.+3_`%F^[)\GGP__`$B[
M>^I9^%)]LMVY_4S]P?W4(?BIX^#K;_YQ:?ZS?=D^3SX?_I%V]]2S\*3[9;MS
M^IG[@_NH0_%3Q\'6W_SBT_UF^[)\GGP__2+M[ZEGX4GVRW;G]3/W!_=0A^*G
MCX.MO_G%I_K-]V3Y//A_^D7;WU+/PI/MENW/ZF?N#^ZA#\5/'P=;?_.+3_6;
M[LGR>?#_`/2+M[ZEGX4GVRW;G]3/W!_=0A^*GCX.MO\`YQ:?ZS?=D^3SX?\`
MZ1=O?4L_"D^V6[<_J9^X/[J$/Q4\?!UM_P#.+3_6;[LGR>?#_P#2+M[ZEGX4
MGVRW;G]3/W!_=0A^*GCX.MO_`)Q:?ZS?=D^3SX?_`*1=O?4L_"D^V6[<_J9^
MX/[J$/Q4\?!UM_\`.+3_`%F^[)\GGP__`$B[>^I9^%)]LMVY_4S]P?W4(?BI
MX^#K;_YQ:?ZS?=D^3SX?_I%V]]2S\*3[9;MS^IG[@_NH0_%3Q\'6W_SBT_UF
M^[)\GGP__2+M[ZEGX4GVRW;G]3/W!_=0A^*GCX.MO_G%I_K-]V3Y//A_^D7;
MWU+/PI/MENW/ZF?N#^ZA#\5/'P=;?_.+3_6;[LGR>?#_`/2+M[ZEGX4GVRW;
MG]3/W!_=0A^*GCX.MO\`YQ:?ZS?=D^3SX?\`Z1=O?4L_"D^V6[<_J9^X/[J$
M/Q4\?!UM_P#.+3_6;[LGR>?#_P#2+M[ZEGX4GVRW;G]3/W!_=0A^*GCX.MO_
M`)Q:?ZS?=D^3SX?_`*1=O?4L_"D^V6[<_J9^X/[J$/Q4\?!UM_\`.+3_`%F^
M[)\GGP__`$B[>^I9^%)]LMVY_4S]P?W4(?BIX^#K;_YQ:?ZS?=D^3SX?_I%V
M]]2S\*3[9;MS^IG[@_NH0_%3Q\'6W_SBT_UF^[)\GGP__2+M[ZEGX4GVRW;G
M]3/W!_=0A^*GCX.MO_G%I_K-]V3Y//A_^D7;WU+/PI/MENW/ZF?N#^ZA#\5/
M'P=;?_.+3_6;[LGR>?#_`/2+M[ZEGX4GVRW;G]3/W!_=0A^*GCX.MO\`YQ:?
MZS?=D^3SX?\`Z1=O?4L_"D^V6[<_J9^X/[J$/Q4\?!UM_P#.+3_6;[LGR>?#
M_P#2+M[ZEGX4GVRW;G]3/W!_=0A^*GCX.MO_`)Q:?ZS?=D^3SX?_`*1=O?4L
M_"D^V6[<_J9^X/[J$/Q4\?!UM_\`.+3_`%F^[)\GGP__`$B[>^I9^%)]LMVY
M_4S]P?W4(?BIX^#K;_YQ:?ZS?=D^3SX?_I%V]]2S\*3[9;MS^IG[@_NH0_%3
MQ\'6W_SBT_UF^[)\GGP__2+M[ZEGX4GVRW;G]3/W!_=0A^*GCX.MO_G%I_K-
M]V3Y//A_^D7;WU+/PI/MENW/ZF?N#^ZA#\5/'P=;?_.+3_6;[LGR>?#_`/2+
MM[ZEGX4GVRW;G]3/W!_=0A^*GCX.MO\`YQ:?ZS?=D^3SX?\`Z1=O?4L_"D^V
M6[<_J9^X/[J$/Q4\?!UM_P#.+3_6;[LGR>?#_P#2+M[ZEGX4GVRW;G]3/W!_
M=0A^*GCX.MO_`)Q:?ZS?=D^3SX?_`*1=O?4L_"EV_P#F5_9*_JYY\]7YVH$\
MRO[)7]7/"4">97]DK^KGA*!:6=M^_?7SI/9^M-2WD5L<$IVIV]$TWKI8`;#)
M0Q!B0Z(BR+5=WI94:L'119&PCXTJ<TB4XV]-;QAE6/,I,)`I7I6M[VL(#NDK
M<N7.ACW%-3R4""ZAYB.I$TC$B*Q(EOJC0V?+(?;SEV9)3EME/[+SF,I1YLX\
M.7!9X+Q<(0F7VHKQ*`S*?DIA,1'B$5F4_.4RJ0B"S&<?2^[-7&1EQ+*4Y<RW
MC*L8\N/'BBN"\OCHO_Y?$_\`&/@__'8__CGAX_!?\+_X[X?^!_X3_P"+Q@F"
MJK=F[J5H;3VZ-UVZ3++5G0NN;=L^_AJFZ,,6Z-7Z97YUE)18H5XG!2@S,'#W
M,1&9;T5#SGAC*TX\58AH!58N(:TN/`!47V;[W:>ZH=.5=X-D!]BE=0IKNJK-
M@-2P0LQL%R!N&378M49;!3[`(%KFL.V>-\8C$_P:QA?D4YX8\PD`5Z%BY[6L
MSG@H+&]S?K80[3]6NH0;Z_F]G=NM"0.QVL2PL$)?I`O79>J66YADW4PNQ-$@
MY\N#JDM3$:/"F(RO"<9<QC.58E14#K3F,SAG215=@3$^)*1*<BD(4MN#(DQ)
M[D6?%DMP)<-'J3(LYQAYQ$*5#1]T\V[E"VL?2K&,<R6>"J7878'4NK3VC:U<
M[G#@E^R.R6M3Z;9@I=,1K?<%UL];I#;1$;\0/A!Q]=K4R0_.>=2QC*$M(RMY
MQMM4)`XK%SFM%3TKSU%N@/MJBR;ZNL7G5<.):M@5=\#N03"HEG2C7EP)4Z;:
M,C'RLQI-/L,@=B:)G*>PF6.DL/*2WES",!0J@@BM**UWYT2(J.B60A1%S/6S
M#1+GQHJYF(S'Q<G,-+[S:I>(T3]M<RWYO3:^[5X)^GE66"UK[>]L=?\`2[1)
M?L#LD#?[C5!=IU]3&*[JH*/M-W/6'9UN%4FHP*\&(&@4,FY./&8[?EQ*2I6%
MX\F%JSA.82`*K![@QN8C!0#J3WWU/V]+[>I@*D[PT=MC1!*I0=IZ7[,ZZ=U'
MLZM0[]`FDJ18,!))8O#(5^T1QLE,60S)4K+C"DJ1CS(RL"'<%&/;)6G$+<]L
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M0Y7=E5D/<J`1C$F&\VZKGQ44X),@H4IQB?.BRA4UI[/E:RMM*O!>$YQG&,L%
MM%"*CI6>46&(S(PLP*1F'%>G3,++0$9AP8SBV9,Z9A4G&8D*,\VI#CKGE;;6
MG*59QG&<<)@J0TQV1H6]KCV-I%*CV1DKU@W&UI#8,LU#@QA16V/T*I;&9(4Z
M7!*$5EZV[7[G$PF2\B*XI_#B<-91A*U0$'@L6N:^M.A7[YE?V2OZN>59T">9
M7]DK^KGA*!/,K^R5_5SPE`GF5_9*_JYX2@3S*_LE?U<\)0)YE?V2OZN>$H$\
MRO[)7]7/"4">97]DK^KGA*!/,K^R5_5SPE`GF5_9*_JYX2@3S*_LE?U<\)0)
MYE?V2OZN>$H$\RO[)7]7/"4">97]DK^KGA*!/,K^R5_5SPE`GF5_9*_JYX2@
M3S*_LE?U<\)0)YE?V2OZN>$H$\RO[)7]7/"4">97]DK^KGA*!/,K^R5_5SPE
M`GF5_9*_JYX2@3S*_LE?U<\)0)YE?V2OZN>$H%^I]1:DH1YU*5G"4I3YE*4I
M6?#"4XQXYSG.<_1CBB4"T<L7>^E%+38=>]:-8;:[E7ZIEI5>MF-$C@,73]&L
MD%S+$ZOWSL?L(W4M+B#@Q].431HTF9,0UXREV$E>/+R5'1BM><$T:*E<-)/W
M-KUX.Q*OTFZT#7\>+;%JLNY>U-YB(5].,2XE2A]>Z&U,1C/W2&24YG"OHPXK
M'TY8^1/;#U`>O_D6,.:C[C0!KQW9?N9C:"';D#HLF3KOJ)H>D!HTPL0BB!<)
M@IMBP;?EX?(E9S,:,A;BW'GW4(3A2E8QS..*65^2(%SZ'`#'`5/K`$GJ"YVF
MZ1JVM7K=/TB":ZOWLD<(X8S(\MB8Z61P:T..6.-CY'NX-8USG$`$J#_4DQD@
M^*G^\ANU1AB],:PD#H<;H@)D1]DK]5]NB*'HZ\27&K0^AE:?@,YR_P#<*3X>
M;&<8W^]U\6YQ%+D,?,KD-,GTW#T?+P7J&^&/B.ZU;?-T+6C9/TTZBV3N<V0V
M`(!O`[ET[L*CV[T*$&M""N>4UUL6MF(@+[7[;@FPD+HYKL:#N]!Z.GI,R_HA
M"RRZ,P+5I"MD)=H9&G8+RX#;F)2693*LIQZB<YQ;8WCV&1D<AC#,Y(:2`RI&
M:M/1J"*\,"N)9[`WSJ%A)JNGZ3JD^FQ:?W]\K+:1\;+(ODC%XY[6$-MC)#,P
M3$B,NB>`ZK2LM4`7=\^&S9M.^X)UAW]7F2)`3\3?^I\)8U\H(D9BDQ4BXZ!W
MS5H\6="?QY'L)&.*;RK&?3SC./'":WN+9_+N&N9)0&CFD&AX&AZ#T+KM>VSN
M3:E^-*W/976G:H8F2\FYADADY<K<T<F20-=D>W%KJ4./2#20KW1WXUMCU=I]
M.-?[N`Q_IF67IQOB/(M:6$_U\EK2O8T)JZ5-<PG[KX:!:R#ZOZU"7%>'CJQZ
METM7@8M!\RNS17:G3'8E^S!=?V`T,V#0TP\['TSLJJV'5^[=;Y(*4W!=NNKK
MI!%68>*GO(4B*4CM2@\Y2<_#2WN`056N:[`<5L/YE?V2OZN>59T">97]DK^K
MGA*!/,K^R5_5SPE`GF5_9*_JYX2@5=E]P:JKUP_!Z?V=1`E\^K<ZXYIQ>V!A
MUD35!D:5.(6)8F7,:EMB(4&`_(<>4G"4QV''?^#;6I/)99W<D/>(XI'6^8-S
M!I+<QP`K3C4@4ZR!Q7J[#8>]]4T'\JM,T?4[G;/>V6O>HK:62#O,CFLC@$K6
M%IE>][&-8#4O>QGI.:#Z,[IU#BOP;7G:NOL5<I3B>PQMAS<`>`T^A!94&`8N
M<4AF;\,]61<\I&COS,*]%N0^AK*L.*PGE[C><PP\F3FAX81E-0\@D-I3TB`2
M!QH*\%L^#W?AU271/>35??F'4([&2#NLW-9>RM>^*T<S)F%Q(R.1[(J9W,8Y
MX&4$K]%[HU";=*,!MK:\+/`Z7#V.::&W,#-6)U\0AY(PKN23'GN9A563`QZZ
M9SGEC^EE*\JPE2<Y.L;QE"^&0!SRP5:15X-"T88NKA3BE[X>[\TYD,FH:)JL
M$=SJ+K"(R6D[!+?,?RWVD>9@SW+7]@PMJ_,"VE00,60[!Z)$Y/X*[JU>-S51
M=;.6=,^]UV(JNAKDF`NHE#2'R"%C(-F05C*@./80F4F0WEOS85C/,FZ=?ORY
M()3G+@VC#B6US`88EM#7JHN9:^%GB7?=U-EM[6IA>S7$-ODLYW">6TSBZCA(
M81(^W,<@F:VIC+'!U""N/^4?U^^/)"OPZ:F^9AK(+II<?^$*L9F"[8<DSH0:
MMD(^">78AHI+&26V(Z\)<<5'=\,?<*\+[VZAE#N1-E<TN!R.H6BA+AAP`(J?
M*%M^";Q2[K#>_DWKG<[BTDNHG]QN,DEM"UCY;ACN71T4;9(W/>*M:'LJ>T*S
MZK7JFWAHR]2KA7+<S7#Y&JV!VM'!YML'9A"D)*5\LL=(D)@%X&7$^JPYY7$>
M;&<X\,\X\MO-`6B=CF%S0X9@15IX$5X@]:\QK6V]P;;?;Q[AL+NPDN[5ES`+
MB%\)FMY:\N>(2-;GB?0Y7MJTT.*E'F5_9*_JYYJ734">97]DK^KGA*!/,K^R
M5_5SPE`NL`;5MZ]@^U'=>OQ>YW8W2-)T;?=&4NAT73\#0B0$>!<>N6OMCV&>
M0D['TKL"PS2<^T6&2YYOCDM(;5A"6\8QS'$DT*U4+GD5(`\W5YE:GY(&ZOUE
MG>;_`/->H_\`LN<M#UE7(?IC['^10NTZ(LU&227=?=G[;U)(>MOW(M]8R_3,
M/D94HQ2(#?LTY,[K*RJ,#0:GL0\25XPVJ4\AE.<N*PGF^*UNIZ<ADC\SLHH"
M:NH3E%!QH":=6*]#HNSMV;D,3=O:=J%\;B\;:1<B!\O,NG1NF%NS(PYIC"Q\
MO+':$;7/(#02L7$U)+(*LB('N_\`:*<JG5*!?K;B'9^E$KZLT8H,^=#;@=RQ
MUJ7@969P?.)3<UWRL*CJ2OS>5:<YR-C>MRYHY1G>6-JT]IP-"T88N!PIQJN;
M/X>;]M1:.NM&U:,:A?/LK;/:2M[Q>1R<J2UAK&.9<,E]K=$VKP\%M*M(&5`:
M&M%JL!^I5CW9.W5BM-4BB9UHK84KTT)':Y"/1FYH24<%1.LCLT4P7AO(=C*?
M0C#S:L*3XXSS&2UN8HVS2L>V)Y(:X@@.(P-#2AH>-."X6I[/W5HFEVNN:SI]
M_::+?/E9;W$T#XX9WPN+)FPR.8&2&)P+9`PG*X$&A4S_`"0-U?K+.\W_`.:]
M1_\`9<YHH>LKSV0_3'V/\BC'7Y&X-;]U=QZ$NO97<782BP>J&E]QU]6XX6J&
M3%9N%KW'N.DGOE,S5NM-;M.C9X2F0<9:EMR5(=0I25)\V<<"M<<11&@AY:34
M4!Z.M=B7F5_9*_JYY5LH$\RO[)7]7/"4">97]DK^KGA*!>/*B<(G"+Y:O<EZ
MS=T?<2[@=O:SH+6NI)FL^N_48'U7KEK["$=FT9YC:VW28;L7<]D=:Y5>JY$1
M:K[52%&K0;,Z0[@:P_'Q'4O.5N^34X.<[#@N)*U\CR&\`*?-AYNKYZUM[`:_
M+>X-4.QO9/<77G:1'9,#V#M86ZD!K#1=BB"M,[FT?9NYAEA=JP1$&$N3M^NV
M@,[(%MM-/DH\$AAQA/I3,J<Q=F)''A^H?U5K>'OH:'T?U'?JT6;[,=8S5_F>
MX1V--ZBV58^P>MKE[)MCZ][`17]@O6NO'E4;0</=-DULW"92W*-^DB5$M,V*
MR\^PS'4S,6VEI2<4CB?,LW-)+G4-1EI["M0D5MXSM--ZWO:FWNO80C_>1Q';
M6>4AZBV"]K2%USO%==S3=BO;4P#SK[Y)89\OX=EE,Y:V5LNK?0TTVI>(VM`,
M:U4;7*&D&N<'IZEU[56HVZT7#L[=Z1UIMFF3.V/;D]W&D;FUA4M`]G8A^#N9
MZ4D]2M>[QW]MPG9%=J-VF8Z'2HR2+8C#QD62S"'I=]1*&W7AT%05))`IV7=?
MS^E?0OWTUZ=NWM+]=]>)I]C/SYEE]KT59ZH.KI8H<CA8.X-`M79)(%$AODHL
M<&'9E+(Y=:2F&RRXI[R)0O.-CO1'J+>\$Q`>4?/"Z%>L_67N<)WAKNT)H=_$
M[HU5<>]W1'0=K?K%C',BJ+U.Z"[.U]U[MRCY`<V/$"+ML/8>,"2;CB!\V>VG
MX=UQ2>8`&OE_X%H:UX<#TBH'J#!034NAM[N])^V#/7ZM['")_)GZ:5'MMJ"I
M=/\`LEJ.-;+;4=]ACW8-ZYRMA;?*7#L+V6@ZT9/QKXY3(@UBS5U]*8\Q#CK;
M.)C3!`TY3EKP%<#ZOL+8JB]?-90AW1_<=PUC8]A=5J[[QITA3!M0Z?[_`-.Z
MTU+K*\:+9'N*TYI6WW/9FW@O7RT=D:B`+QY9-D>Q%.QI&4LIC85ER$'+AQKU
M*%AR"G'-@:<,.KJKY/45B:8ZA-[XN?4G7?8[1UUN.MXD;W[CEKK=PJUTB5=T
MZ5[-Q36J';2CX:%$?P94O!2N,RU>G->CLS(:7%,-N(KJD#S_`*JKFDAH`/$_
MLA7V/\JTYVU1BD/J/2;3W)Z_=DMM34>PW4J9U!L\"C[).N]>>QE)E;.E[B*7
M\K$Q%SI"TMU5(*=--V'X1N76Q[T+U'<*S%<AQ`XTI^I_^'S8+%U<H+@:9.KR
M'R>;YU>(7?'[AM'N^Q/9BZWT^@L6Q5O)S/:^^7DJ579%HLU8^&ONCWY=V@`D
M02*)/U+93DFYF2RN(VF-E4C]JPOFUWH>LN3)C`*>14AWD]L>1KG1-H,7#<W8
MCNOO'M=WO]NJN;XVQ<10D9:W-*ZXW*R#:K("NZ9!`AU)HU:KEB)/SIT=+?II
MD9><=92C&<89,H'SEJ,.5H\I%1ZH\@\JTV[H]8@&M.P7:W35+ZU;Q7VD^;])
MZW[(%XU-3=HE-;Z,U50&*?'LP6E;*!//T74HRBW6-8)UY2=DL.$H$E*W,OI6
MG/)E<#3I`P6#F/:[+T@"A];R>>N(_P`ET4'4`"P^\K>+G=-!;KE=`MK[;WSI
M[74B:'L?X&QGN&VC2%/IW83L1#ULZ!Q)KFM=OUG!6MUZS2,H$.6),J9'<3A[
M"D4#M8UR_J^SZZR:T\S$')7V?9\Q/2KL]E>A;3.;\W`G<\,BI[VN-0L>U'K0
MJ2D+DXLI`#MJX;(NE^BJ4M:?B2FIH&O1[B\_MOIH5C/T*Y64X_-\W!9VXJXG
MJ%//\PHI+>>Q9[VU>Y7N=F-@=;]_;RE]W)VEMR]/\ZGU%;=FU+<MOJVDH^H"
M?72V66LB3$'7A(1;1K2G5%T(B_)I[DA&',^5MT3E<<*U1SC'(XD$UX>MP6@?
MN3-;!V)W!`VHQU.G:A["ZRG^V'=@-CJVI^Q&_-@SJWF]U:P;I8T_O>K3!NAN
MO&H]!$#$^OV=,(-DM;Y;>,OMH;<PML[$\,<%C)4OK2CA3K]7S#YZDFP^G@0=
MUB[B]AK#H395CG6KWHKXQVZ9!5W81/8NQ?;?IO;5%MLU,K%,A.()6'4,B9F+
M8)44)$S@Q&Q)>PI]'F\)3B?*H68.=0TS8^:OKKL^]E.IU*KX]QV5J_5&PM.Z
M-MO>J3:-"538M$N>NI[FIIVC-5MULC7JS?(`ZP#:?(PTO(N*ZVG(^#EJ(IME
M3.6&\HQ08K;;@AIKU_J>I\Y=WO-BY"<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(G"*O=NT25M+4NT]80;8:H4[9.M[U0(=YKF<IL%,
MEW*KE*['M03*7HZOFE?>(XE,>5QI67&L8PM&?!6(1444(J"/(M`=2=GQ'3K6
M.O\`0W;?11+JH&U36`E"KVV-5TFP7SI':18"$P,BV2L7VB""Y/2J#^(_QDH/
M>QP61"DO.)^.GXQ\6YB#3`K4QW+&5PI3UEOMK/=&FMU#&C.F]NZNVR*>3A:)
MVM=@5.\,^&<8SX.8K98BXPO&,_2AQ*5IS]&<8SS($'@MH<UWHFJP?8G2^=T:
MTD4IV`)07C6N@6^M$;)!D.Q0)JFW<#8%F(7DC2'HQ=(6#,C17D(RIMR3^RC&
M<KQSM.NS97//[60L<UP'2'-(H>&%2"?,OH_A7OR7PZW>W<(=<]Q?8WMK<1P.
M#730W5I-`(GU<T.BYSXI)&DT+8^#B`TZ=6+JKONV3]GRR#77@/-O^[:E:!-@
M$OW/,FF:KH5L<M='#!JNS31->>*A2*7IAD7,5,@VXF9F/S)C"&F&L]Q'JNGP
MMB#>\.$<#FD$-HY[FY7$NS%U",&N%#&&M#6DDE?>-*\:_#+0[;1H+5VZY[?2
M]NW-O)!*VTRW>I7ML+:\EEN#=RSB.5F2*TN8A%-IEO:6\=O;RN?(\0L7[?>V
M@A&1B/MNNV"43W9:]B9VFXW=J5L:O!K\%U+$V*2S7*T5(4G8MFV-F@3X).$;
M_M)IN<S-COMN)<B\WNW!:/:*PN:!`UF3LN82PR9!F(#F!F<%I;C@6D<"O0W?
MQH]D:E:LYFA7=K##MVVL?>T=TN[">6REU-UC'S[B-EW8V]AWV&:WEM/;7.AD
MMY8GM<V9;B=0]%W_`*^Z:9H-],CS<D:7PZ,>#D+(;%"*^.J]7K,5CZPVZ)#.
M2UE)5=?*K9?QE@7\P^7QEJBQ659Z?6+V"_O#<0-+6D8U`:227.X-J!2H;48N
MIF.)*^#>/'B'MWQ/WZ[=>V[6>UMI;>DO.C@@?),^XN;ASC#;.=`P1MG9;![2
M'W'([U,&S3R`<+:7>'J%IF?\BOW8C6+%P<7Z,/7%2/8V;M8K*SGRHA!]4ZR9
MN&Q"<UU?W*6V1BLY5]'T<ZG,`OBQD8.)Q5`UL9LOMAVDT)V4=T7:.N6INMX[
M9J*Q=-QC8U5[*]A&MFTZ74,T)6M84J:9U=UW&/2V[%(C6M]HV5/#1JV14!,=
MR0[.)JL`"Z0/I0#V?F]?@NR;F:W)PB<(G"+0S:_6+9]XLF_18$GJ!O7N^XSU
MBGV.WA3AC9]/N,31N-."J]6&687R:#69+T&-.>+(F)G1H,DC!1#=Q*];'>VN
MIVL$5N^03=X@-,K2`QS>;S"78U+N(RTH2&FHI1?IK9'C'LS;FD;7O=3AUX[J
MVP\0,@M988M.NK5VL>^LD]P2_FON&A\D+;8Q&&2:.TN73L,/+,7B=2-HUP+'
MN%0QHR-O21JKL!6YY$X+*EZ3!NFX=Z5_<E-9CJF5B5..TS44ALDL<F5!;RX2
MRR_\*E+KN$;CJ]K(\PR\_N(FB<`"`[+'$8W<'`!TF&:AX5%<!7NI_'39FK:@
M_0==_*1_ALW6]$N&,ADCBNWVFEZ//I5V7!MPUD-WJC3`)S',X"WYD?.)8S-`
MK)T0VQ<ZPW2DVO5VJJ_%Z]R-1O.U;%MV.2NDHP4HUAL`:^8M@ZKQ98LY8*8X
MHK8(7PI(T.G,P7X*6(#:7=\>NV<,G.R2RO[QS.UE8&@!P!;E+L0'8,-0T@N#
MJNP]-I/QE]C[?UD[A-CK.MZH_=3=3`N>[6$=HV*.\@@ELN[27+FR0P7;1;64
MW,M[2>&2YBN7273RR/6GH!NXQ"F)&7^C#9\6-K(FK(ZZ[@`#=E7VIT2%0'[I
M:($?YJQK,C4@Z7T0$UO"HYYI++<]F.G&<8V1;@LF.!=&\M[8Q9&2QKG%^5IP
MSAQI7/BS$M)7:Z+\:'PYL+B,WFEZE+;/?J$?MEII<\FGV5S>OO1:6SW<MVH1
MW,N1TQOR'V;C(ZVDE)"M;<?3#8VR1;CT6WTARY2]K5X_.L4UHM7DO42KZ>@Z
MRKC:V@(:5\4Z)/R"YV;6'$8!'\E7HDI]+2\YYQ+/6;:V=1S'\GE.`&#NTZ0O
M/$CB,K0_TF900*A>(V!\8/:>T;T1SV&HC;[-$G@9`PQ3TO+C5'ZA.09I6Y1)
M"+6SAU`$WEEW:.>&(O:`KKZK=>+'H:5N27830N:S?[@%>J@,(4*%QM8I%/&D
M!5;A8F&`P6<U,E1R2\N15XG*B-M-MYGS,XR[SA:KJ$5^(1$TCEL.8D`%SG$%
MW`D4PXX5^E;P7SOQK\5=)\3(=`@TJWFC?I=A*+F::..*2XO+J1DEP_+%+,PL
M:Z,99!R1*YSWBVMP<BVXYU*^%IPB<(M%^L+:U]M?<X\B%K\-W=9OZU.5?_Z;
M:B_I8S_3Y@/2/S="UM]-WJ?."WM]!_\`^0N__@U__8YFMBTZWKUZV!9[I<-I
M:9CZP#;*L6AW]4Q#M^$2Y26[(ULNE6RLVP@IBNV)$I=!"@IKH3+C#^(9I;#V
M&<H]7.>XL-0@B@9:WG--LVXYE&GHR.:YH[3?3)`=B*MJ*\%]]\-?%#;>C;>L
M-E^(!UNXVA:;F&I.ALI&MK;G3[NVN+9F:>`M%[+-"V[RO89;02Q\P.R!:U7O
MH)MK8-8,4N#9-7Z@K&.NX;3(P?4X=NV#]:DP%U0S]7[_`/6R#7_`0W9:QG!`
M_!RDE8X*X2)L%*1S;+G90:[9V\C92R6:3O!D.;*S+7,*MRD_0NP8<&'-E=VB
M5]>VU\9K96UM8M]PW-EK>O:Q^5<NJR/N76UCW;.+F+GV7=GS^VFWN!R;*8&"
MPF%PZWN2;M\C-F.N_7C8NHMC;'M%B-5^0"N%=K,21#K)6^3<7.[CVX2">R3U
M9M;\P#0#30V&D6F(`=5"GQDI?=0RMMMI/6ZCJ%O>6\<4;7!['.](-&5IK1@<
MVA>*G-5^(.`K6J^/^*WBCMC?>T])T72;6\9J5A=W#FON(K-G=+-Y>8["&XMF
MLFO8C(\W)EO6B:&0NC8Z1KG/.X7H/_\`R%W_`/!K_P#L<Z=?!%HC7$+1[H&Y
ML+2I&<^WUUUSC"DY3GP_*2['_3X9QCZ.3I/F6`^R']:/GE;T\JS3A$X1=)'V
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M)\E_='X]VQ]^.]Q7[GWV]&*3E*NK/?#*<H0UE.='Q,IRVWGQ;;SC-O\`#*&\
M_P!;C]C']#CX+]4^[]+^W.^L3Y+^Z/Q[MC[\=[BO)7ONZ.6IM2^K??):FO#T
ME*TA%4IOP\,X]/.;?G*/#./Z'AQ\%^J?=^E_;G?6)\E_='X]VQ]^.]Q7[]N]
MH_U%._DN=\O56G*%N?@1B^HM&<8QE"E_7#S*3G&/V,Y\./@OU3[OTO[<[ZQ/
MDO;H_'NV/OQWN*\<^^WHU6,X5U:[XJPKT_-C.CXF<*]+'@UXXS;_``SZ6/H3
M_8X_8X^"_5/N_2_MSOK$^2_NC\>[8^_'>XK0_M)VS]M?N/>8FQMX]+O<NEVG
M-%QJRU/T"!L#5H[:6JDG'+(G6&WP]$VB%';)HN#3[KWP))MS'@\XCS>17EQ#
MX6ZF<>_Z7]N=]8M;OBM[F>:G7=L??C^'VI;Q#??)Z]A8,`6'ZE=Y10P4/B"1
M8\?H>!$ACA0^(U`@CH;#5N2AB%#@LH9;;3]REM.$X^C'+\%^J?=^E_;G?6+9
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MCO<5X_;MZ,PM#F.K/?##C:4I;<_`?$\Z$HQX(2A7UO\`,E*<?L8Q^QQ\%^J?
M=^E_;G?6)\E_='X]VQ]^.]Q7XY[[.BW<XR[U8[WN93C.,9<T=#7G&,JRK.,9
M5;\^&,J5G/\`]//'P7ZI]WZ7]N=]8GR7]T?CW;'WX[W%>'VZFAOS5.]G^8N#
M]]W'P7ZI]WZ7]N=]8GR7]T?CW;'WX[W%/MU-#?FJ=[/\Q<'[[N/@OU3[OTO[
M<[ZQ/DO[H_'NV/OQWN*?;J:&_-4[V?YBX/WW<?!?JGW?I?VYWUB?)?W1^/=L
M??CO<4^W4T-^:IWL_P`Q<'[[N/@OU3[OTO[<[ZQ/DO[H_'NV/OQWN*?;J:&_
M-4[V?YBX/WW<?!?JGW?I?VYWUB?)?W1^/=L??CO<4^W4T-^:IWL_S%P?ONX^
M"_5/N_2_MSOK$^2_NC\>[8^_'>XI]NIH;\U3O9_F+@_?=Q\%^J?=^E_;G?6)
M\E_='X]VQ]^.]Q3[=30WYJG>S_,7!^^[CX+]4^[]+^W.^L3Y+^Z/Q[MC[\=[
MBGVZFAOS5.]G^8N#]]W'P7ZI]WZ7]N=]8GR7]T?CW;'WX[W%/MU-#?FJ=[/\
MQ<'[[N/@OU3[OTO[<[ZQ/DO[H_'NV/OQWN*?;J:&_-4[V?YBX/WW<?!?JGW?
MI?VYWUB?)?W1^/=L??CO<4^W4T-^:IWL_P`Q<'[[N/@OU3[OTO[<[ZQ/DO[H
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MV?YBX/WW<?!?JGW?I?VYWUB?)?W1^/=L??CO<4^W4T-^:IWL_P`Q<'[[N/@O
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MWU9<<MCG4&FAKFIU6?'+V+I6K`%MB7_-]/GQ-PO&?I\?'D^"[4S_`->TO[<[
MZQ8'XKFYCQUS:_WX[W%5FUVT]O`5]%)ZT^\3JUM/_!1M8;=[154?'\/ZU,81
MGL:0#L(3^QA*8^$8Q]'AQ\%VI_=^F?;G?6*?);W/T:[MD?\`;7^Y+EM]Y>LT
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MU=#Y^G/53O9G.?ISG.BX/T__`.7<?!?JGW?I?VYWUBOR7]T?CW;'WX[W%/MU
M-#?FJ=[/\Q<'[[N/@OU3[OTO[<[ZQ/DO[H_'NV/OQWN*?;J:&_-4[V?YBX/W
MW<?!?JGW?I?VYWUB?)?W1^/=L??CO<5^I]];0R5)5^2EWJ5Y<XSY5:*@Y2KP
MSX^"L?6['BG/]'CX+]4^[]+^W.^L3Y+^Z/Q[MC[\=[BM+S/N$Z-,F2YC!WWY
M0V"Y4B5P'`E@0X")P1F/3/E8,>H3(5`##O6]&*QEQS++"$(\RO#QSC\%VJ_C
M#3/MSOK%J/Q6]U$U]_\`;'WX_P!R6-_+WT;^^_W^_P#K$`_\Q\?!=JOXPTS[
M<[ZQ3Y+6ZOQ_MG[\?[DGY>^C?WW^_P!_]8@'_F/CX+M5_&&F?;G?6)\EK=7X
M_P!L_?C_`')/R]]&_OO]_O\`ZQ`/_,?'P7:K^,-,^W.^L3Y+6ZOQ_MG[\?[D
MGY>^C?WW^_W_`-8@'_F/CX+M5_&&F?;G?6)\EK=7X_VS]^/]R3\O?1O[[_?[
M_P"L0#_S'Q\%VJ_C#3/MSOK$^2UNK\?[9^_'^Y)^7OHW]]_O]_\`6(!_YCX^
M"[5?QAIGVYWUB?):W5^/]L_?C_<E+*)[D6C*+<*]<%.>^+>4U^?B?FH;'<"6
M>BV#&&'F/@+17VX(QPL,SZWGRUB0UGU$)SYOH\,AX7:K7^<-+^W.^L5'Q6]U
M`@^_^V/OQ_N2VU^W4T-^:IWL_P`Q<'[[N9?!?JGW?I?VYWUBV_)?W1^/=L??
MCO<4^W4T-^:IWL_S%P?ONX^"_5/N_2_MSOK$^2_NC\>[8^_'>XK378'>'H)L
MC9=XVZ5ZO>[)5KSLEVM2+U+U3;-[:?"V694*R.IM>(D:MK3>=8K;A(?61$:'
M\1\+AY;36/.K.?IY#X7:F?\`K^F?;G?6+`_%<W.37W]VS4__`-:_W)1C\KKH
M+_B.][7](+MQ_M*\GP6ZG]WZ9]O=]8I\EO<_X^VS]^O]R3\KKH+_`(CO>U_2
M"[<?[2O'P6ZG]WZ9]O=]8GR6]S_C[;/WZ_W)/RNN@O\`B.][7](+MQ_M*\?!
M;J?W?IGV]WUB?);W/^/ML_?K_<D_*ZZ"_P"([WM?T@NW'^TKQ\%NI_=^F?;W
M?6)\EO<_X^VS]^O]R3\KKH+_`(CO>U_2"[<?[2O'P6ZG]WZ9]O=]8GR6]S_C
M[;/WZ_W)6KH_W&.CO7JXV_8.O^JGN?%;O>:K7:18K/M9&T-V&':E5#!NP`:^
M-F[7V_;G@@R":L<V3Z</+*7'9"LK\W*/"[4QPO\`2_MSOK%6_%<W.TU&N[8K
M_'7^Y+9S[=30WYJG>S_,7!^^[E^"_5/N_2_MSOK%G\E_='X]VQ]^.]Q3[=30
MWYJG>S_,7!^^[CX+]4^[]+^W.^L3Y+^Z/Q[MC[\=[BGVZFAOS5.]G^8N#]]W
M'P7ZI]WZ7]N=]8GR7]T?CW;'WX[W%?1_SX\OR,G"+5?N5W$T]T1T6<[&[[1>
M&=55@P`$6<S1*0;OLVN8LL](D68,B0#,B?#`*+OL179F49:9?E,X7G&%^.*!
M4T"H%<%KYT5]V+J#[B\#;)OK,5V47K&DX@F1L*VW35UJHE9%OF8I(A$%1"E@
MBQVRIAH6*=EOQH^''(\;+:W/+AUKSTM+>*%I'%7O1.\_5?9[E\30-J-6N-K.
M@8VA=BPFG;`>KH>EYJM=O'S%NS*JB*\7(8J5L'3\C84F23PQ+1G,?Q\<8E"E
M"L':O<0Z54N.-F6+L-1XT$L=A5Z&1@I.&QF)<RDT?8SA*82!!R4$95`])V77
MB)4Y)<9"AF34/$Z5'6^VE3*4H5<@;L=H^PS9(X)L@`2FQ*]M&UR&(V9JLMUS
M2M_D:LVF7\^8B6U1*7L&(X+E93G.<R$^+>%H\%\4*4*ACW='JQ&B"9\O=U*A
MPCMET13@\F9*F1&B-G[.18,W0H2*J3#:PY/V;$(LN#D_V"_%W+>,*\%"E"H9
M:?</Z:TX;4RAG=PEUF]"X9FHPZ]6+Y<#AX?/*7<+&=@UNHU4Y85/**:UL#*V
M514O-J#3/.A.([F4T-)2A5KV'M%H"IV</2;/L^O`+A8*35-CAZN6P1@GIU'N
M^PZQJ:LV-L5(@HFH@D-D7,4'5A:$N1IL]E+Z6\+QGDH4HJ"*>Z#T/$`+9:)?
M80$\`I%L#TRQDA=4V(<9CE['/.AZU.'I"T\@\?J%F.U@@-&6`>F4!(E(JX4>
M8[*QAG-RN3*5?Q;M!H2OR%PS^RP@":V*TR<=@G&"P>>R*["6HK2-.S7H)$=&
MELMW6V`YD%K"D85%?BNXE88PA6<2A2BU\Q[HW0]=9@W"/OX=/KY.[B]=CY@J
MC;1+2)=LL,"&4J,1@6,I$LJL;?AT]I^MDL,?++*TK*A<B7A*O+<KDRE<PC[F
MO2`2`-VHCNW$2M`+DYKZ:><UQMO(F3;XZ;LY/$`IZ*$J-:/DS.MSKA"0,5+B
MCFA;[DEQI"?-EE<F4J\+1VJZ[TU#3ECVU4X#,G7=6VS`DMRI!"(6US=K<(H=
M3MH.6,C3(QP4?N%@@0(V8:GUK?G1ON?*^UE<H4H5R=?=GM`;5M8FBZ[VI5;7
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M#,2`?*"[D*>C!W%X+OH(,>2*K+B<<92E"I75>^W3ZZI9Q6]\TR;+=&UXLL/(
MP9$V*##M.VBNAP_S:M&!4"P!9B]PA9->D1I<9B3!)(PW);9PMO*E"E"H'']S
MOI#+#T.P,;C)*";1LL>H:Z**U#N]J'=;#-&C#,"#6WG=;(2503#EF9<5]KS1
MI4;#CK3BT,/J;N4I0JT[]W8ZKZOVB1TQ?MSUBL[(#U0A<S%?G1S;C(@*,J9^
M^R&"I^()D5H;9'J+521J,%>F(,S1,%Z7'BNQVU.8E#2O0E"H_$[_`'46;H^X
M]CXVX8B]-Z\-1Z_?;6JH;!:ETLI*'!C4=NTU)ZI-W4%$=`V*"1Q*DCFHORR6
MU,]3X96'>*&M.E*'@L4']Q?IN>G$X`[<*O4!AJV>/2B&O-JAQ-?A6]FIR*PQ
M8#ABC0`H(T;CWH.XP-ER&2*FR+"O0PE>,\92E"I1L3O)U:U1=[_KN_;20!M6
MJJ>Y?-D1_J;L$J(I%6;K3]Q3/LEJ"U0C51<F56HZI4>&[-3-DHRE+3*UK0E0
M-)Q2A7(IO=[JIL`.P>J6Z*R3'.DZ($=R[&/"IPTYLO:5BTI201T28$0"U=.&
M=JU,B$S"GL1I469$7B0AI'E7E0I0J-TOW#NE>PLPDU+L-1B*BEX:UV&1)^=!
MG#]IETNY;$#LUQLX)&KL06STK7AP@%+P<2!!MD7(Q`DR5MY3P6D<4H5.-4=P
M.NN\KR8USJ;8?UWM`$+"/EDBJE>D5Z*.(!:M8HB<76=68E*D$G0=U%RO@6B"
MYJ69B5*:QX+\H@@5*4(4<MG>[JC1K%MNJVK;,<29T6@<C:*%U"_RAU<*&7*:
MP%JT<Y!JDH%9+T<D;#"-P:^*DSC<QTFPAF(M2O#"A2A6<`]SNKUHH%SVB`W+
M5BE#UWJH=NR]6",@MZ53UD4DWZ#&L9V"X-03'N-$M6V*))@.,8)0YH>3'D1V
MGV\M\4*4*\(O=+JW*Z_VOM-^&:JPM!T-9=F\[#,H+@85*F`";`<R+MP8T,'V
M6M&AQ*4RTY!FPF)>,OM9]/RN-Y4H:TZ4H>"EUI[+:(I-<V_;K3LVN!ZYH2:$
M&[;*/N2W6*<4LU8J=QK0J0B-%??*%K)7KV&>'18")4B<X3CL,(<?=2UE0J44
M`J'>CJ3?%@X]6WG3B,^QA:J?%!WOFPJP*&W/<CG7H%F?7C`R`<#3L[N955YL
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ME"LK7/<-Z=6TQ2*_7-RQBIW8,VQCP0=BE;(03'2:@:@U^SXO,)^G-2-8,`BQ
M.,W)>LJ1++:)#;N5>DM*\S*4H5%5>Z+T+Q2T[!3V(`/515ED57$Z+5=ARYOQ
MT>FRMB_-L@HM/>L":5+U_">.1;%F+]7Y@AE<QB:Y'0IS#*>"92ISL;O[T\U2
MQ?I%WWM5(+>K1.JS^Q/D\2Q6]RH5_=T$Z2U383;-."'WHM?N\"M3'8<[RYB^
M1M/G<1ZK/J,I2A6/D>XCTPB2Z6/F[WKH^??;1(IH&$1"W$?+B6"',IXR7'M\
M:;6V'M>08IG8`0>Y.L"1D%!,I'AY>Q*<PSQE*4*N35G9#1F[I686I]EUN]RD
MB3)Q;()Z2]EL97=A6W5!Z0ZIV,RAI8?8]$,!Y#2LX>:FCW4*3C&,9R((XH01
MQ5*D_<7Z6B)FT1D_>H1LKIJRQJ??P[-;O4PS"L<O8?X)6QE>#PJM()WQ;.SO
M`"^X`:)LQBJT1W5H<6E.64I0K@2/<HZ409UR'&-V-5R3KO4\C>=ZS:]?[4J4
M2I:FC!_GCEV/D++1Q4`8+<@X6EI+KJ9#\IIV*VVN2TXREE(2AXJ:W?O3U(UQ
M<VM?W7>=/!6IW74S:_P3J3$N"Q1H51L=_P#F<P^/%RZ]`(D*-3RQF`+>E-E2
M0L;)E1(SS++BTLI2A4]LW9G0M-H>Z-GVK:%9`T#KN],C[KM1)Z5'%:[?@4VL
M[!E,G751?4PXW3;D+GXPREW*FIK:4^*\Y1B42BB5H[J]5*9)NL*R[QI`R9KF
M("(7:*J7+E2:Z/M&J;EO"N3YS$*')<S!.:HUX;-17F\+;?BC'\(5EU'I\M"E
M"L<SWGZIRM)/=B8NW!\O4D:Z0=<2CT.MW66:B;")G!U<'4670H]:=V#%N$XP
M7B-,C7!29CB93+B6\M.H6I0UITI0UITJ(-^Y%TME*S\JW0BQM-Z^'[2DS*CK
M[:EQ&CZ04$SS<`F6*5:CEQPB<^-%25_+I3K)-*X[C:H^'491BY2E"I!3>_G4
M"_5%J^5;=U?F5-_%+6P6G![:!2]'V,]<&*'-:AV"O"R#@VWYH!A8^3AK,>4S
M!6ZA>6U-K7*%*%8.J^Y%T?N8=@Z"[#T[X*2,OQIA@S!M%7,NB=8:W#[ANQ)%
M<M``/8<PQ6JST2PM.?"^6<(=^)B9?:2M264IE*E.UN]'5;1^P8NKMJ;59I]V
MFT4ILR.,FT_8$R"J@@H$HH=MB[&*JD^LL!P4&)E<YUR8GX/+K*7L(5(82XH2
M@!/!<FP]W>KU8V2/T^3VBT_LLE;)M(9J`"HWVUDXEC&M:]?(13*JM5C,2OP8
M#6UJZIZ=/<C0&L%6?,]C[ORJ'CT)0\5[;+W:ZKTS:-QTS;]S5JK;"U^"+V2X
MC+#%/!@X$77]>QMM'<2[F0$1Z4LF'UA*18),!HBN<P'\TI;.&4+6E0TJE#2J
MK''N=='%#Z*1;W=Z[>R+"<J%1AQM:[>E&YMNK<:,0,U,E78]`=/UJSQ`LQHG
M@>3C0YCPAQ)!MM<+/K\92E"O1`]T;H81"A;$UV%"Q@Q^XFJ(.G%JAL@$VD]6
M)`J#;)!)LU31[X2K4TH<APC9Z:F.##$)+<2;+8DJPURY7)E*N2D]R.L&R+^(
MU;1MT4^S;"/'-XUL34QC\YPM+.=:[*&IV\QV&G(3;;+VN;+8842;EQ2$+<D)
MRSEU/BK$H0E"%3S/NA]"I%$F[)C]BZT_4H%G'U%^0S7+ZZ9<*E*T4ND&5!J2
M*FJW$ZR]30<\QDU&@NAD"H$F8J4F/'><1<KN"4*RED]RCI!4C-Z`F]_5]LAK
M<1*/6M0^NWHZ-9#CAE2.EYX(V"JI(+<6`->O8@F2^3R)^1HR<W,E8:B^9U,R
ME,I7J(^Y?T:$589<BW8&O#`):>-@17"%<O<,HPDG4XE];,%:[(JK=B!52!22
M$<N0-3HD<0+&R69$R2PTZVI3*4RE7K3>S6@MAV$I5*1M2J6BQ!"NU@9@2'F.
MRY0POH\E31.UA\W"&/)'DTR=L,'B2E6<>HV4CNL^HTO"^*%*%1[5O<7K%NP@
M)$ZIW/3KP4.%?D8P>%D3')KY;.KZMNE$)R,_#8=B.O:KNPHVWZV&TNPIB,HR
MI6%I2((XI0JO:C[BW3*\*MR:]NT>O-$1?U6SYS3]B5;`=6JZS*N>QV'<VFH!
ML2)E*JT-<XBPSZKT9A3>5)QEUK"V4I0J?:_[B]<-IFMC@J%L9-@DZD'FRFP2
M+52O,&K@8E:>Q'L/DN92LP:B8E!'\Y3*CP)TJ0QE*O.C'E5X*%*%0>M>XATT
MM@0981>\`\04<JEZO5?>LU9O=*D62EZT'4DO>;561URJP$E8P%>%;&"R794%
MF0RXQ.2MI2TH=RVRE*%20!WCZGV?8)_5@+=E6GWZM;!$ZL)5[$<['=?O9HM9
MJ]#"`ITH0P+M"&;+3"PJ7+&/S(,`L/?@R7F9;:F<*%*%<*R=].H50O&SM<63
M>E3$W'3E?+V/80J1'/*9$1*_%KTP^,'%V0[H6U6X#'MPE4X"(DSC</).)AZ(
MA4AG"V4I0K`L>XOTTE21T6-N=B0X0U\4VF\MBC;,>BURBA,WY!DS>IK=,5#U
MT^*DZML4>1"/.#2#,L/)CK8P\WEOERE*%2<;WFZJ&-&&.R(O;HV;IVO6D;1C
MEF8KUS43$W4R8KX$-4)](S6\7V+9S!.VBTQ("Q>)4ELE&>;0IE]IQ4RFM.E*
M&M%C)/N`].X`0X?*;SK86%6(U2FV>*>%VH">K,2]:_MFU*E(LE6,`(-F`-&]
M>40R6:5+B,X3$&2,K\JFE)PRE*%9`[WHZJUW:3VEB&UX[^S89>:#)U@)4K]9
ME@R`Q(A1'ZQ%JW52P*N08&3L5#TN?*CQ&G',H4YA;;B4,I(KT)0KEWSN_P!4
MM95_3=JO.ZJN`KN_PHVSZG,/,')<*S5$K&KLN-=Y3HX3,^JU#89MXK$LZ8Q`
M$07"49N3(:6^VE2A2A4`)>Y;T@$R;E`E;W&.%:%>&]<6$&.IVQS%A5<%F;Q7
M,C*[7A%.G&[I&8/ZT/PGIH://@,2A,EIQY*V\IY<KDRE6WV![3:LZV=;[9VM
MV"BZ3M/4FIB[Y8Y].I-@LMF@4THX.\;$NF1HC5FQ!$PR2)9!.8V'X$1MUUYM
M"67/+`"33I0"IHM0NA?O$=+_`')KW=M?=5"FU;45US58EON9:RZDMU*JP(:3
M*($!H<FPV"+%@+-FY6'U1(3>5R'F8<AW"?396K%+2WBJ6D<5VE\Q6*<(G")P
MB<(J[VYJFA;TU=L'3.TJ]"M>NMHT^P46Z5V>VER,5KME&R!1.-XJ2K+$CX:3
ME3+R/!QAY*7$92M*<X`T-4X8K3+H9[<NJO;ZZ6Q^GVI"DDJS)AWB;;]E&Q[#
M-AOEXO*);$ZXV.+$?RRN3#'9AP&&6W,(:@#V&DY^YRK.3G9C4JEU35>SH3T(
M"]+J]:TS;A,OUWMS-)%DST>?=!%7^04K4FK=;1(477)&XG:4.)R)NO'9CI&+
M"8G/LRT,/.NX:\RA-4)JM7IGM/VFG:DK&L=![8UIK=$S6?<7KWM)PUJ,I8PI
M/27<;;L79EB(T,0.OU=<`;6U_!#PA@N40>)B)+",(D0_18C--W-CBKFQJKBT
M/[?-YU!<]E/DMO5@]KAO578#4&@P<"B%H%PK5:[';G);UML_;%EGW$J-NYJL
M6>4P.&+&CP[;PYE3DE*Y#GBB%U4JM-)GL1-.TU>LP/9>TZ]HB:M0C;:*D(DG
M[/(W[K7KA&T%4K]+-[8,[(^&IHY\D9,-!Q[<&7!=E1T#YT%<?UEW/C57.IW;
M/:"O1*)=#8W=%%-W>R]JAO8`)!MM5VD`H]1HV=9[KAG=.!).G]P:WV4/#.;Y
M[)WBY0Y,0[%]-HFT/?:?::4M;-\Y3,%?/:/VRW>SVU-+;E)[1B4B[Z?KG7FO
M1I%<KY64T4#ZVW0SLO<%.=EEK)++.4G;@!IF"TS(?D2QQ,:.(K?DNQ<(5`Z@
MIT(#10BE>U[LH?4I-5OF^*:?31=;=9NOFBIM9U<3K"Q>C>MW8>N[U@R=ILR;
MR:;MVU+9&K4,.]-'?*A4/X94IJ'E<M]I-S"J9EL5VLZ``^TF_--;;+WN=6*O
M2]?[8U[M.D#AB7G]IC[56"X[4T_YVJ8V@$0TI;K06.C5*C2DNS)F/'",)SYH
M'4%%`:*G]8^W9MT7&%%=N;TH5LNU?N'1:"'G4/5)6D5IW4'1&WV&TTX<3"D;
MY9Y;NR=AR;D5<*D&I*!D'+L=F)#])A7JBX="M54E*]L3LIJYK#VM]W:"&GJ[
MV*OV\*78+3KG?ES8F1=D!NS-:+"+G3BW8[%/C3@8;L2IR'FKQ:Y"E2QF,S&'
MD.X2U<PZ5<P6R5H]MH$61[=HH/LHB/K?1L95J9:H,T#&F2]^:VHX.AF*M5+$
M^W-99!XA;PTU3+9G*4264Y$O14-I1(RM,S<?*I7CY53G4?VK+UUEW-J'>Y#L
MV5N=KU_3H>E;%48]+#!=>V#0831E*UK7:T,:SB=>1MNA;`UT+L[LF2;FAU*7
M+9:&LOOJF9I=440NJ*+W;^]I4=V#%7@/;-G-)A62[=X-@`D0H%O!N@['VNH@
M.HU&1,E5:\@)9R'K68*7)FPGW,P#C;N&G&6\)\<@^B!U%*]%>W9L/4L'N%52
M6QM=EJSV7KV[AX0Z+#[C9N``IM\S8RL=RQ`;!N6P:C6,K*+,\U_Q!70,V=Z3
M:WY"E9<RN%U4)"I.A^S(_K][<1$+O2.S/WAU.[2=>;R/;I,A%<FWC>K]/'T[
M<Z('UD5(;/4ZC55D"48P[CYS!A#O!R/F'CSW/Y.E7,IYMCVOKWLS;7::R?A/
MH8^@=GX>N&2V,0=Y0MC5INC5#057EB1SE>W@$U9F(8<TEF0T5:K;%E@*(XPP
M11F.C.0=2GD4S84Z56GV*BF[I0KK#WPJ(<U-LFHDZ=97JP5,W6ZZB&=D-S[_
M`+A1-YVLY:YY3:%ONTK8X'XZRREXFRSM-A%I"''GWV^,_0KF5[=7_;IV+I'4
M_735]KV/KD@WUWWOKW;$`K2P^YG5W011]&VK3\B`8C[9W/L[ZN'#3]@:G^0(
MJ`"B(84TR.3ESU,0N!-5"ZN*UX[B])NV>X-Q;^$T6HA9W77<=V$[H(?$&J=%
MV([O&K]9T=>JG*!G"=PAQQVHTM0!!0J-E#%%WI0N3&C26XA#/H4$#SJ@@#RJ
M]NMO1_9%<ZG=UNLED@S]=#^Q`^Z":):+S<E;KV`);V+H4!JPIF[7=VV&;%?@
MU(.!E8KS9">W-@UK$,1ASTH#3N83B"H3B#TJ,[G]L7;E_P!H]IKK4-LZJ!#>
MP\'6,T7*LE7W67L51L6KJCH((+@D``?>0+45AJQ0WHIJ5(>S6V;`A@@IEHBC
M#2,\H<!1*BG2L+LOVQNPFY;_`-AK[?\`<FD8A7L_IR!K:_SZ54>P==DU,F.U
MT]KY!"@@V^PZJ,Z/DM,QI7K&A1(W#=]7X6>SG#"F68"GD0.`4QV9[-VDKA?8
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MNS=D;OEBU?72.EX.G,5:CW;5$?8`JN&QYB?K"6@B8$I#'/ABJ/))RJ(WA;-Z
MR55#1/;%[&A0G9.NA^P.EY4+N7I6XU'L&0+Z:NJ"`W:ESOG:+9\RSZAC#-LQ
MAM=HL*T]DLQFQ11!28H<(QE4SXF0MU%S#UDS>PK=M_MR7[<6D[EJW<&_8@\M
MOOM<+[+]D3>F]?P:T(-#:Q2:Q6*KK#6U<V5/VN.#B6"&KZE+(3#J#JB&84[Q
M8;S*9^%F:AJ.I`:*JZ?[:G:.J42[:S>[+ZCL`0X3ZN[,K]R.Z<N4N_,;NZ>U
M3KY6-4&+=EK:T6LV6AV='78:[98"(<4C(60E*BS8Z\-*3<PK6B9AQ45(>S(4
MN>PZUNZ_;V%M[C<VW2ML[$*T*BD:Y63\25V)O>Z]UZD`#2-N,E16MKD'.5V&
M+^)ERY\$[4XIE]Q]UU;"6?HZ$S='0MS.DW3O<O66;;V-E=@FMIU)G4VE-$ZG
MIP0+=:Y7*Q2=$A;#6`-T*5VS;(O%:$;(N5;)#HYYNKPP`.5)$XFXB9DRWE)A
M-5":K6<K[0(X]"T;-,;29DW71.FND6IZK8XXVWP!N,=5[]L*W78M+J4&]1JT
M<3LT;=&8<%LK&GK`N1%/-..*=SC%S*YE,=1^VS>ZMT=E=-;OL^J1VD7;KV;@
M7W5+^_@)IP'I2Y:@LY-_!*\[TO5KIMRLT;5ZV8<FKDPD`(_*;?B14.-9RY,W
M:JA.-0JRV![0,A^Z;PAZ;N>OZ#IG<N@UZ39!'6M^V._TK+^O[I5"I]HQ&WP*
MI=^)V6PV]TN0)V8*5L#DIZ0Z@@F0XV^W<_7Q3-U\5/J#[1U0KU[N92V[-L]G
MILVF]E*/1G(MDV9`VDP+[(6MBQDR6W-@S-A%'=\V2G"I4H%`FVJ.34\*AB\O
M)5(AY==9DS*F[/[..RMQC8\G>?9L9FZA]9P-*UVQ:/IEWU#"B4'7^B]IZEU:
M3+CAVU9TVPGYY_:Y$M;QDJ8Y6C@S.`GP"8GG<<9P.`P5S*42/:/V$3/;KV"4
M[)P4W?LAKG8&M=I585K88-TY6@$J=J'\#$+4M=@RH=T"#M3U[3L,6W%,'3,=
M<6=*Q"1`\Z\.,RF92387M:[(L6QM]6:I;YIX*I]L+#<@._0AW6)(\=8TO9;O
M6[Q!%ZI-,749#K&S(*XAH:Z4GQ"0YUDM'E8A(?&H3)9AU)F4PZE>W-=.EF[#
M&RM:;%KMJJVV1U8`;6I!L`3&P*Y+8M>\;_L+9&NI,>P/+B6#8QNU51J;"E-R
MF%38)&?E7J3L^C"X$(75%%4.U_:?W#M1VUJ+[UU<H?7=L;1V'H8$C7&RP:8(
M[=7<ZF=O]A"=PVFI;FK]LL$Q$RA0`(F169-87!9R]+4IUY:4MW,!\WD0.`5R
M[-]MRZ;DK@FKVG<XJD"3FHNIVG]I,:XJY<M*GUOK1MS9FXID.F$]TV/:\G$:
M['+0&A.YLR;&Y\`/EIE9EJF8RU,U$S*KZO[7786F:PV+HD)VKILW5>W]%2=4
M[+(6;2ZSFT#Q6I=>++U<U-,A6K-TC!@H!K6J:M/L28PU!.4;`2LP)<**6>9C
MW,*UZ4S#BK*D^U>+CZ+VQUJIVVC5"U'N3M?KS?EI0,C2[E<XU"I%#T\/F:W@
MV';A+8\8I.L>Q=.0R#\PQ%)P4B)3H_X)2<(7AFQKTT3-T]*U7*>QM9"<$21>
M[-MN7X5K(_HPC:I&OG5M;"U+`Z>7'JSJ*)L2`Q9HN"EOUJ0.1[$@A&5'0ZY+
M+QVVF4D/.TS^17,MRY?MYW'8.GKI3MR[@&RM@[>[9Z=[.;1L^FQ-]T^)@1]0
MPM05453=5S`^RYNQZ05<I.F1R4V%!]1%!B0]+3A+?IQT3-CAU*5Q55]9O;"V
M9UXW`#NKFT-56RKQ-,UG3Q5V/4MP5.YR&*3KVYZ]$VID2!W4SITM9K:V=BE;
M#,-5DK,DEW"$B,_'5)9S'I<"A<"/*O([[7&RIK>H*N(WM3(>OJSH#K!K#9\8
MCK(O/MUAO/4B@[:J>NK+1B[=YBAZY5+64VLJ2<'$(!24E@8AJ+*;5)<<;9DS
M!4#<_8A;LVMC.MX'8.2+6.K5CF:JV*6"6N[;2HFR[/I?0VHIDHE=KG?C9RVZ
MT&C=0EAXX%)?3F!4[?,!LO(BQX^<,^*N==G':CI[/[&LD8\.]0JFS/Z?=K>K
M>4204HKY)?9*%J2'#M_F8+CE_"U-.LW/4AXSAV7\8GR/LY:SE>(-/76(-/76
MD0+VC#.K.PM5V[IG8-(CTRN;/N]RB438KG8<T5#A;O\`DS/RF!]TK&_JP:M)
MV"0T)+=;1:%'`JTEFFUP,MQ?*YEFPH5<U10KG=C?:4LW8GLOO7;LS=H&E4C<
M@TVIN*'JMZ+[!$$RG5D/USCAI3!7:6-,3JC'-`XEEDO(J;-DF?"I%_-683KW
MF!U!1`Z@6R.L.EFU8.P:QN_<FV*'9=NR.U;_`&4V0WKG7QZH:\FQAO3ZR]0J
MC2*0&L-XMYX3F"`(0S$XC/GSG9<Q+[*6VV?0]*%W0.%$J.`5/[)]M/9YX%,$
MZ]WK2JV_L*J=U-([BF6W5Q6VHE:%[F=C#.^C*]<18E[`(KNVZ"R6=%0YY#),
M/.]?,A^#C+##>*')F6!ZL>TAGK/W"(=HHNY6K*+=F[:D!Z`]4WXV0+6VBMD(
MV+,0ZX?E9>FF,N@5DGEQ_P"VY`7#G@CU,80+JBB%U11>%;]IXSI/7&B)G6[;
M-=!=E-754E2KSM/=0+8^ZJCLFO6;56=5E(<>J'-JQ3M&$T>,AHA4@@DK'KXK
M*9,/X++,^0YAFJ<>"9J\>"CVO/9L8U,Y;44O=<DE"M>E-\:&7"O8NSV@<!K>
MS]":AT_3KQ3J\_=45.C;0`3-4>)\F&@0<V@(35!E>"H<1Y#/5,RD&Q/:\VY.
MONP-F:G[`4&K6K9VIG^O%G;O.I2UU!Q-/6[06E=-WXB$'P-@5IUK9$,SI2$:
M"2'W71F&I#L&;&D(SAY(.'2F933K![5HCJYV$/[JIVTYDL':M7[XU_8:)*"+
MS')G=D;/IMCHFR9!/)-657.N:NI0^K''<,I0<:&0'TXC?#>FJ%U10H3444&Z
MA>T4]U8WMIC>L?=+!TK0J:;IVQ:^-I[X8-M##.BM3:<UO9)*'K`16*LVO<4V
MPY:D?M_Q0NQIAKQCX)IU5+JBB%U119SL#[3<#L+"OHNU[-:0-M>S.X>SQ+$&
M!;P;X8YV7TP'U95<2I]5O%?G%XNOR`Q4^9%=<^"-,N?#NL(QCS9!U$#J*8]:
MO;VV#HHGVB@%=B:]/U;?X?:4<47%!]P0[F%*;')/SF?G8,_N&Q:<4+`MSWT8
MR$K(:?,REI3\A>?5]2%U:(2"M1)7LF7:VZ3U?K:W[OHE:N.C*<?KFJK[KNL[
MA*O12E@F]>H9PP>9W#NS91-(RZ:_U(=K9H*+F#A#@ZR^:,Q'=C>9W+/CY%<P
MZ%L;*]OKM($``:A1.QFFVZ;I#L(+W;UHKMNT?82*X+>=D;4V(<@[NL879@<_
M=S"&-G9#07@[H.%B./Q-DQGI<E>6YF"E1TJ,W/VNMR[`DW45:-W:5)4"=9-_
M[KI=/*Z%*6%C\/79^M+#;6%;(<+[(6S;-$Q)9ZQ*##H;8NQQ63$3.2N)0>-)
M>9@/.E578;VA]WC7BBR78.AVI=SZT6SK[82EG']CBYNB0;$[V8P'@:\D3.QK
M\*[5.DA>P,8./QL1BWF/@`*%_&H??RMMF5S!;!V+VZ]KW?K+O#75WV]K8KN[
M>FZNO^X[#9`M$V+4]1CD]=FM"@*G31]<"[<;VC&B&:AH>*V0*1;3#)_,"+ST
M=<=MIAI+,*X<%*BOD5<0?9]8/;BI&Z=C;(KRR2!CU#W#1J:`NCM/V=I]WJ5:
M.MH^B22NQ]@7N]/3:>?LLH^%*E"92;&;)DHCBG?B_60S8)FZE@-=^TGMK6YS
MKS9,[\H^Q[1K[5UHH^XKI=JMML%8]AV^[[;M&S;3LP/$UMNBH5M\M,8LV![0
M^TP[*,:;A,9PSY<+0H7`JY@LTKVT>TI34^O-<F>Q.AX<\'U.,^W_`'DT%T7>
M'XISJJ=#ZY'2+%61IK<DW-?[`07*7-PW/><EUUYLJA3@WU(367&854S!?EV]
MG(&YK,/"U[=!3VYH78FR;=*7C:1S?QZMD-=S[UV'N%;T_71=+W=2++JH$#?W
MQF5)S4B@2.6,PG)DQAW,E2$L_K)FQ\B[8Z;0SLG5\O7&Y$4&XCB`%ZFD!-?!
M6-BL$Z5*KD0#-`F8=VM-T,&OC6U2VY#LF8YF1&=0ES"G,...8>93IP6H'MI>
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M=^]FHY;J<US6S8>5S8G-H/;90(C7`X%267L7<C-AV8,C=>#$T'4P$@EKZS)V
M7KQAC:YIIN$MBN0!3Q)).G/27)#R<2BR&8R/A\Y4KP6CQU"VLC'$\W+1(]U'
MMR/]K&/:)I1W1@VIQ74P;6V')I>D7<VZ((]1O;EL=[!W"])TZ(E]9WR"/EW0
M:&M/+MBYYS@`=ERX3&S-WN,ZI<>ZT&X[MRG2H^R6%;3UH[G3L-DTQ`CD"+C9
M3+=V1+$N+GX;#Y?<0AOTE8]7.,<IM;`&8"Z:0P=CVM_MF%:##LXX=JG7P7(D
MVEX>LDUEL>[;=S+"-KK$^]U^/?-QB+W,8#'6T+9`(<UUD:2<X[`)7@]L[>*(
M.TY#768V],IY.%$UP/QM76;:]OCY!N0/EEATE93$>E-P!#3<_+)C++KB'<,I
MQEU*L<HM;#-"#=-RO!SGEO\`:S2M#AVJG"K:]?!9,VCX=NN-&B?NZW;!?0O=
M?/\`>Z_(TQ[8FO;&]HCS71?(3"'6V9K2W.3D(*R<;8>X7;)K05(Z]EXH"UUV
M*4O]J5LG7SS&J3KS$UR36)XAHEDK;WX;T=EO,L4AZ*O,C&4J\$*\,#;60BE>
M+EID8XAC<C_;!AV@:4;7J=0X+AR[7V*S2=6O8]SP/U*RNG1V5OW&]!U&$%@;
M<,E+.7;!P<YW+N"V09""*N"BV=M]A,4NQG\=3#^;8+M48."H?X8]38EVBMNM
M.+?N#%AR8^0B8\5Q*49A2G$3%^;Q2GPQGF[N>F\]L??&\DLJ7\N3LN^EI2IK
MUC!=R-D^&/O_`&NFG>MM[RS63I9KSWKU++;S@@"U,'*YTCG"IYL;3$*4)JI=
MC8&W<WANO9T"6Q3U4S!US8/X1J#F(U:\B<S<T7-;P1^L"Y6"6,0_F&&_@?-G
MU?/Z?T\T]WL^1S.\-YV>F3(^N6M,^:E.&-./1Q71G;.R/R>.IC<L'OX+_DBR
M[C>9C;\S)WOGY.2&\OVWDYN=3L9<V"B2=M=A,T4'8L]33Z;B0MKH4QKW\,>I
M\S*_641L.M7-ZRX,?5XE&>D9RUB#'<5-3G'FRGR\W=ST[O#H^^-Y`94/Y<E"
M[Z7+2H\YP7=G9/AB-Q7&EC>ML="BLA+%>^]>I99K@NH;40<KGQN#>USGM$1X
M`U4LE[!V\Q:MC!HN@"TVMU>KRR]$N"=C4!B-M"Q,Q1ST:HP0CQ%)BIR)DF4^
MSB:40U$1F-E2E82M&<Z6VUF88GFX:)7OH]N1_M8Q[1-*.Z,&U.*Z6#;.QY-&
MTJ_FW-!'JMY>-BO+7N-Z7:?`7/#KE\H9RKEK&M8[E6Y=(>8`!5KJ89K9^\UC
M-7RW.L9MDA;R\V%L05G:VLEN:C%QS46!$-$)B"N8ES;GB7G)^&!&7GFT,Y:7
MC#JDXYF;2PSRM%TW*QH+#RW^V&E:`4JVAPJZ@QKP7/?M#PZ;=ZQ"S=UNZVL8
M&/LI/>Z_`U*1T3GNB8WEYK4LD#82^YRL<79VG("5[G]E[N;QM?+/6HU(S3)+
M36ML)VEK5K\,D=9=^$Y*'9<*8Q2$LC&T3<H,^@M27/2Q^V8SCD%K8'DUNFC.
M.W[6_P!KPKCAVL<.S7KX+7'M+P^>=%YF[+=@OV$W_P#W??GWK<(@\-?2/]]U
MD)BK:YP"W.>P05RHVQMS.F]7P'^NIB*(MP=B=L0\K9NNG6M1E'/7]8(0'-$L
MS[F[']-'B^(2\PKU,>&?N<\AMK$1RN%RTO8ZC!D?[8.L&E&^9U"M4NU=A,T_
M6+F/=,#[VQG++*'N%\#J48I25CS'DM0ZI[%R6O&7$8A1Y6V>P.*G<#6.J!]5
MF!V:()JU,_##JC$F[U]]UY$JV13F2_R8!'A-H2O,.<MN6YA?@E.<XSS9W/3N
M<QG?&\IS*N=RY.R?I:4J:]8P79C97AD=:L;`[TMAI-Q:.DN+KWLU'+:3``MM
MG0\KFS.>21S8@Z,4J30A2Z/?]MNWD+7G]"%HM.GTY@Z6V$K8E"=A@;4X*DS'
MJ.[6VB&;"1E1R33</)!AM4%2G<.85Z:59YI-O9BW=(+AIF#Z!F1]2VM,V:E!
MAC0X]'%=)+MK9+-NW&J1[EA?KL5^88[+N-X'36XD:T78G+.0QKHR9>2]PF`;
MD(S$!0[\+?83\'T*S?DF'_KN_;G`DO6OX8]3?&P:PD?B2W=5VGYQ]6I$9V=G
MX;X!MW,W"L>?*?)]/-_<]-[R8N^-Y&2N?ER4+J^CEIFX8UX+O?R)\,/RGDTC
M\M;;\GFV(E;?^]>I9'W&?*;46_*Y[7!GMG.+>41V:YL%,9=_VVS<KR"C:$+3
M*K7JA,-T^\IV)0F(NP;0P-'RXM)B5]X@DY6Y,Z?)?BXGD&VX3:HV7%*PA:,Y
MT"WLS!'(;@"9SP',R/[#:GM$THZ@H:#'%=%!MK9,F@Z=J,VY88]9NKYL5U:=
MQO"ZRMS(]KKMTP9R9VL8UDG)A+I2)`T#,UP4<1M/?"@6N2*^KAULQ:3T\=?*
M]^%K5RGM7!HQ6+#A6*<226^7VUDD-><F)BBU.R6DLY;6G#BDXSM[II_,E;WM
MN1C06'ER>V&E2T"E6T.%788UX+M7;.\-QJ.JVK=XVQL;.V8^SG][=0IJ$KHW
M.?`R/EY[8QR!L1DN`UCB[.TY02N?(V5NQN3M9IGK::DL4U&%:WE)VCK=I.XE
M9GKC90.9<)X=I.<0DXD^)C#./*KR?U^,XYB+6Q(A)NF@O]/VM_M>'3AVL<.S
M5<:+:?A^^+1GR;LMV27Y_?S?>^^/O9V`ZKR(Z7?;['[USXC-Z*_8NRMUO$-6
M1I'6XS$A7")ZVQB2MH:W>1J"3\4MGX,C%9)JDW56(R</></AY'@KR^/FQG'!
MM;$-E(NFES#V!RW^V>48=GJ[5%)MI^'[+;698MUV[[BQ?2QC][[X'4VY0<S'
M&/+:]KLTN<APKP6*5M;?N*W?2J>JQY9ZN6*"+I=6_"]JM+^Q@4B?(C3+/#+Y
M+?*ZPP/A-(DYB$5M2G,.X0A.5ISCF?=-.YL;.]MY;FDN=RY.P:>B12KJG"K<
M%S1LSPU.JZ;9G>5L--N[5\EU<>]FHTL9FL:YMNZ/E\RX+W$L$D`=&TMS..4@
MJ4P[]MI^[U.ORM#%851-4^,<LU_5L.AOQ*9:714Z9(H\FN,$%'SDJ(2CLP\S
MX3:X*U2,.)7Z:%YQI-O9B!\@N`9FOHUF1_:;4#-FI085-#CA3BNFGVULJ/;U
M[J<.Y(9-<M[YT,%GW*\#KJW$C&MNVSEG)A:YCG2\F5PE`86$9G-"AGX7.POX
M/G+-^278/KNBX)!MZT_#)J;XUVKY&9EYNV+3\X^K2(J2&/A/@,N_&^;/J>7T
M_IYO[GIO>>5WQO(R5S\N2F:OHY:9N&->"[_\B/"_\IQI'Y;6WY/&QYQO_>O4
ML@N.9E[IW?E<\NR>V<X-Y5.S7-@IC*O^VV;M:`$?0A:74A%-D':[?D[$H3,2
MW6MH3!FL46/772.#X:5))2'H>"$MM$%"H^75+]-:,YT"WLS`R0W#1,Y]"S(^
MK6U(SUI0X4-!CC3BNAAVULE^W[/4Y=RPLUN>_;#/9]QO"ZVMS(]INW3AG)E:
MV-K9>3$XS$/#`,S7!1=.UM_9K5%+*ZJGD6"Q6.:+N-4_"]JO,C7@&/-88B6B
M88P7^565B?$<6_B(.6Y*;PWY%IPI6,<W=ST[FR,[VWEM:"UW+D[9IZ(%*MIP
MJ[!=P=F>&@U;4;(;SMCIEK:LDM;CWLU'+>S.8XNMVQ<KF0%C@&&2<-C=FS--
M`5F)6R-TLEMHPHW7$S,&U`:N5KHRG9^N&&]NSTO,H0+'P7B:9E+6XTXM?K%T
MLM8PWX9SXYQS`6MB61.-TT.>>V.6_P!K'632CO,VJX,.U-@266CW$NZH([N^
ME#;Z+WOOB=-90DR/>(\MT`0!EMBYV-:4!7JC;+W<Z]JIN1UK-16KEES&R'U;
M2UJ]C3N$DT1&\D6VBBEW;U1ZLR_^)_7\$I]//[9GPX-K8`34NFDL]#VM_MF'
M1AV<<.U3K6<NTO#YD>LNBW9;O?84[B/>^_'OG[67'(3'2TH_VO\`?62I.;T<
M5PU[2WND)L@@CJ\<<+U4[`'4(!C;.KTN[3#22TJ%-L4`BHM\!461PUEN;F,5
M4S(=2]AI"<N)5C&7=-/YD3>]MR/:2\\N3VLTJ&D4JZIPJVHPKP6]NSO#@ZAI
M-J[>%N+&]MGOO)O>W4*:?*V-KVP/9R\]R7R%T0DMPYC2W.XY2"I%%O\`MMZX
M:_!R-"%HE6LM5A&;M=U;$H3T76MD?@D)$NG30#)!1NTR8,R,Q'S-&MNPW,R<
M+2K*$+SC4;>S$$D@N`9FO(:S(_MMJ.T#2C:BIH['!=7-MK9+-"U/48MRPOUB
MTO7Q6EIW&\#K^`/8UMTR8LY5NU[7/?RIRV5HC+2,SFUAF=N=A?J$3LF.I5@S
M=(EN:"#]<_ADU+\85K"X"Y+ET;L_SCZN0XS,W&(WP+KN)JE9\^$^3'CS?W/3
M>\"+OC>065+^7)@ZOHY:9CAC7@N^_(CPP_*2'2ORVMO>!]B97WWO7J66.X#\
MHM3;\KGN<6]OG-:8@!E)S8*8N[`VXB\%:\WH(L]4(=-<.C=@8V+041#%K0)8
MFMT9NN+(XL$*4Z3<7"^8/-I@X4WZN5>FK&>:1;V?=Q(;@<XOH69'U#:TSYJ4
M.&-./1Q71,VSLAVWH=3=N6!NN27XA?9=QO"Z*WYA8;LSAG)>T1@2\EKC,0[)
MES`A11.V.P.:?4SBNJ)Y-I-6F2'LM(_#!JG,JF5QI2,1[?)/X+_)#D>4E6<X
MA0G%S$>7[I/TXYM[GIW.?'WQO*:RK7<N3M.^EI2H\YP7<G97AF-=O=.&]+8Z
M/;V;98+OWLU'+=3FN:V;#RN;"YN`YLH$1K@5(9>Q=RLG]FC8W7<Q-"U($^1U
M]8T[,UVPSM@PVF'EFO#Q;Q))&G/2%/NXQ)+)9CI]#/CG[I/CK%M9&.)QN6B1
M[J/;D?[6.LFE'>9M3BNL@VML.33=(NYMTP1ZA>W+67L'<+TG3HCFK.^01Y+H
M-HWVNV+GG/@,"N''V9N]UO5*G^M)J,NY3)+&R6U;3UJ[G3D5HRS`CSB*FBF4
MW=$L4XN=AL-Z[B$-^DK'JYQCE-K8`S4NFD,'8]K?[9A6@P[..':IU\%OEVEX
M>L=K0CW;;O;81M-B?>Z_'OHXQ%[F,!C_`'IED`AS760$G..P"5XKV=O%(_:<
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MZ&R?##\H+;3#O6V]Y)K)TLMY[UZEE@G!`%J8.5SI'.%7<V-IB%*$U4Q3?]MY
MO2:ZK099-.S3L'<[#SL6A9AIM617QF:/]6L$/K#F5@E_:?S##?P/F_;/-Z?T
M\T=WL^[\SO#>=GIDR/KEK3/FI3AC3CT<5T1VULD;=.J#<L)UWO\`R>Y=QO,W
M=^9E[WS\G(R\OVWDYN=3L4S8*'_A;["?44%8OR3#_P!<2-JD!C.O?PQZF^,K
MU;:CX<8N+UE^<?5XE&DOYRWB%'<5,3G'FRGPYO[GIO>'1]\;R`RH?RY,7?2Y
M:5'G."[W\B?##\HKG2_RUMO>**R;+%>^]>I99YRZAM1!RN?&YH[7->T1'@#5
M2R7L';[%HV0(B]?B\VNU6L2R]"MR=CZ_8C[2L+,8>[%J4`,\127J4B;(DOM8
MF%$,Q&\QLJ4K"5HSG2VVLC%$\W+1*]]'MR/]K&/:)I1U,,&U.*Z6#;&QI-'T
MJ^FW-!'JEY>-CO+;N-Z7:?`7/#KE\H9R[EK`UCN5;ETAY@`%6NIB&MG;R6/U
M=)<ZRFV9MO*S8>Q1N=K:S6O40V.:C0(A@A*04S&N;<\2ZY/PP(R\\VAK+2\8
M=4G',S:V&:4=Z;E8`6'EO]L-*D##LT.%74&->"YK]H>';;G6(F[NMW6]C"QU
MC)[W7X&I2.B<]T3&F/-:ED@$)?<Y6N+LX.0$KVO[,W<VC:RF>M1J0NFRV&=;
M-XVEK5O.XXSA=^"],'*<*832$QQ;:)N4&?06I+GI8_;$YQR"UL#R:W3>V.W[
M6_VO"M#AVL<.S7KX+"/:7A\YVBA^[+=K;]A-^?>^_/O6X1!X:^D?[[S2$Q5M
M<X!;G/8(*Y,38^YWC>L!\GKH8AB+<&9G;#/JV;KI]G4A5SXKU09`<R240N3K
M'HM^,@2EYA7K8\,_<J\(;:Q$<KA<M+V.HP9'^V#K!I1OF=0X+5-M784>GZO=
M1;I@DOK&<LLH>X7P.I1C+29CS'DM0:N[%R6O&7$8A1_.V>P6*C;3>.IY_-G"
MV>((K-*_#%JC$FZ5YY;J9-MC'LE_DH*/"0A*LPYJT2U^?P2G.<9YL[GIW.9'
MWQO*<RKG<N3LGZ6E*FO6,%V8V5X9>_EEIYWI;>]%Q9NEN+OWLU'+:S@#+;.A
MY7-F<^I'-B!C%,3B%+6+_MMR\BJ\]H,M'ITVG-'26PL[$H3D0-:EBGYCM'<K
M39#-AG2F23:(>2#+:H*E.>IA7IXSGFDV]F+<RBX!G#Z!F1^+:TS9J4&&-#CT
M<5TDFVMDMV[-JC-RPNUV._,,=EW&\#I;<2!HNQ.6<EC3&3+R7.$P#<A;F("A
MOX7.POU`A67\DJP?7:1;W`DO6WX9-2_&P*N@<F4W=EVCYQ]6Y$5V=G,7X!MW
M,W"L>IE/D^GF_N>F]X,7?&\C)7/RY*%U?1RTS<,:\%WWY$>&'Y32:3^6UM^3
M[;$2MOO>O4LC[C/E-IW?E<]K@SVSG%O*(.6N;!3*9?\`;;%QO@*+H0M.JM<J
M4PU3+PG8E"8B[%LS`X=*BTR&`?(I.5F3.G2GXN)Q%MN$VJ-EQ2L(<1G.AMO9
MF&.0W#1*YX#FY']AM3VB:4=04-!CBNA@VULF30M-U&;<L,>LW5ZV*ZM.XWA=
M8P%[VNNG3!G)N&L8UDG)@<Z4B0-`S-<%'T;2WNH)K<@OJ\=;+VH[/'7T!G;.
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M.!<(6)&QBBMH:W>;U!+S)<:S`(Q&2>95U6EA*7?4#X>;\%>7Q\V,\&UL0V8B
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MI.',*]-"\XTFWLQ`^07`,S7T:S(_M-J!GS4H,*FAQPIQ732[:V4S;][J<>Y(
M7ZW;WSH8+/N5X'75N)&-%VV<LY,+7,<Z7DRN$H#"PC,YH,,_"YV%_!]FS?DE
MV#Z[XN'R/&M/PR:E^-S5OE?QGUX^M7SCZM8B_,?[4^`]7X[S?MGE]/Z>;^YZ
M;WGE=\;R,E<_+DIFK3+EIFX8UX="[_\`(CPP_*?WH_+:V_)[N/.[_P"]>I9.
M\<S+W3N_*Y^;)[;SLO*IV*YL%,I5^VTS=;6`C:$+3*D&IL@[6KZG8E"8B7&U
M-"8,UBC1JZ\12>"2I)*0]#P0F-H@H5'RZI?IK1G.@6]F8&2&X:)G/HYF1_9;
M4C/6E#A0T&.-.*Z&';6R9-OV6I2[DA9K<]^V&>S[E>%UK;F1[#=NG#.3*UL;
M6R\F)QF(>&`9FN"C"=J[[S6J&65U8.HL%CLDP5<ZIG;NK%/ZZ`L3F8\6TS#&
M"WRJS,3H;BY&(@Y;LIO"/(I.%YQCFWNFG\V1G>V\MK06NY<G;-/1`I5M.%78
M+MW;,\-AJVI60WE;'3+6T;):W'O;J%+Z8L+G6[8N7S+<L<`SF3AL;B<P.4%9
M65LG=3)/:42-UO,S!]/@*DZY+)VAKAAO;TW#[3:1H^&\33+I:ULK4YZI?#+>
M,(\OCXYQS%MK8EL1-TT.>>V.6_VL=9-.U_\`#5<*':FP)+31YY=UV\=U?2Y;
MZ/WOOB=,90GF/<(\MT`0&Y;8O=C7@"O7&V7NUV1JIJ1UK-1&+CAS.R)*MI:V
M>3I[*2*8J$D6FBF7;MZD'.97_$^'O!./3S]W]'!M;`"8BZ:2ST/:W^V8=&'9
MQP[5%E-M+P^9%K+XMV6[Y+"G<6^]]\/?/L9CD)CI:4?[7^^LF/:]'%<16TM[
MX!;((XZO'%&:J<@CZ%7?PLZOP]M(/(*R8<RP0">2ORZHLCQS3<S,8HIF0ZEW
M#:,9<2K',NZ:?S(F][;D>TE[N7)[6:5`(I5U3A5M1T\%O&SO#@ZCI5J=X6XL
M+RW>^\G][=0II\K8VN;"^/EY[DO>71"2W#F-+<[CE(*D46_;:>N5!!2-"E8E
M5LE3A&;I>5;#H;T77%ED#B$J739E?:(9.6>3`G1F(N9PUMV&XJ3AQ*LH0O.-
M1M[,022"X!F:\AK<C^VVHHX&E&U%31V."ZN;;6R6:#J6HQ;DA?K-I>OBM;3N
M5X'7T`>QK;IDQ9R;=KV.?)R9W-E:(RTC,YJA?X7.PWU!GV3\DJP?76-;F@D+
M6_X9-2_&DJPL>J2Y=46CYQ]6XL9F=C$;X!QW$U2L^?"?)CQYO[GIO>!%WQO(
M+*E_+DH'5]'+3-PQKP7?_D1X7_E+%I/Y;6WY/OL3*^^]Z]2RLN`_*+0V_*Y[
MG%GMG.:TQ`#*3F4S<OVVTWDO7D:$+.T^%3G#@S8.-B4)$,U:4BHTQNCM5M1'
M%A@RG23KD/Y@\VF#A367,K]-2<\T"WL^[MD[P.<7T+,CZAM:9LU,IPQH,<:<
M5T+=M;).W8-4=N6$:[)?B&2R[C>%T5OS'--V9\G)>T1ALO)8XS4=DRY@0HC^
M%GL#]3JD<_)0/_6DU9I8FS4?\,.J/B:77V'$)C6R2?\`F_R0['FH5E6(<)Q<
MMOR^"DXSG'-W<].YSX^^-Y36`M=RY.T?I:4J*=9P7=_D5X9>_M[IWY:6WO/;
MVC9+>[][-1RW4Q!S6S8>5S87,-!S90(S7`J0R]C;F9.[.'1NNIB8&J(5^?KV
MPIV9KMAG;19O$3+($>,>))(4UV1EYW&)!9+,=/HY\<_=)\=8MK$QQ.-RT/>Z
MCQD?[6.LFE'>9M3BNKAVKL*33M(NIMTP1W]]<!E[!W"^)TV,YJS/D$>2Z`HW
ML6Q<\YL!@5Q8VS-W.XU3E_K4:BYN4I]G9*5;3UJ]^!R,V89@LS".6BF<7=,@
M6M4["`WKK2E'I9_;<XQRFUL!SJ733D'8]K?[9A6@P[..':IU\%NEVEX>L.M<
MO=EN\6#`;'_N^_'OHXQ%Y:RL?[TRR`15NL@).<=@$KUKV=O)(S:,M/64VLA4
M"L*'KH5C:NLTN;=&R#,F!+,#YBBOPE+;@"F6Y^6"^67G$.X:3C+J58Q>ZV&:
M(=Z;E>"7GEO]K-*T(IVJG"K<,*\%FW:'AV;O1X3NZW%M?0O=?2>]U_339&Q-
M>V)[>7FNB^0NA#[;,UI;G<<A!65B;"W`_9];"977TO"KUJK,0M?;8K9&OGX^
MK+`]'(.R:I/#,D5%K=(AOQF&LS!2'HB\R<*2K*4+\,'6UD(I7BY:9&/HQN1_
MM@P[0-*-KC@ZAP7#GVQL:/2-6O8=SP2:G97;H[.V[C>AVHPAS`VX9*6<NV#@
MY[N5<%L@Y9!%7-K$\[;["_4<[8<=2[!FWCK6P&#:_P#PR:F^+L-:<C+=>N3-
MDR8^KXR-&?3AK,&0XF8K*O-A/EQGF[N>F\]L??&\DLJ7\N3LN^ERTJ?.,%W(
MV3X8?E#;:9^6MM[QRV1EEO?>O4LL$X<`+4P<KG2.<VKN:QIB%*$U4QQ?]N9O
M2Z[G09;%.33OGJ=A_A%H.8:[5\J3,^H^*U\P^L*97S+.8?S#+?P/FQZGF]//
MCS1W>S[OS>\#GYZ9,CZY:TSYJ9>&-./0NB.V=D?DX-4_*6'W][_R>Y=QO,PM
M^9E[WS\G(R\OVWDYN=0Y,N;!0[&V^PN:0!L&>I=@Q;R-LD!C.O\`\,FILRZ[
M6FHZ'6+D]8_G'U?)QI+ZLM8@QW%3$93YLI\N<<W]STWGNC[XWDAE0_ER4<[Z
M7+2H\YP7??D3X8?E#<Z9^6UM[QQ6398KWWKU++/.7$&U$'*YT;FBCN:]HB-:
M`U4KE["W`Q9MDB8W7PO-K]4K<HK0;8G9&OF(^U#[,<>['JL`.\226J+\M^2^
MWB850S%1F-E2E>"T>.D6UD8HGFY:)'OH]N1_M8Q[1-*.IA@VIQ72P;8V-)I&
MDWLVYX(]3O;ML=Y;=QO2[3H27AUP^4,Y=R&AK'<JW+I#S``*M<L6SL[>*X.K
M)#O64VS,N!.9$V,/SM76;B]0#V#<>!%+$9*"N8]U;G"'7)^&0^7G6T-995C#
MJDXYF;6PS2@73<K`,AY;_;#2M!AV:'#M4'3P7,?M'P[;<:S$S=UNZ"QA:ZQ?
M[W7X&IO,3GNC8TQYK4LD`AS7.1KB[.#D!*\Y&S-W-)VMECK2:E*ILN,SK9*=
MIZU:_#'&=,/07Y@[+I3&*0F**;1.R@SZ"UH<])./5QG'(+6P/)K=-&<=OVM_
MM>%:'#M8X=FO7P6,6TO#UYT42;MMV"_8XW__`'??GWK<(@\-?2/]]YI"8:VN
M<`C.>P05RXFQMS/'=8CI/74Q"#6T(P0V%8E;,UV^SJ8NYB7EX`0&,DE$;D]'
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M#-AFRFB#:(GS!EM4'*G/4POT\9SS2;>S[N9.\#G!]`S(^I;7T\U*##&G'H71
M/VULINW9M4;N2%VN,OS"RR[E>!TMOS`T78G+.2QI83)R7.$P#<N7,0%#,;<[
M"_4$=9/R2K!BZ2K<X$G:X_#)J7XT96$#T26[JNS_`#CZN2HSLW.8WP#3N9N%
M8\^4^3/CS?W/3>\&+OC>0&5#^7)0NKZ.6F;AC6E%W_Y$>&'Y2RZ5^6UM[P,L
M1*R^]Z]2RR7!>6FU%ORN>UP9[9SG-$1!R@YE,9E_VXQ;[^#BZ#+3:O6JG,,T
MJ[)V+06(NR+*Q`'R8M-A`7R*3=7DSILE^/B<2;:AMYC96I6$+1G.@6]F88Y#
M<`2N>`YN1_8;4]HFE'4%#1N.*Z*#;.R)-#TS4)MRPQZQ=WK8KNT-C>%UC`7O
M:ZZ=,&<JX:QC6/Y,!=*1(&@9FN5,?A[[9_F&VK^M\?\`2&T/^S_8_P#.#_Z_
M.=[WZ/\`C!GVF7_(O>_!MX*_I(LN/XDUCW%;I\Z-?`4X1.$75!8_?.]I"HV`
M[5;+WPT>&L59/%JP>$S2)YN4,L`(C)$EA4A.`*D?%P2,-UI>$Y5CS(SX9SCZ
M>99'<:++*Y;.=6/<`Z:=VY=U@]4>PE!WC+US'`RKNQ2I)%]RMQ[.X5:`.D<3
MQT'"4%'`<O#7E\WCEA7CX?1XBUS>*A:1Q6X?,5$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$
M3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1?S0O;WUMUEA;F]Q79/;'8&D:
M!4NR';#9OM[Z^?W./L19^2SMJ[;!L>Z++K)NLU6V.5_9-0BN4_`LR3P+#PU3
M'TOD&,JQA7(=7"GG6XUH*=2[(_\`=`:+8M7[P]S[65O90Q;-<2M*4&SM-N-O
M-)L%-M^^*X8RP\RMQEZ.L@-<4VM"E(6WG"L9SC.,\QEX!23@%V-7*H]L"/?S
MOGV9U8;*`*5T\WI(NEANE@[)[KE"C^OZO[<]*LZ^L8;I_$8SI@Y5[CLJU#CL
MRT/SH1*"^A_X9M3Z$*5CAE`/3_E6.%`%(J_[E?=RM;.ZV4;8MTT6>M6PJ)U"
MNBM0"=*V:K7+L97^VS&P+!LZ]Z<(R-GF\UJF])002&@P\N*601;@RY!5P7\=
M`;0RBE4H%1.K_>2[47K55++G>PW5&L5K88SK)8=@=P/P*6E6FNH5MVSH;L!L
MVX==-DU29MQN.>OK5RT]71,2?--"5QOKLTEZ)EYT8A^Y!Y?,F4*PAWO*=FQM
MTMSNXHU*U4-D]%X^]0NN:KJ1>U[3JO8>.M.N=O%26XJO-W)K?;]-@P;?:)V8
M>2`5%,)AW(4)=C@E69ZD3(*8=:91[*I!OW*.W<]B7OR'LK6*=@5C2&S]53BY
M4W4P&F#P^J>XY6]2QMBB8#^T9G72'MHYJ]]ML82(6^/3I,E_&<&$PGV?4N4<
M/FX*Y1PZ%W^ZI[:;;O?47J_OVD=<MH=C+!N?7-8LMJ'4QK4FBB8"3/KL:;*/
MD:?NS=H^&*%F2GJ8BQ!QT]Y6U(<1(>CJ0^O"@J03184QHK;U7M;;FY9UHINV
M.H&X^O=8DU2?C%KNFSM"FXII^<\P*?KHE6D-S7BWAS"Q\UV2W,4S$992PKR2
M$O>FE4(`X&J<%\\E&U5>-:9:3UXV[M:B;&G^]WMGK;6[9M7:W8+L#506F-8:
M4[`&:94"FO\`8&XU0K(!$/MJ<^[F1GR$M,9R=(DXC-(QGAT_2K.O7U+9?HQ[
MH_:[LOV[TAJR^@-3UFD7[16K[59Z(S&&!KQ,3;>I-,WR2WU1?F6QI-^)TB5M
MFPR*FB&NLJ!1(K6<9-O%6'8BCF@!0M`"T&A]AMD:Z]TG=%AJ5RG;.V#6^\_:
MZNQ.O=*[+;YLF^;GKT)TYM%IHM/L?5(JZ1T!5^K\38@N')7:X3*;`P5^&3%3
MG*G$KM.SY**T[*G-T]ZSM35^M=GN8;<.@=A6\;-`VZC[=I^CG!FH;X7QU;G]
M@-I]4B#UTWV%&5S8>FK2F&&F+@SC5N+,SVX$<$T8C3<M,@JF45\BLCM1[BW<
M=K4V\B93<FD=*ZKOVV.^VCZ#=)FI[6J53(/6S3]X+T#7S-VA[2"N%]Q=D#\M
MM@$0BM0G8&*\K`^'/G3$H;@:*^LH`/G+:/MKWIWIU0ZH=$R%(O>O->R+SU0L
M^RCVS-ZU&Q[+C;'VAIW1>M[9KSJ^-^`N%2EL[0[.&S\]B)/7(F%7<B)"8$*9
M,<PA,#024`!)\ZH:<?W<U[?/OR;WN^PKB,V.;V7NB*!;@$;U6K5I<)2](:ZG
M!*+7BJ;Z8CA$4%BUNPFG@<4,Y\7&?E.Y==>3Z%PS-`3I`5"N=KY^@YNVKATT
MV$>WCU2UWM'8MGZWW'8&UMV;JI[.TJ7[5'9[<.XJ=4+W8=@R3.S-<C-E4^N.
MS!Y,@<#C"Q*>U`3$G-H7%M*X'C_PJTK@>/\`PJ][K[H7N!:;W-LO5I>!I7<=
MAU3UD,[)131E&;H%AVT2E=3K'V3A;;U]4T[@LVTBE*INQ$1:+*'P0DT;+BC9
MCJS+!IQH?B96D5\JE&TJHC=_<<[*U.PU?;M%[E:-[.5H1U$[A2:Z]KW1]YIN
MG-L;"H.W>L<0C?&PN=D'/KN4ZXZ]V01/FE5B62B.@*R6CLO1GY$]V`#1PITI
M0*=!_<J[RV\9?,4';/5VP5C2>@.Z&W('8`GJ:TQ=4]L1^A-G4W6&LKW4)P/8
MQF%K/7I6;>I/S<G$=L@V1.J[RXKS0^4X_%91Y4H%M!4^_P#V#O/M8+[*4LU4
MW^P.-_TC0$:V7+689[7^"-I[:T70TZRQP^J=RWNC;-`AZU;UNLFZO;%!#,F-
MEYC,9/GCM3*`ZG0I09J="U*,^ZKW7JFP.VNOK$>T2,'Z4N\+4IJ\G:4,A$>O
M`(-V:TSU^D]LMBZW$;D*6\KJV\:ZO1G8.8YN-5Q@]J-#3"($A2)TUNY6T!Q5
MRA2^1[JG9*-MS3M4KVTM!;3#%J_H>+7@5;TIL*IV#NS6]LD]SBMH=GM&*L]W
M40I.M.NL/6\0@381"/"Y334QYPBQ#(!G5,HITIE"ID3[J'N+5N@,[/NEIZ^6
MP<]JG7=N^JX+1%MK#Z;+OKVOMW=WZPC!F1M@^K(;55_TU&%*:^&P^=A%Y/JK
MB.-1L8N5M>GYBKE'S>=2FU>YW[BNFQ^UC5FF:1W.JI"NQ%7K];J&C;52YJ;9
M1.H'7+MP"V(2E/;6L?QE8HS.[2(B:*3\/F>)!_%N3H\AQSTIE:5*-*D`3W.>
M\Q8+K:PCK3U\-5FLA`]QNMC#TH?<8?8"H2_</JG4B#+JUAUUN.S4#7,HKKFS
MRITUP22ML!D\)PJ)(<A/YPAE;P^;@F4+6`C[F/;EW9V[=V#-V:8CWH%HJH5D
MYJ0G%^HU6ZR3)W?'8NMK#JNW,[,V@*U*4[)AJ/7H>(I2W$J9!E?&83)6Q'D#
M?B+E'!7*.'0NRWN;[EFT-5^V]U;[.:RM8BG[8W]2(5M&2MB:/C"@-B+!NO5W
MW(2K)*NW3=U8"ZJ7;R=20S#858+,6FM._`!(Y2?(C/)Q#>UE*@;VJ*X.V7=7
MLSJZN])+#J:K5,NWW>`UO3-?5)JQD^+USV?VU^#*UZRM9R7$-0WW=4BM;LWV
M42CO8:<6\*A>$I'J+2L`,:]"@`Z>A=8NU?<N[>;`:VO7(V]M7ZA&U7<6O#.S
MGZ[K$Y`MG12N4CW,-:=:V=6]A[`0V/$B6!.]M.E9%NDR7VZZM0@822PTL1-9
MG,Y!H'S>19`#YO,NPCVV^]_8WMS<>V@/;X[7PT+KV"5FA*]5/D8R^:7L#6T-
MU:^3JJ_B1-_NIQZ:]5->##,::=AU@RY*D3%)&9'.#I+F+@!2BQ<``NJS1U)V
M!KOV^.DFR^T%BM6M^NW:#;_665V\W34.WW;^[7`]HN5IC;M@`%-YF]@E!">K
MM?N>^B%6'VIRC3XHO,.=\/+GMQ<)\,C3,0.*R/I$#BM9MPGNP5TK!B9J$IO/
M;^@]1:,]PNX=<KY*[.=JJ!?*KUCJ?:O4=.U=VFJ>=<$VK=VD,:("V`U+K(NT
M3/-:*:);4U+E+<CXD44Z>."HIZJ[R_<@]P;9/3C573^;IC;--NQV^TQ-[FV"
M[:_$DP/8&G4M[2PPM*'VV=M/7\:L%+<-V0X50-KT"SV.6VOXB-$9@0)\C&#6
M@DU6`%5%?;8NVS[5VRW_`%TEL2Z%(D74G8U=;3;3=AM8(.6A>ZGWVJ-?+M`R
M99J%)6)JX,9!:2VMA>14&-%0XW'::PBN`H#\W!4\/FZ@M#NH7<3N6%D:/W$S
MOX7V&3)T/[<&O-Z4X]5;$2)7^W[M[:=PM.VH("F-;"FC=;[@HDR'&B&9RA\^
M26G#(T>3&B,LI:Q2!P\_SE2!PX+?KH][D'9_>_1ONQV)V*UJ4G=='Z9);4H&
M:C#$-QJW>9&@R^TCFE=BU2K['V`N*2U-;H3$!U,X@+L4F')2V3&#9S3C>8YH
M#@%B0`:+6[:ONB]WM0T^P@;YM#KA3+#6[9:3;>^;%I"V-:YLDQKHOH+MOJ_J
MG`I#>UL/1=B[9NVV2U:$EL&9$\A``*Q"'/E'DMX!K3UJ@!<6_P#N=>XN/>V7
M?ALK2=#JU3B=N+8C3EITC:3ETK0_I]8.ICI779Z[1]H!X\VRWU'8LB%F3TBF
M$"L!6WV(SKSCN$,K4RA2T9WO[9TJZVP5K>5KL=K:@=@KZ?O58M=4O]\MFPA%
M\]XF]=.':P`NUBV8XY0D1-=SOF[+C,2;"BD8;+$2'%'+^':91T_-@E!\WF6O
MK_O1]ZW]0VNVR6=!TZ1/W17ZR0N1H=040.K\V?2^RUKG:+W$#,]@PP4:;>.Z
M8KX6*2M!BK6-QTW.;P"5,6&8EW(*JY15=D'3/W"^P.YN_MYZW[E_!Z+!OZ@1
M>JM0]7!!UM^HA$12]%'SD/8]W<V!"V323B2^RR#+"3E)8KUDB_".`RSKD::T
MYB6@"H6)`I5=<QGNOV.T+/["'Z#<*RW8@]R[$QHUMW7<BSD,752/NT]C]<N`
M*NC9VR:?H2`?$TL-%AUSZR3`$!#24PU%6V<0HF<J`TK\V"RH#\WD7"N_NK=M
MJ,1V=LFM[FI:(FXPO1"T5D/M_5\#7H'KU2=B=+-F[?*W*;4-C]@J^`K-?W5N
MFBIK6<S#[F&ILMQJ!**$/E\5]E'#SIE"VAU)W7[!]@/<WZMT/9EXIVN45K9&
M[`A?J=38EFCVP17$]"JCL@)MF_6QRT)@W_75_NM](YK6)8"'';^5L+BR'I<:
M?AN$`-/S=*E`&K'[8]UKLZ*[5]I=*ZGM>IS(6G%8E(H$*W:I1!*ZSO('N'U)
MZY'46,,'W43O-S`EZQOLN38G%Q]1;+*A1Y89MT:AR0\#10$H&BBI#?7N"]LK
M0U0]';'W3K36QBN[UU15'YE7U_;:;=NXQS7_`+O);K3=%ZEF0-AN8UQ`H>K-
M4"S%L%M8L#,B-9WFI*V(#K*LT-'S>96@X_-P6^VW=7;@V[[QA=^NBHMLU_I'
MK%U3V(Z-M'9?LKIX;4+&2VWV;>2=H^LM1/)U=N(\=D4Z`R6'W)4<<N'#CMJ6
MMIQQ',<,GEJH",JZ0K3M>Q)ZPOE=';\[$VCM?>NB?9\][IM;/[@W6\1U5OP=
M9-90Z>Y9*W-,O0.MFP0FY)YFMU:'6(H21)J'Q*X\>3#CM/XSZ<>%<%E3''A7
M!=D6K)NVM8>W[[X=5LEAO.I=GZ;"[NBUW0D;=^\-WR>N\*%U:@3Z;?M3]@MR
MST;4N52WN\PNXBI328#`F8^_"999EQ9:4XX%S>I8FF8+GZ+C^X%U#+:6H86=
M6ZL"[<;+N.QZ[I&Q;2W1WC,4;7&@.I(.]VJH4S;>W2]`L@J[=FMDUR3E4=QH
M@'JGS/U8;4MW"VECE/J(:%5"`]XCM`:HM&DF>Q_4^FUW8-_TK`M_:@AI2TIU
M3UVL&W.JO9#=FPNL-MJY';D1HKM+KY>]1@!<TC,+#WFX]A;:*CXLO&$*N0>5
M7*%-*[[O?<VQF@TB;$T-0[T8U!!GO]4;KK[8\.YUH00]OI[M6KNU9KM!/3[`
M/Z\"=Y)32Y8M%==RQ&PJ.LA@QCTN3*/F\ZF4**P_>@[#YUCU<)LWJAS-B'MX
M6"J[1&FM1Z\C4W:-,"[XZZ:Q*Q-;[:IW9ZUZ_N"J_7-URY")U!39YTQR)B5-
M'B(HPIAQD%3U)E%5+^EW?SL%3.P'3SK-:KL*LNK-K%MOB7X<H:SLG>)6RF.P
M7<E+1.[?639=7V/6Z`#'ZT$L"K$`"6VO"XD:3#-9'N/0%-BT4)0@4KTK:P9M
M'65D]\R9K/7O9"YQM@Z^UJ;([[UQ=MW&':K<U6G4M=SK7K]HKKZW+B5%P7K0
M<'D;(MEI3`=*02Q5B"J>^B;(B0)]`I]#5:_7'W4^T<KM5V2T9JFX:E)APVQZ
M5K+73EMU)B&7U39/R]M`]1K?'M%9"[M*72UCW:KMF<7C2CT6GNEG8L>>,C9#
MO(>=N44!*N44JJ1VO[A?:W8#NA]1;'W)K769>%O'K$(FPZK1+=4;OV^-UKW9
M+IUOV83U:1B;!7BA5F@T+2`HC:@Z&CL=Z/:WF);C,-V*I5#1\WF5H./S<%OU
MW"VW0M:^Z/T[)#MX[%&W6#*)0-VZ<;O^QQ0B)U]GZ3[`'X.Q*]J>3#@Z9MVG
MQ%KK;Y/9-K>R1-UZ6"`,1Y$/U<L2,1BTJ#T2N[>LV4#<ZW7KA52L,[6+6#$V
M6N&Q[GK0#($[`CE`Y6"]X8]6&0'RFWFE>&/,A>,\P6"SG")PB<(G")PB<(G"
M)PB<(G")PB<(G")PB<(G")PB<(G"+H5L7^[^^R9L+;5^AFNO`LUMTHM[:E^!
M1]];L18([&R;)8Y3=G)`8.S6LB!5GL8XGB+G#+4=Q<9Y#./!K.$Y\QX"RS.6
MP/1[JK[6OM_;)V_0^G@@)K/85PG4NG[6%*O>T+@E\P`*8@4^N.S[V=L(,>;:
M*['0RF+$?;DNN3VTK2KP3A,<7.XH2X\5VHER@"OC9Y@Z0$A1#*,/%"A65#'C
MFD+RU$P[.F2UM1TI4I:&\9<5X9SE*?Z.,<Q6*X3;-9N`9J6TS$)"B8B9"C2D
ML*8=^4E&<Q)K$9U3;$R$U):;\JL)]//W./Z6/`B@U,UWJ+KQI2OZZKHH13=-
M:<U^*!CH1>6]/&UZBZ[KT2%!>+E3LB=.GM@@`-K+DN:\\_E+&%N.*5CQY<2?
M*G'SK"O;ZT(Y<Z33G[A7G;UM6G!+#40BQ1!TX?I%F414!G2V_E:GAH0N\/EI
M93/S'0MUAY/E\Z%XPH5:%7.L0)=BN0UC!SD)Z/F*[%7"C+BO1%)2G,9QC+>6
MG(ZDH3CR9QE.<8Q]'T<BBJNR=@=)4G8@74%GV/5J]L4X.'$0M0(2\Q9\N$6=
M-Q@:6OVKX-J2<D5F>T/C*<2_.<ANHCH<4C..6AI7H5H>*MF!/AE(,(E`?1)A
M$8D>="D(PI*9$26RB1'>0E:4KPEUEQ*L8SC&<8S]..11<&*3KLTF3#0IX>48
M"+@S3`N-(AO$!3AAF0Z-E$(C:E2(3A..PZIE;B4Y>0E64YSC&>$7-Q#'1WOC
M4Q83,AF'B)\7AAAMYH>VO+V(OKX2E;<-#F,J\GCA&%8\?#QX11NCV>E[`K@;
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MFURPQ!EJ`20YF"5$QW@]B%.0Y\<@#G8;F17!Q6+EU$D7+QY76\MKRTY]"L>/
MT9X1<MH4*91%;8&CVD04OHA-M0XR$0T2L*3)1%2AO&(Z9&,YPYA'AA?T^/CP
MB]C$&!'9:8C0X;##,;X-AEB.RTRU$QX8^%:;;0E"(V/+C[C&,)^C]CA%%ZM9
MZ+9$E@U0)!";%1)R`!6"(0TJ$%+!RA`3+$J0RTF(S+%EPTEAQI'W3#["DJPE
M6.$4F4/&K5.<7!@J4293').*C,95/8:;<80Q.7E&<RF6VG%(PESS)PE6<>'A
MG/"*$&+[JJN#)UA-VND"1=3EE*U.*S2H:/'`D!PO)<Q752%.X^"GQ`\',A^$
MG.'4L,^92/*GZ%"BFS#(R5'9>CL0GHTAAEYA;;+*FG8^8_I,+;\$^537PKWE
M3X?1AM7ACZ,^'"*.5JWT.Y3+;"JAZN6*=0[3)I5TCB)4*<_5[@R$"EI=<-H8
MRM0\RV`.P'G&'/!S$>2UG./!6.$4E9'#H[+4:/`A,1X[+<9B.S%8;98CM*2X
MTPTTA"4-,M+3A24XQA*<XQG&.$4/L5DUO7\FX-G)58;Z54/WJPQ"GP#>/J>!
M7%;LEE*,O(SAT0-<=9Q*><QE*<Y3YOZ'&*+&UC:.HMD3AX2IW.F7*>_0J-M\
M8-%$AQ=U>NM@.F6=>7^(PTIWPKUI>KT[`V:G&&Y&8COIJSY,\N(5Q"E!NT5*
MMO"(!TP'%RR3V&0(Z4^PB;.>9?@P%_*A^/-*D8ANEHZ'5-(REA+Z<KRE.?'D
M468<&"W<34NCX#N">49(I<B1UX(99;0RWF;A3><2\M--I3CS^;RI3C&/HQPB
MA=Z*ZZ`CF0=TECA$3:QYC7<6,E4J#.MMCM0R9%9"Q7P^&RCA24&@2%Y?0M#D
M:+&6]EQM#.5I(M!PG6_VU;):++JX1D;/LU8GL50_3W=Z;H;5B?+G3`N0<:'/
MV,U"/Y:+C9$"2S$^)3'G,.17\(?0IO&57+*KE91_HKTFJ0K!JQTR>!#QG!(9
M)"?NK=4.''49)P``86VZK9"4--3RI"-%993X(4ZXA&,>.<<9G*5*VMH@_7$>
MO1*91\")P+5CK6OV!S<MPZY59@$/"BX`2II-^>122AA9S"7,ONK?6T]CSJ5Y
M\YSCCQ47.B7B@N2Q$:%8J]F;8K%::>%:CRHN'RUFI;A]RW@(>$>"I!*O/5TD
MJ8SCQ4RJ*]E6/%*N,4Q4I9'CHZ?+'A0F$J<];RLQF&DJ>]=V7ZO@A"<9<^)=
M6[YOV?.I2OV<YSPBX`J2`F8,1!"8*DPB\R":8C14L(P8<9CS9Z)2/2;1(D/,
MSFUN+^Z\_J?3G.?'A%2!?LUUC'D#80UMC6\<A6;R&I!R#.)0O.,O$F02C"QS
M^'6\MXE0IE;G,N2$YRS!?&2FWG&EQ'TMVA5H5F"_8/KT&*,A"VTM<L%IFP)V
MJO@,G!<F0C8K#%>E%JC.1'6]\"8AXLHE,Q$CT\,/D(C3V4NOLH6H4Q5U?"1/
M%7]K1O%6<*5^TM>.<^MF1C*ON?IS\1XK_P#M_NOV?IY%%QUB!*V93#@P<MB;
M*Q.FLKA1E,RYB5-.)F2FU-Y0_*2N.WG#B\97C*$Y\?HQX$4.8OVLUW#%<B66
MKN74G)DA,P8LJ&X7F3@4.>3F!'7F/,MT@&@19$AV(I?K1VL96I"4JQG)%R:]
M9]<["C'&ZP8J=Q@CI+8H_P#*9`PU!8DSH$*P-PIZX^7XRU2AY5B5Y595A27D
MK_H\8JXK-'?JR,&%C=B:#11(X6N<:(E&(F(L80"2Z54_.>?;RG$(5AI<C'F^
MY9RG*\>&?IX47,A9$$$1SD!,"5@C%B2(Q6.VRM<N&ZPIV$XW+2GSNLJCRLY;
M^GP\KF?#Z%9X182LG*3<HT@[4YP"PPGI$7U30CX2;$GNO"Q12%(9)L)6P3:=
M$RX;K3[;CC:F\H\JON?#!%(EP1[BV7G(<-;C"GE,.KCL*6RN4XAQ_+*U(RIM
M4AY"5+\N<96K&,Y\<XQPBU7W9UCZMVPL?W#N8%(8FX@"HM@M3NS]F5`:S`'I
M9&"T28M;N@0-&;;R\A&,I83E:U^*LY4K.<T$\`J">A1K[.WJ!YYB\:P,X<(K
M:=)+QMS=6'"+C*/28=(KQL7SSW&6\>5"GLKRE/T8\,<N8I4JPJ9J'KGU89+D
MZY!12&[])%`"+]@NEWMKA^6+AG2(H1$:N-BLCV9+<',]Q+,5*5.H2OQPK"<>
M$J2F)5N4;8E!V;#(%J(?&VB``/EZO+(CFWE18QL+(<@%H424\PTW*3'?:4WE
MZ.IQASRY\JU8QR**!7O7^B+_`'_5;%Q@@2M\U+=9NUM?"&2,F/+"6NT4#8]#
MD64H%%2F8T]@Y2SECCM_-&G8TA:77&\*?82MNU-%:E7?\)$^*^-^&C?&_#?"
M?%^BU\5\)ESU?AO7\OJ_#9=QYO)X^7S?3X>/(HH"3MFKJV?%THJ1JX@XU4[1
M>!P9]B+'P,IE;DC(=JLBUX8Q""!84HW';??=6RVXIW.,95Y5^5BF*S=9-TJX
MQ&K+4I]?L,.),-@XYP.N%-:8F#RCPT^-C3X^%X0IDO`6U(0A7AEYKZ?'..$6
M0$2`!II!X.F#+2\],822:BI;>6]"E/C9B,NN,MR/%J3%6TKQ^C/E^CQQX<(N
M<D>-2\Z^F#!3(D/)>?>3&8P\](2EC"777,(\[CR416L85G.58PVG^QQX$7DJ
M"/6XRZJ'#6['R_\`#N*CL*<9R^ZAZ3Z*\HRIO+S[25K\OAYEIQG/TXQPBP#E
MAIKUI16UD@<FX-#UJ4*0N-*-0ADYO,G^VVV\.R!T,DW"4MO#WIHDX85E'G]-
M7E(I2A*$)2VA*4(0E*$H1C"4H2G&,)2E./#"4X3CZ,?TN$7[XX\/'QQX>'CX
M_P!#P_I^/]+A$\<?T\?T/Z/]/Z,?U<\(GCC]CQQ^SG'[./V<?3G'_P!/&.$3
MQQX>/CCP_I^./#]GP_\`ASPB_>$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M4)C4Y,1ORT[KK:*HVY<==ZTU^=B28DB`4FXJ-VM18L=GDH$5Y128Q5;(F*-;
M>_K7H^$+<0SG'A:X45Z%IO:.EFY;#8.P$$=>0]4KNWMEKV+7KR-VINLB?I\C
MYW134-([24YYO3@*QB9%8?6T;&N,$'7?34M6,NR,YM0K54U!]L[8S=&=J!6?
MI>S-3ZI(&PX]T<MUEB:P(#S=N._(]:-C:_4`L>K;6(&X#UDPH5$8B.#L*2/)
M/Y9D,7,$J*K,B_;3OT\D-B;!NU!M%::)1B5N>D-6TB9VB+7&H^!^O+S#(Y3!
MF4K5<ZFO.5M+CTI+F"[_`)X\-7Q*I[-ZZ55E[IZ)7_;@?75?(W&D%V@?7JM:
M=LMEM;5G)G1I>O5BYB;3.J4-2Y$(D$WJNU1Q]L3/=9?4*%,>.)CF4(8@=1`:
M*X=C=/7[M;;Y;1%\/TB86ZIU_KU1(]2M^P*P"KYL5G<;;MCLU.J]E!U6ZB8D
M;8\/`UB?'??'.17G(JX[JT.8E5*_/6IY?V\-WV`--I3MQU+5]9VX\FT6.@UR
M5?U@:/#CXWB+;U%KR$B(%A2];3PNWVW9#KS0[*)4)QMN#AAYGX;+,/55J%L7
MO'JCLS9%_M\.GF];U/3NQ:;UR`GU.,V)F^5.5UNV'?=C5^%1A(F)'K34"PD+
M`-B9ENRV7!4>,\IF,^O+/D@(]52OKK69WVP-C-.4^4)W#`"GV*]LN+;;B'EG
MQQJ+<;66M\@;>`ZOE\LZ<(&*F9%ULLUDR%2D0$CM^:8RE$5NY@KF7/<]N78Z
M[&0L89CKQKU-D17/,!HD6_1!NKC`J9-:%WO7TEZ.U(,7C5XAE&:VZ\@3$]<X
M30AD>PE"),J$J%<W7WHR>TCLI)Q@G0U4>?UM%:CMHV)$(D2=LNV!=28.6!;1
MH8Y+"#2IT04)3O3+OQ##Y3#CHN//1+(D!=5"56^K_;</4RV:J^>&=:3*%K`W
M1S,X<)'6-J=LMJI5P*S5@EO"R/3KT<3I*P@$)IS:<RFDPICJEMQ74Y2^S(7>
MNK<8Z<;#(;W[3;&LEPI;M-W[J*_ZL@!1XQ_,MQBU1*K!KA"XCE"(?S1VHCAA
M"'G,HJ6]=J;GX1(UEQV)E7`!*X*A17M=EV0X6*FU4*F$GQ6Q9ELD4D8?3'_"
M$8JFWJ_J:[B6W%BFR!33,K8L)\0]*::=C9&IS'PRM+647,F8+(ZG]N?:U&V!
MKJW/[C?JL.L!C46.FB'X,XIJIZ=(VNM\-JV/9M29JA.NVY>P84LE%E#109F6
M)1E8@@M,.1"%PHE<%B2'0_<NQ;F3MZ[^=K8FK=AKB[KL/<22AI`7K",="VL'
M?!>*W'.YS:1&T2-UE`T1GJ]*D5VP1F?C!B651W&8>PE0/65L]1.BETTALZ5L
MK:5BH-L=8%7-FM!*X/D8&U8]>@.G0=L/@(:J_6`HA=H7K<@_)]."J=Z1=3,F
M;/>S+FRX750FJH_57M:W.IDZU$N%RHQBF@%ZK9E5T8HTV"-5O6[6LXX^BR*H
MBO"&,UP--ULLN-3-(DX[,XW*;:B1?&7))7,/50NJK[T9T`G:50>57;F(K)6T
MZ.MNK3%FJ40TT<39;!K?KQ61MU9=GS\9?E`[UK2U6)'G6EU<^TO/^?$F3-==
MA=50FJHL%[7NP(=+:@KV77:_=1X.,#K)L5,LA9%+ARH&UQ5Y@UF;#&49`L1L
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M2]H`[B&C:QI4HZNK403)(A6J`$G?A3==IU4#MA);;U=N!'8[$PJPDH/@-R1#
M*U0ISF(CL`7842N'E5=2O;1V#/>*K.;F&7!B^0K=L._#[*$:CP1O90U4]ZBP
M%]HJ:R)`R<@*Y8=SL2HJS+A`W%36AJFI7JQV<LW,F;J62^S^W)5W'W-<[(H0
MUVXQ40]D/D\7F.J>7*[4=V):-EQ4"Y>7#=YF"0H<,E,IV-ZT5K/GE(;C,,.3
M,$J%F]"=#MKZU'[Q1;+]1)<O:NM-D4L3!KL":@(`.WZGZR`SCR(;`"KPXXXG
M8:++*R8S<5R9E1#"9,PA*0^0DBZJ55*D?:IV4B-":';<KLV,)B5VF#0JT%ZY
M$SK&A0=G5S48*44P(MKZ)VGA%\CD13D>,P^LO#6Y'E#7U,3HUS!,P68:]L?:
M\<M+.?A5K12R?7FTE6+N?EGYEGF#;+9&[*0NV5#0(?(781Z+!B!2C?Q!!R:.
M81EXH\TS%@QV9,R]0WI)LS46\.O0^G5<=;J0)N.K[&_8HK4F`!TU'H57J$?:
MA.LRI%G;GPK%NZQ!9DHVVN`X@PE^/E;CTCXO*%:A*U6R%9Z26*)V3B[KLI6@
M$15>V[:-E"LM03,^V6Y^RM[I6(,VYPFU@:+MNL!6SH=8!.PUR$YKP]6,KCIR
MQ#8E<**5PHJHV5[?VY-@V'8#T6^:\J0`EL,M?J?&%SMCDX>+/8K38RF=F1::
M<ES@6EME5():9:7W*;)8B7(TM14AB#*RTIAF"H*C!GVUMHV<-9`+MMU?0(=U
M;@I$D:`[=<'>KXN%?#UFGTWK)+E0QT"`*M+9EDC*E$(K$>.:@H5@9(3\&Z.N
M9,P68D>V_=F1KY:),TH1M9PF5F[$J\H9<0NM]K16ZKK6H4<9<$PLDRZAVOG:
MI//BFG&IOPA9QE#:L>=^5R9DJHE8?;"VX2<9:QM6E'Y\9BPRD[*/,V1C9,EH
MKBZLE]:>=Z%9`<;7VU%6;,VS//MSUJG39OC!G)4C.;F"9E-JU[<=YJI?4ML&
MVRDO76F[9U[;S-C,2#Y^2/H=-INK`+='&-%P<F!9(H2143;(7TX]:D#$%T28
M4N`W\>-(,R55Z-=,K+GLT2["S+D&E2FMHU:W5-MQLZLU6:;%KFP@=WJ(^2Y*
MS#AM7+-J'YDH92EA]L?C#V%>5KRXUPHI7!5G?^F6_=CW/:5Q.'-,1"]P(;'U
MY5RL*5<5HK_739=;NM/4`CUM%:@P15YIR+0NQ+>1*EMV6PD2&),F%$Q"1&M0
MK4*R;KU3V2[<'VJ-C4"M27/LFO=VT*84;.5,N9"Q:?IB`)K<(J`KIV/(BRMB
M:XDV8Y"4W$;/R6($>1)Q'7/0^!'JT4JHULCHQ:-D]@R>QS5@I,F@D=CTV]&8
M$]D_,L][KM?G:5FL:GND+R-`9-&I)#5$PD$;R])97-/OX7%C_P!N.D6;"BM<
M%RMO],-B;AW;.-62ST4AHF5>X%ZF4HM]:IYBR-2F>M\.P4NPAOVNK.5MIG0T
MIUCQ6^F6L\IMYAI#+JI8&@\JE?74<ZU]#=@Z1V[6+^;O5.,"*_EN<18$1+`V
M8MEBGZN*4ZP6@UF?GX51Z6:*_3*6N1(E08S>77,.9]-`NJ%2:JFHOM86@-32
M8ZNV76H"R2[,K)/%='3@@K8.L0TO3TL)JZY/S*Y9(+->L,O6DR438>#F8,:4
M67E,:8GUL/W,F97-M7H=L>^C.M@N'M)"FM-::7K$SDR;..98/>A6,OW8%*<#
M%3AV6>A@7@9%IV<&=DAY2DOOR6%2!\F5"`T5<U+VX]IU@\^5*737VR(CE_\`
MGLT/L*9;I=>L[,J3L!\9L8T"K@JN/QMFZJAW.,/KZ<SYK[\,<A/S@>VF"P.N
M9"0HA#]K_;\&D-4F%L;6HQI%59J5?,BT7:!-U+`"44547UZOB04PHT).ZF1W
MPEN:PJ%B./\`+AE4U>/#C,$S!;`[EZ,7JU]<DZ!UG:*%5Q,3<NUKU7XTX9+9
M%4ZIW1.R9-'&U/#@:S-!26NS=RAS&T18<=Q7PBTP)PM_+4MN!PK52N-54]H]
MLZ\3HGHB[1K$PD[+9+6X?;8UR4,<V#+V=<;K-WI"3#<E.D]L5^LD1H,8])]/
M*H>'VUR6F6F&EW,%:JR-U=5=Z&^UX_<.NL427#F3VKI%M=@+6,44&2:9GKPH
M+IBW8$MON*UD<DZO,D84J&Q/=A%#LM2X6,*><FRHI1*X45'BO;,[`))+G&=S
M4#$I&NP=.68#0;%$FFB0.B5ZKB311"1T<XJ;794,BF-)FFB[N8TY68J1J5O1
MG+F"5"F.?;CV=7$SH]'LVF'H3H&S":@/M@.Z?(]1&30.K,/7J@U^NSQL=5FL
M4H'+'D4Y>AL?`3LN.XFM_%CITS!*J*5GVQ]LUU4:8FW:GEX3(@3S-:DMFF1%
MPKX':.[+T)T7:Y8"HUL5,U*0KVTV`\K$<)%AQVV7_0#?#K3%Y<P3,MB]`=%[
M=J`T5LT_9`[-IL>O=C44Q:*XR?P;@0;13=``=?"Q,PN0<D/@--DM8F\@VGW,
M*9CE$+1Z;[TS*X754JL1ISH*9I@[9^;5)U=#G[&T'<-&,B*>(,D0%:'6,%5`
MLV1"E6!F&2EB[B:KDJS&H2D-I6;,R?NY#GJ39(E4GJ5(3O:VNZ:;71==M]!J
MQ-Z=.+['K]6<-U^KW$[)+[?S6#CQ)=:-2G"&IQ&RH3@%_`Z/.1(#MHC2AB_A
MID6Y@F9;&5;HB3&:H[!T>SVH#:[1O:XU5\K;B#-@?E3=:ULM7IJJ&?E2IKY-
M\?,BQS"%,,NXC966=RI*O4<RJ9DKBM?7/;:V^!DNE:YL.LRIXC<C^P0DH@0(
MS/B!+!BQE&#CU074(=6S?9(`PP!1^VH*Q&X$1^-9H\9GY8JYL*)4*(4;VS][
M3@>MS1/8@349)&N(HF12*4</9A:5M;NL*U53EGILM`E1&P6S9QH4[(N/HE`K
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M6L4.;3"E:`UPC..1;M\!7^MDHBA=#2E$DFMJ*TID@`D8R]RY@E0O40]MG>,@
MG*=#;9I57PO9NU+0$LD91\W9JR*V2*#0#%A2X2`L3+#=#.1BOAY#Q*-9*ZK*
M<(M!6#EX8ZS!*A>\][9]]-U2XOQR&GZ]=3,JE9U\`#*M#^O-*"`=EVD<.5>G
M,GJ\9AF:B4)V\29DC)@-N.1(PGDI^7R&QA2`S!*KN&`)/)$QD6;(I1EM<MN2
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M0[(S!!O'D<)U0U*C^#SL6*PD2$P4(J&C-EP-<]:QQ_1UN=Q4BAMW<`Z9U4MI
M9$ZU2M7Z_%#B=@J379=$S8!M!@060FXLD416I#J\?+<?$8=S:BJ>JMWNL=-V
MA3NQ.YIY6A;6KU9M=P)$2=Q-B6&2Y4P0V'=#0:N'3.;C:J7MZ@XK!7UAMG'A
M*X?K`AD<!EOR5X<:CXG@AX+M+YBL4X1.$3A$X1.$3A$X1.$6HVY^X]#TIOC2
MG78K3[O:+WO(:9.@)0`IJ8'7@%?KUJIE1,%CLW9NT=>D"KL,A>8CV!U?B'##
ML5M]QN(OT_*J@5%50*BJS-"[K=2]I&*57]<=A=67<[L<Y=*Y10]9M0\N2M)C
M78X<8NL81"AK=D26J\&,P9KS_EQ'S#GQ7T+4U)86XH0E"K*W;N*J:#UJ<VM>
M&#+U3K<ZK13;@*''G31\2TVX#4,&GV)4V`RD,`>/HG$7?4\S`^.^ZE#BD8;4
M`J@%<%UW#_>AZ8S:H;O;\K8X>FU<1?35I/&JT"@)`Q*)9=WUQ++@=5L<L1DC
M<V="%RP2,+ASGY0*5"GNI8CNO*CW(5<I5DO>Z]TD@PED#.UH0",,W;9M%7')
MIT1"<UV?KS6Z'8MMO3.3"W0VO;6C1!OY421A]3V5,8>:8SE_##*5,I5L6OOU
MU0JMG?I^=P5"P'`FQ16M;ZQ6[``GL:L)EJ7>[XV>V/,DEH,:O5""$UP53+GX
M4^B++8RPXE*T.X;924H59773LIJOM12CNQ=.%91^EA-@W37#5@=8CM0#I:BD
M_E)<H!<CS)>98&1+\<1WG,,O*PG.%M-JQE/(01@4(IQ5^<BB<(G")PB<(G")
MPB<(G")PB<(G")PB<(G"+4#;7<_7>H.Q6J^LYBK7$S=MIU65>8YT<8U'7Z?4
MZ</L\&JDSMAF;(VE1#YC`N5-^)D0JX-/$FX++C_PV4I\,T"HJK3"JDFN.Y_5
M+<!FBUW5V_\`6-]/[,9N<FAA:O9X18I9HNO,-*NLL?`C*7)^#KC<EA<AYQ*&
M\-RHZ\*RF0QEP6D<4H0K$W7N2HZ$H+^R[XDHFIP;5KRK%IHJ/%DK#9V/L*KZ
MX''R:)<V"AFN`BUL8EE'TJ6Y%'-/O);<RWY%`*H!5====]Z7IA8*BU?77]E5
MVG)K;EC+&;-6`0QX#YK]L[7HT%/`-VV59YUA,3]5S"#,<="G):"SX,Z2MAA]
M:F;D*N4JSV/=<Z39'@2A/:T&NP26X+II*R/6"0%'_@RN%-A;9()E;*1@T\NM
MURUQ],&?E$U.)")&4HPZECR2?AV5R92K4L7?WJ97;(]5\[EIIF:#V'8-:;#F
M`["!EB]1G*OJ[:6VC9#9\Z04B)K==@US3AZ,N:G$AM!6&N(K&'&I'H3*5*%6
MMUZ[#ZT[/Z^D;2U(0F&*0B\;#HD`U*CL1V#4_6MT-44T6$X8E2\O`IQ<$\N&
MZYZ3[D?*<NM-.>9M(@@T*$45Y<BB<(G")PB<(G")PB<(G")PB<(G")PB<(G"
M)PBZ[=+>Y]U?V[2ANQ#1I_1U/M.QXFK-=%-SV[30U[8]OF/3F,#P0>A;5V";
MKLB*J$E4B+98X*?&:DL..1TH=PKF1:0:*Y3P6Y&K=Q:MW<!)VG4=[KFPZV&M
M!^E$CM6(-E!46UU:5B#8P69K'C'<(!)^<L24(4KT7TJ;5G"T*3C&A'%2E.*U
M:[!^XKU[ZQ;9K^G-LIO(JRV8UIX4,)0*_`G5WX#<[FWXP6V2R&3D>5$J-5(:
M6)13TQ<?_B]^<.2E#V)7BW0TD5"H!(JJ@8]XCIDS$K[]E.V^DRC@W7I^8,LX
MFOHEU&L;+L\*H@+#=)`6U&A-?9A&IZ$$8*Y*R\%/AER'CSMX7<A5RE7.$]R3
MI@6<W,B=O.E59&BR$!FZ/V8Z&B,2P!J+17ZU>JJN`2)9L=,M4C8X>*-E,8]6
M5*FM-I9_;F,NLI4H5P2WN4=3@Y:&`=OS4T\?WAKS1%##BI-?)SMFF]E1=$SP
MEVUZF*><9L.LH,'L37GI9?"V\)3E_#+3RD-)>92E"M]>8J)PB<(J5[':89[%
M:(VQHN1>[WK!C:M(.4EW8>L#&*]L*G(-Q51<GZ<;RT_@6?'X5YX[WD5Y%X\?
M#E!H:J@T-5\+WO#>SP'ZA%/;T@Q.\?>/=OY0'>#6VE7WMV[@1;5ZU9L[L=M5
M^UGX"HOU>V`*_9C3O%SR>"?N?H^G<QU:X`8+:UU:X#@OIXZ'>SN(Z*;SG;O@
M]XN\?8AZ;1+#1?J!V*V^B]T-EL^4`$U6)L.D5!S]9!V0.&H\CS?<-27L>'W?
MT:W.J*4`6LNJ*4"[D^8+%.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1:[7_JYJ+:.XJUNN_`46BR5/5%\U"#&%XPJ:"'@MB6"GV$\<'ID
M#7#`FW-N4MB-&GPYD=;460^GPRI:5HM32B55&]8O;MU#U;O<#9M9NFT;U>1]
M"*ZO;/;")U"4Z[07`6C*?4Z^[$JE+J<#PH-(Z\UX5`DH:1+EMXE2"+DV7(S(
M12XG#H5))6TV]-/5+L)I;:^B;XHFW3-Q:[N&M;/(!RFH!V$&N8&<`G$0,]^-
M,9'G1S,_+\*0IIW#$IM"\H5Y?#,!H:J#`U77G)]G#JE\DV&$"E]K5E&QV:BT
M3F!K)7OBA*J1U(M'3L`Z#01J4^'&4FBV^:<DI=:>1+M#JI;J5,K<BKN<K+,5
M,#/M7Z#L,V45-7+;<XL0'[:A$R'SJHQW)\C=$GM=-N91UB-2FH;,W,WN':'8
MN&FVV&,QA^/34EA[$AF*E2H>8]G;K+9,'H-DM^YS5:(?6J+6:J_9JM$%Z\![
M!5LXOL6O5*4.I4,V\/NMYVP3L$ATK*)3(L]J,S#>C0&E0W&<JYBMX>N'7P1U
MOI)^HC;Q>MD$+=L2[;4MUVV,]5G+18;IL$I\XLA"2U2ZO3:S!BNSO'+,>(.C
MM,-^"$X\,8Y":J$U6P'(HG")PB<(G")PB<(G")PB<(G")PB<(G")PBU?V=U`
MTIN/:<W;.QP*[0=F:)MG7M`\@@8Z,&4NZEE%+"3`OJ&9/`+=,;<7$^/AS65)
MBKRG"?-X+Q02!0*U5:]9^@>L.LE^E[5"WO:6Q=D%J5-H5@M^QR-/D3CX);6L
MQ03XV#3Z73P\676*EI^OAXJHD:,EZ+"R]*3(F.N254N)PZ$)JM@.QVAZ3VAT
M-MSKOL=TW&H^YJ#8]>V6;6IS0NRC!UC'/0%%ZV4?B3F1M@#NN)E09"F7<,2F
M4+RA7E\,P&AJH#0U6BQ'V@>KCJ=BJKIG:5*E[%M+-QDRZV?K6<UPW`T94-$A
MLUN(9J!:!&'"!-/0:1%D-2&7C\Z:^\EQF1F/BYBLLQ6<+^U-U[.((_,+;MIQ
M\K4]C5&=*0=JC;SL3:`[ML.LA!*$TOX=LDA/<NTN1E81Z+;D4=XMK2R^F2S%
M2I44+>SMUF/XLT<W<=T$1A55OA504JR5*+%UG5;I$[`R2=.I[\&C1B$P1&NW
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ME:+>-UU2#3#VJS$VO0K-4IXJ[P=,%-`6/7U;MKQNC%#'R<7;^N@<L\L;*'39
M<F=/;=D*BNLQX[,5<Q7:MS%8IPB<(G"*FMO==]%;^>U_(W9J6A;3>U3=ANR-
M:NWBMCK"NC7X-G"A5OK*B#+V1-@'JQC+,EKRNH_H9Y02."H)'!7+R*)PB<(G
M")PB<(G")PB<(JFM.\]54F]A];VNW1@5K-A9-ABLSX!=L)#$QH-E)HD'K9@>
MJIUEP@.I9I^$R1FQ7I[(><N.EW$1_+=HE%*M?WVH;3I%3V1K\Y%L]'O(`7::
ME8H*)"(1ROFHC4X45AIELQY/PLZ&\AQO*T)SE"L9\/IY$7J9V+2'[*9IR;,+
M:LH"<`%E!,MY4)]LG:1<TW7QT5<Q##!*>3$CGY#;,9;SF&V5Y5C'ESPBR$.Y
M5`@L>U`M5;G.%IA$<*;AG!DE9(@'S(P7@CT,REJF3!>8CN)+3?F6QEM?GPGR
MY\"*O@N_M7'[C=:..,&\$]=DG`EO-$:->PM`%GV60<AVNM[0,UJ!K<G8FV;)
M#5F!$*OR_P!MSCT_%MW"+0\4HK"B7&HSW8+$&TUR8\3G$Q8UF(;&2'2!,+E_
M!@=!;9E+7+G"<Q7?B66\*<8]-7GPGRY\(BX#^PZ0U#8G-6<028EPT$8:`<I%
M@ESAJB\4"HE`@!/F$Z<.8,36H[TAEM;++BOVQ2<8SG!%&;[O#6>MZN-N-A/R
MIX0W:8=)!YI%<M&S"QRVSY,R&Q7PU=UR&M5@*DDR!TA+K;$5SX?T',N^3"%9
MPHE%*8=]ITN"W/58!XU.8X"1*A'W<UPT)5:(K<P!"L``\D<;KA8DP[CR0I\>
M/+\^,HRWA:5)P1>UB]TB4PN3&N55D1FI`V*Y(8L(AUAN4:FNC@\9;K<Q3:)!
M8@RMB,C.?,^\A2$84K&<<(N/5=A4F[-MKJUF%%UNL$)2(;,CT2?P8L\2J\Z<
ML3*PP3;@,V`/*B8?4SAE;S*L(4KP\>*(JT)]H]!AK.?IA/9(B)::OMO6^B3H
M1R$;5-@;8VZ`"VG7-/REL6M$F3:0%@BR69+.7(3:%+P\\VIEY+=H5:%<JI=D
M=.7?9!S4U=LY!^\`)UL%OPB5.N]?#%B="F"Q]X&U*W6"N"ZA=R%/F&HJ";(>
M?.=A>LG+J4I\<X4/%**\^11?/?I\5[B/<_?GN"/TSW+[OUNU]UX[J77KWKW6
MU6ZR];]AP8=4KNN-77*++D66\U-ZQRYCDR\/MY]=U[.$-)SY\^/AC,T`&'$+
M,T`&'0H;W^UO[H72KIMV`[4A?=ZV3L$KI*CYN4*EFNH'4T*)L3K1@4/4.GE!
MU*D3X3#C4]6?.TG*\9QCE;E<X"GST&4FE%]%P.2],"!Y<A?J2)0L?)?<\J4^
M=Y^(RZZORHQA*?,M6<^&,8QCFM8+K"]VC;._M8:DZS`NN.X)6B+WOKO7UBZX
M$MF0*53-@$*[3=OV`R!L,J!6;Z*,5R;,92VT\WZC25>9KRX6G"E>.30#6O4L
MFTKCU*'_`)"ON7_KK-N_H6=0/O0XJWJ^>E6]2XOMWW?M6'[C>X3U4[)=H3/:
MD9UW!]0C^O+O8-5ZNU46@_ALI>SK+;(+XK5X(./F,XD@8:&UR%/+2EG[GR^9
M?FKJ4!`HC@*`A=Q?,%BG"+Q6M+:5+6I*$(3E:UKSA*4)3C.5*4K.<82E.,>.
M<Y^C&.$6LP#N+UVL\NKP@E\E3)%PL#-;#852;_$;1/(/59BNRS<B;5X[%7K]
MU>O(1->*DU1!EBR7A_+7Y7Q#?FM"K0K82P'A%5`&[18)J!H&MB"1XV1<;>=;
M@"`\)X@2FN-1VWI#B(L..M>4MH4O.$^"<9SX8Y%%`+ON_5FN*R,N-VMT4#63
M%?LEH&EY$`Q(C2@51HQG95AFI3!'2GT9'4:O32/I*0E]UF,M+:%N8\G+0E**
M&J[7]?DO1&/PAQE_'S*R.@/M`;4]"GD;C7P%JK@Z$09!.09<\A7[4.DY8;<4
MZRB8WAU*%9\O%"K0JV(NP*1+B9FHM8%AI&0:)+<\E%&3!\BRQ6)H""6'$7(L
M\03+Q9*%L1933,A?FQC"/'Z.2BBAU^WSK'6\.ES3Q<T73L4I+#4>)KVD7G:Y
M6S31X4C8I^18?6%<MY5V%`"B9$AZ5EE,5I#?@IS"E)QF@$HI[&N-2ER4P8UF
M`.SUXE^`])>!\P3D>_"C$$.0<OXEMN#Y1*.T^E2,*9=?;0O"5+3C,18H=LW7
M98Z:K`Z[5>78J]96J:9"MFH'S*#;'JV/MZ*XN(IY+KAGZL%8\[,=O"G$QG,+
MSC&,9\"+ED;[3!E//;`DV02[3*P'-GSMB'2D%QT`37(<F><EJ<$_&K?^6Q8;
MJG&VDK=\493A.5?1PBJG6O:G1&V3S53I]V>1;WHCT]%-M]3NNN+CB&U!KQ5$
MERJ[#KM7/-M31-K'S(F51\?&0Y.'V/4:2M2;0A6BR-4[(Z<NNR3>I*_9Y[UY
M`SK6+?A$:==P`8J4HD@5$NPNIV\_7!E/NQ*H2#D1)*.'GSGH6'L*=2E.%9PH
M:5Z%**\^1$X1?/7H8![C'=39'>6TU?W.[UUXI&E.^G83K?0-95CJ_P!:K\.%
M4K6*ZK)!/.6:Z5)RQSYBV;+EI>9#CJ\X92K*U*5GF9RBF'0LSE%,.A1#OO0_
M<]Z0=4]D=HAWNX;%V=)U>5U<M5"/=1>J5?$66'<=NT/7Y&#-,AZ8Z3'H2/M;
MKJ7&,>?SMXQCP\?'!N4FE/GH,I-*+Z0^8+!=4GNP;5["Z^J732C];MU3>O\`
M<.R'?#2_76Q;-&4:C;#)A*1?*AM`B84/K6P@YJNR)>)];B.(4IM"\>GX87A*
ME8SDVF->I9-`QKU*,_D*^Y?^NLVY^A9U`^]'BK>KYZ5;U)[;%_[1)[)>XUUH
M[*=DRO:!/6#8/7,/KW8!W66M=6E\"MJZ,@;,.PY@3600.)>]$J62TVX[EYST
MV<9QE/F5CAU*`A#3`A=P/,5BG")PBK+:.XM=:9%"36Q[`H`.-E_DHYUH0<./
M.26AI`V0EOPZ^-*S(0,$"$RB!,B^VV/&0(SLF4\RRA2\4"J+]U[N#7FU)5M@
MT8\LO+I!G(.Q1Y`<Z%=CR%+DMQ2$!!T8,R<KA5<%_$$M!^)%S_AW?AY#OIK\
MLHBCE@[$ZJJNT8NGK"3LPFZ2JW-N"'96N-D)I+%5&8B)*6"?M!-35K,8*%R2
M$:/)>D%VD1Y<IAAS*7GFT*M#2JM#2O0I!8MT:NJA,\%.W,3%+U?7MAVM8!C'
MQ1*<)U]5DCEF[+,C#(\QUN-&06CJ;:\,R)*7/%AMS&%9PH5*+%U;L!IZZVTC
M1:I>1QRUB+-8Z<1$08A53D6Q5*KTRY6.`N4L>B"I`NN;"#/K?2ZJ.I4]#27%
M/86VA0JT*EXK8E',CB9>#9A7RP/;2U#)3IK^1<:-;P9URLD@&72B8:79S)]K
M,1&$>9+[WAAK*_,GQBBSCUBK\9X?'D'0[$@M);ABF'B<)IXG+>;F/,Q1[2WT
MKF276A\A24-X4I26',XQX(5X$5<7_?FH-6V.+4]@7D75[!-UMLK;\4>18)9R
M]KC3Z:\YLFSIDQX+\/$:J-6J`X^SES$IQM_*VFG$MNY1:$I10XAVVT",+T$/
M+NL[#NRZK0KO5B;%&V#,K"*KM,Q]7=<F;3;XE5?JU"C76P?VB.P=F#7)$S.&
M4I]3.$Y4*M"MD.11.$3A$X1=9_N^[RW%UTZ![<VIH.\*UMM8?;=#5:LWA%>K
MMJ<KJ-C=@-8:Z-SVJ_;!Q:ODGL5^TRDH1)CK3A2L*QY58PK&3`"ZAX+)HJ:%
M5?GHK[EWCGP]ZS;OAX_1X]+>H&<^']#QSBH8QG/_`-3'%6]7STJWJ4.ZDV+N
M1J?W-MG=/NPG<BP]M:!'Z.4GL77"%GTOIW4I&N7"P;UL^N)D5G&K:\*<)0\!
MJUA6/B7EI\[ZON/%.%<IIEJ!3%#2E0%W8\P6*Z!@S'?_`+==XO<7U_K3W%KE
MU=U=U:V[I?7="H55ZX]>MF,/P+SUSUQLTS.G6'8=5EV)<E5BL,K*4KD.I2A?
MAC.$X2E.?9`&&*RP`%0L%W+T9[H/5WJ3V8[(AO>+V=;"^B-%[1VV+K!/ISU(
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MU9[7;=-(-'K3M`.9LL:R5"PB3=:U^NM$ZHX!GZM=L*J22<M1.33YMPA:U4AQ
M0S$2+#R0RVS'^'80TL7)F5R1/;VUY'D6TC--O6<Y<=]47<1PW=8<^X23`G7L
M>H?5ZKGQYX[,!F"K!*GL3%%U1$/.R/!3C2\I\5,RE5KS4_:<;@B[(FU[=$$+
M*<:"-"[17=:I#$J8[#:UA!L1*GNR[82^KDZWC];JQ(:'XA0F/F*F&V/AF4MN
M7,KF4IF>VJ8.SV9I6^:BK29$RN'9S6L]$)J&!1.JL6,1#JU3QB^3,#=:6$99
M72)L<_\`$2"%C:^-]="'<L(F9,RL6J^WR,:T;4]&7ZWB;%5*UV"$[FR)`5XY
M7!>0`$8D<.H,&?FYSKMZ7Q329F",\P1FL>?X/"W(K+*4LV-5*J,W#VU@]WO%
MF/&;93UUJ82V83KXMW6;9&P2I.RJK=Q,63L2PD;,^W=9^IS-ICKI\CX:*\*'
M1%Q_,IUW$AMF]=6JAMT]J"J%<154JW5:FLMS3[I&OP-?SPU8L+%C8N@GU#T:
MCW:GE)LZIAKQ(6'4F4VF/+:\<XPAU:<`Y,RLK6?1B^Z?W@*W-7-I5BS9!C;!
M6AP$Y2B0>6_6[_9Z#*M;)D\(M:T&)H$+5ICXV5+AR9K\^8VT\^B)&;94S5%$
M)J*+/73H5BU=@2F^8NSU#72.RZ%M==.>J>)HF1<-7O:OC40F0F(L$21)D!*W
M6[4,PM"&\J8MGF^YS!1A]FPHF;"BD-$ZI;.J^T/KZ8VK1BXFO[%VSM.B5T?K
M,Z+E1+;O&7`1>7+6:?V42^="@X%\O#"QHD8?EIV>S(EN2LQ<-NRN"E5OAR*+
MYZ.A/<KJ+UZWY[M]/WUVAZ^Z6MA'W.]GGX%8VKN'7]`L$X'*TCH6!',Q`]I/
MBR$D6_.&R&4R$-J:RZPM'F\R<XQL<"0*=2S()`IU+'>\_P"X-T.VE[6W=2@:
MT[H]5;_>K/J%T;6J93=_ZKLEJL1)RS5U38\$`$6J65+SEH2I6&8[3CF4)4KP
M\$YS@QK@\$@\4:#FX+Z#:S_S;K_]Q!7_`,X1^:U@NGOWK[A4]?:TZ%7B]V8!
M3*94_=:Z,6"T6RTEX`"N5P$*NQV:4,G#11^*.%"QT-E;K[[[B&FFTY4I6,8S
MGF;.GS%9-Z?,ML_M1?;5Q]'V@/3#])K36?\`Z^+EX9YCE=U%3*[J*TI]O7;^
MI]Y>Z1[NNPM+;-H&W*$0I?MV08-UUI;Z_>:I,FC=6[EC$8<:P5D@3%/RA\E.
M6WVTNY6RYC*5XPK&<<R<"&BOE63O1%?*N\+F"P3A%PB4".5'3Q<KS_"DH4J!
M)])?IN?#S&'([WIK\,^1?IN9\,^'T9X1=<6O>DNUZ59M53"6XJ%::92K76+'
M:Z5+UC9!L6UR]94#7>J=1'V)<'9V$Q[)2Z?0W2&&YS)`3FSD_F"(B,CQZ&<B
M0LJK93;VDKS;=:[0INM=L3ZT;VF3*++$=D0"&T:Z*KEF".5BR5:MU[)^LRJZ
M*2*D+E#VX<UIN,20E:TNLK>9<@..*GG6,VUUJSM[66N];&;6P-BZZV=0K5$G
MP@3CV35#IQ1P86HAB-(,9PN5>]63YX`G/:6AKS3W9#<5*/+'P!IBBU-B^V,W
M#P`2SN-US(1<I*WY-)0Y)G0V=IWNZUJ(ZXBS(PA-:I-D%UMK.,9\[`1M_.,9
M=RTW<RN902'[2[4^:>S>]JU6X"2%((TR"-DZE8;84ZK7&Z:'7K03'.VZ0!58
M*Q^&+U67XT1B4_D4EYZ0N5*<>:N9,RVVD='J(4A:4`')D693M+;LW?N(-5A@
MR=6H#BMKDMFD`-<'JKY\>L-"HOX1,-MX1ZD>8B'C&6&DN>5$S%2JU<N_MG_)
MW+'=::6A68TB@[&=@U82%74SA;:IN=OP[5[&#++V`#I(V4^?W<U**2#4,BM^
M4!CO)6A3F$L7-T*ARQ9_VM;250,<:V_7H"$N4NW6;(2@+$W@YLL'6]-1+K9H
M>QHMFAS&9]\/ZE?DH<E1'X<!TXY(<ARGHL?C,F97+UFZU[D$]?-V:FV*`UQJ
M<?NL;L>'@/3JT+&SJF0L>OJGJP04=KU3N=JIF6I`FN/$YC4<O(=DRWTKRZQE
MQR.Q"<:H2%*FO;TUD"/4&STQP<-L%"%4]44[:AQS8=F(6^J;)TQ=E6B3<K?;
M"5Q;P3KNG&*[F.F?X1Q4G#+2TLM896S*56:I'539U:V@J^EMJ48J'`;(VIMF
MAUR#K,Z,E0[INE,.!=';8<>V20^>!@]?F&8H>+$C#E(=(,ORW9.8F&WH2$K@
MM[N11.$7SU>W7W6Z=Z`MWN=T7>O:GKMINZN^[)W`.M5':.YM>4.S.!"#>N8T
M$N@'9[",)J&3)$!]MI_#7I+6RO&%9RG.,9N:32@Z%F032G4L'[SW?[HMMSVV
MNPNNM5]R>KNR+_9BFB(M<I%%WSK"UVP_)B=CM1$I4<-7@=GG%B;T<?">?6EE
MI>4,M+7GP2G.<5C7!V(*-!S<%]&/-:P72S[SEUINN&?;$O>PK96J)2*K[KO6
M@Q9[C<3@RLU>N"(M#W:J45.GS,J$*$CHR<^+C\AUMI&/I4K&.9M%:TZEDWI\
MRVY^U%]M7]8!TP_29TW]^/,<KNHJ97=16E_MF[5UCNKW`O>7V+I[8E(VI0#F
MU>F38:[ZZM(2YU(LL9U1`BB2!MBKLXB)G*@$X3T=[TG5>F\TM"O!2<XQDX$-
M%52*`57=[S!8IPB<(M8.SW7PEOX!7Q@2W0:>1&XNX`G-*`9%CB3:/M'7]CUK
M>X4.%%-`'85E:"6+,H5-4\ZQ'FQDX?COLN+1R@T5!HL!K[K)8`4_?Q*X;/GN
MD-W%*>IPQJV&3U@='0*%%D"@)^658L!UQ6P2M:Q`%%IL!(^!)A"8V&H;*EOY
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M0ZSLF8?%!K`(L&5@-=IMNM]@5VI`2%:O%;7FQU2X4HJ[$)RT/QE,V>6ER&KT
MD8<9DJKDW[TY,]EYFJK5=[V.IULJE%DU&Y1*H`DDPQR!=2-67MJM"Y),S&GQ
M*Q<ZN,(!?!W#SR&9C;ZLK6QY%@:(#11LMTHV"8DU<'(V]4&]?(T_H[26P1[>
MLC&;?8J?HFZS;J'<K%@SL=(>K&+:Z2?A$GWQI)#$=6%Q6VWL87A5*KL'$(+M
MBX#9^2.FFD164E)8B#)&"Y$[",8D.P!\T@6EPXJW/'*&W)+ZTI^C*U9^GF*B
MR/")PB<(NG'W\",`1[7NZRQ6=$&"QFR^IY$D1GR&8<$?`A=MM'R9DV;+D+;8
MC1(L9I3CCBU)0A"<YSG&,<S9Z2R9Z2VC5[H?MK(4I&?<!Z7^*593GR]F],K3
MXISX9\JT7-2%I\<?1G&<XS_0YCE=U%3*[J*T.Z_[^T7V']\S;%MT'N35VZZL
M*]K#6``G9-47VK[!!#CK/:S81!X-.*U0H5@Q2C,$C'>7'6M+J6GD*RG&%)SG
M(@AF/6J?1QZUWN<P6*^?;K%VWZK=<_<8]YD+V`[)Z(T@9L'9'K24`B-M;:H>
MO"AL8QTVU!$?(B1UL.B9A&`Q+;RTX\RA;:'/N59PK.,9S():*#YJK,@EHHI=
M[HON,^W[?/;;[YTND]W^I=NN%JZB]@:_6*M6^PVIS=AL1TOK&R0!04&&'6N0
M0*E24V0AIB.PVXZZXK"4ISG/#6D$$@TJH`002,%VR]7,XSUEZZYQG&<9T3J/
M.,X^G&<9U_7_``SC/]+F)XJ'BKVY%$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%0MDZK=8+D=*6BW]<-"VJS')2IQJ
MQ633^O3ATO.6E*%S"A<G791`A*6A"<9<=<6O.,8QX_1RU/6K4K#)Z9]/D*2M
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M)[)5@#?*J"MX9DG&9D1XY%H788!&"W/88ENH0]A&'$H=7C&<85G&7#@BI_\`
M(PZ>?FH=:O\`,5J[[UN7,[K*M2K1U[J'4^I(Q*%JG6&N]90S4AB68B:]I5:I
M<8M*BMK9C223%;&#6ITB,RXI#:W<+4A*LXQG&,\A)/%16)PB<(G")PB<(G")
MPB<(G")PB<(G")PB<(G")PBC=NIM0O\`7R%2OE5K=VJI;#"2M9MP,99*^33%
ME,S8J2`8S%FC9F(TR,V\WAQM7D=;2K'@I.,X(J._(PZ>?FH=:O\`,5J[[UN7
M,[K*M2I_K[0^CM2SYY75>FM4ZS*%8:!Y0EK[7=0ID\E`;>3);@SYE<#C9$R&
MW(3AQ+3BE(PO&%8QX_3P23Q4JK6Y$5'6[K%UKO\`8"%MO?7K1UVM193"RMFM
MVIJ%9+`35%BL08RB!DR`FD9JH\*,VRWEQQ7D:;2C'@E.,8M2%:E1O\C#IY^:
MAUJ^GZ,__H*U=^QG]G'_`#6XS'K*5*V,APX8Z'%'CXL:#`@QF(<&##8:BPX<
M.*TEB-%BQF$H9CQH[*$H0A"<)0G&,8QC&.11<GA$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X18>18J_#-C:U+.AXMC,Q)Y`/7Y!.$P;*P!68^"DT:*=?3/G1!N9
M;6)#C3:D,Y=1Y\X\V/$BYT*=!)Q6IPV9%(0G\*RQ,A2&9<5["%J:7EJ0PMQI
MS"'$93GPSGP5C./V<<(L$"NU,M!*P!ZU;JQ8B]3FX&VD4"/BBQ*M$5+?;3`L
M$&!+D2@TW+D5U.&I*6W/%M6/#[G/@12/U6O5]#U&_6]/U?1\Z?5]+S>3U/3\
M?/Z?G^CQ\/#Q^CA%QB1,<&'3BY@A"$B1<200)E"4MB".'0(;2Y$N=.FRG&HT
M2)%8;4MQUQ24(0G.59QC'CPBP]9NE.N@7%EIULK5LKN7)3.#]9.BSP7+L)64
M3&L%1<J5!RY$6G.'4^IXMYQX*\.$7A7[Q2K;7$W&JV^KV:HJ;G.IM-?L`DS7
M%-#''F23B3@Z7)&9;'O1G$/Y]7P:4VK"O#*<^!%G9$^#$AN$94V)&'M,_$NS
MI$AEF&W'\N%>NY*<6EA#/ESC/FRKR^']'A%Z9)<3"G0!DPH.B$BJ)K@L?)FQ
MF)Q)L:TV^17`B.NHD3$0&74K?RVE6&DJQE7AC..$4:E;+US!D5.)-O\`28<J
M^X;518TJU`H\BZ8>Q&RSFILNST.6/#N)C/E^#P]YO51X?UR?$BFW")PB<(G"
M+HQJ_;GW6>Q.[.XU5ZKZNZ`,ZLZN=G;/UOADM]7KL*$OUCG5NET6YNG),&@U
M*RUY$5Z+>66L92\TO+C:L>GC&,*5G1HI6N*RH!QJH1VP[9>]CTZZY[;[.[-U
M+[7YVAZ9K'UNLX:E;)[3S+82&()CAKL8!&,T(.)=(840PM.)$J.WY49^[\?#
M&0#7&@K5`&DTQ7?J)F+("AD]Q"6W)P^',<;1G.4(7)C-O*0C*ONLI2I?ACQ^
MGPY@L5U^^Y3VHW;U3U5I0GUXI^KKIMC>G:_1?6*KP-R$[6'U^-F;I*E0L<\<
MGTMB7868XN;$94O+##ZO24O.&UJQC',F@'CPHJ!7BJ2R<]^O_%U[3&?^[C:7
M;KZ?^[].L,9X['E5[/E4TZ']K.VVV.Q7<KK%W`HW7:K;`ZM#.MYJ"9ZX']D6
M"HV,?ORL7RS8:F2=F"PAA$T(Q5&&\X;B-MY<=<\%+3A*N"!0$=*$"@(7:7S%
M8IPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB
M<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"
M)PB<(G")PB<(G")PBZZNQW6[=6R]]B+CK$K7*7B36Z0T/W02;P;.ZFG4,5V$
M$F!0JG,3ZZ8.-[`8W5#PA40M!;8^`D.2%X4W$0]0114'!6AU4TAMG2/7[KYJ
M<G9Z``?U<T=%W<+5J>5(@;%6,E+$NK`JI/+W)TG5'1D"9!6]+D*++?4RXC*$
M^IYTB035#B5HB'ZK]Q->;)VKL?7@:'B1+L6Z&10^1LRD5UVX`]G[EVO>:PJI
M$ZKKX.:KP6O,;!C%C;5MGG"$@A!9;'*83'SB5E4=*M0O,MTZ[;C2XR\,V&Y7
M>ZGJ1<*]L:;'[1;(K1&3,1>-F3=7P*V4?(-1ZO7*QFT5DV_&&,1&9*:],C2&
MI*I2F9RH2H5T,=7^S#^A^U="NUYF[$M^ZM(6<`,6=V*:-!9.U"=UW^GXX`.M
M<4J"UQ7R.N+!3(;<.%#2+85!\CD1>67''Y45"E157]1J#L<CUUO^IK7KMV.1
MLU&V.&9B;&NU!RU8B%L8.#6`5D)=?J71QH4+.AS&DN3A8]$Z/&<SG]MDM^=<
MZ:I@M`OR1.Y$^D'*H/CJJXNVCK2*"#9VV*L)(U9N>"KH*SSM[-:CHU.H&_BF
MQJB*DUD//?#R9X0<B#*EK60Q(EIRJ%:A>]SJ'W=.?"@9-P.A]9S*>:``=<']
MVF+Q#HH1R)>89.F[!/&72LK:*[:1)A9PZ<Y%F20[,),9J9!:B(:FJM]5*A;2
M=HM$;E["'.NNT]?!Q%#NFKHVV8+D>X&6FB@*!MZ12-8VE4=\1$)M/25:AD6(
ME%2E2?*4CP&E^7*E.-0$#`J`T6NQ[I=N?&O--ZA"ZBUT2%U+J!+ZH1;85N@E
M$;4Q%1/4A,%M.OPE@))J;FEMUF4X/9@X8G*)B(N?.PV\F0Q:BOJJU'LKN2#R
M24R`V^6&9#SLOS6UP,SHY'*&&)TAB%(5*BH0PI4^$TW(RA./VK+OIYSG*<YS
M@L5D^$3A$X1=/?M4?X6?=Z_]:CM;^`?KOS-_`>99.X#S+->^W_)$=\?\BDC_
M`+3USB/TQYT9Z07:?6O^;E?_`+B"O_G!CF"Q74][P'_-WVZ?_6Y="?\`M^9Y
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M&DX\/HYD'N`HLLQX*`$/8/\`:Y+PWQIC1>P30N6E")HHSVH[8EQ4YI#J'DLS
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M)PB<(G")PB<(G"+B3YT09!F$B$AN)`'Q)$Z;*>SY6HT2(RN1)D.J\,^#;++:
ME*S_`$L<(J9T3V1TIV7IV-@:1N[%XIKA%H7%L#82R@(1*4^'A'XRP_UI#`WC
M4"6%(,R6941#T5YI7BAQ7E5X4@CBJ01Q5VMNM/)RIEQMU.%*1E3:TK3A:,Y2
MM&<ISG&%(5CPSC]G&>115UMW<&L-":]L&V-RW<!KG6]5R)Q8KE:)F(`,/D\<
M&UH/B;*RE>&LD3QB+%:^C/F>?1C^CQ2O!`*X!6`[-AL8?R]+C,XC-8?DY=?:
M;Q'8SA6<//\`G7CTFLX1G[I7ACZ,\(L&%M]<L,L_!$DT29=8L;U2-,N,2X:H
MMACB1AUX<SF;'C)GJ;$F8SWJ1\NLYPYG&%^9"TI(O4U>::_:V:*Q:0+]SD5N
M1<6*NP4AO'':I$+,@9-B2-;=5)R&9-OHB9D>7TOB,^GX^;&<8(H+?.PNDM7W
M`7K_`&!LRJU2[&]>;%VP(JY8AADR1UQJ5H._L>WQ(24..O"*BP>B+EJQCS82
M[XI2K"5^52J*:9V#1T4UK8;UK!1:.]57KPBTS2,>"&Q3XXC!Z59'9DQ;#;`B
M(&S\2\\ORH99^Z7Y<8SPB]3NQJ2W'J$M-B@R8M](BA52DC\2";!B8=`D;.'P
MV\/9E-Q8I$"*?DM2'\M1U(1C&%^9:,*(IBTZT^C#K#K;S2O-A+C2TN(5E*LH
M5C"T9RG/E6G.,_TLX\.$7LX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1.$3A$X1.$3A%0VY^S>C>O9*@AMO7MBIF=HDB8F@"$`K18RM
MFFA$#G3.((VJ!#DU$42T7C*DR'4-QV$OHRM:<9Y0">"H!/!7CB9$SXXQ*CYS
MA_,7.,/M?1)QE*<Q\_=?0_A2\8\G]=XYQ]'T\BBY'"*LX&Y=5D]J6S2`^^5N
M5MNB4NL;%N-`:(-YL=<H]S(GQ57LQ2%GP^'%&2%7GM-+SGZ,Q\Y5A.%(RHBD
MEFNM7IXETW8B[$$:RZ(9<>;:DD'<+.FH-=%*3#&L3)JV91DDRQZB6\MHROS+
M4E"5*P19Y4Z$G.,*F14YR^N-C"I#6,YDM-*?<CXQE?\`P[;"%+4C^NPC&<YQ
MX8X18BI6VL7VL`;K2CXFU5&TBH1RMV0#.8)A3H8BPB2/*BB,5;D:=`FQW$N-
M.MJ4AQ"L93G.,\(JIUAV=Z_[I9I<C5.V:??(VQ`NPK%1Y-=(YFQ[.$U1=H&M
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MJ;U_!=6>MVF-`@6@>4:QU_6ZT:*U\1\C@6FVQ!L?ZX71R`M^7)21N5F5*)RG
M'WWY#LB4M3KKB\J5G$FIJH34U55=Z>GKW=[7E(TR8V:<UIK*/L)JY;/7415:
M)V^WB`U0MD"M580Y=P5NI<"(W=C(XK+<GAR.5(&)0QAA]2)+0&F*`T72_)]J
MKMW=]V7VJ7`G02-=E:8&56R]G;]0*G8/PW2L@^E===I$H.G:%GMKU=BP.NYU
MX:R2KX[ZJ$RDN5$DS\S4*QGF%%EF"V4J'LTV85(HA6V[SKMOLNOF-6-UNR3Z
M;:%E0DFE?DT#+<0"$,7MDX(E7JJZ-*#)#D2=&EXAV!QK,CRX>R],Z9E='0;V
MSK5TXOU#NY^]ZRNRZKI/:FF/($UPJOV`*#MNW:SLRI#PEN5-<)'1<#,`E@F\
M81(*S9$J.IR4^IAQY\YP*A-5R^U_MIW_`+)]B3/9(=V,FTBQB:G7-7ZRI3=-
M`DZ2/UE/H.WZ+MN!<I+\/-X(6&YL[U-O171)@2/:7"&9FQ)RXC2VX'4%$!H*
M+401['=W812F9>XM,AX0ZI[MH]GKM2TV:11(=4V=I:/I[`2A42UW>S@ZUFTR
MH7UGL)&+\"8</$"&42WX\G#+>6=7,N>CV7-PSS&P3!#?VJ:OF\:\"T3(G6FJ
M#-0!QF0&B]GZA`.2AX^U1/F>:SC9>41),E3\]R`/0E3R,NI;CLXZDS+M^ZC]
M;H?5?6]EUB'G!WJS-VSLZ_U,-7@RZ^#I]=OUFDV.'41@GXJ5'C,"'ICN598]
M)EUUQ:\-IRK/C@358DU6T?(HG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G
M")PB<(G")PB<(G")PB<(G")PBU"WQU/$[YW[U?W!8;$8'!NN6=KD6Z]7K)>:
M87L%AOD>A-U^6JR42U5>8X$!/4]U4X3-^,&ED2$HD,+2WX9H-`0J#0+1'K3[
M2\_3F\-?[9V#L6@["':SOEGN0>MP->%!:;7:WJF?KE>W[>U&K7881/LV:?LS
MC]CL33+;<K(V`J,VRXSA:<BZHH%2[!=U?,%BNACM)[7FY;/=>RW9ZH;A,[%V
M7N5-[#G-"_5&@MT*X:>QC2SNMM2QW39:BFB+S#V@0C=A9-6QL(8'DSD6(R+<
M).2%9APH!T+,.PHJ<T?[0G88@G4FRK[L37VGS02CO!)NLZ]0FF3=5%D.PT;=
MJ:!/LE3O!@>7KHA`>/B!"62*Q0SLM<2,ZZU$Q)FTN'0A<.A66`]E<]4"^BIU
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MJ<3%M"VG5/-)D(DPO4S+O0Y@L4X1.$3A$X1.$6F]<W%:B/;_`&'K%O8E(/Z]
MJ%/'JM%98'#0Y/6ESL**`[KFM.GWS;Q:V72Y1"YDB2B)B-1!HN0!QCTWYF%3
MK3"JO0M;[E[@-EI78O:^OTUP*8H:3%'U3I8E:&[%K6GF-OC;WK.F[:08W1-K
M]AK!(<+>W2UE4`9$FD8&:.62II3C[:47+@K3!8JO^Z%/M.`C@'18^=FTE7!P
M,:UMV,^?B1ZS6*?;[^1M0>!0IKH-"@MMPJI,MJEKM.8JE*R/:<;<RRI19E'N
M;0HD25&.ZM#Q3V092R!Y03:.++K\L'K^MPNT;9(:N0ZB?'+?I@78%/'D6(XJ
M4_DW8<1(R7\,MNR65,JDVKN]-BO>L=E;2=I8*,Z)V/J_5=8J!2RRP`();+G<
MH6JR<BX7Z367B@^I1+JXY,5+=`-D&(&4LJ@?%?M/!;C12BKN/W:W66T)M'L(
M)&4$<+E;UU30M?5FPEG7X51H-GU]K`D?)SS(^OP56"SS;)<9;T#*W5CY4=47
MTUMH7G"F45HK3H4PU%[@ELM>RM6:6NNE4C[H<B5"'L:Q5NZ+,5D,4N]2F6>K
MDJPY-IX!@]"D11REF(K[P^6*7(0B(@HA"W>"W"J95'[I[FQ$%L39FNZEI4-=
MYU!(V:3$)IVI.K@PW4:.[NF%;)V))36"V\6:*8TC/A1XD+)`4N3*2VZ497&E
M)0R]*47G"]RRS%+G-UT-Z]-O6V!;1&II#LG9S\"I)V]/V96-;R8C=BD:Y^(F
M:T8DV=#S1F-"?+..,+9<#L8SA[C+Y4HH8U[G-ZL-BIDNG:AIDH'9J>?B1Z4;
MVZP,MSVPQR-$%YQ(V[&HI5ZN:^""MBD6ADUJ-/=L>4M/J8'IRVARY1TIE62G
M^ZF3$.$X9+KI-45K55GV&TQ1VR6I`V'*)U.WW.ACA5AF4<>+*-3A54PT=<7F
M.^)DR\9AQRK#3KV)E2BN"I]W+C)A]H3MXI-"KD700FH#8->'WD^8<);`E;.W
M#J2QP)9^/0_F4BLEK=KJ*@&_$!.DI*9"VE0?B<)9RR\%**M*M[GA2UQ*M/C:
M/"C1]U,"=?U\H:VZL</B[3EOZO05B6YS.MGGZMK44QLI*OG>6Y1)QV)Z2A#2
MWD^5E5HI/([Z7FIZ9ZZ7$CK$)L"Q;5T!0-HVPB(N$L*'&66_W;4&KP,`(.!T
MV[SC-=F7/;+4B5.9\/A!4-;C#,M]UF.IEQ2F*K8G[IA7,@1+3K&I481%F5\W
M86+[L:6X3)4@CI'8=^*NA2%5IARJ1B8^^UT<';;;($27D?SF2.B.R(B'&5,J
MX`?W4;4_8U,3](C9@XA)'B80`+<#*+`'FU&X;NJ.VYQ.4<HXIOR/3-81\UN*
M1BA,OJ7*02>'J87Y;E3*I0Y[G-O'C1Q,UUT@16+B]6A>NTB=LSK(\1-71C2Q
MBN)M\0;JG$ZLA6:WNF(\0DPVB[[$Z(J*Q'DI=;D<9>I,JSM5]PR];$M^H0P/
M4%:I-?V1M"LU;YG;MC8+G%5Y$8(Q?FE!P5:0)%V*&>N0J.$],D1CE&T2%.YB
M*5'2Y,H2BF$[N%L&[[_H&EJ(`JM7&R]\G:Y9+%(MS%AL4W76LI.Z:_<AA:J9
MIZVJ+9[9<-5-N"&G)<G,VN/NR42(LI&6VE,*I3"JIG/N-;8HU@WA/V#J^F6F
MDT:\V+7-;;H-Q*)L,"W0-@]F@%5@G14JGS7Y(PS6]*0W34UMW#X=YU;L>#.:
M6I+#*,*)E4LWGWIVG2];:0W97:B(KU)+:X[)WS?%;+,/6H]4:[J0>,KS-VJ\
M^`X+60!4BY%F#)5J1"9E2*JB4MQB),9]#``<.E`.A9P=[D@N,,J,2=0?K)8B
M(T'7S>*];!F9$?:UMONU]4ZVJ3X)D?,E"D;2O>K/0ANNN9^$R9C)\C^$*4IE
M3*J_KON<V6WD*^0%:G#5X=80YOY$)O=_;JP(@]-BZ[M]4L-FOLNJ+F4=$&FF
M"<.=!4%G,O''H3467(CO?%)N5,J[3];WD9LR@TW8`=F1#@7&L`+,R-FJ8R2$
M8/"(9;`@LW'=>:CEAJ9F&I+6%9]-U*L<P6*FW"+KS]RSM;N#J-H_75OT/2]<
M7O:6U.S&@>N=5#[8+V4'1(I+>5VCTF(9.DZE%GGH\05,F-.+RPP^K#?FSAM>
M<83FM%2J!547FR^_3C.<8U)[4&<8SG'CC=?;+PS_`-W'CIG&?#/_`'<8YEV/
M*KV/*I9T<[9]O-G]H>V?5+N%KSKI4+UUQHG7:^C377&U[)M=7L`[>[&RI"8D
M^5LJOU@HS."HH:$JPW$2WE;RO!:\>7/(0*5'!"!2H7:IS%8KHOIW;WW7NQFV
M.W(?JWISH%^"GK3VJV+UE@$]Z;/[`UV_6*?0`]2./'9@RBZ_M=?:C2X5OCIQ
ME$E"O40O'IX3C"E9T:`*UK194:.-5"NUG;[WJ.G'7S979C:VD/;,,Z\U,.$&
MK4+HNW^SI"WS1I2S!*UEL!"-ZN!B)$YI\VASRR)D=OR(5]UX^"<@&$T%50&D
MT%5W_P`=W+T=A[.,)RZRT[G&/V,9<0E6<8\?I\,9SS!8+KU]RKM9N;J7I[4E
M@T!2M:7K:NYNTFB.M-6%;=,6<#0H)#=ECDUJ*<.$Z?#('X\87-2TM>6([ZO3
MRK.&UYQA.<F@$XJ@5*H_-E]^G&<X_!'[4&?I_9QNSMCX9_[N/'3.,_3R]CRJ
M]CRJ;=$.V';/;?8CN-UB[?:^Z]T[875P7US-Q"O7.T[%M50L8[?59O5F;;E3
M-D`:T7:FA8]59;4E$-#>7'7/!2TX2KD<``".!0@<0NTKF*Q3A%7.W#DJN:WM
MA>#<Z_KR='&I8A76TQ(,X)79A"7&'19\F&5,UX3(?P_+2B,F7-CQ,RE-^NKT
MO/C(<4"TE)=E-K%>BU1VW7I#6=V&;5IK7YN%71-+*&(IZW]@ZAI^S110:PVJ
M!KM^S21Y&7\$\Z7377YBD28\EV`IIQ>5!F\BM,:+6+'N:[+K-`!`9=7I]GVD
M3$[(4Z7MQ:33R%+-UNR;GE5NK;MIE1`V2H5&[P*)IR8W9(0VR/NQ3F',Q8JQ
M[:I*;E5IZRSU%]P3;"MAV**>&TLR$M,AH/J<18+N"H%4#1ZW2*3<K39-F;$^
MH\UP#/+HL$UJ$EIF8/<<1"8S\/EQV3P6BB4P7B4]TXJ5M+$>MTBN1Z*(LL9)
MHV'M4VRG[=5#)D?`J,K7L8I3Z\'+E2CHXHF8TPY,'O1?3<&DI*L*4EE3*KIU
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M/1*K(^3P1-9*&;4NR'YK3(IV7#"P4+>C,%)`R7+885`VJ46O+'NFVK"Q1F1H
MV2MJPA`JA]*8LKOEBO(`;&V0</KNKM6:D(3-H58BPH4(B(&1\&DOJ=F-C<)(
MKN5*++7/W+K*')4^P-T>G0M<%`]VM4T.#V*/M6Y'AE=V'JVLUT.=ICM>'CZ+
M9B0RQELE13TJ4N+E+*HTUS+$C&&5*>NKMU7WN.;"V^'U7/U16!\5NW#-=V^Z
M5?;K=S"1KG9*ONJXUS-#PBA!&[Q4E!]+262!!Y\4_#(S,1VXDC$9]S$(PJE%
MBZEW*ONW.Q6K=5U2O5RGU"5<=@DK>0S:&K-9S%$J\+=]1`U\L&74F8U#NL[8
M&JW)Y`;B6^Y'$_#X;FJ>5+CLB*!*4"U8']WNU&R!U6%!&BE-O]CVE`I(/7U.
MU[K6V;#NFN$:U[%V^#OFMM7[8M=HJJ;?+IJG`9J&Z18EAH@":N7Y9D]EB+:`
M)0+#%/<2[8TO-AJ=JK6N2FUZ1M>VE++6:\$)21,C3]=T/9H6*T)>9,2)LLYC
MM+5IT7)%M3BG0<);3;6758?XRCU$H%M36^U-O":SWW)E;AKVTC.H;_U[C(V1
M,I5.K%1F5#<AZA,3B0DA2[Q8*R:JTH66(21,A_(\G`B.L)G-R%(1,E2BE%D-
MW=L+E!!;F$ZNN`.?;@?:#KQJBB1*/"I%NNLC7NT0/7V=8"($#:K.)K)XP]/V
M(63#F39#$!K'DPKSY9\%W+2E5:+)7'N'LKKGK#KBK?=%$%-I[*(I'WH1%.1Z
MR6!@5;*H^O(5G4-`PKY2&#C;>S`;YB.\?@`8A!YV+&).^I%PY*5X*4JJ\V'[
M@.P7^IB=ZT"FT:K7-G9=GUU9:Q:[,8,1*LX+U+<-A#O2)KJU;BF+%)=AAU,(
M90\%(1Y?J0R$F.]'DK!N-%:8T5G:N[V'[KOD!U]L6EU`[(U/+5?8%B"W5T_7
M`-MA+V^Z.55Y4ZFUQ-MK$P?I^0J2^XH<2B2B#32($AF/,DLJ850C"JK<1W-O
MM?3];#U_U7;SVQK7L.J@>N9N6/UH[I230=E6*J(GWC:4=JSDQ0AH%77(97)4
M/(=G6J3%:'?#15N-HN5*+!S_`'2#T*ODK_GKU!9UP@61)@R97<D05:9>$-[D
MA!F+!7GM?NB:QF78=,36YSF2DIL?`DMR?,^XAV,EEZ$R^NLF0]SV3$N0W7\#
M4-</VF<7,:^<2(VL377FMJ"[\1I4:$S:']5MBY6OC40=\SBDV\J-*B/-J6&0
MC.',LO3T)E4J&]][3=`=HF5W5WR2SZCU\K<NP:O(M@F>,L=3E0&0U.K5>MQ0
M8!APE[$OS-AAP2+C&'FDTV5C,1QZ6W'1,J46]&CMHP]TZFHVT84:+!:MX;$]
MX?"D%Y4<:0CRI(XJ,2\?KU3.Y<&DX3S#B9@R!*;<;4EUAI>%(Q#@5#@K6Y%%
MTH6+MW[F.UNXG<CKWT^U-T@GT/J19-+U8E8^Q6Q=YU:WV0AMK3H#::7X<'75
M'MP54$6LH[&SE;D=S.$MYPA?BI6,Z-`!-:E94%*FJB>_.P_OC]>-&[CWY<-*
M^UN3JFE-7WO:UE&U_<O::2>(`=?UDE:2T(+'GZF'07RLF`+<0PA^0PTIW.,*
M<1CQ5@`PF@K5*-.`K5=PVB=@3MLZ0TWM0H/B"26S-5:\V`1%P''G8(V=<ZB(
ML<L?"=D9S(=B0Y!)3;:E_=J0G&5?3X\Q.!HL3Q6KGN7]J]C=,>I5GWGJ6H4N
M\[#C;%T9KFKUS89$V)ILDEN7=%$U,U+.D*XT^:C0Q?UR^)RIAMQ?BU_6*_K<
MUHJ:%5HJ:+7A5D]^E*E)QJ7VGUX2K.,+3NOMGA*\8SX84G"],)7C"L?3CQQC
M/]/'+V/+["O8\JRW4'MKW7M/=7<?33N9K;K%5;%K[K;K+L17K)UKN.T;:()C
M=B;$O%!;"F7=EUNJRH\R`_1GW588BJ1X.(\'%>.<)A`I4<$(%*A=M/,5BNDL
MMV\]S;;W;CN;HCJ#J7HY-U_U'O6J:%-L/8?8V]:O<K*1V3IBI;7S+C0-=T:W
M`_@1V;$N+G*G6',^1'@A7W2L9T:`":XK*@`J:J$]D.S'O@=8NOVZ^QEYTI[7
MA6G:,U?=MK6@76=Q]I)=B)`J*`G6(I"!1B.J!8Y\K(A0%I80_*CM*<\,*<1C
M/CP`PX"M4HTX"M5W5:GN$O8>K-:7^?#CCYUXU_3;A-@0UNN1(,NS5T::DPXK
MCW[<N/&>FJ0C*_NLI3C.?IY@>*Q5@<(G")PB<(G")PBA>-;Z[Q9)MSQ0J7BX
M$?@\D+7BK`\62?D>_`DP/C3N(/S25\#)%17&?.ZKTEQFE)\,MHS@BZ[]J]I>
MM)0OL/4O8/3\^74]:[<ED)):!6(UHI$695L1M@5>P6K"%#I[9R^W`-/AH&Q8
MA1N<ZWY9ZL1Y:_'*AZ%:'B%L>&&U*GZMV%NG7.DPFNKU9R4N[6D;NY8S7SX<
MW6\IJTJP7^TQ%7"*'JE*K8UZ<RX,?EPOE;:LP58Q(\V8BTGKO<&<1&TZD!NK
M6IZVWM*6K5%"K)J3("@\;+N`K45TOKMO!(UZT^'U);JAMY@FRO$59@DY!]&=
M!9<EHRS:*T\JL+4G<_2VY*YO6J4S4^N':AK+JW2MP6"H-E:A-'GK"="7B==-
M5%JC`$K1&$Z^DUV$,DD)4;TI,Z8^VB-A$;"GA!&)2A'KKF5#N=2$:KK$G>.H
MTI8NK(6SS*[0=3;`:K%2J.)^N:O5;)=@>[Z7JNQ/1/KK8AXV!-&BB,7PB)>;
M6AF*\MBD8X(0LM;.ZVB*WN"K06=5OGDA)"(9>_PJF*C'M3CK!JVWWLS:5.SF
MFI;U8?JE(AQIORQ]4EMA#RWV\LQ6TN3*:*4P4FNO9'2M"*:QM`/2N+2'["#;
MX;B$ZI3:XW?;E8XFP]2ZJJC<49/2*AG6-C3]MH=22(DXC+0U*7GE^DZO+:AX
M)11$AWSZBBAPS;;NMK3\LL#PRM5;8GX,JM#5:I3(V;MVUUH(8)&(!-PAK1X=
M))$QS_H2)1=A>!#1.;CRY4/!6A4?,=X=`P+4+?J'7TY)F&2#M=EW4CK^M!Y$
MJJ5VPE*;53`6/#=FV:Q5VRVBN%@X1A:(S\>5$PZ]'8AO-/N*%*%676^WW3S8
MFWZ!KH'6XAVX6F$]$K%C=H=<7!&Q+A7)DG,),R2_]8VH%G9J)`3+<A0WX3,X
M,Y$(N1_[5]=0TJI0\51(GN]!+;`V4`N/7NC$]:XN^Y]86^T`1UCG28(C55^V
MR)<KNPU6[7("C6HUL1NK$S@\<,,D8L?#D_,U3.<X>>4P\JI"O73G:OJUODN`
MU94-5$,AK=$/`\K*Z]HTC7#!\=&MJ2^O)Y`$:/`RA62$U<3D8='IG@Y,(>WY
M9JO5BH=$$(00N&)[L=5;W;A^CLT4A-E%[Q*T!@*8JFO7ZBTUF(-DQ1,QU=HE
M!LAC+2D>E7$)<L2&X3[L@.RQ#?=:4/%2A5?'^X.@ZAM3;M/V?UL15:!2G9PJ
MW[653Z78@4S\&K$L-5)]F@0$*+(!21N'!X#'HS)$5S*F5M1HZO5XRFE1Q5IZ
MZ\]I=PNK6ONN>N]_!]3:^57INV0U"@5RZ0=>4N146]<%;9;KT8$D(J;#62!3
M7%-K]A-@F@\R3')$5M,19+;DW+F`!)HE#6BD=W[S]3@BKS6[WJFW-T>O+M-8
M)VDUK&H2]:6A(69LFI-"A$A\X_DF.N!W09T2-^)AL1GEB&5OY8AO0I#RA4H5
MRQO>OK`<D@QPG5-Y)/S9H`?4FXVN*>Y$)[4?+518;6%=(JL:1*[Y#G28,QJ<
MAY%=2W"3):+90VRXI0JT*@NOO<8Z[V`9(/"=1'L[TL5=JUG+4JH52LS;+9=E
M+HH<M,I.3KTX.2<M.OZG;$(E2S38YC,),QH<],5&DL-LI]1,I]163<>X77#6
M50U:7VGKE`F3V$U6[N`J-`U:JGXS\@GK0];#0DI`E2A-IMY<F'8*#_6CBIB,
M^MA$]<1$QOU%#T="E"5EJ7VRU==K[JC2](TE:($>?8[9J2YQ[)4JR`!:2>#4
M?<19S79.(+)&8+A<Y^!-QIN"-P\'6,=:=7+PO+$=U0\4ITK=*%0J,-F$B`ZE
MU,?/,SA90O.A5T/%F%28/#*0I$E)8AMO3IP=,9O$5YU2G(^&T^GE/EQX8J+@
M.:MUB\+*A'M<T1T*=G329L0Y4*^L69)$B$$N1(%8"A^8A&=/*C(TIYUY"W'9
M$=IQ6<K;2K"I12,-7PE=;GL@Q<,6T5,%+`21#92SB:;-RUSBQ23Y?I=F3Y;B
MEN+S]*LYX19CA%T]^\[_`('^F7_K3/;R_P!8`#S)O$^8K)O3YEW"<Q6*Z>^L
MW\L[[I?\7#VZ_P"]_8[F9]`>=4^B/57<)S!1=07M-?\`.KW7/_6V=EOX.M%\
MS=T>99.Z/,N3[\?\DAW4_P"@-2_A5H/(ST@C/2"[:8'_`(C#_P#)(_\`\Q1S
M%8GBNHGWC_\`F%T(_P#6Q>W_`/PM*YFSB?,5DSB?,NX'F"Q74#U*_E>?=]_R
M?^W%_!1N+'_[.9'T1ZJR/`+M^YBL4X1<(D-'&1TX07@0BHDI#DCR8PE%8G#B
M,"8RN/,@SH4IMV-+ARH[BD.-.)4A:%92K&<9SCA%2NW+5KW06M7;?.K(`=51
M!W6HF9"'5UKT(\/ZSUJK@U01@B`OSRJ['6Q@8GR):C+CLXPIIM'F31BKQ6B5
MU[V=7Q[,"\3M`&$XR04(W4?NNM:E`)ZII=OKEZL\-ZY2HLD]**2=F#*Y*<'C
MXBY;,K$K*"#D-YS#2[E/6J`5)"7?#IL[59DRR:Q-1Z6Q$'P24HYKBAR:BB]9
M(6)=:U5DBBP3:Z2MY*=JJ0_`E1G9%:3B#%?R5;0N*M;*:I0KF`^Z/4H@1A+K
M&DK7,)V$^-*U>4+U-28KESW*8^I#\BJ`";QN''E;-'L;:B2)1-]Y@2IEV4ZT
M4>0E:E*%2AHH9K#W%NK4FE!W`^G3\"UL!JX>):_UM1*E/S`MQ6O.[)O`84K)
M*N?"D->S9DITE(*,",RYF'G8/QBTOJ12TJT*N:)V\TA7=>3.P9W4INM0;5N?
M9U*<-A*K6BEB.C])AMG2I>X['-C2ATQFM0M5:Y+$<*DK<*1(:LP6F'7G$-.2
MAX*4/!5\[WSZOE*Z3FUW5YF0W89)1FXS"6O:U+JH>Z%1>RWT`=B$JP4L&#)2
MX5JEGW6I@ILW`D1GDMO2D+FMM.J%6A6"*>X9U8&_4S,W319%&I\0X]K\A(KN
ML8\RJ7VFV(?3VJ;6*Q+LC35&LT>MS)L[+<B2*G#HT!Z!(CLD,IA*92E"LA+[
MT=&!"6*<1UG)$U)J39;$'S,U'5(U:FQZ38K:N'<PE4Q+S978IG8U7.1!LE`A
M,EDS$>?E)AM/,RGV4\4H5/X'9C4(.@1]LW;KH;J94EO7>]=571=&IIB[@"FK
M\W:9?=F7)Z-/C#($QRCZM?(D9,*>1D2TM,1XBY[JXZ'%#PJI18R9W,Z_:_/:
MQ!475$Q_7LZHD+L:LM0I(82/U94HQLD%`6Y\0TF`G%6P0(FU37(.5S8;<CSM
M17_BWO(H2K0GCQ4KZS=G-<;?L*!U?U!($7DV_$M.QSE,J4*36J59+%4Y,H5C
M8-N=9"EYEALD&OD(4<BQ"EQG$1&FI$AC,F(V\((4(HL8%[R=9B=H/#PE#MDN
MQ:I)68=9Y06CU0Q*UW0Z^@<NR[*GRJ_8"4H10X+UH:;F0V?&Q1UR',R!+:$/
M+0H4HN>KNMH0:3$2;+JG9=+($GJVY*)636]?BO`3MZ<M)378XK,''B3[I2_C
MJZ3)0'X.9D5E./3G/PYK[<9Q0I15[:NX76JDB[CJVD]>3-A#.WIJH'*V,US2
M:UK6TW$MLJJTBYP'VY<MF$7-BH!_Y])S(@>A.A1,MXD?$J0UQ0JT-?*L!6^Y
MG4`(Q"L@CKV7:MHZGM2Z]+HNEJ?%EVP)2*NJ\7M&LYTR<#+/5[50H1F5(9G)
M&.K\C38]F7)\&<*%*%6#O7MC3J9NVE5JZ:81=Z/'U[2-@4VT)K0ZU7DIL#:)
M.]":E5=<AYKB(P4QEFAJ^*E3I`]I7QB$X>3AI7G`*`%2'3W9?KKM:PC='UW1
MELJ0@J0-E0<2UZLIP3790\-<,V-4D?'&F2D?YP8=KQ>?'?7#;RI8YUUUQI;T
M3,I0\:JD'BJKUOWRU(>'Z_NMWT+9Q&W;2653*FQ5*55CI#-HOMFJ,M.K@=RE
MG![^+/'J.PZZ;L;SKD$(M+TE34I]V'(9992A"R^P^TVE:/OS;>J=B];66Z4J
M5%9VSMM-6I-A#G_DXKK:3K5JOPA*<%RE5"D>P$6`IZ0B?/A282'68RHZGG8J
MAI4)0T6'V_VHTOM?J,=V32-/M[`J%TO@S4]N`VN(.`M#`MEAXM%GM!@C42Q%
M\@-;HME>GIP(FOSOBR.8[R6929K#0`@T0#%3>B]J.KEH-0XM*TB<(6:JD#%$
MDMUO5%0=-T>G:XGU]LK8YHR(21::MKRN';K`^'@/1(YG"9Z)K0OX-2I6%"I0
MK-]7-P:+[$W?=Y#7-)D9%V"IT>!?5VL@).,2LCB&PJDUKV,`#F+70HM.'C8;
MA1+8J:_#E3+%-5(;1,5*3D01Q0U"WO%"A8(;`"A!L`.'%1(X\6)%0XX\:-@1
M&DL184"#$;9BPXD9E&$-MMH2A"<8QC&,8YBHN?PBZ?>B?\I;[UO^5_I=_J@4
M_F1]$?-TK(^B%LM[HO\`)J^X!_$P[,_P-W'D;Z0\ZC?2'G5L=,O]#[JC_%KT
M7_!?5N'<3YT/%:'>^G]/M_3OXT_1#_72T3S)GI>H?G+)GI>HNX7F"P73W0OY
M>'LE_P"J^ZP?ZRG8GF?T'JK(^B/.NX3F"Q73WT!_E$/>P_C'=5O]335G,G<!
MYED[T0KM]WO^2O\`<3_B8=C?X*[/R-](>=1OI#SK:GK-_HW]??\`(CJC_L&!
MX/%17=R(G")PB<(G")PB<(NJ,QN#I";W9N+6VP-0-CWEVNYQ=@W@\1J)<+8+
M/K:N#BY9XO3@5],;&%PID*[_``@J3,`1HA0@\B&SE4F5!;DY4=3!94-*J7'K
M[[>_X-)>E9!]5LUOLTY1:Q9Q<*U[3/M.$+>[)V`*+6NZ2C^3`N7A[&"-@F+(
MI(QE26,E?#UVL+=JJ=JJC3EI]M8Z9/Q"962].73*"T2N%@LV[&B2&WK98@@I
MYBS%3B;>"VE6R/753Q\SXQ+!`$UZ$^2FXA0VE,.TG:5D!MB]*6('9PK0*($,
M0M*Z9K^NMHS*/7(C*;C0F(=^;K^K*E(1+&XM3_Q`^?!BY;4B/)E3&6FI3G[+
M2AP4Q6GMJO70U9'5E'GTG;HFN@$:+VI#NQ_:\NWR:[7;4V+VL+HUCI5YW):-
MF6K73,#3K4:PC8P0J%`OM.2D)8?8?F,7M<5<5,3%=ZK@-4C8!/K?N'KP6VO=
M0.JZ=9K5\%>;3#@[>US=:O#VD3*3MGW043IM=H-Z+#SL8M*EK"*D(8F05(3$
M\6->*8]:V;-WWIJ`O8;2MH&B!UPZIQM65BBPK1,9!Q`E>-S]+F:^1K!TD8'!
M2$6ND!=;DS&'W<3TJ%^9N.XWG&79CQZU,>*I.P&/:TKE5GV6`[7I:1M)/W42
M!J-IV*%/-`]<4TY#+P:W#^L0!FF2[M4P4F'*C*=%HNT;"4R_F#2TJR[2O:5B
MS[7[:^456W$BU!'-UN!(OU>)O+NP5L2W1[AL`V_#FMIQ#;;+B;D6L,S%>FIS
M-=D-//)AN)B(4R[2F*_:)?\`VV@MN$2M=V6DB+/JZ'<)(P37)-_'QXN%V&\V
M(ZR_5(N&0]Q-1[;<[0X+C2(A"=')OF&AB$/LST-NU1,>E6]L*)U4,=<!1PQ5
M15]T)<;L&+CHP54MV#,L/8W93E4(6O"GB@J9!5)M6X)TLBK+K4B!A^0IMI+[
M2&\3&OE3&OE4'TG9O;]BG*,O35CI<VRVZZV(U4)[1FY'#AJ[209E9BP3R]ED
MSY[LRS`]HRWHL\D[ALVDUAV*Y)4^TO-.;I0U5:;1J73_`*PWFKQB'7'8:VGB
M@*QU.T@3QN94C&RZZV7MFMM8CPIS9L-\\H1-HC3XJ&L:]4*R1R+4XY!=6PML
M*GI3$K"S=Q]+#,W;EGNNAK9$CFA%M,[9)6"%!.0".U=3@XIFY:.9KHZ[F/F&
MR1@U;3B&1</(,W,=RB/,E2W<X7:.Z%<5/CVQ.M>MH_5RLPM/F+.YNBAWRQ:\
M9NFQZ'#)B:ULM[6T6_Q[*=WMM\40NEMLWX11\=V'"DGBKL=N0TS^U>"'9CBI
MBN6)8]N`[2C%4!.:R+UB@QVP\L/@V<8<&8;+'1H=V-.+$8DO/Q9SLI)4+*HD
M9;=>M#,J-)SA4=YMVDQ7AJAOH7O0(V&K`J*X28OBZ^Q%.6.YQ]@O;`@#34>+
M9PMP^LLFT&#,J#J<C*@V>&2=>DJ"OS&9F76U.Y=H*XJN:T][9!&NFJ\J$.HW
MRVN.,$*+,M.QA1NOC-=60/K.#/KL"LV>8@1>+)]6!#&%A746FQ"UQ$2L26G/
M3X[7%,5,;Z<]L>Q,""MWL&NYP_7=,I>O@[;9Z[M!FZ=BLV>13PC0D),:%W!F
MJUDZ9SZBF9[]=:F3,/KB*=>PH,W0IBLQKR]="[#M`QM@#@#5[S13]]*9LYL^
M6KC!$ZYL_8NG;C<,U9ZP)'%ENW"X%8,`U.'JRN%8_)`>PP\ZA"CN"N*NR[=Q
MM4U_6`/:=*S-VV(LNR0.J0T"HD:O7Y+EOL'F>AL$R&S+!1`0&#\N\DQ+TV4P
MF3#D1WHV'FY+"G)0\%**.:^[_=:KU4A5PGW!W78\PT1?B,[`CL#,HC!:,+OY
MB9+*")9NNPH$4//>1'D.S4L%'H$G(]<II"7%BT\$H5L]KS8](VQ5(-WUY88E
MGJY&04AQBD1N5'QB<%)RPQ>!*ASX\0A`GC"L!YA]A]IMUMQO.%)QR$4XJ*;<
M(M=.T74_0O<W5^--=CJ0[?M>)M-;NK(6/:+?394:TU"8HA6S4,_1CU:L4*8)
MFJ]1O+4M&//X9SC/ACPH)!J.*H)&(6A?V$/MD?XF-G?I:=N_QZ<RSN5S.6UG
M4[V]>I72$ML0]UKUJ4I)S:\6J0K^9.;+VILHK88='^>?56*\0V?=;C+B1PV+
M)-PTB.MI.</YPK&<)3Y<2XNXJ$D\5NGR*+JOV-[+/MR[5V5L7;MPTI;5WW;%
MP*7_`&`6K?8;LA2(5BN!K#"2AU^OTK;5?KL69,1&;2KX>(TGRH3C&,8QCF6=
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M7MB6/YK:3TO7A>-7&1CQMZ+/O4@/.AV"G$0@TJ2$"'\B;E`KE.;GI^/<8G,U
M9O,UU3L%Q4I>;VEEVEZ,:R]OH6S?-TF[6W8Z7,,-Z-D3S]TV+8PH>]423>';
M+-!E7B<TZ?V.-EV$U)GV[XB<6#MQIKK9&*S'F90J[@F*X%ZO7MJ5RBV1]^:!
MM#5'M.`SD6I6"\$=@N7I#8"OY*URTM'(ECE'FI&FXD=VS,$\(9(`W<.D$2TR
M/,[28KW5<Y[954@%G8$RBUO%/`@/FU6^LMM/#ZQ&DU4?1VF@(449/5AX]*J5
MGA(-N`TOS9$:7%F$UK\6'^.TG:*D-ZO'5C6C]<US&T<>O6I9]>8WN<NE<E@#
MNLJ'5>P2[%I25<B`NR7Z'9"5?M0>T%<$F`8LC'8&S),Q;.%N*5D`?54Q54E=
M?>WN=V3KNVR=SA54ZM*M=6S0#1VP%AELL@X1;VY5KO\`?;-,F6@V!BAMUOJ@
ME#4V0/?R2'I&ST,2U1YU[05Q6=(S/:KB*%?,;/61Q:S(*&X1-=VW(-NK6)TQ
ML+)R1/-FH]PK+XR#J=^)#BS'XC@JOA)[45M@4U.3R=I.TI)6[?[<6RAE>*2&
M*N#7FR7S5::>>FV4+E9"SV^X,V(?<:R-*N5T]59=NL95X>3)IEAAI$FOX.1&
MEO*1QVD[2QFQ0_3N3JKK&4!U^]7?0)/>A<L!+T^VEW`-BM6X9MFU(2)7ZSWB
MZ!]@[#&7JV;9DY4/@R"\RR(<>7F+-')D8R%:^5,?55B:MT5TWVK'O>QJYHZT
M#9%*W#L0&7A6/.Q@I4C8Z!9IRC$0;2)%ERXYK<R8RN6,KKL)D/+:>;<2-2EQ
M&,C48(2>"HFM;NZ;:MM#-V_)RV5JVQ:K=FP[])=>&R(NKB$ZMDXU`;NH@!LX
MT`MEEMD$M/#AE1F3$ZNSI<Z'+4+4[*\]H3TIB?,O+63/1FR[)`ZK1ULMU/L\
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M;6(-"P3QAP%`L26Z<)8D$FHR9\Z(,BQY+SS##3:52K4K/&^N&D;):[7=C^O1
M!FR7B,+B6N82D%9<4U'#2Z1-@MR1#Q!89'C(UJ`]?+<="I:!,9#^7$-X3Q4I
M4KTCNM>E!FOLZL9I*)E$44^<J"&C]IL2UD$CFPT=Q9<^<)'%L0`K#4*(QF3E
MB'"9:CL(;9:;0E4I4J#2>D/5J:N>N=J>!/R4F.R"B9UDNDUHE`>PWE52(,RK
M(ZU-UTA]I#[=8=2JNM2D)?1"2\E+F%2E2K(U1U_U%I#)AS651Q7I5@;@M'2,
M@Y9;&6,(&>OB!\R,6DR;*35Q$R5I0IQY2L(SA/CY4IQ@22I57)R(G"+K1WC[
M0?0#L7N&\;ZVMIVSE-J[)57G+Q9ZUO;L!KM-C=JM='52ONSPFN]H5:OJ>&5\
M4Q&;6F*E7D1G.<Y4I6<Y![@*#@L@XC!5$0]A#VN"T"<**Z*V$3%DXDB`1&D.
MU7;2;`GP9;2F)4.;#D[P=CRHLEE>4.-N)4A:<YQG&<9Y<[NM,[EVT4ZI5^@U
M&K42I#TB:K2JX#J59%)?E2DC*_7!D4.&'IDS7I,V2F$.AMMX<><<=7Y?%:E*
MSG.<%BJL[)]:=*]NM06+0_8.G9OFK+7-KA$Y6DG[+6')4^I6(7;*[+9.5`P!
ML,!\780L62VJ/+:SE;6,*\4YSC-!(-1Q5!(Q"Z]L^Q#[9&<YSG3.SLYS].<Y
M[:=O,YSG/[.<YSO3QSG/,L[E<SELOU5]MOISTJNMSV+USU@8I]VV!6!%,MMD
M/[5V[LPF4K`$G+,B`R7MH7NY?`PX).>\\C$;#6?,XKQSG&?#D+B[BH7$\5O1
MS%1=9FZ_9]]OSL)M^^;XVCIRSD=I[-D@YM[LM:WQV"UZW9)E;KHRIA)4\'KW
M:57KWQ`^O!XT9"T1$*RAOQSG*E*SG(/<!0<%D'$"BJ4E[!WM;&1TX08T1L`J
M)*1'X!,63[4]LYXXC!E-J9DPIT&7N]Z++B2&E92MMQ"D+3GPSC..7.[K3.Y=
MN5:KH>H5P!4J[#P.K]7""JZ"'I>?D8@APD%@:,AX?E.OR7\1H49"/.XM;BO+
MXJ5G.<YY@L5F^$3A$X1.$3A$X1.$6CE_]OK0>PI]L-SV[(*LEVL]MM%FL(IR
MLKGFUVJ=2SZ*^=8+U<H,LE2K5RUP!-C!Y)B6TQ/&)2O+L5Z5'?RS$*U(4,^S
M2TXTN2\.O^VJY*>KU<`L3*;,UY2)4-8%+3;IEM=1UT%;E%IK?Q*8JY*'D`,$
M9F`J1V)&<)9BE5AV_:RT$W`'P\6>_NJ@$21;S2AFH)HU9`X2V9,.OL5:;JF1
M4!WS&#MXY"1B,/:^$:=9>8].7'1(XS%,Q5M!^B>HQ]5N-"*';Y:J%<26K</T
MJQSZU(`"J/IRWD+I2-5P&855@S)E#8*$W69B2#TXE.A>##TQ2<9\9F*54=#^
MV]UG!+G9'!S[*'K*V7#M8FAT8J55<:O@TUJ6KOL`6)H_4]EJNS#82<(<=>\1
M<S"6G6GF([[3,4J5^&O;PU#?!*A.YKMMO>C<.H6"E51[9UBKD[%`@&0M?KPX
M[2!X"HU\,$O58%5Y/PAW$99-^1*D/S'93JVU-7-U)7J4BV3T5U;MVTG+#L*V
M[,L`VPOULJ1IZS%<A5W-IKP&KU)RV,/#ZI%L;)4_4:L@;.9^/S!RS*D.,,,2
M%-O-S,0F8A55-]MZK'[397;?M_:-GH]PHX`-;Q4N32X5@NMQK+=A"5:TV,F+
MHT&%$;H=2EC(PB.)8&MNR1V'R29^5KPNYE<RF=G]N[2]NVDYM4M:-G*)JM).
MYL`T&*NX%'V`R9LYLFH0_-I\RP!1$^5:Y&9`^).9B2G&F7GT.R&L.\F8\%*E
M9ZU]#M1VD8]`^LFR`DA991MDD(.!,2&YJBNVB[D>1&GUJ<.*!9;NZ#+$N!+9
M?B3H66XTA#C.7TO,Q2JE57ZDU"O:-B]<Y-KMA?5P`MKJ?3(JT5H6?KL37%CJ
M=X'C5E`U>@0",<G=JPJ7(\836&XTM<5C#32&O(KC5*XU6&J_2NDT*TQ;=KW9
M.W*04^K-.J1SY*9J+[5H"ZZH%4H%#C&TF*435Y*VQ462'DC9CM3YTF0B:B3"
M<3#0JE5FMJ=2Z[MS8TW8U@V9M""]*UFC64:KBW->KK0.(R;7:V;167#&OBUG
MKMM<M\443EOQ";48D\`&,S&'XD;X=:M`E56DOVYM#'4R(=V(WZ]`YZRMD)`#
MAT;`@3=P6%J+&L6]L2ZN#KYF!LDO%AMH\L64P$B93YXP]ES.5<N8JYNI620Z
MC5'#.A6:G>[]1\=>==YU345CX>L;@LS1U?@]\PVS9VIK?8&%D,YUF-\"`[Y;
M/3YGO!['J8\DJI54(-]MRJ(.6#!?;^U'Z8I^@B:D"'S*9'GQ-:T*%JN0%U98
M"3]$?5.K(2S:>#2(4R-B.><C-O,32$K$A[*KF5S*QM7]*:SJG=M'V`!,$)]3
MUOK_`&"!JL`Z13-L.;-LL[7YA%^?\`&#BW@M1&!27R=U[,H@A^WF&\N-Q?0:
MXKA12N"\U]!-/LQX^1%EV2$,B]@R]JUNQ1#-<ED:W?G)(R>/.0(I:ID`LQL,
M0$,/,19L65%<\%(D-O-K4C,S)588)[=&D@]@L=E<L&P2Q6S/6:>2(DI%'R<D
M&KW2[;3;Z;(6N'18EL.R[9]<Y9)QDA.E0X)##?P+$6*CX;-S%*E<J'[=F@VY
M,)XK-V!8HPZXJMD0:6L(QJ%\.I&U7,U"7D.`%39]2R5VY.(Y8>>7(S/'#'<O
M^,)&%,Q2I4CJ'1/1]7U75M/38LVVTVJ[1K^V6H!\'KJ/$.6"J`X5:K\&R@JW
M10%7,"H005$;<RN!B;*>C)?>D+>RI>94\4J:U46VM[=>D=O7.3;S]@V**:ER
M94U56KY*J1ZS`F2*8W04OUV*3IQ6;5,IK*,,/?+9$7,U+3").7F8S#2+F*5*
MVPU_K,5K=RU)!F#\H=;+39+G+$%G1,B$/L5NLQRTV":,>BB(11*)TPWAG#+\
MA]IJ/$9PVE*\O./8J*Q^$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%0W9W44[?
M>B=A:>'$(@:5?QH\'@_)DD8;]994<%RI-I"2!253&[76(T9<\/X9;;^:QX_J
MK0WYU8H-#548&JU8M_M?=?+9B_Q62]VJ@;81,I-)`JM%UI%@0H5BA6:-902'
M26N2A&P"",VTND(C9Q\KD&1BPWQ>868K6,7,5<Q5NW?I+J6\Z=INEB,^S,@*
M%=[+?ZV8>9I=C,QC=QS?V+(F5"N-.L=2(1)PO9I>(UAX6MR*EUIYE:)+#;V)
M4UJI7I43,>WOIV>P-:#VS:%1='ULA1ERJ\:J_KS:`;O&PK_8Z6\DQ3RT5@4>
M-[$?0Z^PVU/8C0(:(S[*D/K?N8I4J"[%]O81#H`R#H6VFZWLBJ&;,7I-FN!]
ME<<%*O8?7]5MD]EZ!3R['QV*OKZ/'CID#9T=3<J8VI"''V)4('=?!6O6K4)]
M(Z98V->1K#L+8JAM4T]K/2MVJH-ZI#JCMRH:O-1[*&A7%HG5#UP&Q)IUMU4Q
ML,:&*F0WUQ9"W65*PJ54JH$!]M'2%:`$ZN$M>R1`&QUH_KRXP0;FO:XNZ:F.
M"ZR);UC9)]=UZ*(2PXUBI1?^,VW6K'.2[*:G$93,EUK-S%,Q4FKGM\:4KU=+
M5_YM<YF3\";!-$8Z*%6%353Z?O2BO3FPU*H=;JX^=BO=@3*//&@M86[&A.+P
MM33WQ$S%*E1=WVS]'S2];/&;3L2REJD^H:`FV=O6AY8W7.;5(O&-61&2&MWH
MD6NLVR8]+:*--HM#6'5-)*8:\$8N8IF5\VWJU4;9K?5>I%W+8@>A:O$56M+!
MBRX7+5]K-016<BQ-V41KT_S2DRJA">03%8%EXB_7Q$E1T2'DJE>E*]*G-=U$
MBH$K0Y5[?8A(:ZE-EVFQC,-A9<E=WV'-K$B/9!).4*=<&XJ+`26W!B*0\PYD
MBM4C#V6FL)546K@[VY]5-5(!1K%L?;UUK0L#.KIV+8)VO84J_0<D;%8Z]-NY
M&I:ZK$LI9*M>;B7L+19I4<D2-$GGRK\_'IMHN8\5:J7`^C6O@]VJ6RG[S?3>
MP:CBYE8ES,#=52+%)OMY7=$F-A*)M:S9D#2B85\G,($0,Q:NM+45QX6Z_%;=
MY*I5;K\BB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PBPXZP@C!"P"A1<>0)50E%#V6!#E,OR@)6:%%V.(.*L-J4Y"F2
M0)R',0VYA*E1I+;F,>5:<Y(N!`NM0*V`E4Q=G`D;,'CYEE@,$K"EEAD?$C$1
M3A""P\Y(AX3)SA&<.)3G"LXQG'TXX19=DJ.D$IP=F6RX4&11\V?"2K.7XL0J
MN>V.?=3X>&&Y:QDC"/I^G+2N$6*Q<JJJTNTA%@%KM[`Z,7?KB);:RT<7,5+3
M#GR(:,Y=CQ9:A[^&EKPG#F67/+X^17@127A%@/K56_K!]5$G!:[+B/B6X";F
M,.E&(RFLO-ORH3:U/Q&GVDJ4UEW",.I0K*/-Y5>!%G^$49%W2HG#1:N!;,"+
M'@++<@V'&E(4T@):=)%0Z%$8L9YQV'G)4',C9PYA.</Q749QA2%8P12;A$X1
M8Z`6&E%D6Q\QF6L21<$DDM9SG,,DRQ&E.PWO'&/*\B/,:7G'T_0O'"+(\(G"
M+%+.AFCD6LN%(*+#-%3CL0*J2U@E)##)@X>1*,P\J]9R#"G%XK3KF,>5#DAM
M.<^*L>)%E>$6+,G`U='N%3Y8<$&-/PHKA`K-CP(:91*;'&CHV9,IQIKXB>1E
MM1V&_'SNONH0C&5*QC)%Y!C`JQ"!5@!$89<(<&P3`8L/?;E0"8HG%:FCB,&4
MRI34F'-B/H<:<3G*5H5C.,^&>$7Z.+#2V)V1LQF9@:1E"9WHYSGX4E"RE,N&
M[XXQX/,97CS8_P"[PBX\NQ`H!D379I<=$/'89<@%$2);+1`I!`?+\&Y<&*M>
M'9,<3\VB_$+3C*6OB&_-X>;'B1<L64&FQH\R&(0BP<M"BDQ14;*8G#B0Z<PB
M5"GP)L9;L:9"F1G4N-.MJ4AQ"L*3G.,XSPB\"Q<2`&S3)TF/#"!S"Y1`H5F1
MQXZ#&;\//(F39;C4:,RCQ^E2U8QCA%D>$3A$X1.$6&$6$$?670$+CRRP!F57
MC:8$IF4H4=A,QI$L1/PTI68I",Q-96MI?@M*7$YSCZ<<(N'.N=1&6`54R%F!
M0K0<6T@/79!2&T;)*?@V`FQF&+4]B:\A\?5";R%81Y5H'R,XSGT5^4BDO")P
MBP#-KJ\D](JT>Q@G[-#1(=EUUDM`=.16XD8),E.2!2'U3F$1HEE'.N94WC"&
MY\=6?##S>5$6?X1.$3A$X1.$3A%B99X+!+"`,TK`BFC[1)X(*?DM-SRK09N.
M\5<@1E*P[*0.:EM*>RC&<-X<3G/AXXX19;A$X18<U8`=<8A23Q8>'CD3`>OP
M'B,IJ(W,.6`A'$@Q,=;RDI=(%B<IN/':QXK==<2E.,YSC'"+@6JYU:D1!DZV
M'8`**:L0"I"')[N4*)V:TDV`]?!P&D)6]+(E",E#;;:$JS^RK/@A*E8(I/PB
MC,RZ5$?9!E.G68%%MII"7!-:?*0VSI!I<,X0;=BBE/8FNLNPJR1=0O"/*M$"
M1G&<^BYY2+FV*Q`:A7SMLM)@=7JQ5PQ2Q6,^8EL#Q`,"%A/DBY@I/DK;C0AP
MP?&<>?><4E#;2%*5G&,9SPBY8PF.-#1Y@1.BDQ):#$)C"4%]N5"(#I[#<J%.
MAR65+:D19<9U+C:TYRE:%8SC.<9X1<[A%`9FU-:CWZ[%GWNJ0Y%OOA/5U69D
MG![#E@V.&A6(D5HPA+CZ<S[2/@5$H\[";\TA#8]_.4^#2O`BR].NM0V'7XML
MHEF"6^L3I9B##/UPE%+B)4ROF2%=-QH\^$Z]&>>%'14F(^E*LY;D,+1GP4G.
M.."+DQ[36Y9Z95XAP9*L0YIUXB&C3&9!`<AE@-*<20CM+6N"[B)88#V&W?(M
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M592JO0ZUB(*&6YS#'I`AJ(RWG<,L)\J'%0NJ*(2J;L'ML[F*2-FR6+?KI#EP
MC?!S9$:T7@:4VN2A7LA;!U_VI()T^WUMJT2H9'$:4/D!K.&<1&])UJ3'?RVS
M<P2H6=+>W/M^U"RD&QWS7$6RI%;"F1]HUR7L>+;;;L"UTNX`:99[`#(2YM<K
M\74B;2D(":;^;RF`L9#J)#2T-0VIF`2H]18L=[;NV!!)@Q".:QDP9`JJ+M="
M*V6UN!+Y#K&PRMCCZ3M9P/KX)!EZDB5.6V,A/MU]MB(VM<9L&B`G$9RYDS*_
M^M_47:/7*X!;P]90NRK"<&S*9L@G).V>',(5R6SI2)6B67CBRRBJ-70:`>8%
MQ7<X=6@WE7JI<?F+7"05":JHKY[:]QLUHWM<:I<Z9KNX;`LUK)T*^5G%BB6L
M&(OL_=)J\,EUQXL>/&GVA_:,0?,]%4MM^*+P^K/J9;9;9E:K.WOI[N&3I_K1
MID%&K9"16+WN<K9#,VYFG:QJ&%=*QLQRC6*IRP]5I\@\8U.9LP_-:B-`1`]J
M9#:PRV*::8=CJXE*BJBTOVW]HQ1Z0M5V'4@$TE1Y0LIM1@Q?V]A`[6>"7T-9
MY-?A,81#GPIERN4+8C4J1/CO*M]>A,NQU,>E*B7,E?66&E^V_OB>5'SB.VPD
MN''IY>ML#!MWOU>CUUU[7DRGDEA)Z:V9MSC&V)4AI1_TBXY,1$5MQUHWG"64
M,P3,%:5[Z5[\M.C>L.LAE\UR)L&EC\HX=,QL2AJ8$B%=PEAILFGRQ=`:@.3:
M]6!\D5+<'AZDY,>D^O!<$0O7%2)45)0$=*SO7/HO==$[NJNP4W@=-JP34H2J
MS(,$R8Q(D6C%*`A;?!="RZ[\8:K5EV%"(7)R7,L.59,$G,Y&X?RJ<H2"%":K
M6F-[9W8CZM6EF?L35\FP%S:#P@?'*GXM4''7QVJVRIMZ"K6SXJ>+*6>@2#,D
M//$DI4M<E&'3&3#;=C9N8*Y@MG:QT]W17=:]DZJJXZ_G63;PH,('E'I5LE#+
MR3AWB^V2T;+V1$,C3*`%XO=6N<4`^PRS8H$6,#AJD?,XB4#694*55"QO;N[%
M.4VC:^L5[U3:ZM1#5=O<!D^9O$Q<ZT`;%IIT55GAS=3C@858J]>U.I8Z?'BH
M4F:0PVT-B,L^=VY@K4+E3?;.V8)K(^E4&]T@`%B4<!6P!)LKL`61U/8(&M]=
M5^_VS7(\:EZ*]/WI8*N2B6/+K\%QL7/^)PN5)<?CK9@E<:KFW#VZ=I$B]C%5
M>=J<-2(("R#=4%!]BM@*Z56/9K"$GFZ:>B2*#;Q%@HY6E5U57BQG9"X8B)8C
M$U4`B\ZTQB9DJ%:O7CH]?]4[>K5ZN9ZF6H8%U?<:6X=?-VBP7YF%<JYI\)#U
M9&R0KX0`_K#7\K6\Z4-D)3%<>R74AL;`PE[,@34*$X+U=4^BETTQ\0"OA>D+
MJ3^C26G22M=FK>T8LXTI7M7UH,(G12HD6/``-3#*$3;K;D5QY]*++)\$1%(D
M+GB:JDJH++[<&\;A7W1]UV7K[8%GL-+F(NURLLFZ(42LN!NU(4G7XZM*'E1\
M?4M_FVRN3"ZU/_$19-89<3!FN?".0;F"5"O/4'4#=NJ]6;C`?A""6"_V_96O
M=BUN>6M5A77[`5U]?1=YFD;:^+I02=5R6RVQJ1I=<>*?DML-MN.RR.$HCHA(
M)0D%:ST_H%V.EE+9*N3NL2"PUN&/DXAVX[`77^RX%VKZ'(R=?W=:`YJ<!U%3
M;-5S3@A:F)TI\JIQ3PQEAZ2Y.N8)4+9G3G1R]ZP$;+;*[(BVRR[-TM?M<6NS
M.F+R.*VJQEUP(U$L1HHT3<,PL5(*F9$9D19'S"&F6M4=WSJ6O,)4JJ:$]"^S
MD*J5RCR]@:JDU$5B*<(@$&[C`8+_`">/=@D;395JMT:L5F;0;?53T:*>-PPX
MGU5N2E,U]*/30IF"M0KMTMT@M.L%[/,Q++4Z+:ML43;=9,$=;/71UD"2MXO5
MHO5LD6[9">29-C3L2HEF1SS[S3Z43_%C$=+SK2!*56O3/M?6HT<08M+>EQ\!
M^MD8D6K@9MZ*#Z`6$:\W15:1"II<F(&%)@3-[VFFYRG',07!YO$CX=E]:D2N
M7,F96]H3H5L'7NZA&S=F["';"AUZ]7F\-_&FC!&7:+38D7)H!L$F"Q6:Z(%7
M($)M^!7FDR#\G$.`PIN>EMN+$A0NPHA-0HA8?;BO"'[+9Z;:Z,U>+48L,NQS
M3LJVO0[0$MUBWV2MH$IF9#L8YO-C";`JL-QR2+)P4KJT3XF!.B0HL-3,E53T
M3VK=O0(<&1BUZHGV5-="!;'8,SB\$[<A(S\G=J=0C1<CK.T#,U$L'T+@4ZMT
M1+CY@D4IR-RS'^$>N8)F"OG7_M_;(U_L;26PXMYK1FP4V_R[%L:T6`W:CQH_
M5\4W7-1@!X\,X%*9,'&1E1F1(I%F?7I,!$O+CBR$:1,&/3,*)51#8_M^]AKA
MM+:NP1FP=;06KCLNO76M0721Y@;&=K5JV<0KUEM5910)\&QF0%4N\$<N'.ED
M)C[H_+PHW7?*/0.`A*A7=NWHP<VEN.X;E&6@`+M4X@`GT8M/DV]4VIN5@7J-
M(#P8&$(D9+8JQ4DQ/:0QEO*72F'$K0ZIQ>`-!1`<**G-$=,][:HV[JR-9;.B
M;5Y5VNNS=I-TJ;-;UYD/7:/J&/0:W%4H12TP[&4WT`GV?X9`J2X^,DS$$"$V
M7ZDR9200A-0L>]T$V[LRS[1M=@+5W6T4OLKL>6K8^-8KB4,6DM8;#V5B:>W)
M<40G8D(98JA`V8#2(C1),A<0+!0I#L22S$C0V8)4*$R?;W[#V&S[%#P2E*U2
M(D5N!+J=CJ=MM4Z!6PYZ=OIXUU<H,:?7,,MZ7E1[L(^=$9(N%GU&&\,!I+3,
M5J$S!6H4BL?0C<&NZ$6O5(/LEM[AH8V-J^:#G&+,3K!EB%K`7K:M?,B4:EC'
MM642XAB+Y-IJ$*AJKDE[+<%O.,14J@^92N*V*WITOO-W=IXW7]DJWR>IZ/#Z
MF!F[X<O[5JI;]<9/LE"%;559#*"3F[PQ2*"M4J5*:=8&PDNI9(KREAN54!5-
ML>VM<)LB=9B-MIX.X)G$2%#2`*WB:+T[`^8,':32:-*DH$YD5K51C&<AUJ@P
M\>,=EY$:+E*&66;J5JI;5>B&R0/6BSZ=L1BA[,/$]W:FV@X'O=CL$FA7:'K4
MMKDC87+-+%4(=,KQ?:<RFRB!%IH47PV0F^>7*+.+DR'V85JE<54T#VP-P.X/
M-VC>,2R&%QZ]+K>P"I([./1CP:@KJX.=D,T"&$!DW6,I;D8`1<L)6=D;+>RU
MD8\X^F1<P3,O=9_;.VC8P1Z5'M%"K)HF9#JKU$K=IMC-(U_16WM\R)FLZI9#
M5$/2(M="6;9=?M$%UBO0GW3==;0U\NRR/F0P<$JKY[`]#"6Z=SC]E9GTAYH;
MI@+3XIT]\_Q>&]CTZG]B`-+M7Q0^.M*HP@_NF&7:D9F?%Q)8Q2VVU.*:<;@=
M10'"BQ%%Z+[;#:LW=JZS;>1-QNO9E+)VFX-$4'2YFD"KO)L=_.K!&Z"Q5QVP
M-F5R1@/-CSXUBCJ8:1F5.FM(9CLB[%*A0P+[;-V9D@FK5L@#;X(.S4VGRB!)
MRPQ3%QZR4`G1OD.LK5#"LB*]B82"4QO!.+$C,"94U67/3PA:D)9E:A1:Q>WS
MV>)4V/K=C9FKRM-&`Y0QC!XS=I)`RT;"Z!#2`TF`=J-RK`J%2E:4<D"I4F$<
M^)P24W\+!>3\;BY@E0KBLG1W;I?KUJ+7T#:%4C[@U%MFQ[N`[%)PSY>!C8RJ
MI?8U1./M2,X+3W6;?:([Q/+J\.28.92<*RXYCQE17R)45\BH)OVM=L5_)D14
M-NC8M4;`RPU8'?/9@E&:IC9<NW2-.'1CVN;0Q*I%]&O+D&ILB01AMEITA>0$
M[PP^NY@F99X?[8E\=GKBV"XTLA5"8D8_:A[YBZD"%OLT'15&UD*5:'FQP2,=
MC4:Q4:/(%3'4I<<A>GC$:(MI+>69,RM[I7IS>&L=U;EEW2N.+#+@5JJ'=G6<
MD8C']PFX5TWC:Y=\9@+DFX)F</%6FN"8TO+K&'`C3:''6Y$3Y7"CB"$-%VB\
MQ6*<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<
M(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")
MPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")P
MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G
M")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB
M<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"
M)PB<(G")PB<(G")PB^2?6_\`O`_=_>MMW8(TOT?ZJ2`.INS)'JL&(;=[S@-)
M&-F;8E%+8S0Z)K\3?:2-8M5\O`FI/O11<*0XZI[Q;3E7AYN;2P`8D^LMF0>P
MMV/90]Y[8/NM6WL_4=@=<Z_H$CUT:UZV['#[`*W665*6\K?Q)@838)52MX%/
M`)=)\GW"G_46ZK&?+Y,>;%[,JCFY5VN2NZO5^%?;MJ^1ML,G8&N-QZAT#=ZJ
M@79'2E=VSOH+!L.H:M.;9"K;\EY$$&W8A!"EC$J2ZV[(;<9>0C&AXK&A6S_K
ML^5Q?K->1K*TNK]1'E;4WCQ6EQ7CX(RC'[.,^'AR**N+GN+7&O;GJ?7URLK(
M*V;RL=@J&K!TF"5=9MEGK%-.;!,`V"D6"^('$6J=62$YIN8_'S*;B.I8]1Q/
MDXHE%'J9V.TE?]+R>Q-7V&%EZ4A!+O9I>Q)R)X,#&K&N2=@$W*ROJ.PQLMJO
M!Y56G+^-4UB,_&8^(96XPMMQ5H:TZ4IT*74K9])V&JRXJ1621;J18.%,2I(,
M^&'JFGZC6;R'<#$38L=`LPV=6;>/>3,&N2X>'75QU.XDLOM-Q%/,.(4I2$K1
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MVN]?E-K`BFN)97=D83%UW]>\65AR)::ZT\4AQO%R,\GS>"MYQIPX=:VFAIB.
M'6NQ[_=2-1[8U_NOW*+9?>NNV^N]5V(0U*=U]6-G46^59J$%E7+>)>/5@QJ\
M!A<BT.U`48B19#Z5.NJ^X<=\,N8SF2D4&-5'D4%%V/;L]J?L-;^\AKMUK2QU
M:HNW#OUH_8&QX2SOJ8O75G5VD=,1ZG8I(]8U3#.T]*[[HIF6#A*5Y98@[.0J
M0WA]+>,<V%/(L<V%%3.CO9\W\Y&U_4]VZQU,#U2'O6AHV]-:BMQ6+8=?[+VS
M4F@>W-'VCW%N3)6NB$_7#L'>MP5'XX%,3(FR(PA;Y*0ZN/'1D7CHXJYAT<5L
MG>O;S[XN=`=?5&J]C6;7VVT53>G5MZT4N]LU*)K71>\M"4>'KW:"H>VP-6C;
M(OXC:-7.GV)<L^].<3E]*6,--K4GDS#-PP2HKY%K%<?9;WA'.7K5=#JNLYVO
M4Z5N-"J'8BQ[..(N=DU),]OUOK!4^E]EU<FNR(L.@1NR,9&RI!7XUT>F1GXQ
M$7)92\\R#Q\WG3,./3_PKF6GVC.P^U:7<Q-IU?K2I"9&J.PB]4:M:VS)*`]7
M;<LW0;I?HS13HV:+"0AK"J#O+2%AG12,=G&!64123"/7=QAN9@KF7.Z=:_N8
MKWD;'&GTYPW9*,9[SVK<N],1]OPK3;`>U%=<7-)U?8\&ZZYK-,;`ZZ@1)P"F
M31A^P1S(Z%)DP$0V$R\+'T/64/HJ/[6]HSM09L>Y+-5:'JF78-HQ.T+<JUHO
MXB`?EU"T^Y[^5V!U.09L%*.AYPC?N@"<ZMDDS(\L4/EN+B$X\J`^[YKG'S>9
M,RD%1]F;:9P[IDCN&D4ZV`J=.Z:B98.X[51<9]3T]2[3W&.]A-.0Y-?I%$K1
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MJ^Z6YM;[D[I"@W9X3J^[:3UY=U]?NI<K4-8N<K<58%].W=UL]A7[(X)EW4)`
M"[;5/&?.77W*7&37%A9<)TL09=1F`*#!9@5HHO=O>BV3KBS9U^>T/K<W?Z[7
M.QD*[U\%L^VQD1[]I0UOP=69X2>9UG!41UO?&="R$KF1XTJ:-DD4ID,->G'3
M/!@*9?67E??>CV=K`I("6KKE1IM@K4';PFQU4!M.SKM5RMFJ'NX<8M8]-")V
MLV<V[4@F;U2;CF2<M<&:+?LK*,QG,L)^*H97S)E5X[&]T^W4'J'UZ[(N:@H#
MA?<!W:L`I!)[;3$UO)CZ=@;$*_)-;[`!5NTIM6P^P$?7^(NN@SL9A9(B3:C/
MN)>:RV[CEQHIEQHJ-VQW@[LTSI"6N561(M?;7<?=KL7KO2=0H^K7MGS:CJ?1
M.TMFS2-73KL14`A<FQ&UUI60!F$)F"$J%.L#9!R6KRMLLW*,WDHJ`*^11VS>
M\[=BVZ!;VMP^GA^FIU/3"'0=A[$EUV<$F7L]TR33=[=AB35`*2]/ZA'BM]EV
M@[T1V>DZXPOUTL*;3EBY,/*F5<?5/O$=AV-7=<#-[T33[JYLRW::U//NK5_S
M3RMLN)C0&C-Q;'G,@9M*!4NOV,[(WC'C5,,T07DHH*2RO$;P9:X+1UH6JQM2
M>\S:M@["T/2#NFZ``1M'LO;M`V^8&V9/MSU4?87K%JB_5MH%69C6PY!C.S&U
MD"854\,(Q%2@LX(6^[B#,F'J*%J[=SV])@,Z3!HT9OLX@:0=@).`:<!F`B26
MUX1\>,F/VZ(_('N>/BE:F6U9QC^MQS&BBT+WON/MX,WEV"7JHX=@ZTTH+I$\
MDDF(T[)UR/`G--G[(<:S"F"']V'=I.W.2*=&Y8DXK;<3"T2<9SA:%T`4QXJB
ME%#(ONK69YNMO2]2U06Z<VB(KF04Z_Q<G&JF=L^N:FN%+Q!3-A@=@TDCL>.H
MV/G*;G8PTGT!RVER'X-RIE4YT5[D5KVYL[4&N)6K:S#<NK\D?;R@B]#),6$3
ME.7IV,S0'Y<MJ#L>+38--8<.203Q>&IDLP\V^RI#L?$+:(6K#6CW$-H3#>Q*
MA3Z)KF6Y5S>Z6Y=C`;"GDR%,K.G)N_!),58H3]#,#!^Y3:M*LD8(F2TJ`U",
M)4\IU,=*I;*F565H[N)N3;>\M=T:PU76U%K=II&QK@F!%L!PV5/1W`FOC>M(
M,.<1``DQ[")BS#;AJ,RV\TY&]-QE7@P[XB``E!15S/\`<UN,<?@ZC3=>@0X,
M`Q'D5<[="T&^W"U5-\U1]FB-;!&ZH\FPP-+[=IAV+9).<^+8&&T00A/K);Y<
MJ45R4_O(;V!$[8W*FU"B6/6/7#6UXM=;L(>]SBCVU+!7#>U88=@9,'UN2"'U
M0@-U:ZIZ<P^0=Q(G)2VTM#65.2G!2BI,I[E^QZ?<3U1N>DJSEW6L"Z3=FS0%
M[RE$X90RNVYMMMFL19V$-L]N`U:D:@E/S66ASKV")!IE2VFV<N2+E5RJ<J]P
MRT+ZFV+L/-U<$I-E%['_``4PJ7;K&6S!=N8(2R]>H+YE`$7$0R(LD$J+B/R7
M8$.2J#ZJI#>5MLN0-QHI3&BUKO'N<;>E,WPS4F=0T@<1TJ5,4X7;[EAR;JBW
MC(&YRL4EMMYRIK^!M.P(VMXF*<'SA4,LT1CNJ\W]9(H:%:>NK-E>Y5MP20=&
M$-+T#+C]0O%I!.3MK":QDD.#FMW@:X2E/W+%58PF%(T<ZY8DQFW(0[)Z*C,Q
MIN.X^^RA,JL?5O?FR;CA;F&C@=2KY*I=:"VWZ85"%")^;*-AZL&?-/%0A`0C
M->C#[18FFHT$NW%D3(S*)4+)6#(5)CPBBE%0B?<VVX1!1*A#IU#F6G.NGY,C
M;M+N0<[3K389M,LM@BVW4@P]'#.WL/1Y]87"L\.-$D_!D7EMXRVB/X/7*%<H
M4ML?NKV"E#_GIO2X:R@7Y\62N50+H5.R*F-1$C6ZX4NZQ\U+'R[;FK=;PR9`
MX)1GP3*88CIRC+_BF9:IE7;K33KMEJP(U*P*;)3![.#<0*59-C!=BB^,.QA(
MY5A*$3,@CL>1#<5E*%X=85A:$+PI.,5BI-PB<(G")PB<(HU<RAD'3[6;K@5=
MDL(>M'2@&O-KRVX>,CQ<J6+"MK3XJ0LI.90QC./IQESA%\]5"]U&]ZPT?1;_
M`#]WTCN7:=AJJQS8@X_7ANBPVAM@9TM&VC>NHU,M]"II4+L/?=I,.."*12"4
M5-G&SX[L,\1>D+8QG/+7R+/+BIK/]X??8N79)DWJWKOZMH78XE,\FX+<W8II
M%:M]-T>/;8#FI<P0+<E?7,ODPJ*_/5#R6@ICIDY:?4IE"95Z\>\GNL$=I-1N
MG5VDHL5MVQ6Z4W)K.WR*ZTZ"DW':.N"\&$;N5'I\=.S;#:=1DY=;$NYPS/&N
M)0M],EIQ.60=:91UJ+6+W@NR45ZJ61&F=(5FOX"[%N$BLG=O3A:[\#E:(L6Q
M-2UV'=KC3:H`J=W:-5(E)*1'5JBR832&F9;>4/O8N4)E"[9M)]MU[8ZY:+WO
M%U5L"SKV_4?GTT5K&ORC$2N$8;N()*/(S<UT@NF`\1:=3#>S&6W);;RMIQUG
M+;[N!%#18D4-%#NR>Y-PS:1I-6H*SNV@V3878!6O"X`>'TF&VB0KD+3FW+RX
ML&YN;ZV:Q%07C=1@NN2I>/77%COM,XPZXC"J`.E``M38?N'[PU!/GZ]W94Z5
M9;A3P]@?O-P;-1ZJ"=.P`EVPENF`X4!ZQV>KU2PZZ=0;DP1TV2TP:8>REAIC
M/K7*#P5H.A>MCW6KBL?&R]JRBMDB8&+&&+CWZ(0'Q[,QNU&H+#:K4_!F/#Z3
MKD0RY@FETK.B,3&W&FX1*8I3V8S*$RJ^-L>X!8=="-*G&->4MYW96@H&[25&
M+;&2U>R+Y2?4`RJKK*.%"F!5U;JSMN^;%B*'L--`X+CZ&\X7A;<RJ45#WKW`
M>R]7I6V%,4+6,6RTL*500L$ZTG2H:M7.P:ZW'<ZCBOBV:!7LFZ%6%Z==P0=)
M/MSWDS\9QGRM>"KE"M`MK]^]SK%I[83.M!U*J9"67J%&OHO8-@MLT1K8+1;7
M<!^KC5UMYE@+*Q`"4G85E#+EI;=SZ@:=F3ZC7D5E,#:BJ@"IZL>Y'8K\5U32
M*AKFBM[(V);(8,H`-;!)J:JE=>9T7.C7UZ*/JCAN96+<*VD2DUU]R/%:*LCH
MZL.)P\_F,RJT"E6Y^^MDUI?=DT^$'TM";I]IE5:`WL/9AJK6`<W7M:,;.GV^
M\C(M3)P@%.V'B0BO5*1B5ZDXV_'QA+_K+9C@U**N)'N*;V:9>/\`X`Z%$K9H
MKD)31Q/8%LB6^.3.63L!4JI&O$+&OW((9R$2Z\3GC"8RY*F$%X[3.'%QG5O7
M*$R]:XSGN3[=KUAJM2N6C*6DT9,1'Y4FO[&6R#EUQVQ!*2H&!(7,;5%3=CSC
M$V85B#FDR5.BH?I)0M[+CS4RA,JA1SW,-Y5AS%@LU!TX&%Q=7A+;,K&;V52N
M4_:AFD-DQBX,J<!5TG97JCKS;&!Y`/`BN$9)%'Q,-F3G+(]VY0F4*Z>P_>^]
M:%V]<8`ZOU?8M+SIW6%MK=#9+NA-E#2]I$;U-EKYD7*"QGY6IP[6OAS5@GS7
MHV0Z'?4\C:L*0],M0H!55Z&]QG;SQAV.C7E&-D+!/KS=5J4B]08OUHF$5:UH
M;=6T\;K0ZQP;Z2(VNY+M,G+LIU0VN9]/.5YPIUBY0K1;6=-NZT;MJY<W44G\
M'\("Z/<K3!@RMTU;Q)]$BVUXP/&2A8MW,9W4EAJ)N;AKUL09%C3$<SXM86YB
M110BBWMY%$X1.$3A$X1.$3A$X1.$3A%U0>Z[VRW;T]IO7G9VGO5("&=TDW]S
M5"+5H%F(WK4X35.P#!:MBU28<N<$GM'8X\BB7"4U)RF`IKS>FZXE630#Q630
M#Q77%K3WFNSFN=7#:=N;4@#9NVJ'I6B$-D[3*FPVMX$[8%DV)3:0:VI8*.)&
MP8P#K\"D71R)**CV\M1B020T\XRAW+D?(L'1P5RCH5KU7W3NT)[8C\/\'NN5
M$;?=J?6-=ZE?N.8\"F#]O5KVX45&9MZS!:)9SA)L.;[5GR$`D&>9AE8<20UZ
M#GI,/1F44^;RIE'S>JM@>K'NKV3?>]*)K&ZZOH6L:_:](D-I%U2+[8)=_K7U
M:TSHW:QNV2:Y/I@L3(U`?G[BF"`9?$Y,F0_5Y^76$K\[4:%M!50MH%UWJ]W/
MO"G4EU/H%5>FWHU>MS[>UE"W[JX]KEJ5U?OG4+L3N_K&#J$.(/RN\SJ[L#2<
ML8HLOP<L3T=AC/D^(=6G+*VOD66456SSWO([OF1]M#ZAUZUE8BVM+0="0S,[
M;!*."+":!ICL?M:SER<,#4CEA&NW\9UUR4IZ\PVX!()9H3V7L^BI3\R!3*%6
MNQ?>OVW1;AO2W(I>L7:I1JU`&4W1I*V&&K?!LP#:O8@98FMH'X]";;I&S[SK
MC2S)("%D3\C'1A6!(9<DRY#$4@R!,JOTS[N.U0YPN/-:CTC0:\4V,Z%H^R-E
M;9O(+786CA]F]P=<2W]M'1FK#$RO7B\%.IF8E9@BXA1F82M,*/YW'6TM2IE"
M90MT^A?=RS=QR78J+8-51]9QM,[.E4H.C%F9+FY,5H]<@"PUYK[C$0M3KV)Q
M3D3ID20TVWF&8B9:\WE6M4<*+$BB[$.8J)PB<(G")PB<(G")PB<(G")PB^>/
MJ[NCWE>ZNO+!OO5VQ?;<H=(D;@["ZIK->V#U\W]8KI%KVG-WWG5;6#AT#O,>
M,G+,9IF);B66&6LJ<Q]QC./#&9#1ABLR&C`UJMBUZU]]-QWUU[V]JA;WD6WZ
MR^L/953OIN.+=<1ZF=_Y7Y%NN*5G'CX94K.<_3GD['E4['E52&>GWN]6'<-8
MW\;V/[4Q';E,%.AZQ;7]`]P,-B8KL2R#\2FZNUV<;ILHY'&7(O$8)OCG2,>(
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MLYRTK\H#S-YRTXI/T>'W*LX_8SQV/*G8\JB]1T1[V5$`A:S5=S^U6,#5Y)+Y
M0R[UQ[4%ID9TU+DD#<MTP:[%D34XB<(S'I$V5(D.R)C[JW'EK4K.<VK/*E6^
M52:/KGWUXC"8L3?/M5Q8J64QTQH_6/LNRPEA"<I0REEO?Z6\,H2K.,)\/#&,
M_L<G8\J=GRK\5KCWUEOHE+WQ[52Y+;4B.B2KK'V64^AB8MMR6RA[._\`+B6I
M2V4*<3C/@O*<95C/ACCL>5.QY5^OZZ]]>4PJ-*WS[5<F,MUMY4=_K)V7>84\
MT\B2TZIIS?ZF\NMR&TN)5G'CA:<*Q]./'CL>5.QY5Z%ZP]\]SUO4WE[4CGQ+
ML5^1Y^K_`&35Z[\##6(+SWFW]GU78>&$8:4KQRWA"?+X>&..QY4['E7F[K3W
MTI"TN/[U]J=Y:8TJ&E;O6'LJXM,2=E&9L5*E[^5G$:9EM/JH_K7/+CS8SX8X
M['E3L^5(VM/?2AK4Y$WK[4\5:XL6"M<;K#V586N%!2XB%#4IK?R<JBPT.JPT
MWG[AO"LX3C'CGCL>5.QY5X-ZP]\]GX;T=Y>U(U\&B6U#]/J_V31\*W/5A<YN
M-Y=_8]!$Q:<9=PGPPYG'BKQX['E3L^5>UO6_OJLX=PSO?VJ6L/R'Y;^&^L79
M9&'I4G_QF2[A._\`&')$C_OUY\5+_HYSQV/*G8\JY**)[\+2?(UV"]K)M'F6
MKRHZT]FT)\SBU.+5Y4]@<8\RUJSG.?Z.<YSQV/*G8\J\_J1[\GYPOM:_HV=G
M/]H+CL>5.QY4^I'OR?G"^UK^C9V<_P!H+CL>5.QY4^I'OR?G"^UK^C9V<_V@
MN.QY4['E3ZD>_)^<+[6OZ-G9S_:"X['E3L>50:J;]]S[2?>GI;UU[;W;I3L7
M6?;%OLA&5)T#J+<=%N-:GZ.U&K84-Y12^[;MXEV*5GRF&EHQ"6KTD+QA2<J2
MI-HTM)%:A*-()%5N+[H'9C9/3OHCV`['Z@A5`CLK6PBFO5*)?AI4O3W"-HV5
M3*4XL\-"&`!69$CPK(ZYA+$QA?J(3GS9QC*<QHJZBC14T*UEQK/WT<)\F-Z>
MU/A'QWS3R8ZP=E,)^9^KZ_S#RXW]X?'>O]WZW_">;Z?'QX['E5[/E7LSKKWU
M\_1G?/M5YQ^S]/63LOGZ?VSZ?\/_`/\`?5?_`'6?Z>>.QY4['E7BO6_OJ.9;
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M3.8PIS?RE89FI:3AY/\`6N83CS8SX8X['E3L^5>A6J_?)6EQ"]V^U`I#T#Y4
MZA75OLBI+HOSJ<^6N)SOS.%P/46I7HY\6_'.<^'T\=CRIV?*L:[I/WN'[7$O
M+VYO:D=M\"O2ZG"/N=9NSRYT6MSYL<C,#L>;L+EAJ))FQ6W%^"//G*<8\WE\
M<<5;Y4[/E6?5KWWVEI6E>_/:M6EW&<.)5UE[,*2YC*%MYPO&>P&<+QEMQ2?I
M_H*SC]C.>.QY4['E473HCWL\6@K<U[G]JM^RFJN-I)`A+ZX]J9K2ZF*F$B$0
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M7_2E/VSF5($7JZW<MB;"5;41O-B0VC/I9SY<^.,\.`%".E'`"A'2MP][=B*[
MHJTZ$`V>ORR`C=FS9^N)-H;F08PW7OHT.V6R'9C[4M/J2A!`O7XH?/HJ2MI\
MHTZKQ;0O'(!50"JUXUW[B_7RZ4NAV"YU^YT"V;+JL8L)UY+U_:[H=),$]@CM
M?#JJ)E5.M$H=K//F[,-5(@0?7S$^8?MWERS(RW<I2A4B;[X:GE=:`':`#5;'
M9P-@/5^GR!-8&Y*/C[E.:98)"7CS<-L<2'4DREP85(Q/7BPB$.1&SGUXSS2)
MEQHE,:*!:LV]T/MO86I[9#B)-=[/[KJZ*HZBW`=D"#@+$T5"2BM&*[:(\2LT
M:P7`5KAIJ-*3!@S+%!"LXP[(90PG-(=2G0K0T\BLL?WRZ^/X/Q+@W::H?JUU
MOM6F@2&O;D7D*KVN[ML6F&-HC)(ZLO1B6JQ;>N"<HF>C9=%ADIRS*?0XI&'9
M0J4*F1'MQH^#0C>QZ]@S9JU7-Q4K2%QD!:B7B.5B[6*XUK795@ZT3'#W&F-<
M/V)'SU2<+R-;C.LK\'6\MX4*4*BUY[LZ9KFFIVZ0=<N5U#Q[N*IDP&S13U=L
ML0^5J\>XUXF<#6D.-+#`!.IRQY*.2<CK:4/GQWD>9*O##*4H5F*%W8ZX;&L.
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MO1MP50.EF%/L3S"$8@MJ]/"?'.<IRI6=&@`FM2LJ-`!-<5#^TVPO?.ZM=:]]
M=DS^Y_;'M070^H[]MHK60_77LE"*GX%"K1&R2Q`^;-[`+B1)D]@<IMMQQ*D)
M6K&58\/'@9":8H,I-,5W<:>MI*_:CU;>S+41@Q==<TBVE61[;K,!DE8ZR,,3
MFH3+[TEYJ(W*F+PVE;CBDHQC&5*S].<3Q6*L;D1.$3A$X1.$3A%T]>Q=_H#(
M_C8]]/\`71WIS)_'U%D_TEW"\Q6*<(G")PB<(G")PB<(G")PB<(G")PB<(G"
M)PB<(G")PB<(G")PB<(G")PB<(G"+J%[F?RJ_LP?W0]PO_5@%\S'HGU%D/1*
M_??E_DG.V_\`<S47\/\`JGAGIA&>D%V\\P6*<(G")PB<(G")PB<(G")PB<(G
M")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PBZ>_;X_E`/>Q_C3]:_]2W3
M',G<!YOU5D[@/,MX^U%*ZYW"E1U=DU8;IXADVY'>41LHW#2BL!L+,PR[5UMD
M'"4A,YIF&AO.9"Y;C:8^%/*2G,!/0H*]"B0OH1UH";#';0'U<Y%L8BP1K6+:
M^N-CP&@6%BRUZU8(-"U3\,Y2X7JHW.(SF50V6XWE99;]>3Z[,4J:44BB=+=`
M#=2D](!ZT8!ZX*6.NVU80/:[%`7"L-<B`(39(7.9(8ECG#:*ZTX42TI+9*3(
ME2'TK?E/N+5-:I4KB5WK7UPB;GS?:NU)C[-I.04@]#'VXQEI_,NOSX-)5:1*
MIJV2#0T0Y.=&-K_:\+?==4EQ6$90J4J5%+3TJZPM3"E@M,JU#I%SN4^'F<0V
MK:8.'4;0M%IEV/401UXPW\+0MF6K8Q3$VNL9PQ-D3D(0E/H1$L7,4J58D3J/
MHV!0+CKB(',L4^_7P+LZUQ,VZP.NE=@B;"$LTFUN3Y!!V2V5L]AK\>08\BDM
ME'5.Y?0O+SOGE2E2H6$ZU]8+/KRVZ+$GB5L%M6X1:;AE&U#AN]03=<>7K8%$
M*V-!EX]#@!QVLW:NU$<6EOX80_&7A3R'UY5*5/%9Z9UPZY:SOL?L%-;DU(X'
MGCT$C+]L,1@10F17(JU6Q8X+DM<8BZ,DVZ0P-:7X-(?(94I"UI8RTJ3@E2<%
M0VY>H&D=KVF#0-<[,AZYV6+Q8<WB.+,64Y='];F;87V+>ZU'9&WJO?(4&#^^
MT3'T$&B(]Y@G!2_!?9:B8;M3Q*M2MK*=UFU%1+A5[W4!182>J59E4P4ZQ9SL
MF"[6),$:/6')P)<^3%)L,X"Q'4*=2IU$B.E>%>/F\TJ5*K8'D473;T-)C1WN
M(>];\P(08/G['=5O)\9+CQO/X]-=78QE/K.(\WCE&?V/Z6?Z7,W>B/,LG<`K
MD]W6P`9/M9^XBS'-B'WG.F78I#;3)*&ZXM:]6V5"$H0AY2E*6M6,8QC'CG.<
M8Y&@YAYU&^D/.MP.LW^C?U]_R(ZH_P"P8'D/%0\5=W(B<(G")PB<(G"+IZ]B
M[_0&1_&Q[Z?ZZ.].9/X^HLG^DNX7F*Q3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1=0O<S^57]F#^Z'N%_P"K`+YF/1/J
M+(>B5^^_+_).=M_[F:B_A_U3PSTPC/2"[>>8+%.$3A$X1.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1=/?M\?R@'O8_P`:?K7_
M`*ENF.9.X#S?JK)W`>9;K]G^N#_8A>K8SA0%'!T6YP[4:"6$6\8'GTCRU?*P
MF?@L.8AYDPWPN5LK>0O#3JDK3X9QX\@-%`:+5S=73[8FYMW[FLT'`9=&CKUZ
M1IE&VRS(E:MO-WL%&EU?<):7#K12>7<!#A%<H<T9\1"94U::_,6A'E?Q,30:
M!4&B];_4'?M6TWV<J+EU![4GVCKK;=1ZD;5*L(^SVPN;M6VK\Z;V/.+EV!H\
MH5*[+0-<^"EY\8T+UU24J>PTPJ"?52H5;'?;:W"2E@)@C8FKJO'8V".V$D`#
M`$HX_6,D=LL=>AU;U82>$2"$*K`Z\S,`1&(2:Z]Z$O#F7D0VW!4BY@E5<K?0
M"<+ZVE-$UVR4\5*5L[1>RJV39!3VQE<.:WHFF:S;[&-C^L]*AW`]:Z$8LL:<
MUG#JBQ)#SZ\OKD/YF;&JE<:K!6SHALVP=43NA15@U'52EEV;(N+P(,#)O:TJ
M()>NL4AD=263X@]*&DEVJ&S<9+V1R7%EI4UJ.[%DO-%V685JE<:E4T0]K"_.
M&9A$=<M90&R5FP<.2!`XU73-JE/VG?UA9L]D*,""LV5::I-WG\Q&O-.M2\$A
M6'69T%]]N9#N97,IA.]LNSQIU??#6C692%@M3C=E@V@%8W&6KR(VF$V'8-Y`
M4Q9;_K[DG!ZO&`L39&6UJ@2WL.R,L-8BOS,E59NTO;[G;&WYM;<\*Q4JIDK?
M)KYFB6X37YF-CT6TLHZRBC=GBEF5Q&VC<>M:"EQ(,IEY+JV3BX[N4L)>2^S8
M44JMBNF'7H]UGT[G75C,BS!%RRRS>5`Y4Z2&B(6#KP->8")@T(S#6;D@7"TM
MF/!C-)GD7\KS*D*>G2H34H34K;/D4779NWVE?;>[(;0M.ZMY=0M2[*VK=G!;
MMLO%B@%G#9UP*&'UX4N>[%+167%00HJ/&;\$8\&V4X_[O,@YP%`<%0YPP"J=
MSV(O:#=;6TYT'T4XVXA3;B%C3RDK0O&4J2K&3WAG"DY\.,[NM7,[K7:L!!B*
MP##5H!`8%`J\*'`P@N*G*8HT0)ALP!L",E2E*2Q#AQT-HQG.<X2G'T\Q6*RO
M")PB<(G")PB<(NGKV+O]`9'\;'OI_KH[TYD_CZBR?Z2[A>8K%.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%U"]S/Y5?V8
M/[H>X7_JP"^9CT3ZBR'HE?OOR_R3G;?^YFHOX?\`5/#/3",](+MYY@L4X1.$
M3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%T
M]^WQ_*`>]C_&GZU_ZENF.9.X#S?JK)W`>9;0=ZQ'8NXT.G4/K3"GM70C:I%X
M)69-O*T$*(A:J"3[I5096U!@%FF^%RVE#KT)X7F+A@T'P1BONLL+<7B"G2H*
M=*U>(;%]Q0Z^^=K\.\5@+:1NR]DB:V5TW3'2]%;IZ^PC^NM+RUR8SC\I=]C5
M>E-DY,G+Q-;I!SX%^'\4WEB]E7LK'7?L/WY?F"X-3U1LZ')$6FGACCJM/.,U
M\X1'WPV/V"+1.<K5HF$:F0I$N%+@%8:PPQ[,1Q;9YE[TX<ZT:E`L?O:D]Q'0
MNB\:X:W,[/-]'#'7[8ORP^79>K%\VV-J$&3M(KYBK.,[-U81JOQ+!+'G)1TS
M9.&U^#KF,A3IZTP448VQ[G0,:H3!J)>"/#E@(3/Q^N+1:B]?B"ZU?&Z/%8(L
MZP-OWD1L9\+7E6N6Q)-.B9<]]+QJN^JKY>[*=E9RK6'W"ZK+LSL%J]3D5(M9
M34U_8-*$O0]DSX^_ZI7X=1)V8FB.T*UZ(UC:C,V(4"IAO*&BV)&9;K49Q#ZC
M5>RMPNAF^;=NRCW.1<[+8[U-#W9,`3;BFOQ5.AK@(UCJ0\>"*D59A%6FJ$WV
MW%XP]UM7KRQ<=MS*G\(S)=CA0K$BBWSYBHG")PB<(G")PB<(G")PB<(G")PB
M<(OG2Z72O=7Z.Z=/=?AWM="=SB1N^>R^P06QX7>?1-"8L5?W#O[8NU0+N:H5
M`'"(AZ,)M[++C;TA2_.WG.4HSGR)V'*[&OL+,Y2:U6V?Y8WNP_J:(?\`.+]>
M?O(Y*,Z_84HWK]A/RQO=A_4T0_YQ?KS]Y'%&=?L)1O7["?EC>[#^IHA_SB_7
MG[R.*,Z_82C>OV$_+&]V']31#_G%^O/WD<49U^PE&]?L)^6-[L/ZFB'_`#B_
M7G[R.*,Z_82C>OV$_+&]V']31#_G%^O/WD<49U^PE&]?L)^6-[L/ZFB'_.+]
M>?O(XHSK]A*-Z_83\L;W8?U-$/\`G%^O/WD<49U^PE&]?L)^6-[L/ZFB'_.+
M]>?O(XHSK]A*-Z_83\L;W8?U-$/^<7Z\_>1Q1G7["4;U^PGY8WNP_J:(?\XO
MUY^\CBC.OV$HWK]A/RQO=A_4T0_YQ?KS]Y'%&=?L)1O7["?EC>[#^IHA_P`X
MOUY^\CBC.OV$HWK]A/RQO=A_4T0_YQ?KS]Y'%&=?L)1O7["?EC>[#^IHA_SB
M_7G[R.*,Z_82C>OV$_+&]V']31#_`)Q?KS]Y'%&=?L)1O7["?EC>[#^IHA_S
MB_7G[R.*,Z_82C>OV$_+&]V']31#_G%^O/WD<49U^PE&]?L)^6-[L/ZFB'_.
M+]>?O(XHSK]A*-Z_83\L;W8?U-$/^<7Z\_>1Q1G7["4;U^PGY8WNP_J:(?\`
M.+]>?O(XHSK]A*-Z_83\L;W8?U-$/^<7Z\_>1Q1G7["4;U^PGY8WNP_J:(?\
MXOUY^\CBC.OV$HWK]A/RQO=A_4T0_P"<7Z\_>1Q1G7["4;U^PGY8WNP_J:(?
M\XOUY^\CBC.OV$HWK]A/RQO=A_4T0_YQ?KS]Y'%&=?L)1O7["?EC>[#^IHA_
MSB_7G[R.*,Z_82C>OV%4(H+[AO9_W!^A&[MX]#1G5C4W55/:>;:K2KM=J3=T
MPW)W3I7ZB5V#"KE.%`B\;X8W`:PXYA$A/D?\RL(2A2LNR&D`U)3``@%;@>[5
MH+;7:'V\^R&B]%5N#;]LWD/1<4RLDK"(JD(S.K6U:);YD)^Q'7XP@5A8FOR,
MI=?7A/FQC&/'.<8S&D!P)X*-(!J53OY8WNP_J:(?\XOUY^\CEHSK]A6C>OV$
M_+&]V']31#_G%^O/WD<49U^PE&]?L)^6-[L/ZFB'_.+]>?O(XHSK]A*-Z_83
M\L;W8?U-$/\`G%^O/WD<49U^PE&]?L)^6-[L/ZFB'_.+]>?O(XHSK]A*-Z_8
M3\L;W8?U-$/^<7Z\_>1Q1G7["4;U^PGY8WNP_J:(?\XOUY^\CBC.OV$HWK]A
M/RQO=A_4T0_YQ?KS]Y'%&=?L)1O7["?EC>[#^IHA_P`XOUY^\CBC.OV$HWK]
MA/RQO=A_4T0_YQ?KS]Y'%&=?L)1O7["?EC>[#^IHA_SB_7G[R.*,Z_82C>OV
M$_+&]V']31#_`)Q?KS]Y'%&=?L)1O7["?EC>[#^IHA_SB_7G[R.*,Z_82C>O
MV$_+&]V']31#_G%^O/WD<49U^PE&]?L)^6-[L/ZFB'_.+]>?O(XHSK]A*-Z_
M83\L;W8?U-$/^<7Z\_>1Q1G7["4;U^PGY8WNP_J:(?\`.+]>?O(XHSK]A*-Z
M_83\L;W8?U-$/^<7Z\_>1Q1G7["4;U^PGY8WNP_J:(?\XOUY^\CBC.OV$HWK
M]A/RQO=A_4T0_P"<7Z\_>1Q1G7["4;U^PGY8WNP_J:(?\XOUY^\CBC.OV$HW
MK]A/RQO=A_4T0_YQ?KS]Y'%&=?L)1O7["?EC>[#^IHA_SB_7G[R.*,Z_82C>
MOV$_+&]V']31#_G%^O/WD<49U^PE&]?L)^6-[L/ZFB'_`#B_7G[R.*,Z_82C
M>OV$_+&]V']31#_G%^O/WD<49U^PE&]?L)^6-[L/ZFB'_.+]>?O(XHSK]A*-
MZ_83\L;W8?U-$/\`G%^O/WD<49U^PE&]?L+D^VAJ?M.`W-[AW8/M'H0?UR*]
MJ]YZGOM(UQ"V[2]S/P`%#T#1M4SW9UKI+<0?EZ26J2WDMN1HZTH>QCP5A/G5
M'$8`=`1Q%`!T+MQYBL4X1.$3A$X1.$6+#A`M=@-"J^(%@Q;#DAUD:'@1!D!E
MV7(=ERW6H<)IB.VY*EOK=<5A.,K<6I6?'.<YX193A$X1.$3A$X1.$3A$X1.$
M3A$X1.$3A%_-&!=T>P@Q_MCV![7^XY[G-?TN$]P*T].]74SJYN[$6P50N5E[
M'O9;81F'=\%QY6DZNHX&$P.JXYN)..2'\L-S(J&?%7(H.``K3I6Z@Z`*T7<9
M_NJ';3LWV6V)WW%;\[-[N[&@*%"TDG7<S<5OL1]T9"*G=PQ9!@<%/DRBJQ.L
M@\1"<F1D.K4VII#2EK]/"LX2`"E%B\``47?U>_<0CTCW%*=TN?H;$O71?6;S
M]LW4V:5ARJ]@3=4O^V=>:577OAO)*E6K26HK&<]?#V'$N)A,I1G,E/CAEJ*K
M"F%5&KI[M6C8D_KN*U73=F[7F=A"?7M^$X*I-F@1J71.SFH=T;=U5>+#YQ$E
M7EFBM+$$3H&<LOCV?5D/J0B.O"F4]*N4J#Z,]YW0FQ>O%`V?=J+ND)MZR`-(
M+(:%I6F-D7"]6:Q[GU`>W*.FZ9`M`V#6RM;,T^C64@V>:::CY'@)+J\)RIA+
MU+"#3H0MQHIL6]V;0-DM5-K>CW;)L:$3O^BZ^>N?X,]I.44J*WUJI.XZ/6-;
M6D/5YH^S;ALE%)09L((]\.AE"G6YKL9[#;;DR'I3*>E>(3WFNE)B)39<J;N*
MK?6_9UTU9(C732]WJ\JE$==W>B:NNMKOK92"RFN:_KFU=DB*Q),94[';-NOL
M9^B%-7'9')E*FW7?W&:9VA[;6S0FJZG8WM:UC1IS:$+:]HK5IJ3-Z,5_>9O2
MTYW7+)P5%&W/6[Q"NS<QS<1Y27GX^<81AI;3C@M(%2H1056F'7CW?]D[1-[3
M$[1H&BM3$Z3N/0>NY6NB%UVHSNO4;NX^R\+0[M(WKJVPZS!V.-9'1!".5#6X
M"U/U_.E/YC.$66FLRG:6TX*EM."VB%>\7U`.C7R`0?V"+2)<[5T:D`X77O9:
M[#MF!O$AM0=IFR:H$K#MOW:K;.>TX;6+GQ_!C#+33DC+"',9Q,A3*5A]I^\C
MU?H6OHEVKM=W+>5W'JU;>T.G4Q]5W(#6=JC*QJ"P[K7KT-;28?,>-=F:369<
MDFWB._'#8CO-2G$RF_AE4,-:(&E6*][J75D!KIV_WZ7L"D?)DVF'<P!77%OP
M:J5AH/4L!W2O0.>/R+;G+>`:3L+,C"L-8^(()5#1C,C&4<F4UI\W4F4J*3?>
M/Z5`9U@'74MM?74BJZP/;/L:=@:=N]66%37]=N[CEZ])1IX_$Z%M>1IS#-K9
M`N-)DJ"26G%92[E3*60IE*W4U!V2UGN+3@#>4"09H5(L,B?#CJVR,_!Z1BRQ
MQB8$6V\DU(2,F1)LR$I4&;"E2QY&.I#T5]YM:59A%#10BAHK""[2UE9"4<-7
M=C40\7EX=S%%!;?7RA*3AAI;[^8\&"0?E/898;4M?E3GRH3G.?HQGD472]M;
MW(NY^CK_`-THU_T?UI*ZTZ@2^O3TZ90]A[C.;&N0;M!LL=5]:X$5:1J^+"?/
MAJJN4^7AM2%J64PS'@_$H<RO&8:#2G$K(-!I174>]X#KO6)C5G.JL8O7;]&5
MZ=5*4&\AM]L;GC]FCW5^?K$I3#0H=5`<J!L"MS(3J)I>/(1(8RYG'PJVGES(
M2F4K9O>??O0G7O6&D=I[`8V9B!V&(B1>K:<'UG:)6S#4\E22>Q)$"509T0:>
M%EP]0"RI,D<^V@FMYGX6/'D2UML+@:2:!0`G!5C9_=@Z;5&\[DUX7M5WS9-+
MQIS1!B%K:VS&]@6P-9]<4:PZTU*EJ!F7?]F5J^;?K`.<&BM)DLE##;/W7HRU
M1[E*N4JKIGNP5(IMEK60'5.R*)`9C].B9"Z[YUSL_7$&(OL[V'N&AS5#*`GZ
M:X4JU]J,VG/YAN$%($D)2)2E2&H,)V8MEP3*I1`]X;I\7KBK`&C;Z,2R5DHX
M.@4^#H#92KUN`-M*M;.M6JMCZDJKX9@C=M6[*%Z<L>!1YG"(2G1RDR%,86VI
M;(4RE6WM3W'^M&IM%Z)[$%)6Q[;KWLG756O4+>NM8VZZ6FQ@6-0V#>Q`C*JX
MN!DH"CA]754B4FKG)CHB(B.(<RE>,)S,IK3J4RFM%`*Y[MG3BRUZRV6.:V:*
MA56J;KOA2%9-1WBNG,T?16F->=A;);(X(L+BE5A[-IO:H$[7LK:0\7C3\(;;
M2^VZTBY2KE*@FV?>%T!3:GO@WK2A[EW,6Z_WK5NO;;!J^NK.@'-L>Q-KZ_U2
M3%"K%'%E$*.4PCL".\\/DQXT@GE'D'_$-J4^V#2IE*L3L![CE,ZS=LZCH?:=
M1LL76EKT96-H2MKUZKVNS-4,W;-Y"]+C?PFL"!4@=1=>-$CL'US4UY&&9,G"
M5(])MYQL&U%4`J*A6MUZ]P#K+V;(;B@:QMY/"=)1,'K01M==)U029H#IJ[UN
M'M2F3RS;35GUK/L&M3\1DHSX(RX+<4I"6G&''H6D<4((5#RO=_ZEP]9`]J20
M79)D-:219RI@7.M.W$76V:Y`Z^'[9-[XK-757,3SFBP^LBT4U*L,?U&8[,AJ
M.XVF<XB(JY"KE*Q5Q]Y_I-2[/9Z[*F;J/0ZH_9D$;O4-%[#M&N94&AQ-<F]C
MGA%W$B7P96MZYIVV`!TS/9<5&C"B+:TJ<>SZ'&0IE*QFV/=WTH$@[+!ZD`7*
MT[(U_?(-*&Q=@4:ZZ]UQL-VK]M]7=4-[9UQL,D'^4769IZQ[-AOSD0<N(SB5
M%5A66EOK993TIE/2O63]Y?K(1LM$K.K@FR-COVGLC1-&&B,>DV00,"4J],[A
M1`[#"9+HF9BT:>48T=8(31!KT$N9'2)"O)';0XZRGV$RE8^T>]AU&SI.V[-U
MBG9]]MT*/:\4K6,?4U[S<+/%$:5+;Y`[*DU\>*F&1VCSNMQ[9;ZR*:]-J$]A
M"FL2\9C8N0U3*:T64W5[F<[3HGV[#Q^CBPE5[:T.Q[GWE?Y\&\6*EZ,U)K;0
M4;=^R)L6=5`LIV66:8G)9@OSO1C(B1WGW4*SA*.0-K7R(&UJK4HWNE=:=@V;
M55`!U_?\;:.V=DGM7P-3G="[#![(I)JMUW75X*G-I5@@+9DZ]H[6NMK@K&@T
M04V/=#S/40XIUMQE+*?43*5,=E>Y%U1U!8-AUC8MQ/ULUJJR;"KEZ@OTNR2I
M`7&M='5;L(>L/P\"#*DSJM/H%W#MBYT=#K90T3CC(V')J_2Q,I*F4J$CO=9Z
ME2JM:K(7F[3II#7]%VS?MD4*[ZEN=9V1K@?I2TZGJ=["W6FSX"20>T1Y.[ZQ
M,A0OVQ1$631+C*<92I6+E*N4JPA_N#Z!(ZT[-;C:A;8CZOZF7&Y4;:MUGZHN
M$$)*-:VM!FH;+>H+TF`V[L`+KLP`E8,3AB'HL5MI2O.KRJPF936G25,IX=*K
M^V^ZWT^IUKCU0A8-@DLHOMOHUDLU;U?<K%2Z#&I.RQ&EC>Q;_:10Z2,J^J,[
MA,)K,<^^KX*24BS/)G,>%+?9N4IE*K/3GO&=;=A(U`)OE<V?I^\[DV+>*()J
M]GH]A>B5",([#V7K9K>S;!L?RR$/K(?;^R0&!`AU:5-_.OB8:U83$=D<%A5+
M2K"V7[F^KM/;^[`:+ONM-Q9E:8'=:XU3)4B@62^E-Y[![)(ODJOZUU97`0M3
MQJS"QU)>D*0E]25QXI)YS+#(Q]S+*2*IEJ*KRW9[D-%HFH>G6_\`5%3M6\=6
M=J]PB]?0X]%J5M-;-9!D]1[@V!ERLZT@"560E>1EBUD@5.#RVHC@_*Y>9*FE
M15)X#220>(0#&BDVHO<]Z@;TW%0-*:QO)RQ6/9]*`W&DV!-.L$*C&)MBU=#W
M=!UY]:9L1B+#V>QJ"<BQ2@KR6Y$2!A:7<ID-N,)%I`JH6D"J]-J]SCK%4#^[
M@A)K<DN)HLL[4#-M":2V,:HM[VC%N=+UO.TOJ6W#@;X?86WX6Q-AA@:@,-SX
MITC,6AGU4Q)JXS*4H5YUCW.^J%K&M3X1V]P);4+6KAZNGM;VP+:*:<V?V?(=
M.A5*N8&?`:GUR[5[L`)DAS0Y].'1K3.9:\YB*;>6RE7*50Q/WG.NI/%/9U9K
M_>FPI]JW7UYU>B-(U/>*FAZG[^V9?M5Q-PUITJ!=^MM)K5PU98!CSD=*,/$X
M26D+PTZV^ID/2F4K/*]Y7IV:I%BLFO)>TK]8HMC8K5*H5=U'>"MRV5$+T;8N
MQJWLRE5L<,DES>F2U*U/8BV;`VVEIF`(?RM"75,-/,A3*5NSUNWNSN;JKH3L
MC<F0-"1MO1NK=NGX2S2?JY5I&P:4"M$H:T=*I'^J.'2C'H-/OI:4XE*<J2E6
M?#D(H:*$8T5BC]O:F+3H8L5M#79,F0D-1(`X?=:U-G3I;ZL(9BPXD8FY(DR'
MEY\$H0E2E9^C&.12BZM;9[C.]:3VJV'32^F=53NJFNNX^A>E!^]C]AVYG>L&
M_=A]7ZKM]*O3=!>I#U),4B%<]L#0TUAHVT30RXJ4VTYAM3:LPT$>6BRIAY5D
MYGO,]</KK0:O`I.ZH`TCM386O-Q';SJZXTA[0P*B==K-V0;V)>`)$,^2CUBP
M4@!\2VE[X69"@M37Y;++D)<=;(4RE;4:?[[:&WEH+978?7[&SB%9U')+0+Y2
M'=7V[.X!!4?50%[@"&M808$ZS$25HI5L$E!;<=IW$F&295G*%8>2U"T@T4((
M-%18;W@.G1QS5C,-_<&'=HSAXY6<Z>N$B'K200[#3^J>5;=+#XLT+1(L/?L)
M%><>>DN,K?E,/LJ=BJ4^AE(5RE2+K;[C%-[5=J+II+5-2LKFL:MHA.UQ&U+5
M6;33_P`(!!K==SU#(F:\BGQ<,?;M93'J:^[!.17E)DNH5CR);RTMP6T%4+:"
MJTNZV^\#L7;!*_0=J470^IR=6W9UVUJ2U[*NFUFMRZ>?W9OY>FY^O=[:NLNL
MJ_9A5S'B\L$!-L$LR]>E)+ZV,DF6HZI+E+0$+:+9\3[QW4`^'64!B^PY:5-G
M:KC4JMP^O&S%6K:<#>D3;I'2]DU>#=#M2KA5MFC-(GI(P@SY8^&&FER51\._
M<S*4RE1WNC[GL+2W7#I[V*T,YJ0U2.W^P*L!K5\WZ2V72:)5:9;-*[$W`*LU
MAAT*CW6_,$I::4P-Q!2*6XS*F_MWIX;5G`-J2#T(&U-%AM6>\EI.X:NT++N@
M:14-Y[TT:.VF/IP7)2X:M`6"U0=G.:LJQW:L84.CA'=UR=1&G:U&GPXI-;#"
M6IL>)*<:9<I8?40M-<."S5']Y7K"_0*,>VBU?:K8B6BJ+LV_D:UK6]VG4E;V
M.>Z]5KLQ;M%`MG1PR`M@VC4-1'E6-T.G.)F0D=;F<8D(7'3,A3*>A;9:&[Y]
M:>S&QK'JW3%SG7"U5&3N"+8\1Z^6C"13ND=GC]0V]4@Q)CMP<LD+B0\`RTJ4
MDQ"8?E1LK9:4O$((Q*A!'%;C<BB<(G")PB<(G")PB<(G")PB<(G")PB<(G")
MPB<(G")PB<(G"+XO-:^P'[J>@=J=@+CI?LI[?Q:G[CWZ4[!@J?O?3MOV^/U]
ML\5;[@?U5N"G#;'19<&J;EUV/M\B/&*15N,JPXI#S4AM#>$[<[3QK5;"X$47
M8G[%/L[]C_:\O';2[]A=T:JW$5[(8UU-9(:\3<_F39ZLF=C&[06LSMK!!FWG
MSLV[H=0ICS^+B7<JPG'E\8]X=2BCG!W!=@5O]ISJ+>MO6?L19:_8"'8JQ=A:
M/V'B;Y7,!8VE4R&OX%1`@=6U*QYKJE"M,NT^I?)9813;JI0\G/\`-(]=_#S>
M.8TIT+',:4Z%7VO?9VT9K6'6&@>\.SDTI1[1UX+TJP'+EKT@4JM4ZQU+<6N=
M9:M%-IU='%N4-.LMYG0)#$J-(*RX[C4GXU$Y*I2V<JYB5GI?M(:&C`:-"H^U
M>PVK[EJZC]>:%K3:U%N-.C[!I`GKGJ3:&C`$H5(.:].UN7/N^K]PG1MB^-&R
MH\K+S3\5J&_':<2S%,Q6:&^U!UJK%#;UWK^P[BUP#&[,T_MBJRZ?=1L<[2K;
MHWKJ(ZST*3631:M%IK&(E*",$7W9"I,MX]YI?K)3GT<,Q3,JGI'LG]=:0-Z^
MC,;@["6Q/6SU@6OYMUDZ--D%ZND6.AW25J(E(;T9"2S6IEUU[&*/F("8-Q?>
MGDFW#*V)[[6;G*9BMD.L?MT:?ZJ[7L>UZ+>]Q61TE0[%JJHT6^6:NF*%JO5]
MBVN<W.Y1=?CAM0"&VA0VZV6;F,^5(%)R8+C<5;[C4>/AJ%Q(HH22J>JGM`:!
M`&F#-BVYV4VFJMR-5C]60MI;%`VEK46NM1;]KO9*O:DJI'%*@V$_2">Q:F.:
M(/62:</.AX;4)DBPA&%<9BKF*UUZ0^TOL#5>Q95W[&W",X+UB4ZXQNNE.U]M
MRU;*%UL#UH+=CI-+%NSM@:OIQ*JZUC@]_P"1X^K86;)0\#O6E6&<XYC.*75&
M"%W4K3@>QUU.'E1LY%YWS('#-03-,L@YEGH,EI=>)=<;QU:(S?K"O6GUVB/2
M-8WR4Z@=%*1Z^P<1@DV/3)=DJ?9RF8K-V+V9]"W.587KGO'L]9H5LIMEK]C"
M3+EKJ(&*V^[]3873&\[=>BB]5P76MBVG30B!AW+;B`T8G#Q(C#V</2&GF<IF
M/0K3MOM<:&M6\-I[Y9N6UZG:=OT*54+9"J,_7PV.BP/ZE&:/:V6(L4O71'8$
M"UP];A8L1(_)E=6>?:S)D"7GW7EN3,:44J:45F:`]OGK5H7KPYUD720FW]83
MK_:-HFPFX:7K2P5\G>;;87K.1*0M=`J/6=3U"!"*/>8>.!`!8X?A/BRREQ3C
MBX7$FJ$DFJM>B]1NJ.K[0-O&M.L77G7=T#IF)$6^BZ6UO4K0*20AOCIZ1M@`
M5H>6@IG#Y3K#V&GD^JRXI"O%*LXRJ3TI4JKME]#=-;5-=C#MC,;`C3.SLSK-
M.V"D0<$Q6![W5*U,7#6^*JA^ORUC4$"D=*2^'U2LRF?%+68^?NN`XCU$J52M
M]]I_0%YSLN1]>=O`".TOPB)L+\6;K:RB'(^T.S=D[6VH5.I6P-9W"B6RMRMA
MVJ5#^5GAA4>L.EIIQI<EI$O%S%7,5G-M^UUH+;?3S471^=:MIU[2NG*X'J`9
MF"3I%K+62M"J@1I/P%QC[0H5^J9.;D84<DPB,<7$)`2C;$L0^/=8:\K,:UZ4
MS&M>E5X][-?5E);<9(/9-NUN/MI`LM`@A#5'1-U=L<1:=8WN'MNB70AKXAL<
ME>6+QJ$*5919C-A#QI/QB68*&9\IIQG*9BIJOVN-3D[+6;7==V=E=E%Q8K1D
M:XO["OU:LSFUSO7KL#:^QFO;5?9,NC)FMSHUMO9D6N`%=$!&JY.P/BP8R(T1
M;#,F;J6/T_[3?7W3UAH5GB;!WO>"^I[#K5W5,C8-TKIK\'FLM-4C=-#U5H<!
MF#2Q*W=5TH7ONP/L_&*E'Y<M49<PG(3&;;X+B4+B5:1;V\-'&-+];-%2C6QT
M4[JUKZWZVUU+8/AD'R`"Z]<;YU?+/VN:JMKB$R;.O-B3I##D>/$0@JAEY2%-
M(4PN9C4GK4J>*H+8_LV]<-B"2@QO9W8>COGP!&E6(S2+I3H)@YKRP=4]7]/[
M=0)3QC7AR*P`MVL=/`Y4QUAEHB@PPX_&DQV751^4/(5S%>=Q]G/KO=;ON78Q
M'9F]X5TVY2:]1HED$F=:0CVNAM6V/JS;("16CZ=7+.V]RO7C38-\1'N<FT0`
M,1$B$,8B0Y+K.68^HF8J[.R?MTZD[2;4K.UM@[!W*)F"Z)4M772GTZRU@-2-
MO:WJ.UA&Z&:;L<7*IA,F\-+WL!#<F.B)@B6N&VY$;=:8DR4.@XA0&BY76#VZ
M=!=4H&Y@-%=M%@J&YH\L).I]M12DAZE1IQ2YF)-#KTRGTRHV,P(>F7T@A<ZQ
M3SAQ<5,6.J=EF*RA,+B4))5`/^SQJ.3K*IZWD=FNYDAV@1;!3*%>9.VJM+M]
M*T/:]7"=,63KE5V96N7J:(U>=UV!@L2I+0C%I?)Q&2JRZB3:)6+G/4%<V-<%
M,"WM&=520.WUB)-VA7ZU;P'9&JK"`+0$C0J_7>S]-TC0[N)KGQE5GO1(]<KN
M@0;0++ZY*XBE252,RO51AMF*F8JG=6^SW47'-E&]_P"UME6TO9-U[ZO.NJK5
M[<*_!WJ>H[3[EU;M<VFFCRFOHIN+;+Q)U54HMJQ.E%(:/@Y;0OX9,IUYVE_4
MKF4_J/LY]:J(+?"52[;@""(V[J1N:J0!TK5T%--BTJ=LU[&K8,N%JV.1M%`L
MPC<5@%$W[&^:LCPR2PTV5:5"B.-3,2F8J*"_9)ZT5_5@K5M8VKV$J+=>(V:'
M6[O436IZU>`FKKAI^3HBQZ7:FA]01`16FF-;R,,R"9$?,MSQ-I!)9C,_'KYN
M<IF-:K:_9?M\Z!VY0=):QO7US*TK16F-DZ&KH=L]%A?6"@;4TGG0EH:M4N*)
M;F/ETTG/J1)<%R`N,1\'TX^Y2C&.8A2I47T1[;^I]&[/JF[W-F[PVUN>O3]D
MD3.S-LVBJE['?G]C4'4FK4MW%JLTBJ!EQ:3K[28(:%:'11R&L(D/R<2I,EUY
M5+JX="$U\RJ&[>VD#W]W"[B;RWN+KT'66].J=+ZF4X-0+E9E70J+^:R;;?\`
M<ED<E@`XG7^RHY*!71`10MPLKX"M1Y$B1]TF(TS4``ZU<U``.*Q%K]F+0MW!
MOQ+-O3M(0N-M_"VSN_::+OKV+?NPHS<LW3Y"S`]H.,:K35X@88]H.HM#&*X+
M`?"1!/P_BMJ1*2]<Y\B9BM]:'U>U?0M0[.T?':,V.@;>M^_[A=A]HF1"#T]_
MLG>+G?=CAFW(H^`R@"HG>YT>&RIM;C,+TVW''5)RXK&IK52IXK2-CV;.K8ZE
MZ&UX$MV]`E-TQK8/IRUAH5[#NI[(ZO"[6C;R:J/8*:0J4V>?:(;:;DF9LX&[
M7R4Q10A&<D9AS'F,W,5<Q7.K_M#=>*YM?7>W8E]W%,/:XO%OM0T<8D:K,C25
M=LN][/V2$:PF3"6JY-E$TBC[;NIB8.=#SQAR3!)/0"1&?#PTRVS&E$S%6AO;
MVY=9[SVS;MVN;7WCK/8ED9T83"F=:GZ3#3K_`&-UW(;$7KK:U.BVN@6UC%MQ
M6-K'Z^2B$L$0!(,2<;>'9?PW(0#B!10&B]MF]N34!+K]USZ^4?86Z]/#>J]N
MC["U%L;7-M`8VA!OJ*;L.G$;;8#=TJ-Q!V4I8T[1,D":9(W,>60E96IO#7BU
MEF-:]:5QJHCU[]J3K+U?W14=RZAF7T,]3J)5Z=$I)"32"]<*%:EJL3I<=?C5
MAF45>T9-IE:_"L,2XS5A9`R)WGGJ'?&N+?R+B10JEQ(HO&V>UII^V&]V3E;G
M[-5^M[AO$C;XK6]9V8+%Z]TYOR;L>B;>F;ZU>!549#B]DYV;KD<8C*L;]@%C
MGWI[<.$Q')3F7P=1,RAS?L]Z`:+T(\UMSL>V6KI0#9-E3DW:EY?[%W&M]I?R
MR1ENW6MS73F9A1.^9,TBMH!\@AJAS50L,XBLQ6V&<^1,Q4GQ[4/7Z&'I`T#>
MMU5R?KH9H@74K$,LE0>+CT=?-^[#[#U"2\V4HI`//DF+5M`N.*X?BN,R0[J&
MVVV9",2<LQ3,57=7]EGK=1*7!IU`VCOZ@NUB\MVC6UOIAC50"XZRJV=?W[5)
M#5M=*0]2)C'JB;USLTP+FS[%'-VB1AUB2HK\7$C/M,Q3,5NWJ+J)K#5.FOR>
MR$VQ[CTLQ2=9:Y%:WW@FJ;`J06EZMUQ4-<B*_#"/U6`/F0#;=.:,$T3FY>'S
M<N2^WZ3:FV&H22:]*E>GI7.K?2OIQ3;`%MM0ZE]9JK:JV2B&J[9JWH?5@.P`
M#$!W#T$L%,BZK%)"B4-Y.%M/L.-NMJQXI5C/%3UI4K7BP^V+IBV]C;;V$LFS
MM_$X-TVY4=^G-"IO(`7HJ1NN@:QK^J:-LE88-3!U]?.5(%5X$V`R]8G![)B(
MS-^'R\RSE%S&E%<QI14/1O8]ZLT6IPZ;&V)OHP&2='SC+9$YK,<JTU=CKO?>
MJYJ@6%-4U76X\L'<],[!E0S1%"&[+/)-(**)X(.29#]SE,Q5_P!3]LW2]5Z=
M[5Z7XO6U"M%V_P"O]9[PMW6E:V!'P@?6!(9D8U0M:U'7N(0<93X#2X\D!)8+
M8^(R41.S,E>K,QKF4S8U4-I'M'];Z.!G`HEMV\4024#<FS)I:A#EJ?!]OL]V
M6U0Q=7UU7JX(BRMR..-*B0H,>$P"7\%'99\C;J&8_-ZRN8JS>L/MTZ@ZJ;*L
M^R*1>]QVK)?7<W3U5I6P+/7S-)U;J5_9MJVQ`U]K^"*J((TP'"6BYSVXSY.>
M3(?`*9CNR'$1V/3%Q*A<2J<J'L_Z"KA:(8L>W.R>V9%8DZ<'ZP:VSL,#;,:M
MUMH_=D#?]/T[7R#5+&'K%0IU^%1$$W[%,,V*4*BLQ$%&4HPK+,?(KF*U[Z*>
MTWL'4-^=O?9"XL26M8E>ML;KU4Z%MRT;-%5T#UE%=EJ[3Q<HI?M6TDH`UPU6
MNQKT$95\?-B,#`M#TNP$7G5JY2ZHP5+J\%NS;_;BUF?T/U0T15-O;[U+&Z8F
M*^<TELO7%CHC&S8$^O:RN&HVEG9]NUS;JF7;(4R]$&I*?D[6%N.)6CR>7PS,
MV->M8U5-TOV8>J.OK9K^W56P;;C3Z=1IE-LOS,O0+!.VS/DEMMV-J]WZS'-<
MS[?!N+5IW?82;V:V0KXPA*=BIF0Y$>#%9:9R5<Q6;I_M!=9J><`O,VW=1W7X
M"HQQ,?2MAMU=G:KF;"3UBB=.R&\R`F/389Q_:AGK_$^3R5)((!?$.N3VAK<U
M7KX%Q*9BK7Z4^VSUOZ$D+>6T8W=GBEXUOH[65@GW>PQ+#)D"-#U8C6`1=IR.
M'%99LEQ44>)6.5]*2A56'_(UX81R%Q.!4))6_P!R*)PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(G")PB<(NH?9VN.W,G=&_MMTDQ>H%:J>YZ)%I%9@
M["V\_/V?3W]<]?X$VE!-9R)C&GZQKF)<B!DG-LT!EXPN5"FQG5-QW):LYX4H
MLL%7`?M7[@ST'629FM2:S9@U/59/)H':CX%F"2#U1@P*,(73P9U$O5%N+$TH
M3'0.C$1\)G+10L_ZK;JC4H%<767L)W-ONX=8UO9]%G!==D*B4^L)@WK*Z@'K
M2]"QLKXF]#BV:.*$UQA@_7@,&!#-JK9&>-)YEJ"MN2&,1H0*>5"`J8,]A>]0
M'8UH)"JOLPY)-737(5ZIOZ"O>-=4MBN[&V>-ME!KYYJ(68LJ2=$)BBCMG@,M
MQ"2&4965A(CMLNVC4P5Y=+=K]P3%]@4#=P>P3JA6]5)3,/V[7MOK-ML%A$"-
M?.)MDL[+J0VFN%SMQ-680\-25R\I@(Q*9B-,^I*EP@="&G0J?I79+W&;.P<.
MPM:E'8=5FQC`FLVC1EDK)'9";3/T>*;HQ`@06!9J>*&_>[.Y(?@X))0H#Y7"
M4UB+)ER;1J4"L`?MCM?6.J>R=C!IVP+ML63V$==!2[=H;8@.R%-</!ZLJ2-J
M.J'P9HM68N3#$H=`>EPDB77O.MU^$B1DC&F%:)A55R+[.=P9VT@6GQZI%%M%
MPN]B#1J<;TW8;>5JNNYFSJ4^[N$E9B5P(0XQX+6+P2PNMR)3L6(+'PR#:/ES
MK2Y%H*52@6P]YW?W`$5CIU)&4G$(K?0T63OJ8YK>\%LP;1'+ZU%R:T[7*W6[
M:0I3):M';,90[-<A1X\@,RTN;A&%L2I08I0+7![MA[B+;5+1C2]BS;WH%Z<M
M=87HFVQZW@=D'LQVBV&$9B2#R9I=L=5ZP:GBW"@GX8A9E`TYG2L9P/M&I0>H
MO27WUV\UQ;=A[:P3V;L^C5NOA7JT$N>EK)J&NW<7:BNE-;@L@:V5>B)@WNP6
MJ82)LQ7W$STHBS,H'PFB#4="@X)0'!;)]GMU=NM:[!U?3=5UZ79T2-9R9M]L
M433=SMM(D6F54ME(=.QYE1'GRK.*U;:J'><%>I!?3&+LMM)+/2DL1(`"H**O
MMNW+MYL#KMU=L-1([6H.PK7:K*`V*FO:U)*)O*3'L8VK6&Q@X4(<4`U:0\'9
M*L29+`1J:R\RF7&'*D_`M,*E7"JM#KUN#N'8NPTF@;@J<8?KX-5CT-1E6O[=
M7?K+FOJ"Q0NS(IK(&53ADZXG'B,9T'DXI]N/&0^Q"0UC+[X@4P0@4J%KP0[(
M^X76&*!%(T`[9CQPOK^TD<#]`6:""6"N,'4WUPUO.?%JLTL:1URJU'9"'WU#
M5.H&K7)GI5#7"G6C4P7JLF\/<JI-8C2I@ABU/G8T/,\Y&Z_VT:K7JHU2U]:\
M2/D%6C[%.61=ANEXEU=<=L<^N+#$Y?\`%MYF;,2HU*-5L=Q.SO:G33])*:_I
M4K`R'H^P;`VA)7J^T6RC!C+=#V$2GON6,>RI]GZ@6*M#77H$R4!RN//:3ZLY
MR5Z4.``H`%2$GMUW?69O=?I`:??R]/`0)0@:0Z[7NGS3>L[+-W,B%V`LCKL&
M6]5K8/9I`C`ZDK@))&&7W'V1\C$EI,6T"4"DPCL9W_M%ZI%*@5$H$A60)2PE
MBNTG05W<`UY12_ZGCO;/')/AJNV\LIKZS'7)44J^+S`(#7TY#LL0LR)DHU*!
M7/3-Y]IRO62W6NVB+`$V(&W:'IQ2X0='V^6Z'UB0(4Y=GOM&U!.$#+Y<F:E'
M-3HB67Q*G8\B*]C_`(W9@YGSU!5,*K):*V-W6O2;HK;E=<IZ;-J&]3JF)'ZV
MFUV10+]6!VOH=>PR:)F":3DR[3+@3F(B2L8Q'R(PRWE7I25N"!T*8+4RD[!]
MP.J:R!%Y+]_NTL^JS6F&5V!I[9C!J@SPE`LXY+EC$5EN38BP>RG)+4MH:^#F
MH@OM-YC#Y*DH;S>S598+<$_O7L7'U?UDM;=9OH(K;JP9,[(@Q-!%MA6XQ=0B
MZJS6=<3Z>(L`*/01^R!\XU.R9G2Q,>#D<QAY4%3RHF90+&@6KE>[">X#:JB;
M+GA]HHM8$9CC9UEC=9[F=NLH7<I@]QJUB:E\O`F"9*A/.*%J'C!4C&$252W'
MY;<%<J1:-]56@]5=I.A#MC<Z_:SEV^%<9]\`:LI,6\PK`&+C;<1NXZC!)%EC
MN,V;$)TB7EEUN(6_E];+DO*TY?RI*\XQ/%3I76(6WWV^)R;Y+H%'VY+IU]L=
MRL&M:M<M0;5'68Q2B<&Y#[!)G6%;M?-:<E:K)U`4H.$>^!EG,FG%1,242([T
M:T'2K0*]=#7;N$?WUK5&ZY%C@4>?1MA%I8\9J8G5*LY8K17=4GZ]4;,14\:3
M"F:^='G68,R0]'7+<D2&'?,[Z*.#2F'%0TZ%1DWM+[B@B!"*@M+$]CQY4V$Y
M8(*](V^HDZG88`@$<V1KB!$FE([Q\-6YYAP0"L:$NPS+L5U;;LK+2UYM&JT"
MSAK>7N,5,G6!LVK#;%'/6YF1//,Z9NL$4&^%OFW:<+UQF+6!M]*20EU#4407
M=./-0\#T%D*<EQ6)</RJ-2@5V];ML=MBNZ@5.W@-($*S9=+?7V2^-TZ;I`RC
M6Z>0'3VZO83Q;Q$/RH44BZ-B)A%2,R0J&Y\:/@*;Q+EP@4P0TI@M:*ON;W#"
MTLELF)6K27*TNL$JY)H1'3]OK]`VJ;+6]E$"97(9]=1LE?=I4<JO#K\@?&EN
M)@JAN/S8[/S6;:-3!2`]V'[B&ZY*H0ZI[*L,FQV$4Q1-E"-";*UN:M6MQV-S
M/6JXFFUQDQ-46!H^`JPUF$2Q#E2HLS$J/%<9F^9A0)0*;TG:_;MG37:?9,D;
M<C6RDW'3S55K]AU3>*N(U]%*`-:B]TC->U&:-L!2]B-0/DCTADD-ADV3LH;Y
MD-SU95Z\H,`F%56$3M+WOF'V!IJF6BK5EZEUC%UNHWK=L:R?4&9A[4KLF]U"
MJKKD4M=_K5$N!9"A;R_F4-R&_EP1"0+?7.M&I0+8;2EO[<BM=]@Y]T6<*EE4
MS:VR].YN.J;-"GUBT2MM[_B`*1,!C2UDLEI$M5D#6R,,1'<DD8D":W%C*DMK
MBXY#10T6ITGN#W"K"ZY./`S%2G6LG0X==@VC4=M,3=P6*=:]0:W(!8@?,\5C
M7M:FC[40*0#"!0%LA/\`AFY$*)-4X,>M`K0+LUZKW/=!RK%P>_VI;VP!9(?-
MAFF]<&*$*,5TS1J%9I&$L.NDPK4NNV^SE`B643,REM"O.ZC+B77%8FG0H?(M
M)=@Z\[@_A@[`[CI96^,`:GO*IQ:+3&-A;<E2MKT]ZK]=(F*@+UQ-F1]2T[6H
MZS.')\VQC&W2;[C,V.\IJ.Y-RO($8!444!%]K/<&>':R0]KDFZ9+2#R[%)5U
M^VNZ!S$(5IC#[1B-FF`["S/U;=W)#.8[#`QB?`:CY8FF9#KB.*-2@5V=8^P/
M<B_[DU]7-GT2<"US-I)!1HH=UM<@$JR/06KEAR_PC.*4+!`DO60.-'PX!9VO
MD9HN9B<H'&7(;1'A`Z$-.A4O7^V_;P[<;Z8K=7E;6<U$$G6BU:^K&L[2+7`F
ME+E"&$=.UDO#L2J[L>6W6A3TT#8<,R<351I.([F4K>2FT"4"O2B[$[JW>D]R
MZGL<:JMVZIZMO0K6)>E4:X""4+846-L4!6R=&F%J["!W1BTB@P:Q0D#R9AZ'
M*(89=<9]1J*S,*BB8*K(]_[9EK-JG5P^N;C'`]0FJE6+M9(E*V6#18E#=T6V
MMM.E[@<=EQ+\,GZ6KP`M.EL2IS/JE'EOR/5=<99N'%,%Q>T-@[CQ=P[@#Z],
M[M:I3-Q9E`2%.UY:Y\<74RVE]*"1E6JY,/&<%E1Y[9Q$V_)G-,R"8F=$>7Z\
M6-A_#@4H@I17MJ7=G<4OKKM)8;MKY+5OU>W*-ZTH[5(N;14O)KAV^.D=;BY9
M0``&7R79:15@RQQ`5-+(R1/*4N3E&68S,(&%%,%KV#VY[EA(C-VL0UX0'F:C
M1IM5QI%6OK`Q4-FV5B[0`V+`Q.DV!;M<6[@D[-BRVLK<6-AXPYGT<K5E1O!7
M!7'U]W%W<N%UUG)V`)3G7+ID37K+G&F[E69EE%V.%V(ER;F2*VP-2BM4ETPC
MKRKPEQTA(\-Y)A+BLKQ-BK0-$-%6VP.R';D!L>\1B`DX`H=8W#8*HC:S.H;T
M]7:5K<_<`=>#RPM8EX!JVK=1@-C#R8S<&P193TU,P5-EH>6-B*!*!1"-V+]P
M6UZQJ&S@E27:<76J1;341X/35S'#@I`7J/6A\/8Y2`]PQ-LX385IV"65\LF.
MJBH;#-L-94ZT\^JT;P3LJ\]7]B^R+'::B:+VN<AXCR+?LJFJ@XU%,$+V'2JH
M&W:9`[A?M44L\)HIHJ_1PK+(125((#I*B$9M3$EIQB$"E0E!2H4#$=HN[<O;
MB!LK75P:ULOL!60"&)&A[E#L\JE&K99:R9`QB2PBZ3$'5,.(C%Y4Z29PVN)*
MS*9-.N-X#/6C:)0>JIMO3L!WGJNU]]@M3ZP8L@JIC`/X'*T]KNZ&HMWD/-Z?
M?8)2+O%$!Z=$C6&7:+A$F878,OC4U^.OX1KRO+F0`=*4%%$!_8_NW,M=AA&0
M)RN45K8+8R'9QW6S95MM0L/&QLCZ@P<TA0:N02<+=`^NUR42DQC$Y-6D&G8T
MN6.RZRJ#:#U4H%'2G9'N;8+?3[&T$VAKNFP:CBCWU;'6C81^(#N$R%UNG[,O
M$>J.BY!BWRJ`;EVR`"5$2^-EL)EN1\D4Q\^HH$H%N!UWW'OPU0=AF-[@Y@O;
M:PIVY4G4`;6I,9*%UBJUD#"6S#7-,^6UE;-=ICV68[Y.&[^V)C-YPEER3G$@
M='!0@="Z_)?8OW"[56JW-Q6-@A[%7+2<-4X>,Z^;'^'W%$A4W8Q3*=B2HXZI
M-5$!32_U>80/=8A-6-V6IB.]+<:^*3E0+*@5VS;S[A$2^5RG2523C!*[M5Z/
MM"%I$^,$U"N3MX7S4I"QE:Z/M::O87LZQK0VV(60\T2,\2]=I"8BFD8=E3!5
M/8-Y^X'/KI8.[5=A5`M;]?6Z5(F4[35^(64+;1NGZZ;=N0M5B;,UP2*;LHI^
M'%$CY[,YHG+PRR))JE9E0E&I@LILC>?N!/1@]:'PK_%7:*@:M5AL%5Z\V,?+
MI@N48V-8@J:XIB%9U33H`%1Q(F5'(2(<Y]PUGTATMZ3'=AJ!,%L)IK?/:0[M
M$#C;+9"J:BA(*SKN3FZ#MM:?1L>P$M?TL'H81/)R)+\JNU&V7CUHUJCQY3)Y
MIESRR/0B2WTP@='%,$O&S.UE&[-[;=&.78IH>MV*A7.8+QI6QW-E=!<A=8*A
M9`FO#P)GXDBMJ/9;_8I,4<P3+9G!,H2UAK&6GV%/*IA3RK7`[V2]PDTP@J,U
M_>F"H5&NK\)J8G1MV`CB+DRA'4)UEL!\X,8)L8N-\,P,RUBY)-N%&BY3*<"O
M1'VI=HU6@5M:A[/=OD;'I*MT5QH=I6'5[,:L]RQJ;;8V79ZP,SMUZ3<I33^J
M0SE1LE<DU6LQ<"YC0A1-DLX_$A2L2HBXL('1Q2@]52+N?N'MD&VL[KG2(?8`
MZDNT*&0-6^LZD.6IX9(^"NMGGV&KGQ8HW!*$X#M.@"'1[[T)_'S;TV(,]Z2P
M_$-`IB@`HJLU[N'OP[]5=?)<N$HQ,MHFG6*SW+KK9LNUJCSME4>`5W4]8YBP
MM8.&&G#]A!M!$J]*,+#,&%-*BH6_,M`G963$;R]QM%AU95S%8'(;N;M0)D[B
M2TI=A@D>5O->TY*+:Z*C*\-M_P`F':U3;K1,45(3!#;KX1$>5+QF.^Q*E&I1
MJOFD=J-I7;J+L+<*AXH%M*"!39Q5>=KTYZ)5*C+-3*3$LR4/3&QM[E3I%-.6
M$9!A3%.SHKL*)Y<*?:RZH*T4H*K74)W/[1GJ3'Q7JY<;DY.+V]N!L^O];KU&
M'2->#K%)H0*]S8CC!8*`L#=D'R7B0K+,\I`88<?^2R&DHCO6@5H*J+DMT^X5
M<]>4TC:1-WH<RWG]9L)K-(Z_WUNQ?-:X]UC*V:NEC<1])RH`+ZS<[U)G%9K`
MZ)`8K68/BA6'VI2C4P7-"]AO</-.FZU7:'9JPT'HD$M'GVK0]R+2Q5EI.I-L
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M2\W8>RPE45M^<\TJ,%F*>QYI##2<@T+(`*NHON5WV$.@OG=5T*`T2$D[?7B1
MC:4Z%@_4JC8-SU,M6GG,:^@PD[NOA;2LE=9"1$.PIOQ^49?0J(I+S*E%LH[V
M_L4'J86[$DJ15_K4DI7V!VO!5S=GM5\+?MDBZ)1S.P#$\,&?`)BB3+1DSCX?
M$>/&9?2R^ZA&'\J8T4IC14+IGW"[K>-E(K-V#:6HH$V;J9:)BS;5;&$0]*.Z
MRT60>"UZ<."FPFP;@Y;-DD##"D2(<)5<9:RIQ"LN.LBW!4A;/]V=J6S6FH:W
M8Z!L,%0Y1N_@!,D[+L&NZQ/,5^2"LAF0&H]SVZ!L>F`-M)J%LN0W+0B,*(,M
M.P6Y<6;+AOH@&*@6BJ?='MU>"1Y3=,KUVRY%BJA*OEFQJ.Y7F87UE;KD,FT:
M@#:I;$QP`:;0U)L33A$F^%P<C^25,0TWF1EE"N5978_N6;.!G'=:"Z9JL'L$
M9..5BU$Y=PL),!6+70MN$*I;)RFR-4`.SZ6:I=9FRX,EOSO0G);*IF&O24VZ
MRCBE!Q7N)>X<(D64SL76FB]36`X.UO26[UL--U'YLPG-N=ZY0H5$*'AU.]9P
M1KV\=A4.GV9Y&$@="!R'?21)=PVRR]"4ZU:.O.^]TVW6^P,0;2*?1+K0>MD_
M<-!8<NL>_,RC#-$B&%NV&54X!.NPPD2RF8J&V'9C)1^!Y)*(KK$A+C<+:>:J
M47#T?W@VK<+[J71\^H4BR6D\<BUBW7*1?G6C0&#21>U(NP35\JP#7(P=7]@W
M.;J&06K09EN)!EBBJ'5NQD1LX>$"E4HN-LOOGD?;3%:+:^T=88-4V/=7A8*P
M;-<<OH_\"-Y(5=J))J<JAS(8;=NQC`?!?70UJ6I92$VZ[ZS*H^''`:E%&X?N
M6;!1,&P#^L]-AYMF@Z]=$PD[G,2)E-A[:'";#4MB[5CRM>#7*OI^L!C+,8^:
M:P^EDNK$=C"FU8=Y<J9>I<5SW/KI@?5#KFIJ#"$V[8U7UZ%@JV,?F'S6)+&C
M(-MM0?QH4"O/5J.>[`"'0J\SLS"XMG#R(R52O"*RA**$4WW1-BC-<M6"UTW7
M]WL@RE5@^>AC[_BO/VVQ633B;BY'U"%C4J9()4RE6,#+5;)$QZ3,`0R#;OB_
MAO#&65"U;8Z2[KVK8'8).@KY1:55"\07LJ#.)5J[D[7\PN6L+W:*L;;%#<5B
M"2#UR2+KF)L=XZT*S*]?*(JY*V74)A;054(6O%6]T^VVET_-#Z7JUAKU+G0"
MUFFU[8!R06,4NU$M#B*8U0P<JBQY9.WR9N]XRI$8I\H\S0U7E;0Y)0VRRJY5
M+AO>6Z.=?K?LJVM]=[4H_P!BYFH`Z9&T,1-)B*A/TL+V+@81OWU,D.V,CEUN
M6,<8>'HRZ4E_#97Y&\84H*^HE%5=C]SB^F\[9':=U!K<?=HE!/6T-9+C:#L'
M(,/2]<=AK*0@WT''I*3Q"V52PZ5D0T#O[6'+<(.(:F*:8^(DW+UI138I[FNP
M:\\&B$-+4TLFS&I;M8,@]I--`B=/KMLWC2BSA`S9`%;#"[C<"FC9,BNPVY$F
M)(C$T>=_*HCGJS*$HN(6]PO>9PMKVD@->ZJI]SVH[IVP:_;F;!,V=B>%O6]*
MO59("Y,0:&Z1IKSFNB+KDQ^3$93\2[GY2]/6TO#=RA*!<.#[H5N2DA)1KJD3
M7E"1Y]NIV/<`:NVU4FQTXT5BPJFQ(IH41,U_22U7></'2DQG,$?,Q(=4E+?I
M\94RJYKWW\)U[2W7K9D*M55#>[G;<&/$5V(HW]33-=*,TY&:_5IU:Q;;=E5P
MFH0M;,!Z!%RTG#\C$*0DFW`,4IBJK'>Y#M*HU(%'V1K'7L^[@*)43MSBA]BD
M8Q"_3+EKBO7<3,U0$=HD5TVJK1CC<RYLY;9;!P%X?8S(;4C&64)18797N17-
M\SLF-JJ=K!JMLE1X*B70[;AS]8G(JNV+%0[0]32T4&1A7J^[$AJBO!0:G$1T
MM"9RD25*3G/*&I165NCOM?\`2&ZMUZ_<K=$OPD9=J/5:%"C6]L19]>YL5'Z]
MRI=HVV+^4(8"ZD>/[7E*8..3LNN$&TP,(2EQ#K4#015*5"D.T^\FPJH-TM8*
MAK,21)[8Z]%-R2*?:;Y"'UZOX`T0[M$[&Q9:M4+=+/$$`:G)@#WHSR!\ER4V
M\M.$X\>`T=*E%B^PG<+=^NM]U0!0AFMRM`7I:O[H+U"S%YX6W%@:*#VAN%V;
M05B`+`F/B$UJ@*U`4RTEKX]S*)+J&7N`!3RJ@"F*DNO^_1R]ZKWQL96KP]95
MK&U5(!7&+#>QT>`U%O6P)NO(,O:RA\<F5UTY1I$+YK9,/15)BC%YRUYU-.*P
MIBE,57J/<>O9&Q#JM6-<:>MA0T=G@(3U>W(;)CAS=+"!;!;[@97'UQF:U2KV
M+*O/4&4EC'SYB)EUWX=M><MLH2BB3GNJ6./4WK*G66K#JQ=5'69R/6-S2R<'
M8"K?38UM`C].E/J*G%R3K-<Q,;8+^66<`<-./-H>\/2Y<J95C=F>YYLRA7*Q
MU=S7NMYS^J33CNP8]9N%@)JL3->I>Z(UKHM:=L%2KDZ!8GMG:_A-#Y[T3X-V
M'EY"/77X+X#04RA;#GN]]B`Z,UAM250*5'+W&R;7$%F".R8;-+G1].N6Q4X?
M0+8%'V)FPW?9[%6RBKAW4LNN2G767UX7&4ER4Q4IBHKM'M9O=[2'7C<@0=7M
M=0;]MVR/6T`&+L6`_*U6"KVP"%<!I(VW7A`7`L)R0!AOF4-PD*BX2N-$F^.?
MB>*"I"4"P(CW!-ZRI5>GE-%:NB54DQ13!:1`VY:)YZ`"NL'35I;3!@/ZM'P9
MY>#4MUP$90N0PRLE#D)\^&,MN990K0*:;^[[V_2U^V15<Z\HKH$`9D4FAV`U
M=[!%G6"[B:OUZN)9BP"(-*D#P8B4*WXEF`Y\Q4A4@.XJ4[%:D)6T#:I14&;]
MQ(Z:&`]X'^J>NK13*B'?N5&F_7%5CVX#EE@9T:M-;CS=;I%!")"P"$,R9,0D
MG&`^%NJRMS"6.7+T52BN"^=[-A`M.Z&W1&!ZW"(L&QMU5N^U8M?QCM>O`G5-
M(VN38A:RN8H?8U3+3<"M%CK"#O3;D/2W<PWU)RA?G@:*D)166YW?*.Z5W#M#
MZ@B*T3U9L\#HO(JU6$JD?-VX_9PE4M(EZ2-K;TAH.#)62(F)*4EN/.<\Z77H
M;252$,N-%*8JK]Q=_K@&U?UFOE'K%/!O;HUYJ#=1<;;;<E!0L"M5VU<-/:JU
M4PS7R,>\W!8RYOIEO)^&7!'^26TA;BTI0RXJ@+T0/<8(F;T5E5.K`[QKHN?U
MAIVCO5RU1"(^5MW84^_LUF>]9!P66TY7K02"($RU84ML4\/PYCU%2'$-LOKI
M19VW=U]?=?\`M#8=$0==:OJM0)V,00O5\&&8=(<%6VQD=(ILMNV)%?K(L9)R
M\(W/`=^88DR4.+BH3(F)<?RS%4J*J4J*K7^I^Y3O.1/MFRBE%U]9=4B:N&L;
MM!KEE(1[U7H5Z#ULUK]/QRZG+:-$W,G\?,%O9A1_E?DEQFW5Y]/-R]"M!PZ5
M/R/N1VV)DH6.!]/U:B:Y)R0]RV=`V<3L.OK4=56.R!8?)J\M.N7)1?6\M&D$
MMMRHK[!9^P2VX#3;C3+JI,RIE7$;]S38[LLE6".J=458^R,JHQ^TD=XB9FM*
MA;#@/61X@>M5DAAW2#FKFL;-0*A&HD!^)(/#LQE.81,9=;N5**9VOW"+7JFB
M:$*GJ96-AE[AU8USO*X#!-OP'V/<C-L"^D0B:HH<:N285@A!2D=9(P_F1&:'
M"%*<2UGR8QF9<4RJ'J]S78[-;=MLS4&L(-8KDNGB[B?<W&DBT]*L]DW+%68I
M@VO5TX_9@$&N:8DNO1X;TNP-29JO(,?;@O9=94HI)!]R"[EC<:"&U-0R@YIR
M-;+#)B;.*O$:O0)5_JU!>IYL>S176Q^_P$BRHEE0#[S,."RMA*I65/8SAE2B
M[0B@FE;*JKHPT-JU_I%FA1W'QY2&)M55L`Y3C4R*MV)+;GB"T)3K3;K><I<1
ME24JQ].,9YCP6*D<>/'B1V(D1AF+%BLM1XT:.TAF/'CLH2VRPPRVE+;3+3:<
M)2E.,)2G&,8QX<(L'FH5-5I1>55>NJNS895<;N&0@W-I17E2OCE`D6#,;YLD
M,J;^W9BX>]#+OW?E\WT\(I%PB<(G")PB_/*GS>;PQYO#R^;PQYO+X^/AX_L^
M'CPB_>$3A$X1.$7YE.%8\%8PK'BE7AG&,X\4YPI.?I_HI5C&<?TLXX1?O")P
MB_%)2K&4JQA2<_LX5C&<9_\`IXS]&>$7[PB<(O4^PS)9>C266I$>0TXP^P^V
MAUE]EU&6W67FG,*0XTXA64J2K&<9QGPSPBPN:I5E5K-,56@"J?D(BLYJ>0P[
M-:S7&X.!C=?R"S&^5Y"-C<8CIB>EZ&&,>GA/E^CA%S0X8/710X#7Q0T$##PH
MXX0&#P8HP4+'Q&DL1(`X=":8AP845E&$-M-(2A"<8QC&,8X19+A$X1.$3A$X
M1.$3A$X1.$3A$X1:K$>U>F!FT[/JZT0K#6<5P]-JA79=IJZ1>HG;F/U@'W.3
MJ:K]*?R/BFH6M9#95:IJ(T5QN&ZAMY;S&6\6AI56A67%]D.K-J,JK<#:FI2<
MZ`3UVD>ET]7,CYYR^-&#FN6:R1D/8'&S1;`N8_"1!<>?2XVO.,)7X\4*4*YE
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M<J0WA6>!C@HJRUCVGZ[W^5,4--#J):)%T9HI(#L*`/H5LD;.BJ,5Z31_ABCS
M*SUR"+KTF$ZS#=E^"$)PTM;2VU*$%6A4NA;IZQ'G1\X?M/1Y=X^2-%1DV+<:
M--<,%M=C?B3Q.));(.*FD*6&;P[(?2I3D"(GSJ4AOZ>*%*%<)NS=7`<?.UU6
M[3D$;OE\'5XUVG6RKY"[.>B#\@`E9"DIQ)8H[Y(`]3&(,/*L*PRO*V\J2O.&
M/!,>"XS?8CJ[.,M"'-H::S)$V-%;K\J1<:"Y&FW)IIX3/K=3<07>?DVD'B+B
M#,B,(3*CK6VQE/CG">*%*%<63V)ZQCZ3I;8Z[A0FZYN]=3C:4D^`F,3N4?:Q
M&KB8CU7$RL1BCT)[ZSP'3&6FO[3BY]27A*49\%"E"OR-VGZEN6%2XFZ--Y)X
MJ4<]FT-6JKX%KK!>[3:FRVW<DRL"74S+P/>CYB)E9<S+1YE(\<X5E0I0J2R-
MRZ#J.Q+#J0I:J'2[M7J3!VH1!F98&LJD4XM+M\^7:A^)KT/YE!$R*,0EE)#2
M5(@X;2\^I/GPKBAXJ4*@<_:?3^XNU\$<MFI?EU6MX:T4+)@[70U7-VB31EVJ
M"?HSSA"('N&(=2M:WGG(WQ++"G\Y7C#B4YPH0K0A7X`*ZW/SC#=7)4@T3P_-
M=/H`3`)&=B4U-GUH@X82.<>?Q(;(!Y4![+WW6'HKK"ONFEI3%%(E@@;C$:,X
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MDSCSMIPG/BG&,<(N*BM5QN-"AM@`C<,:['?'14"H*8T!^(AYN*]"82QAJ*[&
M1(<PVIO"<HPM6,>'FSXD7LE@`,]<YR<$$37"D'Y63<EC8<E9$;C*L_+IRGF5
MJEP?%><^BYYF_IS]'T\(N:J#"7Z?GAQ5^DUEAKS1VE>DPIM32F6_%&?(TII6
M4Y3CPQE.<X_8X15MMV_T?3U(,[/N@]R0-!)#!$I&"XD\V0F6VPBJE7JV,Q*=
MB1TN6"RG8D-'Q$B/#;6_A;[K3*5N)HQP15]7^P>A"$"/'L!(%JN9?"+(]RG;
M<;`ZWL]AM!J"T@A7YU5L4R(0*V%MOR1Y",M/)EH4RN.Y(C/QWG5"KBL<?[#]
M/H=,+6:=M[2$JJ&JA=79$\#<:D1<LE4UK7RKUSC!LU^>^1/-5&OYE8=8A>JY
M%:6I*4I\WAEBF*SH?875NFU+7,.!>-,5FJH#0P^LV)]IJ(YK`J?#+0&AU>44
M((DNJFQ:L0:?2A2G7LCI6'?,IA[RJ%,5R+7NC0E2I%<VQ)+UL]3]DWJAU&N6
MFEBV;K%MEON]F'4FJN,SZS&)MRFF"RVT/SW5XCCX\9QQYUM#*LI4-:=*4*NK
M``$F"/%I"B4C!+L-\6.P-AX@C7QRTNCWA\3#/P\-V"ZG"F5-I3EI6,93X9Y%
M%K=N;M1J31MM&4B]!+D\U]7PML-V$#3'#E.H=>LMP1K\`6MI!AY+PY@M:I'P
MJ,1H\I;:?,ZZEMA*G,4`E6E5)X?8SK?(K^+%*VKJT$.8CTI91BQVJK@9]<D7
MT*P;I@FRCR4^/(`&#(=G#L>))2V\MN.K*4YPTK*5"E"LW)VYU^,S?J],V1J,
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MJK[\'=FARZ\B[!9:N[&V'09RT!JQ&)?6DX$4V6<4R/`0Q$SXZ0SX-QFXK_JJ
M3AISRJ%*%105LGJ1LVQ#AH.]ZV,S-+*K>SAC`6V11U7$XM(6P#JU:$M#"4*K
M6>(S`)3,L+=3,8'3'4/)PS*PTO#$)BK"`[.Z[['+31U9OVG+T;)UZ25(PP=E
MIEF(D:J!+R@LLA,:@S)LB8!#G&'HRW5X5'8DI6C.4KQG'%"E"L!=^Q?7+68I
M-GL.P-?11$J;&B$"PHO726(:F0PDC!E$VALMZ>N,V.,"DMJ;;>4VV2AKSA+#
MJ',*%*%1.O=INI!^BCK#$V+J<9KER$:BSIYP[2`-;J4NL308^74K7'(DX[-;
ML#;]PC^D.?;2[A+^<Y2GU$8<4*4*]NQ.Q?4O4=JK6O=@V_6=3)WJNU^2.06:
M!#JZ]2B+EK?K)`F<EHC@(]5D$JS.:B*<>]#XQ:$HQA3Z,J4)2A.*SEMV)UJJ
M#VS=[DSM((FM%5-VJ[+L`,F//G-=5F#(E&GP1H?`FR,USTER7WG4.ML.^FE>
M%Y\C><)8\$Q4AB;4ZU36PU;@;$TC,8FA`-MKP2':Z+(C2ZY(LC0FL60-`8G+
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M0J+@`]D4"S$[`&K]QKIDG545]VQ1!Q6)*6)9M8F&=K3TI;3JFDL'`Y!B3%7A
M64O,O(4G.<*QXD68@VFL$W76!MC`D'F82B3S,$N/ENM#D2Y0]<]UN/(<6W"1
M/@OL9=SC#>'F5H\?,A6,$4/U9N/7>Z0I`_KDY(-#11)D40S.`V.LSHTF6&$V
M08^H3:1(4JH8=K1Z"2'34LYB$1\QF3&<=9<2O(BB+-;$V%4=44FQ;$OA1P+4
M:K!P1-DF!9<W(8CJ?9BM)BA@$`H;*S),J0VTS'B1GY#SJTH0A2LXQQQ10K7G
M8?3FTLD6J?<V7)X8I"!&@EC#V&CV,+82)2R!H5:,UJ\":Z>%6:00J)!*1TB,
MW-\C&',M>DXTM=H0K0A61'MU4EO1X\6SUZ3(EDB06*Q'-#7GI)@,VMXP)CM-
MR5+>)"FFE*DL)QEUA*<Y6E.,9Y%%C)VQJ*.14'I5I#8BWTK,"5"?'EHF##A(
M?6K%;YC$4G#^('H;CUNI$92G7'4,^6*I/F\^4I4199-JK"W&VD6,"MUXU(K3
M3:3`]3CMCB-.OR@#:,2,J6:C,,K6Y%QC+Z$(5G*<8QGA%^?6NK?*'[!]9`'R
M&+(7$DF_G`[Y1'E-3,#G(SY+XGX-J0V05AA2%+PK#V?)G'F^CA%P6;Y374R<
MKL@J$N&@N]*C%I*0LV/#!&9X`F2=@E_@IB!#!86^TB9EOX5["/.TXMM259(L
M>;VEK:M_+_GE[J@U14E41`Y$@Z.P[,(7TBD12H[+2'UN*^M))?HP5^'DD+QG
MR*SC&<X4*+.$;;5!'FP6LU>&90PY*7\Q-#87EC-.1&G9"OB9+7E8;=GL)4O/
MW.%/-XSGQ6GQ(LJ^1'QE+1)G0XZVT>HXAZ2RTM#?HR)'G6E:TJ2CT(;J_'/T
M>1I>?V$YS@BIH+V4T;8BYFO!-B""5CKP.;8#-;CQBV;'`@#1D4R18=KZAR3"
MC<$9-9>>&)942;0XGS,8SGPY:%6BG)K9>OJY7#EN.7*N#*U67HL:QF996(W"
M`RISL%B)$,+]3.1LQ]TG'2EI["'/%Y'W/W6.11>FI[3US>@0.RU2YUXP%LDY
MP6#F,D66,DBK++LAX1'BS,QYOS=F.PMQ<13:9"6TY5E&$_3Q1%^PMI:Z(3;N
M.CW.OHFZV+QP5[CS"#(Y=7)S!08W$9*9(9BI:8EC+!#<:?QE3#F7O(E>7$K2
ME0HIDQ/@R75LQIL20\WA>7&F)#+KK>&I#T-W*VVUJ4C#<N,XTKQQ]#C:DY^E
M.<8(N7PB<(G")PB<(G")PB<(G"+I3W">Z.W&_;>19/=(Z[4@;8[Z8O\`'UY%
MW1UZ#FM>[M8TR)Z^/'2%@EW-JU2XX&NA9"L!\_+GF",EQ>9*5LL>CGCU+(5Z
ME2$.@>V7'D5MZ7[GW6`JR&(291&`3WWHJ5!*QS]V/72Y1DMN;.4\ITN_.@1X
M;I)PMF&B`IQY,QZ2M:':ZDJ>I;!7+:GMW["VQ=KK9O<`Z<H!&30:V`HT7L=H
M:9+0:?$:4!V8>38)6=]M$%J+UX!KB.M.^9?S2:E:$Y;:4IB!P*8T5??#^V(Q
M72P<=[E'6*`3GJER(%E1O_K@X4#3WYO7.?%FQ,_6E'F7!D=;QOD3E6/%,Y_&
M<_<,^5VNHI4]2])=SV['3\LU6/=#ZI5E@5F=+UN)7M_K,=BTHO9%5M%REE'B
M%S3*NP\Q$`N-0X4M;3(SXO*D9=RTUY7:ZBF/4H58"71`?%$"JUWOZ86Z)1^K
M>W]9"2%D[>:0K4S8FUM@SB<.BV"T0!;Q:!7D:CK)\^P-*1\RG6\61U#<-/PR
M%*=KJ*N/4H[95=*9H/8(,)[@73*,0+:?ZX:?J=RQW"TS"+1K53[(%-[L[(K@
MMR938?8MECUX(WB(V[)P757&L.R(B)2\H8]13%;KT[L'[<<>O[!`6[O+U'CB
M[=MJ;>Q(BB=R:/2&P(('5:WK.B"&B].V=6#"VVJ-2X+LN-EU47$QY:?!W#3;
MF9VNHJ8KUW;;7M57/5]JU+([S=9,U2[6#79NSQ;-W/I&RD%(^O+U7[NP$RQL
MG;%I:ABCJP7P4UN/Z6'8[ZLY\5I1E+M5K1.TJ.V%`]J&X7,%9ZUWXZ?:W#A6
M18:/1ZGO;KS&J0^K09]3.R8%>!LW2(%'&Y-EI,"<W-F1"3#3WK*5$==6V\S>
MUU(,P51XU?[;$T;,&'_==Z]$<V%FW1KJ8@=B-'B[-9H-FUC6-:8$R+"_M$H2
MD@%M52.2G#RBBT-V=XJ@-B\83X6KNI6IZE:UMM?18K1-,:Q!>Y1TJ&`:U;-X
MF=MV-.\M%_.+0&WM5M@B+L/J8HG?3Z0Q,M+OCR$$)4^5.BH3Z[KLUU3J7IC6
MM"H*KF#V_:W'RXLEKW&>L'DAT*LT%EG\H?KFG+<*M[.HNSDDVW_K0IU!(B1H
MC,=Y?[&6Y#B_I<PE6':ZBF/4LE:K1[?5FJ6EJJW[I/6`(O5&O*?JXD=@;NZU
M2BMMJFOKA0[W3GHR"]N(CJG9!MBUT/6]-CL/HDM*=2IE.<LK88]28]2HES6'
MMM2!#42?[JO68F45--E",PGOK2A"`2)6"OSZ<0?EQI>W7CLYA53L9AG#,TI,
M0Y*F-./>K'CJB/VKNHJU/4KPWR4]M3?)B6HO[E/5VOT^71:+655(/V!Z^(?;
ML&K1&U0VO[.S9FKM$+-0QL;;I',T4G&(\[+#"4K8;S)1(@S#H*@J.A0\>$]L
MB)*CNO\`N4]4)(\ZX.9VH`3O'KX@->P\2ZTO9LX.+^)V!-+5#!F_TAB1*E_%
MD)S\&2^RZ\Y*RS/95=U%,>I6WU.O_MP=2,V-%2]ROK/;V+C@._:LW#L;U[>G
MDBH@+%CN%&)PRV0,P7CENFG;"13AM>))0_(SC*&T-HX.8]"&IZ%NI]HA[?\`
M^?/T[_2:TK]^W,<KNHJ4*?:(>W_^?/T[_2:TK]^W&5W44H4^T0]O_P#/GZ=_
MI-:5^_;C*[J*4*?:(>W_`/GS]._TFM*_?MQE=U%*%/M$/;__`#Y^G?Z36E?O
MVXRNZBE"GVB'M_\`Y\_3O])K2OW[<97=12A3[1#V_P#\^?IW^DUI7[]N,KNH
MI0K9#7^R->;9JH^]:KOM+V722RYC0JXZ_M(.Y54FX.EO#R#8^PUR<2$35P9\
M9QA[#;RLM/-J0KP4G.,3AQ45+]M;%J$=J`M6=O[ZUIU[%7B1$#"+9M(WKB!6
M2Q`?+CG9%7(@-I2XM6O((\.&NQ2X=S[J8)>D(2MA>4OMT*BM<%TKV6F=-@1"
MD#=8>XAT_D!+"[5*_N,H;[%:`"0`U$JFR-<[-:`:TH$5TU!"A6B%'5$"08A&
M"@#$1"AH4]':2['SJ>HK+M=15GVFB>W)92`GT_<YT"*K0^$!9>J\/?FA40'"
M%;U)7-/CR\-N/=H@MN9*!5Y#TG,R&04EWR)AJA(Q(Q*@)'0G:ZE[%4WV[32[
M"B]>YSUSM4(M2=@4,5#B[GZZUY5?$[+&[PQ9I4:;#N$F9**8L6_3,R*XM:4,
MQF(L12'$ID.R7:ZD[745LI6]N>WN$T/#TC([^]4GT_7\=LLS9A>^M+#'"=GB
M[D@;HG*9&3=@''&(A0]!^&<5(F39BF'%..R'9&5.JG:K6BE'5K0JPKCV#]LN
M]GI5DL7=;0N2LQF*P_\`(N^#51&^G#83'8]$%4=V`P<9STDX\ZVHR%NJ^Z7E
M2LYSQVAT)1W457]FV#[5]QV>"VE:>W'3JTF*?J@9JRBM6_?VD+B]3$B3T\]$
MN`8W:+@6.?6]$F2S_;KK[C^5Q6W<KR[C*^.UY4H[J*TY(:<]M]RMVJK!O=`Z
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M+V_[B7604S::0%KTRC"NQNE``RS%*Q,$3@CMOL<>UE5D(K*0;;$>8Z*E&1N)
M+_IRW8OIP$!4="#,.@JJJ1!Z@66AW(CN'W)NJ58W+L*Y+MY`[KSL#UX>8K;@
MMO=XRN1X<R+.J[<B2Z+W1(407$CP<^>,C$=QMW*Y2F/0,$QZL%EX-(Z!B1F1
M0?W4.NP^,3^81[3YMP]>BCA<98[M9[Q;A\&49OA&>-R7F%X$=B2^].EQF1RE
M..R'Y2W4*GJ3M=2N/4I/VUM1;<K.U`_?WJT4S6==5BF1@9/?>D,X69K.M*YJ
M--EC3&KVF"*8)TJLL)D0HT%MQ<UQQW,K+*OAL0YB*44H[J5(@=0^V#5F["\`
M]RC0[)4P6C'1Q$CV!Z[DD`B<`3LP%!<B0\V*,A^-\BN0*!(;4O&9$*F#&_,G
M/K+5:NZE>UU*QX@KVSXUEUW9E>X=UK=DZ]$U\;'AYWOUX1#+N`/E"FI\U&++
ME;4F0Z(0M7DS]SE7T9^C'':ZBIVNI2FPFO;GL$K4:GO<2ZSM#=4Z3;TNT,7O
M;K]+18(D'7EUUR&LDIY^U9^`)0!FP23[C+2,L/O99QX(0VK#D[74E'=147I4
M+VWJ+K[?6O@WN*]9/A=T5URKP3LK>FBB)VH"G+7>+[A+[IB]DX%H4Q<-A$7F
MV7&(D'$7R-YC*?7*E2J<QZ%:.ZBHD<IGMSVT;<J_:_<SZX$JSM&9>++M$9`W
M/UU$S;'>]KC2]4VH;!&DV^7.J`"R4"QD!L`5'];(:4^V18DJELH5Q5W4G:ZB
MM_-:]S^E%$IX:IE_<`ZEV_Y".#AQQ1S>6AZZ]@8&!"@[+;\`+<6QV9$B0/=E
M+4TVRTE<C+;;:&T(3B$'J4H[J*GOY?W1#\]?J1^DAIS[\N2AZE,KNHJ;Z^[9
M=5]MV:-2]5=E^O\`LVXS(TR9$J>OMRZYN=FE0Q[.9$^7&`URQDBC\:#'3E;S
MB6LI:1CS*SC'T\4*$$<5?;[[$5AZ3)>:CQH[3C\B0^XAEAAAE&7'7GG7,I;:
M::;3E2E*SC"<8\<_1R*+Y\MS1.HM^/;MLT?W(>F(V#>)%ALD.H4#;^IZ.6OI
MR5)<)`4;-=D;K?UJ5M]6AH4"&62*!%$I8R8[\X>FJQY^;!4=!68KU%5IKVK]
M0C]'L=MM?=SV_M/;?N5QM-@C!`5XZY3`]*JI25V,BIH;<`9N:UB1X6T0]V1Y
MA"#"*DHT29!]1N1(D>F^RJ>@&B8]14DK5!ZA4\>V)K_N@]%8T0Q"!A[G-?O.
MM))F>%'7VA7V3%#DG-_?%,RX[NK1$`>]/<(?"Q9$Q2TO+RQAM4]13M=15V=>
MG.@/7K;D#8U=]P'I4^,$ZH!408$A;IUN!7%,#];:LUV4=;B#MS8J::B6?U>D
MZN%D6N;DP6DN9F?1YG(:D4H5"''H*MC3V\.I5;U=8*AMGW+^J9_8-MV#,V%;
M]L:C[&4/5EBMYF9"&PU/ETS=OW)V$RQ&'MP(L""]'&P0T.%"880B-YUPUK@$
MH>HKE[$VCT!O.G-GZB<]RG3D^+LX<%%S"UX[AZZN$@'%%&HQ1]0#*=AA2`>6
M0994TJ1%E,/MJ]-Q"\+:3QVJUHE'=2UUVM4?;CMUVK=EH/N!=2*6#$2Q4@E6
MB_8^K6=\L278++8K-?B-M3O83;SVSI<\XA4(H3FS,L8]?#R7TN(PU:NZ05>U
MT@JF$Z<Z;R4S<SO=/Z6#R1TM97C-FK&Q-5!S@T59-<4S7QA%4'KW=)I8:=9?
MJ6W-D9:$M8%/O(4(5!<BX<D*GJ*=KJ*OF2QT4(Z%U9J-[W'.G8,OK+>Y#L%%
M(5[>=!?J!"TI&W=`*L3*O9]V'9A"A*,V>.^9%29SL(O&9DQ\LL8DX4RQK6B8
MUX%4D/U#T<#O!9Z/<PZ@%Y`&QSIV6)/8``PZ:&H)T4^-L[\E/8M+4+<3D^A-
M1GR[:$C'(\UQ3D!S+24JM3U)VNHJ>U!KIZ[TW?T;8^^_0"M7VTDM47(A'K>U
MM80==T6QT'6>O*#ED#70N[(^9YQ2J1\?-GN2W1Q4B\YB1`=AN+85,:UH4H:U
MH55K`/J0]O@*+/\`=#HU;=3,65_:MNVK:-K=:'CMC*/6X58WM2B!<3<"R8VD
ME5C\YF!G`Z`S<EY\@S*4IU(INXTX%*'J-5FT:DZ2?/Q\^1[G'1Z6)KX@*"KH
MYV[:::5&$C3>FYS,*6S%W)'%R%UT7JM^.(EJCKG,9)-)6]F+!:BN*GJ*=KJ*
MRIK7O2NWB;&7NWN4=#CVSC$J@/1#,786N`M9C#Z2Q-%2JS*C1=\NW%RN6<4N
M'(FL1S$7SE1L9]7G;:0RF5/0#1.UU%6[N.#T`VS9]$',>Y5U>KP[3M*H5*,!
MF=[:C))O\&F$V1$MPI/G[4<FQ\V'4-JO%6=]=<YU+=L5*4XXY$PAX,PZ$&8=
M!54#-4^WY$&VF)+]QCH[)*DJY50=:M;%[TE&LE>E#JO4J_;BBB&=LNO.O6SZ
MM+0O#"XV?@7\,/*?PC*EJNZBG:ZBKAK:?;XJ>J=PZY#]_ND>).V:G4AQ`B]L
M[2*!<FXU':FT]H-6^T!X^S6U6:08>V!#@2O.^U*S'%)5A_Q4VEEC7@4H[J*K
M*-KOV^Q5PU9:`GN*=+AT:DR*?)L0&#N#6H`8:,@+-2[<9OPMNJ;K`YB[%-D*
M'$B_'SOF#>(;SF'VY&4)2I4]13M=14IVI'Z2[`W)>-O0O<']O9MXU<L7L-7+
M1<-16$=9"$ZHZHIA"K;N=:W./SLZD`X>K&R`&(AL<L:6E(?4IW$1"70KU%*.
MZBK8ZN[!Z4]9+3=S(WW&^FUP&[&:H,>S,%MOZA@F8C&M:5-HP1->*Q-JN-0_
MG[,>`8,IDL2D2[%(,ST8;<*9Q'AJ>@J$./05O%^7]T0_/7ZD?I(:<^_+DH>I
M3*[J*?E_=$/SU^I'Z2&G/ORXH>HIE=U%;4"BHLZ+&G`9*`9"F8$,J',"ID<B
M+*BR,=N6/)#2$1QZ).@3HCR'67FEJ;=;5A2<YQG&>11<_A$X1.$3A$X1.$7S
MZ^S3U'ZH[2Z63+KLWK'UZV-<BO:[O2V4MM[TOK>WV8DB!W&W:/@HGGK!6B!6
M8B%`C-L,X<=5AMEM*$^"4XQC-Y-?46;B0<"NU7\@3HG^95U*_1QT[]YO,:GK
M6.9W64_($Z)_F5=2OT<=._>;Q4]:9G=93\@3HG^95U*_1QT[]YO%3UIF=UE/
MR!.B?YE74K]''3OWF\5/6F9W64_($Z)_F5=2OT<=._>;Q4]:9G=93\@3HG^9
M5U*_1QT[]YO%3UIF=UE:RP-&]%3_`&Y/]8*M[?\`U*-0-<Z1$[6V_L3&B=.-
M1*+8;_:W0>H-;H$-Z^D?,[!=0-8LAF3E<F,H=`'1%Y;=P0:RBU-*U*M74K4K
M9K\@3HG^95U*_1QT[]YO)4]:F9W64_($Z)_F5=2OT<=._>;Q4]:9G=93\@3H
MG^95U*_1QT[]YO%3UIF=UE/R!.B?YE74K]''3OWF\5/6F9W64_($Z)_F5=2O
MT<=._>;Q4]:9G=93\@3HG^95U*_1QT[]YO%3UIF=UE:S0=&=%3_;@]U@JWM_
M]234'7>D16U]O[#3HG3C42B6"_6MT'I_7"1#>OI'S*P78%6+*9D^>3&4.@#8
MB\MNX(-91:FE:E6II6I6S/Y`G1/\RKJ5^CCIW[S>2IZU,SNLI^0)T3_,JZE?
MHXZ=^\WBIZTS.ZRGY`G1/\RKJ5^CCIW[S>*GK3,[K*?D"=$_S*NI7Z..G?O-
MXJ>M,SNLI^0)T3_,JZE?HXZ=^\WBIZTS.ZRGY`G1/\RKJ5^CCIW[S>*GK3,[
MK*?D"=$_S*NI7Z..G?O-XJ>M,SNLI^0)T3_,JZE?HXZ=^\WBIZTS.ZRGY`G1
M/\RKJ5^CCIW[S>*GK3,[K*_<=!>B>,XSCI7U+QG'TXSCKCIW&<9Q_1Q_Z&\5
M/6F9W65H_P"PZ-'!O;[C"!$"$*$BNU?>H:+%C8K$$<-'0.XV[(L$?`@Q6VHT
M.%"BM(;::;2EMMM.$IQC&,8YD_TE7<?46!]UBAT;9O:GV:J/LFF538-*/]WM
MF1SM/O%=#VRK&F(_3W?T^.P6KYZ'/$DF6)T1IY"7F5I2ZTA>,84G&<1O`^9&
M\#YEO?\`9X=`/S&NGGZ,VE?O)Y,SNLJ5*?9X=`/S&NGGZ,VE?O)XS.ZRE2GV
M>'0#\QKIY^C-I7[R>,SNLI4I]GAT`_,:Z>?HS:5^\GC,[K*5*?9X=`/S&NGG
MZ,VE?O)XS.ZRE2GV>'0#\QKIY^C-I7[R>,SNLI4I]GAT`_,:Z>?HS:5^\GC,
M[K*5*?9X=`/S&NGGZ,VE?O)XS.ZRE2GV>'0#\QKIY^C-I7[R>,SNLI4I]GAT
M`_,:Z>?HS:5^\GC,[K*5*?9X=`/S&NGGZ,VE?O)XS.ZRE2GV>'0#\QKIY^C-
MI7[R>,SNLI4I]GAT`_,:Z>?HS:5^\GC,[K*5*?9X=`/S&NGGZ,VE?O)XS.ZR
ME2GV>'0#\QKIY^C-I7[R>,SNLI4I]GAT`_,:Z>?HS:5^\GC,[K*5*?9X=`/S
M&NGGZ,VE?O)XS.ZRE2GV>'0#\QKIY^C-I7[R>,SNLI4I]GAT`_,:Z>?HS:5^
M\GC,[K*5*?9X=`/S&NGGZ,VE?O)XS.ZRE2GV>'0#\QKIY^C-I7[R>,SNLI4K
MK?VYUTZ^:']X'VGW=':)TWIEVRZS]Q)NQN:HUA2==N6!L5K+3JA:#:Z@##J*
MH&J(2,Q\/Y<PSE]SR>'G5XY`DM-?(K4Y2NZO9O\`@VV%_P!![9_>&?S!8CBN
MD;V;>C_2R^^UAT.N5ZZ@]7;I;[)UNUZ5L5KMF@-3V.R'BDH=E<HD:.&*E,*%
M)\E?TN//NN.+S].<YYFYQS'%9.)S%=EWV>'0#\QKIY^C-I7[R>8YG=94J4^S
MPZ`?F-=//T9M*_>3QF=UE*E/L\.@'YC73S]&;2OWD\9G=92I3[/#H!^8UT\_
M1FTK]Y/&9W64J4^SPZ`?F-=//T9M*_>3QF=UE*E/L\.@'YC73S]&;2OWD\9G
M=92I3[/#H!^8UT\_1FTK]Y/&9W64J4^SPZ`?F-=//T9M*_>3QF=UE*E/L\.@
M'YC73S]&;2OWD\9G=92I3[/#H!^8UT\_1FTK]Y/&9W64J4^SPZ`?F-=//T9M
M*_>3QF=UE*E/L\.@'YC73S]&;2OWD\9G=92I3[/#H!^8UT\_1FTK]Y/&9W64
MJ4^SPZ`?F-=//T9M*_>3QF=UE*E/L\.@'YC73S]&;2OWD\9G=92I3[/#H!^8
MUT\_1FTK]Y/&9W64J4^SPZ`?F-=//T9M*_>3QF=UE*E/L\.@'YC73S]&;2OW
MD\9G=92I3[/#H!^8UT\_1FTK]Y/&9W64J4^SPZ`?F-=//T9M*_>3QF=UE*E:
MA>X-T,Z-5GH3W<LE;Z8]4*_8:_U&[(FP)X)UUU`)-!#(K3ERG"RX@I`I\><-
M)C9K"'F)#+B'674)6A6%8QGE#C48E5I.8>=;K]%/]"+IQ_%6Z]?P1U#D/%0\
M5M3R*)PB<(G")PB<(NGKV+O]`9'\;'OI_KH[TYD_CZBR?Z2[A>8K%.$3A$X1
M.$4$VCLJG::UK?\`;FPR[0&AZQIMDOMQ,O8\R!E:J8B6<,S,-^.%/.,P(3F4
M-I^Z<7X)3XJSC'`QP0"N"U']O/6UQ`:6,;OV\'>#;\[?W<IV8V\)F^9PC37+
ML/%C]7:A=>>1B2W'TGI@)7ZQEG*E(^.'2GT_=2%YS7<:=`5/5T+?/D43A$X1
M.$3A%!-H[*IVFM:W_;>PR[0"AZRIMDOMQ-/X\S8RM5,1+.&IGIXSA3SC,"$Y
ME#:?NW%^"4XRK.,<`5-$XX+4?V\];W$#I<SO';P=X+OSM_>"G9?;HF=YG"-,
M5=1XL?JW4+KKR,26V-*:8"5^LJ9RI2/CATI]/W4A><Y..-!P"IZNI;Y\Q43A
M$X1.$3A$X1.$3A$X1.$73Q[%_P#H&/?QN.^O^N;O#F;_`$ED[CZB>Y#_`*:/
MLJ?QY-I?ZF?87D;P/F1O`^9=P_,5BG")PB<(G")PB<(G")PB<(G")PB<(G")
MPB<(G")PB<(G")PBZ@>V?\K[[0G^3;W(?X,-)<R'HGU%D/1*[1MF_P"#;8/_
M`$'MG]X9_,5B.*ZZ/9!_DC/;T_BOZV_O7GF3O2/G63O2*[3^8K%.$3A$X1.$
M3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$6EWN0_P`GAWS_`(F7:#^!*[\H
MXA5OI#SJ4=%/]"+IQ_%6Z]?P1U#@\4/%;4\BB<(G")PB<(G"+IZ]B[_0&1_&
MQ[Z?ZZ.].9/X^HLG^DNX7F*Q3A$X1.$3A%UH=T_+V)WCUPZ%P<XF5>V%6.T/
M:B.G&'&&^NNC+.)F4VAF&U80G,?>^^\!1BF?/_;M>"'V\I4E*N9#`55&&*[+
M^8J)PB<(G")PB<(NM#NIY>Q.\.N/0N!X3*Q;BS':#M2PG"7&&NN>B[.)FU"A
MEVU>3&6-\;[P%%J9\_\`;M>"GV\I4E"N9#`560P%5V7\Q6*<(G")PB<(G")P
MB<(G")PB<(NGCV+_`/0,>_C<=]?]<W>',W^DLG<?43W(?]-'V5/X\FTO]3/L
M+R-X'S(W@?,NX?F*Q3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X1=0/;/^5]]H3_`";>Y#_!AI+F0]$^HLAZ)7:-LW_!ML'_`*#VS^\,_F*Q
M'%=='L@_R1GMZ?Q7];?WKSS)WI'SK)WI%=I_,5BG")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(G"+2[W(?Y/#OG_$R[0?P)7?E'$*M](>=2CHI_H1
M=./XJW7K^".H<'BAXK:GD43A$X1.$3A$X1=/7L7?Z`R/XV/?3_71WIS)_'U%
MD_TEW"\Q6*<(G")PB<(M,NL&BKW3=F]INP.YODSFU^P.ULP`<4(2=+CZ7UPU
M`W.I^@*+%FO1HOEE31L@I;2S3:,(:/6R:SA3B64+S2>@<%33@%N;R*)PB<(G
M")PB<(M,NL6BKU3MG=I>P.YODSFU^P&U?EX**$).EX%+ZX:@;G5#0-&BS7HT
M7R2IP^25MQ9IM&$-';7-9PIQ+*%YI.``X*D]`6YO(HG")PB<(G")PB<(G")P
MB<(G"+IX]B__`$#'OXW'?7_7-WAS-_I+)W'U$]R'_31]E3^/)M+_`%,^PO(W
M@?,C>!\R[A^8K%.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M%U`]L_Y7WVA/\FWN0_P8:2YD/1/J+(>B5VC;-_P;;!_Z#VS^\,_F*Q'%=='L
M@X\/:,]O3Q^C_P#5?UKG^J+\<?U<<R=Z1\ZR=Z17:?S%8IPB<(G")PB<(G")
MPB<(G")PB<(G")PB<(G")PB<(G")PBTN]R'^3P[Y_P`3+M!_`E=^4<0JWTAY
MU*.BG^A%TX_BK=>OX(ZAP>*'BMJ>11.$3A$X1.$3A%U!S/8I]M665L!AK4VT
MP\BSV:R7`O$K/:SM750SMBMYN=8[&1B@*YN<8$'**FR3\AQ$>.TWZCF?!..9
M9W++,Y>G["7VW?\`%WO'],SN-^/;C.[Y@$SN3["7VW?\7>\?TS.XWX]N,[OF
M`3.Y/L)?;=_Q=[Q_3,[C?CVXSN^8!,[D^PE]MW_%WO'],SN-^/;C.[Y@$SN3
M["7VW?\`%WO'],SN-^/;C.[Y@$SN3["7VW?\7>\?TS.XWX]N,[OF`3.Y/L)?
M;=_Q=[Q_3,[C?CVXSN^8!,[D^PE]MW_%WO'],SN-^/;C.[Y@$SN3["7VW?\`
M%WO'],SN-^/;C.[Y@$SN3["7VW?\7>\?TS.XWX]N,[OF`3.Y/L)?;=_Q=[Q_
M3,[C?CVXSN^8!,[D^PE]MW_%WO'],SN-^/;C.[Y@$SN3["7VW?\`%WO'],SN
M-^/;C.[Y@$SN3["7VW?\7>\?TS.XWX]N,[OF`3.Y/L)?;=_Q=[Q_3,[C?CVX
MSN^8!,[D^PE]MW_%WO'],SN-^/;C.[Y@$SN3["7VW?\`%WO'],SN-^/;C.[Y
M@$SN3["7VW?\7>\?TS.XWX]N,[OF`3.Y/L)?;=_Q=[Q_3,[C?CVXSN^8!,[D
M^PE]MW_%WO'],SN-^/;C.[Y@$SN3["7VW?\`%WO'],SN-^/;C.[Y@$SN3["7
MVW?\7>\?TS.XWX]N,[OF`3.Y/L)?;=_Q=[Q_3,[C?CVXSN^8!,[E^X]B;VWL
M9QG&O-Y8SC/CC..YO<;&<9Q^QG&<;V\<9QQG=\P"9W+L%ZS]8]+=/]/@-#]?
MJG(I6KZR1LI<0`EV2SVZ4T2N%B)VRR395@N1@_8B,DI8#$F2XJ1*=SA;N<8\
M$XQC$))-2H37$J`]N.C76_O$#H%?[%52R6.)JVW2;W0IM2V3L;5IZMVF8!)5
MB25@6365IJ1Y+CP(O)CJ1F3EO*'5?<^/`)'!`2."TT^PH]O'][G9+].#N7^/
M3F6=WD3,4^PH]O'][G9+].#N7^/3C.[R)F*?84>WC^]SLE^G!W+_`!Z<9W>1
M,Q3["CV\?WN=DOTX.Y?X].,[O(F8I]A1[>/[W.R7Z<'<O\>G&=WD3,4^PH]O
M'][G9+].#N7^/3C.[R)F*?84>WC^]SLE^G!W+_'IQG=Y$S%/L*/;Q_>YV2_3
M@[E_CTXSN\B9BGV%'MX_O<[)?IP=R_QZ<9W>1,Q3["CV\?WN=DOTX.Y?X].,
M[O(F8I]A1[>/[W.R7Z<'<O\`'IQG=Y$S%/L*/;Q_>YV2_3@[E_CTXSN\B9BG
MV%'MX_O<[)?IP=R_QZ<9W>1,Q3["CV\?WN=DOTX.Y?X].,[O(F8I]A1[>/[W
M.R7Z<'<O\>G&=WD3,4^PH]O'][G9+].#N7^/3C.[R)F*?84>WC^]SLE^G!W+
M_'IQG=Y$S%/L*/;Q_>YV2_3@[E_CTXSN\B9BGV%'MX_O<[)?IP=R_P`>G&=W
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M_P`>G&=WD3,4^PH]O'][G9+].#N7^/3C.[R)F*?84>WC^]SLE^G!W+_'IQG=
MY$S%/L*/;Q_>YV2_3@[E_CTXSN\B9BGV%'MX_O<[)?IP=R_QZ<9W>1,Q3["C
MV\?WN=DOTX.Y?X].,[O(F8I]A1[>/[W.R7Z<'<O\>G&=WD3,4^PH]O'][G9+
M].#N7^/3C.[R)F*?84>WC^]SLE^G!W+_`!Z<9W>1,Q3["CV\?WN=DOTX.Y?X
M].,[O(F8I]A1[>/[W.R7Z<'<O\>G&=WD3,4^PH]O'][G9+].#N7^/3C.[R)F
M*?84>WC^]SLE^G!W+_'IQG=Y$S%/L*/;Q_>YV2_3@[E_CTXSN\B9BGV%'MX_
MO<[)?IP=R_QZ<9W>1,Q3["CV\?WN=DOTX.Y?X].,[O(F8I]A1[>/[W.R7Z<'
M<O\`'IQG=Y$S%/L*/;Q_>YV2_3@[E_CTXSN\B9BN$2]A;VX#(X@',4WL*6$%
MH4H:4%D^ZW<.>-)#IS"XTV`0@R]X/19L*9&=4VZTZA3;B%92K&<9SCC.[R)F
M*[9Z'2:WK2CTS7%,'Y$T_7]4KM)J@M4J5-4-K=4$0P0(?F;.>DSI>88N`TWZ
MKSCCKGE\RU*5G.<X<5%*^$3A$X1.$3A$X1.$3A$X1.$51GM_:-JV=BILNX=9
M@%:A:KS^U<&;O7!N=;LVW+6*L[><2R+/U6;L67T?`JF^CB5Y\>GYO''.9'I]
M_+R^5#*[G5Y=&N.?+Z66@[67II6G2O;Z;X:>(FL#2CI.A:O<C7'3#3N5:3R=
M^-M7O`M,K#W@P4/-$6;ET.>E%[-D[YTCIL4#.[:V[K;602SN.-5PO?+K7:F-
M/.LQ$3W6P\TX0A1R*VX3B7E8:4O.&LX5GZ,^/);:??7KW1V<,LKV^D&-+B.C
M$`&F.&*QVGX;>(6_+VYTW9.AZMJ^H68!GCL[6>YDA!<6`RLB8]S`7@M&8"KA
M3BL1/[+]=A5NJ=`)[TU&/O-\B5R?2*?-V%58UFMT&XKRW4YE;"/%$$34:RN8
M\L!<=MQ,O/T-95S8W2]2?"^X9;S&",N#G!CLK2WT@XTH,O37ATKFVWA)XI7F
MB7NY;3;FMR[=TU\[+NZ997#H+9]J*W+9Y1&61.@&,P>YIC'IT7.7V$T.TO+;
MFYM7MKQL[\"F4+O5:2K&X?*E?X+<IR2QG\(/D5C/RC_Q_P`,_P#!<Q&G:@<1
M!+]BYOH.^Q_Z3AZ'^=P\JX[?##Q'>W,S0=8+?>CWUJ+2?^;.'OAZ'\"K_P!9
M^P_YZD(;;&K[%&O<P!L2E&HFKBYFO[)DBK.&GQZ"=KL;XT^'N+L68ZW7"86'
M^VRF)>6G&&_NEX3CZ>:GVEU&8VR1R-,H!95I&<'`%N':!/`CBNKO]E;PTN73
M8-3TO4+>;6((IK!LEO*PWD,[LD,MJ'-!GCE=V8WQYFO=@TDJMQO;KJL8IE@V
M*)['Z.)4"ID1`BT76!M*ERZK72I]24`QIL\P96,&3C"UXQ&:>=0M_.<>3&><
MIVCZLR=ML^VG%P\$M:8W9B!Q(%*D#IIP7K+OP/\`&6QUZUVM>[4W##N6]BEE
MM[1^GW3;B>.'&9\4)B$DC(J>V.:TAGT1"E87?^C+&UKY^O[BUD;9VRBRN:N=
M%7BMSV]B-TQ#[EN725Q2+J;.FL-Q7<S\P_6^$PVK+OE\,\TOTZ_B,@DAE:8<
MO,JUPR9O1S8=G-T5I7H727_AGXBZ4_4X]3T+5[>313`-0$EI.PV1NB!;"[#F
M#N_>"YHAYN7F9ADK4+U@^PNA[,WKUVN[FU<=;VW,L(_5K@B]5H@C8T^I9<3:
M8=(5%).XM$JN9:5B<W"]947*<^IA/ARR:=J$1D$L$K3"`9*L<,@=Z)=AV<W1
M6E>A9ZAX7^)&DNU1FJ:!K%L_1(X'Z@)+.=AL67-.[ON\T8[NV>HY1ERB2HR5
M0OV%T-7]DC]-G=S:N#;;+.C6!>LB=ZK4&^D7C#*I(EJ%4Y))LY*<)QT*6PE#
M&<NHQG*?''#-.U"2V-['!*ZS%:O#'%@IQJZE,.G%+'PO\2-3VG+OS3M`UB?9
M,#9#)?QV<[[-@B(;(7W+8S"T1N(#R7C*30T6(#=I.M5CG7@8`W]IPV1UD'.V
M#8T`5LBHSYE$!5B7\!9#-OCQ2SKM=&`9O[3,?EX:;C.?<N93GZ.9OTG5(FQN
MDMYFME<`PEC@'EV+0W#$D8@#BN;?^#OBSI5OIUYJ>VM=M[75YX8;%\EC<L;>
M37#<\$5LYT8$\DS.U$R/,Y[<6@A9EOL%HEUQQEK<FL''6M8)W8ZVB\UM2V].
MK1YT;36G!+.4Z^6CZ<&,_P!H9Q_X7F!T[4`*F"6G-Y7HN^R?Z/AZ?^;Q\BX+
MO#'Q&8T/?H.KACM8.E`FTGH=3!H=/'8_AH.'=OLW^8O=8-]:0J>O`FW+1M[6
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M]8K=:J``N]4-7FC1PDNZ4\4?%S[-4XMEAY(5V38PD64Z2#,'8*<O1%2&VTR&
ML>9'FQ]/-3[:YBA9<21O;!(2&N((:[*:.RG@:'`TX+I;_:FY]*T2SW+J>GWM
MOMW472MM;J2&1EO<N@=DG;!*YH9*87]F0,<XL=@ZA58A>V75VQQKM,K_`&)T
MF;B:U%OF]AR16SJ;/8HP>+,6.DE;:[%,.HKX]@@VIA;TK+3:7<91G/FQX<Y3
M](U6(L;);3M,IHRK'#,>-&X8FF-`O7W_`(*>,.E2Z?!J>UMP6\^K3"*R;)87
M3'7<KFA[8[8.B!F>YA#PV/,2TY@*+*`NR_7:S@J]9ZYO34AZMVZ]1M7U4\'V
M%52(>Q[(F,ID1*$#(Q"CL0I<)+"\+;',K7+6C.,X;SC/,)-+U**1T4MO,V5D
M>=P+'`M8.+R*8-_SC@N'J/A+XI:1J-UI&J[=UNVU6QTYVH7$,ME<,E@L6DM=
M>2L=&'1VK7`@SO`C!%"Y<K'8G0>8J)V-TZLS"=V8K2[<O%\K.8[FWD*\BM7H
M>^9^FJ_I5]&1&,_'8S_X+D][=0KEY$N;E<WT'?8_I^'H?YW#RK2?"WQ*$QMS
MH&L\\:1[ZEO<[C,-,.(U`CEU[G3_`*S]A_SUYW_L+H?5-D`TW9VYM7Z]MMI:
MC/5JLW2]5JLGK`S-(Y$1'0PDP2ASB3<HKCX9O+*%X6_]QCQ5]'%OIVH7<3IK
M6"62%GI.:QS@*"N)`(&&/F6.V?##Q(WII-SKVT-!UC5-$LRX3W%K:3SPPEC.
M:X2R11N9&6Q^V.#B*,[1PQ7C$[$:$(;)FZ:@[HU;,VV-5.00UE&O=9?OL%8L
M9\Z))EU-LDHY'5`$?VT]A3&/3C_MBO!/T\'3=0;;"]=!*+,TH_([(:F@[5*8
MG`8\59_"[Q*MMIQ[\N-`UB/9,H867[K.<6;Q))RHRVY,?*=GE]K;1_:?V14X
M+S`=@]$6IVAL5G<NL+`]M.+9INM&@MYK1)R_PZ4N0BX2J:B&2>59(]77%=P0
M7#]9,/+:L.Y3Y<\2:=J$0D,L$K1$6A]6N&0N]'-4=G-T5X]"QU+PP\1]&9J4
MFKZ#K%K'HS[=E^9;2>,63KH`VS;HN8.0ZX#FF$2Y3+F&2M0N1'WQI*7K*5NJ
M+MS6TG3\%,I<S:+%UKKNOXJ(17(.8J1;D$%`64Q36,Q',J?QY)/[7GP7]',3
MI]\+H6)AE%Z>$>4Y\17T:5X8\.&*UR^&_B#!NYFP)M#U9F^9"T-T\VLXO79X
M^<W+;%G..:+VQM&8L[0[.*EE'OE(V;5Q=WUS;JU>Z:;3)6&M50-CK%7BJ84R
M0/EJ'F!,B5`F)BSXCK+F6W%>1UM2<^"DYQS5/;SVLI@N6.CG;Q:X%I%17$'$
M88KI-Q;;W#M'6)MO;JL;O3=>MRWFV]S$^">/.UKVYXI&M>W,QS7-J!5K@1@0
MI9S2NE5<6#<>HJE;`U"M6T]<UF\V+,;%?IE@N]:#6LYF:\J/#P(KI$G&+DLR
MY",MM>BROU%XRE/CG'ASDQV5Y-"ZXAAE=;MXN#7%HIQJ0*#U2O5:9L3>^MZ+
M/N31M&U6[V[:YN==0VD\MM#D&9W-G9&Z*/*T@NS.&4$$T"L?G&7E5&W;E4&!
M)X^_:JVR"JSY.+9S3IP6V)KDH+_RS&/$5RL0Q#XG_P#&D2%MJC_]_A/-H@F+
MVQACN8\#**&KJ\*#B:]%.*[5F@ZY)>VVFQV5V[4;QL;K>(0R&2=LOV)T+`W-
M*)/^3+`X/^AJL&UMG5<BCN[-8V7K][6S"%N/[!:N5<<H[+;4K$%QQVV()*`M
MH;FJPRK.9&,8=SY,_=?1S,V=V)^ZF*3O7TF5V;K]&E>'D78OV5O*/<(VC)I.
MIMW6X@"R-K.+LDMS@"V,?.)+.T`&8M[7#%28?9*Z6`1[4*/!2=7ECOG$2R#R
MD&:`E",LYDX*QS$9]P<\.^'3ESUTN9:\F/-YO#Z>:G12,D,+VN$H-,I!!KU4
MXU\BZBYTK5++4G:->6UQ#K#)>4Z!\;VS-EKEY;HG`/#\V&0MS5PI51NQ;6U=
M4`@6S6S9-!J]<LC;#M=L%BN-="!#[4F&DA&="E21&-`*MR("\/H4PXYA;.<+
MQXI^GFV*TNYI'10Q2/E;Q#6DD=&(`J,<,5VVE[,WAKFH7&DZ+I.IWFJVA(GA
M@M9Y982UV1PECC8Y\9:_L$/`H[LG'!?IK:NKZW"JI*P[(H0$=>G8C%)GFKA7
MA<*XO$&F'X#-5E3B+#%A=FL2FELIB*>RXAQ.4^.%8\3+2[E<]L<4CG1US`-)
M+:<<U!A3IK1+#9F\-5N+RTTO2M2N;K3FN-VR*UGD?:AA(>;AK&$PAA:X.,@:
M&EI!H05C+%N_2U/.O5:V[>U?5K-&3%7(KEBO]4"'8Z9K*),-3P@F6BD&DRX[
MB7&LJ;QAQ"L*3XXSC/,X["^FCYT,,KXC]$&.(PXX@47+TOP]W]KFFMUC1-#U
MB\TAY=EG@L[F6$Y"6NI+'&YARN!#J.P((-"I`_L.@1;C"UW)O-/C[`(CUEA]
M%?LP5FXSQ3:7EN$X58<FI-RA[:([F5/(84WC"%9SG[G/AJ%M<&$W(C>;<&A?
ME.4'J+J4KY*KK(]K[FFT*3=,6G7SMLQ2B-]V+>4VK)#0"-]P&<IKR7`!I>'8
MC#$)#V%0"%O):^@7BGSKZ&A-DC%(AV8+)MXH<]AE3,\E6F9JS,&$ZF0WE+KK
M*$*PXGPS]UCQ.MKAL(N71O%NXT#BTY2>H.I0GU4GVON6UT.+<]SIU]'MJXD+
M(KMT$K;:1XK5D<Y8(GO&5U6M>2*'#`K]#;!H5CL-AJ->N]0/6NHK:;M=8#64
M,4L-86_G.&46$+!FOD@JWLXSA.)+3659_8X?;7$4;9I(WMA?Z+BT@.\Q(H?4
M4O\`;&Y-*TNUUO5-/OK;1;X$VUQ+!+'!<`<3!*]@CE`Z>6YU.E2_FE=&G")P
MB<(G"+&&#0:NC9)FP%A@(1"PUF85,3XHP;$P^^W&9S)G376(K&'I+R&T^96/
M,M>$X^G.,<R8Q\C@R,%SSP`%3ZP7+L-/O]4NV6&F037-])7+'$QTDCJ`N.5C
M`7&C07&@P`).`7J+V$!7_EGSXX'"?.S$&O!OFY.$-^;GR>7,#08SXU]GX\P0
MRROT(S7G>=\N?*G/AGE9'))7EM<[*TDT!-`.)-.`'2>"SL=+U+4^=[VV\]QW
M>!\\O*C?)RH8Z<R:3(#DB949Y'48VHJ15>Y!D0X7D5]LJ-6>B#HAB4$1.BJ+
MQA$^3-A02D@;AW,UD=-F#I#33ZD8:<=8<2E65(5C$R/#!(0>6216F%10D5X5
M`(J/*%@ZPOFV+=3=#*--?*Z)LI8[E.D8UKWQMDIE+V->QSF`YFM>TD`.%:A*
M=G.M@,L1`FNPFCPYP02?#E@I3;%"'EAA>*^N+)%$1TL^S,A$HTIM3;C#B$NH
M<3E.4XSCPYS6:7J<C!(RVG=&X5!$;R"#T@TH1Y5[BS\(O%?4;*+4M/VQN&?3
MIXA+'+'IMX^.2)P#FR,>V$M>QS2'![26D$$&BN_&<9QC.,XSC.,9QG&?'&<9
M^G&<9Q]&<9QS@+YX00:'BOWA%#3>Q=?UI9%JPW>I`W1"HB"K):Q"![PYR>.(
MF(#<UJ5+:<C.3A(>7)92O&%.L177$XREM><;X[:XEH8XWN!X4:36A`-,.@D`
M^4@+OM/VMN;5FQ/TO3[VX9.'&,QP2/#PQ[(GEA:TAP9)+'&XBH:^1C30N:#S
M1]SJ)5@!)&6BOSV+6N8U6'8A@>^BPNCF)4H@R%RW(5\S>'QH3RWT,^=3*&5Y
M7C&$*\,703,+@]C@64S5!PKPKU5J*5XU7'N=!URRDN8KNSN8I+(--P'1/!@#
MRUK#+4>UA[GL#"Z@<7-#:YA7$IVCK53$V3C8%,Q'&SS8L@^JS!D,PB-:%2#M
MAA275S$H9D@PD1V9+0K.,QXK2W5^5M.58S[I=5`Y;ZD`CLG$.-`>'22`.LX+
MFG9V[!)'$=,O^;+'%(P=WEJ]D\C88'M&6I;-*YL49&#Y'-8VKB`O3)VUJR$8
M17Y>R*+%..(RX@0_:P31%2,08A3"O@USDOX\PV>Q(3XI^Z8=0O'BE6,YHL[M
MS.8V*0LZ\IIQIU=8(\ZV0[)WC<6)U.#2M1?IP-#*+:8LKG='Z093[(Q[#C@]
MKFG$$+*1;[2)I&RB(=MKDHI36\.VV!',0'I5:;]'XCS'66WU+%^#'W>?6PC.
M$_3GZ.8&WG:UKW,<&/\`1-#VO-UKAS;:W#;VMI?3V-TRSOS2V>Z)X;.:Y?:2
M123'#LUQP6)#;;U9881$D"V-2"P\/)S#+38%H"R8HV7AV3'S&GOM3%-Q'\2(
M;S>4KRE6'&5I_KD*QC-]G=QN#9(I`YPJ`6G'S8>4>NN;?[)WCI=Q%::CI6H0
M74[,T;'V\K72-HUV9@+:N&5[75%1E<T\'`G*P+_1BD*42'7&L3A\&P1JG,G1
M3HQZ)&M$R?"%PJ\_(;DJ9;-321&.PS&SG#SKS[:$)RI:<9P=;7#'!KF/#BW,
M!0UR@$D^8`$D]0*X5SMK<5G<,M;JPO([J2U=<M8Z&0.=;M8Z1\X:6U,3(V/>
MZ2F5K6.<X@--,)$W'J:?.@#(.RJ-,)%#+]>&P(EH#2)DXY&7';D"HD9F8MY^
M:RY+:2IM*<YQEQ/]ECQV&RO&M+W12!H;F)+30#KX<%V$VQ-ZVUO)>7&DZC':
M0P"9[W6\K6LB<"6R.<6@!A#7$$FE&GJ*R9#96NQ0.)9B5ZJ$&NSX[TN`<E6(
M2R)G18\J-"D28<]<O$:4PQ,F--+4VI24..)3G.,JQS!MK<OD,38WF4&A&4U'
M3B%Q+;:>Z;S47Z1::=?2:I$X-?"V"0R,<YKGM:Y@;F:2UKG`$`D-)&`*]!_:
MFLZK(7$LNP*:!E-BHQQ<<O8Q,!_`>9,9'PR?I29;:\PI<Z0VRTYC&4N.+PE.
M<YSCECM+J85BC>X5I@TG$"I'GHMNF[-W;K,0FTG3+^YA,SH0Z."1XYK&E[HZ
MM:1G:QI<YO%K02:`+S![/UQ9GRD6O7NHFI(.8('&6!E@%S'A1"P.-M`H!!MB
M2M<.:9<>0F*TYA*Y&5IPC"O-CQ26MS$`9(WM#@2*@X@<2/(.GJ6.H[0W5I,<
M,VIZ;>V\5Q'*^(R0R-$C(03,]A+0'-B`)D<*AE#F(H5P\[@U1ABRROPE47,:
MF169]M?3:@BF:U!D);4S-..)FY0+B.)>1G#CV4(^ZQ]/T\O<KRK!RI*O-&]D
M]H]0PQ*W_D-O3F6D/O3J/-OWEEL.[RUG>VM60C)61PH>RVIP."YX39>N[(Y-
M:K]ZJ1IT:'B6`@V,L(J:Y!!3HR)D0Q+1'E+5'&R(CB74O+\&\MK2KQ\%8SG&
M2UN8J&2-[074%014C`@>7R+C:AM+=.DMC?J>G7MNR6=T+#)#(P/F8XM=$TEH
MS2-<"TL%75!%*@KB2]MZM@>O\9L:D1OAJ_!M;_K6@*CTZR37%;&GU>,S_DD@
MN<QAA_\`X-W+[?ESGU$>.3;.[=Z,4AJXM]$^D.(X<10U'D*WP;)WC<Y>1I6H
M/SW3[84MY36XC#C)#Z/V1@8_.STFY'U`RNIR(VS];32B0D2_TR286\(C-C&+
M,&=G.R#\%TH#CLQD3,O//EQK"Y$9"<94\RG*T8RGZ>0VETUG,=&\,QQRFF!H
M>CH.!ZBM4NT-UP69U"?3+]EB&RN,A@E#`V%XCF)<6T`BD(9(30-<0UU#@N'G
M<&I_E>3>-FT%8?TIK^";=O`.P5,CE!D$'$26YZFG$PEV,?AWRYSZ>9\?&?#+
MS?FO<KS/R^5)GPPRFN-:='3E/K'J*W_D-O7OGO>=(U(7V9@Y9MI@^LG-+`6E
ME1G$$Q;7B(9:?8WTY4/:6LR+Y2-`V%2IKX1X%&+M1;0%?6,?L\B%$K;,Y+<U
M68SA^61CM0\+\,R77VT-^92TXS'6ETT`NC>`ZM.R<<M<U,.BAKU46F?9V[;6
M.&6YTS4(X[ALSHBZWE`D%NUSIRRK.T(6L>Z6GV-K'.=0-)6/K^Y]1VLK$!UC
M9E&L)F>Y/9A"@UH#DB$ET5E])-MF)$ENOK7`7&=2]C"?VM;2TJ\,I5C&4EC>
M0L,DL4C6"E26D#'ACY>A<G4]A;WT6S?J.KZ3J-K81!A?)+;RL8T24,9+G-``
M>'-+<>T'-(P(K9G.*O))PB<(G")PB<(G")PB<(G")PB<(G")PB<(OE`[M?\`
M*G^\$_W"]OO_`.>JKSZSI`'=]O\`_;/G.7]H?B__`,`^++_&=Z?L;E2+_>(O
M]%_I+_=PQ_!U7^<;P_`.IWU?I?U7KJO_`&O/];WB!_%XOY;.M3M[?RK'M5_Y
M+/;R_OU&YW6G@?DOJW[;=_L7+[5X<_X-/&7^F-Z_N3E<1K_E5W_WEW'][X7.
M.P#+_P#:_P"J5X73_P"!M_V2_P#CO78%U$_P:>]]_&K[A?\`8*7SS6J_PS1/
MXM;?/:OS)XW?VM^+W_<W;'\L8OGCT%_)`=^/\OG6#^_&>?0+L#\KM/\`VB3]
MBQ?U`\2/\<7AK_=O7_W(+L\Z>_\`-_V#O[F>Y'_>R]<\]JX&;<'GLO\`B+\B
M^.7\Y?&3_;=B_NEHL#TB_P";_L$_Y4^_W]]"G,MP@<[7OUEI^P*[/XPO\Y_&
M4_H?9O[E&O?VP_\`:*-#?]*.OW_9-/-6E`?!].>G))\]ZT^"_P#NNMQ_Q/6?
MY0Y:F]0_\-7O6?Q1>[7\(\3G=:J!W+1/X[;?.<OM7C?_`&`\`/[[[4_D+UMP
M%_Y:-?\`NT$#^]+'.I<!A_>?]4KXE?\`\!@_VM'_`+HY37OW_("=-O[F=8?^
MP![G%V\!^7MWYY/W1BZ#XM7^\LWW^VZ__+85U=]VO]%_V?\`_(9;_P"%(7ST
M^@`>^6K?MK/V`7Z_^+Y_K?\`''^\-K_5[UV'^X5C_C3WT/\`I/[97_PAN=)M
MX#EZ!^MO?GE?E_XL7\"^+K_%-^_]*NT_I_\`RK/N??\`0?II_!%GGD=8_LMI
M?ZZX_=2OQSXY?X,_"'^D-T?UDOFSZ=_X/?>0_BXV_P#A6SSZ+K0'/TG^,#]B
M]?U;\=O[3^!7]Z;;^KBMB>E'^A+[?7_KO=9?]B1'.-K('OYJ/]!R_LW+Y?X_
M_P"(+Q._V>]0_E<JL]/^#4+_`.\AR/\`YJWSA,`[P[^[?ZI7DC_:RX_V4Q^J
MI![[O\HKT>_Z,:[_`(=2W-.Q@/R<O?U[OV#%U/\`[<W^%KQ#_CE[_5$2QNJ_
M_:+MO?W0W7_J[$N9W('P=Q>:/]U8N9O'_=:Z'^U:5_7<:R?0[_EWV,/\G?N1
M_P!\-B<;A`_[]_7V?_1KB_&/_F_XQ/\`2FQOV%BI_K?_`-FRV+_Y+L+_`%HU
M\XUX!\)+1T8?N"\QNS_>NZ7^NLO_`"^NT[V4/Y,WK5_Y+LO^%^_\\MO?^TUS
M_P#+_<V+\<_'_P#\6N[/U]A_5EFNU+GE%^-UTR5ZY]4:)0.Y%%[>0ZD7VY8M
MY[M(;`UW8(<5_<.[*K9;:3>T!'U*#?>A7*ZQB&L700NK*".9P-GQ<M-.Q9$=
MY3?M9(=7GN+*XT<O%FV"(,>*\N)S6CF\PXM;1^9S\PQ!Q!!%?WIJF@^,^X]R
M[$W'X'R7T&R+7;NE,LKZ%SAIFE7$%M&-9.I3`/M;1S+\7EQJ`NV^WPR![V31
M2L#NW!`UFQT=`AQ%GK$8[54C5M)+RQESK[!,1B,MO!X>1F3A]G%-O^'QC$MU
MYF4WZB'E*QA>?(9C%<9^P\M?7A5IH>H@`M/412F%%^)77<FE;A-\TV=Y+;7N
M<'E-DM9C')F!Y+V-8^WD(KRGQM:Z,Y'1@$M74M09G6KKYU'[**W+7D3-*ZX[
MN;:2`I4TE.GNV.SA-T"YNMZ^N383L9-DFD;K'ANN.')RX#J\+D$W?AT/NI]=
M<,U+4-8MA8NI>RV,>9P`%`Z,YW4:,.R3Z(KT-%:+]K;E@\6/$WQMVF-AW1CW
M]JOA]IIFNV1L8(+>72I&7TP;!"[D-9:NE:T6D(F:"V*T9S71L.;UB:ZYHUK;
M=N[-O_7\J4VWV@$WO*M?$A>T>O?6C=;NL(M4U=%N1FM%@]=G318:O17BQTDZ
M*A%K,10IE4?+D%W&N[CU+O;+.UCN0V&U+.V"R:://F>6@@D`DG*T9BU@QKV@
MNOW?I_BF=V6.R-HZ9N:&ST3:$EG^_8Y-/UK7M*&H.N=0=:Q3QRSL9)+-(VVM
M(&W$MM80.$@E#;AAI(`C:9_J$1U;5=;67;>DY^U^WKVX=FZ<+:_IP/;M4@VD
MY;`DC75>N%YJ<2L:?VM<+3*CD&04XLVP(`38,1Z6DDW*YSG]TCU@74TC8;X1
M6_+9*'N,;BT-.<M:XNDC:T$9PWM/:X@9:+Z#J3MFZ9XX1;PUG5;31/$"/1=M
M#3+#5([VZFTVY?;Q6THOI[6TN77&IZ=;6\;X77D-LY]S>07$T<)M'0K+2F:)
M;=,>W[8-M;E'=69M4Z>'WJI"VUJ_5]XJ1Z:JI:B&R3&+%<"-DUNT82"KS4V(
M";1FQ3`9.1EK,%UJ2EO$<^&^U".S@-V'W@S&-\C7-&:0THT-?2KJ%U<@<T>D
M*+A0OW'HF_O$W3-DZ#+O&"]WU"+A^FZAJ%I<PL[SJ4C8N1:L@OC%SIG127CC
MW**[MXLXN&/B+JIV7;;99L+V1N@GJ#1\NT>VUJHQ3M9[*U4-L%=V/8V"FRY>
MR]%TRNVB?`F`QEGDR*VDD!#>%NRW/$-M/)5"PESE6L,,?[VLFS3ANI2!SV2$
M%C:,R2N+0:EO;HYWM>#ZCM8>SVEHFBZ21M78,.N;AAL_%?48KJ_L-1DAGL8#
M'8-L-7NI[=CVS26[6WQ@O+K_`+MS0WKWL(N"6[X['HE1WWN/JMJ*V:FJ@-4K
M6\?LMO865KH@A8OENL_J0"UMJ,K8)\!\G.%_A,L3<F<VXOQDQ:MF,OQ9D.HS
MT%M/-865W>13/<!+R8B"<M7YB^0`&@.1N'47U&("_.&U=QZYX;;$WEO?1=:O
M;@,U5V@Z1)'/(R#F7_>YK[4HX6/$;).X0.9$YH]KDU`3-I)$QPU(V'(C*[1W
MXTZ?ID`W&]P?KJ08ZV$`\9[L5?W@%6US2Q>VJ1?'IR#PK6'R.5\^6,9$3!:@
MP0G'<*Q$S)K+';VP/O3''ED,9T^8<X$\EE7/<8W,X%]1DKF!S.:<AH"?MFUX
MI1X/:;8,M;^33W^&.ML=KK)7#1+(37%]=2:;=V8889-0YK>YB=US%<"ZN[25
MME,8+=\F2KD6;`[!:AU/0#.F+58ZG[@.Z=E6:V`)MC9[*O58^QMLKLJ'MBE%
M:>)>J-<!PK+&#9L3A><+M`](1,!A*9#"FY(6G3IKNX;.R-^GQL:T@<C,.6&&
M-X<<Q.4NR90YASYC@5Q=5F@N?#+7-Z;EM]?LM*O?#/2K""VF9`=!%Q"[38[!
MVG7<=S(+F>9T$EUW)MM%<:?,=0-S(3%('2+J:_59EG]O:NU#(Q>Z]>5;L:QV
MK'C<Q<W6LO2@4J!L!C;S,?&"XV59NP;@R9%24PA1&2UF3']5"%.8U:N)6Q:C
M+-F[C(^'D$URNQJSE]!I#F!R\!@:+JO&J/68-(\3]4USG#8&J7FAG;KY,W=+
M@-F:^R.FEWM4C;?11/%(;>H@8X12Y"0U=W'/#K^?2<(G")PB<(NM'W#]VZZS
MJK:'6^0:3`W%:`^FR%#IQ%"(9'9F;AN$4#AP-;1WG$R;L5#SP#N2D:`V\Z-9
M=9>?PAIS"^>GVY8W'>XM2RULF&0/<,0S+&35_0T$'LD\<0%^M/BO>'VZ1O/1
M_%:*W,FQ;.?5&7ETPET=AW73))G/OG`9;2.5DS>[OF<UL[FO9&2]I"D?N(ZY
M!;<K76/6UE66CA;=VWU\-E$`)!\2>#24:^VO.$V`$6C?MPPY7C,2/.AOX\<-
MR8Z,YPI/BG.G;L[K62ZN&!I>RS<0'"H/;CP(/01@5U/Q7=TZCLG5MW;KTD0N
MO['9-[(UDS!)#*TWNG,DAFC=A)%-$Y\4K#Z4;W`$&A%;]1[ELFQ=R]VU+<XU
M<?;NG^L>B]9WL_''J@UW8KH_:6^#%;VI4O#'HX"["JQ:)/>BHS_Q645+@JQX
MQO%7*U:&VCT2":S/[UFNI7M'2RL<0+'>5C@1Y6T=TKU?C;H.U-+\!MOZUL*4
M.V1KF[M7O[.%S\\]B'Z?H\4^G7/3S;*XCDA;(?X1;B"Y&$U!:=]U]19?N!:&
MS)I%2DH)=:.SY0GE^M!GL3RJ-E=:\M$9RG(2OBB"?BWLI=<\SF/57X9^Z5X\
M6WN)QMZXH]X(NH`.T<!DFP&.`P&'D"\=MO<VXH?BS;DY.H7K#%NW0(XZ3RC)
M&;#7:L91_99V65:*-[+<,`NP#]CZ,?1C'//+\SIPBTVVYU@U]L/8!ZZ6+8$R
MORRX^N9)A6I`N&PC(V).J5;,J?<>CDH\MJ.>+P8DA+C><+*.I;5ZF$>'=6>J
MW-M;M@CC#F@FAH3QHYPZJ8-)'^:.A?=]D>+VY]K[9MM`TO3&7,,$L_+E+9'$
M\QS+F>*@#F%I=#;32,((I;L+AE+J\E&I]8#?P3'L[EQ%@:[NMD;U_.?M0A<<
MM9;+?)9>S!2YB<1D2;G9B(MN2#DK??=(.J7)D.Y7+<<5R=[NW\Z/D5=(QN<9
M3@UK*-(`'9:#1XH*<`,%J=O3=]W[]Z;[PY[G5-/@-ZP6\H,<$%FV."6*)C`V
MUMV2&.[C#&-A:!%$S+"U@4!/=7]>DV2\FP;RQ$'._6PS7H4*4!#5D`,L`B-+
MNTYT0\5DBYC!?7\I:"'P^((IJ'-<ELQ(^7W%N<AFJW+2T1P5=V02:EQ(-&XT
MK@_A6KJ@-)-%Z73?%_=%H^"+3-NY[H=VBG>YLTL\TD,KFVC!*(VR-,5ZT&'.
M9KATL387S2\MK6\`5UAT9`KEG,?AHB%T%ZG&)C[62M(MRO!T`WG0@J^SQ@\\
M/K%D;`Y99@1Y4Y*TP\Q_(R\RZI:N9/U2_=*QG(((?0M#34UQ+`2TN;7$D#C7
M$$+DWOB]XBW.JVEC[P/@=!>NC?;QV\@GE,P$LEFR1\+[B`S5=,^.(@RY\TC'
ML#0I;%':Z@,[8#.]B=4DSNRC0PHL8NR0Q:(=N)_+RL(:H4_L,_$9%V+X!/I1
MH\%F6]%=5E;LK/@KFDNNG&%XMIA'$"*Y:]D5!-<@-6UXDD5ZETDUWNJY?HM^
MS:^LPZ;I-O)&)!`Z0NMH\\;W\P64+C)!G.:1\SHVR-&5D(J%X6'4FA;\\HEG
M<P)Z:?E6^,!EBKH&7'5*DW&_[$LL2%!A'$#CTD2WLA:'$O-ON0V&&WL>FIQ2
MLH[O4+<9.2[*T-K5I^E8QM2145R>J:C%9:7O;Q(VU&+0:#<MM[9ELZ9LEK+F
MRMM;.Q@<][X3)"V0V(+2US&RO>]G:#0%[C>CM<C:;8*A<=WQ009C8_UK<S'+
MA*:Q63<2H.2:T+3'DF'X8>4+<GQK(N,PF'!=D-,O,0HL=2D+,O[E\[9H8"Y_
M*R\"[,,W:/"IK0LJ:D"H+B5AI_B'NJ[UZUUS0MO/N;]VE=V%8I;HW$3KD-GD
MS-B#I6R!C[$2/,LK6.?')<32@%O%K_6*M!R]</TK<[J24ZGEY$6?)F3#LDM`
MG1ZXP7M58D0[J.PT`@RH\&3$@KP0KPV5-<6W%3F5X92:I*]CHYX.R'@4H!0B
MM&N[)Q(J"<'N`Q."VZGXNZM?65UIFX-`!M([Z)KF-:V%L;V.G,5O<!UH^LSV
MNE9),##>SQQ-:^8\E>IW1&J)NO:K6ZKNP2BMU]=ME4(H0,A+(U#@6>W5-J6B
M$:@G0Q5U8:Z1$L0YL"?#EQ9\]J/AWQQAEW(7]XVY?+-`[FNRAX`+:EK74J""
M,6XD$$$`FG2-C/$?>EON>]U;6=OS'5;H6S;R-D4L!<^WMKDM+XGPRQ@2VKB^
M6*:&6.2&%\I9B7LY=XU!0MAW6#%'[[`P[,!$TL=)`1B`MVQDRE&LD9L;*M3-
M8ME6)SF5F(#C.$I:C$8L];C<:<PRIV&O&"\N+:`EUNXQ.<XUH:`.&.7,UP&!
M\H(Q+2:.6C;N^=R;7T"2:ZVW<R:3<SW4C9G,D$$<=W`XR-MS<6UQ&PB)[7U+
MGP20AKIK>20,G;9+=;IEAK=S:KFVJM*,2]@:WGR+#"F"CPRM[&HS=`!`@D\;
M]8GI#[Q8S3HS;@Z3/3/=7,4RE[U<H<YQC)/'*PRPO#!&_LD$%S'9R2#EZ`XX
M@4PK2F"\F[5M>TO5;!^JZ)>,L6:9?,;`]LD,D]C=F\FFE9)R`T".*ZD<V>.$
MPM$8D<S)F:HO3-3:2HU?,5%K9HPC9MM@CE6%&RUQ@/DI\.Q#(P^?%I%;>,K"
ML(E3(B)3S0N,U\6^A&7_`%%(2K&V>[OIY!-RB(H7!Q`;@*&HS.I7R#,30<*+
MN->WKX@[BU.#6WZ1-%I&B7,5Q)%':O$;'02.>QUW.(A*<K7&-KKB1W+87"/*
M'$+CG->ZW&9M:SN]*_7Z_9!FPZN-;?*58).#/7D[6X6U6L6&452HG-49JJ84
M=&6FG`[SSC2\O.(8PS8[BZ?DY=NYTK2QQP<0<H<8\*8"CJGZ84(H*UVZ=N?=
M=V+)NG;<N;G4[66RN)"([B5DHM(9WZ<>0V/VMG*N#*\ASA<M:U[<C72<SCQ-
M`!Z2-FC1.ZH@@%22`798YBS"JX7>J<T8W`$U8K:"\TG!G2:5"J%+0.89RX/4
M[F*Z]\7G+:&V:=0?.X.?`722`L.4N&:M2X-`!&;,ZIX\0*8U.V?Q,O\`<%U'
M=7N@/GU'4(I;!YMY)XA<LD+Y+B.WB;&]C;M]S=&=[LLP;S&1\@![G21T[UPH
MESS7&)6]8R\#3.;;K^2&:I<$S'L&Q6I-C(F6)0]Y$(PBS3@+\X.U'B,,QH4>
M0VUA]M&%M;(]2N(,Q%N<6Y7US$49V0,<1E!`=4U)(X5H>TT[Q5W'H'>I(=N/
M!E@[M>ME-T^)T-B6P,B<UX+XC;LF9#=.?(]SY7QO>8W.ROB]$ZS:7"G&2^M]
M[`))VF2F35?A,S*C8@U5)+AAYTJ61!#RT:0_",5>ICDR$*D1E*C#6I#3K:F_
M4QMN-3OGQY+JW=RWX$T<TN&(H#3H<XTP.+B""NWW'XM[^O\`3W6.Z]N7+-.O
MV&*9Y;<P2W$8=*QK63/C<T.BN+F<L(8\"2=\3V/#LJYL'K/JNP5`8PWOY@KK
MS#]I54"%:*5B`E9*5!19+`^Y:QA.1&.O`;!4F#K+#"8[`]`Q25-Y;2MQ,.IW
M<<Q/=R+GLY@X..%<H[)&%0XL)-2<W%:+CQ;WEIFN32/VRZ'=&6W[RR>.X?2-
MKS!"!;21AT(FAN7VCGO+WS&X!#PYS6FY:K1*@#W`$+CMNUXG:G@5D=GTU<]G
M!H["/W.^7]\R/$"+?`CIB1Y]]?3YY(PDVEAE&6E,KRI>>%+/,^S<QT+A#F;1
MU,`0UC*$EIZ&#@X8G&J\'K.Y-<U#8UQ8W6AW4.C"Y@#+H,/*A=#:V=F(GRRV
MSW9G,LV&D=Q`XO>X/$C0&K:CG4KXVG")PB<(G")PB<(G")PB<(G")PB<(G")
MPB^4#NU_RI_O!/\`<+V^_P#YZJO/K.D?P?;_`/VSYSE_:#XO_P#`/BR_QG>G
M[&Y4B_WB+_1?Z2_W<,?P=5_G'\/_`.<[[];^J]=7_P"UY_K>\0/XO%_+9UJ=
MO;^58]JO_)9[>?\`?J-SNM/_`++ZM^VW?[%R^U>'/^#3QE_IC>O[DY7$:_Y5
M=_\`>7<?WNA\XS/0_P#M?]4KPNG_`,#;_LE_\=Z[`^HG^#3WOOXU?<+_`+!2
M^>:U7^&:)_%;;Y[5^9/&W^UOQ>_[F[8_EC%\\6@OY(#OQ_E\ZP?WXSSZ#=_V
MNT_]HE_8L7]0/$G_`!Q>&O\`=O7_`-R"[/>GO_-_V#O[F>Y'_>R]<\]K'I;@
M\]E_Q%^1/'+^<OC)_MNQOW2T6`Z1?\W_`&"?\J??[^^A3F6X?LVO?K+3]@5V
MGQA?YS^,I_0^S?W*->_MA_[11H;_`*4=?O\`LFGFG2O]7L_ZR3Y[UI\%_P#=
M=;C_`(GK/\H<M3NH?^&KWK/XHW=G^$>)SNM5_@6B?QVV^<Y?:O&_^P'@!_??
M:G\A>MN`O_+1K_W:"!_>ECG5.Z/[S_JE?$K_`/@,'^UH_P#='*:]^_Y`3IM_
M<SK#_P!@#W.)M[^WMWYY?W1BZ#XM7^\LWW^VZ_\`RV%=77=K_1?]G_\`R&6_
M^%(7SU&@?SEJW[:S]@%^O_B^?ZW_`!Q_O#:_U>]=B'N%?\J>^A_TG]LG_P"$
M-SI-O?8]`_6WOSROR]\6+^!?%U_BF_?^E7:=T_\`Y5GW/O\`H/TT_@BSSR&L
M_P!EM+_77'[J5^.O'+_!GX0_TANC^LE\V?3O_!][Q_\`%QM_\*V>?1M:^SZ3
M_&!^Q>OZM^.W]I_`K^]-M_5Q6Q/2C_0E]OK_`-=[K+_L2(YQ=9_GS4?Z#E_=
M'+Y?X_\`^('Q._V>]0_E<JL_'^#8+_[R'(_^:M\X;/X0[^[?ZI7D3_:RX_V4
MQ^JI![[O\HKT>_Z,Z[_AU+<T;&_LY>_KW?L&+JO_`&YO\+7B'_'+W^J(EC=5
M_P#M%NWO[H;K_P!78ES.Y_U=Q>:/]U8N9O'_`'6NA_M6E?UW&LGT._Y=]C#_
M`"=^Y'_?#8G+N'_Z]^OL_P#HEQ?C'_S?\8G^E-C?L+%6!K?_`-FRV+_Y+L+_
M`%HU\XUY_K*;ZG[@O,;L_P!Z[I?ZZR_\OKM-]E#^3-ZU?^2[+_A?OW/*[W_M
M/<__`"_W)B_'/Q__`/%KNS]?8?U99KM2YY1?C=<)X:.D2XL^1`A/SH6',0IK
MT5AV7$P[CRNXBR5MJ>CX<3]"O(K'CC]GF0<X`M!.4\0N1'=W44#[:*61MM)3
M.P.(:ZG#,T&CJ=%0:+F\Q7'7&=APWVU,O18SS2W,NK:=8:<;6[G.<Y<4A:<I
M4YG.?ISG'CRAQ!J":K:R>>-XDC>]KP*`@D$#JJ.CR+T9$BLQ)$#(P?F#,2I$
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MJ%[_`$T>?U?(CU?)Z?J>7'G\GCYO)Y_#S>3S?3X?L>/)7HZ%KS.RY*G)6M.B
MO73K7'4/@+FMDEPHBR++"XK)!49E4UJ,XK"W([<K*,OML.+QXJ1A6$YS].<<
MRS.RY:G+U="VBYN6VYM&R/%JYP<69CD+A@'%M:$@8`TJB($%J8^0;AQ&Y\II
MIB3.1'91,D,L>;+#+\E*,/.M,Y5GR)4K.$^.?#DS.+<I)RCHZ%'7-P^!MJ^1
MYMF$EK"XEK2>)#:T!/20*GI7ZS!A1Y$J9'AQ6)<[+2ITIF.RU(F981Z;&93Z
M$)=D99;SY4>?.?*GZ,?1P7.(#230</(DES<2Q,@ED>Z".N1I<2UM34Y031M3
MB:4J<2N5R+2G")PB<(G"+BO084A^+*D1(K\J"IU4*2]':=?AJ>1Z;RHKRT*<
MCJ=;^Y5E&<>9/T9^CE#G`$`FAX^5;F7%Q%&^&)[VPR4SM#B`ZAJ,P!HZAQ%:
MT*]ZFT+\N5H0OR+PXCS)PKR+QC.,+3XXSY5XPK./''T_3R+6'.;7*2*BA\HZ
MCY$PVWAQ3N$(PZI*4*<PE/J*0C*E)0I?AYLI2I><XQX^&,YSRU-*="9G%N2I
MR`UIT5/31,MHRM+F4(RXE*D)<RG&5I0O*<K2E?AYL)5E&,YQ^QGPQ_2Y/)T)
MF<&E@)R$UIT5'##U5Y\+%.$6K.\M1:^V++,3S^R8^OY*(5$BG)D"14XDM2:3
M8RFP*XU89!]F6A^`TXF3+C,NH1EA<?,II>,MJYVMA>7%NT-CB,@J^@.8^D`Q
MU*=/`$]-:'BOL?AWOC<^UH(+73-)=J<1DO'1->VY<W]]P1V4YA;"6D/(R1O<
MTG.'\E[3G"P@'1@QL%3VZUM&K3I,G%H9A$UU8%80]BJ1L53A$Y->#.GGH"CT
M$311RLD\KG1LR')3KD3*)"6FMDE^[F/YL3P!EJ,Q!#@7$9C2M"7'LX&E!6HJ
M>PU+Q$NWZC?/U;1[R.)G=R^,7$T$L%S%)=2LY\HA#Q"^2[G'(I"_(V%C9@Z,
MO?6,KJGK(H);6,WW+:'!@4P!#E?6**>B0\CJ4#UIM-V<3+V0B4PB;6!$>,N.
MQ-AM`7,XRG&?N4\Y0U:Z8^CK<9G.!/9IQ<7QT`:!@XDU(.=>NA\9MW6EZ6W>
MVV.NI[ELSV\AT+GY[N:_T\,CB@9'5EQ*^0/?%*Z\%:D8E99KKG2A=V:DB=]P
MT7@05>F`P%ADB[$XH%%V'^$.$+N0Z996;?;YK.RG4/S";D^-)EYPEM7DD^$C
MF!U*9\%'VYY!&);5N)9D):0W*T9,`VA`\V"X3_%/7[S;YBO=M2';T\(;--`V
M2`<YUEW)\EK(V`VULPV`+(H&PR1Q]IPS1>U*82M15<J;8-B]O5!)_7A\%+N>
M(<9`^$/EPJ,W0WQQ891KY3W:TF?F&M]F'+==A(SC++D60E/CS2+R5C,CX7\N
M1IRUQ)!?GJ"YCLU.!(QZ:A='#O?6++3W:?>:'?'3-4MIFVN9Q>][779O&OCD
MN[.Y$^3,&.EC:V4X2-FB)HJ_D]:*C36Q$43N6OLR769%:%L7*<Y(.60LFGC*
M%]4?K%.N3CL\$X7J*LI$R8)3`KTULC40WV$/(Y+=3EFS%\#J>D2T8-&8OS4#
M<#1WI`MS<75!HO31>+6MZ\Z>:]T&Y=$US9Y#:L#88(^]27G>>0RU`9,([D5N
M8YK?O%6R7;IXY'1NRM^ZUZQ)7DGL"T;H;`1\6&H%#$1PP.KSL6R4FKTZKR2&
M+/'/#"X:RSJX,AM+DM.-28K<IO*/IRC*L+?4[IL`MXH,QRN`-":ASG.IEH06
M@DX<#0KA;:\6-W6NWH=LZ/H!N9>ZW,<3A$^<.@N[BZN&L[NZ&2*6!D\DKA&Y
MKF2.C<'<'`3L+UYKD`OKPLQLU4M^D:OFTX1"^$"21IZB%8-CB'S1F'+DS\F'
M[!-.BILZ;E68DF8)86ZTO#N4XX[]1D<R1ABH))0X\00\$4`I2E`'`#B`XT."
M\[?^*&J7-CJEE)I`9%J&L-NI7YI6OAO(WP.ABB<UK.4(60W$445.9'%<R-8]
MI8":=QU,IUH!CWI/8&*31+'C1(1\(@9)K"*;(N$<E$#!&S%JLQR8B3L6(,<A
MRWR\Q3<R!'BMX4EMAIKF^^\T3R!;$4))K7-FRTJ:-:!V,U0&C`D]9/N3XU:[
MH^HRLAVR^%S)7R2B4R-N.]-M3&Z64Q6]O"TML77#98V6T0=%-+,X@ND>^1T_
MK;K8&2=16MQ!#FT!=U"7B!)*S$FXP@HDHQ+/O2M>B;L)BJ(W6;#DIDSTYCS,
MY7EM*U(0IM6J?4KF1M98'-M2PM-!2HIV>V6'!H(H,0NKUWQ7W7J-HUVK:%<6
M^T)M/EM'MC;RG2Q\LMA#;V2TD=R[1CF&.$A\6`<6AS@X9<9HJJV766:(QO,:
M1""]H/G8QVG3G'9$2X)63D5H#+6<O=W%PR0"VEHA%F%`:&MJDPV,-QFEJRO.
M#K^:*ZYYMR'F*E'#Z'#,11C#0M!!)S8$XE<&[\1=9TG=WY1R;=EBU";1Q"Z&
MZ8`UUK2-L\S1#9VDCHYK:.2!TLSIR(Y9"Z5[0&B.5CK)2*D>`0!N[Z\Y&LT8
M.AFK2QP-<\M&@FJ;?S3FMULVAAX-@];*THJK*8Y1$/!1_P!#",^BZWMEU2>:
M-SG0.JRO:!-!4.8,_9QHUV7BVN45Z0NUU?Q<W#K>G7-S=[>NA+:/E)N&R3!D
M;GQ75G$+ZMN1+R;:<6X!?;F4V\?,+O;&.XEGZM:E4?L%EL&]$5^-:++LTA`:
MB'1E3>$$;^7L_P!9!@4W"L$&8OR7,R^Y-CJRM$R2RN-(;RE3C?+%JMWRVQ1V
M^8L:P'`NJ&!M"06GZ$8'H!J"MVC^,6]AIEKI.F;=-U+9VE@QY=#)<B5EG%;\
MB26)T+VXVL3&Q/%#&QS98G@AKE:IO00!HKLRRS]DBX,JPZY%5JU"R8P?&IE>
MK@*+7_J>0<$QS@LH$%A9=8+OLNX)1W&_FDI461%>90^GB,U"0LBB;$2ULI<T
M@G,7&N85H02<S1Z)]$5!!HO&Z?XE:F^STC2;;29I(;759)[>2.1[KJ:>9TW>
M6"1T,D<LDK;BV8YI@>T]WA$T4S)'1FK9'4FN&70I%WL),E6.0[4YR"K+(!],
MYP%72+&MI(%EPL_.;>&@G#3C$AZ40?(,3);JG%+]9Y?+&L2,#FBV`B&;#'"I
M&>N%,3EJ`&@$`=07L8O&S5;!EQ:LVQ&S2F"Y88R9AD$T[#?MF(C#"))A:M>Q
MD<+(7Q0L#0W(QO.J'6W5@87$'Z\V]6I)VO-VD06(S)F+;''4JV54Q"=K`NNQ
M;U!'TUN$-(_,&WF<8;?6SZS[+R<^*<)M2NGN+KF%PC=E(`&6KFN!S%V0EU2*
M4Z*T!"XVN>*^\;^\?=;HT.[9IUT;>6-C6]V<^ZMKB)XN))W6;WW1=(SDN8[%
M@?RXWL.!R\_0M6OFM=:C\;U$R1]''6D;5+179'SBOEB$V$W$,RYKELO=XFE_
M@J0,*P)$9LJEMN'-EYQZ3*/23BW4)K>ZE<;=P=(6ES78$"M0!E8T"KBT@Y>(
M'$XKA6WB1K.V]V:M<_DY,RZU&6WDN;>=O*FC8UY=$U@MK.T9%GNY+>9DAMRX
MRQ0^G([.>3K3KW3=>[`%#A&WPQ:-#*#;>%H<J,*<ND4=5Q=Q"U8:,,M6+,S-
M0KX6Z+BJ\1KC[T>*PVJ2E'JI=EUJ,UQ;N>^%S206E^.6KBTN)&6F8EM?2H"3
MAPIIW9XGZ]N?;,UU>Z'/!*^%]M+>-=(+5S[B2UEN'R1&#+WF:6U$@]O:QKY)
M'"$NR%F[W.B7Y[3A$X1.$3A$X1.$3A$X1.$3A%\[?^\P]N>R73+HEK3:'5W;
M=@TW?S/9^C4DI9ZY!KI"=,JI/7VTRT\*XS9@AV`F-*(@XCJE)92[A3"<87C&
M58SLC`)H>I9L`)Q7PS_;X>\/^?EM7_JSJ/\`%QS;D9U+9D;U+[%_]UP[R=M.
M[NK.X9SM=N^S[L+:]V=K`+2YUF&U4<[7Q1NFFR)6%$35J]7VG6YLV,VXK+R7
M58RG'ESC'CCFJ1H:11:W@`X+ZI>:U@OE`[M?\J?[P3_<+V^__GJJ\^LZ1_!]
MO_\`;/G.7]H/B_\`\`^++_&=Z?L;E2+_`'B+_1?Z2_W<,?P=5_G'\/\`^<[[
M];^J]=7_`.UY_K>\0/XO%_+9UJ=O;^58]JO_`"6>WG_?J-SNM/\`[+ZM^VW?
M[%R^U>'/^#3QE_IC>O[DY7$:_P"57?\`WEW'][H?.,ST/_M?]4KPNG_P-O\`
MLE_\=Z[`^HG^#3WOOXU?<+_L%+YYK5?X9HG\5MOGM7YD\;?[6_%[_N;MC^6,
M7SQ:"_D@._'^7SK!_?C//H-W_:[3_P!HE_8L7]0/$G_'%X:_W;U_]R"[/>GO
M_-_V#O[F>Y'_`'LO7//:QZ6X//9?\1?D3QR_G+XR?[;L;]TM%@.D7_-_V"?\
MJ??[^^A3F6X?LVO?K+3]@5VGQA?YS^,I_0^S?W*->_MA_P"T4:&_Z4=?O^R:
M>:=*_P!7L_ZR3Y[UI\%_]UUN/^)ZS_*'+4[J'_AJ]ZS^*-W9_A'B<[K5?X%H
MG\=MOG.7VKQO_L!X`?WWVI_(7K;@+_RT:_\`=H(']Z6.=4[H_O/^J5\2O_X#
M!_M:/_='*:]^_P"0$Z;?W,ZP_P#8`]SB;>_M[=^>7]T8N@^+5_O+-]_MNO\`
M\MA75UW:_P!%_P!G_P#R&6_^%(7SU&@?SEJW[:S]@%^O_B^?ZW_''^\-K_5[
MUV(>X5_RI[Z'_2?VR?\`X0W.DV]]CT#];>_/*_+WQ8OX%\77^*;]_P"E7:=T
M_P#Y5GW/O^@_33^"+//(:S_9;2_UUQ^ZE?CKQR_P9^$/](;H_K)?-GT[_P`'
MWO'_`,7&W_PK9Y]&UK[/I/\`&!^Q>OZM^.W]I_`K^]-M_5Q6Q/2C_0E]OK_U
MWNLO^Q(CG%UG^?-1_H.7]T<OE_C_`/X@?$[_`&>]0_E<JL_'^#8+_P"\AR/_
M`)JWSAL_A#O[M_JE>1/]K+C_`&4Q^JI![[O\HKT>_P"C.N_X=2W-&QO[.7OZ
M]W[!BZK_`-N;_"UXA_QR]_JB)8W5?_M%NWO[H;K_`-78ES.Y_P!7<7FC_=6+
MF;Q_W6NA_M6E?UW&LGT._P"7?8P_R=^Y'_?#8G+N'_Z]^OL_^B7%^,?_`#?\
M8G^E-C?L+%6!K?\`]FRV+_Y+L+_6C7SC7G^LIOJ?N"\QNS_>NZ7^NLO_`"^N
MTWV4/Y,WK5_Y+LO^%^_<\KO?^T]S_P#+_<F+\<_'_P#\6N[/U]A_5EFNU+GE
M%^-UIS7NY56M7<XQTW"Z_P!BI)5W3=PVJ6VL>KA.L:\GD:===<4\I1:/*.P(
M4G8$\9C9$201*#/5#P5^6)B0]+^(:BVF%5:855A7C?T&D]CM`==GJQ-(S]]4
MG?%TA6IDC&8@5IG1F-69FCYHQQA<DB]8_P`*#?HK;<;3'^#7Y\*]1/E4PJE,
M*K]TMOZ#N6]=F:/$K,T`]ULW9"TN0(RR,:<S;9DS3VJMNXL`^.PPRX+B-Q=I
M-P<L.J<<R["6YYO*XE*1%`#UH11:`'O=`V95JIMW>A[I],QU1TEO_8^C[WMT
M1OJHS[]%@ZPW7,T99-A0-,3ZB&=)"6+)#5+P/9/+).P<9]!M^1Y&',LO17%7
M*.%<5NKV.[65SJW9=/R]L`L@M%;*L!:CVWL',/P(%,TI=WX+4S74;:$69':4
M#I6R);$L4Q8E24P1IKX*++2VF>T\C$"O#BH!7SJ8=:=W3NQ>JQVX<ZZL>MZI
M<2QJ;K&'<'?1M%OU<B9EFD[,+UU<*',I:-B"T8*P1$O+D^,,D1E2O1DN.Q6!
M%,$(H:*_>11.$5*[SW%C3=<K4R!5YEXN-^OE<UEKRFPR48)BPW*S8G2H[)`]
M,9E1@(,2$$3B4^9EF0MF%"=RVR\[Z;2^=867?97-<\1PQQE[W4K1K:<`.))(
M`%14D5(&*]_X=;%.^]5NX+F\CT[0M-TV>_O;IT;I>1:V^1KBR%I:Z:6266&"
M&(.8'2RL#Y(V9GM:,W$G<E;LDR=6)E(N%!OEDUEL.FS",8UBNW.L?!2)+`\]
M#9BQCP0L%+020^8EF.MZ%-:RXRR[YVD+^S[E*UK7"2&2,/8ZE*M=7B.@@@@B
MIH0<2,4\1=BG8FJVD%O>1ZAH6I:;!?V5TUCHN?:W&=K2^%Q<Z&6.6.6":(N>
M&2Q/#))&97NKG?\`V-NFEW;81!Z)LE_I&LM:2-L[0O;UF$T<&,K,-XTN<#HK
MQV#(B7^_CP]<F$)(WUQL6-&S&2Y-2[+9;SR=/TV"]#&R7#8YY9>6QN4O)=AB
MZAJQA)`#J.)-:-H"O5>&?A7H&_F65KJ.X[33-PZOJS=-T^S%O)=S27#A$&2W
M8A>UUG9OEGBACGR3R2/$Q9`60O<MG0A>'8`P@\.R]D>;&0"\',AAR,_F&2BM
M3(N7XSR4O1WLL/)\R%XPI"O'&<>..=4]AC>8W>DTD'U,%\AU"RGTR_GTVZR]
MYMYGQORD.&:-Q:ZCA@X5!H1@1B%J>"[26A_:%!IUTT5:M>TS;UWV%KW5=O/V
M`;BTF3^O0UHL;L^U:O7`BFZ?5K:`I1*8'FXE3W'&$QE3&(7Q37.WDTJ$6LDT
M-PR2>%C'O:&G*`\M%&R5(<YI<`X4&-:%U"OM.H^#VCQ[0U+7=`W'9ZIKVAZ?
M97NHVT,+^[Q0WLMO`&6^H![HKFXMIKJ"*YBY<+0\RB"2XY+U=^[-L!](:QM&
MS#0PH<C@$"HH^OA,1LF+)9+*<&56I5D6J:]&A-3K':3<.$TX^XVPTI_"W%)0
ME6<<&QM'WUTRU80TNK4G@`T%SG&F-`T$X=2^>^'^R[[Q"W?9[2T^:&WEN3(Y
M\TN;E0000R7%S/)D#GED%O%+*YK&E[@S*T%Q`43TINPILHWLFAW:B+UIM'4Y
M"LLVZJ-66+<PSP:[!5':A9:[:X@P)@L*+,1I<9Q+T*(_'G0)#>6U(2V\[MOK
M%EJR*X@DYMI,'979<IJTT<TMJ:$8'B000>L#NO$#P^L]IZ?I.Y-OZD-6V?K4
M4YMKDP.M91+:2\FY@GMW22\N2,NCD!;+(Q\,T3PX.+V,A7:#M1$ZY3=9`V:P
M#M%AV?-M:!S5IV?4=15H2)I@J%/,EBEPN>,B6U*F&($./'QCU7WYB?#PQC/-
M^E:4[4A*\N<V.(-KE8Z1Q+B0`&MQZ"2>@!>@\(/!N;Q4M]7U%]Y<V>F:1';%
MYM]/N=2GDDNI'LBCCMK7VP]F*:5[_18R(UQ(6R=1+%3M6KIHZ%9KADL&'$28
M&,9AV..'FS(K4B0.8/CFVH!EF*XYE"93*4M/IQA:<>&<<ZV9C(Y71QNS,#B`
M:%M0.FAQ'F/!?)];LK+3M8NM/TZX==6$$[V1S.B=`Z5C7%K7F%Y+XBX"IC<2
MYA[)Q"U&E]RD1;T>C?@M+KTO5MZ5_K8?W(NTA([\7;5C(`:]%;BZ_>8P4F4:
M#=;1`"2BV9C<A$]Y2VX3L-I<K';MT:MNT\T=]?`9A'E/V,`GT^`<6M+@VE*#
M%P)HOMT'@.Z;;EM-[\0#?UYMV;78=+%O*X.TV!DT[BZ]!Y;;M]K;S7<=MRG,
M,+`U]PR=[85NL^\U&9>D/*\C+#3CSJ_!2O(TTC*W%>5&%*5Y4ISGPQC.<\Z0
M`DT'%?`(XWRR-BC%9'$`#K)-!Q6NG7GLB$[%O;<6`IUSJ([5NQ8U!8<O8:;6
M#=ICS*)3;W!M;54+1(1ZNB"P^XLJA,D&F9KL9*'G&F?5PTGLM1TR331#S'L>
MZ6//V2'!M'.86Y@2"06FM,*X`FE5]2\4/"G4/"V/1&ZG?V%]=:QI;KPBSE9<
M16[FWEU9OMS<1N?#/+&^U<)70N=$UY=&Q\F3.=D.=8OE2<(M']S]7JAL.^VB
M]&]HQJLP4CUS)H.N-!9;BSZW6CP4"8D%%G!\J).A5JPGTLN8PTI+4Y:TY_:,
M9SWMEJDUO;LMV19R*T/D<X$BE#@7!E?-Y5^A=A>,&N;7VU9[=T_1WWDD+I^5
M*'/)<R>>&6:)L8A>US'SP69<.T"Z)K2/;"%+*[H(3%,:@L@?:DF>C7,VWE*3
MY$"RB+1!O-F-F;K)-E9$J:0L!,Q72S$9Z=&?8\TQE4UU#F'<1V]4NH/+)HGQ
M4YH:'<1E+&@-H,``'`FA!P[(X572ZIXE7LUCKFDWVC,C=JL=M'=U,D9MWVEO
M%%:MBC:UK(8XIXWR-AD8^D3A;L<TLYKJ7D]/ZW9*_-A$MW!\AV(=PK4$=7Q0
MY-5'U<X(9J&TPDI)BSV`XM1`+"AMK;048BA7XS;3;&(C4>*SS1K,D<@<V!V<
MEKB23F+@<T9P:!@23Z)+@22:DD^^B\<M5TK4X[BUV]/WYTEM.]\TC^\/N(I3
M<Z?*WE6\,(R2NE<";=\ETR1[WR&9\LS\T)ZI4\02/*D;A&GMISRU:N8V0;2G
M$>)<J]:"!8M;#%*&VZ`HY+.3SLF$M:W&EPVI2FVU^?*<XUOU:9[6T@+;0`M-
M.EI:`&AQ::4`!Z:TJN!>^,^NWMI;"+0I;;9T<,]K(V+TG6L]NR.*VBNWVS^2
MV)D,<H`#A*Z,.<W+4&8)T4'LM4V]KXYMH%)%6R_KM-\S5E/)*!<%;4<N$^MS
M85IM]U`UM$DW-;;:RU`B>>/'7AUMYYSU6]7?WQ2PW$<+@]D>5F;@:-#0X%K6
MEV'E.)P(&!Z(^(M]I.M:'N?3M$N67EEI@M[/O%.7+R[>*U9.U]O;6LTY;"QS
MG9II*/>W(]C&Y'5\YU)%!Y[+LW=]=<D6U%E!'8EDK8YU!:T7LQ=WKX>IC"[=
M$4'N9V8:2MM&?CVHQ2"])]%;C[K:>0-7=(VC;=U&4(RN.#6AN4..7%HIY*M(
M%<`5Z9OC9>7]LYD&WKH161@FA=!.\&.WLXK06<-TX6SN;:PMB(<1R7/MYHXN
M8UL;'&07CJU1R>PK+L<[N+%:@S[TU<I4"-(AU]X"?2S2(Q]^!9FC\.8*,DPM
M*K["I&$I6PB*VKR*P[Y<ZH-5G;;LMF09G"/*#QJ.UEJVAJ`7/-.FOD76;>\8
MMPVFV+3:NG:%WNXBTXVK7N:Z<30UNW0A]N87-DBCENKUX94AYD<,P+*J<#.N
M,",0K))&QX\A\+I!.GF!*``5=<+:\76Y@^=.EBUS'B$KYE:9$$F\O$WX1:(B
M(ZD9RO#Z-#]2<6N9RB`Z?F5J:A]00*TI@VK1A7&OD7G[OQ4N9;6[M':4YD<^
MX??-TAFE$\=Z)VO8QL@:&-Y=NV:W8#%S09'2AP#3&ZH_R1!MC%C2"M^QG9KC
M`>,&EA1@V?78U<@;`AWRJQ0[Q6R&;04F#-LPH<N*0FF9SK[C*6',.O9P]CF^
M_+HWEO=SEJ:@D@YBS(ZM&AH!CJ"`T4XB@P7MOAONM*O);4;:>VW#I72MED>R
M=T[[)UG<.E$<$5O&V337RQR0Q6L36-<9&9&#(I'2>KU)IY&&[4-H@RFQJW>(
M=P'*+X63'B8DV)%%G!RZ8*N`_P!"?:7!BG'2/G2\IYI*?*I*%I7IGU2:9IYT
M3A:N86FF!)&(.8M.#:\.KU%U6X/&#<&NVLD>N:/<0[5N].=;/Y5(WR.8YTD3
MQ=26KZLMQ)1L%"T,<34%S2W)!^OHPOJ\!08>ZACD2B[$1815BJ?B1>1=0\3#
M5+B%46>W7./"E`+`^W-6/@+@(<=;93';BJQE:H_47,NG7!@-9(LI:[#LD]HC
M*UM01A4UZ:DKBWWB;=V.\+G<L^@3";4=+,$D%SV`;25U;IT9M[:U<]LT(=$)
MIA,6M<\RNF!RC`TWJK6Z+:*LR,V]6Y`N2NI/":Q/!P%&D1*@0H5U<B:ZGMVM
MMT9!)6FI/358S%GYAP2BV&<I2TRXG.?5I+B)Y?"X/&:K@33M![>V,N)#74XB
MI;4\2%V.O>,NJ[CT>\DN]#NVW;!<B2X9,_E%URR\M`Z^8;<B1\=O<MB'MD/-
MFMVR2`E\C#A[%T_H*RYXX9W>@+&/F=GNBFFG8(%0F1L<G=))L-#(M62,N=$5
M>;A.D3HB\>2>O*XKJ$XSGRYQ:Q/D;&R#,6AE>FN0-H2,N'8:`#T<5SM+\<MR
MML;;3[#;QN);:"P$A(?-S&V,=JV*5S#`X,=W2VA9#(,80&S,)IC<=DT!!D&]
MK6N;L,9&>NE'%@K&$+"F8]/`A:Q@#(I<S*!IX)9Q<$"\#,NH?P69=;65?=BO
M1G6,.*X<6H.#(86Q$ADA+2#VB75S<06DFK?H3Z(!!!7A=*\3+B+3]%T:WTN9
M[+#49)H)8Y"ZYFEN.<VZ;VX9;>1\PFM6EG=G-<+>-DT<K),HJ>1T]B%G0I-S
M?KSUB<=JDW)!@%7LQGW*S5R@37K]>CQR34YAR!6"9Q/JORIRI[4^0[CR*]5;
MG+&LE@<WN_M?:%*GZ)P+ZX4Q<&\`*4`ZE[2/QTFLF7%HW;36Z6!<-R&:;,T3
MW$<MZV9SF%A#[B.T.5D<(A=#$PYAD:WFU;JQ1``J/`H&TZ[)/"(ENK9L@1PN
MP11]*M];-1/JZ(`0;G"B558R&4Q.;=\5ID*;RMU&4JQE&,NJSR/S7$+A&XM<
M`.S5S7#$DM.:I%/)T+CZSXQ[CU*]=<[ET:Z9IL[[:>)C*0N?=6T\3N?),^U<
MZX$CH^2YN!8"&L<"#FSI/KX+ONN-:BT;G#IC4(?:X%=/5Y"K!7C),K$2++RR
M+EMN-N*$&V*/'+#I$9DHUE,<A)^[0PGT>8-U%UO<RNY#JR%I(.!`&(`RM:!V
MLI!+>('3BNNM/$Z\VUNK5KMV@3F74I;9\\,_M,T4<;N9$V,6UM;1L)NW6T[)
M'6[JOAB[+I#S%[-:];`.O-AB6X&U0IF&.(C[.&JTP5"S?88FKC+>`JX4>?19
M')"JJ%"W/X-Y:ARWY,>(RVIY.%NY7+K4WW-LXNA<UQ!:7`G(2XM+B1E](EM1
MC0$DTX+'=GBOJ6Z-KSON=&N+>>6)]O+<-D?W-\EQ);37$KX3`&]XEEM>:T"<
M,8^61PC-&9=W^=$OSTL:8,B*\+G&SY4:###(ZY9(N8G11@L?$:QXNRIT^:ZQ
M$B1V\?URW%I3C^CGA%\\/O3=^K;I:S>V5'ZQ=GZ_5A^SN_\`JK7V\4T.V4$\
MP>U$4=:^L0:UN24'/E5<?0K]ODHS%4WC/_#)^CFQC:UKU+-HK6O4N_"L[9U7
M=2:PM-V7K^VF6XSTQ8FLW*N'B:(<=;33\M<`42E2DQF''T)6YE'E2I:<9SC.
M<<UT*P5@<(G")PB<(G")PB<(OE,_WO\`4E'MJ:ARI6$X_+(UOCQSGPQX_@MW
M1S9%Z7J+./TO47\WCUV?_DB/_NL<Y"W+[Y?]S&6A>EN^OD5A7AN+3?CX9\?#
M_P!`+#S1+Q"U2<5]JO-2UKY0.[7_`"I_O!/]PO;[_P#GJJ\^L:00+?;_`).^
M?.<O[0_%_P#X!\67^,[T_8W*D7^\1?Z+_27^[AC^#JO\X^P"!J=]7Z7]5ZZK
M_P!KS_6]X@?Q>+^6SK4[>W\JQ[5?^2SV\O[]1N=S8.'Y+ZL.GFW?[%R^U>'/
M^#3QE_IC>O[DY7$:SCYJ[_[R[C^]T/G'81D_^V/U2O#:?_`V_P"R7_QWKL"Z
MB?X-/>^_C5]PO^P4OGF]5([YHGDMK;Y[5^8_&[^UOQ>_[F[8_EC%\\>@LX^R
M`[\?Y?.L']^%<]_=N;^5NGFN'(D_8L7]0/$C_'%X:_W;U_\`<@NSSI[G_P!'
M_8._N9[D?][+USS^KD%VX*=)LO\`B+\B^.7\Y?&3_;=B_NEHL#TBS_Z/^P3_
M`)4^_P!_?0IS+<)!FU[]9:?L"NS^,+_.?QE/Z'V;^Y1KW]L/_:*-#?\`2CK]
M_P!DT\TZ41\'TXZ<DGSWK3X+_P"ZZW'_`!/6?Y0Y:F]0\X_#5[UG\47NU_"/
M$YW6JN'<M$Q_Z[;?.<OM7C?_`&`\`/[[[4_D+UMP%SCYT:_]V@@?WI8YU3R,
M/[S_`*I7Q._'[Q@_VM'_`+HY37OW_("=-O[F=8?^P![G$V\1^7EV>BLG[HQ>
M?^+5_O+-]_MNO_RV%=77=K/_`.J][/\`_D,M_P#"D+YZC0'#WRU7'_E6?L`O
MU_\`%\_UO^./]X;7^KWKL0]PK./FGOH?3_\`W/[9/_PAN=)MX@1Z!7Z6]^>5
M^7_BQ#]Y?%U_BF_?^E7:?T__`)5GW/O^@_33^"+//(ZP1^2VECIS7'[J5^.?
M'+_!GX0_TANC^LE\V?3O/_Z/?>0_BXV_^%;//HFLN;S])Q_Y<?L7K^K?CM_:
M?P*_O3;?U<5L3THS_P#J2^WU_P"N]UE_V)$<XVLN!UO4?Z#E_9N7R_Q__P`0
M7B=_L]ZA_*Y59^,X_!J%_P#>0Y'_`,U;YPV$<]W]W/U2O)'^UEQ_LIC]52#W
MW?Y17H]_T8UW_#J6YHV,0-NWH/'.[]@Q=3_[<W^%KQ#_`(Y>_P!41+&ZK_\`
M:+MO?W0W7_J[$N;+DCX/(ATTC_=6+F;Q_P!UKH?[5I7]=QK)=#LX^>^QA_D[
M]R/^^&Q.-P$'W]ITOL_^B7%^,>/^[_C$_P!*;&_86*L#6_\`[-EL7_R787^M
M&OG&O"/A):>C#]P7F-V?[UW2_P!=9?\`E]=IWLH?R9O6K_R79?\`"_?^>6WL
M0=S7)'#VO]S8OQS\?_\`Q:[L_7V']66:[4N>47XW6J9C25N(=W]=]C698--$
MJG5?<6E24%R7,397+;?MM:.O(65$@I@*@.`V0^MYZ)#JI2'D/N,I2TM*EK1:
M]FGE5KA15YVMTUO0MNCK'V=Z]B->7JZ]>XN[*>>U-LJY&=;";Y0-ZA*5&-20
M&PPU.V%FMW"J6'7`B5&;EAY,*=#7+86['<4T[B@BA!04I0K/=,]([3U='["[
M&W?]2AVT^SW8`MO.QTO79HM::?K<:WKG6VIJ?1A]Q.`*F1NA$?4=70Y1,HH2
M+:D$ICZ6(R&&VU+A(.`X!">K@M=.N?M9:'J)S86RM^:EU]L?;EA[;]A>P=;.
M2S%MM==@#KUO2V;'U1/?IU@DQZ7'N53`$A^5.(%+S")1\N,ON+2E]5+CT<**
MEQZ%=/<[JQ:.Z4NCZ`V!("Q.DY.*7LG96O0#IJ!L/=Y(4[$QKK3+"AD.)BKZ
MOP:5D_8B3!%).>Z+A#6&VXTB:]F`TQZ5`:8]*M;J-2-]ZOT]#U;V$N`;9EBU
ML=,TRC;8@RY#EBVAJ(.XRWK6V[.&NBAD8-MKZNK;@V)$-4J%.(PED&74)F9C
M1QH<0AIT+9WD43A%K?V4UC<M@B-76/76`4J]Z5W%5]OUT#9B4H(#MJ18:ST^
MQU6;8(0PW(K[Q>H74AB),Q"EMLST,9<:RUY\X[/3+J&W?+%<YA;SPNC<6BI;
M4M<'`$BM'-%1485IBOJWA/N_0=LWVL:5NGO+-N:_H5QID\T#&RS6W,EM[F"X
M9"^2)LPBN;6'FQ<V,OA,@8\/R@_O6O6%RUZ(VA8MB?(XUZW3N*T[@L0&M$91
ML%4L%@]9J-=JL$_-&`Y-@>$5"ECL2YN841#\Y;^6VL->3.9J=U#</BCMLQMX
M(6QM+A0NH7.+B`32KG&@J<*5-5/%C=^A;GOM'TO:W>'[<T#0K?3()IV-BFN>
M7+<7,]P^%DDK81+<W4_*BYLA9"(P]Y?F`HSM%K+LMM39M:'AZ'J_976JM!AI
MV=JZS;EL.KU['VE$,.SH+NT$"]0[#19M:U-B)$>A`$OL1")-2GR29++#$?'/
MTJZTNUM7NDDEBU)Q($C8Q)D92AR5D9E>ZI!?0D-P;0DE?1/![=WA-LW:-W<W
MVI:QI/BS=SOA9J%OI<.H"QT]T08\:>9-3LC!?W)=(R6\+'RP0`1VIB?))*=^
M("YCL&&X1CL1"#D6.N?$BR5S8T68ME"I4>-,<C0W);#+^5)0ZIEK+B<85E"?
M'RX\^[*'$--6UPZ,/,OS9<M@9<2,M7.?:A[@QSFACG-!.5SFAS@TD4):'.`.
M&8TJNOK3FLNT2.PY7;V_]>:HL\^<0MU>J%R#[LLA&/I;4TQYY\)5]:ZIF:9%
MCD6&RX'0,V@R^;^8E'\YQAU$&+%@H]%>W6E>]HL]/DF8`&ES3$T<R3I<^3F$
MT;4Y&AN5O5F)<OTWOO=W@^[POAV/X::IK5G;1Q6TUS:RZ5`PZKJ30!+<7^HM
MU21YA@SS>]]JRTY%NRA+'7$TUR[93LWJDYNC2]FHM5)BQ%NP5HUSIT\XF4H&
MFX:ROM8V55XIO,%#TUD*2.U-B-+=9;=>9C/+6AM:TX1GK-+NV65ZV>4$PT<U
MP''*]CF.I7"H#B16F/2OD_A'O/3M@[^M-Q:S%-/H?)N[6Z9#EYO=;^SN+"X=
M%G(898X;E\D37.:USVM:YS02X170VN-D#MC;NW?M<76:K:]P?@V`CZ)5+++N
M@^JU#5@,S#%*GVV77*EDN<.G[86ENI:@-,QHJX[6%N.)<5S;J%S;.MH+&T+G
MPPYR7.;E+G2$$T;F=0`-:.-2:X#!=SXD;JVI=;5V]X>[+FN[W1=#[_,^\N8&
MVK[BYU&:)TF2V;/<\N*&&VMHVETSGR2"5^5C2T+Q[!4389^ST*V4K46@]T0P
M(*^UPO6=P)2`L(Q=P9`HAEZ;?5T^^MC@KR1#D4^)4.3DE&=9=0]YXN([]TZX
MMXXI(9YKB`N<PAT>(.6N#F9F5.-6NK@:BF-1EX8[CVQIND:EHFX-<W+H$]S<
MV<\4^F5F@D%L9BZ*ZLQ<V9?*.:)+.Y$YY$C7L='EF,L<PZQ:C)Z&Z_ZGT^9.
ML6,K0*@/!3RD)N2R*S);4[(='@6)JW)D>M!52/@AC;N?4;'QV4J\%8SC&C5+
MQM_J$UXQI:R1Y(!X^<TZ3Q=Y25T/B[O>T\2/$S6M\V%NZUL]3OGS,C>6F3*:
M-#YBT!KIY<O-G<WLNF>\BH-5ISLKII;]C[XEEY%0H0+7Y+?6K-YE+R`VCM6`
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MASV=P7M:&NEDU74;YIB(<XN9R;N,$N##G#QE(`<=@.=<OF:<(M*]O]/V=K[`
ML5U=O*PL2R,5W,T(T"^(\2=6KYJKA2V""2T5Q,R"%MYME&<-XSCXY.?'Q9QY
MN\L]9[I;M@Y>8MK0UZ'$.(I0\2UOK>5??MC>.3]E[9M=`9IPN)K5T^24S9?:
M[B:*XECR<MPROEMK1QJ<>21]&:2L+UKE`SFJS478!#.=0DK?*K\9T3`?^=QM
M@6HZ3N3EIEOX<F23!:N$F(^9$-R$U\Q97*4TIIQ,5K2_4Q)',PQCVX-KB<,C
M0&Y>B@<":&N!I6HJ>FU#Q8AU'3M9L)M,B_[\BMFS.$CQRG65O#':BW:*,;%'
M/&]^242NY#VPAX>TS/IR=T9G&PDP*5V5%A#\0;'7!8(#4\-UZ/5+V#8JNP1T
MS)HP8M$MVP@1L',7&"B&QCL5MI.'HK+#+7-;KS6/#VQ$NJ"278YF',PB@#10
MDU[/:K7`DD^[M_C$V^GZ@S4+/27R77,@GDFFN:SNN+.8W%D]O*BBMVB":27F
M?O<NN&R.>>7,^21^9%=*5"W3]DDW]-@O\XU6+>*,%`<B,#:NX:Q$[$8L)D0/
M-MRRCAY9F5&PC$IM$5A_.<)6XAM2<'ZX'!L0CRVX:YI`..4M``!(PI0'AB1T
M"JX%[X_B[9;:3#IAM=LQP7%M)%',UTIM)8(X(H8I7Q%L8A$4<A/+<9'L%2UI
M<#-%]8RAJG;-HUDN,.,(VC>WK>?G5D7+P35"(6DU<B0*-'M1&R`X"/FY!AEM
MUN+E*XS3GJ-Y=<PMO0-49'-%/$PE\4>4!QPJ&AH/9#2<`3QX]-%T#?%VST_7
M=(W%I-C(^^T?31;0LGD;R\[+>*U9,YUNR"5YY3'N+725$CFY7!C"UU<HZ3'&
MYBICVRPYA1F)9DV9HY2')K,<]?2ES)WBZ4].+*A0*Q$Y-F8EQDN9D,12C#TK
M&%9DJ;3R??R,B@B+<I;EHZF#`T-:[LX@92#P):0.BJ]2[XP.G.@$#-)G@%N^
MW[N8;L,)ALX[6.TM;KV@\Z"-L#XY"T,?);O9#4<H.,CMO3&/;=D'KT_L*>-A
M'+S'O21(L1B+/$EG6Z9!.S!AKYDOT214/KH)'2\J.I+.8>590O#BD\U0ZV8;
M9L`C!<V/+4G`CM$5%.`+W'CT\5U6B^/4NB[4MMNQZ9'+<6^G.L^9)+F9)&#=
M/A;)%RQ6..6^NGE@>"[F@9FEH*E@WK%+@SJV27>6G7*_I;&BLA_JQ%S62-.=
MK4Z&0=FPOCDFUS2-MS!(.H210QF-#^&\GG4F2WJ=JK7-<WEX.GYM<W:#LP(Q
MI2@;4<*U-?(NFN_%Z"YM[NT;IS@VZU_WWYO>'=X9="=CF!C\G*#&6W-A:3`7
MYY>;FR@Q.JZ3TC/D8,1R3MO,`Q"0-'#V1U59>`AP(*\Q-K5Z+$40)O6HD9"[
M,&1"""$XF^Y(:9\CZ''\YD\Y8UV-KC2&K#4FKL22WEFM!E`+"10-%.C#!>PB
M^,'IMK<O;%HG,L9#)(\ON")I9IK1VG3.=DC%O'%+8220F&&W8UCG9HW-C'*4
MBI_31F@/#;%7K=&(74)>H]L$3CHB9@!'@2(4&%8QZA`TS&D.$[`J)Z[DUQ]W
MR.I1A#6,>IZFJ;6N\`Q2,(@='E(!%:U)::D<!6E*>KPIU>N>/+]S1RZ7JEB^
M+0+C3G6TK(96\YSPY[H'\V2)S1'#FR-B#&U:79GDY,N6A=5C:=95O73NP6Q*
MJ?=D7T,=`!Y$B3,L`*#E5)DDHMH)'FHT8+8<HGOQX2H^',L-I8<C*QES.!U:
M/O3KD1USQY"">@GM4R@<1@":\34%<*X\9=/.[KO=+-,,XOM/[G+#-*UK6PS/
M_?;8W6\<)<Z6&L+'RA]`]YD;*"&J-TSI=*I-@`2H-[$SZZ(<J&61Y"H..&*Y
M&JQ6B6ET?2#&+!X!XA6V5*4M/K-/JA#R>8K?F2PVKFV?6VSQN#HR)79L0[!V
M8/;5PIC1KATBI;4\2NUU[Q\AW!IES#<:=/'JDXN:O9<@13NN([RW#[N+D^VN
MCMKF,'*Y@EF@$SZ&1X6-,]$F#9JP$Y&S)T:.5);/("HL`%\,Z#1LV7<SY0>W
M)R7<Q*'OVZ[RYLUO*$8F-JRS^U^.'$Y,U[(QK1$"6A@-3QR90#PP.5H`ZN.*
MY5C\8V33["UM(M)C?+#%I[)'/FS"4V#;6&-Y;RQE>+:TCBB<">4X!_:Q:;7.
M=;9Q<YLNQJN$5Y[95.%5&?69P1]-5@Q*EFMO4K$-P.7$6YG`65#,.9<P4]5#
MII3L?+"V?V[B,U-K(XHLAI$\N#@>T<V;/6H+<>S]#]#0UKAXO3O%>VL=.TG2
MA8O;'I-])<LG9*WO#W7//%WF$L4ML>:UUJ*&WREMJ&2B1K^Q5<OI*?G."2KN
MY)+5CBOUR3*FL4T2Q`C.T:NSZK1U@8L"2/F0W1`.QF69*Y$B3B5DFXM*&%97
MZG+&N1MJP0#EG-09C7M$.=6M1B0TB@%,O2O9P?&"TVW9-9,T%ATI[9VM8;J0
MO<+N=EQ=\YSVO:X2306KV!C(S'R&M+I!ERY.O]*HU)#CF*C;8>#C<*WUD@0.
M!ID@>U2;4"-!6PH$4/-0D#I(A15,A+SRY&7W$*2KR(4E*,)-<,[R9F'EU:X`
M$5S-(-22#6M*84HN)J?C_+N"^EDURRD][C);3L9#*UKS=V\T4IEFD?$\O;+R
MRPM:&9&D$9G`EV>/=53=EH6NZG)OT8',UN,LL<6X*"RBX@H2LL9BO3)IIBSE
M29=^([2))0:MAB9'7E)5W&'?1QZ*M<>K1Q7$LHC+FREM:FA`;B`,H`]+*ZI!
M]$85Q76:;XRZ?I.Y-4UN+37W$&JS0.D$DK8I(XX'&=K(C;QQQ!PNVV\X>^)X
MK;L[&<YQ^:UZER]=7<6<;N\$U7@I<<3$IG5IQ-V'#JX*N("KU2/;,FGFU`X(
M.VIBREKBYD3&(+:5YQEQQ?%UJ[;F`LY9;*YI!H[LDDM+G9:<26U&-`3Y%=V>
M-<.Z=O3:>[3Y+?5+B!\<F2<=T>^>2UFN+EUMR@><^6V,D8$@9$^9SF@AK6K=
M+G2+X$JBWYHO6?9K3.R=`;E`NVC5FVJJ2I5[KS!4J#>+UTLWAN=";+@Y@\N.
M6ZA./!V.\TZG^@K'`-$X+XG/>6]E3VY.G5D]M87U_P!&D:9$[']]M7:)V^E_
M9>S;&JSZQM+C2#->;78K65R%7(QG/EEPOAY:/-GRNX^CPW,<XUKT!;6N<:UZ
ME]-O33V6?;IZ!;@E[WZKZ0(:[V9-IIN@/G9.R]EVUG-5L)$*4*C4B[=:S8Q.
M7YM>B*P]Z7K(PUX)5C"E>.LO<X4*P+B<"NU/F*Q3A$X1.$3A$X1.$6*+@@E@
MC(A'PPHW#;>3(;B%Q\0E&1(0E:$/H8FLO-)>0AQ6,*QCS8PK./'Z<\(HW^#'
M6O\`B\HW_5,!_P";^$J5GPU;KM<0^W7@`4"W*6AR4V&%P1:)+C:<H;<?1!88
M2\MM.<X3E7CG&,^&.$6:X18E\""E?,,R0HF1DOB.DKZXZ&]\S3$\/A4D/495
M\;B-Y<>GASS>3P^CPYF))!2CB*<,3AYNI<V/4M1AY7)N)V<C-RZ/<.7F]+)0
M]C-]%EI7I7Z1!`S#3#!<,**,1<YS&9(CHDYJ/G*,-YRPW)9=0UG*,>7/EQCZ
M/HX;)(PU8X@GJ-$M=2U&Q>Z2QGFAD?Z18]S"[&N):03CCCTKU.5JNNRXL]T`
M%<G041VX,UP5!7+AHAY\8B(LE3&7HZ(N?^#PA6,(_P"]\.7FR@%H<[*>(J>E
M9MU;560/MF7-P+:0N+V"1X:XN](N;6CB[Z*H->E>>:^!SGQR$$9S\S^=>.1L
M/.?G'AX?-O'T?^4_#'_#_P#"_P#QN3F2?3.X4XGAU>;R+'WSU(<+B?[#ROLC
MOL7^CX_8_P#,]'R+D,BA<=,Y$<;`803>>D$DLPX[22#\A/DD/3DH;3B6\^CZ
M%J<\V58^C.<\A>XTJ3AP\GF6J2]O)3&Z665SH6AL9+G'(&XM#*GL@'$!M`.A
M8UNI51F'('-5FO-#Y;C3TJ"V%&HAR78_TL.R(J8V&'G&<X^X4I.<I_H>',N=
M,79B]V8=-35<M^MZU).VZ?>71N6`AKS+(7-#N(:[-4`](!QZ5RV0`*-B`F.%
M$L)%8DX%X9'0VL#<3,*Q,Q`PAE.(>)6%9]3T_+Y_'/F\>0R2&M7.QXXG&G7U
MK1)J6HRF4RW$[C-EYE7N/,R^CGJ>UE^AS5IT+\8KX&-@?B,$$1\"5R'!6&!L
M)K`QR7X_%+'X;93\&N3XY]3+?EROQ^GQX,DAK5SC7CB<?/UJR:GJ4O-,MQ.X
MSAHDK(\\P-]$/J>T&_0YJTZ$>KX&02;,/A!#Y=K+:FBKPV$X2:4RG*6LMSEL
MJDHRTG/@GP5CRX_8X$D@;D#G9.JIIZR,U/4HK0V$=Q.VQ=6L8D>(S7C5@.4U
MZ<,5ZF:O6HZYKL>O`V'2;+\<BXR)@-+(,2E^I)8FK1'2J6S(7]*TN>9*\_3G
M&>4RRF@+G4'#$X>99R:QJTK8V2W5RYD3@Y@,CR&%HHTL!=V2T8`BA`X+VX``
M<9SG`01C.1F`N<X&P\9R&QCPP)SG#/CD9C'_`(#_`(+_`.+R<R3Z8\:\3QZ_
M/Y5A[YZD10W$].=S?LCOLO\`I./V3_/]+RKRD`0<L>R)E!A4D5&PUB.,D#H;
MP^/AA.4L89A.,JC-893GP1Y4X\N/V.!)('9PXAYZ:FOKJ1:EJ,-TZ]AN)F7K
MZYI&O<'NKQJ\',:]-3CTKB/U.K26H;$FM5^0P.;RT/9?##G6H#2EX<4U#;<C
M*1%;4M.%92C"<9SCQY1-*"2'.!/'$X^=;H]:UF)\DD5W<MDE-7D2O!>:4JXA
MU7&F%37!<F0`!3,SLRP@B5DIF*HGF0-AOY(J@^'P2IWJ,J^+S#\,>EESS>G_
M`-[X<@DD;2CG"G#$X5XTZEJBU/4H.7R;B=G)S<O+(X9,_IY*'LYOHLM,W35<
MMD</CRY4^/`AL3IR6$39K,5AJ7,1&1Z<9,J2A"7I"8[?W*,+SG",?1CPQR%S
MB`TDY1P"TR7=U+`RVEDD=;1DEC"XEK2XU=E:31N8XF@%3Q6,9JE6CIFHCUL`
MP@DTIDBED..:3/94O+BFIJ41DXE-*<SYLI7YL9S]/[/,C+*:5<[#AB</,N7)
MK6L2F-TMW<N=$:LK*\Y#2E65=V33"HH:+VL5NNQF(\:,`"QXT2<DG$CL"H+3
M$8DA.$H(1VFV$MLSDIQX8=3C#F,?T>0RR$DESB2*<3PZO,L)-6U6:1TTMS<.
ME?'RW.,CR71GBQQ)J6'Z4]GR+R^KP#RX1\C#^3!+YSA'RR%Y<&,Y\<E<)]#P
MP2SG_P`/_P`+_P#&XYDGTSN%.)X=7F\BQ]]-3KF[Q/FY7*KS'_8O]'Q^Q_YG
MH^1?L^O@2LEB84"""4N+A.(LJ>-AS),;"'/61AA^0RXZSA#OW6/+G'@KZ?V>
M&R2,&5CB`>HD);:GJ5E$Z"SN)XH'^DUDCVM=44-0T@&HPQZ,%^(KP!LBLPV#
M#H+N>?+A5`R$DBYEUOT7,KG88Q)7ZC/W"O%7TI^C/T<<R3+DS.R=533UD=JF
MI.M18.N)S8BE(S(_(*&HHRN7`XC#`XK]8KX&+F"J,$$1LBTR4#,L#8;.1R)N
M59F(@Y;93F(F7E6?5PWY<.>.?-X\&20UJYQKQQ.-.%4DU/4IA()KB=XF+3)6
M1QSEGHE]3VLM.SFK3HHO)(((@:H*@,*2'7YL+$I'Q$C5X6[ZZ\*@X9Q%5YWO
MN\^*/I5]/[/',DS9\QS]=37UU#J.H.NQ?NGF-\.$F=W,%!04?7-@,./##@N7
M"@P1L5J$.AQ1\-CS89B0H[,6*SA:U.+PTPPAMIOSN+RK/AC'CG.<_LYYBYSG
M',XDN\JT7%S<7<QN+J1\L[N+GN+G&@H*DDDT`IB>"Y7(M*<(G")PB<(G")PB
M<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"
M)PB<(G")PB<(G")PB<(G")PBX$X4+)YBJ)#8!!4&0B7"S.AQY>8<MO\`X.5%
MR^VYF/(1_06CP5C^AGA%S^$3A$X1.$3A$X1>#CB&FUNNK2VTVA3CCBU82A"$
M8RI:UJ5G&$I2G'CG.?HQC@`DT'%4`N(:T5<5K"[VTUK+*T*!4H5CNHS92YC-
M0MHF.("U$]*C3FA;$2OG;H8J\:UR)Y!["6DB?CO%C"I'_BZ%.8[H:%>-9*Z<
MLC?#3.TU+FU%:N:P.+:#CFRXX<31>[;X>ZW';W<NH.AM9[(-,T3R]\T8+2XF
M2.%DIB#6C'FY.U1GID!8$=W&JD@-BPE]<;+K(,?#&&;B2+)H4EFB5D[=#FO@
M5FL*0-Z,.2QQ.T5<HCTAF"$R/%'NR'V6VU-9=V/T"9LG*9-"^0DAH&<9W!@>
M6MS,%"&N;B[*"7``DUIRI_#>_CN>YV][8SW3W.9"UG/!GE9"RX?%'S(&`.;%
M+$:R\MCG2-8QSG!V7DS>X=&#KUU'L-,V'7Y^Y7F&--CR42I>OLMPBT`D!60K
MD2WR8PJ65C6)EW+)5<!R$VVYF7B/X)\\9H%S)S3#)$]EN/;2"[VNF:M:LQ`R
MG%N:N&6JPB\-]5N1>/LKJSFATT$WCFF:EL&F0/+ZP@N#3&1FB$@>2!'GQIF:
M/V\TE?";HT<;+B4KV$_JP04LE;-@PMAO#6,.1@(@M-AHAY(%8SB'83,A3#TM
M"_!I"E)6E.NYT'4;9F=S6N]JYA#7`EK/IB`:T'214#I7&U3PZW1I,`GFBCD(
MLQ=/;'(Q[XX#QD>QKLV5AJ'EH<&$=H@$$[.\Z9>%3A$X1.$3A%5.X-N!--UF
M'8C`:PV-TH82#$5^K,#'S96<@.8L<Y,;YT5""6FQM;KL^<[EZ4UYFXJD-^=Y
M;;:P%4I54]/[DZXC09AB%5]D%P`W8U=UP0-Q*[`AL)EVRJ:[N%=/C!AHV+L-
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MG0W23$M<2:VE]G*'<>?G-9J-ZR(P-D=RRTMQH:`C*0TFI:"TD$-(J,#4+OH-
MSZ_;V3]/CN9#:OC+*.H\M8YAC<V-SPY\37QN+'B)S`]A+'5;@N'*T-J*9+!3
M7Z0-]6N>G@<VS))QH3K4>QO7"%&,CHTYH?9(0RUR'"4-@BU*9ASEJ?82VXK*
MLY-U._:US1(:/XX"N+<IH:5:2WLDMH2,#4+9'NS<4<<L3+I^6:N:H:7`F,0N
M+'%I=&YT0$;W1EA>P!KB6BBQ43K5HR%'FQ6M=B'69XZ4&<3.DEB2HH65\N\@
M02Z1(RG0808L3&6/APE1XPQQK"XB&5^*LYNU?4G$.,KJ@UP`&..)H!F)J<Q-
M2[Z(E<B3>^ZI7LD=>R!S'AXRAC:O&;MO#6@/>[.X2/?F=*#20N&"E5-T_JS7
MJD.4K7]4K<AN1/EMS1H:&V0;D%(\&*3=;(K:7/0LC'&1TO\`@YCU<,I\WCX<
MT7%_>W6%Q*]XH!0DTPK3#AA4TZJKK]2W'KVL`C4[RXF80T%KGG*0TN+06UR]
MDN<6X85-%9'.(NE3A$X1.$3A%"-@ZXI6TZ\NJWT"Q8`2Y;$[$1R3/@/,S(R7
M6VY$0@*E024)U<=]UAS++R/6C/.LN>9IUQ"G!%"+!UQTI:#(D^8H<!90(7EG
M![P\B<"1TD)],!:YG9E#PA0<.)0YM!K4,,]%DM/171K2HZF\M.NI7:E6I6$@
M=3.N0YYF2C4M7G261<\+\4=3/LDF0,)#2H63%GR+#.)O$L)!&Y0]E4A3JXP]
M[,5E2(^$MX5*5*O<,'&UX.)`!XR80@&-@AQ4-+CSJ8@T9%:A08R79#CK[B6(
MS"484M:EY\/'.<Y\<\BBR7")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")P
MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G
M")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB
M<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"
M)PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<
L(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
